US8227661B2	NNP	O
-	:	O
Methods	NNS	O
of	IN	O
identifying	VBG	O
agents	NNS	O
that	WDT	O
ameliorate	VBP	O
or	CC	O
modulate	JJ	O
effects	NNS	O
of	IN	O
PRO1328	NNP	O
gene	NN	O
disruptions	NNS	O
-	:	O
Google	NNP	O
Patents	NNP	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS-REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
divisional	NN	O
of	IN	O
,	,	O
and	CC	O
claims	VBZ	O
the	DT	O
benefit	NN	O
under	IN	O
35	CD	O
U.S.C	NNP	O
.	.	O
§120	NN	O
of	IN	O
,	,	O
parent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/221,669	CD	O
,	,	O
filed	VBN	O
Aug.	NNP	O
4	CD	O
,	,	O
2008	CD	O
now	RB	O
abandoned	VBN	O
,	,	O
which	WDT	O
application	NN	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/457,708	CD	O
,	,	O
filed	VBN	O
Jun	NNP	O
.	.	O
3	CD	O
,	,	O
2009	CD	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
,	,	O
and	CC	O
claims	VBZ	O
the	DT	O
benefit	NN	O
under	IN	O
35	CD	O
U.S.C	NNP	O
.	.	O
§120	NN	O
of	IN	O
,	,	O
international	JJ	O
application	NN	O
PCT/US2005/02723	NNP	O
,	,	O
filed	VBD	O
Jan.	NNP	O
27	CD	O
,	,	O
2005	CD	O
,	,	O
which	WDT	O
claims	VBZ	O
priority	NN	O
under	IN	O
35	CD	O
U.S.C	NNP	O
.	.	O
§119	NN	O
(	(	O
e	NN	O
)	)	O
to	TO	O
U.S	NNP	O
.	.	O
Provisional	JJ	O
Application	NNP	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
60/544,195	CD	O
filed	VBD	O
Feb.	NNP	O
12	CD	O
,	,	O
2004	CD	O
.	.	O
INCORPORATION-BY-REFERENCE	NNP	O
The	DT	O
contents	NNS	O
of	IN	O
the	DT	O
text	NN	O
file	NN	O
named	VBN	O
“	NNP	O
Sequence	NNP	O
Listing	NNP	O
P5202R1	NNP	O
”	NNP	O
and	CC	O
created	VBD	O
Sep.	NNP	O
6	CD	O
,	,	O
2006	CD	O
,	,	O
being	VBG	O
62	CD	O
kB	NN	O
in	IN	O
size	NN	O
,	,	O
which	WDT	O
was	VBD	O
filed	VBN	O
with	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
Patent	NNP	O
and	CC	O
Trademark	NNP	O
Office	NNP	O
on	IN	O
Sep.	NNP	O
27	CD	O
,	,	O
2006	CD	O
regarding	VBG	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/457,708	CD	O
,	,	O
and	CC	O
which	WDT	O
was	VBD	O
later	RBR	O
filed	VBN	O
regarding	VBG	O
related	JJ	O
application	NN	O
U.S.	NNP	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/221,669	CD	O
,	,	O
filed	VBN	O
Aug.	NNP	O
4	CD	O
,	,	O
2008	CD	O
,	,	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
.	.	O
FIELD	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
compositions	NNS	O
,	,	O
including	VBG	O
transgenic	JJ	O
and	CC	O
knockout	NN	O
animals	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
using	VBG	O
such	JJ	O
compositions	NNS	O
for	IN	O
the	DT	O
diagnosis	NN	O
and	CC	O
treatment	NN	O
of	IN	O
diseases	NNS	O
or	CC	O
disorders	NNS	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Extracellular	NNP	O
proteins	VBZ	O
play	VB	O
important	JJ	O
roles	NNS	O
in	IN	O
,	,	O
among	IN	O
other	JJ	O
things	NNS	O
,	,	O
the	DT	O
formation	NN	O
,	,	O
differentiation	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
multicellular	JJ	O
organisms	NNS	O
.	.	O
The	DT	O
fate	NN	O
of	IN	O
many	JJ	O
individual	JJ	O
cells	NNS	O
,	,	O
e.g.	NN	O
,	,	O
proliferation	NN	O
,	,	O
migration	NN	O
,	,	O
differentiation	NN	O
,	,	O
or	CC	O
interaction	NN	O
with	IN	O
other	JJ	O
cells	NNS	O
,	,	O
is	VBZ	O
typically	RB	O
governed	VBN	O
by	IN	O
information	NN	O
received	VBN	O
from	IN	O
other	JJ	O
cells	NNS	O
and/or	IN	O
the	DT	O
immediate	JJ	O
environment	NN	O
.	.	O
This	DT	O
information	NN	O
is	VBZ	O
often	RB	O
transmitted	VBN	O
by	IN	O
secreted	JJ	O
polypeptides	NNS	O
(	(	O
for	IN	O
instance	NN	O
,	,	O
mitogenic	JJ	O
factors	NNS	O
,	,	O
survival	JJ	O
factors	NNS	O
,	,	O
cytotoxic	JJ	O
factors	NNS	O
,	,	O
differentiation	NN	O
factors	NNS	O
,	,	O
neuropeptides	NNS	O
,	,	O
and	CC	O
hormones	NNS	O
)	)	O
which	WDT	O
are	VBP	O
,	,	O
in	IN	O
turn	NN	O
,	,	O
received	VBD	O
and	CC	O
interpreted	VBN	O
by	IN	O
diverse	NN	O
cell	NN	O
receptors	NNS	O
or	CC	O
membrane-bound	JJ	O
proteins	NNS	O
.	.	O
These	DT	O
secreted	VBD	O
polypeptides	NNS	O
or	CC	O
signaling	VBG	O
molecules	NNS	O
normally	RB	O
pass	VBP	O
through	IN	O
the	DT	O
cellular	JJ	O
secretory	NN	O
pathway	NN	O
to	TO	O
reach	VB	O
their	PRP$	O
site	NN	O
of	IN	O
action	NN	O
in	IN	O
the	DT	O
extracellular	JJ	O
environment	NN	O
.	.	O
Secreted	VBN	O
proteins	NNS	O
have	VBP	O
various	JJ	O
industrial	JJ	O
applications	NNS	O
,	,	O
including	VBG	O
as	IN	O
pharmaceuticals	NNS	O
,	,	O
diagnostics	NNS	O
,	,	O
biosensors	NNS	O
and	CC	O
bioreactors	NNS	O
.	.	O
Most	JJS	O
protein	NN	O
drugs	NNS	O
available	JJ	O
at	IN	O
present	JJ	O
,	,	O
such	JJ	O
as	IN	O
thrombolytic	JJ	O
agents	NNS	O
,	,	O
interferons	NNS	O
,	,	O
interleukins	NNS	O
,	,	O
erythropoietins	NNS	O
,	,	O
colony	NN	O
stimulating	NN	O
factors	NNS	O
,	,	O
and	CC	O
various	JJ	O
other	JJ	O
cytokines	NNS	O
,	,	O
are	VBP	O
secretory	JJ	O
proteins	NNS	O
.	.	O
Their	PRP$	O
receptors	NNS	O
,	,	O
which	WDT	O
are	VBP	O
membrane	JJ	O
proteins	NNS	O
,	,	O
also	RB	O
have	VBP	O
potential	JJ	O
as	IN	O
therapeutic	JJ	O
or	CC	O
diagnostic	JJ	O
agents	NNS	O
.	.	O
Efforts	NNS	O
are	VBP	O
being	VBG	O
undertaken	VBN	O
by	IN	O
both	DT	O
industry	NN	O
and	CC	O
academia	NN	O
to	TO	O
identify	VB	O
new	JJ	O
,	,	O
native	JJ	O
secreted	VBD	O
proteins	NNS	O
.	.	O
Many	JJ	O
efforts	NNS	O
are	VBP	O
focused	VBN	O
on	IN	O
the	DT	O
screening	NN	O
of	IN	O
mammalian	JJ	O
recombinant	NN	O
DNA	NNP	O
libraries	VBZ	O
to	TO	O
identify	VB	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
novel	NN	O
secreted	VBN	O
proteins	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
screening	VBG	O
methods	NNS	O
and	CC	O
techniques	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
the	DT	O
literature	NN	O
[	NNP	O
see	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Klein	NNP	B
et	VBZ	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
93:7108-7113	CD	I
(	(	I
1996	CD	I
)	)	I
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,536,637	CD	O
)	)	O
]	NN	O
.	.	O
Membrane-bound	JJ	O
proteins	NNS	O
and	CC	O
receptors	NNS	O
can	MD	O
play	VB	O
important	JJ	O
roles	NNS	O
in	IN	O
,	,	O
among	IN	O
other	JJ	O
things	NNS	O
,	,	O
the	DT	O
formation	NN	O
,	,	O
differentiation	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
multicellular	JJ	O
organisms	NNS	O
.	.	O
The	DT	O
fate	NN	O
of	IN	O
many	JJ	O
individual	JJ	O
cells	NNS	O
,	,	O
e.g.	NN	O
,	,	O
proliferation	NN	O
,	,	O
migration	NN	O
,	,	O
differentiation	NN	O
,	,	O
or	CC	O
interaction	NN	O
with	IN	O
other	JJ	O
cells	NNS	O
,	,	O
is	VBZ	O
typically	RB	O
governed	VBN	O
by	IN	O
information	NN	O
received	VBN	O
from	IN	O
other	JJ	O
cells	NNS	O
and/or	IN	O
the	DT	O
immediate	JJ	O
environment	NN	O
.	.	O
This	DT	O
information	NN	O
is	VBZ	O
often	RB	O
transmitted	VBN	O
by	IN	O
secreted	JJ	O
polypeptides	NNS	O
(	(	O
for	IN	O
instance	NN	O
,	,	O
mitogenic	JJ	O
factors	NNS	O
,	,	O
survival	JJ	O
factors	NNS	O
,	,	O
cytotoxic	JJ	O
factors	NNS	O
,	,	O
differentiation	NN	O
factors	NNS	O
,	,	O
neuropeptides	NNS	O
,	,	O
and	CC	O
hormones	NNS	O
)	)	O
which	WDT	O
are	VBP	O
,	,	O
in	IN	O
turn	NN	O
,	,	O
received	VBD	O
and	CC	O
interpreted	VBN	O
by	IN	O
diverse	NN	O
cell	NN	O
receptors	NNS	O
or	CC	O
membrane-bound	JJ	O
proteins	NNS	O
.	.	O
Such	JJ	O
membrane-bound	JJ	O
proteins	NNS	O
and	CC	O
cell	NN	O
receptors	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
cytokine	JJ	O
receptors	NNS	O
,	,	O
receptor	NN	O
kinases	NNS	O
,	,	O
receptor	NN	O
phosphatases	NNS	O
,	,	O
receptors	NNS	O
involved	VBN	O
in	IN	O
cell-cell	JJ	O
interactions	NNS	O
,	,	O
and	CC	O
cellular	JJ	O
adhesion	NN	O
molecules	NNS	O
like	IN	O
selectins	NNS	O
and	CC	O
integrins	NNS	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
transduction	NN	O
of	IN	O
signals	NNS	O
that	WDT	O
regulate	VBP	O
cell	NN	O
growth	NN	O
and	CC	O
differentiation	NN	O
is	VBZ	O
regulated	VBN	O
in	IN	O
part	NN	O
by	IN	O
phosphorylation	NN	O
of	IN	O
various	JJ	O
cellular	JJ	O
proteins	NNS	O
.	.	O
Protein	NNP	O
tyrosine	NN	O
kinases	NNS	O
,	,	O
enzymes	NNS	O
that	IN	O
catalyze	VBP	O
that	DT	O
process	NN	O
,	,	O
can	MD	O
also	RB	O
act	VB	O
as	IN	O
growth	NN	O
factor	NN	O
receptors	NNS	O
.	.	O
Examples	NNS	O
include	VBP	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
and	CC	O
nerve	NN	O
growth	NN	O
factor	NN	O
receptor	NN	O
.	.	O
Membrane-bound	JJ	O
proteins	NNS	O
and	CC	O
receptor	NN	O
molecules	NNS	O
have	VBP	O
various	JJ	O
industrial	JJ	O
applications	NNS	O
,	,	O
including	VBG	O
as	IN	O
pharmaceutical	JJ	O
and	CC	O
diagnostic	JJ	O
agents	NNS	O
.	.	O
Receptor	NNP	O
immuno-adhesions	NNS	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
can	MD	O
be	VB	O
employed	VBN	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
to	TO	O
block	VB	O
receptor-ligand	JJ	O
interactions	NNS	O
.	.	O
The	DT	O
membrane-bound	JJ	O
proteins	NNS	O
can	MD	O
also	RB	O
be	VB	O
employed	VBN	O
for	IN	O
screening	NN	O
of	IN	O
potential	JJ	O
peptide	NN	O
or	CC	O
small	JJ	O
molecule	NN	O
inhibitors	NNS	O
of	IN	O
the	DT	O
relevant	JJ	O
receptor/ligand	NN	O
interaction	NN	O
.	.	O
Efforts	NNS	O
are	VBP	O
being	VBG	O
undertaken	VBN	O
by	IN	O
both	DT	O
industry	NN	O
and	CC	O
academia	NN	O
to	TO	O
identify	VB	O
new	JJ	O
,	,	O
native	JJ	O
receptor	NN	O
or	CC	O
membrane-bound	JJ	O
proteins	NNS	O
.	.	O
Many	JJ	O
efforts	NNS	O
are	VBP	O
focused	VBN	O
on	IN	O
the	DT	O
screening	NN	O
of	IN	O
mammalian	JJ	O
recombinant	NN	O
DNA	NNP	O
libraries	VBZ	O
to	TO	O
identify	VB	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
novel	JJ	O
receptor	NN	O
or	CC	O
membrane-bound	JJ	O
proteins	NNS	O
.	.	O
Given	VBN	O
the	DT	O
importance	NN	O
of	IN	O
secreted	JJ	O
and	CC	O
membrane-bound	JJ	O
proteins	NNS	O
in	IN	O
biological	JJ	O
and	CC	O
disease	NN	O
processes	NNS	O
,	,	O
in	IN	O
vivo	JJ	O
studies	NNS	O
and	CC	O
characterizations	NNS	O
may	MD	O
provide	VB	O
valuable	JJ	O
identification	NN	O
and	CC	O
discovery	NN	O
of	IN	O
therapeutics	NNS	O
and/or	JJ	O
treatments	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
prevention	NN	O
,	,	O
amelioration	NN	O
or	CC	O
correction	NN	O
of	IN	O
diseases	NNS	O
or	CC	O
dysfunctions	NNS	O
.	.	O
In	IN	O
this	DT	O
regard	NN	O
,	,	O
genetically	RB	O
engineered	VBN	O
mice	NNS	O
have	VBP	O
proven	VBN	O
to	TO	O
be	VB	O
invaluable	JJ	O
tools	NNS	O
for	IN	O
the	DT	O
functional	JJ	O
dissection	NN	O
of	IN	O
biological	JJ	O
processes	NNS	O
relevant	VBP	O
to	TO	O
human	JJ	O
disease	NN	O
,	,	O
including	VBG	O
immunology	NN	O
,	,	O
cancer	NN	O
,	,	O
neuro-biology	NN	O
,	,	O
cardiovascular	JJ	O
biology	NN	O
,	,	O
obesity	NN	O
and	CC	O
many	JJ	O
others	NNS	O
.	.	O
Gene	NNP	O
knockouts	NNS	O
can	MD	O
be	VB	O
viewed	VBN	O
as	IN	O
modeling	VBG	O
the	DT	O
biological	JJ	O
mechanism	NN	O
of	IN	O
drug	NN	O
action	NN	O
by	IN	O
presaging	VBG	O
the	DT	O
activity	NN	O
of	IN	O
highly	RB	O
specific	JJ	O
antagonists	NNS	O
in	IN	O
vivo	NN	O
.	.	O
Knockout	NNP	O
mice	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
model	VB	O
drug	NN	O
activity	NN	O
;	:	O
phenotypes	NNS	O
of	IN	O
mice	JJ	O
deficient	NN	O
for	IN	O
specific	JJ	O
pharmaceutical	JJ	O
target	NN	O
proteins	NNS	O
can	MD	O
resemble	VB	O
the	DT	O
human	JJ	O
clinical	JJ	O
phenotype	NN	O
caused	VBN	O
by	IN	O
the	DT	O
corresponding	JJ	O
antagonist	JJ	O
drug	NN	O
.	.	O
Gene	NNP	O
knockouts	NNS	O
enable	VBP	O
the	DT	O
discovery	NN	O
of	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
the	DT	O
target	NN	O
,	,	O
the	DT	O
predominant	JJ	O
physiological	JJ	O
role	NN	O
of	IN	O
the	DT	O
target	NN	O
,	,	O
and	CC	O
mechanism-based	JJ	O
side-effects	NNS	O
that	WDT	O
might	MD	O
result	VB	O
from	IN	O
inhibition	NN	O
of	IN	O
the	DT	O
target	NN	O
in	IN	O
mammals	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
this	DT	O
type	NN	O
include	VBP	O
mice	JJ	O
deficient	NN	O
in	IN	O
the	DT	O
angiotensin	NN	O
converting	VBG	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
[	VBZ	O
Esther	NNP	B
,	,	I
C.	NNP	I
R.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Lab	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
74:953-965	NNP	I
(	(	I
1996	CD	I
)	)	I
]	NN	O
and	CC	O
cyclooxygenase-1	NN	O
(	(	O
COX1	NNP	O
)	)	O
genes	NNS	O
[	NNP	O
Langenbach	NNP	B
,	,	I
R.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
,	,	I
83:483-492	CD	I
(	(	I
1995	CD	I
)	)	I
]	NN	O
.	.	O
Conversely	RB	O
,	,	O
knocking	VBG	O
the	DT	O
gene	NN	O
out	RP	O
in	IN	O
the	DT	O
mouse	NN	O
can	MD	O
have	VB	O
an	DT	O
opposite	JJ	O
phenotypic	NN	O
effect	NN	O
to	TO	O
that	DT	O
observed	VBN	O
in	IN	O
humans	NNS	O
after	IN	O
administration	NN	O
of	IN	O
an	DT	O
agonist	JJ	O
drug	NN	O
to	TO	O
the	DT	O
corresponding	JJ	O
target	NN	O
.	.	O
Examples	NNS	O
include	VBP	O
the	DT	O
erythropoietin	NN	O
knockout	NN	O
[	NNP	O
Wu	NNP	B
,	,	I
C.	NNP	I
S.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
,	,	I
83:59-67	CD	I
(	(	I
1996	CD	I
)	)	I
]	NN	O
,	,	O
in	IN	O
which	WDT	O
a	DT	O
consequence	NN	O
of	IN	O
the	DT	O
mutation	NN	O
is	VBZ	O
deficient	JJ	O
red	JJ	O
blood	NN	O
cell	NN	O
production	NN	O
,	,	O
and	CC	O
the	DT	O
GABA	NNP	O
(	(	O
A	NNP	O
)	)	O
-R-β3	NN	O
knockout	NN	O
[	NNP	O
DeLorey	NNP	B
,	,	I
T.	NNP	I
M.	NNP	I
,	,	I
J	NNP	I
.	.	I
Neurosci.	NNP	I
,	,	I
18:8505-8514	CD	I
(	(	I
1998	CD	I
)	)	I
]	NN	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
mutant	NN	O
mice	NN	O
show	NN	O
hyperactivity	NN	O
and	CC	O
hyper-responsiveness	NN	O
.	.	O
Both	DT	O
these	DT	O
phenotypes	NNS	O
are	VBP	O
opposite	JJ	O
to	TO	O
the	DT	O
effects	NNS	O
of	IN	O
erythropoietin	NN	O
and	CC	O
benzodiazepine	JJ	O
administration	NN	O
in	IN	O
humans	NNS	O
.	.	O
A	DT	O
striking	JJ	O
example	NN	O
of	IN	O
a	DT	O
target	NN	O
validated	VBN	O
using	VBG	O
mouse	NN	O
genetics	NNS	O
is	VBZ	O
the	DT	O
ACC2	NNP	O
gene	NN	O
.	.	O
Although	IN	O
the	DT	O
human	JJ	O
ACC2	NNP	O
gene	NN	O
had	VBD	O
been	VBN	O
identified	VBN	O
several	JJ	O
years	NNS	O
ago	RB	O
,	,	O
interest	NN	O
in	IN	O
ACC2	NNP	O
as	IN	O
a	DT	O
target	NN	O
for	IN	O
drug	NN	O
development	NN	O
was	VBD	O
stimulated	VBN	O
only	RB	O
recently	RB	O
after	IN	O
analysis	NN	O
of	IN	O
ACC2	NNP	O
function	NN	O
using	VBG	O
a	DT	O
knockout	NN	O
mouse	NN	O
.	.	O
ACC2	NNP	O
mutant	JJ	O
mice	NN	O
eat	NN	O
more	JJR	O
than	IN	O
their	PRP$	O
wild-type	JJ	O
littermates	NNS	O
,	,	O
yet	RB	O
burn	VBP	O
more	JJR	O
fat	JJ	O
and	CC	O
store	NN	O
less	JJR	O
fat	JJ	O
in	IN	O
their	PRP$	O
adipocytes	NNS	O
,	,	O
making	VBG	O
this	DT	O
enzyme	NN	O
a	DT	O
probable	JJ	O
target	NN	O
for	IN	O
chemical	JJ	O
antagonism	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
obesity	NN	O
[	NNP	O
Abu-Elheiga	NNP	B
,	,	I
L.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
291:2613-2616	CD	I
(	(	I
2001	CD	I
)	)	I
]	NN	O
.	.	O
In	IN	O
the	DT	O
instant	JJ	O
application	NN	O
,	,	O
mutated	VBN	O
gene	NN	O
disruptions	NNS	O
have	VBP	O
resulted	VBN	O
in	IN	O
phenotypic	NN	O
observations	NNS	O
related	VBN	O
to	TO	O
various	JJ	O
disease	JJ	O
conditions	NNS	O
or	CC	O
dysfunctions	NNS	O
including	VBG	O
:	:	O
CNS/neurological	JJ	O
disturbances	NNS	O
or	CC	O
disorders	NNS	O
such	JJ	O
as	IN	O
anxiety	NN	O
;	:	O
eye	NN	O
abnormalities	NNS	O
and	CC	O
associated	JJ	O
diseases	NNS	O
;	:	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
including	VBG	O
atherosclerosis	NN	O
;	:	O
abnormal	JJ	O
metabolic	NN	O
disorders	NNS	O
including	VBG	O
diabetes	NNS	O
and	CC	O
dyslipidemias	NNS	O
associated	VBN	O
with	IN	O
elevated	JJ	O
serum	NN	O
triglycerides	NNS	O
and	CC	O
cholesterol	NN	O
levels	NNS	O
;	:	O
immunological	JJ	O
and	CC	O
inflammatory	JJ	O
disorders	NNS	O
;	:	O
oncological	JJ	O
disorders	NNS	O
;	:	O
bone	CD	O
metabolic	JJ	O
abnormalities	NNS	O
or	CC	O
disorders	NNS	O
such	JJ	O
as	IN	O
arthritis	NN	O
,	,	O
osteoporosis	NN	O
and	CC	O
osteopetrosis	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
embryonic	JJ	O
lethality	NN	O
.	.	O
SUMMARY	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
A.	NN	O
Embodiments	NNP	O
The	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
comprising	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
that	WDT	O
encodes	VBZ	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
comprises	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
a	DT	O
DNA	NN	O
molecule	NN	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
having	VBG	O
a	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
transmembrane	NN	O
protein	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
any	DT	O
other	JJ	O
specifically	RB	O
defined	JJ	O
fragment	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
or	CC	O
(	(	O
b	NN	O
)	)	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
molecule	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
.	.	O
In	IN	O
other	JJ	O
aspects	NNS	O
,	,	O
the	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
comprises	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
a	DT	O
DNA	NN	O
molecule	NN	O
comprising	VBG	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
cDNA	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
transmembrane	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
any	DT	O
other	JJ	O
specifically	RB	O
defined	JJ	O
fragment	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
or	CC	O
(	(	O
b	NN	O
)	)	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
molecule	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
concerns	VBZ	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
comprising	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
a	DT	O
DNA	NN	O
molecule	NN	O
that	WDT	O
encodes	VBZ	O
the	DT	O
same	JJ	O
mature	NN	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
human	JJ	O
protein	NN	O
cDNAs	NN	O
deposited	VBN	O
with	IN	O
the	DT	O
ATCC	NNP	O
as	IN	O
disclosed	VBN	O
herein	NN	O
,	,	O
or	CC	O
(	(	O
b	NN	O
)	)	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
molecule	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
comprising	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
is	VBZ	O
either	DT	O
transmembrane	JJ	O
domain-deleted	JJ	O
or	CC	O
transmembrane	JJ	O
domain-inactivated	JJ	O
,	,	O
or	CC	O
is	VBZ	O
complementary	JJ	O
to	TO	O
such	JJ	O
encoding	JJ	O
nucleotide	JJ	O
sequence	NN	O
,	,	O
wherein	VBP	O
the	DT	O
transmembrane	NN	O
domain	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
such	JJ	O
polypeptide	NN	O
are	VBP	O
disclosed	VBN	O
herein	NN	O
.	.	O
Therefore	RB	O
,	,	O
soluble	JJ	O
extracellular	JJ	O
domains	NNS	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
are	VBP	O
contemplated	VBN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
fragments	NNS	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
coding	VBG	O
sequence	NN	O
,	,	O
or	CC	O
the	DT	O
complement	NN	O
thereof	NN	O
,	,	O
that	WDT	O
may	MD	O
find	VB	O
use	NN	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
hybridization	NN	O
probes	NNS	O
,	,	O
for	IN	O
encoding	VBG	O
fragments	NNS	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
that	DT	O
may	MD	O
optionally	RB	O
encode	VB	O
a	DT	O
polypeptide	NN	O
comprising	VBG	O
a	DT	O
binding	NN	O
site	NN	O
for	IN	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
or	CC	O
as	IN	O
antisense	JJ	O
oligonucleotide	IN	O
probes	NNS	O
.	.	O
Such	JJ	O
nucleic	JJ	O
acid	NN	O
fragments	NNS	O
usually	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
10	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
15	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
30	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
40	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
50	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
60	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
70	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
90	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
100	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
110	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
120	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
130	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
140	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
150	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
160	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
170	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
180	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
190	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
200	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
250	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
300	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
350	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
400	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
450	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
500	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
600	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
700	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
800	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
900	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
and	CC	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
1000	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
wherein	NN	O
in	IN	O
this	DT	O
context	NN	O
the	DT	O
term	NN	O
“	NN	O
about	IN	O
”	NN	O
means	VBZ	O
the	DT	O
referenced	JJ	O
nucleotide	JJ	O
sequence	NN	O
length	NN	O
plus	CC	O
or	CC	O
minus	CC	O
10	CD	O
%	NN	O
of	IN	O
that	DT	O
referenced	VBD	O
length	NN	O
.	.	O
It	PRP	O
is	VBZ	O
noted	VBN	O
that	IN	O
novel	JJ	O
fragments	NNS	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleotide	JJ	O
sequence	NN	O
may	MD	O
be	VB	O
determined	VBN	O
in	IN	O
a	DT	O
routine	JJ	O
manner	NN	O
by	IN	O
aligning	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleotide	JJ	O
sequence	NN	O
with	IN	O
other	JJ	O
known	VBN	O
nucleotide	JJ	O
sequences	NNS	O
using	VBG	O
any	DT	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
well	RB	O
known	VBN	O
sequence	NN	O
alignment	NN	O
programs	NNS	O
and	CC	O
determining	VBG	O
which	WDT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleotide	JJ	O
sequence	NN	O
fragment	NN	O
(	(	O
s	NN	O
)	)	O
are	VBP	O
novel	JJ	O
.	.	O
All	DT	O
of	IN	O
such	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleotide	NN	O
sequences	NNS	O
are	VBP	O
contemplated	VBN	O
herein	NN	O
.	.	O
Also	RB	O
contemplated	VBN	O
are	VBP	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
fragments	NNS	O
encoded	VBN	O
by	IN	O
these	DT	O
nucleotide	JJ	O
molecule	NN	O
fragments	NNS	O
,	,	O
preferably	RB	O
those	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
fragments	NNS	O
that	WDT	O
comprise	VBP	O
a	DT	O
binding	NN	O
site	NN	O
for	IN	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
isolated	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
encoded	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
hereinabove	VBP	O
identified	VBN	O
.	.	O
In	IN	O
a	DT	O
certain	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
concerns	VBZ	O
an	DT	O
isolated	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
comprising	VBG	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
having	VBG	O
a	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
transmembrane	NN	O
protein	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
any	DT	O
other	JJ	O
specifically	RB	O
defined	JJ	O
fragment	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
concerns	VBZ	O
an	DT	O
isolated	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
comprising	VBG	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
to	TO	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
encoded	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
human	JJ	O
protein	NN	O
cDNAs	NN	O
deposited	VBN	O
with	IN	O
the	DT	O
ATCC	NNP	O
as	IN	O
disclosed	VBN	O
herein	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
concerns	NNS	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	NN	O
polypeptides	NNS	O
which	WDT	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
10	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
20	CD	O
,	,	O
30	CD	O
,	,	O
40	CD	O
,	,	O
50	CD	O
,	,	O
60	CD	O
,	,	O
70	CD	O
,	,	O
80	CD	O
,	,	O
90	CD	O
,	,	O
100	CD	O
,	,	O
110	CD	O
,	,	O
120	CD	O
,	,	O
130	CD	O
,	,	O
140	CD	O
,	,	O
150	CD	O
,	,	O
160	CD	O
,	,	O
170	CD	O
,	,	O
180	CD	O
,	,	O
190	CD	O
,	,	O
200	CD	O
,	,	O
210	CD	O
,	,	O
220	CD	O
,	,	O
230	CD	O
,	,	O
240	CD	O
,	,	O
250	CD	O
,	,	O
260	CD	O
,	,	O
270	CD	O
,	,	O
280	CD	O
,	,	O
290	CD	O
,	,	O
300	CD	O
,	,	O
310	CD	O
,	,	O
320	CD	O
,	,	O
330	CD	O
,	,	O
340	CD	O
,	,	O
350	CD	O
,	,	O
360	CD	O
,	,	O
370	CD	O
,	,	O
380	CD	O
,	,	O
390	CD	O
,	,	O
400	CD	O
,	,	O
410	CD	O
,	,	O
420	CD	O
,	,	O
430	CD	O
,	,	O
440	CD	O
,	,	O
450	CD	O
,	,	O
460	CD	O
,	,	O
470	CD	O
,	,	O
480	CD	O
,	,	O
490	CD	O
,	,	O
500	CD	O
,	,	O
510	CD	O
,	,	O
520	CD	O
,	,	O
530	CD	O
,	,	O
540	CD	O
,	,	O
550	CD	O
,	,	O
560	CD	O
,	,	O
570	CD	O
,	,	O
580	CD	O
,	,	O
590	CD	O
,	,	O
600	CD	O
amino	NN	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
or	CC	O
more	JJR	O
.	.	O
Optionally	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polypeptides	NNS	O
will	MD	O
have	VB	O
or	CC	O
have	VB	O
no	DT	O
more	JJR	O
than	IN	O
one	CD	O
conservative	JJ	O
amino	NN	O
acid	JJ	O
substitution	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
sequence	NN	O
,	,	O
alternatively	RB	O
will	MD	O
have	VB	O
or	CC	O
will	MD	O
have	VB	O
no	DT	O
more	JJR	O
than	IN	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
or	CC	O
10	CD	O
conservative	JJ	O
amino	NN	O
acid	JJ	O
substitution	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
sequence	NN	O
.	.	O
In	IN	O
a	DT	O
specific	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
without	IN	O
the	DT	O
N-terminal	JJ	O
signal	JJ	O
sequence	NN	O
and/or	VBD	O
the	DT	O
initiating	NN	O
methionine	NN	O
and	CC	O
is	VBZ	O
encoded	VBN	O
by	IN	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
that	WDT	O
encodes	VBZ	O
such	PDT	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
hereinbefore	NN	O
described	NN	O
.	.	O
Processes	NNS	O
for	IN	O
producing	VBG	O
the	DT	O
same	JJ	O
are	VBP	O
also	RB	O
herein	RB	O
described	VBN	O
,	,	O
wherein	VBP	O
those	DT	O
processes	NNS	O
comprise	VBP	O
culturing	VBG	O
a	DT	O
host	NN	O
cell	NN	O
comprising	VBG	O
a	DT	O
vector	NN	O
which	WDT	O
comprises	VBZ	O
the	DT	O
appropriate	JJ	O
encoding	NN	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
under	IN	O
conditions	NNS	O
suitable	JJ	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
recovering	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
from	IN	O
the	DT	O
cell	NN	O
culture	NN	O
.	.	O
Another	DT	O
aspect	VBP	O
the	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
is	VBZ	O
either	DT	O
transmembrane	JJ	O
domain-deleted	JJ	O
or	CC	O
transmembrane	JJ	O
domain-inactivated	JJ	O
.	.	O
Processes	NNS	O
for	IN	O
producing	VBG	O
the	DT	O
same	JJ	O
are	VBP	O
also	RB	O
herein	RB	O
described	VBN	O
,	,	O
wherein	VBP	O
those	DT	O
processes	NNS	O
comprise	VBP	O
culturing	VBG	O
a	DT	O
host	NN	O
cell	NN	O
comprising	VBG	O
a	DT	O
vector	NN	O
which	WDT	O
comprises	VBZ	O
the	DT	O
appropriate	JJ	O
encoding	NN	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
under	IN	O
conditions	NNS	O
suitable	JJ	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
recovering	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
from	IN	O
the	DT	O
cell	NN	O
culture	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
agonists	NNS	O
and	CC	O
antagonists	NNS	O
of	IN	O
a	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
defined	VBN	O
herein	NN	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
the	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
or	CC	O
a	DT	O
small	JJ	O
molecule	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
comprise	NN	O
contacting	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
with	IN	O
a	DT	O
candidate	NN	O
molecule	NN	O
and	CC	O
monitoring	VBG	O
a	DT	O
biological	JJ	O
activity	NN	O
mediated	VBN	O
by	IN	O
said	VBD	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
a	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
composition	NN	O
of	IN	O
matter	NN	O
comprising	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
or	CC	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
herein	NN	O
described	VBD	O
,	,	O
or	CC	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
carrier	NN	O
.	.	O
Optionally	RB	O
,	,	O
the	DT	O
carrier	NN	O
is	VBZ	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
or	CC	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	JJ	O
thereof	NN	O
as	IN	O
hereinbefore	NN	O
described	NN	O
,	,	O
or	CC	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
,	,	O
for	IN	O
the	DT	O
preparation	NN	O
of	IN	O
a	DT	O
medicament	NN	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
condition	NN	O
which	WDT	O
is	VBZ	O
responsive	JJ	O
to	TO	O
the	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
vectors	NNS	O
comprising	VBG	O
DNA	NNP	O
encoding	VBG	O
any	DT	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
polypeptides	NNS	O
.	.	O
Host	NNP	O
cell	NN	O
comprising	VBG	O
any	DT	O
such	JJ	O
vector	NN	O
are	VBP	O
also	RB	O
provided	VBN	O
.	.	O
By	IN	O
way	NN	O
of	IN	O
example	NN	O
,	,	O
the	DT	O
host	NN	O
cells	NNS	O
may	MD	O
be	VB	O
CHO	NNP	O
cells	NNS	O
,	,	O
E.	NNP	O
coli	NNS	O
,	,	O
or	CC	O
yeast	NN	O
.	.	O
A	DT	O
process	NN	O
for	IN	O
producing	VBG	O
any	DT	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
polypeptides	NNS	O
is	VBZ	O
further	JJ	O
provided	VBN	O
and	CC	O
comprises	VBZ	O
culturing	VBG	O
host	NN	O
cells	NNS	O
under	IN	O
conditions	NNS	O
suitable	JJ	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
desired	JJ	O
polypeptide	NN	O
and	CC	O
recovering	VBG	O
the	DT	O
desired	VBN	O
polypeptide	NN	O
from	IN	O
the	DT	O
cell	NN	O
culture	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
chimeric	JJ	O
molecules	NNS	O
comprising	VBG	O
any	DT	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
polypeptides	NNS	O
fused	VBN	O
to	TO	O
a	DT	O
heterologous	JJ	O
polypeptide	NN	O
or	CC	O
amino	NN	O
acid	JJ	O
sequence	NN	O
.	.	O
Example	NN	O
of	IN	O
such	JJ	O
chimeric	JJ	O
molecules	NNS	O
comprise	VBP	O
any	DT	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
polypeptides	NNS	O
fused	VBN	O
to	TO	O
an	DT	O
epitope	NN	O
tag	NN	O
sequence	NN	O
or	CC	O
a	DT	O
Fc	JJ	O
region	NN	O
of	IN	O
an	DT	O
immunoglobulin	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
antibody	NN	O
which	WDT	O
binds	VBZ	O
,	,	O
preferably	RB	O
specifically	RB	O
,	,	O
to	TO	O
any	DT	O
of	IN	O
the	DT	O
above	NN	O
or	CC	O
below	IN	O
described	VBN	O
polypeptides	NNS	O
.	.	O
Optionally	RB	O
,	,	O
the	DT	O
antibody	NN	O
is	VBZ	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
,	,	O
humanized	VBN	O
antibody	NN	O
,	,	O
antibody	NN	O
fragment	NN	O
or	CC	O
single-chain	NN	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
oligonucleotide	IN	O
probes	NNS	O
which	WDT	O
may	MD	O
be	VB	O
useful	JJ	O
for	IN	O
isolating	VBG	O
genomic	JJ	O
and	CC	O
cDNA	JJ	O
nucleotide	NN	O
sequences	NNS	O
,	,	O
measuring	VBG	O
or	CC	O
detecting	VBG	O
expression	NN	O
of	IN	O
an	DT	O
associated	JJ	O
gene	NN	O
or	CC	O
as	IN	O
antisense	JJ	O
probes	NNS	O
,	,	O
wherein	VBP	O
those	DT	O
probes	NNS	O
may	MD	O
be	VB	O
derived	VBN	O
from	IN	O
any	DT	O
of	IN	O
the	DT	O
above	NN	O
or	CC	O
below	IN	O
described	VBN	O
nucleotide	JJ	O
sequences	NNS	O
.	.	O
Preferred	NNP	O
probe	NN	O
lengths	NNS	O
are	VBP	O
described	VBN	O
above	IN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
phenotype	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
is	VBZ	O
a	DT	O
mammal	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
mammal	NN	O
is	VBZ	O
a	DT	O
rodent	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
mammal	NN	O
is	VBZ	O
a	DT	O
rat	NN	O
or	CC	O
a	DT	O
mouse	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
is	VBZ	O
heterozygous	JJ	O
for	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
phenotype	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
as	IN	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“	JJ	O
anxiety	NN	O
disorders	NNS	O
”	VBP	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(	(	O
circadian	JJ	O
test	NN	O
)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding	NN	O
,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations	NNS	O
;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
and	CC	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level	NN	O
;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells	NNS	O
,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta	NNP	O
,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
decreased	JJ	O
thickness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density	NN	O
;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area	NN	O
;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass	NN	O
,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat	JJ	O
;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM	NNP	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2a	NNP	O
,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
cell	NN	O
derived	VBN	O
from	IN	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
isolated	JJ	O
cell	NN	O
is	VBZ	O
a	DT	O
murine	NN	O
cell	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
murine	NN	O
cell	NN	O
is	VBZ	O
an	DT	O
embryonic	JJ	O
stem	NN	O
cell	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
isolated	JJ	O
cell	NN	O
is	VBZ	O
derived	VBN	O
from	IN	O
a	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
which	WDT	O
exhibits	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
phenotypes	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(	(	O
b	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
phenotype	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
;	:	O
(	(	O
d	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
and	CC	O
(	(	O
e	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
modulates	VBZ	O
the	DT	O
identified	JJ	O
phenotype	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
comprises	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“	JJ	O
anxiety	NN	O
disorders	NNS	O
”	VBP	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
,	,	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(	(	O
circadian	JJ	O
test	NN	O
)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding	NN	O
,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations	NNS	O
;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
and	CC	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level	NN	O
;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells	NNS	O
,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta	NNP	O
,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
decreased	JJ	O
thickness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density	NN	O
;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area	NN	O
;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass	NN	O
,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat	JJ	O
;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM	NNP	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2a	NNP	O
,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
which	WDT	O
modulates	VBZ	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(	(	O
b	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
;	:	O
(	(	O
d	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
and	CC	O
(	(	O
e	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
is	VBZ	O
modulated	VBN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(	(	O
circadian	JJ	O
test	NN	O
)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding	NN	O
,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations	NNS	O
;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
and	CC	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level	NN	O
;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells	NNS	O
,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta	NNP	O
,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
decreased	JJ	O
thickness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density	NN	O
;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area	NN	O
;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass	NN	O
,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat	JJ	O
;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM	NNP	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2a	NNP	O
,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
which	WDT	O
modulates	VBZ	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
observing	VBG	O
the	DT	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
observed	JJ	O
behavior	NN	O
of	IN	O
(	(	O
b	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
observed	JJ	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
observed	JJ	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
;	:	O
(	(	O
d	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
and	CC	O
(	(	O
e	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
modulates	VBZ	O
the	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
includes	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Such	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“	JJ	O
anxiety	NN	O
disorders	NNS	O
”	VBP	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
behavior	NN	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
said	VBD	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
the	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
eye	NN	O
abnormality	NN	O
;	:	O
immunological	JJ	O
disorder	NN	O
;	:	O
oncological	JJ	O
disorder	NN	O
;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“	JJ	O
anxiety	NN	O
disorders	NNS	O
”	VBP	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(	(	O
circadian	JJ	O
test	NN	O
)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding	NN	O
,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations	NNS	O
;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
and	CC	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level	NN	O
;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells	NNS	O
,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta	NNP	O
,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
decreased	JJ	O
thickness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density	NN	O
;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area	NN	O
;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass	NN	O
,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat	JJ	O
;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM	NNP	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2a	NNP	O
,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
contacting	VBG	O
a	DT	O
test	NN	O
agent	NN	O
with	IN	O
a	DT	O
host	NN	O
cell	NN	O
expressing	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
;	:	O
and	CC	O
(	(	O
b	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
by	IN	O
the	DT	O
host	NN	O
cell	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
evaluating	VBG	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
capable	JJ	O
of	IN	O
affecting	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(	(	O
b	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
condition	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
;	:	O
(	(	O
d	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
and	CC	O
(	(	O
e	NN	O
)	)	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
on	IN	O
the	DT	O
identified	JJ	O
condition	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
condition	NN	O
is	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
which	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
affecting	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
pharmaceutical	JJ	O
composition	NN	O
comprising	VBG	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
capable	JJ	O
of	IN	O
affecting	VBG	O
the	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
immunological	JJ	O
disorder	NN	O
;	:	O
oncological	JJ	O
disorder	NN	O
;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
,	,	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	NN	O
in	IN	O
need	NN	O
of	IN	O
such	JJ	O
treatment	NN	O
whom	WP	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
disorder	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
disorder	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
disorder	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
said	VBD	O
disorder	NN	O
or	CC	O
disease	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“	JJ	O
anxiety	NN	O
disorders	NNS	O
”	VBP	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
cell	NN	O
culture	NN	O
,	,	O
each	DT	O
cell	NN	O
of	IN	O
said	VBD	O
culture	NN	O
comprising	VBG	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
said	VBD	O
cell	JJ	O
culture	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
the	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
eye	NN	O
abnormality	NN	O
;	:	O
immunological	JJ	O
disorder	NN	O
;	:	O
oncological	JJ	O
disorder	NN	O
;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
developmental	JJ	O
abnormality	NN	O
in	IN	O
said	VBD	O
culture	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“	JJ	O
anxiety	NN	O
disorders	NNS	O
”	VBP	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
said	VBD	O
culture	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
genewhich	JJ	O
encodes	NNS	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
phenotype	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
phenotype	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
phenotype	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
phenotype	NN	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
phenotype	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
exhibit	VB	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
exhibit	VB	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
physiological	JJ	O
characteristic	NN	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
genewhich	JJ	O
encodes	NNS	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
exhibit	VB	O
the	DT	O
behavior	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
exhibit	VB	O
the	DT	O
behavior	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
exhibited	JJ	O
behavior	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
behavior	NN	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
behavior	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
host	NN	O
cell	NN	O
expressing	VBG	O
said	VBD	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
expression	NN	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
said	VBD	O
polypeptide	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
have	VB	O
the	DT	O
condition	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
condition	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
condition	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
condition	NN	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
condition	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
immunological	JJ	O
disorder	NN	O
;	:	O
oncological	JJ	O
disorder	NN	O
;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
,	,	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
cell	NN	O
culture	NN	O
,	,	O
each	DT	O
cell	NN	O
of	IN	O
said	VBD	O
culture	NN	O
comprising	VBG	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
treating	NN	O
or	CC	O
preventing	NN	O
or	CC	O
ameliorating	NN	O
said	VBD	O
disorder	NN	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
said	VBD	O
disorder	NN	O
.	.	O
In	IN	O
yet	RB	O
further	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
the	DT	O
following	JJ	O
set	NN	O
of	IN	O
potential	JJ	O
claims	NNS	O
for	IN	O
this	DT	O
application	NN	O
:	:	O
1	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
phenotype	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
.	.	O
2	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
1	CD	O
,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
is	VBZ	O
heterozygous	JJ	O
for	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
3	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
1	CD	O
,	,	O
wherein	VBD	O
the	DT	O
phenotype	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
as	IN	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
4	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
5	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
6	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
7	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
8	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
9	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
10	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
11	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
12	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
10	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
.	.	O
13	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
10	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
14	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
10	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
15	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
16	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
15	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
17	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
18	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
19	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonias	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
20	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3	CD	O
,	,	O
wherein	VBD	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
21	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
1	CD	O
,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(	(	O
circadian	JJ	O
test	NN	O
)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding	NN	O
,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations	NNS	O
;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
and	CC	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level	NN	O
;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells	NNS	O
,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta	NNP	O
,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
decreased	JJ	O
thickness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density	NN	O
;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area	NN	O
;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass	NN	O
,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat	JJ	O
;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM	NNP	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2a	NNP	O
,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
22	CD	O
.	.	O
An	DT	O
isolated	JJ	O
cell	NN	O
derived	VBN	O
from	IN	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
23	CD	O
.	.	O
The	DT	O
isolated	JJ	O
cell	NN	O
of	IN	O
claim	NN	O
22	CD	O
which	WDT	O
is	VBZ	O
a	DT	O
murine	NN	O
cell	NN	O
.	.	O
24	CD	O
.	.	O
The	DT	O
isolated	JJ	O
cell	NN	O
of	IN	O
claim	NN	O
23	CD	O
,	,	O
wherein	VBD	O
the	DT	O
murine	NN	O
cell	NN	O
is	VBZ	O
an	DT	O
embryonic	JJ	O
stem	NN	O
cell	NN	O
.	.	O
25	CD	O
.	.	O
The	DT	O
isolated	JJ	O
cell	NN	O
of	IN	O
claim	NN	O
22	CD	O
,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
phenotypes	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
26	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(	(	O
b	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
phenotype	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
;	:	O
(	(	O
d	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
and	CC	O
(	(	O
e	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
modulates	VBZ	O
the	DT	O
identified	JJ	O
phenotype	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
.	.	O
27	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
26	CD	O
,	,	O
wherein	VBD	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
comprises	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
28	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
29	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
30	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
31	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
32	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
33	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
34	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
35	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
36	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
34	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
.	.	O
37	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
34	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
38	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
34	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
39	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
40	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
39	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
41	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
42	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
43	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation-associated	JJ	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
44	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27	CD	O
,	,	O
wherein	NN	O
said	VBD	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
45	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
26	CD	O
,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(	(	O
circadian	JJ	O
test	NN	O
)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding	NN	O
,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations	NNS	O
;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
and	CC	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level	NN	O
;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells	NNS	O
,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta	NNP	O
,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
decreased	JJ	O
thickness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density	NN	O
;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area	NN	O
;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass	NN	O
,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat	JJ	O
;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM	NNP	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2a	NNP	O
,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
46	CD	O
.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
26	CD	O
.	.	O
47	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
46	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
48	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
47	CD	O
,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
49	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
47	CD	O
,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
50	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(	(	O
b	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
;	:	O
(	(	O
d	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
and	CC	O
(	(	O
e	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
is	VBZ	O
modulated	VBN	O
.	.	O
51	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
50	CD	O
,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(	(	O
circadian	JJ	O
test	NN	O
)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding	NN	O
,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations	NNS	O
;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
and	CC	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level	NN	O
;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells	NNS	O
,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta	NNP	O
,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
decreased	JJ	O
thickness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density	NN	O
;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area	NN	O
;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass	NN	O
,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat	JJ	O
;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM	NNP	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2a	NNP	O
,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
52	CD	O
.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
50	CD	O
.	.	O
53	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
52	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
54	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
53	CD	O
,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
55	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
53	CD	O
,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
56	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
which	WDT	O
modulates	VBZ	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
observing	VBG	O
the	DT	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
observed	JJ	O
behavior	NN	O
of	IN	O
(	(	O
b	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
observed	JJ	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
observed	JJ	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
;	:	O
(	(	O
d	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
and	CC	O
(	(	O
e	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
modulates	VBZ	O
the	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
.	.	O
57	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56	CD	O
,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
58	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56	CD	O
,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
59	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56	CD	O
,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
60	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56	CD	O
,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
61	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56	CD	O
,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
62	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56	CD	O
,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
63	CD	O
.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
56	CD	O
.	.	O
64	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
63	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
65	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
64	CD	O
,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
66	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
64	CD	O
,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
67	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
said	VBD	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
determining	VBG	O
whether	IN	O
said	VBD	O
test	NN	O
agent	NN	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
the	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
eye	NN	O
abnormality	NN	O
;	:	O
immunological	JJ	O
disorder	NN	O
;	:	O
oncological	JJ	O
disorder	NN	O
;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
developmental	JJ	O
abnormality	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
.	.	O
68	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
69	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
70	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
71	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
72	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
73	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
74	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
75	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
76	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
74	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
.	.	O
77	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
74	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
78	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
74	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
79	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
80	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
79	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
81	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
82	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
83	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
84	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	NN	O
said	VBD	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
85	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(	(	O
circadian	JJ	O
test	NN	O
)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding	NN	O
,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations	NNS	O
;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
and	CC	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level	NN	O
;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells	NNS	O
,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta	NNP	O
,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge	NN	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing	VBG	O
;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
decreased	JJ	O
thickness	NN	O
,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density	NN	O
;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area	NN	O
;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass	NN	O
,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat	JJ	O
;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM	NNP	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2a	NNP	O
,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels	NNS	O
;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
86	CD	O
.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
.	.	O
87	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
82	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
88	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
87	CD	O
,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
89	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
87	CD	O
,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
90	CD	O
.	.	O
A	DT	O
therapeutic	JJ	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
67	CD	O
.	.	O
91	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
contacting	VBG	O
a	DT	O
test	NN	O
agent	NN	O
with	IN	O
a	DT	O
host	NN	O
cell	NN	O
expressing	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
;	:	O
and	CC	O
(	(	O
b	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
by	IN	O
the	DT	O
host	NN	O
cell	NN	O
.	.	O
92	CD	O
.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
91	CD	O
.	.	O
93	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
92	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
94	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
93	CD	O
,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
95	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
93	CD	O
,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
96	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
evaluating	VBG	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
capable	JJ	O
of	IN	O
affecting	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
(	(	O
c	NN	O
)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(	(	O
b	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal	NN	O
,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
condition	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
;	:	O
(	(	O
d	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(	(	O
a	DT	O
)	)	O
;	:	O
and	CC	O
(	(	O
e	NN	O
)	)	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
on	IN	O
the	DT	O
identified	JJ	O
condition	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
.	.	O
97	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
96	CD	O
,	,	O
wherein	VBD	O
the	DT	O
condition	NN	O
is	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
.	.	O
98	CD	O
.	.	O
A	DT	O
therapeutic	JJ	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
96	CD	O
.	.	O
99	CD	O
.	.	O
The	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
98	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
100	CD	O
.	.	O
The	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
99	CD	O
,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
101	CD	O
.	.	O
The	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
99	CD	O
,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
102	CD	O
.	.	O
A	DT	O
pharmaceutical	JJ	O
composition	NN	O
comprising	VBG	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
98	CD	O
.	.	O
103	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
immunological	JJ	O
disorder	NN	O
;	:	O
oncological	JJ	O
disorder	NN	O
;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
,	,	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	NN	O
in	IN	O
need	NN	O
of	IN	O
such	JJ	O
treatment	NN	O
whom	WP	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
disorder	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
disorder	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
disorder	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
94	CD	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
said	VBD	O
disorder	NN	O
.	.	O
104	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
105	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
106	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
107	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
108	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
109	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
110	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
111	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
112	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
110	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
.	.	O
113	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
110	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
114	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
110	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
115	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
116	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
115	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
117	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
118	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
iseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
119	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
120	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103	CD	O
,	,	O
wherein	NN	O
said	VBD	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
121	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
eye	NN	O
abnormality	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
cell	NN	O
culture	NN	O
,	,	O
each	DT	O
cell	NN	O
of	IN	O
said	VBD	O
culture	NN	O
comprising	VBG	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
said	VBD	O
cell	JJ	O
culture	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
determining	VBG	O
whether	IN	O
said	VBD	O
test	NN	O
agent	NN	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
the	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
eye	NN	O
abnormality	NN	O
;	:	O
immunological	JJ	O
disorder	NN	O
;	:	O
oncological	JJ	O
disorder	NN	O
;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
;	:	O
lipid	JJ	O
metabolic	JJ	O
disorder	NN	O
;	:	O
or	CC	O
developmental	JJ	O
abnormality	NN	O
in	IN	O
said	VBD	O
cell	NN	O
culture	NN	O
.	.	O
122	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
123	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
124	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
.	.	O
125	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
126	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing	VBG	O
.	.	O
127	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
128	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality	NN	O
.	.	O
129	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
130	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
128	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
.	.	O
131	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
128	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
.	.	O
132	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
128	CD	O
,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
,	,	O
retrolental	JJ	O
fibroplasia	NN	O
,	,	O
neovascular	JJ	O
glaucoma	NN	O
,	,	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
,	,	O
corneal	JJ	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
neovascularization	NN	O
,	,	O
corneal	NN	O
graft	NN	O
rejection	NN	O
,	,	O
retinal/choroidal	JJ	O
neovascularization	NN	O
,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(	(	O
rubeosis	NN	O
)	)	O
,	,	O
ocular	JJ	O
neovascular	JJ	O
disease	NN	O
,	,	O
vascular	JJ	O
restenosis	NN	O
,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(	(	O
AVM	NNP	O
)	)	O
,	,	O
meningioma	UH	O
,	,	O
hemangioma	NN	O
,	,	O
angiofibroma	NN	O
,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(	(	O
including	VBG	O
Grave	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
133	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract	NN	O
.	.	O
134	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
133	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
135	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability	NN	O
.	.	O
136	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	VBP	O
;	:	O
papilledema	NN	O
;	:	O
optic	JJ	O
atrophy	NN	O
;	:	O
atherosclerosis	NN	O
;	:	O
angina	CC	O
;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
;	:	O
hypertension	NN	O
;	:	O
inflammatory	JJ	O
vasculitides	NNS	O
;	:	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
;	:	O
tumor	CC	O
angiogenesis	NN	O
;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
cerebrovascular	JJ	O
disease	NN	O
;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
137	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis	NN	O
;	:	O
rheumatoid	JJ	O
arthritis	NN	O
;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
;	:	O
spondyloarthropathies	NNS	O
;	:	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	JJ	O
)	)	O
;	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
;	:	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
systemic	JJ	O
vasculitis	NN	O
;	:	O
sarcoidosis	NN	O
;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
;	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
;	:	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
;	:	O
diabetes	VBZ	O
mellitus	VBP	O
;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
;	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
;	:	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O
138	CD	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
,	,	O
wherein	NN	O
said	VBD	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis	RB	O
,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis	NN	O
.	.	O
139	CD	O
.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
.	.	O
140	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
139	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
141	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
140	CD	O
,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
142	CD	O
.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
140	CD	O
,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
.	.	O
143	CD	O
.	.	O
A	DT	O
therapeutic	JJ	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
121	CD	O
.	.	O
144	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
phenotype	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
phenotype	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
phenotype	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
46	CD	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
phenotype	NN	O
.	.	O
145	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
exhibit	VB	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
exhibit	VB	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
52	CD	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
.	.	O
146	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
exhibit	VB	O
the	DT	O
behavior	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
exhibit	VB	O
the	DT	O
behavior	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
exhibited	JJ	O
behavior	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
63	CD	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
behavior	NN	O
.	.	O
147	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
host	NN	O
cell	NN	O
expressing	VBG	O
said	VBD	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
92	CD	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
said	VBD	O
polypeptide	NN	O
.	.	O
148	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
have	VB	O
the	DT	O
condition	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
condition	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
condition	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
98	CD	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
condition	NN	O
.	.	O
149	CD	O
.	.	O
A	DT	O
method	NN	O
of	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
immunological	JJ	O
disorder	NN	O
;	:	O
oncological	JJ	O
disorder	NN	O
;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
,	,	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
cell	NN	O
culture	NN	O
,	,	O
each	DT	O
cell	NN	O
of	IN	O
said	VBD	O
culture	NN	O
comprising	VBG	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
139	CD	O
,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof	VBP	O
,	,	O
thereby	RB	O
effectively	RB	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
said	VBD	O
disorder	NN	O
.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIG	NNP	O
.	.	O
1	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA33786-1132	NNP	O
”	NNP	O
(	(	O
UNQ201	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
2	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
FIG	NNP	O
.	.	O
3	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO233	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA34436-1238	NNP	O
”	NNP	O
(	(	O
UNQ207	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
4	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
3	CD	O
.	.	O
FIG	NNP	O
.	.	O
5	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO238	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA35600-1162	NNP	O
”	NNP	O
(	(	O
UNQ212	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
6	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
5	CD	O
.	.	O
FIG	NNP	O
.	.	O
7	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO1328	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA66658-1584	NNP	O
”	NNP	O
(	(	O
UNQ688	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
8	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
7	CD	O
.	.	O
FIG	NNP	O
.	.	O
9	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO4342	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA96787-2534-1	NNP	O
”	NNP	O
(	(	O
UNQ1896	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
10	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
9	CD	O
.	.	O
FIG	NNP	O
.	.	O
11	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:11	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO7423	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:11	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA108809	NNP	O
”	NNP	O
(	(	O
UNQ2964	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
12	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:12	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:11	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
11	CD	O
.	.	O
FIG	NNP	O
.	.	O
13	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:13	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO10096	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:13	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA125185-2806	NNP	O
”	NNP	O
(	(	O
UNQ3099	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
14	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:14	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:13	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
13	CD	O
.	.	O
FIG	NNP	O
.	.	O
15	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO21384	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA177313-2982	NNP	O
”	NNP	O
(	(	O
UNQ6368	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
16	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:16	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
15	CD	O
.	.	O
FIG	NNP	O
.	.	O
17	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO353	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA41234-1242-1	NNP	O
”	NNP	O
(	(	O
UNQ310	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
18	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:18	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
17	CD	O
.	.	O
FIG	NNP	O
.	.	O
19	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:19	NNP	O
)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO1885	NNP	O
cDNA	NN	O
,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:19	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“	JJ	O
DNA79302-2521	NNP	O
”	NNP	O
(	(	O
UNQ868	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
20	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:19	NNP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
19	CD	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
PREFERRED	NNP	O
EMBODIMENTS	NNP	O
I.	NNP	O
Definitions	NNP	O
The	DT	O
terms	NNS	O
“	VBP	O
PRO	NNP	O
polypeptide	FW	O
”	NNP	O
and	CC	O
“	NNP	O
PRO	NNP	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
and	CC	O
when	WRB	O
immediately	RB	O
followed	VBN	O
by	IN	O
a	DT	O
numerical	JJ	O
designation	NN	O
refer	NN	O
to	TO	O
various	JJ	O
polypeptides	NNS	O
,	,	O
wherein	VBP	O
the	DT	O
complete	JJ	O
designation	NN	O
(	(	O
i.e.	FW	O
,	,	O
PRO/number	NNP	O
)	)	O
refers	NNS	O
to	TO	O
specific	JJ	O
polypeptide	JJ	O
sequences	NNS	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
The	DT	O
terms	NNS	O
“	VBP	O
PRO/number	NNP	O
polypeptide	NN	O
”	NNP	O
and	CC	O
“	NNP	O
PRO/number	NNP	O
”	NNP	O
wherein	VBD	O
the	DT	O
term	NN	O
“	NNP	O
number	NN	O
”	NNP	O
is	VBZ	O
provided	VBN	O
as	IN	O
an	DT	O
actual	JJ	O
numerical	JJ	O
designation	NN	O
as	IN	O
used	VBN	O
herein	NN	O
encompass	NN	O
native	JJ	O
sequence	NN	O
polypeptides	NNS	O
and	CC	O
polypeptide	JJ	O
variants	NNS	O
(	(	O
which	WDT	O
are	VBP	O
further	RBR	O
defined	JJ	O
herein	NN	O
)	)	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
described	VBD	O
herein	NN	O
may	MD	O
be	VB	O
isolated	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
sources	NNS	O
,	,	O
such	JJ	O
as	IN	O
from	IN	O
human	JJ	O
tissue	NN	O
types	NNS	O
or	CC	O
from	IN	O
another	DT	O
source	NN	O
,	,	O
or	CC	O
prepared	VBN	O
by	IN	O
recombinant	NN	O
or	CC	O
synthetic	JJ	O
methods	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
PRO	NNP	O
polypeptide	FW	O
”	NN	O
refers	NNS	O
to	TO	O
each	DT	O
individual	JJ	O
PRO/number	NNP	O
polypeptide	NN	O
disclosed	VBD	O
herein	NN	O
.	.	O
All	DT	O
disclosures	VBZ	O
in	IN	O
this	DT	O
specification	NN	O
which	WDT	O
refer	VBP	O
to	TO	O
the	DT	O
“	JJ	O
PRO	NNP	O
polypeptide	NN	O
”	NN	O
refer	NN	O
to	TO	O
each	DT	O
of	IN	O
the	DT	O
polypeptides	NNS	O
individually	RB	O
as	RB	O
well	RB	O
as	IN	O
jointly	RB	O
.	.	O
For	IN	O
example	NN	O
,	,	O
descriptions	NNS	O
of	IN	O
the	DT	O
preparation	NN	O
of	IN	O
,	,	O
purification	NN	O
of	IN	O
,	,	O
derivation	NN	O
of	IN	O
,	,	O
formation	NN	O
of	IN	O
antibodies	NNS	O
to	TO	O
or	CC	O
against	IN	O
,	,	O
administration	NN	O
of	IN	O
,	,	O
compositions	NNS	O
containing	VBG	O
,	,	O
treatment	NN	O
of	IN	O
a	DT	O
disease	NN	O
with	IN	O
,	,	O
etc.	FW	O
,	,	O
pertain	VBP	O
to	TO	O
each	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
individually	RB	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
PRO	NNP	O
polypeptide	NN	O
”	NNP	O
also	RB	O
includes	VBZ	O
variants	NNS	O
of	IN	O
the	DT	O
PRO/number	NNP	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
.	.	O
A	DT	O
“	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
”	NNP	O
comprises	VBZ	O
a	DT	O
polypeptide	NN	O
having	VBG	O
the	DT	O
same	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
the	DT	O
corresponding	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
derived	VBN	O
from	IN	O
nature	NN	O
.	.	O
Such	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
can	MD	O
be	VB	O
isolated	VBN	O
from	IN	O
nature	NN	O
or	CC	O
can	MD	O
be	VB	O
produced	VBN	O
by	IN	O
recombinant	NN	O
or	CC	O
synthetic	JJ	O
means	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
”	NNP	O
specifically	RB	O
encompasses	VBZ	O
naturally-occurring	JJ	O
truncated	VBD	O
or	CC	O
secreted	VBD	O
forms	NNS	O
of	IN	O
the	DT	O
specific	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
(	(	O
e.g.	NN	O
,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
sequence	NN	O
)	)	O
,	,	O
naturally-occurring	JJ	O
variant	NN	O
forms	NNS	O
(	(	O
e.g.	NN	O
,	,	O
alternatively	RB	O
spliced	VBD	O
forms	NNS	O
)	)	O
and	CC	O
naturally-occurring	JJ	O
allelic	JJ	O
variants	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
which	WDT	O
are	VBP	O
mature	JJ	O
or	CC	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
polypeptides	NNS	O
comprising	VBG	O
the	DT	O
full-length	JJ	O
amino	NN	O
acids	NNS	O
sequences	NNS	O
shown	VBN	O
in	IN	O
the	DT	O
accompanying	NN	O
figures	NNS	O
.	.	O
Start	NNP	O
and	CC	O
stop	VB	O
codons	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
bold	JJ	O
font	NN	O
and	CC	O
underlined	VBN	O
in	IN	O
the	DT	O
figures	NNS	O
.	.	O
However	RB	O
,	,	O
while	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
disclosed	VBN	O
in	IN	O
the	DT	O
accompanying	NN	O
figures	NNS	O
are	VBP	O
shown	VBN	O
to	TO	O
begin	VB	O
with	IN	O
methionine	NN	O
residues	NNS	O
designated	VBN	O
herein	RB	O
as	IN	O
amino	NN	O
acid	IN	O
position	NN	O
1	CD	O
in	IN	O
the	DT	O
figures	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
conceivable	JJ	O
and	CC	O
possible	JJ	O
that	IN	O
other	JJ	O
methionine	NN	O
residues	NNS	O
located	VBN	O
either	DT	O
upstream	NN	O
or	CC	O
downstream	NN	O
from	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
position	NN	O
1	CD	O
in	IN	O
the	DT	O
figures	NNS	O
may	MD	O
be	VB	O
employed	VBN	O
as	IN	O
the	DT	O
starting	VBG	O
amino	NN	O
acid	NNS	O
residue	VBP	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
“	NNP	O
extracellular	JJ	O
domain	NN	O
”	NN	O
or	CC	O
“	VB	O
ECD	NNP	O
”	NNP	O
refers	NNS	O
to	TO	O
a	DT	O
form	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
is	VBZ	O
essentially	RB	O
free	JJ	O
of	IN	O
the	DT	O
transmembrane	NN	O
and	CC	O
cytoplasmic	JJ	O
domains	NNS	O
.	.	O
Ordinarily	RB	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
ECD	NNP	O
will	MD	O
have	VB	O
less	JJR	O
than	IN	O
1	CD	O
%	NN	O
of	IN	O
such	JJ	O
transmembrane	NN	O
and/or	NNS	O
cytoplasmic	JJ	O
domains	NNS	O
and	CC	O
preferably	RB	O
,	,	O
will	MD	O
have	VB	O
less	JJR	O
than	IN	O
0.5	CD	O
%	NN	O
of	IN	O
such	JJ	O
domains	NNS	O
.	.	O
It	PRP	O
will	MD	O
be	VB	O
understood	JJ	O
that	IN	O
any	DT	O
transmembrane	NN	O
domains	NNS	O
identified	VBN	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
identified	VBN	O
pursuant	JJ	O
to	TO	O
criteria	VB	O
routinely	RB	O
employed	VBN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
identifying	VBG	O
that	DT	O
type	NN	O
of	IN	O
hydrophobic	JJ	O
domain	NN	O
.	.	O
The	DT	O
exact	JJ	O
boundaries	NNS	O
of	IN	O
a	DT	O
transmembrane	NN	O
domain	NN	O
may	MD	O
vary	VB	O
but	CC	O
most	JJS	O
likely	JJ	O
by	IN	O
no	DT	O
more	JJR	O
than	IN	O
about	RB	O
5	CD	O
amino	JJ	O
acids	NNS	O
at	IN	O
either	DT	O
end	NN	O
of	IN	O
the	DT	O
domain	NN	O
as	IN	O
initially	RB	O
identified	VBN	O
herein	NN	O
.	.	O
Optionally	RB	O
,	,	O
therefore	RB	O
,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
contain	VB	O
from	IN	O
about	RB	O
5	CD	O
or	CC	O
fewer	JJR	O
amino	NN	O
acids	NNS	O
on	IN	O
either	DT	O
side	NN	O
of	IN	O
the	DT	O
transmembrane	NN	O
domain/extracellular	NN	O
domain	NN	O
boundary	JJ	O
as	IN	O
identified	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
or	CC	O
specification	NN	O
and	CC	O
such	JJ	O
polypeptides	NNS	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
associated	JJ	O
signal	NN	O
peptide	NN	O
,	,	O
and	CC	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
them	PRP	O
,	,	O
are	VBP	O
contemplated	VBN	O
by	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
approximate	JJ	O
location	NN	O
of	IN	O
the	DT	O
“	NNP	O
signal	NN	O
peptides	NNS	O
”	CD	O
of	IN	O
the	DT	O
various	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
the	DT	O
present	JJ	O
specification	NN	O
and/or	IN	O
the	DT	O
accompanying	VBG	O
figures	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
noted	VBN	O
,	,	O
however	RB	O
,	,	O
that	IN	O
the	DT	O
C-terminal	JJ	O
boundary	NN	O
of	IN	O
a	DT	O
signal	JJ	O
peptide	NN	O
may	MD	O
vary	VB	O
,	,	O
but	CC	O
most	JJS	O
likely	JJ	O
by	IN	O
no	DT	O
more	JJR	O
than	IN	O
about	RB	O
5	CD	O
amino	JJ	O
acids	NNS	O
on	IN	O
either	DT	O
side	NN	O
of	IN	O
the	DT	O
signal	JJ	O
peptide	NN	O
C-terminal	JJ	O
boundary	NN	O
as	IN	O
initially	RB	O
identified	VBN	O
herein	NN	O
,	,	O
wherein	VBD	O
the	DT	O
C-terminal	JJ	O
boundary	NN	O
of	IN	O
the	DT	O
signal	JJ	O
peptide	NN	O
may	MD	O
be	VB	O
identified	VBN	O
pursuant	JJ	O
to	TO	O
criteria	VB	O
routinely	RB	O
employed	VBN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
identifying	VBG	O
that	DT	O
type	NN	O
of	IN	O
amino	NN	O
acid	NN	O
sequence	NN	O
element	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Nielsen	NNP	B
et	FW	I
al.	NN	I
,	,	I
Prot	NNP	I
.	.	I
Eng	NNP	I
.	.	I
10:1-6	CD	I
(	(	I
1997	CD	I
)	)	I
and	CC	O
von	$	B
Heinje	NNP	I
et	CC	I
al.	NN	I
,	,	I
Nucl	NNP	I
.	.	I
Acids	NNS	I
.	.	I
Res	NNP	I
.	.	I
14:4683-4690	CD	I
(	(	I
1986	CD	I
)	)	I
)	)	O
.	.	O
Moreover	RB	O
,	,	O
it	PRP	O
is	VBZ	O
also	RB	O
recognized	VBN	O
that	IN	O
,	,	O
in	IN	O
some	DT	O
cases	NNS	O
,	,	O
cleavage	NN	O
of	IN	O
a	DT	O
signal	JJ	O
sequence	NN	O
from	IN	O
a	DT	O
secreted	JJ	O
polypeptide	NN	O
is	VBZ	O
not	RB	O
entirely	RB	O
uniform	JJ	O
,	,	O
resulting	VBG	O
in	IN	O
more	JJR	O
than	IN	O
one	CD	O
secreted	JJ	O
species	NNS	O
.	.	O
These	DT	O
mature	NN	O
polypeptides	NNS	O
,	,	O
where	WRB	O
the	DT	O
signal	JJ	O
peptide	NN	O
is	VBZ	O
cleaved	VBN	O
within	IN	O
no	DT	O
more	JJR	O
than	IN	O
about	RB	O
5	CD	O
amino	JJ	O
acids	NNS	O
on	IN	O
either	DT	O
side	NN	O
of	IN	O
the	DT	O
C-terminal	JJ	O
boundary	NN	O
of	IN	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
identified	JJ	O
herein	NN	O
,	,	O
and	CC	O
the	DT	O
polynucleotides	NNS	O
encoding	VBG	O
them	PRP	O
,	,	O
are	VBP	O
contemplated	VBN	O
by	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
“	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
variant	JJ	O
”	NN	O
means	VBZ	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
preferably	RB	O
an	DT	O
active	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
as	IN	O
defined	VBN	O
herein	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
with	IN	O
a	DT	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
sequence	NN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
any	DT	O
other	JJ	O
fragment	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
sequence	NN	O
as	IN	O
disclosed	VBN	O
herein	NN	O
(	(	O
such	JJ	O
as	IN	O
those	DT	O
encoded	VBN	O
by	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
that	WDT	O
represents	VBZ	O
only	RB	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
complete	JJ	O
coding	NN	O
sequence	NN	O
for	IN	O
a	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
)	)	O
.	.	O
Such	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
variants	NNS	O
include	VBP	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
wherein	VBP	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	NN	O
residues	NNS	O
are	VBP	O
added	VBN	O
,	,	O
or	CC	O
deleted	VBN	O
,	,	O
at	IN	O
the	DT	O
N-	NNP	O
or	CC	O
C-terminus	NNP	O
of	IN	O
the	DT	O
full-length	JJ	O
native	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
.	.	O
Ordinarily	RB	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
variant	NN	O
will	MD	O
have	VB	O
or	CC	O
will	MD	O
have	VB	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
will	MD	O
have	VB	O
or	CC	O
will	MD	O
have	VB	O
at	IN	O
least	JJS	O
about	IN	O
81	CD	O
%	NN	O
,	,	O
82	CD	O
%	NN	O
,	,	O
83	CD	O
%	NN	O
,	,	O
84	CD	O
%	NN	O
,	,	O
85	CD	O
%	NN	O
,	,	O
86	CD	O
%	NN	O
,	,	O
87	CD	O
%	NN	O
,	,	O
88	CD	O
%	NN	O
,	,	O
89	CD	O
%	NN	O
,	,	O
90	CD	O
%	NN	O
,	,	O
91	CD	O
%	NN	O
,	,	O
92	CD	O
%	NN	O
,	,	O
93	CD	O
%	NN	O
,	,	O
94	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
,	,	O
96	CD	O
%	NN	O
,	,	O
97	CD	O
%	NN	O
,	,	O
98	CD	O
%	NN	O
,	,	O
or	CC	O
99	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
to	TO	O
a	DT	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
sequence	NN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
any	DT	O
other	JJ	O
specifically	RB	O
defined	JJ	O
fragment	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
.	.	O
Ordinarily	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polypeptides	NNS	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
10	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
20	CD	O
,	,	O
30	CD	O
,	,	O
40	CD	O
,	,	O
50	CD	O
,	,	O
60	CD	O
,	,	O
70	CD	O
,	,	O
80	CD	O
,	,	O
90	CD	O
,	,	O
100	CD	O
,	,	O
110	CD	O
,	,	O
120	CD	O
,	,	O
130	CD	O
,	,	O
140	CD	O
,	,	O
150	CD	O
,	,	O
160	CD	O
,	,	O
170	CD	O
,	,	O
180	CD	O
,	,	O
190	CD	O
,	,	O
200	CD	O
,	,	O
210	CD	O
,	,	O
220	CD	O
,	,	O
230	CD	O
,	,	O
240	CD	O
,	,	O
250	CD	O
,	,	O
260	CD	O
,	,	O
270	CD	O
,	,	O
280	CD	O
,	,	O
290	CD	O
,	,	O
300	CD	O
,	,	O
310	CD	O
,	,	O
320	CD	O
,	,	O
330	CD	O
,	,	O
340	CD	O
,	,	O
350	CD	O
,	,	O
360	CD	O
,	,	O
370	CD	O
,	,	O
380	CD	O
,	,	O
390	CD	O
,	,	O
400	CD	O
,	,	O
410	CD	O
,	,	O
420	CD	O
,	,	O
430	CD	O
,	,	O
440	CD	O
,	,	O
450	CD	O
,	,	O
460	CD	O
,	,	O
470	CD	O
,	,	O
480	CD	O
,	,	O
490	CD	O
,	,	O
500	CD	O
,	,	O
510	CD	O
,	,	O
520	CD	O
,	,	O
530	CD	O
,	,	O
540	CD	O
,	,	O
550	CD	O
,	,	O
560	CD	O
,	,	O
570	CD	O
,	,	O
580	CD	O
,	,	O
590	CD	O
,	,	O
600	CD	O
amino	NN	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
or	CC	O
more	JJR	O
.	.	O
Optionally	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polypeptides	NNS	O
will	MD	O
have	VB	O
no	DT	O
more	JJR	O
than	IN	O
one	CD	O
conservative	JJ	O
amino	NN	O
acid	JJ	O
substitution	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
sequence	NN	O
,	,	O
alternatively	RB	O
will	MD	O
have	VB	O
or	CC	O
will	MD	O
have	VB	O
no	DT	O
more	JJR	O
than	IN	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
or	CC	O
10	CD	O
conservative	JJ	O
amino	NN	O
acid	JJ	O
substitution	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
sequence	NN	O
.	.	O
“	JJ	O
Percent	NNP	O
(	(	O
%	NN	O
)	)	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
”	VBP	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
sequences	NNS	O
identified	VBN	O
herein	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
the	DT	O
percentage	NN	O
of	IN	O
amino	NN	O
acid	NN	O
residues	NNS	O
in	IN	O
a	DT	O
candidate	NN	O
sequence	NN	O
that	WDT	O
are	VBP	O
identical	JJ	O
with	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residues	NNS	O
in	IN	O
the	DT	O
specific	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
sequence	NN	O
,	,	O
after	IN	O
aligning	VBG	O
the	DT	O
sequences	NNS	O
and	CC	O
introducing	VBG	O
gaps	NNS	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
to	TO	O
achieve	VB	O
the	DT	O
maximum	JJ	O
percent	NN	O
sequence	NN	O
identity	NN	O
,	,	O
and	CC	O
not	RB	O
considering	VBG	O
any	DT	O
conservative	JJ	O
substitutions	NNS	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
sequence	NN	O
identity	NN	O
.	.	O
Alignment	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
determining	VBG	O
percent	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
various	JJ	O
ways	NNS	O
that	WDT	O
are	VBP	O
within	IN	O
the	DT	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
using	VBG	O
publicly	RB	O
available	JJ	O
computer	NN	O
software	NN	O
such	JJ	O
as	IN	O
BLAST	NNP	O
,	,	O
BLAST-2	NNP	O
,	,	O
ALIGN	NNP	O
or	CC	O
Megalign	NNP	O
(	(	O
DNASTAR	NNP	O
)	)	O
software	NN	O
.	.	O
Those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
can	MD	O
determine	VB	O
appropriate	JJ	O
parameters	NNS	O
for	IN	O
measuring	VBG	O
alignment	NN	O
,	,	O
including	VBG	O
any	DT	O
algorithms	NN	O
needed	VBN	O
to	TO	O
achieve	VB	O
maximal	JJ	O
alignment	NN	O
over	IN	O
the	DT	O
full	JJ	O
length	NN	O
of	IN	O
the	DT	O
sequences	NNS	O
being	VBG	O
compared	VBN	O
.	.	O
For	IN	O
purposes	NNS	O
herein	NN	O
,	,	O
however	RB	O
,	,	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
values	NNS	O
are	VBP	O
generated	VBN	O
using	VBG	O
the	DT	O
sequence	NN	O
comparison	NN	O
computer	NN	O
program	NN	O
ALIGN-2	NNP	O
,	,	O
wherein	VBZ	O
the	DT	O
complete	JJ	O
source	NN	O
code	NN	O
for	IN	O
the	DT	O
ALIGN-2	JJ	O
program	NN	O
is	VBZ	O
provided	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
.	.	O
The	DT	O
ALIGN-2	NNP	O
sequence	NN	O
comparison	NN	O
computer	NN	O
program	NN	O
was	VBD	O
authored	VBN	O
by	IN	O
Genentech	NNP	O
,	,	O
Inc.	NNP	O
and	CC	O
the	DT	O
source	NN	O
code	NN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	NN	O
has	VBZ	O
been	VBN	O
filed	VBN	O
with	IN	O
user	JJ	O
documentation	NN	O
in	IN	O
the	DT	O
U.S	NNP	O
.	.	O
Copyright	NNP	O
Office	NNP	O
,	,	O
Washington	NNP	O
D.C.	NNP	O
,	,	O
20559	CD	O
,	,	O
where	WRB	O
it	PRP	O
is	VBZ	O
registered	VBN	O
under	IN	O
U.S	NNP	O
.	.	O
Copyright	NNP	O
Registration	NNP	O
No	NNP	O
.	.	O
TXU510087	NNP	O
.	.	O
The	DT	O
ALIGN-2	JJ	O
program	NN	O
is	VBZ	O
publicly	RB	O
available	JJ	O
through	IN	O
Genentech	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
South	NNP	O
San	NNP	O
Francisco	NNP	O
,	,	O
Calif.	NNP	O
or	CC	O
may	MD	O
be	VB	O
compiled	VBN	O
from	IN	O
the	DT	O
source	NN	O
code	NN	O
provided	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
.	.	O
The	DT	O
ALIGN-2	JJ	O
program	NN	O
should	MD	O
be	VB	O
compiled	VBN	O
for	IN	O
use	NN	O
on	IN	O
a	DT	O
UNIX	NNP	O
operating	NN	O
system	NN	O
,	,	O
preferably	RB	O
digital	JJ	O
UNIX	NNP	O
V4.0D	NNP	O
.	.	O
All	DT	O
sequence	NN	O
comparison	NN	O
parameters	NNS	O
are	VBP	O
set	VBN	O
by	IN	O
the	DT	O
ALIGN-2	JJ	O
program	NN	O
and	CC	O
do	VBP	O
not	RB	O
vary	VB	O
.	.	O
In	IN	O
situations	NNS	O
where	WRB	O
ALIGN-2	NNP	O
is	VBZ	O
employed	VBN	O
for	IN	O
amino	NN	O
acid	NN	O
sequence	NN	O
comparisons	NNS	O
,	,	O
the	DT	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
of	IN	O
a	DT	O
given	VBN	O
amino	NN	O
acid	NN	O
sequence	NN	O
A	DT	O
to	TO	O
,	,	O
with	IN	O
,	,	O
or	CC	O
against	IN	O
a	DT	O
given	VBN	O
amino	NN	O
acid	NN	O
sequence	NN	O
B	NNP	O
(	(	O
which	WDT	O
can	MD	O
alternatively	RB	O
be	VB	O
phrased	VBN	O
as	IN	O
a	DT	O
given	VBN	O
amino	NN	O
acid	NN	O
sequence	NN	O
A	NNP	O
that	WDT	O
has	VBZ	O
or	CC	O
comprises	VBZ	O
a	DT	O
certain	JJ	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
to	TO	O
,	,	O
with	IN	O
,	,	O
or	CC	O
against	IN	O
a	DT	O
given	VBN	O
amino	NN	O
acid	NN	O
sequence	NN	O
B	NNP	O
)	)	O
is	VBZ	O
calculated	VBN	O
as	IN	O
follows:100	NN	O
times	VBZ	O
the	DT	O
fraction	NN	O
X/Ywhere	NNP	O
X	NNP	O
is	VBZ	O
the	DT	O
number	NN	O
of	IN	O
amino	JJ	O
acid	NN	O
residues	NNS	O
scored	VBD	O
as	IN	O
identical	JJ	O
matches	NNS	O
by	IN	O
the	DT	O
sequence	NN	O
alignment	JJ	O
program	NN	O
ALIGN-2	NNP	O
in	IN	O
that	DT	O
program	NN	O
's	POS	O
alignment	NN	O
of	IN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
and	CC	O
where	WRB	O
Y	NNP	O
is	VBZ	O
the	DT	O
total	JJ	O
number	NN	O
of	IN	O
amino	JJ	O
acid	NN	O
residues	NNS	O
in	IN	O
B	NNP	O
.	.	O
It	PRP	O
will	MD	O
be	VB	O
appreciated	VBN	O
that	IN	O
where	WRB	O
the	DT	O
length	NN	O
of	IN	O
amino	NN	O
acid	NN	O
sequence	NN	O
A	NNP	O
is	VBZ	O
not	RB	O
equal	JJ	O
to	TO	O
the	DT	O
length	NN	O
of	IN	O
amino	NN	O
acid	NN	O
sequence	NN	O
B	NNP	O
,	,	O
the	DT	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
of	IN	O
A	NNP	O
to	TO	O
B	NNP	O
will	MD	O
not	RB	O
equal	VB	O
the	DT	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
of	IN	O
B	NNP	O
to	TO	O
A	NNP	O
.	.	O
As	IN	O
examples	NNS	O
of	IN	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
calculations	NNS	O
using	VBG	O
this	DT	O
method	NN	O
,	,	O
Tables	VBZ	O
2	CD	O
and	CC	O
3	CD	O
demonstrate	NN	O
how	WRB	O
to	TO	O
calculate	VB	O
the	DT	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
designated	VBN	O
“	NNP	O
Comparison	NNP	O
Protein	NNP	O
”	VBZ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
designated	VBN	O
“	JJ	O
PRO	NNP	O
”	FW	O
,	,	O
wherein	WP	O
“	JJ	O
PRO	NNP	O
”	FW	O
represents	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
hypothetical	JJ	O
PRO	NNP	O
polypeptide	NN	O
of	IN	O
interest	NN	O
,	,	O
“	NNP	O
Comparison	NNP	O
Protein	NNP	O
”	VBZ	O
represents	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
against	IN	O
which	WDT	O
the	DT	O
“	NNP	O
PRO	NNP	O
”	NNP	O
polypeptide	NN	O
of	IN	O
interest	NN	O
is	VBZ	O
being	VBG	O
compared	VBN	O
,	,	O
and	CC	O
“	NNP	O
X	NNP	O
,	,	O
“	NNP	O
Y	NNP	O
”	NNP	O
and	CC	O
“	NNP	O
Z	NNP	O
”	NNP	O
each	DT	O
represent	NN	O
different	JJ	O
hypothetical	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
.	.	O
Unless	IN	O
specifically	RB	O
stated	VBN	O
otherwise	RB	O
,	,	O
all	DT	O
%	NN	O
amino	JJ	O
acid	JJ	O
sequence	NN	O
identity	NN	O
values	NNS	O
used	VBN	O
herein	NNS	O
are	VBP	O
obtained	VBN	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
immediately	RB	O
preceding	VBG	O
paragraph	NN	O
using	VBG	O
the	DT	O
ALIGN-2	JJ	O
computer	NN	O
program	NN	O
.	.	O
“	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polynucleotide	NN	O
”	NN	O
or	CC	O
“	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
”	NN	O
means	VBZ	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
which	WDT	O
encodes	VBZ	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
preferably	RB	O
an	DT	O
active	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
as	IN	O
defined	VBN	O
herein	NN	O
and	CC	O
which	WDT	O
has	VBZ	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
with	IN	O
a	DT	O
nucleotide	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
a	DT	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
a	DT	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
sequence	NN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
any	DT	O
other	JJ	O
fragment	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
sequence	NN	O
as	IN	O
disclosed	VBN	O
herein	NN	O
(	(	O
such	JJ	O
as	IN	O
those	DT	O
encoded	VBN	O
by	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
that	WDT	O
represents	VBZ	O
only	RB	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
complete	JJ	O
coding	NN	O
sequence	NN	O
for	IN	O
a	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
)	)	O
.	.	O
Ordinarily	RB	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polynucleotide	NN	O
will	MD	O
have	VB	O
or	CC	O
will	MD	O
have	VB	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
,	,	O
alternatively	RB	O
will	MD	O
have	VB	O
or	CC	O
will	MD	O
have	VB	O
at	IN	O
least	JJS	O
about	IN	O
81	CD	O
%	NN	O
,	,	O
82	CD	O
%	NN	O
,	,	O
83	CD	O
%	NN	O
,	,	O
84	CD	O
%	NN	O
,	,	O
85	CD	O
%	NN	O
,	,	O
86	CD	O
%	NN	O
,	,	O
87	CD	O
%	NN	O
,	,	O
88	CD	O
%	NN	O
,	,	O
89	CD	O
%	NN	O
,	,	O
90	CD	O
%	NN	O
,	,	O
91	CD	O
%	NN	O
,	,	O
92	CD	O
%	NN	O
,	,	O
93	CD	O
%	NN	O
,	,	O
94	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
,	,	O
96	CD	O
%	NN	O
,	,	O
97	CD	O
%	NN	O
,	,	O
98	CD	O
%	NN	O
,	,	O
or	CC	O
99	CD	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
a	DT	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
a	DT	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
sequence	NN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
sequence	NN	O
,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
any	DT	O
other	JJ	O
fragment	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
.	.	O
Variants	NNS	O
do	VBP	O
not	RB	O
encompass	VB	O
the	DT	O
native	JJ	O
nucleotide	JJ	O
sequence	NN	O
.	.	O
Ordinarily	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polynucleotides	NNS	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
5	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
6	CD	O
,	,	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
35	CD	O
,	,	O
40	CD	O
,	,	O
45	CD	O
,	,	O
50	CD	O
,	,	O
55	CD	O
,	,	O
60	CD	O
,	,	O
65	CD	O
,	,	O
70	CD	O
,	,	O
75	CD	O
,	,	O
80	CD	O
,	,	O
85	CD	O
,	,	O
90	CD	O
,	,	O
95	CD	O
,	,	O
100	CD	O
,	,	O
105	CD	O
,	,	O
110	CD	O
,	,	O
115	CD	O
,	,	O
120	CD	O
,	,	O
125	CD	O
,	,	O
130	CD	O
,	,	O
135	CD	O
,	,	O
140	CD	O
,	,	O
145	CD	O
,	,	O
150	CD	O
,	,	O
155	CD	O
,	,	O
160	CD	O
,	,	O
165	CD	O
,	,	O
170	CD	O
,	,	O
175	CD	O
,	,	O
180	CD	O
,	,	O
185	CD	O
,	,	O
190	CD	O
,	,	O
195	CD	O
,	,	O
200	CD	O
,	,	O
210	CD	O
,	,	O
220	CD	O
,	,	O
230	CD	O
,	,	O
240	CD	O
,	,	O
250	CD	O
,	,	O
260	CD	O
,	,	O
270	CD	O
,	,	O
280	CD	O
,	,	O
290	CD	O
,	,	O
300	CD	O
,	,	O
310	CD	O
,	,	O
320	CD	O
,	,	O
330	CD	O
,	,	O
340	CD	O
,	,	O
350	CD	O
,	,	O
360	CD	O
,	,	O
370	CD	O
,	,	O
380	CD	O
,	,	O
390	CD	O
,	,	O
400	CD	O
,	,	O
410	CD	O
,	,	O
420	CD	O
,	,	O
430	CD	O
,	,	O
440	CD	O
,	,	O
450	CD	O
,	,	O
460	CD	O
,	,	O
470	CD	O
,	,	O
480	CD	O
,	,	O
490	CD	O
,	,	O
500	CD	O
,	,	O
510	CD	O
,	,	O
520	CD	O
,	,	O
530	CD	O
,	,	O
540	CD	O
,	,	O
550	CD	O
,	,	O
560	CD	O
,	,	O
570	CD	O
,	,	O
580	CD	O
,	,	O
590	CD	O
,	,	O
600	CD	O
,	,	O
610	CD	O
,	,	O
620	CD	O
,	,	O
630	CD	O
,	,	O
640	CD	O
,	,	O
650	CD	O
,	,	O
660	CD	O
,	,	O
670	CD	O
,	,	O
680	CD	O
,	,	O
690	CD	O
,	,	O
700	CD	O
,	,	O
710	CD	O
,	,	O
720	CD	O
,	,	O
730	CD	O
,	,	O
740	CD	O
,	,	O
750	CD	O
,	,	O
760	CD	O
,	,	O
770	CD	O
,	,	O
780	CD	O
,	,	O
790	CD	O
,	,	O
800	CD	O
,	,	O
810	CD	O
,	,	O
820	CD	O
,	,	O
830	CD	O
,	,	O
840	CD	O
,	,	O
850	CD	O
,	,	O
860	CD	O
,	,	O
870	CD	O
,	,	O
880	CD	O
,	,	O
890	CD	O
,	,	O
900	CD	O
,	,	O
910	CD	O
,	,	O
920	CD	O
,	,	O
930	CD	O
,	,	O
940	CD	O
,	,	O
950	CD	O
,	,	O
960	CD	O
,	,	O
970	CD	O
,	,	O
980	CD	O
,	,	O
990	CD	O
,	,	O
or	CC	O
1000	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
wherein	NN	O
in	IN	O
this	DT	O
context	NN	O
the	DT	O
term	NN	O
“	NN	O
about	IN	O
”	NN	O
means	VBZ	O
the	DT	O
referenced	JJ	O
nucleotide	JJ	O
sequence	NN	O
length	NN	O
plus	CC	O
or	CC	O
minus	CC	O
10	CD	O
%	NN	O
of	IN	O
that	DT	O
referenced	VBD	O
length	NN	O
.	.	O
“	JJ	O
Percent	NNP	O
(	(	O
%	NN	O
)	)	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
”	VBP	O
with	IN	O
respect	NN	O
to	TO	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-encoding	NNP	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
identified	VBN	O
herein	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
the	DT	O
percentage	NN	O
of	IN	O
nucleotides	NNS	O
in	IN	O
a	DT	O
candidate	NN	O
sequence	NN	O
that	WDT	O
are	VBP	O
identical	JJ	O
with	IN	O
the	DT	O
nucleotides	NNS	O
in	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
interest	NN	O
,	,	O
after	IN	O
aligning	VBG	O
the	DT	O
sequences	NNS	O
and	CC	O
introducing	VBG	O
gaps	NNS	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
to	TO	O
achieve	VB	O
the	DT	O
maximum	JJ	O
percent	NN	O
sequence	NN	O
identity	NN	O
.	.	O
Alignment	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
determining	VBG	O
percent	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
various	JJ	O
ways	NNS	O
that	WDT	O
are	VBP	O
within	IN	O
the	DT	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
using	VBG	O
publicly	RB	O
available	JJ	O
computer	NN	O
software	NN	O
such	JJ	O
as	IN	O
BLAST	NNP	O
,	,	O
BLAST-2	NNP	O
,	,	O
ALIGN	NNP	O
or	CC	O
Megalign	NNP	O
(	(	O
DNASTAR	NNP	O
)	)	O
software	NN	O
.	.	O
For	IN	O
purposes	NNS	O
herein	NN	O
,	,	O
however	RB	O
,	,	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
values	NNS	O
are	VBP	O
generated	VBN	O
using	VBG	O
the	DT	O
sequence	NN	O
comparison	NN	O
computer	NN	O
program	NN	O
ALIGN-2	NNP	O
,	,	O
wherein	VBZ	O
the	DT	O
complete	JJ	O
source	NN	O
code	NN	O
for	IN	O
the	DT	O
ALIGN-2	JJ	O
program	NN	O
is	VBZ	O
provided	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
.	.	O
The	DT	O
ALIGN-2	NNP	O
sequence	NN	O
comparison	NN	O
computer	NN	O
program	NN	O
was	VBD	O
authored	VBN	O
by	IN	O
Genentech	NNP	O
,	,	O
Inc.	NNP	O
and	CC	O
the	DT	O
source	NN	O
code	NN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	NN	O
has	VBZ	O
been	VBN	O
filed	VBN	O
with	IN	O
user	JJ	O
documentation	NN	O
in	IN	O
the	DT	O
U.S	NNP	O
.	.	O
Copyright	NNP	O
Office	NNP	O
,	,	O
Washington	NNP	O
D.C.	NNP	O
,	,	O
20559	CD	O
,	,	O
where	WRB	O
it	PRP	O
is	VBZ	O
registered	VBN	O
under	IN	O
U.S	NNP	O
.	.	O
Copyright	NNP	O
Registration	NNP	O
No	NNP	O
.	.	O
TXU510087	NNP	O
.	.	O
The	DT	O
ALIGN-2	JJ	O
program	NN	O
is	VBZ	O
publicly	RB	O
available	JJ	O
through	IN	O
Genentech	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
South	NNP	O
San	NNP	O
Francisco	NNP	O
,	,	O
Calif.	NNP	O
or	CC	O
may	MD	O
be	VB	O
compiled	VBN	O
from	IN	O
the	DT	O
source	NN	O
code	NN	O
provided	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
.	.	O
The	DT	O
ALIGN-2	JJ	O
program	NN	O
should	MD	O
be	VB	O
compiled	VBN	O
for	IN	O
use	NN	O
on	IN	O
a	DT	O
UNIX	NNP	O
operating	NN	O
system	NN	O
,	,	O
preferably	RB	O
digital	JJ	O
UNIX	NNP	O
V4.0D	NNP	O
.	.	O
All	DT	O
sequence	NN	O
comparison	NN	O
parameters	NNS	O
are	VBP	O
set	VBN	O
by	IN	O
the	DT	O
ALIGN-2	JJ	O
program	NN	O
and	CC	O
do	VBP	O
not	RB	O
vary	VB	O
.	.	O
In	IN	O
situations	NNS	O
where	WRB	O
ALIGN-2	NNP	O
is	VBZ	O
employed	VBN	O
for	IN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
comparisons	NNS	O
,	,	O
the	DT	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
of	IN	O
a	DT	O
given	VBN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
C	NNP	O
to	TO	O
,	,	O
with	IN	O
,	,	O
or	CC	O
against	IN	O
a	DT	O
given	VBN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
D	NNP	O
(	(	O
which	WDT	O
can	MD	O
alternatively	RB	O
be	VB	O
phrased	VBN	O
as	IN	O
a	DT	O
given	VBN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
C	NNP	O
that	WDT	O
has	VBZ	O
or	CC	O
comprises	VBZ	O
a	DT	O
certain	JJ	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
,	,	O
with	IN	O
,	,	O
or	CC	O
against	IN	O
a	DT	O
given	VBN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
D	NNP	O
)	)	O
is	VBZ	O
calculated	VBN	O
as	IN	O
follows:100	NN	O
times	VBZ	O
the	DT	O
fraction	NN	O
W/Zwhere	NNP	O
W	NNP	O
is	VBZ	O
the	DT	O
number	NN	O
of	IN	O
nucleotides	NNS	O
scored	VBN	O
as	IN	O
identical	JJ	O
matches	NNS	O
by	IN	O
the	DT	O
sequence	NN	O
alignment	JJ	O
program	NN	O
ALIGN-2	NNP	O
in	IN	O
that	DT	O
program	NN	O
's	POS	O
alignment	NN	O
of	IN	O
C	NNP	O
and	CC	O
D	NNP	O
,	,	O
and	CC	O
where	WRB	O
Z	NNP	O
is	VBZ	O
the	DT	O
total	JJ	O
number	NN	O
of	IN	O
nucleotides	NNS	O
in	IN	O
D.	NNP	O
It	PRP	O
will	MD	O
be	VB	O
appreciated	VBN	O
that	IN	O
where	WRB	O
the	DT	O
length	NN	O
of	IN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
C	NNP	O
is	VBZ	O
not	RB	O
equal	JJ	O
to	TO	O
the	DT	O
length	NN	O
of	IN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
D	NNP	O
,	,	O
the	DT	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
of	IN	O
C	NNP	O
to	TO	O
D	NNP	O
will	MD	O
not	RB	O
equal	VB	O
the	DT	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
of	IN	O
D	NNP	O
to	TO	O
C.	NNP	O
As	NNP	O
examples	NNS	O
of	IN	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
calculations	NNS	O
,	,	O
Tables	VBZ	O
4	CD	O
and	CC	O
5	CD	O
,	,	O
demonstrate	VB	O
how	WRB	O
to	TO	O
calculate	VB	O
the	DT	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
designated	VBN	O
“	NNP	O
Comparison	NNP	O
DNA	NNP	O
”	NNP	O
to	TO	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
designated	VBN	O
“	JJ	O
PRO-DNA	NNP	O
”	NNP	O
,	,	O
wherein	JJ	O
“	JJ	O
PRO-DNA	NNP	O
”	NN	O
represents	VBZ	O
a	DT	O
hypothetical	JJ	O
PRO-encoding	NNP	O
nucleic	NN	O
acid	NN	O
sequence	NN	O
of	IN	O
interest	NN	O
,	,	O
“	NNP	O
Comparison	NNP	O
DNA	NNP	O
”	NNP	O
represents	VBZ	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
against	IN	O
which	WDT	O
the	DT	O
“	NN	O
PRO-DNA	NNP	O
”	NNP	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
of	IN	O
interest	NN	O
is	VBZ	O
being	VBG	O
compared	VBN	O
,	,	O
and	CC	O
“	NNP	O
N	NNP	O
”	NNP	O
,	,	O
“	NNP	O
L	NNP	O
”	NNP	O
and	CC	O
“	NNP	O
V	NNP	O
”	NNP	O
each	DT	O
represent	NN	O
different	JJ	O
hypothetical	JJ	O
nucleotides	NNS	O
.	.	O
Unless	IN	O
specifically	RB	O
stated	VBN	O
otherwise	RB	O
,	,	O
all	DT	O
%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
values	NNS	O
used	VBN	O
herein	NNS	O
are	VBP	O
obtained	VBN	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
immediately	RB	O
preceding	VBG	O
paragraph	NN	O
using	VBG	O
the	DT	O
ALIGN-2	JJ	O
computer	NN	O
program	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	NN	O
polynucleotides	NNS	O
which	WDT	O
are	VBP	O
nucleic	JJ	O
acid	JJ	O
molecules	NNS	O
that	WDT	O
encode	VBP	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
which	WDT	O
are	VBP	O
capable	JJ	O
of	IN	O
hybridizing	VBG	O
,	,	O
preferably	RB	O
under	IN	O
stringent	JJ	O
hybridization	NN	O
and	CC	O
wash	NN	O
conditions	NNS	O
,	,	O
to	TO	O
nucleotide	VB	O
sequences	NNS	O
encoding	VBG	O
a	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
disclosed	VBN	O
herein	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polypeptides	NNS	O
may	MD	O
be	VB	O
those	DT	O
that	WDT	O
are	VBP	O
encoded	VBN	O
by	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polynucleotide	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
full-length	NN	O
coding	VBG	O
region	NN	O
”	NN	O
when	WRB	O
used	VBN	O
in	IN	O
reference	NN	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
refers	NNS	O
to	TO	O
the	DT	O
sequence	NN	O
of	IN	O
nucleotides	NNS	O
which	WDT	O
encode	VBP	O
the	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
which	WDT	O
is	VBZ	O
often	RB	O
shown	VBN	O
between	IN	O
start	NN	O
and	CC	O
stop	JJ	O
codons	NNS	O
,	,	O
inclusive	JJ	O
thereof	NN	O
,	,	O
in	IN	O
the	DT	O
accompanying	NN	O
figures	NNS	O
)	)	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
full-length	NN	O
coding	VBG	O
region	NN	O
”	NN	O
when	WRB	O
used	VBN	O
in	IN	O
reference	NN	O
to	TO	O
an	DT	O
ATCC	NNP	O
deposited	VBD	O
nucleic	JJ	O
acid	NN	O
refers	NNS	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
portion	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
that	WDT	O
is	VBZ	O
inserted	VBN	O
into	IN	O
the	DT	O
vector	NN	O
deposited	VBD	O
with	IN	O
the	DT	O
ATCC	NNP	O
(	(	O
which	WDT	O
is	VBZ	O
often	RB	O
shown	VBN	O
between	IN	O
start	NN	O
and	CC	O
stop	JJ	O
codons	NNS	O
,	,	O
inclusive	JJ	O
thereof	NN	O
,	,	O
in	IN	O
the	DT	O
accompanying	NN	O
figures	NNS	O
)	)	O
.	.	O
“	RB	O
Isolated	NNP	O
,	,	O
”	NN	O
when	WRB	O
used	VBN	O
to	TO	O
describe	VB	O
the	DT	O
various	JJ	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
,	,	O
means	VBZ	O
polypeptide	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
identified	VBN	O
and	CC	O
separated	VBN	O
and/or	NNS	O
recovered	VBN	O
from	IN	O
a	DT	O
component	NN	O
of	IN	O
its	PRP$	O
natural	JJ	O
environment	NN	O
.	.	O
Contaminant	JJ	O
components	NNS	O
of	IN	O
its	PRP$	O
natural	JJ	O
environment	NN	O
are	VBP	O
materials	NNS	O
that	WDT	O
would	MD	O
typically	RB	O
interfere	VB	O
with	IN	O
diagnostic	JJ	O
or	CC	O
therapeutic	JJ	O
uses	NNS	O
for	IN	O
the	DT	O
polypeptide	NN	O
,	,	O
and	CC	O
may	MD	O
include	VB	O
enzymes	NNS	O
,	,	O
hormones	NNS	O
,	,	O
and	CC	O
other	JJ	O
proteinaceous	JJ	O
or	CC	O
non-proteinaceous	JJ	O
solutes	NNS	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
that	IN	O
the	DT	O
polypeptide	NN	O
will	MD	O
be	VB	O
purified	VBN	O
(	(	O
1	CD	O
)	)	O
to	TO	O
a	DT	O
degree	JJ	O
sufficient	NN	O
to	TO	O
obtain	VB	O
at	IN	O
least	JJS	O
15	CD	O
residues	NNS	O
of	IN	O
N-terminal	NNP	O
or	CC	O
internal	JJ	O
amino	NN	O
acid	NNS	O
sequence	NN	O
by	IN	O
use	NN	O
of	IN	O
a	DT	O
spinning	JJ	O
cup	NN	O
sequenator	NN	O
,	,	O
or	CC	O
(	(	O
2	CD	O
)	)	O
to	TO	O
homogeneity	NN	O
by	IN	O
SDS-PAGE	NNP	O
under	IN	O
non-reducing	NN	O
or	CC	O
reducing	VBG	O
conditions	NNS	O
using	VBG	O
Coomassie	NNP	O
blue	NN	O
or	CC	O
,	,	O
preferably	RB	O
,	,	O
silver	RB	O
stain	NN	O
.	.	O
Isolated	VBN	O
polypeptide	NN	O
includes	VBZ	O
polypeptide	NN	O
in	IN	O
situ	NN	O
within	IN	O
recombinant	JJ	O
cells	NNS	O
,	,	O
since	IN	O
at	IN	O
least	JJS	O
one	CD	O
component	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
natural	JJ	O
environment	NN	O
will	MD	O
not	RB	O
be	VB	O
present	JJ	O
.	.	O
Ordinarily	RB	O
,	,	O
however	RB	O
,	,	O
isolated	JJ	O
polypeptide	NN	O
will	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
at	IN	O
least	JJS	O
one	CD	O
purification	NN	O
step	NN	O
.	.	O
An	DT	O
“	NN	O
isolated	VBD	O
”	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	NN	O
or	CC	O
other	JJ	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
that	WDT	O
is	VBZ	O
identified	VBN	O
and	CC	O
separated	VBN	O
from	IN	O
at	IN	O
least	JJS	O
one	CD	O
contaminant	NN	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
ordinarily	RB	O
associated	VBN	O
in	IN	O
the	DT	O
natural	JJ	O
source	NN	O
of	IN	O
the	DT	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	NN	O
.	.	O
An	DT	O
isolated	JJ	O
polypeptide-encoding	NN	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
is	VBZ	O
other	JJ	O
than	IN	O
in	IN	O
the	DT	O
form	NN	O
or	CC	O
setting	NN	O
in	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
found	VBN	O
in	IN	O
nature	NN	O
.	.	O
Isolated	VBN	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
therefore	RB	O
are	VBP	O
distinguished	VBN	O
from	IN	O
the	DT	O
specific	JJ	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
as	IN	O
it	PRP	O
exists	VBZ	O
in	IN	O
natural	JJ	O
cells	NNS	O
.	.	O
However	RB	O
,	,	O
an	DT	O
isolated	JJ	O
polypeptide-encoding	NN	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
includes	VBZ	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
contained	VBN	O
in	IN	O
cells	NNS	O
that	IN	O
ordinarily	RB	O
express	VB	O
the	DT	O
polypeptide	NN	O
where	WRB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
is	VBZ	O
in	IN	O
a	DT	O
chromosomal	JJ	O
location	NN	O
different	JJ	O
from	IN	O
that	DT	O
of	IN	O
natural	JJ	O
cells	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
control	NN	O
sequences	VBZ	O
”	JJ	O
refers	NNS	O
to	TO	O
DNA	NNP	O
sequences	NNS	O
necessary	JJ	O
for	IN	O
the	DT	O
expression	NN	O
of	IN	O
an	DT	O
operably	NN	O
linked	VBD	O
coding	VBG	O
sequence	NN	O
in	IN	O
a	DT	O
particular	JJ	O
host	NN	O
organism	NN	O
.	.	O
The	DT	O
control	NN	O
sequences	VBZ	O
that	WDT	O
are	VBP	O
suitable	JJ	O
for	IN	O
prokaryotes	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
include	VBP	O
a	DT	O
promoter	NN	O
,	,	O
optionally	RB	O
an	DT	O
operator	NN	O
sequence	NN	O
,	,	O
and	CC	O
a	DT	O
ribosome	NN	O
binding	NN	O
site	NN	O
.	.	O
Eukaryotic	JJ	O
cells	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
utilize	VB	O
promoters	NNS	O
,	,	O
polyadenylation	NN	O
signals	NNS	O
,	,	O
and	CC	O
enhancers	NNS	O
.	.	O
Nucleic	NNP	O
acid	NN	O
is	VBZ	O
“	JJ	O
operably	RB	O
linked	VBN	O
”	RP	O
when	WRB	O
it	PRP	O
is	VBZ	O
placed	VBN	O
into	IN	O
a	DT	O
functional	JJ	O
relationship	NN	O
with	IN	O
another	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
DNA	NNP	O
for	IN	O
a	DT	O
presequence	NN	O
or	CC	O
secretory	JJ	O
leader	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
DNA	NNP	O
for	IN	O
a	DT	O
polypeptide	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
expressed	VBN	O
as	IN	O
a	DT	O
preprotein	NN	O
that	WDT	O
participates	VBZ	O
in	IN	O
the	DT	O
secretion	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
;	:	O
a	DT	O
promoter	NN	O
or	CC	O
enhancer	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
a	DT	O
coding	NN	O
sequence	NN	O
if	IN	O
it	PRP	O
affects	VBZ	O
the	DT	O
transcription	NN	O
of	IN	O
the	DT	O
sequence	NN	O
;	:	O
or	CC	O
a	DT	O
ribosome	JJ	O
binding	NN	O
site	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
a	DT	O
coding	NN	O
sequence	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
positioned	VBN	O
so	RB	O
as	IN	O
to	TO	O
facilitate	VB	O
translation	NN	O
.	.	O
Generally	RB	O
,	,	O
“	NNP	O
operably	RB	O
linked	VBD	O
”	JJ	O
means	NNS	O
that	IN	O
the	DT	O
DNA	NN	O
sequences	NNS	O
being	VBG	O
linked	VBN	O
are	VBP	O
contiguous	JJ	O
,	,	O
and	CC	O
,	,	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
a	DT	O
secretory	JJ	O
leader	NN	O
,	,	O
contiguous	JJ	O
and	CC	O
in	IN	O
reading	VBG	O
phase	NN	O
.	.	O
However	RB	O
,	,	O
enhancers	NNS	O
do	VBP	O
not	RB	O
have	VB	O
to	TO	O
be	VB	O
contiguous	JJ	O
.	.	O
Linking	VBG	O
is	VBZ	O
accomplished	VBN	O
by	IN	O
ligation	NN	O
at	IN	O
convenient	JJ	O
restriction	NN	O
sites	NNS	O
.	.	O
If	IN	O
such	JJ	O
sites	NNS	O
do	VBP	O
not	RB	O
exist	VB	O
,	,	O
the	DT	O
synthetic	JJ	O
oligonucleotide	NN	O
adaptors	NNS	O
or	CC	O
linkers	NNS	O
are	VBP	O
used	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
conventional	JJ	O
practice	NN	O
.	.	O
“	JJ	O
Stringency	NNP	O
”	NNP	O
of	IN	O
hybridization	NN	O
reactions	NNS	O
is	VBZ	O
readily	RB	O
determinable	JJ	O
by	IN	O
one	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
and	CC	O
generally	RB	O
is	VBZ	O
an	DT	O
empirical	JJ	O
calculation	NN	O
dependent	NN	O
upon	IN	O
probe	NN	O
length	NN	O
,	,	O
washing	VBG	O
temperature	NN	O
,	,	O
and	CC	O
salt	JJ	O
concentration	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
longer	RBR	O
probes	NNS	O
require	VBP	O
higher	JJR	O
temperatures	NNS	O
for	IN	O
proper	JJ	O
annealing	NN	O
,	,	O
while	IN	O
shorter	JJR	O
probes	NNS	O
need	VBP	O
lower	JJR	O
temperatures	NNS	O
.	.	O
Hybridization	NNP	O
generally	RB	O
depends	VBZ	O
on	IN	O
the	DT	O
ability	NN	O
of	IN	O
denatured	JJ	O
DNA	NNP	O
to	TO	O
reanneal	VB	O
when	WRB	O
complementary	JJ	O
strands	NNS	O
are	VBP	O
present	JJ	O
in	IN	O
an	DT	O
environment	NN	O
below	IN	O
their	PRP$	O
melting	NN	O
temperature	NN	O
.	.	O
The	DT	O
higher	JJR	O
the	DT	O
degree	NN	O
of	IN	O
desired	JJ	O
homology	NN	O
between	IN	O
the	DT	O
probe	NN	O
and	CC	O
hybridizable	JJ	O
sequence	NN	O
,	,	O
the	DT	O
higher	JJR	O
the	DT	O
relative	JJ	O
temperature	NN	O
which	WDT	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
As	IN	O
a	DT	O
result	NN	O
,	,	O
it	PRP	O
follows	VBZ	O
that	IN	O
higher	JJR	O
relative	JJ	O
temperatures	NNS	O
would	MD	O
tend	VB	O
to	TO	O
make	VB	O
the	DT	O
reaction	NN	O
conditions	NNS	O
more	RBR	O
stringent	JJ	O
,	,	O
while	IN	O
lower	JJR	O
temperatures	NNS	O
less	RBR	O
so	RB	O
.	.	O
For	IN	O
additional	JJ	O
details	NNS	O
and	CC	O
explanation	NN	O
of	IN	O
stringency	NN	O
of	IN	O
hybridization	NN	O
reactions	NNS	O
,	,	O
see	VBP	O
Ausubel	NNP	B
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Wiley	NNP	I
Interscience	NNP	I
Publishers	NNP	I
,	,	I
(	(	I
1995	CD	I
)	)	I
.	.	O
“	JJ	O
Stringent	NNP	O
conditions	NNS	O
”	VBP	O
or	CC	O
“	VBP	O
high	JJ	O
stringency	NN	O
conditions	NNS	O
”	VBP	O
,	,	O
as	IN	O
defined	VBN	O
herein	NN	O
,	,	O
may	MD	O
be	VB	O
identified	VBN	O
by	IN	O
those	DT	O
that	WDT	O
:	:	O
(	(	O
1	CD	O
)	)	O
employ	NN	O
low	JJ	O
ionic	JJ	O
strength	NN	O
and	CC	O
high	JJ	O
temperature	NN	O
for	IN	O
washing	NN	O
,	,	O
for	IN	O
example	NN	O
0.015	CD	O
M	NNP	O
sodium	NN	O
chloride/0.0015	NN	O
M	NNP	O
sodium	NN	O
citrate/0.1	NN	O
%	NN	O
sodium	NN	O
dodecyl	NN	O
sulfate	NN	O
at	IN	O
50°	CD	O
C.	NNP	O
;	:	O
(	(	O
2	CD	O
)	)	O
employ	NN	O
during	IN	O
hybridization	NN	O
a	DT	O
denaturing	NN	O
agent	NN	O
,	,	O
such	JJ	O
as	IN	O
formamide	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
50	CD	O
%	NN	O
(	(	O
v/v	NN	O
)	)	O
formamide	NN	O
with	IN	O
0.1	CD	O
%	NN	O
bovine	NN	O
serum	JJ	O
albumin/0.1	NN	O
%	NN	O
Ficoll/0.1	NNP	O
%	NN	O
polyvinylpyrrolidone/50	NN	O
mM	NN	O
sodium	NN	O
phosphate	NN	O
buffer	NN	O
at	IN	O
pH	$	O
6.5	CD	O
with	IN	O
750	CD	O
mM	NNS	O
sodium	JJ	O
chloride	NN	O
,	,	O
75	CD	O
mM	NN	O
sodium	NN	O
citrate	NN	O
at	IN	O
42°	CD	O
C.	NNP	O
;	:	O
or	CC	O
(	(	O
3	CD	O
)	)	O
employ	VBP	O
50	CD	O
%	NN	O
formamide	NN	O
,	,	O
5×SSC	CD	O
(	(	O
0.75	CD	O
M	NNP	O
NaCl	NNP	O
,	,	O
0.075	CD	O
M	NNP	O
sodium	NN	O
citrate	NN	O
)	)	O
,	,	O
50	CD	O
mM	NN	O
sodium	NN	O
phosphate	NN	O
(	(	O
pH	JJ	O
6.8	CD	O
)	)	O
,	,	O
0.1	CD	O
%	NN	O
sodium	NN	O
pyrophosphate	NN	O
,	,	O
5×Denhardt	CD	O
's	POS	O
solution	NN	O
,	,	O
sonicated	VBD	O
salmon	JJ	O
sperm	NN	O
DNA	NNP	O
(	(	O
50	CD	O
μg/ml	NN	O
)	)	O
,	,	O
0.1	CD	O
%	NN	O
SDS	NNP	O
,	,	O
and	CC	O
10	CD	O
%	NN	O
dextran	NN	O
sulfate	NN	O
at	IN	O
42°	CD	O
C.	NNP	O
,	,	O
with	IN	O
washes	NNS	O
at	IN	O
42°	CD	O
C.	NNP	O
in	IN	O
0.2×SSC	CD	O
(	(	O
sodium	NN	O
chloride/sodium	NN	O
citrate	NN	O
)	)	O
and	CC	O
50	CD	O
%	NN	O
formamide	NN	O
at	IN	O
55°	CD	O
C.	NNP	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
high-stringency	NN	O
wash	NN	O
consisting	NN	O
of	IN	O
0.1×SSC	CD	O
containing	VBG	O
EDTA	NNP	O
at	IN	O
55°	CD	O
C.	NNP	O
“	NNP	O
Moderately	NNP	O
stringent	JJ	O
conditions	NNS	O
”	VBP	O
may	MD	O
be	VB	O
identified	VBN	O
as	IN	O
described	VBN	O
by	IN	O
Sambrook	NNP	B
et	FW	I
al.	NN	I
,	,	I
Molecular	JJ	I
Cloning	NN	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
,	,	I
New	NNP	I
York	NNP	I
:	:	I
Cold	JJ	I
Spring	NN	I
Harbor	NNP	I
Press	NNP	I
,	,	I
1989	CD	I
,	,	O
and	CC	O
include	VBP	O
the	DT	O
use	NN	O
of	IN	O
washing	VBG	O
solution	NN	O
and	CC	O
hybridization	NN	O
conditions	NNS	O
(	(	O
e.g.	NN	O
,	,	O
temperature	NN	O
,	,	O
ionic	JJ	O
strength	NN	O
and	CC	O
%	NN	O
SDS	NNP	O
)	)	O
less	RBR	O
stringent	JJ	O
that	IN	O
those	DT	O
described	VBN	O
above	IN	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
moderately	RB	O
stringent	JJ	O
conditions	NNS	O
is	VBZ	O
overnight	JJ	O
incubation	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
in	IN	O
a	DT	O
solution	NN	O
comprising	NN	O
:	:	O
20	CD	O
%	NN	O
formamide	NN	O
,	,	O
5×SSC	CD	O
(	(	O
150	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
15	CD	O
mM	NN	O
trisodium	NN	O
citrate	NN	O
)	)	O
,	,	O
50	CD	O
mM	NN	O
sodium	NN	O
phosphate	NN	O
(	(	O
pH	JJ	O
7.6	CD	O
)	)	O
,	,	O
5×Denhardt	CD	O
's	POS	O
solution	NN	O
,	,	O
10	CD	O
%	NN	O
dextran	NN	O
sulfate	NN	O
,	,	O
and	CC	O
20	CD	O
mg/ml	NN	O
denatured	VBD	O
sheared	JJ	O
salmon	JJ	O
sperm	NN	O
DNA	NNP	O
,	,	O
followed	VBN	O
by	IN	O
washing	VBG	O
the	DT	O
filters	NNS	O
in	IN	O
1×SSC	CD	O
at	IN	O
about	IN	O
37-50°	JJ	O
C.	NNP	O
The	DT	O
skilled	JJ	O
artisan	NN	O
will	MD	O
recognize	VB	O
how	WRB	O
to	TO	O
adjust	VB	O
the	DT	O
temperature	NN	O
,	,	O
ionic	JJ	O
strength	NN	O
,	,	O
etc	FW	O
.	.	O
as	IN	O
necessary	JJ	O
to	TO	O
accommodate	VB	O
factors	NNS	O
such	JJ	O
as	IN	O
probe	NN	O
length	NN	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
epitope	NN	O
tagged	VBD	O
”	NN	O
when	WRB	O
used	VBN	O
herein	NN	O
refers	NNS	O
to	TO	O
a	DT	O
chimeric	JJ	O
polypeptide	NN	O
comprising	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
fused	VBD	O
to	TO	O
a	DT	O
“	JJ	O
tag	NN	O
polypeptide	NN	O
”	NNP	O
.	.	O
The	DT	O
tag	NN	O
polypeptide	NN	O
has	VBZ	O
enough	JJ	O
residues	NNS	O
to	TO	O
provide	VB	O
an	DT	O
epitope	NN	O
against	IN	O
which	WDT	O
an	DT	O
antibody	NN	O
can	MD	O
be	VB	O
made	VBN	O
,	,	O
yet	CC	O
is	VBZ	O
short	JJ	O
enough	RB	O
such	JJ	O
that	IN	O
it	PRP	O
does	VBZ	O
not	RB	O
interfere	VB	O
with	IN	O
activity	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
to	TO	O
which	WDT	O
it	PRP	O
is	VBZ	O
fused	VBN	O
.	.	O
The	DT	O
tag	NN	O
polypeptide	NN	O
preferably	RB	O
also	RB	O
is	VBZ	O
fairly	RB	O
unique	JJ	O
so	IN	O
that	IN	O
the	DT	O
antibody	NN	O
does	VBZ	O
not	RB	O
substantially	RB	O
cross-react	JJ	O
with	IN	O
other	JJ	O
epitopes	NNS	O
.	.	O
Suitable	JJ	O
tag	NN	O
polypeptides	NNS	O
generally	RB	O
have	VBP	O
at	IN	O
least	JJS	O
six	CD	O
amino	JJ	O
acid	NN	O
residues	NNS	O
and	CC	O
usually	RB	O
between	IN	O
about	IN	O
8	CD	O
and	CC	O
50	CD	O
amino	NN	O
acid	NN	O
residues	NNS	O
(	(	O
preferably	RB	O
,	,	O
between	IN	O
about	IN	O
10	CD	O
and	CC	O
20	CD	O
amino	NN	O
acid	NN	O
residues	NNS	O
)	)	O
.	.	O
“	RB	O
Active	NNP	O
”	NNP	O
or	CC	O
“	JJ	O
activity	NN	O
”	NN	O
for	IN	O
the	DT	O
purposes	NNS	O
herein	VBP	O
refers	NNS	O
to	TO	O
form	VB	O
(	(	O
s	PRP	O
)	)	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
retain	VBP	O
a	DT	O
biological	JJ	O
and/or	NN	O
an	DT	O
immunological	JJ	O
activity	NN	O
of	IN	O
native	JJ	O
or	CC	O
naturally-occurring	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
wherein	JJ	O
“	NNP	O
biological	JJ	O
”	NN	O
activity	NN	O
refers	NNS	O
to	TO	O
a	DT	O
biological	JJ	O
function	NN	O
(	(	O
either	CC	O
inhibitory	NN	O
or	CC	O
stimulatory	NN	O
)	)	O
caused	VBN	O
by	IN	O
a	DT	O
native	JJ	O
or	CC	O
naturally-occurring	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
other	JJ	O
than	IN	O
the	DT	O
ability	NN	O
to	TO	O
induce	VB	O
the	DT	O
production	NN	O
of	IN	O
an	DT	O
antibody	NN	O
against	IN	O
an	DT	O
antigenic	JJ	O
epitope	NN	O
possessed	VBN	O
by	IN	O
a	DT	O
native	JJ	O
or	CC	O
naturally-occurring	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
an	DT	O
“	JJ	O
immunological	JJ	O
”	NN	O
activity	NN	O
refers	NNS	O
to	TO	O
the	DT	O
ability	NN	O
to	TO	O
induce	VB	O
the	DT	O
production	NN	O
of	IN	O
an	DT	O
antibody	NN	O
against	IN	O
an	DT	O
antigenic	JJ	O
epitope	NN	O
possessed	VBN	O
by	IN	O
a	DT	O
native	JJ	O
or	CC	O
naturally-occurring	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
antagonist	NN	O
”	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
the	DT	O
broadest	JJS	O
sense	NN	O
[	NN	O
unless	IN	O
otherwise	RB	O
qualified	VBN	O
]	NN	O
,	,	O
and	CC	O
includes	VBZ	O
any	DT	O
molecule	NN	O
that	WDT	O
partially	RB	O
or	CC	O
fully	RB	O
blocks	NNS	O
,	,	O
inhibits	NNS	O
,	,	O
or	CC	O
neutralizes	VBZ	O
a	DT	O
biological	JJ	O
activity	NN	O
of	IN	O
a	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
disclosed	VBD	O
herein	NN	O
.	.	O
In	IN	O
a	DT	O
similar	JJ	O
manner	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
agonist	NN	O
”	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
the	DT	O
broadest	JJS	O
sense	NN	O
[	NN	O
unless	IN	O
otherwise	RB	O
qualified	VBN	O
]	NN	O
and	CC	O
includes	VBZ	O
any	DT	O
molecule	NN	O
that	IN	O
mimics	VBZ	O
a	DT	O
biological	JJ	O
activity	NN	O
of	IN	O
a	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
disclosed	VBD	O
herein	NN	O
.	.	O
Suitable	JJ	O
agonist	NN	O
or	CC	O
antagonist	NN	O
molecules	NNS	O
specifically	RB	O
include	VBP	O
agonist	NN	O
or	CC	O
antagonist	JJ	O
antibodies	NNS	O
or	CC	O
antibody	NN	O
fragments	NNS	O
,	,	O
fragments	NNS	O
or	CC	O
amino	NN	O
acid	JJ	O
sequence	NN	O
variants	NNS	O
of	IN	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
,	,	O
peptides	NNS	O
,	,	O
antisense	NN	O
oligonucleotides	NNS	O
,	,	O
small	JJ	O
organic	JJ	O
molecules	NNS	O
,	,	O
etc	FW	O
.	.	O
Methods	NNS	O
for	IN	O
identifying	VBG	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
comprise	VB	O
contacting	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
with	IN	O
a	DT	O
candidate	JJ	O
agonist	NN	O
or	CC	O
antagonist	NN	O
molecule	NN	O
and	CC	O
measuring	VBG	O
a	DT	O
detectable	JJ	O
change	NN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
biological	JJ	O
activities	NNS	O
normally	RB	O
associated	VBN	O
with	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
“	NN	O
Treating	VBG	O
”	NN	O
or	CC	O
“	VB	O
treatment	NN	O
”	NN	O
or	CC	O
“	JJ	O
alleviation	NN	O
”	NN	O
refers	NNS	O
to	TO	O
both	DT	O
therapeutic	JJ	O
treatment	NN	O
and	CC	O
prophylactic	JJ	O
or	CC	O
preventative	JJ	O
measures	NNS	O
,	,	O
wherein	VBD	O
the	DT	O
object	NN	O
is	VBZ	O
to	TO	O
prevent	VB	O
or	CC	O
slow	VB	O
down	RP	O
(	(	O
lessen	NN	O
)	)	O
the	DT	O
targeted	JJ	O
pathologic	JJ	O
condition	NN	O
or	CC	O
disorder	NN	O
.	.	O
A	DT	O
subject	NN	O
in	IN	O
need	NN	O
of	IN	O
treatment	NN	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
disorder	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
disorder	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
disorder	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented	VBN	O
.	.	O
“	NN	O
Chronic	NNP	O
”	NNP	O
administration	NN	O
refers	NNS	O
to	TO	O
administration	NN	O
of	IN	O
the	DT	O
agent	NN	O
(	(	O
s	NN	O
)	)	O
in	IN	O
a	DT	O
continuous	JJ	O
mode	NN	O
as	IN	O
opposed	VBN	O
to	TO	O
an	DT	O
acute	JJ	O
mode	NN	O
,	,	O
so	RB	O
as	IN	O
to	TO	O
maintain	VB	O
the	DT	O
initial	JJ	O
therapeutic	JJ	O
effect	NN	O
(	(	O
activity	NN	O
)	)	O
for	IN	O
an	DT	O
extended	JJ	O
period	NN	O
of	IN	O
time	NN	O
.	.	O
“	JJ	O
Intermittent	NNP	O
”	NNP	O
administration	NN	O
is	VBZ	O
treatment	NN	O
that	WDT	O
is	VBZ	O
not	RB	O
consecutively	RB	O
done	VBN	O
without	IN	O
interruption	NN	O
,	,	O
but	CC	O
rather	RB	O
is	VBZ	O
cyclic	JJ	O
in	IN	O
nature	NN	O
.	.	O
“	NN	O
Mammal	NNP	O
”	NNP	O
for	IN	O
purposes	NNS	O
of	IN	O
treatment	NN	O
refers	NNS	O
to	TO	O
any	DT	O
animal	JJ	O
classified	VBN	O
as	IN	O
a	DT	O
mammal	NN	O
,	,	O
including	VBG	O
humans	NNS	O
,	,	O
rodents	NNS	O
such	JJ	O
as	IN	O
rats	NNS	O
or	CC	O
mice	NN	O
,	,	O
domestic	JJ	O
and	CC	O
farm	NN	O
animals	NNS	O
,	,	O
and	CC	O
zoo	NN	O
,	,	O
sports	NNS	O
,	,	O
or	CC	O
pet	JJ	O
animals	NNS	O
,	,	O
such	JJ	O
as	IN	O
dogs	NNS	O
,	,	O
cats	NNS	O
,	,	O
cattle	NNS	O
,	,	O
horses	NNS	O
,	,	O
sheep	NN	O
,	,	O
pigs	NNS	O
,	,	O
goats	NNS	O
,	,	O
rabbits	NNS	O
,	,	O
etc	FW	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
mammal	NN	O
is	VBZ	O
human	JJ	O
.	.	O
Administration	NNP	O
“	NNP	O
in	IN	O
combination	NN	O
with	IN	O
”	JJ	O
one	CD	O
or	CC	O
more	JJR	O
further	JJ	O
therapeutic	JJ	O
agents	NNS	O
includes	VBZ	O
simultaneous	JJ	O
(	(	O
concurrent	NN	O
)	)	O
and	CC	O
consecutive	JJ	O
administration	NN	O
in	IN	O
any	DT	O
order	NN	O
.	.	O
“	JJ	O
Carriers	NNP	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
include	VBP	O
pharmaceutically	RB	O
acceptable	JJ	O
carriers	NNS	O
,	,	O
excipients	NNS	O
,	,	O
or	CC	O
stabilizers	NNS	O
which	WDT	O
are	VBP	O
nontoxic	JJ	O
to	TO	O
the	DT	O
cell	NN	O
or	CC	O
mammal	JJ	O
being	VBG	O
exposed	VBN	O
thereto	NN	O
at	IN	O
the	DT	O
dosages	NNS	O
and	CC	O
concentrations	NNS	O
employed	VBN	O
.	.	O
Often	RB	O
the	DT	O
physiologically	RB	O
acceptable	JJ	O
carrier	NN	O
is	VBZ	O
an	DT	O
aqueous	JJ	O
pH	NN	O
buffered	VBD	O
solution	NN	O
.	.	O
Examples	NNS	O
of	IN	O
physiologically	RB	O
acceptable	JJ	O
carriers	NNS	O
include	VBP	O
buffers	NNS	O
such	JJ	O
as	IN	O
phosphate	NN	O
,	,	O
citrate	NN	O
,	,	O
and	CC	O
other	JJ	O
organic	JJ	O
acids	NNS	O
;	:	O
antioxidants	NNS	O
including	VBG	O
ascorbic	JJ	O
acid	NN	O
;	:	O
low	JJ	O
molecular	JJ	O
weight	NN	O
(	(	O
less	JJR	O
than	IN	O
about	RB	O
10	CD	O
residues	NNS	O
)	)	O
polypeptide	VBP	O
;	:	O
proteins	NNS	O
,	,	O
such	JJ	O
as	IN	O
serum	NN	O
albumin	NN	O
,	,	O
gelatin	NN	O
,	,	O
or	CC	O
immunoglobulins	NNS	O
;	:	O
hydrophilic	JJ	O
polymers	NNS	O
such	JJ	O
as	IN	O
polyvinylpyrrolidone	NN	O
;	:	O
amino	JJ	O
acids	NNS	O
such	JJ	O
as	IN	O
glycine	NN	O
,	,	O
glutamine	NN	O
,	,	O
asparagine	NN	O
,	,	O
arginine	NN	O
or	CC	O
lysine	NN	O
;	:	O
monosaccharides	NNS	O
,	,	O
disaccharides	NNS	O
,	,	O
and	CC	O
other	JJ	O
carbohydrates	NNS	O
including	VBG	O
glucose	NN	O
,	,	O
mannose	VB	O
,	,	O
or	CC	O
dextrins	NNS	O
;	:	O
chelating	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
EDTA	NNP	O
;	:	O
sugar	NN	O
alcohols	NNS	O
such	JJ	O
as	IN	O
mannitol	NN	O
or	CC	O
sorbitol	NN	O
;	:	O
salt-forming	JJ	O
counterions	NNS	O
such	JJ	O
as	IN	O
sodium	NN	O
;	:	O
and/or	CC	O
nonionic	JJ	O
surfactants	NNS	O
such	JJ	O
as	IN	O
TWEEN™	NNP	O
,	,	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
,	,	O
and	CC	O
PLURONICS™	NNP	O
.	.	O
By	IN	O
“	NNP	O
solid	JJ	O
phase	NN	O
”	NN	O
is	VBZ	O
meant	VBN	O
a	DT	O
non-aqueous	JJ	O
matrix	NN	O
to	TO	O
which	WDT	O
the	DT	O
antibody	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
adhere	VB	O
.	.	O
Examples	NNS	O
of	IN	O
solid	JJ	O
phases	NNS	O
encompassed	VBD	O
herein	JJ	O
include	VBP	O
those	DT	O
formed	VBN	O
partially	RB	O
or	CC	O
entirely	RB	O
of	IN	O
glass	NN	O
(	(	O
e.g.	NN	O
,	,	O
controlled	VBD	O
pore	RB	O
glass	NN	O
)	)	O
,	,	O
polysaccharides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
agarose	RB	O
)	)	O
,	,	O
polyacrylamides	NNS	O
,	,	O
polystyrene	NN	O
,	,	O
polyvinyl	NN	O
alcohol	NN	O
and	CC	O
silicones	NNS	O
.	.	O
Depending	VBG	O
on	IN	O
the	DT	O
context	NN	O
,	,	O
the	DT	O
solid	JJ	O
phase	NN	O
can	MD	O
comprise	VB	O
the	DT	O
well	NN	O
of	IN	O
an	DT	O
assay	JJ	O
plate	NN	O
;	:	O
in	IN	O
others	NNS	O
it	PRP	O
is	VBZ	O
a	DT	O
purification	NN	O
column	NN	O
(	(	O
e.g.	NN	O
,	,	O
an	DT	O
affinity	NN	O
chromatography	NN	O
column	NN	O
)	)	O
.	.	O
This	DT	O
term	NN	O
also	RB	O
includes	VBZ	O
a	DT	O
discontinuous	JJ	O
solid	JJ	O
phase	NN	O
of	IN	O
discrete	JJ	O
particles	NNS	O
,	,	O
such	JJ	O
as	IN	O
those	DT	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,275,149	CD	O
.	.	O
A	DT	O
“	JJ	O
liposome	NN	O
”	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
vesicle	NN	O
composed	VBN	O
of	IN	O
various	JJ	O
types	NNS	O
of	IN	O
lipids	NNS	O
,	,	O
phospholipids	NNS	O
and/or	VBP	O
surfactant	JJ	O
which	WDT	O
is	VBZ	O
useful	JJ	O
for	IN	O
delivery	NN	O
of	IN	O
a	DT	O
drug	NN	O
(	(	O
such	JJ	O
as	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
antibody	NN	O
thereto	NN	O
)	)	O
to	TO	O
a	DT	O
mammal	NN	O
.	.	O
The	DT	O
components	NNS	O
of	IN	O
the	DT	O
liposome	NN	O
are	VBP	O
commonly	RB	O
arranged	VBN	O
in	IN	O
a	DT	O
bilayer	NN	O
formation	NN	O
,	,	O
similar	JJ	O
to	TO	O
the	DT	O
lipid	JJ	O
arrangement	NN	O
of	IN	O
biological	JJ	O
membranes	NNS	O
.	.	O
A	DT	O
“	NNP	O
small	JJ	O
molecule	NN	O
”	NNP	O
is	VBZ	O
defined	VBN	O
herein	NN	O
to	TO	O
have	VB	O
a	DT	O
molecular	JJ	O
weight	NN	O
below	IN	O
about	RB	O
500	CD	O
Daltons	NNS	O
.	.	O
An	DT	O
“	JJ	O
effective	JJ	O
amount	NN	O
”	NNP	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptide	RB	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecule	NN	O
or	CC	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	JJ	O
thereof	NN	O
as	IN	O
disclosed	JJ	O
herein	NN	O
is	VBZ	O
an	DT	O
amount	NN	O
sufficient	NN	O
to	TO	O
carry	VB	O
out	RP	O
a	DT	O
specifically	RB	O
stated	VBN	O
purpose	NN	O
.	.	O
An	DT	O
“	JJ	O
effective	JJ	O
amount	NN	O
”	NN	O
may	MD	O
be	VB	O
determined	VBN	O
empirically	RB	O
and	CC	O
in	IN	O
a	DT	O
routine	JJ	O
manner	NN	O
,	,	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
stated	VBN	O
purpose	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
”	VBD	O
refers	NNS	O
to	TO	O
an	DT	O
amount	NN	O
of	IN	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptide	RB	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecule	NN	O
or	CC	O
other	JJ	O
drug	NN	O
effective	JJ	O
to	TO	O
“	VB	O
treat	NN	O
”	IN	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
in	IN	O
a	DT	O
subject	NN	O
or	CC	O
mammal	NN	O
.	.	O
In	IN	O
the	DT	O
case	NN	O
of	IN	O
cancer	NN	O
,	,	O
the	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
drug	NN	O
may	MD	O
reduce	VB	O
the	DT	O
number	NN	O
of	IN	O
cancer	NN	O
cells	NNS	O
;	:	O
reduce	VB	O
the	DT	O
tumor	NN	O
size	NN	O
;	:	O
inhibit	NN	O
(	(	O
i.e.	FW	O
,	,	O
slow	VB	O
to	TO	O
some	DT	O
extent	NN	O
and	CC	O
preferably	RB	O
stop	VB	O
)	)	O
cancer	NN	O
cell	NN	O
infiltration	NN	O
into	IN	O
peripheral	JJ	O
organs	NNS	O
;	:	O
inhibit	NN	O
(	(	O
i.e.	FW	O
,	,	O
slow	VB	O
to	TO	O
some	DT	O
extent	NN	O
and	CC	O
preferably	RB	O
stop	VB	O
)	)	O
tumor	NN	O
metastasis	NN	O
;	:	O
inhibit	NN	O
,	,	O
to	TO	O
some	DT	O
extent	NN	O
,	,	O
tumor	NN	O
growth	NN	O
;	:	O
and/or	CC	O
relieve	VB	O
to	TO	O
some	DT	O
extent	NN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
cancer	NN	O
.	.	O
See	VB	O
the	DT	O
definition	NN	O
herein	NN	O
of	IN	O
“	NNP	O
treating	VBG	O
”	NN	O
.	.	O
To	TO	O
the	DT	O
extent	NN	O
the	DT	O
drug	NN	O
may	MD	O
prevent	VB	O
growth	NN	O
and/or	IN	O
kill	VB	O
existing	VBG	O
cancer	NN	O
cells	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
cytostatic	JJ	O
and/or	NN	O
cytotoxic	NN	O
.	.	O
The	DT	O
phrases	NNS	O
“	VBP	O
cardiovascular	JJ	O
,	,	O
endothelial	JJ	O
and	CC	O
angiogenic	JJ	O
disorder	NN	O
”	NN	O
,	,	O
“	NNP	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
and	CC	O
angiogenic	JJ	O
dysfunction	NN	O
”	NNP	O
,	,	O
“	NNP	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
”	NN	O
and	CC	O
“	NNP	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
dysfunction	NN	O
”	NN	O
are	VBP	O
used	VBN	O
interchangeably	RB	O
and	CC	O
refer	VB	O
in	IN	O
part	NN	O
to	TO	O
systemic	VB	O
disorders	NNS	O
that	WDT	O
affect	VBP	O
vessels	NNS	O
,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus	RB	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
diseases	NNS	O
of	IN	O
the	DT	O
vessels	NNS	O
themselves	PRP	O
,	,	O
such	JJ	O
as	IN	O
of	IN	O
the	DT	O
arteries	NNS	O
,	,	O
capillaries	NNS	O
,	,	O
veins	NNS	O
,	,	O
and/or	JJ	O
lymphatics	NNS	O
.	.	O
This	DT	O
would	MD	O
include	VB	O
indications	NNS	O
that	WDT	O
stimulate	VBP	O
angiogenesis	NN	O
and/or	NN	O
cardiovascularization	NN	O
,	,	O
and	CC	O
those	DT	O
that	WDT	O
inhibit	VBP	O
angiogenesis	JJ	O
and/or	JJ	O
cardiovascularization	NN	O
.	.	O
Such	JJ	O
disorders	NNS	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
arterial	JJ	O
disease	NN	O
,	,	O
such	JJ	O
as	IN	O
atherosclerosis	NN	O
,	,	O
hypertension	NN	O
,	,	O
inflammatory	JJ	O
vasculitides	NNS	O
,	,	O
Reynaud	NNP	O
's	POS	O
disease	NN	O
and	CC	O
Reynaud	NNP	O
's	POS	O
phenomenon	NN	O
,	,	O
aneurysms	NNS	O
,	,	O
and	CC	O
arterial	JJ	O
restenosis	NN	O
;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis	NN	O
,	,	O
lymphangitis	NN	O
,	,	O
and	CC	O
lymphedema	NN	O
;	:	O
and	CC	O
other	JJ	O
vascular	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
,	,	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors	NNS	O
,	,	O
e.g.	NN	O
,	,	O
hemangioma	NN	O
(	(	O
capillary	JJ	O
and	CC	O
cavernous	JJ	O
)	)	O
,	,	O
glomus	JJ	O
tumors	NNS	O
,	,	O
telangiectasia	NN	O
,	,	O
bacillary	JJ	O
angiomatosis	NN	O
,	,	O
hemangioendothelioma	NN	O
,	,	O
angiosarcoma	NN	O
,	,	O
haemangiopericytoma	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
lymphangioma	NN	O
,	,	O
and	CC	O
lymphangiosarcoma	NN	O
,	,	O
tumor	NN	O
angiogenesis	NN	O
,	,	O
trauma	NN	O
such	JJ	O
as	IN	O
wounds	NNS	O
,	,	O
burns	NNS	O
,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue	NN	O
,	,	O
implant	JJ	O
fixation	NN	O
,	,	O
scarring	VBG	O
,	,	O
ischemia	JJ	O
reperfusion	NN	O
injury	NN	O
,	,	O
rheumatoid	JJ	O
arthritis	NN	O
,	,	O
cerebrovascular	JJ	O
disease	NN	O
,	,	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
,	,	O
or	CC	O
osteoporosis	NN	O
.	.	O
This	DT	O
would	MD	O
also	RB	O
include	VB	O
angina	NNS	O
,	,	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions	NNS	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
CHF	NNP	O
.	.	O
“	JJ	O
Hypertrophy	NNP	O
”	NNP	O
,	,	O
as	IN	O
used	VBN	O
herein	NN	O
,	,	O
is	VBZ	O
defined	VBN	O
as	IN	O
an	DT	O
increase	NN	O
in	IN	O
mass	NN	O
of	IN	O
an	DT	O
organ	JJ	O
or	CC	O
structure	NN	O
independent	JJ	O
of	IN	O
natural	JJ	O
growth	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
involve	VB	O
tumor	NN	O
formation	NN	O
.	.	O
Hypertrophy	NNP	O
of	IN	O
an	DT	O
organ	NN	O
or	CC	O
tissue	NN	O
is	VBZ	O
due	JJ	O
either	RB	O
to	TO	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
mass	NN	O
of	IN	O
the	DT	O
individual	JJ	O
cells	NNS	O
(	(	O
true	JJ	O
hypertrophy	NN	O
)	)	O
,	,	O
or	CC	O
to	TO	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
cells	NNS	O
making	VBG	O
up	RP	O
the	DT	O
tissue	NN	O
(	(	O
hyperplasia	NN	O
)	)	O
,	,	O
or	CC	O
both	DT	O
.	.	O
Certain	NNP	O
organs	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
heart	NN	O
,	,	O
lose	VB	O
the	DT	O
ability	NN	O
to	TO	O
divide	VB	O
shortly	RB	O
after	IN	O
birth	NN	O
.	.	O
Accordingly	RB	O
,	,	O
“	JJ	O
cardiac	JJ	O
hypertrophy	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
an	DT	O
increase	NN	O
in	IN	O
mass	NN	O
of	IN	O
the	DT	O
heart	NN	O
,	,	O
which	WDT	O
,	,	O
in	IN	O
adults	NNS	O
,	,	O
is	VBZ	O
characterized	VBN	O
by	IN	O
an	DT	O
increase	NN	O
in	IN	O
myocyte	NN	O
cell	NN	O
size	NN	O
and	CC	O
contractile	NN	O
protein	NN	O
content	NN	O
without	IN	O
concomitant	NN	O
cell	NN	O
division	NN	O
.	.	O
The	DT	O
character	NN	O
of	IN	O
the	DT	O
stress	NN	O
responsible	JJ	O
for	IN	O
inciting	VBG	O
the	DT	O
hypertrophy	NN	O
,	,	O
(	(	O
e.g.	UH	O
,	,	O
increased	JJ	O
preload	NN	O
,	,	O
increased	VBD	O
afterload	NN	O
,	,	O
loss	NN	O
of	IN	O
myocytes	NNS	O
,	,	O
as	IN	O
in	IN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
or	CC	O
primary	JJ	O
depression	NN	O
of	IN	O
contractility	NN	O
)	)	O
,	,	O
appears	VBZ	O
to	TO	O
play	VB	O
a	DT	O
critical	JJ	O
role	NN	O
in	IN	O
determining	VBG	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
response	NN	O
.	.	O
The	DT	O
early	JJ	O
stage	NN	O
of	IN	O
cardiac	JJ	O
hypertrophy	NN	O
is	VBZ	O
usually	RB	O
characterized	VBN	O
morphologically	RB	O
by	IN	O
increases	NNS	O
in	IN	O
the	DT	O
size	NN	O
of	IN	O
myofibrils	NNS	O
and	CC	O
mitochondria	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
enlargement	NN	O
of	IN	O
mitochondria	NNS	O
and	CC	O
nuclei	NN	O
.	.	O
At	IN	O
this	DT	O
stage	NN	O
,	,	O
while	IN	O
muscle	NN	O
cells	NNS	O
are	VBP	O
larger	JJR	O
than	IN	O
normal	JJ	O
,	,	O
cellular	JJ	O
organization	NN	O
is	VBZ	O
largely	RB	O
preserved	VBN	O
.	.	O
At	IN	O
a	DT	O
more	RBR	O
advanced	JJ	O
stage	NN	O
of	IN	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
there	EX	O
are	VBP	O
preferential	JJ	O
increases	NNS	O
in	IN	O
the	DT	O
size	NN	O
or	CC	O
number	NN	O
of	IN	O
specific	JJ	O
organelles	NNS	O
,	,	O
such	JJ	O
as	IN	O
mitochondria	NNS	O
,	,	O
and	CC	O
new	JJ	O
contractile	NN	O
elements	NNS	O
are	VBP	O
added	VBN	O
in	IN	O
localized	JJ	O
areas	NNS	O
of	IN	O
the	DT	O
cells	NNS	O
,	,	O
in	IN	O
an	DT	O
irregular	JJ	O
manner	NN	O
.	.	O
Cells	NNS	O
subjected	VBN	O
to	TO	O
long-standing	JJ	O
hypertrophy	NN	O
show	NN	O
more	RBR	O
obvious	JJ	O
disruptions	NNS	O
in	IN	O
cellular	JJ	O
organization	NN	O
,	,	O
including	VBG	O
markedly	RB	O
enlarged	VBD	O
nuclei	NNS	O
with	IN	O
highly	RB	O
lobulated	VBN	O
membranes	NNS	O
,	,	O
which	WDT	O
displace	VBP	O
adjacent	JJ	O
myofibrils	NNS	O
and	CC	O
cause	VB	O
breakdown	NN	O
of	IN	O
normal	JJ	O
Z-band	NNP	O
registration	NN	O
.	.	O
The	DT	O
phrase	NN	O
“	NNP	O
cardiac	NN	O
hypertrophy	NN	O
”	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
include	VB	O
all	DT	O
stages	NNS	O
of	IN	O
the	DT	O
progression	NN	O
of	IN	O
this	DT	O
condition	NN	O
,	,	O
characterized	VBN	O
by	IN	O
various	JJ	O
degrees	NNS	O
of	IN	O
structural	JJ	O
damage	NN	O
of	IN	O
the	DT	O
heart	NN	O
muscle	NN	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
underlying	JJ	O
cardiac	JJ	O
disorder	NN	O
.	.	O
Hence	NNP	O
,	,	O
the	DT	O
term	NN	O
also	RB	O
includes	VBZ	O
physiological	JJ	O
conditions	NNS	O
instrumental	VBP	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
cardiac	JJ	O
hypertrophy	NN	O
,	,	O
such	JJ	O
as	IN	O
elevated	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
aortic	JJ	O
stenosis	NN	O
,	,	O
or	CC	O
myocardial	JJ	O
infarction	NN	O
.	.	O
“	JJ	O
Heart	NNP	O
failure	NN	O
”	NN	O
refers	NNS	O
to	TO	O
an	DT	O
abnormality	NN	O
of	IN	O
cardiac	JJ	O
function	NN	O
where	WRB	O
the	DT	O
heart	NN	O
does	VBZ	O
not	RB	O
pump	VB	O
blood	NN	O
at	IN	O
the	DT	O
rate	NN	O
needed	VBN	O
for	IN	O
the	DT	O
requirements	NNS	O
of	IN	O
metabolizing	VBG	O
tissues	NNS	O
.	.	O
The	DT	O
heart	NN	O
failure	NN	O
can	MD	O
be	VB	O
caused	VBN	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
factors	NNS	O
,	,	O
including	VBG	O
ischemic	JJ	O
,	,	O
congenital	JJ	O
,	,	O
rheumatic	JJ	O
,	,	O
or	CC	O
idiopathic	JJ	O
forms	NNS	O
.	.	O
“	RB	O
Congestive	NNP	O
heart	NN	O
failure	NN	O
”	NNP	O
(	(	O
CHF	NNP	O
)	)	O
is	VBZ	O
a	DT	O
progressive	JJ	O
pathologic	NN	O
state	NN	O
where	WRB	O
the	DT	O
heart	NN	O
is	VBZ	O
increasingly	RB	O
unable	JJ	O
to	TO	O
supply	VB	O
adequate	JJ	O
cardiac	NNS	O
output	NN	O
(	(	O
the	DT	O
volume	NN	O
of	IN	O
blood	NN	O
pumped	VBN	O
by	IN	O
the	DT	O
heart	NN	O
over	IN	O
time	NN	O
)	)	O
to	TO	O
deliver	VB	O
the	DT	O
oxygenated	JJ	O
blood	NN	O
to	TO	O
peripheral	JJ	O
tissues	NNS	O
.	.	O
As	IN	O
CHF	NNP	O
progresses	VBZ	O
,	,	O
structural	JJ	O
and	CC	O
hemodynamic	JJ	O
damages	NNS	O
occur	VBP	O
.	.	O
While	IN	O
these	DT	O
damages	NNS	O
have	VBP	O
a	DT	O
variety	NN	O
of	IN	O
manifestations	NNS	O
,	,	O
one	CD	O
characteristic	JJ	O
symptom	NN	O
is	VBZ	O
ventricular	JJ	O
hypertrophy	NN	O
.	.	O
CHF	NNP	O
is	VBZ	O
a	DT	O
common	JJ	O
end	NN	O
result	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
various	JJ	O
cardiac	JJ	O
disorders	NNS	O
.	.	O
“	JJ	O
Myocardial	NNP	O
infarction	NN	O
”	NNP	O
generally	RB	O
results	NNS	O
from	IN	O
atherosclerosis	NN	O
of	IN	O
the	DT	O
coronary	JJ	O
arteries	NNS	O
,	,	O
often	RB	O
with	IN	O
superimposed	JJ	O
coronary	JJ	O
thrombosis	NN	O
.	.	O
It	PRP	O
may	MD	O
be	VB	O
divided	VBN	O
into	IN	O
two	CD	O
major	JJ	O
types	NNS	O
:	:	O
transmural	JJ	O
infarcts	NNS	O
,	,	O
in	IN	O
which	WDT	O
myocardial	JJ	O
necrosis	NN	O
involves	VBZ	O
the	DT	O
full	JJ	O
thickness	NN	O
of	IN	O
the	DT	O
ventricular	NN	O
wall	NN	O
,	,	O
and	CC	O
subendocardial	JJ	O
(	(	O
nontransmural	JJ	O
)	)	O
infarcts	NNS	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
necrosis	NN	O
involves	VBZ	O
the	DT	O
subendocardium	NN	O
,	,	O
the	DT	O
intramural	JJ	O
myocardium	NN	O
,	,	O
or	CC	O
both	DT	O
,	,	O
without	IN	O
extending	VBG	O
all	PDT	O
the	DT	O
way	NN	O
through	IN	O
the	DT	O
ventricular	JJ	O
wall	NN	O
to	TO	O
the	DT	O
epicardium	NN	O
.	.	O
Myocardial	JJ	O
infarction	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
cause	VB	O
both	DT	O
a	DT	O
change	NN	O
in	IN	O
hemodynamic	JJ	O
effects	NNS	O
and	CC	O
an	DT	O
alteration	NN	O
in	IN	O
structure	NN	O
in	IN	O
the	DT	O
damaged	VBN	O
and	CC	O
healthy	JJ	O
zones	NNS	O
of	IN	O
the	DT	O
heart	NN	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
reduces	VBZ	O
the	DT	O
maximum	JJ	O
cardiac	JJ	O
output	NN	O
and	CC	O
the	DT	O
stroke	NN	O
volume	NN	O
of	IN	O
the	DT	O
heart	NN	O
.	.	O
Also	RB	O
associated	VBN	O
with	IN	O
myocardial	JJ	O
infarction	NN	O
is	VBZ	O
a	DT	O
stimulation	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
synthesis	NN	O
occurring	VBG	O
in	IN	O
the	DT	O
interstice	NN	O
as	RB	O
well	RB	O
as	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
formation	NN	O
of	IN	O
collagen	NN	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
the	DT	O
heart	NN	O
not	RB	O
affected	VBD	O
.	.	O
As	IN	O
a	DT	O
result	NN	O
of	IN	O
the	DT	O
increased	JJ	O
stress	NN	O
or	CC	O
strain	NN	O
placed	VBN	O
on	IN	O
the	DT	O
heart	NN	O
in	IN	O
prolonged	JJ	O
hypertension	NN	O
due	JJ	O
,	,	O
for	IN	O
example	NN	O
,	,	O
to	TO	O
the	DT	O
increased	VBN	O
total	JJ	O
peripheral	JJ	O
resistance	NN	O
,	,	O
cardiac	JJ	O
hypertrophy	NN	O
has	VBZ	O
long	RB	O
been	VBN	O
associated	VBN	O
with	IN	O
“	NNP	O
hypertension	NN	O
”	NN	O
.	.	O
A	DT	O
characteristic	NN	O
of	IN	O
the	DT	O
ventricle	NN	O
that	WDT	O
becomes	VBZ	O
hypertrophic	JJ	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
chronic	JJ	O
pressure	NN	O
overload	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
diastolic	JJ	O
performance	NN	O
.	.	O
Fouad	NNP	B
et	CC	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Coll	NNP	I
.	.	I
Cardiol.	NNP	I
,	,	I
4	CD	I
:	:	I
1500-1506	CD	I
(	(	I
1984	CD	I
)	)	I
;	:	O
Smith	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Coll	NNP	I
.	.	I
Cardiol.	NNP	I
,	,	I
5	CD	I
:	:	I
869-874	CD	I
(	(	I
1985	CD	I
)	)	I
.	.	O
A	DT	O
prolonged	JJ	O
left	NN	O
ventricular	JJ	O
relaxation	NN	O
has	VBZ	O
been	VBN	O
detected	VBN	O
in	IN	O
early	JJ	O
essential	JJ	O
hypertension	NN	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
normal	JJ	O
or	CC	O
supranormal	JJ	O
systolic	JJ	O
function	NN	O
.	.	O
Hartford	NNP	B
et	CC	I
al.	NN	I
,	,	I
Hypertension	NNP	I
,	,	I
6	CD	I
:	:	I
329-338	CD	I
(	(	I
1984	CD	I
)	)	I
.	.	O
However	RB	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
close	JJ	O
parallelism	NN	O
between	IN	O
blood	NN	O
pressure	NN	O
levels	NNS	O
and	CC	O
cardiac	JJ	O
hypertrophy	NN	O
.	.	O
Although	IN	O
improvement	NN	O
in	IN	O
left	JJ	O
ventricular	JJ	O
function	NN	O
in	IN	O
response	NN	O
to	TO	O
antihypertensive	JJ	O
therapy	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
in	IN	O
humans	NNS	O
,	,	O
patients	NNS	O
variously	RB	O
treated	VBN	O
with	IN	O
a	DT	O
diuretic	JJ	O
(	(	O
hydrochlorothiazide	NN	O
)	)	O
,	,	O
a	DT	O
β-blocker	NN	O
(	(	O
propranolol	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
calcium	JJ	O
channel	NN	O
blocker	NN	O
(	(	O
diltiazem	NN	O
)	)	O
,	,	O
have	VBP	O
shown	VBN	O
reversal	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
,	,	O
without	IN	O
improvement	NN	O
in	IN	O
diastolic	JJ	O
function	NN	O
.	.	O
Inouye	NNP	B
et	CC	I
al.	NN	I
,	,	I
Am	NNP	I
.	.	I
J	NNP	I
.	.	I
Cardiol.	NNP	I
,	,	I
53	CD	I
:	:	I
1583-7	CD	I
(	(	I
1984	CD	I
)	)	I
.	.	O
Another	DT	O
complex	JJ	O
cardiac	NN	O
disease	NN	O
associated	VBN	O
with	IN	O
cardiac	JJ	O
hypertrophy	NN	O
is	VBZ	O
“	JJ	O
hypertrophic	JJ	O
cardiomyopathy	NN	O
”	NN	O
.	.	O
This	DT	O
condition	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
a	DT	O
great	JJ	O
diversity	NN	O
of	IN	O
morphologic	NN	O
,	,	O
functional	JJ	O
,	,	O
and	CC	O
clinical	JJ	O
features	NNS	O
(	(	O
Maron	NNP	B
et	RB	I
al.	RB	I
,	,	I
N.	NNP	I
Engl	NNP	I
.	.	I
J	NNP	I
.	.	I
Med.	NNP	I
,	,	I
316	CD	I
:	:	I
780-789	CD	I
(	(	I
1987	CD	I
)	)	I
;	:	O
Spirito	NNP	B
et	FW	I
al.	NN	I
,	,	I
N.	NNP	I
Engl	NNP	I
.	.	I
J	NNP	I
.	.	I
Med.	NNP	I
,	,	I
320	CD	I
:	:	I
749-755	CD	I
(	(	I
1989	CD	I
)	)	I
;	:	O
Louie	NNP	B
and	CC	I
Edwards	NNP	I
,	,	I
Prog	NNP	I
.	.	I
Cardiovasc	NNP	I
.	.	I
Dis.	NNP	I
,	,	I
36	CD	I
:	:	I
275-308	CD	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Wigle	NNP	B
et	FW	I
al.	NN	I
,	,	I
Circulation	NNP	I
,	,	I
92	CD	I
:	:	I
1680-1692	CD	I
(	(	I
1995	CD	I
)	)	I
)	)	O
,	,	O
the	DT	O
heterogeneity	NN	O
of	IN	O
which	WDT	O
is	VBZ	O
accentuated	VBN	O
by	IN	O
the	DT	O
fact	NN	O
that	IN	O
it	PRP	O
afflicts	VBZ	O
patients	NNS	O
of	IN	O
all	DT	O
ages	NNS	O
.	.	O
Spirito	NNP	B
et	CC	I
al.	NN	I
,	,	I
N.	NNP	I
Engl	NNP	I
.	.	I
J	NNP	I
.	.	I
Med.	NNP	I
,	,	I
336	CD	I
:	:	I
775-785	CD	I
(	(	I
1997	CD	I
)	)	I
.	.	O
The	DT	O
causative	JJ	O
factors	NNS	O
of	IN	O
hypertrophic	JJ	O
cardiomyopathy	NN	O
are	VBP	O
also	RB	O
diverse	JJ	O
and	CC	O
little	JJ	O
understood	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
mutations	NNS	O
in	IN	O
genes	NNS	O
encoding	VBG	O
sarcomeric	JJ	O
proteins	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
hypertrophic	JJ	O
cardiomyopathy	NN	O
.	.	O
Recent	JJ	O
data	NNS	O
suggest	VBP	O
that	IN	O
β-myosin	JJ	O
heavy	JJ	O
chain	NN	O
mutations	NNS	O
may	MD	O
account	VB	O
for	IN	O
approximately	RB	O
30	CD	O
to	TO	O
40	CD	O
percent	NN	O
of	IN	O
cases	NNS	O
of	IN	O
familial	JJ	O
hypertrophic	JJ	O
cardiomyopathy	NN	O
.	.	O
Watkins	NNS	B
et	VBP	I
al.	NN	I
,	,	I
N.	NNP	I
Engl	NNP	I
.	.	I
J	NNP	I
.	.	I
Med.	NNP	I
,	,	I
326	CD	I
:	:	I
1108-1114	CD	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Schwartz	NNP	B
et	FW	I
al	NN	I
,	,	I
Circulation	NNP	I
,	,	I
91	CD	I
:	:	I
532-540	JJ	I
(	(	I
1995	CD	I
)	)	I
;	:	O
Marian	JJ	B
and	CC	I
Roberts	NNP	I
,	,	I
Circulation	NNP	I
,	,	I
92	CD	I
:	:	I
1336-1347	CD	I
(	(	I
1995	CD	I
)	)	I
;	:	O
Thierfelder	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
,	,	I
77	CD	I
:	:	I
701-712	CD	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Watkins	VBZ	B
et	FW	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Gen.	NNP	I
,	,	I
11	CD	I
:	:	I
434-437	CD	I
(	(	I
1995	CD	I
)	)	I
.	.	O
Besides	IN	O
β-myosin	JJ	O
heavy	JJ	O
chain	NN	O
,	,	O
other	JJ	O
locations	NNS	O
of	IN	O
genetic	JJ	O
mutations	NNS	O
include	VBP	O
cardiac	JJ	O
troponin	NN	O
T	NNP	O
,	,	O
alpha	NN	O
topomyosin	NN	O
,	,	O
cardiac	JJ	O
myosin	NN	O
binding	VBG	O
protein	NN	O
C	NNP	O
,	,	O
essential	JJ	O
myosin	NN	O
light	NN	O
chain	NN	O
,	,	O
and	CC	O
regulatory	JJ	O
myosin	NN	O
light	NN	O
chain	NN	O
.	.	O
See	VB	O
,	,	O
Malik	NNP	B
and	CC	I
Watkins	NNP	I
,	,	I
Curr	NNP	I
.	.	I
Opin	NNP	I
.	.	I
Cardiol.	NNP	I
,	,	I
12	CD	I
:	:	I
295-302	CD	I
(	(	I
1997	CD	I
)	)	I
.	.	O
Supravalvular	JJ	O
“	NNP	O
aortic	JJ	O
stenosis	NN	O
”	NN	O
is	VBZ	O
an	DT	O
inherited	JJ	O
vascular	JJ	O
disorder	NN	O
characterized	VBN	O
by	IN	O
narrowing	VBG	O
of	IN	O
the	DT	O
ascending	VBG	O
aorta	NN	O
,	,	O
but	CC	O
other	JJ	O
arteries	NNS	O
,	,	O
including	VBG	O
the	DT	O
pulmonary	JJ	O
arteries	NNS	O
,	,	O
may	MD	O
also	RB	O
be	VB	O
affected	VBN	O
.	.	O
Untreated	VBN	O
aortic	JJ	O
stenosis	NN	O
may	MD	O
lead	VB	O
to	TO	O
increased	JJ	O
intracardiac	JJ	O
pressure	NN	O
resulting	VBG	O
in	IN	O
myocardial	JJ	O
hypertrophy	NN	O
and	CC	O
eventually	RB	O
heart	NN	O
failure	NN	O
and	CC	O
death	NN	O
.	.	O
The	DT	O
pathogenesis	NN	O
of	IN	O
this	DT	O
disorder	NN	O
is	VBZ	O
not	RB	O
fully	RB	O
understood	JJ	O
,	,	O
but	CC	O
hypertrophy	NN	O
and	CC	O
possibly	RB	O
hyperplasia	NN	O
of	IN	O
medial	JJ	O
smooth	JJ	O
muscle	NN	O
are	VBP	O
prominent	JJ	O
features	NNS	O
of	IN	O
this	DT	O
disorder	NN	O
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
that	IN	O
molecular	JJ	O
variants	NNS	O
of	IN	O
the	DT	O
elastin	JJ	O
gene	NN	O
are	VBP	O
involved	VBN	O
in	IN	O
the	DT	O
development	NN	O
and	CC	O
pathogenesis	NN	O
of	IN	O
aortic	JJ	O
stenosis	NN	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,650,282	CD	O
issued	VBN	O
Jul	NNP	O
.	.	O
22	CD	O
,	,	O
1997	CD	O
.	.	O
“	JJ	O
Valvular	NNP	O
regurgitation	NN	O
”	NNP	O
occurs	VBZ	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
heart	NN	O
diseases	NNS	O
resulting	VBG	O
in	IN	O
disorders	NNS	O
of	IN	O
the	DT	O
cardiac	JJ	O
valves	NNS	O
.	.	O
Various	JJ	O
diseases	NNS	O
,	,	O
like	IN	O
rheumatic	JJ	O
fever	NN	O
,	,	O
can	MD	O
cause	VB	O
the	DT	O
shrinking	NN	O
or	CC	O
pulling	VBG	O
apart	RB	O
of	IN	O
the	DT	O
valve	NN	O
orifice	NN	O
,	,	O
while	IN	O
other	JJ	O
diseases	NNS	O
may	MD	O
result	VB	O
in	IN	O
endocarditis	NN	O
,	,	O
an	DT	O
inflammation	NN	O
of	IN	O
the	DT	O
endocardium	NN	O
or	CC	O
lining	VBG	O
membrane	NN	O
of	IN	O
the	DT	O
atrioventricular	JJ	O
orifices	NNS	O
and	CC	O
operation	NN	O
of	IN	O
the	DT	O
heart	NN	O
.	.	O
Defects	NNS	O
such	JJ	O
as	IN	O
the	DT	O
narrowing	NN	O
of	IN	O
the	DT	O
valve	JJ	O
stenosis	NN	O
or	CC	O
the	DT	O
defective	JJ	O
closing	NN	O
of	IN	O
the	DT	O
valve	NN	O
result	NN	O
in	IN	O
an	DT	O
accumulation	NN	O
of	IN	O
blood	NN	O
in	IN	O
the	DT	O
heart	NN	O
cavity	NN	O
or	CC	O
regurgitation	NN	O
of	IN	O
blood	NN	O
past	IN	O
the	DT	O
valve	NN	O
.	.	O
If	IN	O
uncorrected	VBN	O
,	,	O
prolonged	VBD	O
valvular	JJ	O
stenosis	NN	O
or	CC	O
insufficiency	NN	O
may	MD	O
result	VB	O
in	IN	O
cardiac	JJ	O
hypertrophy	NN	O
and	CC	O
associated	VBN	O
damage	NN	O
to	TO	O
the	DT	O
heart	NN	O
muscle	NN	O
,	,	O
which	WDT	O
may	MD	O
eventually	RB	O
necessitate	VB	O
valve	JJ	O
replacement	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
immune	NN	O
related	JJ	O
disease	NN	O
”	NN	O
means	VBZ	O
a	DT	O
disease	NN	O
in	IN	O
which	WDT	O
a	DT	O
component	NN	O
of	IN	O
the	DT	O
immune	JJ	O
system	NN	O
of	IN	O
a	DT	O
mammal	JJ	O
causes	NNS	O
,	,	O
mediates	NNS	O
or	CC	O
otherwise	RB	O
contributes	NNS	O
to	TO	O
a	DT	O
morbidity	NN	O
in	IN	O
the	DT	O
mammal	NN	O
.	.	O
Also	RB	O
included	VBN	O
are	VBP	O
diseases	NNS	O
in	IN	O
which	WDT	O
stimulation	NN	O
or	CC	O
intervention	NN	O
of	IN	O
the	DT	O
immune	JJ	O
response	NN	O
has	VBZ	O
an	DT	O
ameliorative	JJ	O
effect	NN	O
on	IN	O
progression	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O
Included	VBN	O
within	IN	O
this	DT	O
term	NN	O
are	VBP	O
immune-mediated	JJ	O
inflammatory	JJ	O
diseases	NNS	O
,	,	O
non-immune-mediated	JJ	O
inflammatory	NN	O
diseases	NNS	O
,	,	O
infectious	JJ	O
diseases	NNS	O
,	,	O
immunodeficiency	NN	O
diseases	NNS	O
,	,	O
neoplasia	NN	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
T	NNP	O
cell	NN	O
mediated	VBD	O
disease	NN	O
”	NN	O
means	VBZ	O
a	DT	O
disease	NN	O
in	IN	O
which	WDT	O
T	NNP	O
cells	NNS	O
directly	RB	O
or	CC	O
indirectly	RB	O
mediate	JJ	O
or	CC	O
otherwise	RB	O
contribute	JJ	O
to	TO	O
a	DT	O
morbidity	NN	O
in	IN	O
a	DT	O
mammal	NN	O
.	.	O
The	DT	O
T	NNP	O
cell	NN	O
mediated	VBD	O
disease	NN	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
cell	NN	O
mediated	VBN	O
effects	NNS	O
,	,	O
lymphokine	NN	O
mediated	VBN	O
effects	NNS	O
,	,	O
etc.	NN	O
,	,	O
and	CC	O
even	RB	O
effects	NNS	O
associated	VBN	O
with	IN	O
B	NNP	O
cells	NNS	O
if	IN	O
the	DT	O
B	NNP	O
cells	NNS	O
are	VBP	O
stimulated	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
the	DT	O
lymphokines	NNS	O
secreted	VBN	O
by	IN	O
T	NNP	O
cells	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
immune-related	JJ	O
and	CC	O
inflammatory	JJ	O
diseases	NNS	O
,	,	O
some	DT	O
of	IN	O
which	WDT	O
are	VBP	O
immune	JJ	O
or	CC	O
T	NNP	O
cell	NN	O
mediated	VBD	O
,	,	O
include	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis	NN	O
,	,	O
rheumatoid	JJ	O
arthritis	NN	O
,	,	O
juvenile	NN	O
chronic	JJ	O
arthritis	NN	O
,	,	O
spondyloarthropathies	NNS	O
,	,	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
scleroderma	NN	O
)	)	O
,	,	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(	(	O
dermatomyositis	NN	O
,	,	O
polymyositis	NN	O
)	)	O
,	,	O
Sjögren	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
systemic	JJ	O
vasculitis	NN	O
,	,	O
sarcoidosis	NN	O
,	,	O
autoimmune	JJ	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
immune	JJ	O
pancytopenia	NN	O
,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria	NN	O
)	)	O
,	,	O
autoimmune	JJ	O
thrombocytopenia	NN	O
(	(	O
idiopathic	JJ	O
thrombocytopenic	NN	O
purpura	NN	O
,	,	O
immune-mediated	JJ	O
thrombocytopenia	NN	O
)	)	O
,	,	O
thyroiditis	NN	O
(	(	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis	NN	O
,	,	O
atrophic	JJ	O
thyroiditis	NN	O
)	)	O
,	,	O
diabetes	VBZ	O
mellitus	NNS	O
,	,	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
glomerulonephritis	NN	O
,	,	O
tubulointerstitial	JJ	O
nephritis	NN	O
)	)	O
,	,	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy	NN	O
,	,	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(	(	O
hepatitis	VB	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses	NNS	O
)	)	O
,	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
granulomatous	JJ	O
hepatitis	NN	O
,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis	NN	O
,	,	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
ulcerative	JJ	O
colitis	NN	O
:	:	O
Crohn	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
gluten-sensitive	JJ	O
enteropathy	NN	O
,	,	O
and	CC	O
Whipple	NNP	O
's	POS	O
disease	NN	O
,	,	O
autoimmune	NN	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases	NNS	O
,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis	NN	O
,	,	O
psoriasis	NN	O
,	,	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
atopic	NN	O
dermatitis	NN	O
,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria	NN	O
,	,	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia	NN	O
,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis	NN	O
,	,	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host-disease	NN	O
.	.	O
Infectious	JJ	O
diseases	NNS	O
including	VBG	O
viral	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
AIDS	NNP	O
(	(	O
HIV	NNP	O
infection	NN	O
)	)	O
,	,	O
hepatitis	VBZ	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
D	NNP	O
,	,	O
and	CC	O
E	NNP	O
,	,	O
herpes	VBZ	O
,	,	O
etc.	FW	O
,	,	O
bacterial	JJ	O
infections	NNS	O
,	,	O
fungal	JJ	O
infections	NNS	O
,	,	O
protozoal	NN	O
infections	NNS	O
and	CC	O
parasitic	JJ	O
infections	NNS	O
.	.	O
An	DT	O
“	JJ	O
autoimmune	NN	O
disease	NN	O
”	NNP	O
herein	NN	O
is	VBZ	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
arising	VBG	O
from	IN	O
and	CC	O
directed	VBN	O
against	IN	O
an	DT	O
individual	NN	O
's	POS	O
own	JJ	O
tissues	NNS	O
or	CC	O
a	DT	O
co-segregate	JJ	O
or	CC	O
manifestation	NN	O
thereof	NN	O
or	CC	O
resulting	VBG	O
condition	NN	O
therefrom	NN	O
.	.	O
Examples	NNS	O
of	IN	O
autoimmune	NN	O
diseases	NNS	O
or	CC	O
disorders	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
arthritis	VB	O
(	(	O
rheumatoid	JJ	O
arthritis	NN	O
,	,	O
juvenile	NN	O
rheumatoid	NN	O
arthritis	NN	O
,	,	O
osteoarthritis	NN	O
,	,	O
psoriatic	JJ	O
arthritis	NN	O
,	,	O
and	CC	O
ankylosing	VBG	O
spondylitis	NN	O
)	)	O
,	,	O
psoriasis	NN	O
,	,	O
dermatitis	NN	O
including	VBG	O
atopic	JJ	O
dermatitis	NN	O
;	:	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NNS	O
,	,	O
including	VBG	O
chronic	JJ	O
autoimmune	NN	O
urticaria	NNS	O
,	,	O
polymyositis/dermatomyositis	NN	O
,	,	O
toxic	JJ	O
epidermal	JJ	O
necrolysis	NN	O
,	,	O
systemic	JJ	O
scleroderma	NN	O
and	CC	O
sclerosis	NN	O
,	,	O
responses	NNS	O
associated	VBN	O
with	IN	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
IBD	NNP	O
)	)	O
(	(	O
Crohn	NNP	O
's	POS	O
disease	NN	O
,	,	O
ulcerative	JJ	O
colitis	NN	O
)	)	O
,	,	O
and	CC	O
IBD	NNP	O
with	IN	O
co-segregate	NN	O
of	IN	O
pyoderma	NN	O
gangrenosum	NN	O
,	,	O
erythema	NN	O
nodosum	NN	O
,	,	O
primary	JJ	O
sclerosing	VBG	O
cholangitis	NN	O
,	,	O
and/or	JJ	O
episcleritis	NN	O
)	)	O
,	,	O
respiratory	JJ	O
distress	NN	O
syndrome	NN	O
,	,	O
including	VBG	O
adult	NN	O
respiratory	NN	O
distress	NN	O
syndrome	NN	O
(	(	O
ARDS	NNP	O
)	)	O
,	,	O
meningitis	NN	O
,	,	O
IgE-mediated	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
anaphylaxis	NN	O
and	CC	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
encephalitis	NN	O
such	JJ	O
as	IN	O
Rasmussen	NNP	O
's	POS	O
encephalitis	NN	O
,	,	O
uveitis	NN	O
,	,	O
colitis	NN	O
such	JJ	O
as	IN	O
microscopic	NN	O
colitis	NN	O
and	CC	O
collagenous	JJ	O
colitis	NN	O
,	,	O
glomerulonephritis	NN	O
(	(	O
GN	NNP	O
)	)	O
such	JJ	O
as	IN	O
membranous	JJ	O
GN	NNP	O
,	,	O
idiopathic	JJ	O
membranous	JJ	O
GN	NNP	O
,	,	O
membranous	JJ	O
proliferative	JJ	O
GN	NNP	O
(	(	O
MPGN	NNP	O
)	)	O
,	,	O
including	VBG	O
Type	NN	O
I	PRP	O
and	CC	O
Type	NNP	O
II	NNP	O
,	,	O
and	CC	O
rapidly	RB	O
progressive	JJ	O
GN	NNP	O
,	,	O
allergic	JJ	O
conditions	NNS	O
,	,	O
eczema	NN	O
,	,	O
asthma	NN	O
,	,	O
conditions	NNS	O
involving	VBG	O
infiltration	NN	O
of	IN	O
T	NNP	O
cells	NNS	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
responses	NNS	O
,	,	O
atherosclerosis	NN	O
,	,	O
autoimmune	JJ	O
myocarditis	NN	O
,	,	O
leukocyte	JJ	O
adhesion	NN	O
deficiency	NN	O
,	,	O
systemic	JJ	O
lupus	NN	O
erythematosus	NN	O
(	(	O
SLE	NNP	O
)	)	O
such	JJ	O
as	IN	O
cutaneous	JJ	O
SLE	NNP	O
,	,	O
lupus	NN	O
(	(	O
including	VBG	O
nephritis	NN	O
,	,	O
cerebritis	NN	O
,	,	O
pediatric	JJ	O
,	,	O
non-renal	JJ	O
,	,	O
discoid	JJ	O
,	,	O
alopecia	NN	O
)	)	O
,	,	O
juvenile	JJ	O
onset	NN	O
diabetes	NNS	O
,	,	O
multiple	JJ	O
sclerosis	NN	O
(	(	O
MS	NNP	O
)	)	O
such	JJ	O
as	IN	O
spino-optical	JJ	O
MS	NNP	O
,	,	O
allergic	JJ	O
encephalomyelitis	NN	O
,	,	O
immune	JJ	O
responses	NNS	O
associated	VBN	O
with	IN	O
acute	NN	O
and	CC	O
delayed	JJ	O
hypersensitivity	NN	O
mediated	VBN	O
by	IN	O
cytokines	NNS	O
and	CC	O
T-lymphocytes	NNS	O
,	,	O
tuberculosis	NN	O
,	,	O
sarcoidosis	NN	O
,	,	O
granulomatosis	NN	O
including	VBG	O
Wegener	NNP	O
's	POS	O
granulomatosis	NN	O
,	,	O
agranulocytosis	NN	O
,	,	O
vasculitis	NN	O
(	(	O
including	VBG	O
Large	NNP	O
Vessel	NNP	O
vasculitis	NN	O
(	(	O
including	VBG	O
Polymyalgia	NNP	O
Rheumatica	NNP	O
and	CC	O
Giant	NNP	O
Cell	NNP	O
(	(	O
Takayasu	NNP	O
's	POS	O
)	)	O
Arteritis	NN	O
)	)	O
,	,	O
Medium	NNP	O
Vessel	NNP	O
vasculitis	NN	O
(	(	O
including	VBG	O
Kawasaki	NNP	O
's	POS	O
Disease	NNP	O
and	CC	O
Polyarteritis	NNP	O
Nodosa	NNP	O
)	)	O
,	,	O
CNS	NNP	O
vasculitis	NN	O
,	,	O
and	CC	O
ANCA-associated	NNP	O
vasculitis	NN	O
,	,	O
such	JJ	O
as	IN	O
Churg-Strauss	NNP	O
vasculitis	NN	O
or	CC	O
syndrome	NN	O
(	(	O
CSS	NNP	O
)	)	O
)	)	O
,	,	O
aplastic	JJ	O
anemia	NN	O
,	,	O
Coombs	NNP	O
positive	JJ	O
anemia	NN	O
,	,	O
Diamond	NNP	O
Blackfan	NNP	O
anemia	NN	O
,	,	O
immune	JJ	O
hemolytic	JJ	O
anemia	NN	O
including	VBG	O
autoimmune	JJ	O
hemolytic	JJ	O
anemia	NN	O
(	(	O
AIHA	NNP	O
)	)	O
,	,	O
pernicious	JJ	O
anemia	NN	O
,	,	O
pure	NN	O
red	JJ	O
cell	NN	O
aplasia	NN	O
(	(	O
PRCA	NNP	O
)	)	O
,	,	O
Factor	NNP	O
VIII	NNP	O
deficiency	NN	O
,	,	O
hemophilia	VB	O
A	NNP	O
,	,	O
autoimmune	NN	O
neutropenia	NN	O
,	,	O
pancytopenia	NN	O
,	,	O
leukopenia	NN	O
,	,	O
diseases	VBZ	O
involving	VBG	O
leukocyte	JJ	O
diapedesis	NN	O
,	,	O
CNS	NNP	O
inflammatory	NN	O
disorders	NNS	O
,	,	O
multiple	JJ	O
organ	JJ	O
injury	NN	O
syndrome	NN	O
,	,	O
myasthenia	NN	O
gravis	NN	O
,	,	O
antigen-antibody	NN	O
complex	NN	O
mediated	VBD	O
diseases	NNS	O
,	,	O
anti-glomerular	JJ	O
basement	NN	O
membrane	NN	O
disease	NN	O
,	,	O
anti-phospholipid	JJ	O
antibody	NN	O
syndrome	NN	O
,	,	O
allergic	JJ	O
neuritis	NN	O
,	,	O
Bechet	NNP	O
disease	NN	O
,	,	O
Castleman	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Goodpasture	NNP	O
's	POS	O
Syndrome	NNP	O
,	,	O
Lambert-Eaton	NNP	O
Myasthenic	NNP	O
Syndrome	NNP	O
,	,	O
Reynaud	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Sjorgen	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Stevens-Johnson	NNP	O
syndrome	NN	O
,	,	O
solid	JJ	O
organ	NN	O
transplant	JJ	O
rejection	NN	O
(	(	O
including	VBG	O
pretreatment	NN	O
for	IN	O
high	JJ	O
panel	NN	O
reactive	NN	O
antibody	NN	O
titers	NNS	O
,	,	O
IgA	NNP	O
deposit	NN	O
in	IN	O
tissues	NNS	O
,	,	O
and	CC	O
rejection	NN	O
arising	VBG	O
from	IN	O
renal	JJ	O
transplantation	NN	O
,	,	O
liver	JJ	O
transplantation	NN	O
,	,	O
intestinal	JJ	O
transplantation	NN	O
,	,	O
cardiac	JJ	O
transplantation	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
graft	JJ	O
versus	NN	O
host	NN	O
disease	NN	O
(	(	O
GVHD	NNP	O
)	)	O
,	,	O
pemphigoid	RB	O
bullous	JJ	O
,	,	O
pemphigus	JJ	O
(	(	O
including	VBG	O
vulgaris	NN	O
,	,	O
foliaceus	NN	O
,	,	O
and	CC	O
pemphigus	JJ	O
mucus-membrane	JJ	O
pemphigoid	NN	O
)	)	O
,	,	O
autoimmune	JJ	O
polyendocrinopathies	NNS	O
,	,	O
Reiter	NNP	O
's	POS	O
disease	NN	O
,	,	O
stiff-man	JJ	O
syndrome	NN	O
,	,	O
immune	NN	O
complex	JJ	O
nephritis	NN	O
,	,	O
IgM	NNP	O
polyneuropathies	VBZ	O
or	CC	O
IgM	NNP	O
mediated	VBD	O
neuropathy	JJ	O
,	,	O
idiopathic	JJ	O
thrombocytopenic	JJ	O
purpura	NN	O
(	(	O
ITP	NNP	O
)	)	O
,	,	O
thrombotic	JJ	O
throbocytopenic	NN	O
purpura	NN	O
(	(	O
TTP	NNP	O
)	)	O
,	,	O
thrombocytopenia	RB	O
(	(	O
as	IN	O
developed	VBN	O
by	IN	O
myocardial	JJ	O
infarction	NN	O
patients	NNS	O
,	,	O
for	IN	O
example	NN	O
)	)	O
,	,	O
including	VBG	O
autoimmune	JJ	O
thrombocytopenia	NN	O
,	,	O
autoimmune	JJ	O
disease	NN	O
of	IN	O
the	DT	O
testis	NN	O
and	CC	O
ovary	JJ	O
including	VBG	O
autoimmune	JJ	O
orchitis	NN	O
and	CC	O
oophoritis	NN	O
,	,	O
primary	JJ	O
hypothyroidism	NN	O
;	:	O
autoimmune	CC	O
endocrine	VBP	O
diseases	NNS	O
including	VBG	O
autoimmune	NN	O
thyroiditis	NN	O
,	,	O
chronic	JJ	O
thyroiditis	NN	O
(	(	O
Hashimoto	NNP	O
's	POS	O
Thyroiditis	NNP	O
)	)	O
,	,	O
subacute	JJ	O
thyroiditis	NN	O
,	,	O
idiopathic	JJ	O
hypothyroidism	NN	O
,	,	O
Addison	NNP	O
's	POS	O
disease	NN	O
,	,	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
autoimmune	JJ	O
polyglandular	JJ	O
syndromes	NNS	O
(	(	O
or	CC	O
polyglandular	VB	O
endocrinopathy	JJ	O
syndromes	NNS	O
)	)	O
,	,	O
Type	NNP	O
I	PRP	O
diabetes	VBZ	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
insulin-dependent	JJ	O
diabetes	NNS	O
mellitus	FW	O
(	(	O
IDDM	NNP	O
)	)	O
,	,	O
including	VBG	O
pediatric	JJ	O
IDDM	NNP	O
,	,	O
and	CC	O
Sheehan	NNP	O
's	POS	O
syndrome	NN	O
;	:	O
autoimmune	CC	O
hepatitis	NN	O
,	,	O
Lymphoid	NNP	O
interstitial	JJ	O
pneumonitis	NN	O
(	(	O
HIV	NNP	O
)	)	O
,	,	O
bronchiolitis	NN	O
obliterans	NNS	O
(	(	O
non-transplant	JJ	O
)	)	O
vs	NN	O
NSIP	NNP	O
,	,	O
Guillain-Barré	NNP	O
Syndrome	NNP	O
,	,	O
Berger	NNP	O
's	POS	O
Disease	NNP	O
(	(	O
IgA	NNP	O
nephropathy	RB	O
)	)	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
celiac	JJ	O
sprue	NN	O
(	(	O
gluten	VB	O
enteropathy	NN	O
)	)	O
,	,	O
refractory	JJ	O
sprue	NN	O
with	IN	O
co-segregate	JJ	O
dermatitis	NN	O
herpetiformis	NN	O
,	,	O
cryoglobulinemia	NN	O
,	,	O
amylotrophic	JJ	O
lateral	JJ	O
sclerosis	NN	O
(	(	O
ALS	NNP	O
;	:	O
Lou	NNP	O
Gehrig	NNP	O
's	POS	O
disease	NN	O
)	)	O
,	,	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
autoimmune	JJ	O
inner	JJ	O
ear	JJ	O
disease	NN	O
(	(	O
AIED	NNP	O
)	)	O
,	,	O
autoimmune	JJ	O
hearing	NN	O
loss	NN	O
,	,	O
opsoclonus	JJ	O
myoclonus	NN	O
syndrome	NN	O
(	(	O
OMS	NNP	O
)	)	O
,	,	O
polychondritis	NN	O
such	JJ	O
as	IN	O
refractory	NN	O
polychondritis	NN	O
,	,	O
pulmonary	JJ	O
alveolar	JJ	O
proteinosis	NN	O
,	,	O
amyloidosis	NN	O
,	,	O
giant	JJ	O
cell	NN	O
hepatitis	NN	O
,	,	O
scleritis	NN	O
,	,	O
monoclonal	JJ	O
gammopathy	NN	O
of	IN	O
uncertain/unknown	JJ	O
significance	NN	O
(	(	O
MGUS	NNP	O
)	)	O
,	,	O
peripheral	JJ	O
neuropathy	NN	O
,	,	O
paraneoplastic	JJ	O
syndrome	NN	O
,	,	O
channelopathies	NNS	O
such	JJ	O
as	IN	O
epilepsy	NN	O
,	,	O
migraine	NN	O
,	,	O
arrhythmia	NN	O
,	,	O
muscular	JJ	O
disorders	NNS	O
,	,	O
deafness	NN	O
,	,	O
blindness	NN	O
,	,	O
periodic	JJ	O
paralysis	NN	O
,	,	O
and	CC	O
channelopathies	NNS	O
of	IN	O
the	DT	O
CNS	NNP	O
;	:	O
autism	NN	O
,	,	O
inflammatory	JJ	O
myopathy	NN	O
,	,	O
and	CC	O
focal	JJ	O
segmental	JJ	O
glomerulosclerosis	NN	O
(	(	O
FSGS	NNP	O
)	)	O
.	.	O
The	DT	O
phrase	NN	O
“	NNP	O
anxiety	NN	O
related	VBD	O
disorders	NNS	O
”	JJ	O
refers	NNS	O
to	TO	O
disorders	NNS	O
of	IN	O
anxiety	NN	O
,	,	O
mood	NN	O
,	,	O
and	CC	O
substance	NN	O
abuse	NN	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
:	:	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Such	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
mild	NN	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
lipid	VBZ	O
metabolic	JJ	O
disorder	NN	O
”	NN	O
refers	NNS	O
to	TO	O
abnormal	VB	O
clinical	JJ	O
chemistry	NN	O
levels	NNS	O
of	IN	O
cholesterol	NN	O
and	CC	O
triglycerides	NNS	O
,	,	O
wherein	RB	O
elevated	JJ	O
levels	NNS	O
of	IN	O
these	DT	O
lipids	NNS	O
is	VBZ	O
an	DT	O
indication	NN	O
for	IN	O
atherosclerosis	NN	O
.	.	O
Additionally	RB	O
,	,	O
abnormal	JJ	O
serum	NN	O
lipid	JJ	O
levels	NNS	O
may	MD	O
be	VB	O
an	DT	O
indication	NN	O
of	IN	O
various	JJ	O
cardiovascular	JJ	O
diseases	NNS	O
including	VBG	O
hypertension	NN	O
,	,	O
stroke	NN	O
,	,	O
coronary	JJ	O
artery	NN	O
diseases	NNS	O
,	,	O
diabetes	VBZ	O
and/or	JJ	O
obesity	NN	O
.	.	O
The	DT	O
phrase	NN	O
“	NNP	O
eye	NN	O
abnormality	NN	O
”	NNP	O
refers	NNS	O
to	TO	O
such	JJ	O
potential	JJ	O
disorders	NNS	O
of	IN	O
the	DT	O
eye	NN	O
as	IN	O
they	PRP	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
atherosclerosis	VB	O
or	CC	O
various	JJ	O
ophthalmological	JJ	O
abnormalities	NNS	O
.	.	O
Such	JJ	O
disorders	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
the	DT	O
following	NN	O
:	:	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
restenosis	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstrom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
Cataracts	NNS	O
are	VBP	O
also	RB	O
considered	VBN	O
an	DT	O
eye	NN	O
abnormality	NN	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
such	JJ	O
systemic	JJ	O
diseases	NNS	O
as	IN	O
:	:	O
Human	NNP	O
Down	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Hallerman-Streiff	NNP	O
syndrome	NN	O
,	,	O
Lowe	NNP	O
syndrome	NN	O
,	,	O
galactosemia	NN	O
,	,	O
Marfan	NNP	O
syndrome	NN	O
,	,	O
Trismoy	NNP	O
13-15	CD	O
condition	NN	O
,	,	O
Alport	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
Fabry	NNP	O
disease	NN	O
,	,	O
hypothroidisms	NN	O
,	,	O
or	CC	O
Conradi	NNP	O
syndrome	NN	O
.	.	O
Other	JJ	O
ocular	JJ	O
developmental	JJ	O
anomalies	NNS	O
include	VBP	O
:	:	O
Aniridia	NNP	O
,	,	O
anterior	JJ	O
segment	NN	O
and	CC	O
dysgenesis	NN	O
syndrome	NN	O
.	.	O
Cataracts	NNS	O
may	MD	O
also	RB	O
occur	VB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
an	DT	O
intraocular	JJ	O
infection	NN	O
or	CC	O
inflammation	NN	O
(	(	O
uveitis	NN	O
)	)	O
.	.	O
A	DT	O
“	JJ	O
growth	NN	O
inhibitory	NN	O
amount	NN	O
”	NNP	O
of	IN	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptide	RB	O
or	CC	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecule	NN	O
is	VBZ	O
an	DT	O
amount	NN	O
capable	JJ	O
of	IN	O
inhibiting	VBG	O
the	DT	O
growth	NN	O
of	IN	O
a	DT	O
cell	NN	O
,	,	O
especially	RB	O
tumor	NN	O
,	,	O
e.g.	NN	O
,	,	O
cancer	NN	O
cell	NN	O
,	,	O
either	RB	O
in	IN	O
vitro	NN	O
or	CC	O
in	IN	O
vivo	NN	O
.	.	O
A	DT	O
“	JJ	O
growth	NN	O
inhibitory	NN	O
amount	NN	O
”	NNP	O
of	IN	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptide	RB	O
or	CC	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecule	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
inhibiting	VBG	O
neoplastic	JJ	O
cell	NN	O
growth	NN	O
may	MD	O
be	VB	O
determined	VBN	O
empirically	RB	O
and	CC	O
in	IN	O
a	DT	O
routine	JJ	O
manner	NN	O
.	.	O
A	DT	O
“	NNP	O
cytotoxic	NN	O
amount	NN	O
”	NNP	O
of	IN	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptide	RB	O
or	CC	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecule	NN	O
is	VBZ	O
an	DT	O
amount	NN	O
capable	JJ	O
of	IN	O
causing	VBG	O
the	DT	O
destruction	NN	O
of	IN	O
a	DT	O
cell	NN	O
,	,	O
especially	RB	O
tumor	NN	O
,	,	O
e.g.	NN	O
,	,	O
cancer	NN	O
cell	NN	O
,	,	O
either	RB	O
in	IN	O
vitro	NN	O
or	CC	O
in	IN	O
vivo	NN	O
.	.	O
A	DT	O
“	NNP	O
cytotoxic	NN	O
amount	NN	O
”	NNP	O
of	IN	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptide	RB	O
or	CC	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecule	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
inhibiting	VBG	O
neoplastic	JJ	O
cell	NN	O
growth	NN	O
may	MD	O
be	VB	O
determined	VBN	O
empirically	RB	O
and	CC	O
in	IN	O
a	DT	O
routine	JJ	O
manner	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
antibody	NN	O
”	NNP	O
is	VBZ	O
used	VBN	O
in	IN	O
the	DT	O
broadest	JJS	O
sense	NN	O
and	CC	O
specifically	RB	O
covers	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
single	JJ	O
anti-PRO227	NN	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
(	(	O
including	VBG	O
agonist	NN	O
,	,	O
antagonist	NN	O
,	,	O
and	CC	O
neutralizing	VBG	O
antibodies	NNS	O
)	)	O
,	,	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
compositions	NNS	O
with	IN	O
polyepitopic	NN	O
specificity	NN	O
,	,	O
polyclonal	JJ	O
antibodies	NNS	O
,	,	O
single	JJ	O
chain	NN	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
,	,	O
and	CC	O
fragments	NNS	O
of	IN	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
(	(	O
see	VB	O
below	RB	O
)	)	O
as	RB	O
long	RB	O
as	IN	O
they	PRP	O
exhibit	VBP	O
the	DT	O
desired	JJ	O
biological	JJ	O
or	CC	O
immunological	JJ	O
activity	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
immunoglobulin	NN	O
”	NNP	O
(	(	O
Ig	NNP	O
)	)	O
is	VBZ	O
used	VBN	O
interchangeable	JJ	O
with	IN	O
antibody	NN	O
herein	NN	O
.	.	O
An	DT	O
“	NN	O
isolated	VBD	O
antibody	NN	O
”	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
has	VBZ	O
been	VBN	O
identified	VBN	O
and	CC	O
separated	VBN	O
and/or	NNS	O
recovered	VBN	O
from	IN	O
a	DT	O
component	NN	O
of	IN	O
its	PRP$	O
natural	JJ	O
environment	NN	O
.	.	O
Contaminant	JJ	O
components	NNS	O
of	IN	O
its	PRP$	O
natural	JJ	O
environment	NN	O
are	VBP	O
materials	NNS	O
which	WDT	O
would	MD	O
interfere	VB	O
with	IN	O
diagnostic	JJ	O
or	CC	O
therapeutic	JJ	O
uses	NNS	O
for	IN	O
the	DT	O
antibody	NN	O
,	,	O
and	CC	O
may	MD	O
include	VB	O
enzymes	NNS	O
,	,	O
hormones	NNS	O
,	,	O
and	CC	O
other	JJ	O
proteinaceous	JJ	O
or	CC	O
nonproteinaceous	JJ	O
solutes	NNS	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
that	IN	O
the	DT	O
antibody	NN	O
will	MD	O
be	VB	O
purified	VBN	O
(	(	O
1	CD	O
)	)	O
to	TO	O
greater	JJR	O
than	IN	O
95	CD	O
%	NN	O
by	IN	O
weight	NN	O
of	IN	O
antibody	NN	O
as	IN	O
determined	VBN	O
by	IN	O
the	DT	O
Lowry	NNP	O
method	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
more	JJR	O
than	IN	O
99	CD	O
%	NN	O
by	IN	O
weight	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
to	TO	O
a	DT	O
degree	JJ	O
sufficient	NN	O
to	TO	O
obtain	VB	O
at	IN	O
least	JJS	O
15	CD	O
residues	NNS	O
of	IN	O
N-terminal	NNP	O
or	CC	O
internal	JJ	O
amino	NN	O
acid	NNS	O
sequence	NN	O
by	IN	O
use	NN	O
of	IN	O
a	DT	O
spinning	JJ	O
cup	NN	O
sequenator	NN	O
,	,	O
or	CC	O
(	(	O
3	CD	O
)	)	O
to	TO	O
homogeneity	NN	O
by	IN	O
SDS-PAGE	NNP	O
under	IN	O
reducing	VBG	O
or	CC	O
nonreducing	JJ	O
conditions	NNS	O
using	VBG	O
Coomassie	NNP	O
blue	NN	O
or	CC	O
,	,	O
preferably	RB	O
,	,	O
silver	RB	O
stain	NN	O
.	.	O
Isolated	VBN	O
antibody	NN	O
includes	VBZ	O
the	DT	O
antibody	NN	O
in	IN	O
situ	NN	O
within	IN	O
recombinant	JJ	O
cells	NNS	O
since	IN	O
at	IN	O
least	JJS	O
one	CD	O
component	NN	O
of	IN	O
the	DT	O
antibody	NN	O
's	POS	O
natural	JJ	O
environment	NN	O
will	MD	O
not	RB	O
be	VB	O
present	JJ	O
.	.	O
Ordinarily	RB	O
,	,	O
however	RB	O
,	,	O
isolated	VBN	O
antibody	NN	O
will	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
at	IN	O
least	JJS	O
one	CD	O
purification	NN	O
step	NN	O
.	.	O
The	DT	O
basic	JJ	O
4-chain	JJ	O
antibody	NN	O
unit	NN	O
is	VBZ	O
a	DT	O
heterotetrameric	JJ	O
glycoprotein	NN	O
composed	VBN	O
of	IN	O
two	CD	O
identical	JJ	O
light	NN	O
(	(	O
L	NNP	O
)	)	O
chains	NNS	O
and	CC	O
two	CD	O
identical	JJ	O
heavy	NN	O
(	(	O
H	NNP	O
)	)	O
chains	NNS	O
(	(	O
an	DT	O
IgM	NNP	O
antibody	NN	O
consists	VBZ	O
of	IN	O
5	CD	O
of	IN	O
the	DT	O
basic	JJ	O
heterotetramer	NN	O
unit	NN	O
along	IN	O
with	IN	O
an	DT	O
additional	JJ	O
polypeptide	NN	O
called	VBN	O
J	NNP	O
chain	NN	O
,	,	O
and	CC	O
therefore	RB	O
contain	VBP	O
10	CD	O
antigen	NN	O
binding	NN	O
sites	NNS	O
,	,	O
while	IN	O
secreted	VBN	O
IgA	NNP	O
antibodies	NNS	O
can	MD	O
polymerize	VB	O
to	TO	O
form	VB	O
polyvalent	NN	O
assemblages	NNS	O
comprising	VBG	O
2-5	CD	O
of	IN	O
the	DT	O
basic	JJ	O
4-chain	JJ	O
units	NNS	O
along	IN	O
with	IN	O
J	NNP	O
chain	NN	O
)	)	O
.	.	O
In	IN	O
the	DT	O
case	NN	O
of	IN	O
IgGs	NNP	O
,	,	O
the	DT	O
4-chain	JJ	O
unit	NN	O
is	VBZ	O
generally	RB	O
about	RB	O
150,000	CD	O
daltons	NNS	O
.	.	O
Each	DT	O
L	NNP	O
chain	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
a	DT	O
H	NNP	O
chain	NN	O
by	IN	O
one	CD	O
covalent	NN	O
disulfide	NN	O
bond	NN	O
,	,	O
while	IN	O
the	DT	O
two	CD	O
H	NNP	O
chains	NNS	O
are	VBP	O
linked	VBN	O
to	TO	O
each	DT	O
other	JJ	O
by	IN	O
one	CD	O
or	CC	O
more	JJR	O
disulfide	JJ	O
bonds	NNS	O
depending	VBG	O
on	IN	O
the	DT	O
H	NNP	O
chain	NN	O
isotype	NN	O
.	.	O
Each	DT	O
H	NNP	O
and	CC	O
L	NNP	O
chain	NN	O
also	RB	O
has	VBZ	O
regularly	RB	O
spaced	VBN	O
intrachain	NN	O
disulfide	NN	O
bridges	NNS	O
.	.	O
Each	DT	O
H	NNP	O
chain	NN	O
has	VBZ	O
at	IN	O
the	DT	O
N-terminus	NNP	O
,	,	O
a	DT	O
variable	JJ	O
domain	NN	O
(	(	O
VH	NNP	O
)	)	O
followed	VBN	O
by	IN	O
three	CD	O
constant	JJ	O
domains	NNS	O
(	(	O
CH	NNP	O
)	)	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
α	NN	O
and	CC	O
γ	NN	O
chains	NNS	O
and	CC	O
four	CD	O
CH	NNP	O
domains	NNS	O
for	IN	O
μ	NN	O
and	CC	O
ε	JJ	O
isotypes	NNS	O
.	.	O
Each	DT	O
L	NNP	O
chain	NN	O
has	VBZ	O
at	IN	O
the	DT	O
N-terminus	NNP	O
,	,	O
a	DT	O
variable	JJ	O
domain	NN	O
(	(	O
VL	NNP	O
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
constant	JJ	O
domain	NN	O
(	(	O
CL	NNP	O
)	)	O
at	IN	O
its	PRP$	O
other	JJ	O
end	NN	O
.	.	O
The	DT	O
VL	NNP	O
is	VBZ	O
aligned	VBN	O
with	IN	O
the	DT	O
VH	NNP	O
and	CC	O
the	DT	O
CL	NNP	O
is	VBZ	O
aligned	VBN	O
with	IN	O
the	DT	O
first	JJ	O
constant	JJ	O
domain	NN	O
of	IN	O
the	DT	O
heavy	JJ	O
chain	NN	O
(	(	O
CH1	NNP	O
)	)	O
.	.	O
Particular	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
are	VBP	O
believed	VBN	O
to	TO	O
form	VB	O
an	DT	O
interface	NN	O
between	IN	O
the	DT	O
light	NN	O
chain	NN	O
and	CC	O
heavy	JJ	O
chain	NN	O
variable	JJ	O
domains	NNS	O
.	.	O
The	DT	O
pairing	NN	O
of	IN	O
a	DT	O
VH	NNP	O
and	CC	O
VL	NNP	O
together	RB	O
forms	VBZ	O
a	DT	O
single	JJ	O
antigen-binding	JJ	O
site	NN	O
.	.	O
For	IN	O
the	DT	O
structure	NN	O
and	CC	O
properties	NNS	O
of	IN	O
the	DT	O
different	JJ	O
classes	NNS	O
of	IN	O
antibodies	NNS	O
,	,	O
see	VBP	O
,	,	O
e.g.	FW	O
,	,	O
Basic	NNP	B
and	CC	I
Clinical	NNP	I
Immunology	NNP	I
,	,	I
8th	CD	I
edition	NN	I
,	,	I
Daniel	NNP	I
P.	NNP	I
Stites	NNP	I
,	,	I
Abba	NNP	I
I.	NNP	I
Terr	NNP	I
and	CC	I
Tristram	NNP	I
G.	NNP	I
Parslow	NNP	I
(	(	I
eds	NNS	I
.	.	I
)	)	I
,	,	I
Appleton	NNP	I
&	CC	I
Lange	NNP	I
,	,	I
Norwalk	NNP	I
,	,	I
Conn.	NNP	I
,	,	I
1994	CD	I
,	,	I
page	NN	I
71	CD	I
and	CC	I
Chapter	NNP	I
6	CD	I
.	.	O
The	DT	O
L	NNP	O
chain	NN	O
from	IN	O
any	DT	O
vertebrate	JJ	O
species	NNS	O
can	MD	O
be	VB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
clearly	RB	O
distinct	JJ	O
types	NNS	O
,	,	O
called	VBN	O
kappa	NN	O
and	CC	O
lambda	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequences	NNS	O
of	IN	O
their	PRP$	O
constant	JJ	O
domains	NNS	O
.	.	O
Depending	VBG	O
on	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
constant	JJ	O
domain	NN	O
of	IN	O
their	PRP$	O
heavy	JJ	O
chains	NNS	O
(	(	O
CH	NNP	O
)	)	O
,	,	O
immunoglobulins	NNS	O
can	MD	O
be	VB	O
assigned	VBN	O
to	TO	O
different	JJ	O
classes	NNS	O
or	CC	O
isotypes	NNS	O
.	.	O
There	EX	O
are	VBP	O
five	CD	O
classes	NNS	O
of	IN	O
immunoglobulins	NNS	O
:	:	O
IgA	NNP	O
,	,	O
IgD	NNP	O
,	,	O
IgE	NNP	O
,	,	O
IgG	NNP	O
,	,	O
and	CC	O
IgM	NNP	O
,	,	O
having	VBG	O
heavy	JJ	O
chains	NNS	O
designated	VBN	O
α	NNP	O
,	,	O
δ	NNP	O
,	,	O
ε	NNP	O
,	,	O
γ	NNP	O
,	,	O
and	CC	O
μ	NNP	O
,	,	O
respectively	RB	O
.	.	O
The	DT	O
γ	NN	O
and	CC	O
α	NN	O
classes	NNS	O
are	VBP	O
further	RB	O
divided	VBN	O
into	IN	O
subclasses	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
relatively	RB	O
minor	JJ	O
differences	NNS	O
in	IN	O
CH	NNP	O
sequence	NN	O
and	CC	O
function	NN	O
,	,	O
e.g.	NN	O
,	,	O
humans	NNS	O
express	VBP	O
the	DT	O
following	JJ	O
subclasses	NNS	O
:	:	O
IgG1	NNP	O
,	,	O
IgG2	NNP	O
,	,	O
IgG3	NNP	O
,	,	O
IgG4	NNP	O
,	,	O
IgA1	NNP	O
,	,	O
and	CC	O
IgA2	NNP	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
variable	JJ	O
”	NN	O
refers	NNS	O
to	TO	O
the	DT	O
fact	NN	O
that	IN	O
certain	JJ	O
segments	NNS	O
of	IN	O
the	DT	O
variable	JJ	O
domains	NNS	O
differ	VBP	O
extensively	RB	O
in	IN	O
sequence	NN	O
among	IN	O
antibodies	NNS	O
.	.	O
The	DT	O
V	NNP	O
domain	NN	O
mediates	NNS	O
antigen	VBP	O
binding	VBG	O
and	CC	O
define	JJ	O
specificity	NN	O
of	IN	O
a	DT	O
particular	JJ	O
antibody	NN	O
for	IN	O
its	PRP$	O
particular	JJ	O
antigen	NN	O
.	.	O
However	RB	O
,	,	O
the	DT	O
variability	NN	O
is	VBZ	O
not	RB	O
evenly	RB	O
distributed	VBN	O
across	IN	O
the	DT	O
110-amino	JJ	O
acid	NN	O
span	NN	O
of	IN	O
the	DT	O
variable	JJ	O
domains	NNS	O
.	.	O
Instead	RB	O
,	,	O
the	DT	O
V	NNP	O
regions	NNS	O
consist	NN	O
of	IN	O
relatively	RB	O
invariant	JJ	O
stretches	NNS	O
called	VBN	O
framework	NN	O
regions	NNS	O
(	(	O
FRs	NNP	O
)	)	O
of	IN	O
15-30	JJ	O
amino	NN	O
acids	NNS	O
separated	VBN	O
by	IN	O
shorter	JJR	O
regions	NNS	O
of	IN	O
extreme	JJ	O
variability	NN	O
called	VBN	O
“	NNP	O
hypervariable	JJ	O
regions	NNS	O
”	VBP	O
that	WDT	O
are	VBP	O
each	DT	O
9-12	CD	O
amino	NN	O
acids	NNS	O
long	RB	O
.	.	O
The	DT	O
variable	JJ	O
domains	NNS	O
of	IN	O
native	JJ	O
heavy	JJ	O
and	CC	O
light	JJ	O
chains	NNS	O
each	DT	O
comprise	NN	O
four	CD	O
FRs	NNP	O
,	,	O
largely	RB	O
adopting	VBG	O
a	DT	O
β-sheet	JJ	O
configuration	NN	O
,	,	O
connected	VBN	O
by	IN	O
three	CD	O
hypervariable	JJ	O
regions	NNS	O
,	,	O
which	WDT	O
form	VBP	O
loops	NNS	O
connecting	VBG	O
,	,	O
and	CC	O
in	IN	O
some	DT	O
cases	NNS	O
forming	VBG	O
part	NN	O
of	IN	O
,	,	O
the	DT	O
β-sheet	JJ	O
structure	NN	O
.	.	O
The	DT	O
hypervariable	JJ	O
regions	NNS	O
in	IN	O
each	DT	O
chain	NN	O
are	VBP	O
held	VBN	O
together	RB	O
in	IN	O
close	JJ	O
proximity	NN	O
by	IN	O
the	DT	O
FRs	NNP	O
and	CC	O
,	,	O
with	IN	O
the	DT	O
hypervariable	JJ	O
regions	NNS	O
from	IN	O
the	DT	O
other	JJ	O
chain	NN	O
,	,	O
contribute	NN	O
to	TO	O
the	DT	O
formation	NN	O
of	IN	O
the	DT	O
antigen-binding	JJ	O
site	NN	O
of	IN	O
antibodies	NNS	O
(	(	O
see	VB	O
Kabat	NNP	B
et	FW	I
al.	NN	I
,	,	I
Sequences	NNP	I
of	IN	I
Proteins	NNP	I
of	IN	I
Immunological	NNP	I
Interest	NNP	I
,	,	I
5th	CD	I
Ed	NNP	I
.	.	I
Public	NNP	I
Health	NNP	I
Service	NNP	I
,	,	I
National	NNP	I
Institutes	NNPS	I
of	IN	I
Health	NNP	I
,	,	I
Bethesda	NNP	I
,	,	I
Md	NNP	I
.	.	I
(	(	I
1991	CD	I
)	)	I
)	)	O
.	.	O
The	DT	O
constant	JJ	O
domains	NNS	O
are	VBP	O
not	RB	O
involved	VBN	O
directly	RB	O
in	IN	O
binding	VBG	O
an	DT	O
antibody	NN	O
to	TO	O
an	DT	O
antigen	NN	O
,	,	O
but	CC	O
exhibit	RB	O
various	JJ	O
effector	NN	O
functions	NNS	O
,	,	O
such	JJ	O
as	IN	O
participation	NN	O
of	IN	O
the	DT	O
antibody	NN	O
in	IN	O
antibody	NN	O
dependent	JJ	O
cellular	JJ	O
cytotoxicity	NN	O
(	(	O
ADCC	NNP	O
)	)	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
hypervariable	JJ	O
region	NN	O
”	NN	O
when	WRB	O
used	VBN	O
herein	NN	O
refers	NNS	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
residues	NNS	O
of	IN	O
an	DT	O
antibody	NN	O
which	WDT	O
are	VBP	O
responsible	JJ	O
for	IN	O
antigen-binding	NN	O
.	.	O
The	DT	O
hypervariable	JJ	O
region	NN	O
generally	RB	O
comprises	VBZ	O
amino	JJ	O
acid	NN	O
residues	NNS	O
from	IN	O
a	DT	O
“	JJ	O
complementarity	NN	O
determining	VBG	O
region	NN	O
”	NN	O
or	CC	O
“	VB	O
CDR	NNP	O
”	NNP	O
(	(	O
e.g	NN	O
.	.	O
around	IN	O
about	RB	O
residues	NNS	O
24-34	JJ	O
(	(	O
L1	NNP	O
)	)	O
,	,	O
50-56	JJ	O
(	(	O
L2	NNP	O
)	)	O
and	CC	O
89-97	JJ	O
(	(	O
L3	NNP	O
)	)	O
in	IN	O
the	DT	O
VL	NNP	O
,	,	O
and	CC	O
around	IN	O
about	IN	O
1-35	JJ	O
(	(	O
H1	NNP	O
)	)	O
,	,	O
50-65	JJ	O
(	(	O
H2	NNP	O
)	)	O
and	CC	O
95-102	JJ	O
(	(	O
H3	NNP	O
)	)	O
in	IN	O
the	DT	O
VH	NNP	O
;	:	O
Kabat	NNP	B
et	FW	I
al.	NN	I
,	,	I
Sequences	NNP	I
of	IN	I
Proteins	NNP	I
of	IN	I
Immunological	NNP	I
Interest	NNP	I
,	,	I
5th	CD	I
Ed	NNP	I
.	.	I
Public	NNP	I
Health	NNP	I
Service	NNP	I
,	,	I
National	NNP	I
Institutes	NNPS	I
of	IN	I
Health	NNP	I
,	,	I
Bethesda	NNP	I
,	,	I
Md	NNP	I
.	.	I
(	(	I
1991	CD	I
)	)	I
)	)	O
and/or	VBP	O
those	DT	O
residues	NNS	O
from	IN	O
a	DT	O
“	NN	O
hypervariable	JJ	O
loop	NN	O
”	NNP	O
(	(	O
e.g	NN	O
.	.	O
residues	NNS	O
26-32	JJ	O
(	(	O
L1	NNP	O
)	)	O
,	,	O
50-52	JJ	O
(	(	O
L2	NNP	O
)	)	O
and	CC	O
91-96	JJ	O
(	(	O
L3	NNP	O
)	)	O
in	IN	O
the	DT	O
VL	NNP	O
,	,	O
and	CC	O
26-32	JJ	O
(	(	O
H1	NNP	O
)	)	O
,	,	O
53-55	JJ	O
(	(	O
H2	NNP	O
)	)	O
and	CC	O
96-101	JJ	O
(	(	O
H3	NNP	O
)	)	O
in	IN	O
the	DT	O
VH	NNP	O
;	:	O
Chothia	NNP	B
and	CC	I
Lesk	NNP	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol	NNP	I
.	.	I
196:901-917	CD	I
(	(	I
1987	CD	I
)	)	I
)	)	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
monoclonal	JJ	O
antibody	NN	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
refers	NNS	O
to	TO	O
an	DT	O
antibody	NN	O
obtained	VBN	O
from	IN	O
a	DT	O
population	NN	O
of	IN	O
substantially	RB	O
homogeneous	JJ	O
antibodies	NNS	O
,	,	O
i.e.	NN	O
,	,	O
the	DT	O
individual	JJ	O
antibodies	NNS	O
comprising	VBG	O
the	DT	O
population	NN	O
are	VBP	O
identical	JJ	O
except	IN	O
for	IN	O
possible	JJ	O
naturally	RB	O
occurring	VBG	O
mutations	NNS	O
that	WDT	O
may	MD	O
be	VB	O
present	JJ	O
in	IN	O
minor	JJ	O
amounts	NNS	O
.	.	O
Monoclonal	JJ	O
antibodies	NNS	O
are	VBP	O
highly	RB	O
specific	JJ	O
,	,	O
being	VBG	O
directed	VBN	O
against	IN	O
a	DT	O
single	JJ	O
antigenic	JJ	O
site	NN	O
.	.	O
Furthermore	RB	O
,	,	O
in	IN	O
contrast	NN	O
to	TO	O
polyclonal	VB	O
antibody	NN	O
preparations	NNS	O
which	WDT	O
include	VBP	O
different	JJ	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
different	JJ	O
determinants	NNS	O
(	(	O
epitopes	NNS	O
)	)	O
,	,	O
each	DT	O
monoclonal	JJ	O
antibody	NN	O
is	VBZ	O
directed	VBN	O
against	IN	O
a	DT	O
single	JJ	O
determinant	NN	O
on	IN	O
the	DT	O
antigen	NN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
their	PRP$	O
specificity	NN	O
,	,	O
the	DT	O
monoclonal	JJ	O
antibodies	NNS	O
are	VBP	O
advantageous	JJ	O
in	IN	O
that	DT	O
they	PRP	O
may	MD	O
be	VB	O
synthesized	VBN	O
uncontaminated	JJ	O
by	IN	O
other	JJ	O
antibodies	NNS	O
.	.	O
The	DT	O
modifier	JJR	O
“	JJ	O
monoclonal	JJ	O
”	NN	O
is	VBZ	O
not	RB	O
to	TO	O
be	VB	O
construed	VBN	O
as	IN	O
requiring	VBG	O
production	NN	O
of	IN	O
the	DT	O
antibody	NN	O
by	IN	O
any	DT	O
particular	JJ	O
method	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
monoclonal	JJ	O
antibodies	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
the	DT	O
hybridoma	NN	O
methodology	NN	O
first	RB	O
described	VBN	O
by	IN	O
Kohler	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
256:495	CD	I
(	(	I
1975	CD	I
)	)	I
,	,	O
or	CC	O
may	MD	O
be	VB	O
made	VBN	O
using	VBG	O
recombinant	JJ	O
DNA	NNP	O
methods	NNS	O
in	IN	O
bacterial	JJ	O
,	,	O
eukaryotic	JJ	O
animal	NN	O
or	CC	O
plant	NN	O
cells	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,816,567	CD	O
)	)	O
.	.	O
The	DT	O
“	NNP	O
monoclonal	JJ	O
antibodies	NNS	O
”	VBP	O
may	MD	O
also	RB	O
be	VB	O
isolated	VBN	O
from	IN	O
phage	NN	O
antibody	NN	O
libraries	VBZ	O
using	VBG	O
the	DT	O
techniques	NNS	O
described	VBN	O
in	IN	O
Clackson	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
352:624-628	NNP	I
(	(	I
1991	CD	I
)	)	I
and	CC	O
Marks	NNP	B
et	VBP	I
al.	NN	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
222:581-597	CD	I
(	(	I
1991	CD	I
)	)	I
,	,	O
for	IN	O
example	NN	O
.	.	O
The	DT	O
monoclonal	JJ	O
antibodies	NNS	O
herein	VBP	O
include	VBP	O
“	JJ	O
chimeric	JJ	O
”	NN	O
antibodies	NNS	O
in	IN	O
which	WDT	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
heavy	JJ	O
and/or	NN	O
light	NN	O
chain	NN	O
is	VBZ	O
identical	JJ	O
with	IN	O
or	CC	O
homologous	JJ	O
to	TO	O
corresponding	VBG	O
sequences	NNS	O
in	IN	O
antibodies	NNS	O
derived	VBN	O
from	IN	O
a	DT	O
particular	JJ	O
species	NNS	O
or	CC	O
belonging	VBG	O
to	TO	O
a	DT	O
particular	JJ	O
antibody	NN	O
class	NN	O
or	CC	O
subclass	NN	O
,	,	O
while	IN	O
the	DT	O
remainder	NN	O
of	IN	O
the	DT	O
chain	NN	O
(	(	O
s	NN	O
)	)	O
is	VBZ	O
identical	JJ	O
with	IN	O
or	CC	O
homologous	JJ	O
to	TO	O
corresponding	VBG	O
sequences	NNS	O
in	IN	O
antibodies	NNS	O
derived	VBN	O
from	IN	O
another	DT	O
species	NNS	O
or	CC	O
belonging	VBG	O
to	TO	O
another	DT	O
antibody	NN	O
class	NN	O
or	CC	O
subclass	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
fragments	NNS	O
of	IN	O
such	JJ	O
antibodies	NNS	O
,	,	O
so	RB	O
long	RB	O
as	IN	O
they	PRP	O
exhibit	VBP	O
the	DT	O
desired	JJ	O
biological	JJ	O
activity	NN	O
(	(	O
see	VB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,816,567	CD	O
;	:	O
and	CC	O
Morrison	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
81:6851-6855	CD	I
(	(	I
1984	CD	I
)	)	I
)	)	O
.	.	O
Chimeric	JJ	O
antibodies	NNS	O
of	IN	O
interest	NN	O
herein	NN	O
include	VBP	O
“	NNP	O
primatized	VBD	O
”	JJ	O
antibodies	NNS	O
comprising	VBG	O
variable	JJ	O
domain	NN	O
antigen-binding	JJ	O
sequences	NNS	O
derived	VBN	O
from	IN	O
a	DT	O
non-human	JJ	O
primate	NN	O
(	(	O
e.g	NN	O
.	.	O
Old	NNP	O
World	NNP	O
Monkey	NNP	O
,	,	O
Ape	NNP	O
etc	NN	O
)	)	O
,	,	O
and	CC	O
human	JJ	O
constant	JJ	O
region	NN	O
sequences	NNS	O
.	.	O
An	DT	O
“	JJ	O
intact	JJ	O
”	NNP	O
antibody	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
comprises	VBZ	O
an	DT	O
antigen-binding	JJ	O
site	NN	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
CL	NNP	O
and	CC	O
at	IN	O
least	JJS	O
heavy	JJ	O
chain	NN	O
constant	JJ	O
domains	NNS	O
,	,	O
CH1	NNP	O
,	,	O
CH2	NNP	O
and	CC	O
CH3	NNP	O
.	.	O
The	DT	O
constant	JJ	O
domains	NNS	O
may	MD	O
be	VB	O
native	JJ	O
sequence	NN	O
constant	JJ	O
domains	NNS	O
(	(	O
e.g	NN	O
.	.	O
human	JJ	O
native	JJ	O
sequence	NN	O
constant	JJ	O
domains	NNS	O
)	)	O
or	CC	O
amino	JJ	O
acid	JJ	O
sequence	NN	O
variant	NN	O
thereof	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
intact	JJ	O
antibody	NN	O
has	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
effector	JJ	O
functions	NNS	O
.	.	O
“	NN	O
Antibody	NN	O
fragments	NNS	O
”	VBP	O
comprise	VB	O
a	DT	O
portion	NN	O
of	IN	O
an	DT	O
intact	JJ	O
antibody	NN	O
,	,	O
preferably	RB	O
the	DT	O
antigen	NN	O
binding	NN	O
or	CC	O
variable	JJ	O
region	NN	O
of	IN	O
the	DT	O
intact	JJ	O
antibody	NN	O
.	.	O
Examples	NNS	O
of	IN	O
antibody	NN	O
fragments	NNS	O
include	VBP	O
Fab	NNP	O
,	,	O
Fab′	NNP	O
,	,	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
,	,	O
and	CC	O
Fv	NNP	O
fragments	NNS	O
;	:	O
diabodies	NNS	O
;	:	O
linear	JJ	O
antibodies	NNS	O
(	(	O
see	VB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,641,870	CD	O
,	,	O
Example	NNP	O
2	CD	O
;	:	O
Zapata	NNP	B
et	FW	I
al.	NN	I
,	,	I
Protein	NNP	I
Eng	NNP	I
.	.	I
8	CD	I
(	(	I
10	CD	I
)	)	I
:	:	I
1057-1062	JJ	I
[	NN	I
1995	CD	I
]	NN	I
)	)	O
;	:	O
single-chain	JJ	O
antibody	NN	O
molecules	NNS	O
;	:	O
and	CC	O
multispecific	JJ	O
antibodies	NNS	O
formed	VBN	O
from	IN	O
antibody	NN	O
fragments	NNS	O
.	.	O
Papain	NNP	O
digestion	NN	O
of	IN	O
antibodies	NNS	O
produces	VBZ	O
two	CD	O
identical	JJ	O
antigen-binding	NN	O
fragments	NNS	O
,	,	O
called	VBN	O
“	NN	O
Fab	NNP	O
”	NNP	O
fragments	NNS	O
,	,	O
and	CC	O
a	DT	O
residual	JJ	O
“	NN	O
Fc	NNP	O
”	NNP	O
fragment	NN	O
,	,	O
a	DT	O
designation	NN	O
reflecting	VBG	O
the	DT	O
ability	NN	O
to	TO	O
crystallize	VB	O
readily	RB	O
.	.	O
The	DT	O
Fab	NNP	O
fragment	NN	O
consists	VBZ	O
of	IN	O
an	DT	O
entire	JJ	O
L	NNP	O
chain	NN	O
along	IN	O
with	IN	O
the	DT	O
variable	JJ	O
region	NN	O
domain	NN	O
of	IN	O
the	DT	O
H	NNP	O
chain	NN	O
(	(	O
VH	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
first	JJ	O
constant	JJ	O
domain	NN	O
of	IN	O
one	CD	O
heavy	NN	O
chain	NN	O
(	(	O
CH1	NNP	O
)	)	O
.	.	O
Each	DT	O
Fab	NNP	O
fragment	NN	O
is	VBZ	O
monovalent	JJ	O
with	IN	O
respect	NN	O
to	TO	O
antigen	VB	O
binding	NN	O
,	,	O
i.e.	FW	O
,	,	O
it	PRP	O
has	VBZ	O
a	DT	O
single	JJ	O
antigen-binding	JJ	O
site	NN	O
.	.	O
Pepsin	NNP	O
treatment	NN	O
of	IN	O
an	DT	O
antibody	NN	O
yields	VBZ	O
a	DT	O
single	JJ	O
large	JJ	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
fragment	NN	O
which	WDT	O
roughly	RB	O
corresponds	VBZ	O
to	TO	O
two	CD	O
disulfide	NN	O
linked	VBD	O
Fab	NNP	O
fragments	NNS	O
having	VBG	O
divalent	JJ	O
antigen-binding	JJ	O
activity	NN	O
and	CC	O
is	VBZ	O
still	RB	O
capable	JJ	O
of	IN	O
cross-linking	JJ	O
antigen	NN	O
.	.	O
Fab′	NNP	O
fragments	NNS	O
differ	VBP	O
from	IN	O
Fab	NNP	O
fragments	NNS	O
by	IN	O
having	VBG	O
additional	JJ	O
few	JJ	O
residues	NNS	O
at	IN	O
the	DT	O
carboxy	JJ	O
terminus	NN	O
of	IN	O
the	DT	O
CH1	NNP	O
domain	NN	O
including	VBG	O
one	CD	O
or	CC	O
more	JJR	O
cysteines	NNS	O
from	IN	O
the	DT	O
antibody	NN	O
hinge	JJ	O
region	NN	O
.	.	O
Fab′-SH	NNP	O
is	VBZ	O
the	DT	O
designation	NN	O
herein	NN	O
for	IN	O
Fab′	NNP	O
in	IN	O
which	WDT	O
the	DT	O
cysteine	NN	O
residue	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
constant	JJ	O
domains	NNS	O
bear	VBP	O
a	DT	O
free	JJ	O
thiol	NN	O
group	NN	O
.	.	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
antibody	NN	O
fragments	NNS	O
originally	RB	O
were	VBD	O
produced	VBN	O
as	IN	O
pairs	NNS	O
of	IN	O
Fab′	NNP	O
fragments	NNS	O
which	WDT	O
have	VBP	O
hinge	VBN	O
cysteines	NNS	O
between	IN	O
them	PRP	O
.	.	O
Other	JJ	O
chemical	JJ	O
couplings	NNS	O
of	IN	O
antibody	NN	O
fragments	NNS	O
are	VBP	O
also	RB	O
known	VBN	O
.	.	O
The	DT	O
Fc	NNP	O
fragment	NN	O
comprises	VBZ	O
the	DT	O
carboxy-terminal	JJ	O
portions	NNS	O
of	IN	O
both	DT	O
H	NNP	O
chains	NNS	O
held	VBD	O
together	RB	O
by	IN	O
disulfides	NNS	O
.	.	O
The	DT	O
effector	NN	O
functions	NNS	O
of	IN	O
antibodies	NNS	O
are	VBP	O
determined	VBN	O
by	IN	O
sequences	NNS	O
in	IN	O
the	DT	O
Fc	NNP	O
region	NN	O
,	,	O
which	WDT	O
region	NN	O
is	VBZ	O
also	RB	O
the	DT	O
part	NN	O
recognized	VBN	O
by	IN	O
Fc	NNP	O
receptors	NNS	O
(	(	O
FcR	NNP	O
)	)	O
found	VBN	O
on	IN	O
certain	JJ	O
types	NNS	O
of	IN	O
cells	NNS	O
.	.	O
“	JJ	O
Fv	NNP	O
”	NNP	O
is	VBZ	O
the	DT	O
minimum	JJ	O
antibody	NN	O
fragment	NN	O
which	WDT	O
contains	VBZ	O
a	DT	O
complete	JJ	O
antigen-recognition	NN	O
and	CC	O
-binding	VBG	O
site	NN	O
.	.	O
This	DT	O
fragment	JJ	O
consists	VBZ	O
of	IN	O
a	DT	O
dimer	NN	O
of	IN	O
one	CD	O
heavy-	NN	O
and	CC	O
one	CD	O
light-chain	NN	O
variable	JJ	O
region	NN	O
domain	NN	O
in	IN	O
tight	JJ	O
,	,	O
non-covalent	JJ	O
association	NN	O
.	.	O
From	IN	O
the	DT	O
folding	NN	O
of	IN	O
these	DT	O
two	CD	O
domains	NNS	O
emanate	VBP	O
six	CD	O
hypervariable	JJ	O
loops	NNS	O
(	(	O
3	CD	O
loops	NNS	O
each	DT	O
from	IN	O
the	DT	O
H	NNP	O
and	CC	O
L	NNP	O
chain	NN	O
)	)	O
that	WDT	O
contribute	VBP	O
the	DT	O
amino	NN	O
acid	NN	O
residues	NNS	O
for	IN	O
antigen	NN	O
binding	NN	O
and	CC	O
confer	NN	O
antigen	NN	O
binding	VBG	O
specificity	NN	O
to	TO	O
the	DT	O
antibody	NN	O
.	.	O
However	RB	O
,	,	O
even	RB	O
a	DT	O
single	JJ	O
variable	NN	O
domain	NN	O
(	(	O
or	CC	O
half	NN	O
of	IN	O
an	DT	O
Fv	NNP	O
comprising	VBG	O
only	RB	O
three	CD	O
CDRs	NNP	O
specific	NN	O
for	IN	O
an	DT	O
antigen	NN	O
)	)	O
has	VBZ	O
the	DT	O
ability	NN	O
to	TO	O
recognize	VB	O
and	CC	O
bind	VB	O
antigen	NN	O
,	,	O
although	IN	O
at	IN	O
a	DT	O
lower	JJR	O
affinity	NN	O
than	IN	O
the	DT	O
entire	JJ	O
binding	NN	O
site	NN	O
.	.	O
“	JJ	O
Single-chain	NNP	O
Fv	NNP	O
”	NNP	O
also	RB	O
abbreviated	VBD	O
as	IN	O
“	NNP	O
sFv	VBP	O
”	NNP	O
or	CC	O
“	NNP	O
scFv	VBP	O
”	NNS	O
are	VBP	O
antibody	JJ	O
fragments	NNS	O
that	WDT	O
comprise	VBP	O
the	DT	O
VH	NNP	O
and	CC	O
VL	NNP	O
antibody	NN	O
domains	VBZ	O
connected	VBN	O
into	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
chain	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
sFv	NN	O
polypeptide	IN	O
further	JJ	O
comprises	NNS	O
a	DT	O
polypeptide	NN	O
linker	NN	O
between	IN	O
the	DT	O
VH	NNP	O
and	CC	O
VL	NNP	O
domains	NNS	O
which	WDT	O
enables	VBZ	O
the	DT	O
sFv	NN	O
to	TO	O
form	VB	O
the	DT	O
desired	JJ	O
structure	NN	O
for	IN	O
antigen	NN	O
binding	NN	O
.	.	O
For	IN	O
a	DT	O
review	NN	O
of	IN	O
sFv	NN	O
,	,	O
see	VBP	O
Pluckthun	NNP	B
in	IN	I
The	DT	I
Pharmacology	NNP	I
of	IN	I
Monoclonal	NNP	I
Antibodies	NNP	I
,	,	I
vol	NN	I
.	.	I
113	CD	I
,	,	I
Rosenburg	NNP	I
and	CC	I
Moore	NNP	I
eds.	NN	I
,	,	I
Springer-Verlag	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
pp	NN	I
.	.	I
269-315	CD	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Borrebaeck	NNP	B
1995	CD	I
,	,	O
infra	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
diabodies	VBZ	O
”	PRP$	O
refers	NNS	O
to	TO	O
small	JJ	O
antibody	NN	O
fragments	NNS	O
prepared	VBN	O
by	IN	O
constructing	VBG	O
sFv	NN	O
fragments	NNS	O
(	(	O
see	VB	O
preceding	VBG	O
paragraph	NNS	O
)	)	O
with	IN	O
short	JJ	O
linkers	NNS	O
(	(	O
about	IN	O
5-10	NNP	O
residues	NNS	O
)	)	O
between	IN	O
the	DT	O
VH	NNP	O
and	CC	O
VL	NNP	O
domains	NNS	O
such	JJ	O
that	IN	O
inter-chain	NN	O
but	CC	O
not	RB	O
intra-chain	JJ	O
pairing	NN	O
of	IN	O
the	DT	O
V	NNP	O
domains	NNS	O
is	VBZ	O
achieved	VBN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
bivalent	NN	O
fragment	NN	O
,	,	O
i.e.	FW	O
,	,	O
fragment	JJ	O
having	VBG	O
two	CD	O
antigen-binding	JJ	O
sites	NNS	O
.	.	O
Bispecific	NNP	O
diabodies	NNS	O
are	VBP	O
heterodimers	NNS	O
of	IN	O
two	CD	O
“	NNS	O
crossover	RB	O
”	VBP	O
sFv	JJ	O
fragments	NNS	O
in	IN	O
which	WDT	O
the	DT	O
VH	NNP	O
and	CC	O
VL	NNP	O
domains	NNS	O
of	IN	O
the	DT	O
two	CD	O
antibodies	NNS	O
are	VBP	O
present	JJ	O
on	IN	O
different	JJ	O
polypeptide	NN	O
chains	NNS	O
.	.	O
Diabodies	NNS	O
are	VBP	O
described	VBN	O
more	RBR	O
fully	RB	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
EP	NNP	O
404,097	CD	O
;	:	O
WO	NNP	O
93/11161	CD	O
;	:	O
and	CC	O
Hollinger	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
90:6444-6448	CD	I
(	(	I
1993	CD	I
)	)	I
.	.	O
“	NNS	O
Humanized	NNP	O
”	NN	O
forms	NNS	O
of	IN	O
non-human	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
rodent	NN	O
)	)	O
antibodies	NNS	O
are	VBP	O
chimeric	JJ	O
antibodies	NNS	O
that	WDT	O
contain	VBP	O
minimal	JJ	O
sequence	NN	O
derived	VBN	O
from	IN	O
the	DT	O
non-human	JJ	O
antibody	NN	O
.	.	O
For	IN	O
the	DT	O
most	JJS	O
part	NN	O
,	,	O
humanized	VBN	O
antibodies	NNS	O
are	VBP	O
human	JJ	O
immunoglobulins	NNS	O
(	(	O
recipient	VB	O
antibody	NN	O
)	)	O
in	IN	O
which	WDT	O
residues	VBP	O
from	IN	O
a	DT	O
hypervariable	JJ	O
region	NN	O
of	IN	O
the	DT	O
recipient	NN	O
are	VBP	O
replaced	VBN	O
by	IN	O
residues	NNS	O
from	IN	O
a	DT	O
hypervariable	JJ	O
region	NN	O
of	IN	O
a	DT	O
non-human	JJ	O
species	NNS	O
(	(	O
donor	VB	O
antibody	NN	O
)	)	O
such	JJ	O
as	IN	O
mouse	NN	O
,	,	O
rat	NN	O
,	,	O
rabbit	NN	O
or	CC	O
non-human	JJ	O
primate	NN	O
having	VBG	O
the	DT	O
desired	VBN	O
antibody	NN	O
specificity	NN	O
,	,	O
affinity	NN	O
,	,	O
and	CC	O
capability	NN	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
framework	NN	O
region	NN	O
(	(	O
FR	NNP	O
)	)	O
residues	NNS	O
of	IN	O
the	DT	O
human	JJ	O
immunoglobulin	NN	O
are	VBP	O
replaced	VBN	O
by	IN	O
corresponding	VBG	O
non-human	JJ	O
residues	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
humanized	JJ	O
antibodies	NNS	O
may	MD	O
comprise	VB	O
residues	NNS	O
that	WDT	O
are	VBP	O
not	RB	O
found	VBN	O
in	IN	O
the	DT	O
recipient	NN	O
antibody	NN	O
or	CC	O
in	IN	O
the	DT	O
donor	NN	O
antibody	NN	O
.	.	O
These	DT	O
modifications	NNS	O
are	VBP	O
made	VBN	O
to	TO	O
further	JJ	O
refine	NN	O
antibody	NN	O
performance	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
humanized	VBN	O
antibody	NN	O
will	MD	O
comprise	VB	O
substantially	RB	O
all	DT	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
,	,	O
and	CC	O
typically	RB	O
two	CD	O
,	,	O
variable	JJ	O
domains	NNS	O
,	,	O
in	IN	O
which	WDT	O
all	DT	O
or	CC	O
substantially	RB	O
all	DT	O
of	IN	O
the	DT	O
hypervariable	JJ	O
loops	NNS	O
correspond	NN	O
to	TO	O
those	DT	O
of	IN	O
a	DT	O
non-human	JJ	O
immunoglobulin	NN	O
and	CC	O
all	DT	O
or	CC	O
substantially	RB	O
all	DT	O
of	IN	O
the	DT	O
FRs	NNP	O
are	VBP	O
those	DT	O
of	IN	O
a	DT	O
human	JJ	O
immunoglobulin	NN	O
sequence	NN	O
.	.	O
The	DT	O
humanized	VBN	O
antibody	NN	O
optionally	RB	O
also	RB	O
will	MD	O
comprise	VB	O
at	IN	O
least	JJS	O
a	DT	O
portion	NN	O
of	IN	O
an	DT	O
immunoglobulin	NN	O
constant	JJ	O
region	NN	O
(	(	O
Fc	NNP	O
)	)	O
,	,	O
typically	RB	O
that	IN	O
of	IN	O
a	DT	O
human	JJ	O
immunoglobulin	NN	O
.	.	O
For	IN	O
further	JJR	O
details	NNS	O
,	,	O
see	VBP	O
Jones	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
321:522-525	CD	I
(	(	I
1986	CD	I
)	)	I
;	:	O
Riechmann	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
332:323-329	CD	I
(	(	I
1988	CD	I
)	)	I
;	:	O
and	CC	O
Presta	NNP	B
,	,	I
Curr	NNP	I
.	.	I
Op	NNP	I
.	.	I
Struct	NN	I
.	.	I
Biol	NNP	I
.	.	I
2:593-596	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
A	DT	O
“	JJ	O
species-dependent	JJ	O
antibody	NN	O
,	,	O
”	NNP	O
e.g.	NN	O
,	,	O
a	DT	O
mammalian	JJ	O
anti-human	JJ	O
IgE	NNP	O
antibody	NN	O
,	,	O
is	VBZ	O
an	DT	O
antibody	NN	O
which	WDT	O
has	VBZ	O
a	DT	O
stronger	JJR	O
binding	NN	O
affinity	NN	O
for	IN	O
an	DT	O
antigen	NN	O
from	IN	O
a	DT	O
first	JJ	O
mammalian	JJ	O
species	NNS	O
than	IN	O
it	PRP	O
has	VBZ	O
for	IN	O
a	DT	O
homologue	NN	O
of	IN	O
that	DT	O
antigen	NN	O
from	IN	O
a	DT	O
second	JJ	O
mammalian	JJ	O
species	NNS	O
.	.	O
Normally	RB	O
,	,	O
the	DT	O
species-dependent	JJ	O
antibody	NN	O
“	NNP	O
bind	NN	O
specifically	RB	O
”	VBZ	O
to	TO	O
a	DT	O
human	JJ	O
antigen	NN	O
(	(	O
i.e.	NN	O
,	,	O
has	VBZ	O
a	DT	O
binding	NN	O
affinity	NN	O
(	(	O
Kd	NNP	O
)	)	O
value	NN	O
of	IN	O
no	DT	O
more	JJR	O
than	IN	O
about	RB	O
1×10−7	CD	O
M	NNP	O
,	,	O
preferably	RB	O
no	DT	O
more	JJR	O
than	IN	O
about	RB	O
1×10−8	CD	O
and	CC	O
most	RBS	O
preferably	RB	O
no	DT	O
more	JJR	O
than	IN	O
about	RB	O
1×10−9	CD	O
M	NNP	O
)	)	O
but	CC	O
has	VBZ	O
a	DT	O
binding	NN	O
affinity	NN	O
for	IN	O
a	DT	O
homologue	NN	O
of	IN	O
the	DT	O
antigen	NN	O
from	IN	O
a	DT	O
second	JJ	O
non-human	JJ	O
mammalian	NN	O
species	NNS	O
which	WDT	O
is	VBZ	O
at	IN	O
least	JJS	O
about	IN	O
50	CD	O
fold	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
about	IN	O
500	CD	O
fold	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
about	IN	O
1000	CD	O
fold	NN	O
,	,	O
weaker	JJR	O
than	IN	O
its	PRP$	O
binding	NN	O
affinity	NN	O
for	IN	O
the	DT	O
human	JJ	O
antigen	NN	O
.	.	O
The	DT	O
species-dependent	JJ	O
antibody	NN	O
can	MD	O
be	VB	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
various	JJ	O
types	NNS	O
of	IN	O
antibodies	NNS	O
as	IN	O
defined	VBN	O
above	IN	O
,	,	O
but	CC	O
preferably	RB	O
is	VBZ	O
a	DT	O
humanized	JJ	O
or	CC	O
human	JJ	O
antibody	NN	O
.	.	O
A	DT	O
“	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptide	JJ	O
”	NNP	O
is	VBZ	O
an	DT	O
oligopeptide	NN	O
that	WDT	O
binds	VBZ	O
,	,	O
preferably	RB	O
specifically	RB	O
,	,	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
described	VBN	O
herein	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptides	NNS	O
may	MD	O
be	VB	O
chemically	RB	O
synthesized	VBN	O
using	VBG	O
known	VBN	O
oligopeptide	JJ	O
synthesis	NN	O
methodology	NN	O
or	CC	O
may	MD	O
be	VB	O
prepared	VBN	O
and	CC	O
purified	VBN	O
using	VBG	O
recombinant	JJ	O
technology	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptides	NNS	O
usually	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
5	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
6	CD	O
,	,	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
50	CD	O
,	,	O
51	CD	O
,	,	O
52	CD	O
,	,	O
53	CD	O
,	,	O
54	CD	O
,	,	O
55	CD	O
,	,	O
56	CD	O
,	,	O
57	CD	O
,	,	O
58	CD	O
,	,	O
59	CD	O
,	,	O
60	CD	O
,	,	O
61	CD	O
,	,	O
62	CD	O
,	,	O
63	CD	O
,	,	O
64	CD	O
,	,	O
65	CD	O
,	,	O
66	CD	O
,	,	O
67	CD	O
,	,	O
68	CD	O
,	,	O
69	CD	O
,	,	O
70	CD	O
,	,	O
71	CD	O
,	,	O
72	CD	O
,	,	O
73	CD	O
,	,	O
74	CD	O
,	,	O
75	CD	O
,	,	O
76	CD	O
,	,	O
77	CD	O
,	,	O
78	CD	O
,	,	O
79	CD	O
,	,	O
80	CD	O
,	,	O
81	CD	O
,	,	O
82	CD	O
,	,	O
83	CD	O
,	,	O
84	CD	O
,	,	O
85	CD	O
,	,	O
86	CD	O
,	,	O
87	CD	O
,	,	O
88	CD	O
,	,	O
89	CD	O
,	,	O
90	CD	O
,	,	O
91	CD	O
,	,	O
92	CD	O
,	,	O
93	CD	O
,	,	O
94	CD	O
,	,	O
95	CD	O
,	,	O
96	CD	O
,	,	O
97	CD	O
,	,	O
98	CD	O
,	,	O
99	CD	O
,	,	O
or	CC	O
100	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
or	CC	O
more	JJR	O
,	,	O
wherein	WP	O
such	JJ	O
oligopeptides	NNS	O
that	WDT	O
are	VBP	O
capable	JJ	O
of	IN	O
binding	NN	O
,	,	O
preferably	RB	O
specifically	RB	O
,	,	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
described	VBN	O
herein	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
oligopeptides	NNS	O
may	MD	O
be	VB	O
identified	VBN	O
without	IN	O
undue	JJ	O
experimentation	NN	O
using	VBG	O
well	RB	O
known	VBN	O
techniques	NNS	O
.	.	O
In	IN	O
this	DT	O
regard	NN	O
,	,	O
it	PRP	O
is	VBZ	O
noted	VBN	O
that	IN	O
techniques	NNS	O
for	IN	O
screening	VBG	O
oligopeptide	JJ	O
libraries	NNS	O
for	IN	O
oligopeptides	NNS	O
that	WDT	O
are	VBP	O
capable	JJ	O
of	IN	O
specifically	RB	O
binding	VBG	O
to	TO	O
a	DT	O
polypeptide	NN	O
target	NN	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,556,762	CD	O
,	,	O
5,750,373	CD	O
,	,	O
4,708,871	CD	O
,	,	O
4,833,092	CD	O
,	,	O
5,223,409	CD	O
,	,	O
5,403,484	CD	O
,	,	O
5,571,689	CD	O
,	,	O
5,663,143	CD	O
;	:	O
PCT	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO	$	O
84/03506	CD	O
and	CC	O
WO84/03564	NNP	O
;	:	O
Geysen	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
81:3998-4002	CD	I
(	(	I
1984	CD	I
)	)	I
;	:	O
Geysen	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
82:178-182	CD	I
(	(	I
1985	CD	I
)	)	I
;	:	O
Geysen	NNP	B
et	FW	I
al.	NN	I
,	,	I
in	IN	I
Synthetic	NNP	I
Peptides	NNP	I
as	IN	I
Antigens	NNP	I
,	,	I
130-149	CD	I
(	(	I
1986	CD	I
)	)	I
;	:	O
Geysen	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
Meth.	NNP	I
,	,	I
102:259-274	CD	I
(	(	I
1987	CD	I
)	)	I
;	:	O
Schoofs	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
140:611-616	CD	I
(	(	I
1988	CD	I
)	)	I
,	,	O
Cwirla	NNP	B
,	,	I
S.	NNP	I
E.	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
87:6378	CD	I
;	:	O
Lowman	NNP	B
,	,	I
H.	NNP	I
B.	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Biochemistry	NNP	I
,	,	I
30:10832	CD	I
;	:	O
Clackson	NNP	B
,	,	I
T.	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Nature	NN	I
,	,	I
352	CD	I
:	:	I
624	CD	I
;	:	O
Marks	NNS	B
,	,	I
J.	NNP	I
D.	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
222:581	CD	I
;	:	O
Kang	NNP	B
,	,	I
A.	NNP	I
S.	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
88:8363	CD	I
,	,	O
and	CC	O
Smith	NNP	B
,	,	I
G.	NNP	I
P.	NNP	I
(	(	I
1991	CD	I
)	)	I
Current	NNP	I
Opin	NNP	I
.	.	I
Biotechnol.	NNP	I
,	,	I
2:668	CD	I
)	)	O
.	.	O
A	DT	O
“	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecule	NN	O
”	NNP	O
is	VBZ	O
an	DT	O
organic	JJ	O
molecule	NN	O
other	JJ	O
than	IN	O
an	DT	O
oligopeptide	NN	O
or	CC	O
antibody	NN	O
as	IN	O
defined	JJ	O
herein	NN	O
that	WDT	O
binds	VBZ	O
,	,	O
preferably	RB	O
specifically	RB	O
,	,	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
described	VBN	O
herein	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecules	NNS	O
may	MD	O
be	VB	O
identified	VBN	O
and	CC	O
chemically	RB	O
synthesized	JJ	O
using	VBG	O
known	VBN	O
methodology	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
PCT	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO00/00823	NNP	O
and	CC	O
WO00/39585	NNP	O
)	)	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
organic	JJ	O
molecules	NNS	O
are	VBP	O
usually	RB	O
less	JJR	O
than	IN	O
about	IN	O
2000	CD	O
daltons	NNS	O
in	IN	O
size	NN	O
,	,	O
alternatively	RB	O
less	JJR	O
than	IN	O
about	IN	O
1500	CD	O
,	,	O
750	CD	O
,	,	O
500	CD	O
,	,	O
250	CD	O
or	CC	O
200	CD	O
daltons	NNS	O
in	IN	O
size	NN	O
,	,	O
wherein	WP	O
such	JJ	O
organic	JJ	O
molecules	NNS	O
that	WDT	O
are	VBP	O
capable	JJ	O
of	IN	O
binding	NN	O
,	,	O
preferably	RB	O
specifically	RB	O
,	,	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
described	VBN	O
herein	NN	O
may	MD	O
be	VB	O
identified	VBN	O
without	IN	O
undue	JJ	O
experimentation	NN	O
using	VBG	O
well	RB	O
known	VBN	O
techniques	NNS	O
.	.	O
In	IN	O
this	DT	O
regard	NN	O
,	,	O
it	PRP	O
is	VBZ	O
noted	VBN	O
that	IN	O
techniques	NNS	O
for	IN	O
screening	VBG	O
organic	JJ	O
molecule	NN	O
libraries	NNS	O
for	IN	O
molecules	NNS	O
that	WDT	O
are	VBP	O
capable	JJ	O
of	IN	O
binding	VBG	O
to	TO	O
a	DT	O
polypeptide	NN	O
target	NN	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
PCT	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO00/00823	NNP	O
and	CC	O
WO00/39585	NNP	O
)	)	O
.	.	O
An	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
“	NNP	O
which	WDT	O
binds	VBZ	O
”	PDT	O
an	DT	O
antigen	NN	O
of	IN	O
interest	NN	O
,	,	O
e.g	RB	O
.	.	O
a	DT	O
tumor-associated	JJ	O
polypeptide	NN	O
antigen	NN	O
target	NN	O
,	,	O
is	VBZ	O
one	CD	O
that	WDT	O
binds	VBZ	O
the	DT	O
antigen	NN	O
with	IN	O
sufficient	JJ	O
affinity	NN	O
such	JJ	O
that	IN	O
the	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
is	VBZ	O
preferably	RB	O
useful	JJ	O
as	IN	O
a	DT	O
diagnostic	JJ	O
and/or	NN	O
therapeutic	JJ	O
agent	NN	O
in	IN	O
targeting	VBG	O
a	DT	O
cell	NN	O
or	CC	O
tissue	NN	O
expressing	VBG	O
the	DT	O
antigen	NN	O
,	,	O
and	CC	O
does	VBZ	O
not	RB	O
significantly	RB	O
cross-react	JJ	O
with	IN	O
other	JJ	O
proteins	NNS	O
.	.	O
The	DT	O
extent	NN	O
of	IN	O
binding	NN	O
of	IN	O
the	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
to	TO	O
a	DT	O
“	JJ	O
non-target	JJ	O
”	NN	O
protein	NN	O
will	MD	O
be	VB	O
less	JJR	O
than	IN	O
about	RB	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
binding	NN	O
of	IN	O
the	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
to	TO	O
its	PRP$	O
particular	JJ	O
target	NN	O
protein	NN	O
as	IN	O
determined	VBN	O
by	IN	O
fluorescence	NN	O
activated	VBN	O
cell	NN	O
sorting	VBG	O
(	(	O
FACS	NNP	O
)	)	O
analysis	NN	O
or	CC	O
radioimmunoprecipitation	NN	O
(	(	O
RIA	NNP	O
)	)	O
.	.	O
With	IN	O
regard	NN	O
to	TO	O
the	DT	O
binding	NN	O
of	IN	O
an	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
to	TO	O
a	DT	O
target	NN	O
molecule	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
specific	JJ	O
binding	VBG	O
”	NN	O
or	CC	O
“	VB	O
specifically	RB	O
binds	VBZ	O
to	TO	O
”	VB	O
or	CC	O
is	VBZ	O
“	JJ	O
specific	JJ	O
for	IN	O
”	NN	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
or	CC	O
an	DT	O
epitope	NN	O
on	IN	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
target	NN	O
means	VBZ	O
binding	VBG	O
that	DT	O
is	VBZ	O
measurably	RB	O
different	JJ	O
from	IN	O
a	DT	O
non-specific	JJ	O
interaction	NN	O
.	.	O
Specific	JJ	O
binding	NN	O
can	MD	O
be	VB	O
measured	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
determining	VBG	O
binding	NN	O
of	IN	O
a	DT	O
molecule	NN	O
compared	VBN	O
to	TO	O
binding	NN	O
of	IN	O
a	DT	O
control	NN	O
molecule	NN	O
,	,	O
which	WDT	O
generally	RB	O
is	VBZ	O
a	DT	O
molecule	NN	O
of	IN	O
similar	JJ	O
structure	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
have	VB	O
binding	VBG	O
activity	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
specific	JJ	O
binding	NN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
competition	NN	O
with	IN	O
a	DT	O
control	NN	O
molecule	NN	O
that	WDT	O
is	VBZ	O
similar	JJ	O
to	TO	O
the	DT	O
target	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
an	DT	O
excess	NN	O
of	IN	O
non-labeled	JJ	O
target	NN	O
.	.	O
In	IN	O
this	DT	O
case	NN	O
,	,	O
specific	JJ	O
binding	NN	O
is	VBZ	O
indicated	VBN	O
if	IN	O
the	DT	O
binding	NN	O
of	IN	O
the	DT	O
labeled	JJ	O
target	NN	O
to	TO	O
a	DT	O
probe	NN	O
is	VBZ	O
competitively	RB	O
inhibited	VBN	O
by	IN	O
excess	NN	O
unlabeled	JJ	O
target	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
specific	JJ	O
binding	VBG	O
”	NN	O
or	CC	O
“	VB	O
specifically	RB	O
binds	VBZ	O
to	TO	O
”	VB	O
or	CC	O
is	VBZ	O
“	JJ	O
specific	JJ	O
for	IN	O
”	NN	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
or	CC	O
an	DT	O
epitope	NN	O
on	IN	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
target	NN	O
as	IN	O
used	JJ	O
herein	NN	O
can	MD	O
be	VB	O
exhibited	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
a	DT	O
molecule	NN	O
having	VBG	O
a	DT	O
Kd	NNP	O
for	IN	O
the	DT	O
target	NN	O
of	IN	O
at	IN	O
least	JJS	O
about	IN	O
10−4	CD	O
M	NNP	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−5	CD	O
M	NNP	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−6	CD	O
M	NNP	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−7	CD	O
M	NNP	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−8	CD	O
M	NNP	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−9	CD	O
M	NNP	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−10	CD	O
M	NNP	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−11	CD	O
M	NNP	O
,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−12	CD	O
M	NNP	O
,	,	O
or	CC	O
greater	JJR	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
specific	JJ	O
binding	VBG	O
”	JJ	O
refers	NNS	O
to	TO	O
binding	VBG	O
where	WRB	O
a	DT	O
molecule	NN	O
binds	VBZ	O
to	TO	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
or	CC	O
epitope	NN	O
on	IN	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
without	IN	O
substantially	RB	O
binding	VBG	O
to	TO	O
any	DT	O
other	JJ	O
polypeptide	NN	O
or	CC	O
polypeptide	JJ	O
epitope	NN	O
.	.	O
An	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
that	IN	O
“	VBZ	O
inhibits	VBZ	O
the	DT	O
growth	NN	O
of	IN	O
tumor	NN	O
cells	NNS	O
expressing	VBG	O
a	DT	O
“	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
”	NNP	O
or	CC	O
a	DT	O
“	JJ	O
growth	NN	O
inhibitory	NN	O
”	NNP	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
results	NNS	O
in	IN	O
measurable	JJ	O
growth	NN	O
inhibition	NN	O
of	IN	O
cancer	NN	O
cells	NNS	O
expressing	VBG	O
or	CC	O
overexpressing	VBG	O
the	DT	O
appropriate	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
a	DT	O
transmembrane	JJ	O
polypeptide	NN	O
expressed	VBN	O
on	IN	O
the	DT	O
surface	NN	O
of	IN	O
a	DT	O
cancer	NN	O
cell	NN	O
or	CC	O
may	MD	O
be	VB	O
a	DT	O
polypeptide	NN	O
that	WDT	O
is	VBZ	O
produced	VBN	O
and	CC	O
secreted	VBN	O
by	IN	O
a	DT	O
cancer	NN	O
cell	NN	O
.	.	O
Preferred	NNP	O
growth	NN	O
inhibitory	NN	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
,	,	O
oligopeptides	NNS	O
or	CC	O
organic	JJ	O
molecules	NNS	O
inhibit	VBP	O
growth	NN	O
of	IN	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-expressing	NNP	O
tumor	NN	O
cells	NNS	O
by	IN	O
or	CC	O
by	IN	O
greater	JJR	O
than	IN	O
20	CD	O
%	NN	O
,	,	O
preferably	RB	O
from	IN	O
about	IN	O
20	CD	O
%	NN	O
to	TO	O
about	RB	O
50	CD	O
%	NN	O
,	,	O
and	CC	O
even	RB	O
more	RBR	O
preferably	RB	O
,	,	O
by	IN	O
or	CC	O
by	IN	O
greater	JJR	O
than	IN	O
50	CD	O
%	NN	O
(	(	O
e.g.	JJ	O
,	,	O
from	IN	O
about	IN	O
50	CD	O
%	NN	O
to	TO	O
about	RB	O
100	CD	O
%	NN	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
appropriate	JJ	O
control	NN	O
,	,	O
the	DT	O
control	NN	O
typically	RB	O
being	VBG	O
tumor	NN	O
cells	NNS	O
not	RB	O
treated	VBN	O
with	IN	O
the	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
being	VBG	O
tested	VBN	O
.	.	O
Growth	NNP	O
inhibition	NN	O
can	MD	O
be	VB	O
measured	VBN	O
at	IN	O
an	DT	O
antibody	NN	O
concentration	NN	O
of	IN	O
about	RB	O
0.1	CD	O
to	TO	O
30	CD	O
μg/ml	NNS	O
or	CC	O
about	IN	O
0.5	CD	O
nM	NNS	O
to	TO	O
200	CD	O
nM	NNS	O
in	IN	O
cell	NN	O
culture	NN	O
,	,	O
where	WRB	O
the	DT	O
growth	NN	O
inhibition	NN	O
is	VBZ	O
determined	VBN	O
1-10	JJ	O
days	NNS	O
after	IN	O
exposure	NN	O
of	IN	O
the	DT	O
tumor	NN	O
cells	NNS	O
to	TO	O
the	DT	O
antibody	NN	O
.	.	O
Growth	NNP	O
inhibition	NN	O
of	IN	O
tumor	NN	O
cells	NNS	O
in	IN	O
vivo	NN	O
can	MD	O
be	VB	O
determined	VBN	O
in	IN	O
various	JJ	O
ways	NNS	O
.	.	O
The	DT	O
antibody	NN	O
is	VBZ	O
growth	NN	O
inhibitory	NN	O
in	IN	O
vivo	NN	O
if	IN	O
administration	NN	O
of	IN	O
the	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
at	IN	O
about	IN	O
1	CD	O
μg/kg	NNS	O
to	TO	O
about	IN	O
100	CD	O
mg/kg	NNS	O
body	NN	O
weight	JJ	O
results	NNS	O
in	IN	O
reduction	NN	O
in	IN	O
tumor	NN	O
size	NN	O
or	CC	O
tumor	NN	O
cell	NN	O
proliferation	NN	O
within	IN	O
about	IN	O
5	CD	O
days	NNS	O
to	TO	O
3	CD	O
months	NNS	O
from	IN	O
the	DT	O
first	JJ	O
administration	NN	O
of	IN	O
the	DT	O
antibody	NN	O
,	,	O
preferably	RB	O
within	IN	O
about	RB	O
5	CD	O
to	TO	O
30	CD	O
days	NNS	O
.	.	O
An	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
which	WDT	O
“	NNP	O
induces	VBZ	O
apoptosis	NN	O
”	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
induces	VBZ	O
programmed	VBN	O
cell	RB	O
death	NN	O
as	IN	O
determined	VBN	O
by	IN	O
binding	VBG	O
of	IN	O
annexin	NN	O
V	NNP	O
,	,	O
fragmentation	NN	O
of	IN	O
DNA	NNP	O
,	,	O
cell	NN	O
shrinkage	NN	O
,	,	O
dilation	NN	O
of	IN	O
endoplasmic	JJ	O
reticulum	NN	O
,	,	O
cell	NN	O
fragmentation	NN	O
,	,	O
and/or	JJ	O
formation	NN	O
of	IN	O
membrane	NN	O
vesicles	NNS	O
(	(	O
called	VBN	O
apoptotic	JJ	O
bodies	NNS	O
)	)	O
.	.	O
The	DT	O
cell	NN	O
is	VBZ	O
usually	RB	O
one	CD	O
which	WDT	O
overexpresses	VBZ	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Preferably	RB	O
the	DT	O
cell	NN	O
is	VBZ	O
a	DT	O
tumor	NN	O
cell	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
prostate	NN	O
,	,	O
breast	NN	O
,	,	O
ovarian	JJ	O
,	,	O
stomach	NN	O
,	,	O
endometrial	JJ	O
,	,	O
lung	NN	O
,	,	O
kidney	NN	O
,	,	O
colon	NN	O
,	,	O
bladder	NN	O
cell	NN	O
.	.	O
Various	JJ	O
methods	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
evaluating	VBG	O
the	DT	O
cellular	JJ	O
events	NNS	O
associated	VBN	O
with	IN	O
apoptosis	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
phosphatidyl	FW	O
serine	NN	O
(	(	O
PS	NNP	O
)	)	O
translocation	NN	O
can	MD	O
be	VB	O
measured	VBN	O
by	IN	O
annexin	NN	O
binding	NN	O
;	:	O
DNA	NNP	O
fragmentation	NN	O
can	MD	O
be	VB	O
evaluated	VBN	O
through	IN	O
DNA	NNP	O
laddering	NN	O
;	:	O
and	CC	O
nuclear/chromatin	DT	O
condensation	NN	O
along	IN	O
with	IN	O
DNA	NNP	O
fragmentation	NN	O
can	MD	O
be	VB	O
evaluated	VBN	O
by	IN	O
any	DT	O
increase	NN	O
in	IN	O
hypodiploid	JJ	O
cells	NNS	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
which	WDT	O
induces	VBZ	O
apoptosis	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
results	NNS	O
in	IN	O
or	CC	O
in	IN	O
about	RB	O
2	CD	O
to	TO	O
50	CD	O
fold	NN	O
,	,	O
preferably	RB	O
in	IN	O
or	CC	O
in	IN	O
about	RB	O
5	CD	O
to	TO	O
50	CD	O
fold	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
in	IN	O
or	CC	O
in	IN	O
about	RB	O
10	CD	O
to	TO	O
50	CD	O
fold	NN	O
,	,	O
induction	NN	O
of	IN	O
annexin	NN	O
binding	VBG	O
relative	JJ	O
to	TO	O
untreated	JJ	O
cell	NN	O
in	IN	O
an	DT	O
annexin	NN	O
binding	VBG	O
assay	NN	O
.	.	O
Antibody	NN	O
“	NNP	O
effector	NN	O
functions	NNS	O
”	VBP	O
refer	NN	O
to	TO	O
those	DT	O
biological	JJ	O
activities	NNS	O
attributable	JJ	O
to	TO	O
the	DT	O
Fc	NNP	O
region	NN	O
(	(	O
a	DT	O
native	JJ	O
sequence	NN	O
Fc	NNP	O
region	NN	O
or	CC	O
amino	NN	O
acid	JJ	O
sequence	NN	O
variant	NN	O
Fc	NNP	O
region	NN	O
)	)	O
of	IN	O
an	DT	O
antibody	NN	O
,	,	O
and	CC	O
vary	JJ	O
with	IN	O
the	DT	O
antibody	NN	O
isotype	NN	O
.	.	O
Examples	NNS	O
of	IN	O
antibody	NN	O
effector	NN	O
functions	NNS	O
include	VBP	O
:	:	O
C1q	NNP	O
binding	NN	O
and	CC	O
complement	NN	O
dependent	JJ	O
cytotoxicity	NN	O
;	:	O
Fc	NNP	O
receptor	NN	O
binding	NN	O
;	:	O
antibody-dependent	JJ	O
cell-mediated	JJ	O
cytotoxicity	NN	O
(	(	O
ADCC	NNP	O
)	)	O
;	:	O
phagocytosis	NN	O
;	:	O
down	IN	O
regulation	NN	O
of	IN	O
cell	NN	O
surface	NN	O
receptors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
B	NNP	O
cell	NN	O
receptor	NN	O
)	)	O
;	:	O
and	CC	O
B	NNP	O
cell	NN	O
activation	NN	O
.	.	O
“	JJ	O
Antibody-dependent	JJ	O
cell-mediated	JJ	O
cytotoxicity	NN	O
”	NN	O
or	CC	O
“	VB	O
ADCC	NNP	O
”	NNP	O
refers	NNS	O
to	TO	O
a	DT	O
form	NN	O
of	IN	O
cytotoxicity	NN	O
in	IN	O
which	WDT	O
secreted	VBD	O
Ig	NNP	O
bound	IN	O
onto	IN	O
Fc	NNP	O
receptors	NNS	O
(	(	O
FcRs	NNP	O
)	)	O
present	NN	O
on	IN	O
certain	JJ	O
cytotoxic	NN	O
cells	NNS	O
(	(	O
e.g.	NN	O
,	,	O
Natural	NNP	O
Killer	NNP	O
(	(	O
NK	NNP	O
)	)	O
cells	NNS	O
,	,	O
neutrophils	NNS	O
,	,	O
and	CC	O
macrophages	NNS	O
)	)	O
enable	VBP	O
these	DT	O
cytotoxic	NNS	O
effector	VBP	O
cells	NNS	O
to	TO	O
bind	VB	O
specifically	RB	O
to	TO	O
an	DT	O
antigen-bearing	JJ	O
target	NN	O
cell	NN	O
and	CC	O
subsequently	RB	O
kill	VB	O
the	DT	O
target	NN	O
cell	NN	O
with	IN	O
cytotoxins	NNS	O
.	.	O
The	DT	O
antibodies	NNS	O
“	VBP	O
arm	NN	O
”	NN	O
the	DT	O
cytotoxic	NN	O
cells	NNS	O
and	CC	O
are	VBP	O
absolutely	RB	O
required	VBN	O
for	IN	O
such	JJ	O
killing	NN	O
.	.	O
The	DT	O
primary	JJ	O
cells	NNS	O
for	IN	O
mediating	VBG	O
ADCC	NNP	O
,	,	O
NK	NNP	O
cells	NNS	O
,	,	O
express	NN	O
FcγRIII	NNP	O
only	RB	O
,	,	O
whereas	JJ	O
monocytes	NNS	O
express	JJ	O
FcγRI	NNP	O
,	,	O
FcγRII	NNP	O
and	CC	O
FcγRIII	NNP	O
.	.	O
FcR	NNP	O
expression	NN	O
on	IN	O
hematopoietic	JJ	O
cells	NNS	O
is	VBZ	O
summarized	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
on	IN	O
page	NN	O
464	CD	O
of	IN	O
Ravetch	NNP	B
and	CC	I
Kinet	NNP	I
,	,	I
Annu	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Immunol	NNP	I
.	.	I
9:457-92	CD	I
(	(	I
1991	CD	I
)	)	I
.	.	O
To	TO	O
assess	VB	O
ADCC	NNP	O
activity	NN	O
of	IN	O
a	DT	O
molecule	NN	O
of	IN	O
interest	NN	O
,	,	O
an	DT	O
in	IN	O
vitro	NN	O
ADCC	NNP	O
assay	NN	O
,	,	O
such	JJ	O
as	IN	O
that	DT	O
described	VBD	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,500,362	CD	O
or	CC	O
5,821,337	CD	O
may	MD	O
be	VB	O
performed	VBN	O
.	.	O
Useful	JJ	O
effector	NN	O
cells	NNS	O
for	IN	O
such	JJ	O
assays	NNS	O
include	VBP	O
peripheral	JJ	O
blood	NN	O
mononuclear	NN	O
cells	NNS	O
(	(	O
PBMC	NNP	O
)	)	O
and	CC	O
Natural	NNP	O
Killer	NNP	O
(	(	O
NK	NNP	O
)	)	O
cells	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
or	CC	O
additionally	RB	O
,	,	O
ADCC	NNP	O
activity	NN	O
of	IN	O
the	DT	O
molecule	NN	O
of	IN	O
interest	NN	O
may	MD	O
be	VB	O
assessed	VBN	O
in	IN	O
vivo	NN	O
,	,	O
e.g.	NN	O
,	,	O
in	IN	O
a	DT	O
animal	JJ	O
model	NN	O
such	JJ	O
as	IN	O
that	DT	O
disclosed	VBD	O
in	IN	O
Clynes	NNP	B
et	CC	I
al	NN	I
.	.	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
95:652-656	CD	I
(	(	I
1998	CD	I
)	)	I
.	.	O
“	JJ	O
Fc	NNP	O
receptor	NN	O
”	NN	O
or	CC	O
“	VB	O
FcR	NNP	O
”	NNP	O
describes	VBZ	O
a	DT	O
receptor	NN	O
that	WDT	O
binds	VBZ	O
to	TO	O
the	DT	O
Fc	NNP	O
region	NN	O
of	IN	O
an	DT	O
antibody	NN	O
.	.	O
The	DT	O
preferred	JJ	O
FcR	NNP	O
is	VBZ	O
a	DT	O
native	JJ	O
sequence	NN	O
human	JJ	O
FcR	NNP	O
.	.	O
Moreover	RB	O
,	,	O
a	DT	O
preferred	JJ	O
FcR	NNP	O
is	VBZ	O
one	CD	O
which	WDT	O
binds	VBZ	O
an	DT	O
IgG	NNP	O
antibody	NN	O
(	(	O
a	DT	O
gamma	NN	O
receptor	NN	O
)	)	O
and	CC	O
includes	VBZ	O
receptors	NNS	O
of	IN	O
the	DT	O
FcγRI	NNP	O
,	,	O
FcγRII	NNP	O
and	CC	O
FcγRIII	NNP	O
subclasses	NNS	O
,	,	O
including	VBG	O
allelic	JJ	O
variants	NNS	O
and	CC	O
alternatively	RB	O
spliced	VBD	O
forms	NNS	O
of	IN	O
these	DT	O
receptors	NNS	O
.	.	O
FcγRII	NNP	O
receptors	NNS	O
include	VBP	O
FcγRIIA	NNP	O
(	(	O
an	DT	O
“	NN	O
activating	VBG	O
receptor	NN	O
”	NN	O
)	)	O
and	CC	O
FcγRIIB	NNP	O
(	(	O
an	DT	O
“	NN	O
inhibiting	VBG	O
receptor	NN	O
”	NN	O
)	)	O
,	,	O
which	WDT	O
have	VBP	O
similar	JJ	O
amino	NN	O
acid	NN	O
sequences	NNS	O
that	WDT	O
differ	VBP	O
primarily	RB	O
in	IN	O
the	DT	O
cytoplasmic	JJ	O
domains	NNS	O
thereof	NN	O
.	.	O
Activating	VBG	O
receptor	NN	O
FcγRIIA	NNP	O
contains	VBZ	O
an	DT	O
immunoreceptor	NN	O
tyrosine-based	JJ	O
activation	NN	O
motif	NN	O
(	(	O
ITAM	NNP	O
)	)	O
in	IN	O
its	PRP$	O
cytoplasmic	JJ	O
domain	NN	O
.	.	O
Inhibiting	VBG	O
receptor	NN	O
FcγRIIB	NNP	O
contains	VBZ	O
an	DT	O
immunoreceptor	NN	O
tyrosine-based	JJ	O
inhibition	NN	O
motif	NN	O
(	(	O
ITIM	NNP	O
)	)	O
in	IN	O
its	PRP$	O
cytoplasmic	JJ	O
domain	NN	O
.	.	O
(	(	O
see	VB	O
review	NN	O
M.	NNP	B
in	IN	I
Daëron	NNP	I
,	,	I
Annu	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Immunol	NNP	I
.	.	I
15:203-234	CD	I
(	(	I
1997	CD	I
)	)	I
)	)	O
.	.	O
FcRs	NNS	O
are	VBP	O
reviewed	VBN	O
in	IN	O
Ravetch	NNP	B
and	CC	I
Kinet	NNP	I
,	,	I
Annu	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Immunol	NNP	I
.	.	I
9:457-492	CD	I
(	(	I
1991	CD	I
)	)	I
;	:	O
Capel	NNP	B
et	FW	I
al.	NN	I
,	,	I
Immunomethods	NNP	I
4:25-34	CD	I
(	(	I
1994	CD	I
)	)	I
;	:	O
and	CC	O
de	VB	B
Haas	NNP	I
et	CC	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Lab	NNP	I
.	.	I
Clin	NNP	I
.	.	I
Med	NNP	I
.	.	I
126:330-41	CD	I
(	(	I
1995	CD	I
)	)	I
.	.	O
Other	JJ	O
FcRs	NNP	O
,	,	O
including	VBG	O
those	DT	O
to	TO	O
be	VB	O
identified	VBN	O
in	IN	O
the	DT	O
future	NN	O
,	,	O
are	VBP	O
encompassed	VBN	O
by	IN	O
the	DT	O
term	NN	O
“	NNP	O
FcR	NNP	O
”	NNP	O
herein	NN	O
.	.	O
The	DT	O
term	NN	O
also	RB	O
includes	VBZ	O
the	DT	O
neonatal	JJ	O
receptor	NN	O
,	,	O
FcRn	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
responsible	JJ	O
for	IN	O
the	DT	O
transfer	NN	O
of	IN	O
maternal	JJ	O
IgGs	NNP	O
to	TO	O
the	DT	O
fetus	NN	O
(	(	O
Guyer	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
117:587	CD	I
(	(	I
1976	CD	I
)	)	I
and	CC	O
Kim	NNP	B
et	NNP	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
24:249	CD	I
(	(	I
1994	CD	I
)	)	I
)	)	O
.	.	O
“	JJ	O
Human	NNP	O
effector	NN	O
cells	NNS	O
”	CC	O
are	VBP	O
leukocytes	VBZ	O
which	WDT	O
express	VBP	O
one	CD	O
or	CC	O
more	JJR	O
FcRs	NNS	O
and	CC	O
perform	VB	O
effector	NN	O
functions	NNS	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
cells	NNS	O
express	NN	O
at	IN	O
least	JJS	O
FcγRIII	NNP	O
and	CC	O
perform	VB	O
ADCC	NNP	O
effector	NN	O
function	NN	O
.	.	O
Examples	NNS	O
of	IN	O
human	NN	O
leukocytes	NNS	O
which	WDT	O
mediate	VBP	O
ADCC	NNP	O
include	VBP	O
peripheral	JJ	O
blood	NN	O
mononuclear	NN	O
cells	NNS	O
(	(	O
PBMC	NNP	O
)	)	O
,	,	O
natural	JJ	O
killer	NN	O
(	(	O
NK	NNP	O
)	)	O
cells	NNS	O
,	,	O
monocytes	NNS	O
,	,	O
cytotoxic	NN	O
T	NNP	O
cells	NNS	O
and	CC	O
neutrophils	NNS	O
;	:	O
with	IN	O
PBMCs	NNP	O
and	CC	O
NK	NNP	O
cells	NNS	O
being	VBG	O
preferred	VBN	O
.	.	O
The	DT	O
effector	NN	O
cells	NNS	O
may	MD	O
be	VB	O
isolated	VBN	O
from	IN	O
a	DT	O
native	JJ	O
source	NN	O
,	,	O
e.g.	NN	O
,	,	O
from	IN	O
blood	NN	O
.	.	O
“	JJ	O
Complement	NNP	O
dependent	NN	O
cytotoxicity	NN	O
”	NNP	O
or	CC	O
“	NNP	O
CDC	NNP	O
”	NNP	O
refers	NNS	O
to	TO	O
the	DT	O
lysis	NN	O
of	IN	O
a	DT	O
target	NN	O
cell	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
complement	NN	O
.	.	O
Activation	NN	O
of	IN	O
the	DT	O
classical	JJ	O
complement	NN	O
pathway	NN	O
is	VBZ	O
initiated	VBN	O
by	IN	O
the	DT	O
binding	NN	O
of	IN	O
the	DT	O
first	JJ	O
component	NN	O
of	IN	O
the	DT	O
complement	NN	O
system	NN	O
(	(	O
C1q	NNP	O
)	)	O
to	TO	O
antibodies	NNS	O
(	(	O
of	IN	O
the	DT	O
appropriate	JJ	O
subclass	NN	O
)	)	O
which	WDT	O
are	VBP	O
bound	VBN	O
to	TO	O
their	PRP$	O
cognate	NN	O
antigen	NN	O
.	.	O
To	TO	O
assess	VB	O
complement	JJ	O
activation	NN	O
,	,	O
a	DT	O
CDC	NNP	O
assay	NN	O
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Gazzano-Santoro	NNP	B
et	NN	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
Methods	NNS	I
202:163	CD	I
(	(	I
1996	CD	I
)	)	I
,	,	O
may	MD	O
be	VB	O
performed	VBN	O
.	.	O
The	DT	O
terms	NNS	O
“	VBP	O
cancer	NN	O
”	NN	O
and	CC	O
“	NNP	O
cancerous	JJ	O
”	NNP	O
refer	NN	O
to	TO	O
or	CC	O
describe	VB	O
the	DT	O
physiological	JJ	O
condition	NN	O
in	IN	O
mammals	NNS	O
that	WDT	O
is	VBZ	O
typically	RB	O
characterized	VBN	O
by	IN	O
unregulated	JJ	O
cell	NN	O
growth	NN	O
.	.	O
Examples	NNS	O
of	IN	O
cancer	NN	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
carcinoma	NN	O
,	,	O
lymphoma	NN	O
,	,	O
blastoma	NN	O
,	,	O
sarcoma	NN	O
,	,	O
and	CC	O
leukemia	NN	O
.	.	O
More	JJR	O
particular	JJ	O
examples	NNS	O
of	IN	O
such	JJ	O
cancers	NNS	O
include	VBP	O
squamous	JJ	O
cell	NN	O
cancer	NN	O
,	,	O
lung	NN	O
cancer	NN	O
(	(	O
including	VBG	O
small-cell	NN	O
lung	NN	O
cancer	NN	O
,	,	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
,	,	O
adenocarcinoma	NN	O
of	IN	O
the	DT	O
lung	NN	O
,	,	O
and	CC	O
squamous	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
lung	NN	O
)	)	O
,	,	O
cancer	NN	O
of	IN	O
the	DT	O
peritoneum	NN	O
,	,	O
hepatocellular	JJ	O
cancer	NN	O
,	,	O
gastric	JJ	O
or	CC	O
stomach	JJ	O
cancer	NN	O
(	(	O
including	VBG	O
gastrointestinal	JJ	O
cancer	NN	O
)	)	O
,	,	O
pancreatic	JJ	O
cancer	NN	O
,	,	O
glioblastoma	NN	O
,	,	O
cervical	JJ	O
cancer	NN	O
,	,	O
ovarian	JJ	O
cancer	NN	O
,	,	O
liver	RB	O
cancer	NN	O
,	,	O
bladder	NN	O
cancer	NN	O
,	,	O
hepatoma	NN	O
,	,	O
breast	NN	O
cancer	NN	O
,	,	O
colon	NN	O
cancer	NN	O
,	,	O
colorectal	JJ	O
cancer	NN	O
,	,	O
endometrial	JJ	O
or	CC	O
uterine	JJ	O
carcinoma	NN	O
,	,	O
salivary	JJ	O
gland	NN	O
carcinoma	NN	O
,	,	O
kidney	NN	O
or	CC	O
renal	JJ	O
cancer	NN	O
,	,	O
liver	RB	O
cancer	NN	O
,	,	O
prostate	NN	O
cancer	NN	O
,	,	O
vulval	JJ	O
cancer	NN	O
,	,	O
thyroid	JJ	O
cancer	NN	O
,	,	O
hepatic	JJ	O
carcinoma	NN	O
and	CC	O
various	JJ	O
types	NNS	O
of	IN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
B-cell	NNP	O
lymphoma	NN	O
(	(	O
including	VBG	O
low	JJ	O
grade/follicular	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
(	(	O
NHL	NNP	O
)	)	O
;	:	O
small	JJ	O
lymphocytic	JJ	O
(	(	O
SL	NNP	O
)	)	O
NHL	NNP	O
;	:	O
intermediate	JJ	O
grade/follicular	JJ	O
NHL	NNP	O
;	:	O
intermediate	JJ	O
grade	NN	O
diffuse	NN	O
NHL	NNP	O
;	:	O
high	JJ	O
grade	NN	O
immunoblastic	JJ	O
NHL	NNP	O
;	:	O
high	JJ	O
grade	NN	O
lymphoblastic	JJ	O
NHL	NNP	O
;	:	O
high	JJ	O
grade	NN	O
small	JJ	O
non-cleaved	JJ	O
cell	NN	O
NHL	NNP	O
;	:	O
bulky	JJ	O
disease	NN	O
NHL	NNP	O
;	:	O
mantle	CC	O
cell	NN	O
lymphoma	NN	O
;	:	O
AIDS-related	JJ	O
lymphoma	NN	O
;	:	O
and	CC	O
Waldenstrom	NNP	O
's	POS	O
Macroglobulinemia	NNP	O
)	)	O
;	:	O
chronic	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
(	(	O
CLL	NNP	O
)	)	O
;	:	O
acute	JJ	O
lymphoblastic	JJ	O
leukemia	NN	O
(	(	O
ALL	NNP	O
)	)	O
;	:	O
Hairy	NNP	O
cell	NN	O
leukemia	NN	O
;	:	O
chronic	JJ	O
myeloblastic	JJ	O
leukemia	NN	O
;	:	O
and	CC	O
post-transplant	JJ	O
lymphoproliferative	JJ	O
disorder	NN	O
(	(	O
PTLD	NNP	O
)	)	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
cancer	NN	O
comprises	VBZ	O
a	DT	O
tumor	NN	O
that	WDT	O
expresses	VBZ	O
an	DT	O
IGF	NNP	O
receptor	NN	O
,	,	O
more	JJR	O
preferably	RB	O
breast	NN	O
cancer	NN	O
,	,	O
lung	NN	O
cancer	NN	O
,	,	O
colorectal	JJ	O
cancer	NN	O
,	,	O
or	CC	O
prostate	NN	O
cancer	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
breast	NN	O
or	CC	O
prostate	NN	O
cancer	NN	O
.	.	O
A	DT	O
“	NNP	O
chemotherapeutic	JJ	O
agent	NN	O
”	NNP	O
is	VBZ	O
a	DT	O
chemical	NN	O
compound	NN	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cancer	NN	O
.	.	O
Examples	NNS	O
of	IN	O
chemotherapeutic	JJ	O
agents	NNS	O
include	VBP	O
alkylating	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
thiotepa	NN	O
and	CC	O
CYTOXAN®	NNP	O
cyclosphosphamide	VBP	O
;	:	O
alkyl	VB	O
sulfonates	NNS	O
such	JJ	O
as	IN	O
busulfan	NN	O
,	,	O
improsulfan	NN	O
and	CC	O
piposulfan	NN	O
;	:	O
aziridines	NNS	O
such	JJ	O
as	IN	O
benzodopa	NN	O
,	,	O
carboquone	NN	O
,	,	O
meturedopa	NN	O
,	,	O
and	CC	O
uredopa	RB	O
;	:	O
ethylenimines	NNS	O
and	CC	O
methylamelamines	NNS	O
including	VBG	O
altretamine	NN	O
,	,	O
triethylenemelamine	NN	O
,	,	O
trietylenephosphoramide	NN	O
,	,	O
triethiylenethiophosphoramide	NN	O
and	CC	O
trimethylolomelamine	NN	O
;	:	O
acetogenins	NNS	O
(	(	O
especially	RB	O
bullatacin	VBN	O
and	CC	O
bullatacinone	NN	O
)	)	O
;	:	O
a	DT	O
camptothecin	NN	O
(	(	O
including	VBG	O
the	DT	O
synthetic	JJ	O
analogue	NN	O
topotecan	NN	O
)	)	O
;	:	O
bryostatin	NN	O
;	:	O
callystatin	NN	O
;	:	O
CC-1065	NNP	O
(	(	O
including	VBG	O
its	PRP$	O
adozelesin	NN	O
,	,	O
carzelesin	NN	O
and	CC	O
bizelesin	NN	O
synthetic	JJ	O
analogues	NNS	O
)	)	O
;	:	O
cryptophycins	NNS	O
(	(	O
particularly	RB	O
cryptophycin	VBP	O
1	CD	O
and	CC	O
cryptophycin	VB	O
8	CD	O
)	)	O
;	:	O
dolastatin	NN	O
;	:	O
duocarmycin	NN	O
(	(	O
including	VBG	O
the	DT	O
synthetic	JJ	O
analogues	NNS	O
,	,	O
KW-2189	NNP	O
and	CC	O
CB1-TM1	NNP	O
)	)	O
;	:	O
eleutherobin	CC	O
;	:	O
pancratistatin	NN	O
;	:	O
a	DT	O
sarcodictyin	NN	O
;	:	O
spongistatin	CC	O
;	:	O
nitrogen	CC	O
mustards	NNS	O
such	JJ	O
as	IN	O
chlorambucil	NN	O
,	,	O
chlornaphazine	NN	O
,	,	O
cholophosphamide	NN	O
,	,	O
estramustine	NN	O
,	,	O
ifosfamide	NN	O
,	,	O
mechlorethamine	NN	O
,	,	O
mechlorethamine	JJ	O
oxide	IN	O
hydrochloride	NN	O
,	,	O
melphalan	NN	O
,	,	O
novembichin	RB	O
,	,	O
phenesterine	NN	O
,	,	O
prednimustine	NN	O
,	,	O
trofosfamide	NN	O
,	,	O
uracil	JJ	O
mustard	NN	O
;	:	O
nitrosureas	NNS	O
such	JJ	O
as	IN	O
carmustine	NN	O
,	,	O
chlorozotocin	NN	O
,	,	O
fotemustine	NN	O
,	,	O
lomustine	NN	O
,	,	O
nimustine	NN	O
,	,	O
and	CC	O
ranimnustine	NN	O
;	:	O
antibiotics	NNS	O
such	JJ	O
as	IN	O
the	DT	O
enediyne	NN	O
antibiotics	NNS	O
(	(	O
e.g.	NN	O
,	,	O
calicheamicin	NN	O
,	,	O
especially	RB	O
calicheamicin	JJ	O
gamma1I	NN	O
and	CC	O
calicheamicin	NN	O
omegaI1	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Agnew	NNP	B
,	,	I
Chem	NNP	I
.	.	I
Intl	NNP	I
.	.	I
Ed	NNP	I
.	.	I
Engl.	NNP	I
,	,	I
33	CD	I
:	:	I
183-186	CD	I
(	(	I
1994	CD	I
)	)	I
)	)	O
;	:	O
dynemicin	NN	O
,	,	O
including	VBG	O
dynemicin	NN	O
A	NNP	O
;	:	O
bisphosphonates	NNS	O
,	,	O
such	JJ	O
as	IN	O
clodronate	NN	O
;	:	O
an	DT	O
esperamicin	NN	O
;	:	O
as	RB	O
well	RB	O
as	IN	O
neocarzinostatin	NN	O
chromophore	NN	O
and	CC	O
related	JJ	O
chromoprotein	NN	O
enediyne	VBZ	O
antibiotic	JJ	O
chromophores	NNS	O
)	)	O
,	,	O
aclacinomysins	VBZ	O
,	,	O
actinomycin	NN	O
,	,	O
authramycin	NN	O
,	,	O
azaserine	NN	O
,	,	O
bleomycins	NNS	O
,	,	O
cactinomycin	NN	O
,	,	O
carabicin	NN	O
,	,	O
caminomycin	NN	O
,	,	O
carzinophilin	NN	O
,	,	O
chromomycinis	NN	O
,	,	O
dactinomycin	NN	O
,	,	O
daunorubicin	NN	O
,	,	O
detorubicin	NN	O
,	,	O
6-diazo-5-oxo-L-norleucine	JJ	O
,	,	O
ADRIAMYCIN®	NNP	O
doxorubicin	NN	O
(	(	O
including	VBG	O
morpholino-doxorubicin	NN	O
,	,	O
cyanomorpholino-doxorubicin	JJ	O
,	,	O
2-pyrrolino-doxorubicin	JJ	O
and	CC	O
deoxydoxorubicin	NN	O
)	)	O
,	,	O
epirubicin	RB	O
,	,	O
esorubicin	NN	O
,	,	O
idarubicin	NN	O
,	,	O
marcellomycin	NN	O
,	,	O
mitomycins	NNS	O
such	JJ	O
as	IN	O
mitomycin	NN	O
C	NNP	O
,	,	O
mycophenolic	JJ	O
acid	NN	O
,	,	O
nogalamycin	RB	O
,	,	O
olivomycins	NNS	O
,	,	O
peplomycin	NN	O
,	,	O
potfiromycin	NN	O
,	,	O
puromycin	NN	O
,	,	O
quelamycin	NN	O
,	,	O
rodorubicin	NN	O
,	,	O
streptonigrin	NN	O
,	,	O
streptozocin	NN	O
,	,	O
tubercidin	NN	O
,	,	O
ubenimex	JJ	O
,	,	O
zinostatin	NN	O
,	,	O
zorubicin	NN	O
;	:	O
anti-metabolites	NNS	O
such	JJ	O
as	IN	O
methotrexate	NN	O
and	CC	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
;	:	O
folic	JJ	O
acid	NN	O
analogues	NNS	O
such	JJ	O
as	IN	O
denopterin	NN	O
,	,	O
methotrexate	NN	O
,	,	O
pteropterin	NN	O
,	,	O
trimetrexate	NN	O
;	:	O
purine	JJ	O
analogs	NNS	O
such	JJ	O
as	IN	O
fludarabine	NN	O
,	,	O
6-mercaptopurine	JJ	O
,	,	O
thiamiprine	NN	O
,	,	O
thioguanine	NN	O
;	:	O
pyrimidine	JJ	O
analogs	NNS	O
such	JJ	O
as	IN	O
ancitabine	NN	O
,	,	O
azacitidine	NN	O
,	,	O
6-azauridine	JJ	O
,	,	O
carmofur	NN	O
,	,	O
cytarabine	NN	O
,	,	O
dideoxyuridine	NN	O
,	,	O
doxifluridine	NN	O
,	,	O
enocitabine	NN	O
,	,	O
floxuridine	NN	O
;	:	O
androgens	NNS	O
such	JJ	O
as	IN	O
calusterone	NN	O
,	,	O
dromostanolone	NN	O
propionate	NN	O
,	,	O
epitiostanol	NN	O
,	,	O
mepitiostane	NN	O
,	,	O
testolactone	NN	O
;	:	O
anti-adrenals	NNS	O
such	JJ	O
as	IN	O
aminoglutethimide	NN	O
,	,	O
mitotane	NN	O
,	,	O
trilostane	NN	O
;	:	O
folic	JJ	O
acid	VBP	O
replenisher	RB	O
such	JJ	O
as	IN	O
frolinic	JJ	O
acid	NN	O
;	:	O
aceglatone	NN	O
;	:	O
aldophosphamide	JJ	O
glycoside	NN	O
;	:	O
aminolevulinic	JJ	O
acid	NN	O
;	:	O
eniluracil	CC	O
;	:	O
amsacrine	NN	O
;	:	O
bestrabucil	NN	O
;	:	O
bisantrene	NN	O
;	:	O
edatraxate	CC	O
;	:	O
defofamine	NN	O
;	:	O
demecolcine	NN	O
;	:	O
diaziquone	NN	O
;	:	O
elformithine	CC	O
;	:	O
elliptinium	JJ	O
acetate	NN	O
;	:	O
an	DT	O
epothilone	NN	O
;	:	O
etoglucid	CC	O
;	:	O
gallium	NN	O
nitrate	NN	O
;	:	O
hydroxyurea	NN	O
;	:	O
lentinan	CC	O
;	:	O
lonidainine	NN	O
;	:	O
maytansinoids	NNS	O
such	JJ	O
as	IN	O
maytansine	NN	O
and	CC	O
ansamitocins	NNS	O
;	:	O
mitoguazone	NN	O
;	:	O
mitoxantrone	NN	O
;	:	O
mopidanmol	CC	O
;	:	O
nitraerine	NN	O
;	:	O
pentostatin	CC	O
;	:	O
phenamet	CC	O
;	:	O
pirarubicin	NN	O
;	:	O
losoxantrone	NN	O
;	:	O
podophyllinic	JJ	O
acid	NN	O
;	:	O
2-ethylhydrazide	JJ	O
;	:	O
procarbazine	NN	O
;	:	O
PSK®	NNP	O
polysaccharide	NN	O
complex	NN	O
(	(	O
JHS	NNP	O
Natural	NNP	O
Products	NNPS	O
,	,	O
Eugene	NNP	O
,	,	O
Oreg	NNP	O
.	.	O
)	)	O
;	:	O
razoxane	NN	O
;	:	O
rhizoxin	NN	O
;	:	O
sizofuran	NN	O
;	:	O
spirogermanium	NN	O
;	:	O
tenuazonic	JJ	O
acid	NN	O
;	:	O
triaziquone	NN	O
;	:	O
2,2′,2″-trichlorotriethylamine	JJ	O
;	:	O
trichothecenes	NNS	O
(	(	O
especially	RB	O
T-2	NNP	O
toxin	NN	O
,	,	O
verracurin	FW	O
A	NNP	O
,	,	O
roridin	VBZ	O
A	NNP	O
and	CC	O
anguidine	NN	O
)	)	O
;	:	O
urethan	JJ	O
;	:	O
vindesine	NN	O
;	:	O
dacarbazine	NN	O
;	:	O
mannomustine	NN	O
;	:	O
mitobronitol	CC	O
;	:	O
mitolactol	NN	O
;	:	O
pipobroman	NN	O
;	:	O
gacytosine	NN	O
;	:	O
arabinoside	CC	O
(	(	O
“	JJ	O
Ara-C	NNP	O
”	NNP	O
)	)	O
;	:	O
cyclophosphamide	NN	O
;	:	O
thiotepa	CC	O
;	:	O
taxoids	NNS	O
,	,	O
e.g.	NN	O
,	,	O
TAXOL®	NNP	O
paclitaxel	NN	O
(	(	O
Bristol-Myers	NNP	O
Squibb	NNP	O
Oncology	NNP	O
,	,	O
Princeton	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
,	,	O
ABRAXANE™	NNP	O
Cremophor-free	NNP	O
,	,	O
albumin-engineered	JJ	O
nanoparticle	NN	O
formulation	NN	O
of	IN	O
paclitaxel	NN	O
(	(	O
American	JJ	O
Pharmaceutical	NNP	O
Partners	NNPS	O
,	,	O
Schaumberg	NNP	O
,	,	O
Ill.	NNP	O
)	)	O
,	,	O
and	CC	O
TAXOTERE®	NNP	O
doxetaxel	NN	O
(	(	O
Rhône-Poulenc	JJ	O
Rorer	NNP	O
,	,	O
Antony	NNP	O
,	,	O
France	NNP	O
)	)	O
;	:	O
chloranbucil	NN	O
;	:	O
GEMZAR®	NNP	O
gemcitabine	NN	O
;	:	O
6-thioguanine	JJ	O
;	:	O
mercaptopurine	NN	O
;	:	O
methotrexate	NN	O
;	:	O
platinum	CC	O
analogs	NNS	O
such	JJ	O
as	IN	O
cisplatin	NN	O
and	CC	O
carboplatin	NN	O
;	:	O
vinblastine	NN	O
;	:	O
platinum	NN	O
;	:	O
etoposide	CC	O
(	(	O
VP-16	NNP	O
)	)	O
;	:	O
ifosfamide	NN	O
;	:	O
mitoxantrone	NN	O
;	:	O
vincristine	NN	O
;	:	O
NAVELBINE®	NNP	O
vinorelbine	NN	O
;	:	O
novantrone	CC	O
;	:	O
teniposide	NN	O
;	:	O
edatrexate	CC	O
;	:	O
daunomycin	NN	O
;	:	O
aminopterin	CC	O
;	:	O
xeloda	NNP	O
;	:	O
ibandronate	NN	O
;	:	O
CPT-11	NNP	O
;	:	O
topoisomerase	NN	O
inhibitor	NN	O
RFS	NNP	O
2000	CD	O
;	:	O
difluoromethylornithine	NN	O
(	(	O
DMFO	NNP	O
)	)	O
;	:	O
retinoids	NNS	O
such	JJ	O
as	IN	O
retinoic	JJ	O
acid	NN	O
;	:	O
capecitabine	NN	O
;	:	O
and	CC	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
,	,	O
acids	NNS	O
or	CC	O
derivatives	NNS	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
above	NN	O
.	.	O
Also	RB	O
included	VBN	O
in	IN	O
this	DT	O
definition	NN	O
are	VBP	O
anti-hormonal	JJ	O
agents	NNS	O
that	WDT	O
act	VBP	O
to	TO	O
regulate	VB	O
or	CC	O
inhibit	VB	O
hormone	JJ	O
action	NN	O
on	IN	O
tumors	NNS	O
such	JJ	O
as	IN	O
anti-estrogens	NNS	O
and	CC	O
selective	JJ	O
estrogen	NN	O
receptor	NN	O
modulators	NNS	O
(	(	O
SERMs	NNP	O
)	)	O
,	,	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
tamoxifen	NN	O
(	(	O
including	VBG	O
NOLVADEX®	NNP	O
tamoxifen	NN	O
)	)	O
,	,	O
raloxifene	NN	O
,	,	O
droloxifene	NN	O
,	,	O
4-hydroxytamoxifen	JJ	O
,	,	O
trioxifene	NN	O
,	,	O
keoxifene	NN	O
,	,	O
LY117018	NNP	O
,	,	O
onapristone	NN	O
,	,	O
and	CC	O
FARESTON•toremifene	NNP	O
;	:	O
aromatase	NN	O
inhibitors	NNS	O
that	WDT	O
inhibit	VBP	O
the	DT	O
enzyme	NN	O
aromatase	NN	O
,	,	O
which	WDT	O
regulates	VBZ	O
estrogen	NN	O
production	NN	O
in	IN	O
the	DT	O
adrenal	JJ	O
glands	NNS	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
4	CD	O
(	(	O
5	CD	O
)	)	O
-imidazoles	NNS	O
,	,	O
aminoglutethimide	RB	O
,	,	O
MEGASE®	NNP	O
megestrol	NN	O
acetate	NN	O
,	,	O
AROMASIN®	NNP	O
exemestane	NN	O
,	,	O
formestanie	NN	O
,	,	O
fadrozole	NN	O
,	,	O
RIVISOR®	NNP	O
vorozole	NN	O
,	,	O
FEMARA®	NNP	O
letrozole	NN	O
,	,	O
and	CC	O
ARIMIDEX®	NNP	O
anastrozole	VBP	O
;	:	O
and	CC	O
anti-androgens	NNS	O
such	JJ	O
as	IN	O
flutamide	NN	O
,	,	O
nilutamide	RB	O
,	,	O
bicalutamide	RB	O
,	,	O
leuprolide	NN	O
,	,	O
and	CC	O
goserelin	NN	O
;	:	O
as	RB	O
well	RB	O
as	IN	O
troxacitabine	NN	O
(	(	O
a	DT	O
1,3-dioxolane	JJ	O
nucleoside	JJ	O
cytosine	NN	O
analog	NN	O
)	)	O
;	:	O
antisense	JJ	O
oligonucleotides	NNS	O
,	,	O
particularly	RB	O
those	DT	O
which	WDT	O
inhibit	VBP	O
expression	NN	O
of	IN	O
genes	NNS	O
in	IN	O
signaling	VBG	O
pathways	NNS	O
implicated	VBN	O
in	IN	O
abherant	JJ	O
cell	NN	O
proliferation	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
PKC-alpha	NNP	O
,	,	O
Ralf	NNP	O
and	CC	O
H-Ras	NNP	O
;	:	O
ribozymes	NNS	O
such	JJ	O
as	IN	O
a	DT	O
VEGF	NNP	O
expression	NN	O
inhibitor	NN	O
(	(	O
e.g.	JJ	O
,	,	O
ANGIOZYME®	NNP	O
ribozyme	NN	O
)	)	O
and	CC	O
a	DT	O
HER2	NNP	O
expression	NN	O
inhibitor	NN	O
;	:	O
vaccines	NNS	O
such	JJ	O
as	IN	O
gene	NN	O
therapy	NN	O
vaccines	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
ALLOVECTIN®	NNP	O
vaccine	NN	O
,	,	O
LEUVECTIN®	NNP	O
vaccine	NN	O
,	,	O
and	CC	O
VAXID®	NNP	O
vaccine	NN	O
;	:	O
PROLEUKIN®	NNP	O
rIL-2	NN	O
;	:	O
LURTOTECAN®	NNP	O
topoisomerase	VBD	O
1	CD	O
inhibitor	NN	O
;	:	O
ABARELIX®	NNP	O
rmRH	NN	O
;	:	O
and	CC	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
,	,	O
acids	NNS	O
or	CC	O
derivatives	NNS	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
above	NN	O
.	.	O
The	DT	O
terms	NNS	O
“	VBP	O
cell	NN	O
proliferative	JJ	O
disorder	NN	O
”	NN	O
and	CC	O
“	NNP	O
proliferative	JJ	O
disorder	NN	O
”	NN	O
refer	NN	O
to	TO	O
disorders	NNS	O
that	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
some	DT	O
degree	NN	O
of	IN	O
abnormal	JJ	O
cell	NN	O
proliferation	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
cell	NN	O
proliferative	JJ	O
disorder	NN	O
is	VBZ	O
cancer	NN	O
.	.	O
“	JJ	O
Tumor	NNP	O
”	NNP	O
,	,	O
as	IN	O
used	VBN	O
herein	NN	O
,	,	O
refers	NNS	O
to	TO	O
all	DT	O
neoplastic	JJ	O
cell	NN	O
growth	NN	O
and	CC	O
proliferation	NN	O
,	,	O
whether	IN	O
malignant	JJ	O
or	CC	O
benign	JJ	O
,	,	O
and	CC	O
all	DT	O
pre-cancerous	JJ	O
and	CC	O
cancerous	JJ	O
cells	NNS	O
and	CC	O
tissues	NNS	O
.	.	O
An	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
which	WDT	O
“	NNP	O
induces	NNS	O
cell	VBP	O
death	NN	O
”	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
causes	VBZ	O
a	DT	O
viable	JJ	O
cell	NN	O
to	TO	O
become	VB	O
nonviable	JJ	O
.	.	O
The	DT	O
cell	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
expresses	VBZ	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
preferably	RB	O
a	DT	O
cell	NN	O
that	WDT	O
overexpresses	VBZ	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	RB	O
compared	VBN	O
to	TO	O
a	DT	O
normal	JJ	O
cell	NN	O
of	IN	O
the	DT	O
same	JJ	O
tissue	NN	O
type	NN	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
a	DT	O
transmembrane	JJ	O
polypeptide	NN	O
expressed	VBN	O
on	IN	O
the	DT	O
surface	NN	O
of	IN	O
a	DT	O
cancer	NN	O
cell	NN	O
or	CC	O
may	MD	O
be	VB	O
a	DT	O
polypeptide	NN	O
that	WDT	O
is	VBZ	O
produced	VBN	O
and	CC	O
secreted	VBN	O
by	IN	O
a	DT	O
cancer	NN	O
cell	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
cell	NN	O
is	VBZ	O
a	DT	O
cancer	NN	O
cell	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
breast	NN	O
,	,	O
ovarian	JJ	O
,	,	O
stomach	NN	O
,	,	O
endometrial	JJ	O
,	,	O
salivary	JJ	O
gland	NN	O
,	,	O
lung	NN	O
,	,	O
kidney	NN	O
,	,	O
colon	NN	O
,	,	O
thyroid	NN	O
,	,	O
pancreatic	JJ	O
or	CC	O
bladder	NN	O
cell	NN	O
.	.	O
Cell	NNP	O
death	NN	O
in	IN	O
vitro	NN	O
may	MD	O
be	VB	O
determined	VBN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
complement	NN	O
and	CC	O
immune	JJ	O
effector	NN	O
cells	NNS	O
to	TO	O
distinguish	VB	O
cell	NN	O
death	NN	O
induced	VBN	O
by	IN	O
antibody-dependent	JJ	O
cell-mediated	JJ	O
cytotoxicity	NN	O
(	(	O
ADCC	NNP	O
)	)	O
or	CC	O
complement	JJ	O
dependent	JJ	O
cytotoxicity	NN	O
(	(	O
CDC	NNP	O
)	)	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
assay	NN	O
for	IN	O
cell	NN	O
death	NN	O
may	MD	O
be	VB	O
performed	VBN	O
using	VBG	O
heat	NN	O
inactivated	VBN	O
serum	NN	O
(	(	O
i.e.	JJ	O
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
complement	NN	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
immune	JJ	O
effector	NN	O
cells	NNS	O
.	.	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
antibody	NN	O
,	,	O
oligopeptide	RB	O
or	CC	O
other	JJ	O
organic	JJ	O
molecule	NN	O
is	VBZ	O
able	JJ	O
to	TO	O
induce	VB	O
cell	NN	O
death	NN	O
,	,	O
loss	NN	O
of	IN	O
membrane	JJ	O
integrity	NN	O
as	IN	O
evaluated	VBN	O
by	IN	O
uptake	NN	O
of	IN	O
propidium	NN	O
iodide	NN	O
(	(	O
PI	NNP	O
)	)	O
,	,	O
trypan	JJ	O
blue	NN	O
(	(	O
see	VB	O
Moore	NNP	B
et	FW	I
al	NN	I
.	.	I
Cytotechnology	NNP	I
17:1-11	CD	I
(	(	I
1995	CD	I
)	)	I
)	)	O
or	CC	O
7AAD	CD	O
can	MD	O
be	VB	O
assessed	VBN	O
relative	JJ	O
to	TO	O
untreated	JJ	O
cells	NNS	O
.	.	O
Preferred	VBN	O
cell	NN	O
death-inducing	JJ	O
antibodies	NNS	O
,	,	O
oligopeptides	NNS	O
or	CC	O
other	JJ	O
organic	JJ	O
molecules	NNS	O
are	VBP	O
those	DT	O
which	WDT	O
induce	VBP	O
PI	NNP	O
uptake	NN	O
in	IN	O
the	DT	O
PI	NNP	O
uptake	JJ	O
assay	NN	O
in	IN	O
BT474	NNP	O
cells	NNS	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
immunoadhesion	NN	O
”	NNP	O
designates	VBZ	O
antibody-like	JJ	O
molecules	NNS	O
which	WDT	O
combine	VBP	O
the	DT	O
binding	NN	O
specificity	NN	O
of	IN	O
a	DT	O
heterologous	JJ	O
protein	NN	O
(	(	O
an	DT	O
“	NN	O
adhesion	NN	O
”	NNP	O
)	)	O
with	IN	O
the	DT	O
effector	NN	O
functions	NNS	O
of	IN	O
immunoglobulin	NN	O
constant	JJ	O
domains	NNS	O
.	.	O
Structurally	RB	O
,	,	O
the	DT	O
immunoadhesions	NNS	O
comprise	VBP	O
a	DT	O
fusion	NN	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
with	IN	O
the	DT	O
desired	JJ	O
binding	NN	O
specificity	NN	O
which	WDT	O
is	VBZ	O
other	JJ	O
than	IN	O
the	DT	O
antigen	NN	O
recognition	NN	O
and	CC	O
binding	VBG	O
site	NN	O
of	IN	O
an	DT	O
antibody	NN	O
(	(	O
i.e.	JJ	O
,	,	O
is	VBZ	O
“	NNP	O
heterologous	JJ	O
”	NN	O
)	)	O
,	,	O
and	CC	O
an	DT	O
immunoglobulin	NN	O
constant	JJ	O
domain	NN	O
sequence	NN	O
.	.	O
The	DT	O
adhesion	NN	O
part	NN	O
of	IN	O
an	DT	O
immunoadhesion	NN	O
molecule	NN	O
typically	RB	O
is	VBZ	O
a	DT	O
contiguous	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
comprising	VBG	O
at	IN	O
least	JJS	O
the	DT	O
binding	VBG	O
site	NN	O
of	IN	O
a	DT	O
receptor	NN	O
or	CC	O
a	DT	O
ligand	NN	O
.	.	O
The	DT	O
immunoglobulin	NN	O
constant	JJ	O
domain	NN	O
sequence	NN	O
in	IN	O
the	DT	O
immunoadhesion	NN	O
may	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
any	DT	O
immunoglobulin	NN	O
,	,	O
such	JJ	O
as	IN	O
IgG-1	NNP	O
,	,	O
IgG-2	NNP	O
,	,	O
IgG-3	NNP	O
,	,	O
or	CC	O
IgG-4	NNP	O
subtypes	NNS	O
,	,	O
IgA	NNP	O
(	(	O
including	VBG	O
IgA-1	NNP	O
and	CC	O
IgA-2	NNP	O
)	)	O
,	,	O
IgE	NNP	O
,	,	O
IgD	NNP	O
or	CC	O
IgM	NNP	O
.	.	O
The	DT	O
word	NN	O
“	NNP	O
label	NN	O
”	NN	O
when	WRB	O
used	VBN	O
herein	NN	O
refers	NNS	O
to	TO	O
a	DT	O
detectable	JJ	O
compound	NN	O
or	CC	O
composition	NN	O
which	WDT	O
is	VBZ	O
conjugated	VBN	O
directly	RB	O
or	CC	O
indirectly	RB	O
to	TO	O
the	DT	O
antibody	NN	O
so	RB	O
as	IN	O
to	TO	O
generate	VB	O
a	DT	O
“	NN	O
labeled	VBN	O
”	CD	O
antibody	NN	O
.	.	O
The	DT	O
label	NN	O
may	MD	O
be	VB	O
detectable	JJ	O
by	IN	O
itself	PRP	O
(	(	O
e.g	NN	O
.	.	O
radioisotope	NN	O
labels	NNS	O
or	CC	O
fluorescent	JJ	O
labels	NNS	O
)	)	O
or	CC	O
,	,	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
an	DT	O
enzymatic	JJ	O
label	NN	O
,	,	O
may	MD	O
catalyze	VB	O
chemical	JJ	O
alteration	NN	O
of	IN	O
a	DT	O
substrate	NN	O
compound	NN	O
or	CC	O
composition	NN	O
which	WDT	O
is	VBZ	O
detectable	JJ	O
.	.	O
“	JJ	O
Replication-preventing	JJ	O
agent	NN	O
”	NNP	O
is	VBZ	O
an	DT	O
agent	JJ	O
wherein	NN	O
replication	NN	O
,	,	O
function	NN	O
,	,	O
and/or	JJ	O
growth	NN	O
of	IN	O
the	DT	O
cells	NNS	O
is	VBZ	O
inhibited	VBN	O
or	CC	O
prevented	VBN	O
,	,	O
or	CC	O
cells	NNS	O
are	VBP	O
destroyed	VBN	O
,	,	O
no	DT	O
matter	NN	O
what	WP	O
the	DT	O
mechanism	NN	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
apoptosis	NN	O
,	,	O
angiostasis	NN	O
,	,	O
cytosis	NN	O
,	,	O
tumoricide	NN	O
,	,	O
mytosis	NN	O
inhibition	NN	O
,	,	O
blocking	VBG	O
cell	NN	O
cycle	NN	O
progression	NN	O
,	,	O
arresting	VBG	O
cell	NN	O
growth	NN	O
,	,	O
binding	VBG	O
to	TO	O
tumors	NNS	O
,	,	O
acting	VBG	O
as	IN	O
cellular	JJ	O
mediators	NNS	O
,	,	O
etc	FW	O
.	.	O
Such	JJ	O
agents	NNS	O
include	VBP	O
a	DT	O
chemotherapeutic	JJ	O
agent	NN	O
,	,	O
cytotoxic	NN	O
agent	NN	O
,	,	O
cytokine	NN	O
,	,	O
growth-inhibitory	JJ	O
agent	NN	O
,	,	O
or	CC	O
anti-hormonal	JJ	O
agent	NN	O
,	,	O
e.g.	NN	O
,	,	O
an	DT	O
anti-estrogen	JJ	O
compound	NN	O
such	JJ	O
as	IN	O
tamoxifen	NN	O
,	,	O
an	DT	O
anti-progesterone	NN	O
such	JJ	O
as	IN	O
onapristone	NN	O
(	(	O
see	VB	O
,	,	O
EP	NNP	O
616	CD	O
812	CD	O
)	)	O
;	:	O
or	CC	O
an	DT	O
anti-androgen	JJ	O
such	JJ	O
as	IN	O
flutamide	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
aromidase	NN	O
inhibitors	NNS	O
,	,	O
or	CC	O
a	DT	O
hormonal	JJ	O
agent	NN	O
such	JJ	O
as	IN	O
an	DT	O
androgen	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
cytotoxic	NN	O
agent	NN	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
refers	NNS	O
to	TO	O
a	DT	O
substance	NN	O
that	WDT	O
inhibits	VBZ	O
or	CC	O
prevents	VBZ	O
the	DT	O
function	NN	O
of	IN	O
cells	NNS	O
and/or	JJ	O
causes	NNS	O
destruction	NN	O
of	IN	O
cells	NNS	O
.	.	O
The	DT	O
term	NN	O
is	VBZ	O
intended	VBN	O
to	TO	O
include	VB	O
radioactive	JJ	O
isotopes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
At211	NNP	O
,	,	O
I131	NNP	O
,	,	O
I125	NNP	O
,	,	O
Y90	NNP	O
,	,	O
Re186	NNP	O
,	,	O
Re188	NNP	O
,	,	O
Sm153	NNP	O
,	,	O
Bi212	NNP	O
,	,	O
P32	NNP	O
and	CC	O
radioactive	JJ	O
isotopes	NNS	O
of	IN	O
Lu	NNP	O
)	)	O
,	,	O
chemotherapeutic	JJ	O
agents	NNS	O
e.g	VBP	O
.	.	O
methotrexate	NN	O
,	,	O
adriamicin	NN	O
,	,	O
vinca	JJ	O
alkaloids	NNS	O
(	(	O
vincristine	NN	O
,	,	O
vinblastine	NN	O
,	,	O
etoposide	RB	O
)	)	O
,	,	O
doxorubicin	UH	O
,	,	O
melphalan	NN	O
,	,	O
mitomycin	FW	O
C	NNP	O
,	,	O
chlorambucil	NN	O
,	,	O
daunorubicin	NN	O
or	CC	O
other	JJ	O
intercalating	VBG	O
agents	NNS	O
,	,	O
enzymes	NNS	O
and	CC	O
fragments	NNS	O
thereof	VBP	O
such	JJ	O
as	IN	O
nucleolytic	JJ	O
enzymes	NNS	O
,	,	O
antibiotics	NNS	O
,	,	O
and	CC	O
toxins	NNS	O
such	JJ	O
as	IN	O
small	JJ	O
molecule	NN	O
toxins	NNS	O
or	CC	O
enzymatically	RB	O
active	JJ	O
toxins	NNS	O
of	IN	O
bacterial	JJ	O
,	,	O
fungal	JJ	O
,	,	O
plant	NN	O
or	CC	O
animal	NN	O
origin	NN	O
,	,	O
including	VBG	O
fragments	NNS	O
and/or	JJ	O
variants	NNS	O
thereof	NN	O
,	,	O
and	CC	O
the	DT	O
various	JJ	O
antitumor	NN	O
or	CC	O
anticancer	NN	O
agents	NNS	O
disclosed	VBN	O
below	IN	O
.	.	O
Other	JJ	O
cytotoxic	NN	O
agents	NNS	O
are	VBP	O
described	VBN	O
below	IN	O
.	.	O
A	DT	O
tumoricidal	JJ	O
agent	NN	O
causes	VBZ	O
destruction	NN	O
of	IN	O
tumor	NN	O
cells	NNS	O
.	.	O
Preferred	NNP	O
cytotoxic	NN	O
agents	NNS	O
herein	VBP	O
for	IN	O
the	DT	O
specific	JJ	O
tumor	NN	O
types	NNS	O
to	TO	O
use	VB	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
antagonists	NNS	O
herein	VBP	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O
1	CD	O
.	.	O
Prostate	NNP	O
cancer	NN	O
:	:	O
androgens	NNS	O
,	,	O
docetaxel	NN	O
,	,	O
paclitaxel	NN	O
,	,	O
estramustine	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
mitoxantrone	NN	O
,	,	O
antibodies	NNS	O
to	TO	O
ErbB2	NNP	O
domain	NN	O
(	(	O
s	PRP	O
)	)	O
such	JJ	O
as	IN	O
2C4	CD	O
(	(	O
WO	NNP	O
01/00245	CD	O
;	:	O
hybridoma	NN	O
ATCC	NNP	O
HB-12697	NNP	O
)	)	O
,	,	O
which	WDT	O
binds	VBZ	O
to	TO	O
a	DT	O
region	NN	O
in	IN	O
the	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
ErbB2	NNP	O
(	(	O
e.g.	FW	O
,	,	O
any	DT	O
one	CD	O
or	CC	O
more	JJR	O
residues	NNS	O
in	IN	O
the	DT	O
region	NN	O
from	IN	O
about	IN	O
residue	JJ	O
22	CD	O
to	TO	O
about	IN	O
residue	JJ	O
584	CD	O
of	IN	O
ErbB2	NNP	O
,	,	O
inclusive	NN	O
)	)	O
,	,	O
AVASTIN™	NNP	O
anti-vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
(	(	O
VEGF	NNP	O
)	)	O
,	,	O
TARCEVA™	NNP	O
OSI-774	NNP	O
(	(	O
erlotinib	NN	O
)	)	O
(	(	O
Genenetech	NNP	O
and	CC	O
OSI	NNP	O
Pharmaceuticals	NNP	O
)	)	O
,	,	O
or	CC	O
other	JJ	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
tyrosine	NN	O
kinase	NN	O
inhibitors	NNS	O
(	(	O
EGFR	NNP	O
TKI	NNP	O
's	POS	O
)	)	O
.2	NN	O
.	.	O
Stomach	NN	O
cancer	NN	O
:	:	O
5-fluorouracil	JJ	O
(	(	O
5FU	CD	O
)	)	O
,	,	O
XELODA™	NNP	O
capecitabine	NN	O
,	,	O
methotrexate	NN	O
,	,	O
etoposide	RB	O
,	,	O
cisplatin/carboplatin	NN	O
,	,	O
paclitaxel	NN	O
,	,	O
docetaxel	NN	O
,	,	O
gemcitabine	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
and	CC	O
CPT-11	NNP	O
(	(	O
camptothcin-11	NN	O
;	:	O
irinotecan	JJ	O
,	,	O
USA	NNP	O
Brand	NNP	O
Name	NN	O
:	:	O
CAMPTOSAR®	NNP	O
)	)	O
.3	NN	O
.	.	O
Pancreatic	JJ	O
cancer	NN	O
:	:	O
gemcitabine	NN	O
,	,	O
5FU	CD	O
,	,	O
XELODA™	NNP	O
capecitabine	NN	O
,	,	O
CPT-11	NNP	O
,	,	O
docetaxel	NN	O
,	,	O
paclitaxel	NN	O
,	,	O
cisplatin	NN	O
,	,	O
carboplatin	NN	O
,	,	O
TARCEVA™	NNP	O
erlotinib	NN	O
,	,	O
and	CC	O
other	JJ	O
EGFR	NNP	O
TKI's.4	NNP	O
.	.	O
Colorectal	JJ	O
cancer	NN	O
:	:	O
5FU	CD	O
,	,	O
XELODA™	NNP	O
capecitabine	NN	O
,	,	O
CPT-11	NNP	O
,	,	O
oxaliplatin	NN	O
,	,	O
AVASTIN™	NNP	O
anti-VEGF	NN	O
,	,	O
TARCEVA™	NNP	O
erlotinib	NN	O
and	CC	O
other	JJ	O
EGFR	NNP	O
TKI	NNP	O
's	POS	O
,	,	O
and	CC	O
ERBITUXT™	NNP	O
(	(	O
formerly	RB	O
known	VBN	O
as	IN	O
IMC-C225	NNP	O
)	)	O
human	NN	O
:	:	O
murine-chimerized	JJ	O
monoclonal	JJ	O
antibody	NN	O
that	WDT	O
binds	VBZ	O
to	TO	O
EGFR	NNP	O
and	CC	O
blocks	VBZ	O
the	DT	O
ability	NN	O
of	IN	O
EGF	NNP	O
to	TO	O
initiate	VB	O
receptor	NN	O
activation	NN	O
and	CC	O
signaling	VBG	O
to	TO	O
the	DT	O
tumor.5	NN	O
.	.	O
Renal	JJ	O
cancer	NN	O
:	:	O
IL-2	JJ	O
,	,	O
interferon	JJ	O
alpha	NN	O
,	,	O
AVASTIN™	NNP	O
anti-VEGF	NN	O
,	,	O
MEGACE™	NNP	O
(	(	O
Megestrol	NNP	O
acetate	NN	O
)	)	O
progestin	NN	O
,	,	O
vinblastine	NN	O
,	,	O
TARCEVA™	NNP	O
erlotinib	NN	O
,	,	O
and	CC	O
other	JJ	O
EGFR	NNP	O
TKI	NNP	O
's	POS	O
.	.	O
A	DT	O
“	JJ	O
growth	NN	O
inhibitory	NN	O
agent	NN	O
”	NN	O
when	WRB	O
used	VBN	O
herein	NN	O
refers	NNS	O
to	TO	O
a	DT	O
compound	NN	O
or	CC	O
composition	NN	O
which	WDT	O
inhibits	VBZ	O
growth	NN	O
of	IN	O
a	DT	O
cell	NN	O
,	,	O
especially	RB	O
a	DT	O
PRO227-	JJ	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
;	:	O
PRO10096-	NNP	O
;	:	O
PRO21384-	NNP	O
;	:	O
PRO353-	NNP	O
or	CC	O
PRO1885-expressing	NNP	O
cancer	NN	O
cell	NN	O
,	,	O
either	RB	O
in	IN	O
vitro	NN	O
or	CC	O
in	IN	O
vivo	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
growth	NN	O
inhibitory	JJ	O
agent	NN	O
may	MD	O
be	VB	O
one	CD	O
which	WDT	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
percentage	NN	O
of	IN	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-expressing	NNP	O
cells	NNS	O
in	IN	O
S	NNP	O
phase	NN	O
.	.	O
Examples	NNS	O
of	IN	O
growth	NN	O
inhibitory	JJ	O
agents	NNS	O
include	VBP	O
agents	NNS	O
that	WDT	O
block	VBP	O
cell	NN	O
cycle	NN	O
progression	NN	O
(	(	O
at	IN	O
a	DT	O
place	NN	O
other	JJ	O
than	IN	O
S	NNP	O
phase	NN	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
agents	NNS	O
that	WDT	O
induce	VBP	O
G1	NNP	O
arrest	NN	O
and	CC	O
M-phase	NNP	O
arrest	NN	O
.	.	O
Classical	JJ	O
M-phase	NNP	O
blockers	NNS	O
include	VBP	O
the	DT	O
vincas	NN	O
(	(	O
vincristine	NN	O
and	CC	O
vinblastine	NN	O
)	)	O
,	,	O
taxanes	NNS	O
,	,	O
and	CC	O
topoisomerase	NN	O
II	NNP	O
inhibitors	NNS	O
such	JJ	O
as	IN	O
doxorubicin	NN	O
,	,	O
epirubicin	NN	O
,	,	O
daunorubicin	NN	O
,	,	O
etoposide	RB	O
,	,	O
and	CC	O
bleomycin	NN	O
.	.	O
Those	DT	O
agents	NNS	O
that	WDT	O
arrest	VBP	O
G1	NNP	O
also	RB	O
spill	VBZ	O
over	RP	O
into	IN	O
S-phase	NNP	O
arrest	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
DNA	NNP	O
alkylating	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
tamoxifen	NN	O
,	,	O
prednisone	NN	O
,	,	O
dacarbazine	NN	O
,	,	O
mechlorethamine	NN	O
,	,	O
cisplatin	NN	O
,	,	O
methotrexate	NN	O
,	,	O
5-fluorouracil	JJ	O
,	,	O
and	CC	O
ara-C.	JJ	O
Further	NNP	O
information	NN	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
The	DT	O
Molecular	JJ	O
Basis	NNP	O
of	IN	O
Cancer	NNP	O
,	,	O
Mendelsohn	NNP	O
and	CC	O
Israel	NNP	O
,	,	O
eds.	NN	O
,	,	O
Chapter	NNP	O
1	CD	O
,	,	O
entitled	VBN	O
“	NN	O
Cell	NNP	O
cycle	NN	O
regulation	NN	O
,	,	O
oncogenes	NNS	O
,	,	O
and	CC	O
antineoplastic	JJ	O
drugs	NNS	O
”	VBN	O
by	IN	O
Murakami	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
WB	JJ	I
Saunders	NNS	I
:	:	I
Philadelphia	NNP	I
,	,	I
1995	CD	I
)	)	I
,	,	O
especially	RB	O
p.	JJ	O
13	CD	O
.	.	O
The	DT	O
taxanes	NNS	O
(	(	O
paclitaxel	NN	O
and	CC	O
docetaxel	NN	O
)	)	O
are	VBP	O
anticancer	JJ	O
drugs	NNS	O
both	DT	O
derived	VBN	O
from	IN	O
the	DT	O
yew	NN	O
tree	NN	O
.	.	O
Docetaxel	NNP	O
(	(	O
TAXOTERE®	NNP	O
,	,	O
Rhone-Poulenc	NNP	O
Rorer	NNP	O
)	)	O
,	,	O
derived	VBN	O
from	IN	O
the	DT	O
European	NNP	O
yew	NN	O
,	,	O
is	VBZ	O
a	DT	O
semisynthetic	JJ	O
analogue	NN	O
of	IN	O
paclitaxel	NN	O
(	(	O
TAXOL®	NNP	O
,	,	O
Bristol-Myers	NNP	O
Squibb	NNP	O
)	)	O
.	.	O
Paclitaxel	NNP	O
and	CC	O
docetaxel	JJ	O
promote	VBP	O
the	DT	O
assembly	NN	O
of	IN	O
microtubules	NNS	O
from	IN	O
tubulin	NN	O
dimers	NNS	O
and	CC	O
stabilize	VB	O
microtubules	NNS	O
by	IN	O
preventing	VBG	O
depolymerization	NN	O
,	,	O
which	WDT	O
results	NNS	O
in	IN	O
the	DT	O
inhibition	NN	O
of	IN	O
mitosis	NN	O
in	IN	O
cells	NNS	O
.	.	O
“	JJ	O
Doxorubicin	NNP	O
”	NNP	O
is	VBZ	O
an	DT	O
anthracycline	JJ	O
antibiotic	NN	O
.	.	O
The	DT	O
full	JJ	O
chemical	NN	O
name	NN	O
of	IN	O
doxorubicin	NN	O
is	VBZ	O
(	(	O
8S-cis	JJ	O
)	)	O
-10-	FW	O
[	FW	O
(	(	O
3-amino-2,3,6-trideoxy-α-L-lyxo-hexapyranosyl	JJ	O
)	)	O
oxy	MD	O
]	VB	O
-7,8,9,10-tetrahydro-6,8,1	JJ	O
1-trihydroxy-8-	JJ	O
(	(	O
hydroxyacetyl	NN	O
)	)	O
-1-methoxy-5,12-naphthacenedione	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
cytokine	NN	O
”	NN	O
is	VBZ	O
a	DT	O
generic	JJ	O
term	NN	O
for	IN	O
proteins	NNS	O
released	VBN	O
by	IN	O
one	CD	O
cell	NN	O
population	NN	O
which	WDT	O
act	NN	O
on	IN	O
another	DT	O
cell	NN	O
as	IN	O
intercellular	JJ	O
mediators	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
such	JJ	O
cytokines	NNS	O
are	VBP	O
lymphokines	NNS	O
,	,	O
monokines	NNS	O
,	,	O
and	CC	O
traditional	JJ	O
polypeptide	NN	O
hormones	NNS	O
.	.	O
Included	VBN	O
among	IN	O
the	DT	O
cytokines	NNS	O
are	VBP	O
growth	NN	O
hormone	NN	O
such	JJ	O
as	IN	O
human	JJ	O
growth	NN	O
hormone	NN	O
,	,	O
N-methionyl	NNP	O
human	JJ	O
growth	NN	O
hormone	NN	O
,	,	O
and	CC	O
bovine	VB	O
growth	NN	O
hormone	NN	O
;	:	O
parathyroid	CC	O
hormone	NN	O
;	:	O
thyroxine	NN	O
;	:	O
insulin	NN	O
;	:	O
proinsulin	CC	O
;	:	O
relaxin	NN	O
;	:	O
prorelaxin	NN	O
;	:	O
glycoprotein	CC	O
hormones	NNS	O
such	JJ	O
as	IN	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
(	(	O
FSH	NNP	O
)	)	O
,	,	O
thyroid	JJ	O
stimulating	VBG	O
hormone	NN	O
(	(	O
TSH	NNP	O
)	)	O
,	,	O
and	CC	O
luteinizing	VBG	O
hormone	NN	O
(	(	O
LH	NNP	O
)	)	O
;	:	O
hepatic	JJ	O
growth	NN	O
factor	NN	O
;	:	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
;	:	O
prolactin	NN	O
;	:	O
placental	JJ	O
lactogen	NN	O
;	:	O
tumor	CC	O
necrosis	IN	O
factor-α	JJ	O
and	CC	O
-β	JJ	O
;	:	O
mullerian-inhibiting	JJ	O
substance	NN	O
;	:	O
mouse	CC	O
gonadotropin-associated	JJ	O
peptide	NN	O
;	:	O
inhibin	NN	O
;	:	O
activin	CC	O
;	:	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
;	:	O
integrin	NN	O
;	:	O
thrombopoietin	NN	O
(	(	O
TPO	NNP	O
)	)	O
;	:	O
nerve	CC	O
growth	NN	O
factors	NNS	O
such	JJ	O
as	IN	O
NGF-β	NNP	O
;	:	O
platelet-growth	JJ	O
factor	NN	O
;	:	O
transforming	VBG	O
growth	NN	O
factors	NNS	O
(	(	O
TGFs	NNP	O
)	)	O
such	JJ	O
as	IN	O
TGF-α	NNP	O
and	CC	O
TGF-β	NNP	O
;	:	O
insulin-like	JJ	O
growth	NN	O
factor-I	JJ	O
and	CC	O
-II	JJ	O
;	:	O
erythropoietin	NN	O
(	(	O
EPO	NNP	O
)	)	O
;	:	O
osteoinductive	JJ	O
factors	NNS	O
;	:	O
interferons	NNS	O
such	JJ	O
as	IN	O
interferon-α	JJ	O
,	,	O
-β	NNP	O
,	,	O
and	CC	O
-γ	NNP	O
;	:	O
colony	NN	O
stimulating	NN	O
factors	NNS	O
(	(	O
CSFs	NNP	O
)	)	O
such	JJ	O
as	IN	O
macrophage-CSF	NN	O
(	(	O
M-CSF	NNP	O
)	)	O
;	:	O
granulocyte-macrophage-CSF	JJ	O
(	(	O
GM-CSF	NNP	O
)	)	O
;	:	O
and	CC	O
granulocyte-CSF	NNS	O
(	(	O
G-CSF	NNP	O
)	)	O
;	:	O
interleukins	NNS	O
(	(	O
ILs	NNP	O
)	)	O
such	JJ	O
as	IN	O
IL-1	NNP	O
,	,	O
IL-1a	NNP	O
,	,	O
IL-2	NNP	O
,	,	O
IL-3	NNP	O
,	,	O
IL-4	NNP	O
,	,	O
IL-5	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
IL-7	NNP	O
,	,	O
IL-8	NNP	O
,	,	O
IL-9	NNP	O
,	,	O
IL-11	NNP	O
,	,	O
IL-12	NNP	O
;	:	O
a	DT	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
such	JJ	O
as	IN	O
TNF-α	NNP	O
or	CC	O
TNF-β	NNP	O
;	:	O
and	CC	O
other	JJ	O
polypeptide	JJ	O
factors	NNS	O
including	VBG	O
LIF	NNP	O
and	CC	O
kit	VB	O
ligand	NN	O
(	(	O
KL	NNP	O
)	)	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
term	NN	O
cytokine	NN	O
includes	VBZ	O
proteins	NNS	O
from	IN	O
natural	JJ	O
sources	NNS	O
or	CC	O
from	IN	O
recombinant	JJ	O
cell	NN	O
culture	NN	O
and	CC	O
biologically	RB	O
active	JJ	O
equivalents	NNS	O
of	IN	O
the	DT	O
native	JJ	O
sequence	NN	O
cytokines	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
package	NN	O
insert	NN	O
”	NNP	O
is	VBZ	O
used	VBN	O
to	TO	O
refer	VB	O
to	TO	O
instructions	NNS	O
customarily	RB	O
included	VBN	O
in	IN	O
commercial	JJ	O
packages	NNS	O
of	IN	O
therapeutic	JJ	O
products	NNS	O
,	,	O
that	WDT	O
contain	VBP	O
information	NN	O
about	IN	O
the	DT	O
indications	NNS	O
,	,	O
usage	NN	O
,	,	O
dosage	NN	O
,	,	O
administration	NN	O
,	,	O
contraindications	NNS	O
and/or	VBP	O
warnings	NNS	O
concerning	VBG	O
the	DT	O
use	NN	O
of	IN	O
such	JJ	O
therapeutic	JJ	O
products	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
gene	NN	O
”	NNP	O
refers	NNS	O
to	TO	O
(	(	O
a	DT	O
)	)	O
a	DT	O
gene	NN	O
containing	VBG	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
DNA	NN	O
sequences	NNS	O
disclosed	VBD	O
herein	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
any	DT	O
DNA	NN	O
sequence	NN	O
that	WDT	O
encodes	VBZ	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
encoded	VBN	O
by	IN	O
the	DT	O
DNA	NN	O
sequences	NNS	O
disclosed	VBD	O
herein	JJ	O
and/or	NN	O
;	:	O
(	(	O
c	VB	O
)	)	O
any	DT	O
DNA	NN	O
sequence	NN	O
that	WDT	O
hybridizes	VBZ	O
to	TO	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
coding	NN	O
sequences	NNS	O
disclosed	VBD	O
herein	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
term	NN	O
includes	VBZ	O
coding	NN	O
as	RB	O
well	RB	O
as	IN	O
noncoding	VBG	O
regions	NNS	O
,	,	O
and	CC	O
preferably	RB	O
includes	VBZ	O
all	DT	O
sequences	NNS	O
necessary	JJ	O
for	IN	O
normal	JJ	O
gene	NN	O
expression	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
gene	NN	O
targeting	VBG	O
”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
type	NN	O
of	IN	O
homologous	JJ	O
recombination	NN	O
that	WDT	O
occurs	VBZ	O
when	WRB	O
a	DT	O
fragment	NN	O
of	IN	O
genomic	JJ	O
DNA	NNP	O
is	VBZ	O
introduced	VBN	O
into	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
and	CC	O
that	DT	O
fragment	NN	O
locates	VBZ	O
and	CC	O
recombines	NNS	O
with	IN	O
endogenous	JJ	O
homologous	JJ	O
sequences	NNS	O
.	.	O
Gene	NNP	O
targeting	VBG	O
by	IN	O
homologous	JJ	O
recombination	NN	O
employs	VBZ	O
recombinant	JJ	O
DNA	NNP	O
technologies	NNS	O
to	TO	O
replace	VB	O
specific	JJ	O
genomic	JJ	O
sequences	NNS	O
with	IN	O
exogenous	JJ	O
DNA	NN	O
of	IN	O
particular	JJ	O
design	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
homologous	JJ	O
recombination	NN	O
”	NN	O
refers	NNS	O
to	TO	O
the	DT	O
exchange	NN	O
of	IN	O
DNA	NNP	O
fragments	NNS	O
between	IN	O
two	CD	O
DNA	NNP	O
molecules	NNS	O
or	CC	O
chromatids	NNS	O
at	IN	O
the	DT	O
site	NN	O
of	IN	O
homologous	JJ	O
nucleotide	JJ	O
sequences	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
target	NN	O
gene	NN	O
”	NNP	O
(	(	O
alternatively	RB	O
referred	VBN	O
to	TO	O
as	IN	O
“	NNP	O
target	NN	O
gene	NN	O
sequence	NN	O
”	CD	O
or	CC	O
“	VB	O
target	NN	O
DNA	NNP	O
sequence	NN	O
”	NN	O
)	)	O
refers	NNS	O
to	TO	O
any	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
,	,	O
polynucleotide	NN	O
,	,	O
or	CC	O
gene	NN	O
to	TO	O
be	VB	O
modified	VBN	O
by	IN	O
homologous	JJ	O
recombination	NN	O
.	.	O
The	DT	O
target	NN	O
sequence	NN	O
includes	VBZ	O
an	DT	O
intact	JJ	O
gene	NN	O
,	,	O
an	DT	O
exon	NN	O
or	CC	O
intron	NN	O
,	,	O
a	DT	O
regulatory	JJ	O
sequence	NN	O
or	CC	O
any	DT	O
region	NN	O
between	IN	O
genes	NNS	O
.	.	O
The	DT	O
target	NN	O
gene	NN	O
my	PRP$	O
comprise	NN	O
a	DT	O
portion	NN	O
of	IN	O
a	DT	O
particular	JJ	O
gene	NN	O
or	CC	O
genetic	JJ	O
locus	NN	O
in	IN	O
the	DT	O
individual	NN	O
's	POS	O
genomic	JJ	O
DNA	NN	O
.	.	O
“	JJ	O
Disruption	NNP	O
”	NNP	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
occurs	VBZ	O
when	WRB	O
a	DT	O
fragment	NN	O
of	IN	O
genomic	JJ	O
DNA	NNP	O
locates	NNS	O
and	CC	O
recombines	NNS	O
with	IN	O
an	DT	O
endogenous	JJ	O
homologous	JJ	O
sequence	NN	O
wherein	VBD	O
the	DT	O
disruption	NN	O
is	VBZ	O
a	DT	O
deletion	NN	O
of	IN	O
the	DT	O
native	JJ	O
gene	NN	O
or	CC	O
a	DT	O
portion	NN	O
thereof	NN	O
,	,	O
or	CC	O
a	DT	O
mutation	NN	O
in	IN	O
the	DT	O
native	JJ	O
gene	NN	O
or	CC	O
wherein	VB	O
the	DT	O
disruption	NN	O
is	VBZ	O
the	DT	O
functional	JJ	O
inactivation	NN	O
of	IN	O
the	DT	O
native	JJ	O
gene	NN	O
.	.	O
Alternatively	RB	O
,	,	O
sequence	NN	O
disruptions	NNS	O
may	MD	O
be	VB	O
generated	VBN	O
by	IN	O
nonspecific	JJ	O
insertional	JJ	O
inactivation	NN	O
using	VBG	O
a	DT	O
gene	NN	O
trap	NN	O
vector	NN	O
(	(	O
i.e	NN	O
.	.	O
non-human	JJ	O
transgenic	JJ	O
animals	NNS	O
containing	VBG	O
and	CC	O
expressing	VBG	O
a	DT	O
randomly	RB	O
inserted	VBN	O
transgene	NN	O
;	:	O
see	VB	O
for	IN	O
example	NN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,436,707	CD	O
issued	VBN	O
Aug.	NNP	O
20	CD	O
,	,	O
2002	CD	O
)	)	O
.	.	O
These	DT	O
sequence	NN	O
disruptions	NNS	O
or	CC	O
modifications	NNS	O
may	MD	O
include	VB	O
insertions	NNS	O
,	,	O
missense	NN	O
,	,	O
frameshift	NN	O
,	,	O
deletion	NN	O
,	,	O
or	CC	O
substitutions	NNS	O
,	,	O
or	CC	O
replacements	NNS	O
of	IN	O
DNA	NNP	O
sequence	NN	O
,	,	O
or	CC	O
any	DT	O
combination	NN	O
thereof	NN	O
.	.	O
Insertions	NNS	O
include	VBP	O
the	DT	O
insertion	NN	O
of	IN	O
entire	JJ	O
genes	NNS	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
of	IN	O
animal	NN	O
,	,	O
plant	NN	O
,	,	O
fungal	JJ	O
,	,	O
insect	JJ	O
,	,	O
prokaryotic	JJ	O
,	,	O
or	CC	O
viral	JJ	O
origin	NN	O
.	.	O
Disruption	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
can	MD	O
alter	VB	O
the	DT	O
normal	JJ	O
gene	NN	O
product	NN	O
by	IN	O
inhibiting	VBG	O
its	PRP$	O
production	NN	O
partially	RB	O
or	CC	O
completely	RB	O
or	CC	O
by	IN	O
enhancing	VBG	O
the	DT	O
normal	JJ	O
gene	NN	O
product	NN	O
's	POS	O
activity	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
disruption	NN	O
is	VBZ	O
a	DT	O
null	JJ	O
disruption	NN	O
,	,	O
wherein	NN	O
there	EX	O
is	VBZ	O
no	DT	O
significant	JJ	O
expression	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
native	JJ	O
expression	NN	O
”	NN	O
refers	NNS	O
to	TO	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
,	,	O
at	IN	O
expression	NN	O
levels	NNS	O
present	VBP	O
in	IN	O
the	DT	O
wild-type	JJ	O
mouse	NN	O
.	.	O
Thus	RB	O
,	,	O
a	DT	O
disruption	NN	O
in	IN	O
which	WDT	O
there	EX	O
is	VBZ	O
“	JJ	O
no	DT	O
native	JJ	O
expression	NN	O
”	NN	O
of	IN	O
the	DT	O
endogenous	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
refers	NNS	O
to	TO	O
a	DT	O
partial	JJ	O
or	CC	O
complete	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
at	IN	O
least	JJS	O
a	DT	O
portion	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
an	DT	O
endogenous	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
of	IN	O
a	DT	O
single	JJ	O
cell	NN	O
,	,	O
selected	VBN	O
cells	NNS	O
,	,	O
or	CC	O
all	DT	O
of	IN	O
the	DT	O
cells	NNS	O
of	IN	O
a	DT	O
mammal	NN	O
.	.	O
The	DT	O
term	NN	O
“	VBZ	O
knockout	RP	O
”	JJ	O
refers	NNS	O
to	TO	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
wherein	VBD	O
the	DT	O
disruption	NN	O
results	NNS	O
in	IN	O
:	:	O
the	DT	O
functional	JJ	O
inactivation	NN	O
of	IN	O
the	DT	O
native	JJ	O
gene	NN	O
;	:	O
the	DT	O
deletion	NN	O
of	IN	O
the	DT	O
native	JJ	O
gene	NN	O
or	CC	O
a	DT	O
portion	NN	O
thereof	NN	O
;	:	O
or	CC	O
a	DT	O
mutation	NN	O
in	IN	O
the	DT	O
native	JJ	O
gene	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
knock-in	NN	O
”	NN	O
refers	NNS	O
to	TO	O
the	DT	O
replacement	NN	O
of	IN	O
the	DT	O
mouse	NN	O
ortholog	NN	O
(	(	O
or	CC	O
other	JJ	O
mouse	NN	O
gene	NN	O
)	)	O
with	IN	O
a	DT	O
human	JJ	O
cDNA	NN	O
encoding	VBG	O
any	DT	O
of	IN	O
the	DT	O
specific	JJ	O
human	JJ	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-encoding	NNP	O
genes	NNS	O
or	CC	O
variants	NNS	O
thereof	VBP	O
(	(	O
ie	NN	O
.	.	O
the	DT	O
disruption	NN	O
results	NNS	O
in	IN	O
a	DT	O
replacement	NN	O
of	IN	O
a	DT	O
native	JJ	O
mouse	NN	O
gene	NN	O
with	IN	O
a	DT	O
native	JJ	O
human	JJ	O
gene	NN	O
)	)	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
construct	NN	O
”	NN	O
or	CC	O
“	VB	O
targeting	VBG	O
construct	NN	O
”	NN	O
refers	NNS	O
to	TO	O
an	DT	O
artificially	RB	O
assembled	JJ	O
DNA	NNP	O
segment	NN	O
to	TO	O
be	VB	O
transferred	VBN	O
into	IN	O
a	DT	O
target	NN	O
tissue	NN	O
,	,	O
cell	NN	O
line	NN	O
or	CC	O
animal	NN	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
targeting	VBG	O
construct	NN	O
will	MD	O
include	VB	O
a	DT	O
gene	NN	O
or	CC	O
a	DT	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
particular	JJ	O
interest	NN	O
,	,	O
a	DT	O
marker	NN	O
gene	NN	O
and	CC	O
appropriate	JJ	O
control	NN	O
sequences	NNS	O
.	.	O
As	IN	O
provided	VBN	O
herein	NN	O
,	,	O
the	DT	O
targeting	VBG	O
construct	NN	O
comprises	VBZ	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
targeting	VBG	O
construct	NN	O
.	.	O
A	DT	O
“	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
targeting	VBG	O
construct	NN	O
”	NNP	O
includes	VBZ	O
a	DT	O
DNA	NN	O
sequence	NN	O
homologous	JJ	O
to	TO	O
at	IN	O
least	JJS	O
one	CD	O
portion	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
and	CC	O
is	VBZ	O
capable	JJ	O
of	IN	O
producing	VBG	O
a	DT	O
disruption	NN	O
in	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
in	IN	O
a	DT	O
host	NN	O
cell	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
transgenic	NN	O
cell	NN	O
”	VBZ	O
refers	NNS	O
to	TO	O
a	DT	O
cell	NN	O
containing	VBG	O
within	IN	O
its	PRP$	O
genome	NN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
disrupted	VBN	O
,	,	O
modified	VBN	O
,	,	O
altered	VBN	O
,	,	O
or	CC	O
replaced	VBD	O
completely	RB	O
or	CC	O
partially	RB	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
gene	NN	O
targeting	VBG	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
transgenic	NN	O
animal	NN	O
”	NN	O
refers	NNS	O
to	TO	O
an	DT	O
animal	NN	O
that	WDT	O
contains	VBZ	O
within	IN	O
its	PRP$	O
genome	NN	O
a	DT	O
specific	JJ	O
gene	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
disrupted	VBN	O
or	CC	O
otherwise	RB	O
modified	VBN	O
or	CC	O
mutated	VBN	O
by	IN	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
or	CC	O
methods	NNS	O
otherwise	RB	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Preferably	RB	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
is	VBZ	O
a	DT	O
mammal	NN	O
.	.	O
More	RBR	O
preferably	RB	O
,	,	O
the	DT	O
mammal	NN	O
is	VBZ	O
a	DT	O
rodent	NN	O
such	JJ	O
as	IN	O
a	DT	O
rat	NN	O
or	CC	O
mouse	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
a	DT	O
“	NN	O
transgenic	JJ	O
animal	JJ	O
”	NN	O
may	MD	O
be	VB	O
a	DT	O
heterozygous	JJ	O
animal	NN	O
(	(	O
i.e.	FW	O
,	,	O
one	CD	O
defective	JJ	O
allele	NN	O
and	CC	O
one	CD	O
wild-type	JJ	O
allele	NN	O
)	)	O
or	CC	O
a	DT	O
homozygous	JJ	O
animal	NN	O
(	(	O
i.e.	JJ	O
,	,	O
two	CD	O
defective	JJ	O
alleles	NNS	O
)	)	O
.	.	O
An	DT	O
embryo	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
fall	VB	O
within	IN	O
the	DT	O
definition	NN	O
of	IN	O
an	DT	O
animal	NN	O
.	.	O
The	DT	O
provision	NN	O
of	IN	O
an	DT	O
animal	NN	O
includes	VBZ	O
the	DT	O
provision	NN	O
of	IN	O
an	DT	O
embryo	NN	O
or	CC	O
foetus	NN	O
in	IN	O
utero	NN	O
,	,	O
whether	IN	O
by	IN	O
mating	VBG	O
or	CC	O
otherwise	RB	O
,	,	O
and	CC	O
whether	IN	O
or	CC	O
not	RB	O
the	DT	O
embryo	NN	O
goes	VBZ	O
to	TO	O
term	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
terms	NNS	O
“	VBP	O
selective	JJ	O
marker	NN	O
”	NN	O
and	CC	O
position	NN	O
selection	NN	O
marker	NN	O
”	NNP	O
refer	NN	O
to	TO	O
a	DT	O
gene	NN	O
encoding	VBG	O
a	DT	O
product	NN	O
that	WDT	O
enables	VBZ	O
only	RB	O
the	DT	O
cells	NNS	O
that	WDT	O
carry	VBP	O
the	DT	O
gene	NN	O
to	TO	O
survive	VB	O
and/or	JJ	O
grow	NNS	O
under	IN	O
certain	JJ	O
conditions	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
plant	NN	O
and	CC	O
animal	NN	O
cells	NNS	O
that	WDT	O
express	VBP	O
the	DT	O
introduced	JJ	O
neomycin	NN	O
resistance	NN	O
(	(	O
Neor	NNP	O
)	)	O
gene	NN	O
are	VBP	O
resistant	JJ	O
to	TO	O
the	DT	O
compound	NN	O
G418	NNP	O
.	.	O
Cells	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
carry	VB	O
the	DT	O
Neor	NNP	O
gene	NN	O
marker	NN	O
are	VBP	O
killed	VBN	O
by	IN	O
G418	NNP	O
.	.	O
Other	JJ	O
positive	JJ	O
selection	NN	O
markers	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
,	,	O
or	CC	O
are	VBP	O
within	IN	O
the	DT	O
purview	NN	O
of	IN	O
,	,	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
modulates	VBZ	O
”	CD	O
or	CC	O
“	VB	O
modulation	NN	O
”	NN	O
as	IN	O
used	VBN	O
herein	NN	O
refers	NNS	O
to	TO	O
the	DT	O
decrease	NN	O
,	,	O
inhibition	NN	O
,	,	O
reduction	NN	O
,	,	O
amelioration	NN	O
,	,	O
increase	NN	O
or	CC	O
enhancement	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
function	NN	O
,	,	O
expression	NN	O
,	,	O
activity	NN	O
,	,	O
or	CC	O
alternatively	RB	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
ameliorates	VBZ	O
”	CD	O
or	CC	O
“	VB	O
amelioration	NN	O
”	NN	O
as	IN	O
used	VBN	O
herein	NN	O
refers	NNS	O
to	TO	O
a	DT	O
decrease	NN	O
,	,	O
reduction	NN	O
or	CC	O
elimination	NN	O
of	IN	O
a	DT	O
condition	NN	O
,	,	O
disease	NN	O
,	,	O
disorder	NN	O
,	,	O
or	CC	O
phenotype	NN	O
,	,	O
including	VBG	O
an	DT	O
abnormality	NN	O
or	CC	O
symptom	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
abnormality	NN	O
”	NN	O
refers	NNS	O
to	TO	O
any	DT	O
disease	NN	O
,	,	O
disorder	NN	O
,	,	O
condition	NN	O
,	,	O
or	CC	O
phenotype	NN	O
in	IN	O
which	WDT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
is	VBZ	O
implicated	VBN	O
,	,	O
including	VBG	O
pathological	JJ	O
conditions	NNS	O
and	CC	O
behavioral	JJ	O
observations	NNS	O
.	.	O
II	NNP	O
.	.	O
Compositions	NNS	O
and	CC	O
Methods	NNS	O
of	IN	O
the	DT	O
Invention	NNP	O
A.	NN	O
Full-Length	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
;	:	O
PRO10096	NNP	O
;	:	O
PRO21384	NNP	O
;	:	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
Polypeptides	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
newly	RB	O
identified	VBN	O
and	CC	O
isolated	VBN	O
nucleotide	JJ	O
sequences	NNS	O
encoding	VBG	O
polypeptides	NNS	O
referred	VBD	O
to	TO	O
in	IN	O
the	DT	O
present	JJ	O
application	NN	O
as	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
cDNAs	JJ	O
encoding	VBG	O
various	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
and	CC	O
isolated	VBN	O
,	,	O
as	IN	O
disclosed	VBN	O
in	IN	O
further	JJ	O
detail	NN	O
in	IN	O
the	DT	O
Examples	NNP	O
below	IN	O
.	.	O
It	PRP	O
is	VBZ	O
noted	VBN	O
that	IN	O
proteins	NNS	O
produced	VBN	O
in	IN	O
separate	JJ	O
expression	NN	O
rounds	NNS	O
may	MD	O
be	VB	O
given	VBN	O
different	JJ	O
PRO	NNP	O
numbers	NNS	O
but	CC	O
the	DT	O
UNQ	NNP	O
number	NN	O
is	VBZ	O
unique	JJ	O
for	IN	O
any	DT	O
given	VBN	O
DNA	NN	O
and	CC	O
the	DT	O
encoded	JJ	O
protein	NN	O
,	,	O
and	CC	O
will	MD	O
not	RB	O
be	VB	O
changed	VBN	O
.	.	O
However	RB	O
,	,	O
for	IN	O
sake	NN	O
of	IN	O
simplicity	NN	O
,	,	O
in	IN	O
the	DT	O
present	JJ	O
specification	NN	O
the	DT	O
protein	NN	O
encoded	VBN	O
by	IN	O
the	DT	O
full	JJ	O
length	NN	O
native	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
disclosed	VBD	O
herein	NN	O
as	RB	O
well	RB	O
as	IN	O
all	DT	O
further	JJ	O
native	JJ	O
homologues	NNS	O
and	CC	O
variants	NNS	O
included	VBN	O
in	IN	O
the	DT	O
foregoing	JJ	O
definition	NN	O
of	IN	O
PRO	NNP	O
,	,	O
will	MD	O
be	VB	O
referred	VBN	O
to	TO	O
as	IN	O
“	JJ	O
PRO/number	NNP	O
”	NNP	O
,	,	O
regardless	RB	O
of	IN	O
their	PRP$	O
origin	NN	O
or	CC	O
mode	NN	O
of	IN	O
preparation	NN	O
.	.	O
As	IN	O
disclosed	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
below	IN	O
,	,	O
various	JJ	O
cDNA	NN	O
clones	NNS	O
have	VBP	O
been	VBN	O
deposited	VBN	O
with	IN	O
the	DT	O
ATCC	NNP	O
.	.	O
The	DT	O
actual	JJ	O
nucleotide	JJ	O
sequences	NNS	O
of	IN	O
those	DT	O
clones	NNS	O
can	MD	O
readily	RB	O
be	VB	O
determined	VBN	O
by	IN	O
the	DT	O
skilled	VBN	O
artisan	NN	O
by	IN	O
sequencing	VBG	O
of	IN	O
the	DT	O
deposited	JJ	O
clone	NN	O
using	VBG	O
routine	JJ	O
methods	NNS	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
predicted	VBN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
can	MD	O
be	VB	O
determined	VBN	O
from	IN	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
using	VBG	O
routine	JJ	O
skill	NN	O
.	.	O
For	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
and	CC	O
encoding	VBG	O
nucleic	JJ	O
acids	NNS	O
described	VBD	O
herein	NN	O
,	,	O
Applicants	NNS	O
have	VBP	O
identified	VBN	O
what	WP	O
is	VBZ	O
believed	VBN	O
to	TO	O
be	VB	O
the	DT	O
reading	NN	O
frame	NN	O
best	RBS	O
identifiable	JJ	O
with	IN	O
the	DT	O
sequence	NN	O
information	NN	O
available	JJ	O
at	IN	O
the	DT	O
time	NN	O
.	.	O
B.	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
Polypeptide	NNP	O
Variants	NNP	O
In	IN	O
addition	NN	O
to	TO	O
the	DT	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
described	VBD	O
herein	RB	O
,	,	O
it	PRP	O
is	VBZ	O
contemplated	VBN	O
that	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variants	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variants	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
introducing	VBG	O
appropriate	JJ	O
nucleotide	JJ	O
changes	NNS	O
into	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
DNA	NNP	O
,	,	O
and/or	NN	O
by	IN	O
synthesis	NN	O
of	IN	O
the	DT	O
desired	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
amino	NN	O
acid	NNS	O
changes	NNS	O
may	MD	O
alter	VB	O
post-translational	JJ	O
processes	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
such	JJ	O
as	IN	O
changing	VBG	O
the	DT	O
number	NN	O
or	CC	O
position	NN	O
of	IN	O
glycosylation	NN	O
sites	NNS	O
or	CC	O
altering	VBG	O
the	DT	O
membrane	NN	O
anchoring	VBG	O
characteristics	NNS	O
.	.	O
Variations	NNS	O
in	IN	O
the	DT	O
native	JJ	O
full-length	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
in	IN	O
various	JJ	O
domains	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
described	VBD	O
herein	NNS	O
,	,	O
can	MD	O
be	VB	O
made	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
using	VBG	O
any	DT	O
of	IN	O
the	DT	O
techniques	NNS	O
and	CC	O
guidelines	NNS	O
for	IN	O
conservative	JJ	O
and	CC	O
non-conservative	JJ	O
mutations	NNS	O
set	VBD	O
forth	NN	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,364,934	CD	O
.	.	O
Variations	NNS	O
may	MD	O
be	VB	O
a	DT	O
substitution	NN	O
,	,	O
deletion	NN	O
or	CC	O
insertion	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
codons	NNS	O
encoding	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
that	DT	O
results	NNS	O
in	IN	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Optionally	RB	O
the	DT	O
variation	NN	O
is	VBZ	O
by	IN	O
substitution	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
amino	NN	O
acid	NN	O
with	IN	O
any	DT	O
other	JJ	O
amino	NN	O
acid	NN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
domains	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Guidance	NN	O
in	IN	O
determining	VBG	O
which	WDT	O
amino	NN	O
acid	NNS	O
residue	VBP	O
may	MD	O
be	VB	O
inserted	VBN	O
,	,	O
substituted	VBD	O
or	CC	O
deleted	VBN	O
without	IN	O
adversely	RB	O
affecting	VBG	O
the	DT	O
desired	JJ	O
activity	NN	O
may	MD	O
be	VB	O
found	VBN	O
by	IN	O
comparing	VBG	O
the	DT	O
sequence	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
with	IN	O
that	DT	O
of	IN	O
homologous	JJ	O
known	VBN	O
protein	NN	O
molecules	NNS	O
and	CC	O
minimizing	VBG	O
the	DT	O
number	NN	O
of	IN	O
amino	JJ	O
acid	JJ	O
sequence	NN	O
changes	NNS	O
made	VBN	O
in	IN	O
regions	NNS	O
of	IN	O
high	JJ	O
homology	NN	O
.	.	O
Amino	NNP	O
acid	JJ	O
substitutions	NNS	O
can	MD	O
be	VB	O
the	DT	O
result	NN	O
of	IN	O
replacing	VBG	O
one	CD	O
amino	NN	O
acid	NN	O
with	IN	O
another	DT	O
amino	NN	O
acid	NN	O
having	VBG	O
similar	JJ	O
structural	JJ	O
and/or	NN	O
chemical	NN	O
properties	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
replacement	NN	O
of	IN	O
a	DT	O
leucine	NN	O
with	IN	O
a	DT	O
serine	NN	O
,	,	O
i.e.	FW	O
,	,	O
conservative	JJ	O
amino	NN	O
acid	NN	O
replacements	NNS	O
.	.	O
Insertions	NNS	O
or	CC	O
deletions	NNS	O
may	MD	O
optionally	RB	O
be	VB	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
about	RB	O
1	CD	O
to	TO	O
5	CD	O
amino	NN	O
acids	NNS	O
.	.	O
The	DT	O
variation	NN	O
allowed	VBD	O
may	MD	O
be	VB	O
determined	VBN	O
by	IN	O
systematically	RB	O
making	VBG	O
insertions	NNS	O
,	,	O
deletions	NNS	O
or	CC	O
substitutions	NNS	O
of	IN	O
amino	JJ	O
acids	NNS	O
in	IN	O
the	DT	O
sequence	NN	O
and	CC	O
testing	VBG	O
the	DT	O
resulting	VBG	O
variants	NNS	O
for	IN	O
activity	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
full-length	NN	O
or	CC	O
mature	NN	O
native	JJ	O
sequence	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
fragments	NNS	O
are	VBP	O
provided	VBN	O
herein	NN	O
.	.	O
Such	JJ	O
fragments	NNS	O
may	MD	O
be	VB	O
truncated	VBN	O
at	IN	O
the	DT	O
N-terminus	NNP	O
or	CC	O
C-terminus	NNP	O
,	,	O
or	CC	O
may	MD	O
lack	VB	O
internal	JJ	O
residues	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
when	WRB	O
compared	VBN	O
with	IN	O
a	DT	O
full	JJ	O
length	NN	O
native	JJ	O
protein	NN	O
.	.	O
Certain	NN	O
fragments	NNS	O
lack	VBP	O
amino	JJ	O
acid	NN	O
residues	NNS	O
that	WDT	O
are	VBP	O
not	RB	O
essential	JJ	O
for	IN	O
a	DT	O
desired	JJ	O
biological	JJ	O
activity	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
fragments	NNS	O
may	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
any	DT	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
conventional	JJ	O
techniques	NNS	O
.	.	O
Desired	NNP	O
peptide	NN	O
fragments	NNS	O
may	MD	O
be	VB	O
chemically	RB	O
synthesized	VBN	O
.	.	O
An	DT	O
alternative	JJ	O
approach	NN	O
involves	VBZ	O
generating	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
fragments	NNS	O
by	IN	O
enzymatic	JJ	O
digestion	NN	O
,	,	O
e.g.	NN	O
,	,	O
by	IN	O
treating	VBG	O
the	DT	O
protein	NN	O
with	IN	O
an	DT	O
enzyme	NN	O
known	VBN	O
to	TO	O
cleave	VB	O
proteins	NNS	O
at	IN	O
sites	NNS	O
defined	VBN	O
by	IN	O
particular	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
,	,	O
or	CC	O
by	IN	O
digesting	VBG	O
the	DT	O
DNA	NN	O
with	IN	O
suitable	JJ	O
restriction	NN	O
enzymes	NNS	O
and	CC	O
isolating	VBG	O
the	DT	O
desired	JJ	O
fragment	NN	O
.	.	O
Yet	RB	O
another	DT	O
suitable	JJ	O
technique	NN	O
involves	VBZ	O
isolating	VBG	O
and	CC	O
amplifying	VBG	O
a	DT	O
DNA	NN	O
fragment	NN	O
encoding	VBG	O
a	DT	O
desired	JJ	O
polypeptide	NN	O
fragment	NN	O
,	,	O
by	IN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
.	.	O
Oligonucleotides	NNS	O
that	WDT	O
define	VBP	O
the	DT	O
desired	JJ	O
termini	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
fragment	NN	O
are	VBP	O
employed	VBN	O
at	IN	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
primers	NNS	O
in	IN	O
the	DT	O
PCR	NNP	O
.	.	O
Preferably	RB	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
fragments	NNS	O
share	NN	O
at	IN	O
least	JJS	O
one	CD	O
biological	JJ	O
and/or	JJ	O
immunological	JJ	O
activity	NN	O
with	IN	O
the	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
disclosed	VBD	O
herein	NN	O
.	.	O
Conservative	JJ	O
substitutions	NNS	O
of	IN	O
interest	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
6	CD	O
under	IN	O
the	DT	O
heading	NN	O
of	IN	O
preferred	JJ	O
substitutions	NNS	O
.	.	O
If	IN	O
such	JJ	O
substitutions	NNS	O
result	VBP	O
in	IN	O
a	DT	O
change	NN	O
in	IN	O
biological	JJ	O
activity	NN	O
,	,	O
then	RB	O
more	RBR	O
substantial	JJ	O
changes	NNS	O
,	,	O
denominated	VBD	O
exemplary	JJ	O
substitutions	NNS	O
in	IN	O
Table	JJ	O
6	CD	O
,	,	O
or	CC	O
as	IN	O
further	JJ	O
described	VBD	O
below	IN	O
in	IN	O
reference	NN	O
to	TO	O
amino	VB	O
acid	JJ	O
classes	NNS	O
,	,	O
are	VBP	O
preferably	RB	O
introduced	VBN	O
and	CC	O
the	DT	O
products	NNS	O
screened	VBN	O
.	.	O
Substantial	JJ	O
modifications	NNS	O
in	IN	O
function	NN	O
or	CC	O
immunological	JJ	O
identity	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
are	VBP	O
accomplished	VBN	O
by	IN	O
selecting	VBG	O
substitutions	NNS	O
that	WDT	O
differ	VBP	O
significantly	RB	O
in	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
maintaining	NN	O
(	(	O
a	DT	O
)	)	O
the	DT	O
structure	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
backbone	NN	O
in	IN	O
the	DT	O
area	NN	O
of	IN	O
the	DT	O
substitution	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
as	IN	O
a	DT	O
sheet	NN	O
or	CC	O
helical	JJ	O
conformation	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
the	DT	O
charge	NN	O
or	CC	O
hydrophobicity	NN	O
of	IN	O
the	DT	O
molecule	NN	O
at	IN	O
the	DT	O
target	NN	O
site	NN	O
,	,	O
or	CC	O
(	(	O
c	NN	O
)	)	O
the	DT	O
bulk	NN	O
of	IN	O
the	DT	O
side	NN	O
chain	NN	O
.	.	O
Naturally	RB	O
occurring	VBG	O
residues	NNS	O
are	VBP	O
divided	VBN	O
into	IN	O
groups	NNS	O
based	VBN	O
on	IN	O
common	JJ	O
side-chain	JJ	O
properties	NNS	O
:	:	O
Amino	NNP	O
acids	NNS	O
may	MD	O
be	VB	O
grouped	VBN	O
according	VBG	O
to	TO	O
similarities	NNS	O
in	IN	O
the	DT	O
properties	NNS	O
of	IN	O
their	PRP$	O
side	NN	O
chains	NNS	O
(	(	O
in	IN	O
A.	NNP	B
L.	NNP	I
Lehninger	NNP	I
,	,	I
in	IN	I
Biochemistry	NNP	I
,	,	I
second	JJ	I
ed.	NN	I
,	,	I
pp	NN	I
.	.	I
73-75	JJ	I
,	,	I
Worth	JJ	I
Publishers	NNS	I
,	,	I
New	NNP	I
York	NNP	I
(	(	I
1975	CD	I
)	)	I
)	)	O
:	:	O
(	(	O
1	CD	O
)	)	O
non-polar	JJ	O
:	:	O
Ala	NNP	O
(	(	O
A	NNP	O
)	)	O
,	,	O
Val	NNP	O
(	(	O
V	NNP	O
)	)	O
,	,	O
Leu	NNP	O
(	(	O
L	NNP	O
)	)	O
,	,	O
Ile	NNP	O
(	(	O
I	PRP	O
)	)	O
,	,	O
Pro	NNP	O
(	(	O
P	NNP	O
)	)	O
,	,	O
Phe	NNP	O
(	(	O
F	NNP	O
)	)	O
,	,	O
Trp	NNP	O
(	(	O
W	NNP	O
)	)	O
,	,	O
Met	NNP	O
(	(	O
M	NNP	O
)	)	O
(	(	O
2	CD	O
)	)	O
uncharged	VBD	O
polar	JJ	O
:	:	O
Gly	NNP	O
(	(	O
G	NNP	O
)	)	O
,	,	O
Ser	NNP	O
(	(	O
S	NNP	O
)	)	O
,	,	O
Thr	NNP	O
(	(	O
T	NNP	O
)	)	O
,	,	O
Cys©	NNP	O
)	)	O
,	,	O
Tyr	NNP	O
(	(	O
Y	NNP	O
)	)	O
,	,	O
Asn	NNP	O
(	(	O
N	NNP	O
)	)	O
,	,	O
Gln	NNP	O
(	(	O
Q	NNP	O
)	)	O
(	(	O
3	CD	O
)	)	O
acidic	NN	O
:	:	O
Asp	NNP	O
(	(	O
D	NNP	O
)	)	O
,	,	O
Glu	NNP	O
(	(	O
E	NNP	O
)	)	O
(	(	O
4	CD	O
)	)	O
basic	NN	O
:	:	O
Lys	NNP	O
(	(	O
K	NNP	O
)	)	O
,	,	O
Arg®	NNP	O
)	)	O
,	,	O
His	PRP$	O
(	(	O
H	NNP	O
)	)	O
Alternatively	RB	O
,	,	O
naturally	RB	O
occurring	VBG	O
residues	NNS	O
may	MD	O
be	VB	O
divided	VBN	O
into	IN	O
groups	NNS	O
based	VBN	O
on	IN	O
common	JJ	O
side-chain	JJ	O
properties	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
hydrophobic	NN	O
:	:	O
Norleucine	NNP	O
,	,	O
Met	NNP	O
,	,	O
Ala	NNP	O
,	,	O
Val	NNP	O
,	,	O
Leu	NNP	O
,	,	O
Ile	NNP	O
;	:	O
(	(	O
2	CD	O
)	)	O
neutral	JJ	O
hydrophilic	NN	O
:	:	O
Cys	NNP	O
,	,	O
Ser	NNP	O
,	,	O
Thr	NNP	O
,	,	O
Asn	NNP	O
,	,	O
Gln	NNP	O
;	:	O
(	(	O
3	CD	O
)	)	O
acidic	NN	O
:	:	O
Asp	NNP	O
,	,	O
Glu	NNP	O
;	:	O
(	(	O
4	CD	O
)	)	O
basic	NN	O
:	:	O
His	PRP$	O
,	,	O
Lys	NNP	O
,	,	O
Arg	NNP	O
;	:	O
(	(	O
5	CD	O
)	)	O
residues	NNS	O
that	WDT	O
influence	NN	O
chain	NN	O
orientation	NN	O
:	:	O
Gly	NNP	O
,	,	O
Pro	NNP	O
;	:	O
(	(	O
6	CD	O
)	)	O
aromatic	NN	O
:	:	O
Trp	NNP	O
,	,	O
Tyr	NNP	O
,	,	O
Phe	NNP	O
.	.	O
Non-conservative	JJ	O
substitutions	NNS	O
will	MD	O
entail	VB	O
exchanging	VBG	O
a	DT	O
member	NN	O
of	IN	O
one	CD	O
of	IN	O
these	DT	O
classes	NNS	O
for	IN	O
another	DT	O
class	NN	O
.	.	O
Such	JJ	O
substituted	VBN	O
residues	NNS	O
also	RB	O
may	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
the	DT	O
conservative	JJ	O
substitution	NN	O
sites	NNS	O
or	CC	O
,	,	O
more	JJR	O
preferably	RB	O
,	,	O
into	IN	O
the	DT	O
remaining	VBG	O
(	(	O
non-conserved	JJ	O
)	)	O
sites	NNS	O
.	.	O
The	DT	O
variations	NNS	O
can	MD	O
be	VB	O
made	VBN	O
using	VBG	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
such	JJ	O
as	IN	O
oligonucleotide-mediated	JJ	O
(	(	O
site-directed	JJ	O
)	)	O
mutagenesis	NN	O
,	,	O
alanine	NN	O
scanning	NN	O
,	,	O
and	CC	O
PCR	NNP	O
mutagenesis	NN	O
.	.	O
Site-directed	JJ	O
mutagenesis	NN	O
[	NNP	O
Carter	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nucl	NNP	I
.	.	I
Acids	NNP	I
Res.	NNP	I
,	,	I
13:4331	CD	I
(	(	I
1986	CD	I
)	)	I
;	:	O
Zoller	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nucl	NNP	I
.	.	I
Acids	NNP	I
Res.	NNP	I
,	,	I
10:6487	CD	I
(	(	I
1987	CD	I
)	)	I
]	NN	O
,	,	O
cassette	NN	O
mutagenesis	NN	O
[	NNP	O
Wells	NNP	B
et	FW	I
al.	NN	I
,	,	I
Gene	NNP	I
,	,	I
34:315	CD	I
(	(	I
1985	CD	I
)	)	I
]	NN	O
,	,	O
restriction	NN	O
selection	NN	O
mutagenesis	NN	O
[	NNP	O
Wells	NNP	B
et	FW	I
al.	NN	I
,	,	I
Philos	NNP	I
.	.	I
Trans	NNS	I
.	.	I
R.	NNP	I
Soc	NNP	I
.	.	I
London	NNP	I
SerA	NNP	I
,	,	I
317:415	CD	I
(	(	I
1986	CD	I
)	)	I
]	NN	O
or	CC	O
other	JJ	O
known	VBN	O
techniques	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
on	IN	O
the	DT	O
cloned	VBN	O
DNA	NN	O
to	TO	O
produce	VB	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
DNA	NNP	O
.	.	O
Scanning	VBG	O
amino	NN	O
acid	JJ	O
analysis	NN	O
can	MD	O
also	RB	O
be	VB	O
employed	VBN	O
to	TO	O
identify	VB	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acids	NNS	O
along	IN	O
a	DT	O
contiguous	JJ	O
sequence	NN	O
.	.	O
Among	IN	O
the	DT	O
preferred	JJ	O
scanning	NN	O
amino	NN	O
acids	NNS	O
are	VBP	O
relatively	RB	O
small	JJ	O
,	,	O
neutral	JJ	O
amino	NN	O
acids	NNS	O
.	.	O
Such	JJ	O
amino	JJ	O
acids	NNS	O
include	VBP	O
alanine	JJ	O
,	,	O
glycine	NN	O
,	,	O
serine	NN	O
,	,	O
and	CC	O
cysteine	NN	O
.	.	O
Alanine	NNP	O
is	VBZ	O
typically	RB	O
a	DT	O
preferred	JJ	O
scanning	NN	O
amino	NN	O
acid	NN	O
among	IN	O
this	DT	O
group	NN	O
because	IN	O
it	PRP	O
eliminates	VBZ	O
the	DT	O
side-chain	JJ	O
beyond	IN	O
the	DT	O
beta-carbon	NN	O
and	CC	O
is	VBZ	O
less	RBR	O
likely	JJ	O
to	TO	O
alter	VB	O
the	DT	O
main-chain	JJ	O
conformation	NN	O
of	IN	O
the	DT	O
variant	JJ	O
[	NNP	O
Cunningham	NNP	B
and	CC	I
Wells	NNP	I
,	,	I
Science	NNP	I
,	,	I
244	CD	I
:	:	I
1081-1085	CD	I
(	(	I
1989	CD	I
)	)	I
]	NN	O
.	.	O
Alanine	NNP	O
is	VBZ	O
also	RB	O
typically	RB	O
preferred	JJ	O
because	IN	O
it	PRP	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
amino	NN	O
acid	NN	O
.	.	O
Further	RB	O
,	,	O
it	PRP	O
is	VBZ	O
frequently	RB	O
found	VBN	O
in	IN	O
both	DT	O
buried	VBN	O
and	CC	O
exposed	VBN	O
positions	NNS	O
[	VBP	O
Creighton	NNP	B
,	,	I
The	DT	I
Proteins	NNP	I
,	,	I
(	(	I
W.H	NNP	I
.	.	I
Freeman	NNP	I
&	CC	I
Co.	NNP	I
,	,	I
N.Y.	NNP	I
)	)	I
;	:	O
Chothia	NNP	B
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
150:1	CD	I
(	(	I
1976	CD	I
)	)	I
]	NN	O
.	.	O
If	IN	O
alanine	JJ	O
substitution	NN	O
does	VBZ	O
not	RB	O
yield	VB	O
adequate	JJ	O
amounts	NNS	O
of	IN	O
variant	NN	O
,	,	O
an	DT	O
isoteric	JJ	O
amino	NN	O
acid	NN	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
C.	NNP	O
Modifications	NNP	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
Covalent	NNP	O
modifications	NNS	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
are	VBP	O
included	VBN	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
this	DT	O
invention	NN	O
.	.	O
One	CD	O
type	NN	O
of	IN	O
covalent	JJ	O
modification	NN	O
includes	VBZ	O
reacting	VBG	O
targeted	VBN	O
amino	JJ	O
acid	JJ	O
residues	NNS	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
with	IN	O
an	DT	O
organic	JJ	O
derivatizing	NN	O
agent	NN	O
that	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
reacting	VBG	O
with	IN	O
selected	VBN	O
side	NN	O
chains	NNS	O
or	CC	O
the	DT	O
N-	JJ	O
or	CC	O
C-terminal	JJ	O
residues	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Derivatization	NN	O
with	IN	O
bifunctional	JJ	O
agents	NNS	O
is	VBZ	O
useful	JJ	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
for	IN	O
crosslinking	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
to	TO	O
a	DT	O
water-insoluble	JJ	O
support	NN	O
matrix	NN	O
or	CC	O
surface	NN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
method	NN	O
for	IN	O
purifying	VBG	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
,	,	O
and	CC	O
vice-versa	NN	O
.	.	O
Commonly	RB	O
used	VBN	O
crosslinking	VBG	O
agents	NNS	O
include	VBP	O
,	,	O
e.g.	JJ	O
,	,	O
1,1-bis	JJ	O
(	(	O
diazoacetyl	NN	O
)	)	O
-2-phenylethane	NN	O
,	,	O
glutaraldehyde	NN	O
,	,	O
N-hydroxysuccinimide	JJ	O
esters	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
esters	NNS	O
with	IN	O
4-azidosalicylic	JJ	O
acid	NN	O
,	,	O
homobifunctional	JJ	O
imidoesters	NNS	O
,	,	O
including	VBG	O
disuccinimidyl	JJ	O
esters	NNS	O
such	JJ	O
as	IN	O
3,3′-dithiobis	JJ	O
(	(	O
succinimidylpropionate	NN	O
)	)	O
,	,	O
bifunctionalmaleimides	NNS	O
such	JJ	O
as	IN	O
bis-N-maleimido-1,8-octane	NN	O
and	CC	O
agents	NNS	O
such	JJ	O
as	IN	O
ethyl-3-	JJ	O
[	NN	O
(	(	O
p-azidophenyl	JJ	O
)	)	O
dithio	NN	O
]	JJ	O
propioimidate	NN	O
.	.	O
Other	JJ	O
modifications	NNS	O
include	VBP	O
deamidation	NN	O
of	IN	O
glutaminyl	NN	O
and	CC	O
asparaginyl	NN	O
residues	NNS	O
to	TO	O
the	DT	O
corresponding	JJ	O
glutamyl	NN	O
and	CC	O
aspartyl	NN	O
residues	NNS	O
,	,	O
respectively	RB	O
,	,	O
hydroxylation	NN	O
of	IN	O
proline	NN	O
and	CC	O
lysine	NN	O
,	,	O
phosphorylation	NN	O
of	IN	O
hydroxyl	NN	O
groups	NNS	O
of	IN	O
seryl	NN	O
or	CC	O
threonyl	NN	O
residues	NNS	O
,	,	O
methylation	NN	O
of	IN	O
the	DT	O
α-amino	JJ	O
groups	NNS	O
of	IN	O
lysine	NN	O
,	,	O
arginine	NN	O
,	,	O
and	CC	O
histidine	JJ	O
side	NN	O
chains	NNS	O
[	VBP	O
T.E	NNP	B
.	.	I
Creighton	NNP	I
,	,	I
Proteins	VBZ	I
:	:	I
Structure	NN	I
and	CC	I
Molecular	NNP	I
Properties	NNP	I
,	,	I
W.H	NNP	I
.	.	I
Freeman	NNP	I
&	CC	I
Co.	NNP	I
,	,	I
San	NNP	I
Francisco	NNP	I
,	,	I
pp	NN	I
.	.	I
79-86	CD	I
(	(	I
1983	CD	I
)	)	I
]	NN	O
,	,	O
acetylation	NN	O
of	IN	O
the	DT	O
N-terminal	JJ	O
amine	NN	O
,	,	O
and	CC	O
amidation	NN	O
of	IN	O
any	DT	O
C-terminal	JJ	O
carboxyl	NN	O
group	NN	O
.	.	O
Another	DT	O
type	NN	O
of	IN	O
covalent	JJ	O
modification	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
included	VBD	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
this	DT	O
invention	NN	O
comprises	VBZ	O
altering	VBG	O
the	DT	O
native	JJ	O
glycosylation	NN	O
pattern	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
“	NN	O
Altering	VBG	O
the	DT	O
native	JJ	O
glycosylation	NN	O
pattern	NN	O
”	NNP	O
is	VBZ	O
intended	VBN	O
for	IN	O
purposes	NNS	O
herein	VBP	O
to	TO	O
mean	VB	O
deleting	VBG	O
one	CD	O
or	CC	O
more	JJR	O
carbohydrate	JJ	O
moieties	NNS	O
found	VBN	O
in	IN	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
(	(	O
either	CC	O
by	IN	O
removing	VBG	O
the	DT	O
underlying	JJ	O
glycosylation	NN	O
site	NN	O
or	CC	O
by	IN	O
deleting	VBG	O
the	DT	O
glycosylation	NN	O
by	IN	O
chemical	NN	O
and/or	NN	O
enzymatic	JJ	O
means	NNS	O
)	)	O
,	,	O
and/or	JJ	O
adding	VBG	O
one	CD	O
or	CC	O
more	JJR	O
glycosylation	NN	O
sites	NNS	O
that	WDT	O
are	VBP	O
not	RB	O
present	JJ	O
in	IN	O
the	DT	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
phrase	NN	O
includes	VBZ	O
qualitative	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
glycosylation	NN	O
of	IN	O
the	DT	O
native	JJ	O
proteins	NNS	O
,	,	O
involving	VBG	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
nature	NN	O
and	CC	O
proportions	NNS	O
of	IN	O
the	DT	O
various	JJ	O
carbohydrate	NN	O
moieties	NNS	O
present	VBP	O
.	.	O
Addition	NN	O
of	IN	O
glycosylation	NN	O
sites	NNS	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
accomplished	VBN	O
by	IN	O
altering	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
.	.	O
The	DT	O
alteration	NN	O
may	MD	O
be	VB	O
made	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
,	,	O
or	CC	O
substitution	NN	O
by	IN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
serine	NN	O
or	CC	O
threonine	NN	O
residues	NNS	O
to	TO	O
the	DT	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
(	(	O
for	IN	O
O-linked	NNP	O
glycosylation	NN	O
sites	NNS	O
)	)	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
amino	VBP	O
acid	JJ	O
sequence	NN	O
may	MD	O
optionally	RB	O
be	VB	O
altered	VBN	O
through	IN	O
changes	NNS	O
at	IN	O
the	DT	O
DNA	NNP	O
level	NN	O
,	,	O
particularly	RB	O
by	IN	O
mutating	VBG	O
the	DT	O
DNA	NN	O
encoding	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
at	IN	O
preselected	VBN	O
bases	NNS	O
such	JJ	O
that	IN	O
codons	NNS	O
are	VBP	O
generated	VBN	O
that	IN	O
will	MD	O
translate	VB	O
into	IN	O
the	DT	O
desired	VBN	O
amino	NN	O
acids	NNS	O
.	.	O
Another	DT	O
means	NN	O
of	IN	O
increasing	VBG	O
the	DT	O
number	NN	O
of	IN	O
carbohydrate	JJ	O
moieties	NNS	O
on	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
by	IN	O
chemical	NN	O
or	CC	O
enzymatic	JJ	O
coupling	NN	O
of	IN	O
glycosides	NNS	O
to	TO	O
the	DT	O
polypeptide	NN	O
.	.	O
Such	JJ	O
methods	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
e.g.	NN	O
,	,	O
in	IN	O
WO	NNP	O
87/05330	CD	O
published	VBD	O
11	CD	O
Sep.	NNP	O
1987	CD	O
,	,	O
and	CC	O
in	IN	O
Aplin	NNP	B
and	CC	I
Wriston	NNP	I
,	,	I
CRC	NNP	I
Crit	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
pp	NN	I
.	.	I
259-306	CD	I
(	(	I
1981	CD	I
)	)	I
.	.	O
Removal	NN	O
of	IN	O
carbohydrate	NN	O
moieties	NNS	O
present	VBP	O
on	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
accomplished	VBN	O
chemically	RB	O
or	CC	O
enzymatically	RB	O
or	CC	O
by	IN	O
mutational	JJ	O
substitution	NN	O
of	IN	O
codons	NNS	O
encoding	VBG	O
for	IN	O
amino	NN	O
acid	NN	O
residues	NNS	O
that	WDT	O
serve	VBP	O
as	IN	O
targets	NNS	O
for	IN	O
glycosylation	NN	O
.	.	O
Chemical	NNP	O
deglycosylation	NN	O
techniques	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
described	NN	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
by	IN	O
Hakimuddin	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Arch	NNP	I
.	.	I
Biochem	NNP	I
.	.	I
Biophys.	NNP	I
,	,	I
259:52	CD	I
(	(	I
1987	CD	I
)	)	I
and	CC	O
by	IN	O
Edge	NNP	B
et	FW	I
al.	NN	I
,	,	I
Anal	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
118:131	CD	I
(	(	I
1981	CD	I
)	)	I
.	.	O
Enzymatic	JJ	O
cleavage	NN	O
of	IN	O
carbohydrate	NN	O
moieties	NNS	O
on	IN	O
polypeptides	NNS	O
can	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
endo-	JJ	O
and	CC	O
exo-glycosidases	NNS	O
as	IN	O
described	VBN	O
by	IN	O
Thotakura	NNP	B
et	FW	I
al.	NN	I
,	,	I
Meth	NNP	I
.	.	I
Enzymol.	NNP	I
,	,	I
138:350	CD	I
(	(	I
1987	CD	I
)	)	I
.	.	O
Another	DT	O
type	NN	O
of	IN	O
covalent	JJ	O
modification	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
comprises	VBZ	O
linking	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
to	TO	O
one	CD	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
nonproteinaceous	JJ	O
polymers	NNS	O
,	,	O
e.g.	NN	O
,	,	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
,	,	O
polypropylene	JJ	O
glycol	NN	O
,	,	O
or	CC	O
polyoxyalkylenes	NNS	O
,	,	O
in	IN	O
the	DT	O
manner	NN	O
set	VBN	O
forth	NN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,640,835	CD	O
;	:	O
4,496,689	CD	O
;	:	O
4,301,144	CD	O
;	:	O
4,670,417	CD	O
;	:	O
4,791,192	CD	O
or	CC	O
4,179,337	CD	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
modified	VBN	O
in	IN	O
a	DT	O
way	NN	O
to	TO	O
form	VB	O
a	DT	O
chimeric	JJ	O
molecule	NN	O
comprising	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
fused	VBD	O
to	TO	O
another	DT	O
,	,	O
heterologous	JJ	O
polypeptide	NN	O
or	CC	O
amino	NN	O
acid	JJ	O
sequence	NN	O
.	.	O
Such	JJ	O
a	DT	O
chimeric	JJ	O
molecule	NN	O
comprises	VBZ	O
a	DT	O
fusion	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
with	IN	O
a	DT	O
tag	NN	O
polypeptide	NN	O
which	WDT	O
provides	VBZ	O
an	DT	O
epitope	NN	O
to	TO	O
which	WDT	O
an	DT	O
anti-tag	NN	O
antibody	NN	O
can	MD	O
selectively	RB	O
bind	VB	O
.	.	O
The	DT	O
epitope	NN	O
tag	NN	O
is	VBZ	O
generally	RB	O
placed	VBN	O
at	IN	O
the	DT	O
amino-	JJ	O
or	CC	O
carboxyl-terminus	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
The	DT	O
presence	NN	O
of	IN	O
such	JJ	O
epitope-tagged	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
can	MD	O
be	VB	O
detected	VBN	O
using	VBG	O
an	DT	O
antibody	NN	O
against	IN	O
the	DT	O
tag	JJ	O
polypeptide	NN	O
.	.	O
Also	RB	O
,	,	O
provision	NN	O
of	IN	O
the	DT	O
epitope	NN	O
tag	NN	O
enables	VBZ	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
to	TO	O
be	VB	O
readily	RB	O
purified	VBN	O
by	IN	O
affinity	NN	O
purification	NN	O
using	VBG	O
an	DT	O
anti-tag	JJ	O
antibody	NN	O
or	CC	O
another	DT	O
type	NN	O
of	IN	O
affinity	NN	O
matrix	NN	O
that	WDT	O
binds	VBZ	O
to	TO	O
the	DT	O
epitope	NN	O
tag	NN	O
.	.	O
Various	JJ	O
tag	NN	O
polypeptides	NNS	O
and	CC	O
their	PRP$	O
respective	JJ	O
antibodies	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Examples	NNS	O
include	VBP	O
poly-histidine	JJ	O
(	(	O
poly-his	JJ	O
)	)	O
or	CC	O
poly-histidine-glycine	JJ	O
(	(	O
poly-his-gly	RB	O
)	)	O
tags	NN	O
;	:	O
the	DT	O
flu	NN	O
HA	NNP	O
tag	NN	O
polypeptide	NN	O
and	CC	O
its	PRP$	O
antibody	NN	O
12CA5	CD	O
[	JJ	O
Field	NNP	B
et	NN	I
al.	NN	I
,	,	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
8:2159-2165	CD	I
(	(	I
1988	CD	I
)	)	I
]	NN	O
;	:	O
the	DT	O
c-myc	JJ	O
tag	NN	O
and	CC	O
the	DT	O
8F9	CD	O
,	,	O
3C7	CD	O
,	,	O
6E10	CD	O
,	,	O
G4	NNP	O
,	,	O
B7	NNP	O
and	CC	O
9E10	CD	O
antibodies	NNS	O
thereto	VBP	O
[	JJ	O
Evan	NNP	B
et	NN	I
al.	NN	I
,	,	I
Molecular	NNP	I
and	CC	I
Cellular	NNP	I
Biology	NNP	I
,	,	I
5:3610-3616	NNP	I
(	(	I
1985	CD	I
)	)	I
]	NN	O
;	:	O
and	CC	O
the	DT	O
Herpes	NNP	O
Simplex	NNP	O
virus	NN	O
glycoprotein	NN	O
D	NNP	O
(	(	O
gD	NN	O
)	)	O
tag	NN	O
and	CC	O
its	PRP$	O
antibody	NN	O
[	NNP	O
Paborsky	NNP	B
et	FW	I
al.	NN	I
,	,	I
Protein	NNP	I
Engineering	NNP	I
,	,	I
3	CD	I
(	(	I
6	CD	I
)	)	I
:547-553	NN	I
(	(	I
1990	CD	I
)	)	I
]	NN	O
.	.	O
Other	JJ	O
tag	NN	O
polypeptides	NNS	O
include	VBP	O
the	DT	O
Flag-peptide	NNP	O
[	NNP	O
Hopp	NNP	B
et	FW	I
al.	NN	I
,	,	I
BioTechnology	NNP	I
,	,	I
6:1204-1210	NNP	I
(	(	I
1988	CD	I
)	)	I
]	NN	O
;	:	O
the	DT	O
KT3	NNP	O
epitope	NN	O
peptide	NN	O
[	NNP	O
Martin	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
255:192-194	CD	I
(	(	I
1992	CD	I
)	)	I
]	NN	O
;	:	O
an	DT	O
α-tubulin	JJ	O
epitope	NN	O
peptide	IN	O
[	NNP	O
Skinner	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
266:15163-15166	CD	I
(	(	I
1991	CD	I
)	)	I
]	NN	O
;	:	O
and	CC	O
the	DT	O
T7	NNP	O
gene	NN	O
10	CD	O
protein	NN	O
peptide	NN	O
tag	NN	O
[	NNP	O
Lutz-Freyermuth	NNP	B
et	NN	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
87:6393-6397	CD	I
(	(	I
1990	CD	I
)	)	I
]	NN	O
.	.	O
The	DT	O
chimeric	JJ	O
molecule	NN	O
may	MD	O
comprise	VB	O
a	DT	O
fusion	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
with	IN	O
an	DT	O
immunoglobulin	NN	O
or	CC	O
a	DT	O
particular	JJ	O
region	NN	O
of	IN	O
an	DT	O
immunoglobulin	NN	O
.	.	O
For	IN	O
a	DT	O
bivalent	JJ	O
form	NN	O
of	IN	O
the	DT	O
chimeric	JJ	O
molecule	NN	O
(	(	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
an	DT	O
“	NN	O
immunoadhesin	NN	O
”	NNP	O
)	)	O
,	,	O
such	PDT	O
a	DT	O
fusion	NN	O
could	MD	O
be	VB	O
to	TO	O
the	DT	O
Fc	NNP	O
region	NN	O
of	IN	O
an	DT	O
IgG	NNP	O
molecule	NN	O
.	.	O
The	DT	O
Ig	NNP	O
fusions	NNS	O
preferably	RB	O
include	VBP	O
the	DT	O
substitution	NN	O
of	IN	O
a	DT	O
soluble	JJ	O
(	(	O
transmembrane	JJ	O
domain	NN	O
deleted	VBD	O
or	CC	O
inactivated	VBN	O
)	)	O
form	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
in	IN	O
place	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
variable	JJ	O
region	NN	O
within	IN	O
an	DT	O
Ig	NNP	O
molecule	NN	O
.	.	O
In	IN	O
a	DT	O
particularly	RB	O
preferred	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
immunoglobulin	JJ	O
fusion	NN	O
includes	VBZ	O
the	DT	O
hinge	NN	O
,	,	O
CH2	NNP	O
and	CC	O
CH3	NNP	O
,	,	O
or	CC	O
the	DT	O
hinge	NN	O
,	,	O
CH1	NNP	O
,	,	O
CH2	NNP	O
and	CC	O
CH3	NNP	O
regions	NNS	O
of	IN	O
an	DT	O
IgG1	NNP	O
molecule	NN	O
.	.	O
For	IN	O
the	DT	O
production	NN	O
of	IN	O
immunoglobulin	JJ	O
fusions	NNS	O
see	VBP	O
also	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,428,130	CD	O
issued	VBN	O
Jun	NNP	O
.	.	O
27	CD	O
,	,	O
1995	CD	O
.	.	O
D.	NNP	O
Preparation	NNP	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
Polypeptides	NNP	O
The	DT	O
description	NN	O
below	IN	O
relates	NNS	O
primarily	RB	O
to	TO	O
production	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
by	IN	O
culturing	VBG	O
cells	NNS	O
transformed	VBD	O
or	CC	O
transfected	VBN	O
with	IN	O
a	DT	O
vector	NN	O
containing	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
nucleic	JJ	O
acid	NN	O
.	.	O
It	PRP	O
is	VBZ	O
,	,	O
of	IN	O
course	NN	O
,	,	O
contemplated	VBD	O
that	IN	O
alternative	JJ	O
methods	NNS	O
,	,	O
which	WDT	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
may	MD	O
be	VB	O
employed	VBN	O
to	TO	O
prepare	VB	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
sequence	NN	O
,	,	O
or	CC	O
portions	NNS	O
thereof	NNS	O
,	,	O
may	MD	O
be	VB	O
produced	VBN	O
by	IN	O
direct	JJ	O
peptide	NN	O
synthesis	NN	O
using	VBG	O
solid-phase	JJ	O
techniques	NNS	O
[	MD	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Stewart	NNP	B
et	VBZ	I
al.	RB	I
,	,	I
Solid-Phase	NNP	I
Peptide	NNP	I
Synthesis	NNP	I
,	,	I
W.H	NNP	I
.	.	I
Freeman	NNP	I
Co.	NNP	I
,	,	I
San	NNP	I
Francisco	NNP	I
,	,	I
Calif.	NNP	I
(	(	I
1969	CD	I
)	)	I
;	:	O
Merrifield	NNP	B
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
85:2149-2154	CD	I
(	(	I
1963	CD	I
)	)	I
]	NN	O
.	.	O
In	IN	O
vitro	JJ	O
protein	JJ	O
synthesis	NN	O
may	MD	O
be	VB	O
performed	VBN	O
using	VBG	O
manual	JJ	O
techniques	NNS	O
or	CC	O
by	IN	O
automation	NN	O
.	.	O
Automated	VBN	O
synthesis	NN	O
may	MD	O
be	VB	O
accomplished	VBN	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
using	VBG	O
an	DT	O
Applied	NNP	O
Biosystems	NNP	O
Peptide	NNP	O
Synthesizer	NNP	O
(	(	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
using	VBG	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O
Various	JJ	O
portions	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
chemically	RB	O
synthesized	VBN	O
separately	RB	O
and	CC	O
combined	VBN	O
using	VBG	O
chemical	NN	O
or	CC	O
enzymatic	JJ	O
methods	NNS	O
to	TO	O
produce	VB	O
the	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
1	CD	O
.	.	O
Isolation	NN	O
of	IN	O
DNA	NNP	O
Encoding	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
Polypeptides	NNP	O
DNA	NNP	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
may	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
a	DT	O
cDNA	NN	O
library	NN	O
prepared	VBD	O
from	IN	O
tissue	NN	O
believed	VBN	O
to	TO	O
possess	VB	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
mRNA	NN	O
and	CC	O
to	TO	O
express	VB	O
it	PRP	O
at	IN	O
a	DT	O
detectable	JJ	O
level	NN	O
.	.	O
Accordingly	RB	O
,	,	O
human	JJ	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-DNA	NNP	O
can	MD	O
be	VB	O
conveniently	RB	O
obtained	VBN	O
from	IN	O
a	DT	O
cDNA	NN	O
library	NN	O
prepared	VBD	O
from	IN	O
human	JJ	O
tissue	NN	O
,	,	O
such	JJ	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
.	.	O
The	DT	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-encoding	NNP	O
gene	NN	O
may	MD	O
also	RB	O
be	VB	O
obtained	VBN	O
from	IN	O
a	DT	O
genomic	JJ	O
library	NN	O
or	CC	O
by	IN	O
known	VBN	O
synthetic	JJ	O
procedures	NNS	O
(	(	O
e.g.	NN	O
,	,	O
automated	VBD	O
nucleic	JJ	O
acid	JJ	O
synthesis	NN	O
)	)	O
.	.	O
Libraries	NNS	O
can	MD	O
be	VB	O
screened	VBN	O
with	IN	O
probes	NNS	O
(	(	O
such	JJ	O
as	IN	O
antibodies	NNS	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
oligonucleotides	NNS	O
of	IN	O
at	IN	O
least	JJS	O
about	IN	O
20-80	JJ	O
bases	NNS	O
)	)	O
designed	VBN	O
to	TO	O
identify	VB	O
the	DT	O
gene	NN	O
of	IN	O
interest	NN	O
or	CC	O
the	DT	O
protein	NN	O
encoded	VBN	O
by	IN	O
it	PRP	O
.	.	O
Screening	VBG	O
the	DT	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
library	NN	O
with	IN	O
the	DT	O
selected	VBN	O
probe	NN	O
may	MD	O
be	VB	O
conducted	VBN	O
using	VBG	O
standard	JJ	O
procedures	NNS	O
,	,	O
such	JJ	O
as	IN	O
described	NNS	O
in	IN	O
Sambrook	NNP	B
et	CC	I
al.	NN	I
,	,	I
Molecular	JJ	I
Cloning	NN	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
(	(	I
New	NNP	I
York	NNP	I
:	:	I
Cold	JJ	I
Spring	NN	I
Harbor	NNP	I
Laboratory	NNP	I
Press	NNP	I
,	,	I
1989	CD	I
)	)	O
.	.	O
An	DT	O
alternative	JJ	O
means	NNS	O
to	TO	O
isolate	VB	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
is	VBZ	O
to	TO	O
use	VB	O
PCR	NNP	O
methodology	NN	O
[	NNP	O
Sambrook	NNP	B
et	FW	I
al.	NN	I
,	,	I
supra	NN	I
;	:	O
Dieffenbach	NNP	B
et	FW	I
al.	NN	I
,	,	I
PCR	NNP	I
Primer	NNP	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
(	(	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Laboratory	NNP	I
Press	NNP	I
,	,	I
1995	CD	I
)	)	I
]	NN	I
.	.	O
The	DT	O
Examples	NNP	O
below	IN	O
describe	NN	O
techniques	NNS	O
for	IN	O
screening	VBG	O
a	DT	O
cDNA	NN	O
library	NN	O
.	.	O
The	DT	O
oligonucleotide	JJ	O
sequences	NNS	O
selected	VBN	O
as	IN	O
probes	NNS	O
should	MD	O
be	VB	O
of	IN	O
sufficient	JJ	O
length	NN	O
and	CC	O
sufficiently	RB	O
unambiguous	JJ	O
that	IN	O
false	JJ	O
positives	NNS	O
are	VBP	O
minimized	VBN	O
.	.	O
The	DT	O
oligonucleotide	NN	O
is	VBZ	O
preferably	RB	O
labeled	VBN	O
such	JJ	O
that	IN	O
it	PRP	O
can	MD	O
be	VB	O
detected	VBN	O
upon	IN	O
hybridization	NN	O
to	TO	O
DNA	NNP	O
in	IN	O
the	DT	O
library	JJ	O
being	VBG	O
screened	VBN	O
.	.	O
Methods	NNS	O
of	IN	O
labeling	VBG	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
and	CC	O
include	VBP	O
the	DT	O
use	NN	O
of	IN	O
radiolabels	NNS	O
like	IN	O
32P-labeled	JJ	O
ATP	NNP	O
,	,	O
biotinylation	NN	O
or	CC	O
enzyme	NN	O
labeling	NN	O
.	.	O
Hybridization	NN	O
conditions	NNS	O
,	,	O
including	VBG	O
moderate	JJ	O
stringency	NN	O
and	CC	O
high	JJ	O
stringency	NN	O
,	,	O
are	VBP	O
provided	VBN	O
in	IN	O
Sambrook	NNP	B
et	CC	I
al.	NN	I
,	,	I
supra	NN	I
.	.	O
Sequences	NNS	O
identified	VBN	O
in	IN	O
such	JJ	O
library	JJ	O
screening	VBG	O
methods	NNS	O
can	MD	O
be	VB	O
compared	VBN	O
and	CC	O
aligned	VBN	O
to	TO	O
other	JJ	O
known	JJ	O
sequences	NNS	O
deposited	VBD	O
and	CC	O
available	JJ	O
in	IN	O
public	JJ	O
databases	NNS	O
such	JJ	O
as	IN	O
GenBank	NNP	O
or	CC	O
other	JJ	O
private	JJ	O
sequence	NN	O
databases	NNS	O
.	.	O
Sequence	NN	O
identity	NN	O
(	(	O
at	IN	O
either	CC	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleotide	JJ	O
level	NN	O
)	)	O
within	IN	O
defined	VBN	O
regions	NNS	O
of	IN	O
the	DT	O
molecule	NN	O
or	CC	O
across	IN	O
the	DT	O
full-length	JJ	O
sequence	NN	O
can	MD	O
be	VB	O
determined	VBN	O
using	VBG	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
Nucleic	NNP	O
acid	NN	O
having	VBG	O
protein	NN	O
coding	VBG	O
sequence	NN	O
may	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
screening	VBG	O
selected	VBN	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
libraries	NNS	O
using	VBG	O
the	DT	O
deduced	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
disclosed	VBD	O
herein	NN	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
,	,	O
and	CC	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
using	VBG	O
conventional	JJ	O
primer	JJ	O
extension	NN	O
procedures	NNS	O
as	IN	O
described	VBN	O
in	IN	O
Sambrook	NNP	B
et	CC	I
al.	NN	I
,	,	I
supra	NN	I
,	,	O
to	TO	O
detect	VB	O
precursors	NNS	O
and	CC	O
processing	VBG	O
intermediates	NNS	O
of	IN	O
mRNA	NN	O
that	WDT	O
may	MD	O
not	RB	O
have	VB	O
been	VBN	O
reverse-transcribed	JJ	O
into	IN	O
cDNA	NN	O
.	.	O
2	CD	O
.	.	O
Selection	NN	O
and	CC	O
Transformation	NNP	O
of	IN	O
Host	NNP	O
Cells	NNP	O
Host	NNP	O
cells	NNS	O
are	VBP	O
transfected	VBN	O
or	CC	O
transformed	VBN	O
with	IN	O
expression	NN	O
or	CC	O
cloning	VBG	O
vectors	NNS	O
described	VBD	O
herein	NN	O
for	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
production	NN	O
and	CC	O
cultured	VBN	O
in	IN	O
conventional	JJ	O
nutrient	JJ	O
media	NNS	O
modified	VBD	O
as	IN	O
appropriate	NN	O
for	IN	O
inducing	VBG	O
promoters	NNS	O
,	,	O
selecting	VBG	O
transformants	NNS	O
,	,	O
or	CC	O
amplifying	VBG	O
the	DT	O
genes	NNS	O
encoding	VBG	O
the	DT	O
desired	JJ	O
sequences	NNS	O
.	.	O
The	DT	O
culture	NN	O
conditions	NNS	O
,	,	O
such	JJ	O
as	IN	O
media	NNS	O
,	,	O
temperature	NN	O
,	,	O
pH	NN	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
can	MD	O
be	VB	O
selected	VBN	O
by	IN	O
the	DT	O
skilled	JJ	O
artisan	NN	O
without	IN	O
undue	JJ	O
experimentation	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
principles	NNS	O
,	,	O
protocols	NNS	O
,	,	O
and	CC	O
practical	JJ	O
techniques	NNS	O
for	IN	O
maximizing	VBG	O
the	DT	O
productivity	NN	O
of	IN	O
cell	NN	O
cultures	NNS	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
Mammalian	NNP	B
Cell	NNP	I
Biotechnology	NNP	I
:	:	I
a	DT	I
Practical	NNP	I
Approach	NNP	I
,	,	I
M.	NNP	I
Butler	NNP	I
,	,	I
ed	NN	I
.	.	I
(	(	I
IRL	NNP	I
Press	NNP	I
,	,	I
1991	CD	I
)	)	I
and	CC	O
Sambrook	NNP	B
et	VBP	I
al.	NN	I
,	,	I
supra	NN	I
.	.	O
Methods	NNS	O
of	IN	O
eukaryotic	JJ	O
cell	NN	O
transfection	NN	O
and	CC	O
prokaryotic	JJ	O
cell	NN	O
transformation	NN	O
are	VBP	O
known	VBN	O
to	TO	O
the	DT	O
ordinarily	RB	O
skilled	VBN	O
artisan	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
CaCl2	NNP	O
,	,	O
CaPO4	NNP	O
,	,	O
liposome-mediated	JJ	O
and	CC	O
electroporation	NN	O
.	.	O
Depending	VBG	O
on	IN	O
the	DT	O
host	NN	O
cell	NN	O
used	VBN	O
,	,	O
transformation	NN	O
is	VBZ	O
performed	VBN	O
using	VBG	O
standard	JJ	O
techniques	NNS	O
appropriate	VBP	O
to	TO	O
such	JJ	O
cells	NNS	O
.	.	O
The	DT	O
calcium	NN	O
treatment	NN	O
employing	VBG	O
calcium	NN	O
chloride	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Sambrook	NNP	B
et	CC	I
al.	NN	I
,	,	I
supra	NN	I
,	,	O
or	CC	O
electroporation	NN	O
is	VBZ	O
generally	RB	O
used	VBN	O
for	IN	O
prokaryotes	NNS	O
.	.	O
Infection	NN	O
with	IN	O
Agrobacterium	NNP	O
tumefaciens	NNS	O
is	VBZ	O
used	VBN	O
for	IN	O
transformation	NN	O
of	IN	O
certain	JJ	O
plant	NN	O
cells	NNS	O
,	,	O
as	IN	O
described	VBN	O
by	IN	O
Shaw	NNP	B
et	FW	I
al.	NN	I
,	,	I
Gene	NNP	I
,	,	I
23:315	CD	I
(	(	I
1983	CD	I
)	)	I
and	CC	O
WO	$	O
89/05859	CD	O
published	VBN	O
29	CD	O
Jun	NNP	O
.	.	O
1989	CD	O
.	.	O
For	IN	O
mammalian	JJ	O
cells	NNS	O
without	IN	O
such	JJ	O
cell	NN	O
walls	NNS	O
,	,	O
the	DT	O
calcium	NN	O
phosphate	NN	O
precipitation	NN	O
method	NN	O
of	IN	O
Graham	NNP	B
and	CC	I
van	JJ	I
der	NN	I
Eb	NNP	I
,	,	I
Virology	NNP	I
,	,	I
52:456-457	NNP	I
(	(	I
1978	CD	I
)	)	I
can	MD	O
be	VB	O
employed	VBN	O
.	.	O
General	NNP	O
aspects	NNS	O
of	IN	O
mammalian	JJ	O
cell	NN	O
host	NN	O
system	NN	O
transfections	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,399,216	CD	O
.	.	O
Transformations	NNS	O
into	IN	O
yeast	NN	O
are	VBP	O
typically	RB	O
carried	VBN	O
out	RP	O
according	VBG	O
to	TO	O
the	DT	O
method	NN	O
of	IN	O
Van	NNP	B
Solingen	NNP	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Bact.	NNP	I
,	,	I
130:946	CD	I
(	(	I
1977	CD	I
)	)	I
and	CC	O
Hsiao	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
(	(	I
USA	NNP	I
)	)	I
,	,	I
76:3829	CD	I
(	(	I
1979	CD	I
)	)	I
.	.	O
However	RB	O
,	,	O
other	JJ	O
methods	NNS	O
for	IN	O
introducing	VBG	O
DNA	NNP	O
into	IN	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
nuclear	JJ	O
microinjection	NN	O
,	,	O
electroporation	NN	O
,	,	O
bacterial	JJ	O
protoplast	NN	O
fusion	NN	O
with	IN	O
intact	JJ	O
cells	NNS	O
,	,	O
or	CC	O
polycations	NNS	O
,	,	O
e.g.	NN	O
,	,	O
polybrene	NN	O
,	,	O
polyornithine	NN	O
,	,	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
.	.	O
For	IN	O
various	JJ	O
techniques	NNS	O
for	IN	O
transforming	VBG	O
mammalian	JJ	O
cells	NNS	O
,	,	O
see	VBP	O
Keown	NNP	B
et	FW	I
al.	NN	I
,	,	I
Methods	NNP	I
in	IN	I
Enzymology	NNP	I
,	,	I
185:527-537	CD	I
(	(	I
1990	CD	I
)	)	I
and	CC	O
Mansour	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
336:348-352	CD	I
(	(	I
1988	CD	I
)	)	I
.	.	O
Suitable	JJ	O
host	NN	O
cells	NNS	O
for	IN	O
cloning	VBG	O
or	CC	O
expressing	VBG	O
the	DT	O
DNA	NN	O
in	IN	O
the	DT	O
vectors	NNS	O
herein	VBP	O
include	VBP	O
prokaryote	NN	O
,	,	O
yeast	NN	O
,	,	O
or	CC	O
higher	JJR	O
eukaryote	NN	O
cells	NNS	O
.	.	O
Suitable	JJ	O
prokaryotes	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
eubacteria	VB	O
,	,	O
such	JJ	O
as	IN	O
Gram-negative	JJ	O
or	CC	O
Gram-positive	JJ	O
organisms	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Enterobacteriaceae	NNP	O
such	JJ	O
as	IN	O
E.	NNP	O
coli	NNS	O
.	.	O
Various	NNP	O
E.	NNP	O
coli	NNS	O
strains	NNS	O
are	VBP	O
publicly	RB	O
available	JJ	O
,	,	O
such	JJ	O
as	IN	O
E.	NNP	O
coli	VBP	O
K12	NNP	O
strain	NN	O
MM294	NNP	O
(	(	O
ATCC	NNP	O
31,446	CD	O
)	)	O
;	:	O
E.	NNP	O
coli	NNS	O
X1776	NNP	O
(	(	O
ATCC	NNP	O
31,537	CD	O
)	)	O
;	:	O
E.	NNP	O
coli	NNS	O
strain	VBP	O
W3110	NNP	O
(	(	O
ATCC	NNP	O
27,325	CD	O
)	)	O
and	CC	O
K5	$	O
772	CD	O
(	(	O
ATCC	NNP	O
53,635	CD	O
)	)	O
.	.	O
Other	JJ	O
suitable	JJ	O
prokaryotic	JJ	O
host	NN	O
cells	NNS	O
include	VBP	O
Enterobacteriaceae	NNP	O
such	JJ	O
as	IN	O
Escherichia	NNP	O
,	,	O
e.g.	NN	O
,	,	O
E.	NNP	O
coli	NNS	O
,	,	O
Enterobacter	NNP	O
,	,	O
Erwinia	NNP	O
,	,	O
Klebsiella	NNP	O
,	,	O
Proteus	NNP	O
,	,	O
Salmonella	NNP	O
,	,	O
e.g.	NN	O
,	,	O
Salmonella	NNP	O
typhimurium	NN	O
,	,	O
Serratia	NNP	O
,	,	O
e.g.	NN	O
,	,	O
Serratia	NNP	O
marcescans	NNS	O
,	,	O
and	CC	O
Shigella	NNP	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
Bacilli	NNP	O
such	JJ	O
as	IN	O
B.	NNP	O
subtilis	NNS	O
and	CC	O
B.	NNP	O
licheniformis	NNP	O
(	(	O
e.g.	NN	O
,	,	O
B.	NNP	O
licheniformis	VBZ	O
41P	CD	O
disclosed	VBN	O
in	IN	O
DD	NNP	O
266,710	CD	O
published	VBD	O
12	CD	O
Apr	NNP	O
.	.	O
1989	CD	O
)	)	O
,	,	O
Pseudomonas	NNP	O
such	JJ	O
as	IN	O
P.	NNP	O
aeruginosa	NN	O
,	,	O
and	CC	O
Streptomyces	NNS	O
.	.	O
These	DT	O
examples	NNS	O
are	VBP	O
illustrative	JJ	O
rather	RB	O
than	IN	O
limiting	VBG	O
.	.	O
Strain	NNP	O
W3110	NNP	O
is	VBZ	O
one	CD	O
particularly	RB	O
preferred	JJ	O
host	NN	O
or	CC	O
parent	NN	O
host	NN	O
because	IN	O
it	PRP	O
is	VBZ	O
a	DT	O
common	JJ	O
host	NN	O
strain	NN	O
for	IN	O
recombinant	JJ	O
DNA	NNP	O
product	NN	O
fermentations	NNS	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
host	NN	O
cell	NN	O
secretes	VBZ	O
minimal	JJ	O
amounts	NNS	O
of	IN	O
proteolytic	JJ	O
enzymes	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
strain	VBP	O
W3110	NNP	O
may	MD	O
be	VB	O
modified	VBN	O
to	TO	O
effect	NN	O
a	DT	O
genetic	JJ	O
mutation	NN	O
in	IN	O
the	DT	O
genes	NNS	O
encoding	VBG	O
proteins	NNS	O
endogenous	JJ	O
to	TO	O
the	DT	O
host	NN	O
,	,	O
with	IN	O
examples	NNS	O
of	IN	O
such	JJ	O
hosts	NNS	O
including	VBG	O
E.	NNP	O
coli	NNS	O
W3110	NNP	O
strain	NN	O
1A2	CD	O
,	,	O
which	WDT	O
has	VBZ	O
the	DT	O
complete	JJ	O
genotype	NN	O
tonA	NN	O
;	:	O
E.	NNP	O
coli	NNS	O
W3110	NNP	O
strain	NN	O
9E4	CD	O
,	,	O
which	WDT	O
has	VBZ	O
the	DT	O
complete	JJ	O
genotype	NN	O
tonA	NN	O
ptr3	NN	O
;	:	O
E.	NNP	O
coli	NNS	O
W3110	NNP	O
strain	VBP	O
27C7	CD	O
(	(	O
ATCC	NNP	O
55,244	CD	O
)	)	O
,	,	O
which	WDT	O
has	VBZ	O
the	DT	O
complete	JJ	O
genotype	NN	O
tonA	NN	O
ptr3	NN	O
phoA	NN	O
E15	NNP	O
(	(	O
argF-lac	NN	O
)	)	O
169	CD	O
degP	JJ	O
ompT	JJ	O
kanr	NN	O
;	:	O
E.	NNP	O
coli	NNS	O
W3110	NNP	O
strain	NN	O
37D6	CD	O
,	,	O
which	WDT	O
has	VBZ	O
the	DT	O
complete	JJ	O
genotype	NN	O
tonA	NN	O
ptr3	NN	O
phoA	NN	O
E15	NNP	O
(	(	O
argF-lac	NN	O
)	)	O
169	CD	O
degP	JJ	O
ompT	NN	O
rbs7	NN	O
ilvG	NN	O
kanr	NN	O
;	:	O
E.	NNP	O
coli	NNS	O
W3110	NNP	O
strain	NN	O
40B4	CD	O
,	,	O
which	WDT	O
is	VBZ	O
strain	JJ	O
37D6	CD	O
with	IN	O
a	DT	O
non-kanamycin	JJ	O
resistant	NN	O
degP	NN	O
deletion	NN	O
mutation	NN	O
;	:	O
and	CC	O
an	DT	O
E.	NNP	O
coli	NNS	O
strain	VBP	O
having	VBG	O
mutant	JJ	O
periplasmic	JJ	O
protease	NN	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,946,783	CD	O
issued	VBD	O
7	CD	O
Aug.	NNP	O
1990	CD	O
.	.	O
Alternatively	RB	O
,	,	O
in	IN	O
vitro	JJ	O
methods	NNS	O
of	IN	O
cloning	NN	O
,	,	O
e.g.	NN	O
,	,	O
PCR	NNP	O
or	CC	O
other	JJ	O
nucleic	JJ	O
acid	JJ	O
polymerase	NN	O
reactions	NNS	O
,	,	O
are	VBP	O
suitable	JJ	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
prokaryotes	NNS	O
,	,	O
eukaryotic	JJ	O
microbes	NNS	O
such	JJ	O
as	IN	O
filamentous	JJ	O
fungi	NNS	O
or	CC	O
yeast	NN	O
are	VBP	O
suitable	JJ	O
cloning	NN	O
or	CC	O
expression	NN	O
hosts	NNS	O
for	IN	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-encoding	JJ	O
vectors	NNS	O
.	.	O
Saccharomyces	NNS	O
cerevisiae	NN	O
is	VBZ	O
a	DT	O
commonly	RB	O
used	VBN	O
lower	JJR	O
eukaryotic	JJ	O
host	NN	O
microorganism	NN	O
.	.	O
Others	NNS	O
include	VBP	O
Schizosaccharomyces	NNS	O
pombe	VBP	O
(	(	O
Beach	NNP	B
and	CC	I
Nurse	NNP	I
,	,	I
Nature	NNP	I
,	,	I
290	CD	I
:	:	I
140	CD	I
[	NN	I
1981	CD	I
]	NN	I
;	:	I
EP	NNP	I
139,383	CD	I
published	VBD	I
2	CD	I
May	NNP	I
1985	CD	I
)	)	O
;	:	O
Kluyveromyces	NNS	O
hosts	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,943,529	CD	O
;	:	O
Fleer	NNP	B
et	FW	I
al.	NN	I
,	,	I
Bio/Technology	NNP	I
,	,	I
9:968-975	CD	I
(	(	I
1991	CD	I
)	)	I
)	)	O
such	JJ	O
as	IN	O
,	,	O
e.g.	NN	O
,	,	O
K.	NNP	O
lactis	NN	O
(	(	O
MW98-8C	NNP	O
,	,	O
CBS683	NNP	O
,	,	O
CBS4574	NNP	O
;	:	O
Louvencourt	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Bacteriol.	NNP	I
,	,	I
154	CD	I
(	(	I
2	CD	I
)	)	I
:737-742	CD	I
[	JJ	I
1983	CD	I
]	NN	I
)	)	O
,	,	O
K.	NNP	O
fragilis	NN	O
(	(	O
ATCC	NNP	O
12,424	CD	O
)	)	O
,	,	O
K.	NNP	O
bulgaricus	NN	O
(	(	O
ATCC	NNP	O
16,045	CD	O
)	)	O
,	,	O
K.	NNP	O
wickeramii	NN	O
(	(	O
ATCC	NNP	O
24,178	CD	O
)	)	O
,	,	O
K.	NNP	O
waltii	NN	O
(	(	O
ATCC	NNP	O
56,500	CD	O
)	)	O
,	,	O
K.	NNP	O
drosophilarum	NN	O
(	(	O
ATCC	NNP	O
36,906	CD	O
;	:	O
Van	NNP	B
den	VBZ	I
Berg	NNP	I
et	NN	I
al.	NN	I
,	,	I
Bio/Technology	NNP	I
,	,	I
8:135	CD	I
(	(	I
1990	CD	I
)	)	I
)	)	O
,	,	O
K.	NNP	O
thermotolerans	NNPS	O
,	,	O
and	CC	O
K.	NNP	O
marxianus	NN	O
;	:	O
yarrowia	CC	O
(	(	O
EP	NNP	O
402,226	CD	O
)	)	O
;	:	O
Pichia	NNP	O
pastoris	NN	O
(	(	O
EP	NNP	O
183,070	CD	O
;	:	O
Sreekrishna	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Basic	NNP	I
Microbiol.	NNP	I
,	,	I
28:265-278	JJ	I
[	NN	I
1988	CD	I
]	NN	I
)	)	O
;	:	O
Candida	NNP	O
;	:	O
Trichoderma	NNP	O
reesia	NN	O
(	(	O
EP	NNP	O
244,234	CD	O
)	)	O
;	:	O
Neurospora	NNP	O
crassa	NN	O
(	(	O
Case	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
76:5259-5263	JJ	I
[	NN	I
1979	CD	I
]	NN	I
)	)	O
;	:	O
Schwanniomyces	NNS	O
such	JJ	O
as	IN	O
Schwanniomyces	NNS	O
occidentalis	VBP	O
(	(	O
EP	NNP	O
394,538	CD	O
published	VBD	O
31	CD	O
Oct.	NNP	O
1990	CD	O
)	)	O
;	:	O
and	CC	O
filamentous	JJ	O
fungi	NNS	O
such	JJ	O
as	IN	O
,	,	O
e.g.	NN	O
,	,	O
Neurospora	NNP	O
,	,	O
Penicillium	NNP	O
,	,	O
Tolypocladium	NNP	O
(	(	O
WO	NNP	O
91/00357	CD	O
published	VBD	O
10	CD	O
Jan.	NNP	O
1991	CD	O
)	)	O
,	,	O
and	CC	O
Aspergillus	NNP	O
hosts	NNS	O
such	JJ	O
as	IN	O
A.	NN	O
nidulans	NNS	O
(	(	O
Ballance	NNP	B
et	RB	I
al.	RB	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun.	NNP	I
,	,	I
112:284-289	JJ	I
[	NN	I
1983	CD	I
]	NN	I
;	:	O
Tilburn	NNP	B
et	FW	I
al.	NN	I
,	,	I
Gene	NNP	I
,	,	I
26:205-221	JJ	I
[	NN	I
1983	CD	I
]	NN	I
;	:	O
Yelton	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
81	CD	I
:	:	I
1470-1474	JJ	I
[	NN	I
1984	CD	I
]	NN	I
)	)	O
and	CC	O
A.	NNP	B
niger	NNP	I
(	(	I
Kelly	NNP	I
and	CC	I
Hynes	NNP	I
,	,	I
EMBO	NNP	I
J.	NNP	I
,	,	I
4:475-479	JJ	I
[	NN	I
1985	CD	I
]	NN	I
)	)	O
.	.	O
Methylotropic	NNP	O
yeasts	NNS	O
are	VBP	O
suitable	JJ	O
herein	NN	O
and	CC	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
yeast	RB	O
capable	JJ	O
of	IN	O
growth	NN	O
on	IN	O
methanol	NN	O
selected	VBN	O
from	IN	O
the	DT	O
genera	NN	O
consisting	NN	O
of	IN	O
Hansenula	NNP	O
,	,	O
Candida	NNP	O
,	,	O
Kloeckera	NNP	O
,	,	O
Pichia	NNP	O
,	,	O
Saccharomyces	NNP	O
,	,	O
Torulopsis	NNP	O
,	,	O
and	CC	O
Rhodotorula	NNP	O
.	.	O
A	DT	O
list	NN	O
of	IN	O
specific	JJ	O
species	NNS	O
that	WDT	O
are	VBP	O
exemplary	JJ	O
of	IN	O
this	DT	O
class	NN	O
of	IN	O
yeasts	NNS	O
may	MD	O
be	VB	O
found	VBN	O
in	IN	O
C.	NNP	B
Anthony	NNP	I
,	,	I
The	DT	I
Biochemistry	NNP	I
of	IN	I
Methylotrophs	NNP	I
,	,	I
269	CD	I
(	(	I
1982	CD	I
)	)	I
.	.	O
Suitable	JJ	O
host	NN	O
cells	NNS	O
for	IN	O
the	DT	O
expression	NN	O
of	IN	O
glycosylated	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
are	VBP	O
derived	VBN	O
from	IN	O
multicellular	JJ	O
organisms	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
invertebrate	JJ	O
cells	NNS	O
include	VBP	O
insect	JJ	O
cells	NNS	O
such	JJ	O
as	IN	O
Drosophila	NNP	O
S2	NNP	O
and	CC	O
Spodoptera	NNP	O
Sf9	NNP	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
plant	NN	O
cells	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
useful	JJ	O
mammalian	JJ	O
host	NN	O
cell	NN	O
lines	NNS	O
include	VBP	O
Chinese	JJ	O
hamster	NN	O
ovary	JJ	O
(	(	O
CHO	NNP	O
)	)	O
and	CC	O
COS	NNP	O
cells	NNS	O
.	.	O
More	RBR	O
specific	JJ	O
examples	NNS	O
include	VBP	O
monkey	JJ	O
kidney	NNP	O
CV1	NNP	O
line	NN	O
transformed	VBN	O
by	IN	O
SV40	NNP	O
(	(	O
COS-7	NNP	O
,	,	O
ATCC	NNP	O
CRL	NNP	O
1651	CD	O
)	)	O
;	:	O
human	JJ	O
embryonic	JJ	O
kidney	NN	O
line	NN	O
(	(	O
293	CD	O
or	CC	O
293	CD	O
cells	NNS	O
subcloned	VBN	O
for	IN	O
growth	NN	O
in	IN	O
suspension	NN	O
culture	NN	O
,	,	O
Graham	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Gen	NNP	I
Virol.	NNP	I
,	,	I
36:59	CD	I
(	(	I
1977	CD	I
)	)	I
)	)	O
;	:	O
Chinese	JJ	O
hamster	NN	O
ovary	JJ	O
cells/−DHFR	NN	O
(	(	O
CHO	NNP	B
,	,	I
Urlaub	NNP	I
and	CC	I
Chasin	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
77:4216	CD	I
(	(	I
1980	CD	I
)	)	I
)	)	O
;	:	O
mouse	CC	O
sertoli	JJ	O
cells	NNS	O
(	(	O
TM4	NNP	B
,	,	I
Mather	NNP	I
,	,	I
Biol	NNP	I
.	.	I
Reprod.	NNP	I
,	,	I
23:243-251	CD	I
(	(	I
1980	CD	I
)	)	I
)	)	O
;	:	O
human	JJ	O
lung	NN	O
cells	NNS	O
(	(	O
W138	NNP	O
,	,	O
ATCC	NNP	O
CCL	NNP	O
75	CD	O
)	)	O
;	:	O
human	JJ	O
liver	NN	O
cells	NNS	O
(	(	O
Hep	NNP	O
G2	NNP	O
,	,	O
HB	NNP	O
8065	CD	O
)	)	O
;	:	O
and	CC	O
mouse	VB	O
mammary	JJ	O
tumor	NN	O
(	(	O
MMT	NNP	O
060562	CD	O
,	,	O
ATCC	NNP	O
CCL51	NNP	O
)	)	O
.	.	O
The	DT	O
selection	NN	O
of	IN	O
the	DT	O
appropriate	JJ	O
host	NN	O
cell	NN	O
is	VBZ	O
deemed	VBN	O
to	TO	O
be	VB	O
within	IN	O
the	DT	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
3	CD	O
.	.	O
Selection	NN	O
and	CC	O
Use	NNP	O
of	IN	O
a	DT	O
Replicable	JJ	O
Vector	NNP	O
The	DT	O
nucleic	JJ	O
acid	NN	O
(	(	O
e.g.	JJ	O
,	,	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
DNA	NN	O
)	)	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
may	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
a	DT	O
replicable	JJ	O
vector	NN	O
for	IN	O
cloning	VBG	O
(	(	O
amplification	NN	O
of	IN	O
the	DT	O
DNA	NN	O
)	)	O
or	CC	O
for	IN	O
expression	NN	O
.	.	O
Various	JJ	O
vectors	NNS	O
are	VBP	O
publicly	RB	O
available	JJ	O
.	.	O
The	DT	O
vector	NN	O
may	MD	O
,	,	O
for	IN	O
example	NN	O
,	,	O
be	VB	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
plasmid	NN	O
,	,	O
cosmid	NN	O
,	,	O
viral	JJ	O
particle	NN	O
,	,	O
or	CC	O
phage	NN	O
.	.	O
The	DT	O
appropriate	JJ	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
may	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
the	DT	O
vector	NN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
procedures	NNS	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
DNA	NNP	O
is	VBZ	O
inserted	VBN	O
into	IN	O
an	DT	O
appropriate	JJ	O
restriction	NN	O
endonuclease	NN	O
site	NN	O
(	(	O
s	PRP	O
)	)	O
using	VBG	O
techniques	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Vector	NN	O
components	NNS	O
generally	RB	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
a	DT	O
signal	JJ	O
sequence	NN	O
,	,	O
an	DT	O
origin	NN	O
of	IN	O
replication	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
marker	NN	O
genes	NNS	O
,	,	O
an	DT	O
enhancer	NN	O
element	NN	O
,	,	O
a	DT	O
promoter	NN	O
,	,	O
and	CC	O
a	DT	O
transcription	NN	O
termination	NN	O
sequence	NN	O
.	.	O
Construction	NN	O
of	IN	O
suitable	JJ	O
vectors	NNS	O
containing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
these	DT	O
components	NNS	O
employs	VBZ	O
standard	JJ	O
ligation	NN	O
techniques	NNS	O
which	WDT	O
are	VBP	O
known	VBN	O
to	TO	O
the	DT	O
skilled	VBN	O
artisan	NN	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
produced	VBN	O
recombinantly	RB	O
not	RB	O
only	RB	O
directly	RB	O
,	,	O
but	CC	O
also	RB	O
as	IN	O
a	DT	O
fusion	NN	O
polypeptide	NN	O
with	IN	O
a	DT	O
heterologous	JJ	O
polypeptide	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
a	DT	O
signal	JJ	O
sequence	NN	O
or	CC	O
other	JJ	O
polypeptide	NN	O
having	VBG	O
a	DT	O
specific	JJ	O
cleavage	NN	O
site	NN	O
at	IN	O
the	DT	O
N-terminus	NNP	O
of	IN	O
the	DT	O
mature	NN	O
protein	NN	O
or	CC	O
polypeptide	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
signal	JJ	O
sequence	NN	O
may	MD	O
be	VB	O
a	DT	O
component	NN	O
of	IN	O
the	DT	O
vector	NN	O
,	,	O
or	CC	O
it	PRP	O
may	MD	O
be	VB	O
a	DT	O
part	NN	O
of	IN	O
the	DT	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-encoding	NNP	O
DNA	NNP	O
that	WDT	O
is	VBZ	O
inserted	VBN	O
into	IN	O
the	DT	O
vector	NN	O
.	.	O
The	DT	O
signal	JJ	O
sequence	NN	O
may	MD	O
be	VB	O
a	DT	O
prokaryotic	JJ	O
signal	NN	O
sequence	NN	O
selected	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
from	IN	O
the	DT	O
group	NN	O
of	IN	O
the	DT	O
alkaline	JJ	O
phosphatase	NN	O
,	,	O
penicillinase	NN	O
,	,	O
1	CD	O
pp	NN	O
,	,	O
or	CC	O
heat-stable	JJ	O
enterotoxin	NN	O
II	NNP	O
leaders	NNS	O
.	.	O
For	IN	O
yeast	JJ	O
secretion	NN	O
the	DT	O
signal	JJ	O
sequence	NN	O
may	MD	O
be	VB	O
,	,	O
e.g.	VB	O
,	,	O
the	DT	O
yeast	NN	O
invertase	NN	O
leader	NN	O
,	,	O
alpha	JJ	O
factor	NN	O
leader	NN	O
(	(	O
including	VBG	O
Saccharomyces	NNS	O
and	CC	O
Kluyveromyces	NNP	O
α-factor	NN	O
leaders	NNS	O
,	,	O
the	DT	O
latter	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,010,182	CD	O
)	)	O
,	,	O
or	CC	O
acid	JJ	O
phosphatase	NN	O
leader	NN	O
,	,	O
the	DT	O
C.	NNP	O
albicans	NNS	O
glucoamylase	JJ	O
leader	NN	O
(	(	O
EP	NNP	O
362,179	CD	O
published	VBD	O
4	CD	O
Apr	NNP	O
.	.	O
1990	CD	O
)	)	O
,	,	O
or	CC	O
the	DT	O
signal	JJ	O
described	NN	O
in	IN	O
WO	NNP	O
90/13646	CD	O
published	VBD	O
15	CD	O
Nov.	NNP	O
1990	CD	O
.	.	O
In	IN	O
mammalian	JJ	O
cell	NN	O
expression	NN	O
,	,	O
mammalian	JJ	O
signal	NN	O
sequences	NNS	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
direct	JJ	O
secretion	NN	O
of	IN	O
the	DT	O
protein	NN	O
,	,	O
such	JJ	O
as	IN	O
signal	JJ	O
sequences	NNS	O
from	IN	O
secreted	VBN	O
polypeptides	NNS	O
of	IN	O
the	DT	O
same	JJ	O
or	CC	O
related	JJ	O
species	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
viral	JJ	O
secretory	NN	O
leaders	NNS	O
.	.	O
Both	DT	O
expression	NN	O
and	CC	O
cloning	VBG	O
vectors	NNS	O
contain	VBP	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
that	WDT	O
enables	VBZ	O
the	DT	O
vector	NN	O
to	TO	O
replicate	VB	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
selected	VBN	O
host	NN	O
cells	NNS	O
.	.	O
Such	JJ	O
sequences	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
for	IN	O
a	DT	O
variety	NN	O
of	IN	O
bacteria	NNS	O
,	,	O
yeast	NN	O
,	,	O
and	CC	O
viruses	NNS	O
.	.	O
The	DT	O
origin	NN	O
of	IN	O
replication	NN	O
from	IN	O
the	DT	O
plasmid	NN	O
pBR322	NN	O
is	VBZ	O
suitable	JJ	O
for	IN	O
most	JJS	O
Gram-negative	JJ	O
bacteria	NNS	O
,	,	O
the	DT	O
2μ	CD	O
plasmid	NN	O
origin	NN	O
is	VBZ	O
suitable	JJ	O
for	IN	O
yeast	NN	O
,	,	O
and	CC	O
various	JJ	O
viral	JJ	O
origins	NNS	O
(	(	O
SV40	NNP	O
,	,	O
polyoma	NN	O
,	,	O
adenovirus	NN	O
,	,	O
VSV	NNP	O
or	CC	O
BPV	NNP	O
)	)	O
are	VBP	O
useful	JJ	O
for	IN	O
cloning	VBG	O
vectors	NNS	O
in	IN	O
mammalian	JJ	O
cells	NNS	O
.	.	O
Expression	NN	O
and	CC	O
cloning	VBG	O
vectors	NNS	O
will	MD	O
typically	RB	O
contain	VB	O
a	DT	O
selection	NN	O
gene	NN	O
,	,	O
also	RB	O
termed	VBD	O
a	DT	O
selectable	JJ	O
marker	NN	O
.	.	O
Typical	JJ	O
selection	NN	O
genes	NNS	O
encode	VBP	O
proteins	NNS	O
that	WDT	O
(	(	O
a	DT	O
)	)	O
confer	NN	O
resistance	NN	O
to	TO	O
antibiotics	NNS	O
or	CC	O
other	JJ	O
toxins	NNS	O
,	,	O
e.g.	NN	O
,	,	O
ampicillin	NN	O
,	,	O
neomycin	RB	O
,	,	O
methotrexate	NN	O
,	,	O
or	CC	O
tetracycline	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
complement	NN	O
auxotrophic	JJ	O
deficiencies	NNS	O
,	,	O
or	CC	O
(	(	O
c	NN	O
)	)	O
supply	NN	O
critical	JJ	O
nutrients	NNS	O
not	RB	O
available	JJ	O
from	IN	O
complex	JJ	O
media	NNS	O
,	,	O
e.g.	NN	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
D-alanine	NNP	O
racemase	NN	O
for	IN	O
Bacilli	NNP	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
suitable	JJ	O
selectable	JJ	O
markers	NNS	O
for	IN	O
mammalian	JJ	O
cells	NNS	O
are	VBP	O
those	DT	O
that	IN	O
enable	VBP	O
the	DT	O
identification	NN	O
of	IN	O
cells	NNS	O
competent	JJ	O
to	TO	O
take	VB	O
up	RP	O
the	DT	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-encoding	NNP	O
nucleic	JJ	O
acid	NN	O
,	,	O
such	JJ	O
as	IN	O
DHFR	NNP	O
or	CC	O
thymidine	JJ	O
kinase	NN	O
.	.	O
An	DT	O
appropriate	JJ	O
host	NN	O
cell	NN	O
when	WRB	O
wild-type	NN	O
DHFR	NNP	O
is	VBZ	O
employed	VBN	O
is	VBZ	O
the	DT	O
CHO	NNP	O
cell	NN	O
line	NN	O
deficient	NN	O
in	IN	O
DHFR	NNP	O
activity	NN	O
,	,	O
prepared	JJ	O
and	CC	O
propagated	VBD	O
as	IN	O
described	VBN	O
by	IN	O
Urlaub	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
77:4216	CD	I
(	(	I
1980	CD	I
)	)	I
.	.	O
A	DT	O
suitable	JJ	O
selection	NN	O
gene	NN	O
for	IN	O
use	NN	O
in	IN	O
yeast	NN	O
is	VBZ	O
the	DT	O
trp1	JJ	O
gene	NN	O
present	NN	O
in	IN	O
the	DT	O
yeast	NN	O
plasmid	NN	O
YRp7	NNP	O
[	NNP	O
Stinchcomb	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
282:39	CD	I
(	(	I
1979	CD	I
)	)	I
;	:	O
Kingsman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Gene	NNP	I
,	,	I
7:141	CD	I
(	(	I
1979	CD	I
)	)	I
;	:	O
Tschemper	NNP	B
et	FW	I
al.	NN	I
,	,	I
Gene	NNP	I
,	,	I
10:157	CD	I
(	(	I
1980	CD	I
)	)	I
]	NN	O
.	.	O
The	DT	O
trp1	JJ	O
gene	NN	O
provides	VBZ	O
a	DT	O
selection	NN	O
marker	NN	O
for	IN	O
a	DT	O
mutant	JJ	O
strain	NN	O
of	IN	O
yeast	NN	O
lacking	VBG	O
the	DT	O
ability	NN	O
to	TO	O
grow	VB	O
in	IN	O
tryptophan	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
ATCC	NNP	O
No	NNP	O
.	.	O
44076	CD	O
or	CC	O
PEP4-1	NNP	O
[	NNP	O
Jones	NNP	B
,	,	I
Genetics	NNP	I
,	,	I
85:12	CD	I
(	(	I
1977	CD	I
)	)	I
]	NN	O
.	.	O
Expression	NN	O
and	CC	O
cloning	VBG	O
vectors	NNS	O
usually	RB	O
contain	VBP	O
a	DT	O
promoter	NN	O
operably	RB	O
linked	VBD	O
to	TO	O
the	DT	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-encoding	NNP	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
to	TO	O
direct	VB	O
mRNA	JJ	O
synthesis	NN	O
.	.	O
Promoters	NNS	O
recognized	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
potential	JJ	O
host	NN	O
cells	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
.	.	O
Promoters	NNS	O
suitable	JJ	O
for	IN	O
use	NN	O
with	IN	O
prokaryotic	JJ	O
hosts	NNS	O
include	VBP	O
the	DT	O
β-lactamase	JJ	O
and	CC	O
lactose	JJ	O
promoter	NN	O
systems	NNS	O
[	NNP	O
Chang	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
275:615	CD	I
(	(	I
1978	CD	I
)	)	I
;	:	O
Goeddel	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
281:544	CD	I
(	(	I
1979	CD	I
)	)	I
]	NN	O
,	,	O
alkaline	JJ	O
phosphatase	NN	O
,	,	O
a	DT	O
tryptophan	NN	O
(	(	O
tip	NN	O
)	)	O
promoter	NN	O
system	NN	O
[	NNP	O
Goeddel	NNP	B
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Res.	NNP	I
,	,	I
8:4057	CD	I
(	(	I
1980	CD	I
)	)	I
;	:	O
EP	$	O
36,776	CD	O
]	NNP	O
,	,	O
and	CC	O
hybrid	JJ	O
promoters	NNS	O
such	JJ	O
as	IN	O
the	DT	O
tac	NN	O
promoter	NN	O
[	NNP	O
deBoer	NN	B
et	NN	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
80:21-25	CD	I
(	(	I
1983	CD	I
)	)	I
]	NN	O
.	.	O
Promoters	NNS	O
for	IN	O
use	NN	O
in	IN	O
bacterial	JJ	O
systems	NNS	O
also	RB	O
will	MD	O
contain	VB	O
a	DT	O
Shine-Dalgarno	NNP	O
(	(	O
S.D	NNP	O
.	.	O
)	)	O
sequence	NN	O
operably	RB	O
linked	VBD	O
to	TO	O
the	DT	O
DNA	NNP	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
suitable	JJ	O
promoting	NN	O
sequences	NNS	O
for	IN	O
use	NN	O
with	IN	O
yeast	JJ	O
hosts	NNS	O
include	VBP	O
the	DT	O
promoters	NNS	O
for	IN	O
3-phosphoglycerate	JJ	O
kinase	NN	O
[	NNP	O
Hitzeman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
255:2073	CD	I
(	(	I
1980	CD	I
)	)	I
]	NN	O
or	CC	O
other	JJ	O
glycolytic	JJ	O
enzymes	NNS	O
[	VBP	O
Hess	NNP	B
et	CC	I
al.	NN	I
,	,	I
J.	NNP	I
Adv	NNP	I
.	.	I
Enzyme	NNP	I
Reg.	NNP	I
,	,	I
7:149	CD	I
(	(	I
1968	CD	I
)	)	I
;	:	O
Holland	NNP	B
,	,	I
Biochemistry	NNP	I
,	,	I
17:4900	CD	I
(	(	I
1978	CD	I
)	)	I
]	NN	O
,	,	O
such	JJ	O
as	IN	O
enolase	NN	O
,	,	O
glyceraldehyde-3-phosphate	JJ	O
dehydrogenase	NN	O
,	,	O
hexokinase	NN	O
,	,	O
pyruvate	JJ	O
decarboxylase	NN	O
,	,	O
phosphofructokinase	NN	O
,	,	O
glucose-6-phosphate	JJ	O
isomerase	NN	O
,	,	O
3-phosphoglycerate	JJ	O
mutase	NN	O
,	,	O
pyruvate	JJ	O
kinase	NN	O
,	,	O
triosephosphate	JJ	O
isomerase	NN	O
,	,	O
phosphoglucose	JJ	O
isomerase	NN	O
,	,	O
and	CC	O
glucokinase	NN	O
.	.	O
Other	JJ	O
yeast	NN	O
promoters	NNS	O
,	,	O
which	WDT	O
are	VBP	O
inducible	JJ	O
promoters	NNS	O
having	VBG	O
the	DT	O
additional	JJ	O
advantage	NN	O
of	IN	O
transcription	NN	O
controlled	VBN	O
by	IN	O
growth	NN	O
conditions	NNS	O
,	,	O
are	VBP	O
the	DT	O
promoter	NN	O
regions	NNS	O
for	IN	O
alcohol	NN	O
dehydrogenase	NN	O
2	CD	O
,	,	O
isocytochrome	JJ	O
C	NNP	O
,	,	O
acid	JJ	O
phosphatase	NN	O
,	,	O
degradative	JJ	O
enzymes	NNS	O
associated	VBN	O
with	IN	O
nitrogen	JJ	O
metabolism	NN	O
,	,	O
metallothionein	NN	O
,	,	O
glyceraldehyde-3-phosphate	JJ	O
dehydrogenase	NN	O
,	,	O
and	CC	O
enzymes	VBZ	O
responsible	JJ	O
for	IN	O
maltose	JJ	O
and	CC	O
galactose	JJ	O
utilization	NN	O
.	.	O
Suitable	JJ	O
vectors	NNS	O
and	CC	O
promoters	NNS	O
for	IN	O
use	NN	O
in	IN	O
yeast	JJ	O
expression	NN	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
EP	NNP	O
73,657	CD	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
transcription	NN	O
from	IN	O
vectors	NNS	O
in	IN	O
mammalian	JJ	O
host	NN	O
cells	NNS	O
is	VBZ	O
controlled	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
promoters	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
genomes	NNS	O
of	IN	O
viruses	NNS	O
such	JJ	O
as	IN	O
polyoma	NN	O
virus	NN	O
,	,	O
fowlpox	JJ	O
virus	NN	O
(	(	O
UK	NNP	O
2,211,504	CD	O
published	VBD	O
5	CD	O
Jul	NNP	O
.	.	O
1989	CD	O
)	)	O
,	,	O
adenovirus	RB	O
(	(	O
such	JJ	O
as	IN	O
Adenovirus	NNP	O
2	CD	O
)	)	O
,	,	O
bovine	JJ	O
papilloma	NN	O
virus	NN	O
,	,	O
avian	JJ	O
sarcoma	NN	O
virus	NN	O
,	,	O
cytomegalovirus	NN	O
,	,	O
a	DT	O
retrovirus	NN	O
,	,	O
hepatitis-B	JJ	O
virus	NN	O
and	CC	O
Simian	JJ	O
Virus	NNP	O
40	CD	O
(	(	O
SV40	NNP	O
)	)	O
,	,	O
from	IN	O
heterologous	JJ	O
mammalian	JJ	O
promoters	NNS	O
,	,	O
e.g.	NN	O
,	,	O
the	DT	O
actin	NN	O
promoter	NN	O
or	CC	O
an	DT	O
immunoglobulin	JJ	O
promoter	NN	O
,	,	O
and	CC	O
from	IN	O
heat-shock	JJ	O
promoters	NNS	O
,	,	O
provided	VBD	O
such	JJ	O
promoters	NNS	O
are	VBP	O
compatible	JJ	O
with	IN	O
the	DT	O
host	NN	O
cell	NN	O
systems	NNS	O
.	.	O
Transcription	NN	O
of	IN	O
a	DT	O
DNA	NN	O
encoding	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
by	IN	O
higher	JJR	O
eukaryotes	NNS	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
inserting	VBG	O
an	DT	O
enhancer	NN	O
sequence	NN	O
into	IN	O
the	DT	O
vector	NN	O
.	.	O
Enhancers	NNS	O
are	VBP	O
cis-acting	JJ	O
elements	NNS	O
of	IN	O
DNA	NNP	O
,	,	O
usually	RB	O
about	IN	O
from	IN	O
10	CD	O
to	TO	O
300	CD	O
bp	NN	O
,	,	O
that	WDT	O
act	VBP	O
on	IN	O
a	DT	O
promoter	NN	O
to	TO	O
increase	VB	O
its	PRP$	O
transcription	NN	O
.	.	O
Many	JJ	O
enhancer	NN	O
sequences	NNS	O
are	VBP	O
now	RB	O
known	VBN	O
from	IN	O
mammalian	JJ	O
genes	NNS	O
(	(	O
globin	NN	O
,	,	O
elastase	NN	O
,	,	O
albumin	NN	O
,	,	O
α-fetoprotein	JJ	O
,	,	O
and	CC	O
insulin	NN	O
)	)	O
.	.	O
Typically	RB	O
,	,	O
however	RB	O
,	,	O
one	CD	O
will	MD	O
use	VB	O
an	DT	O
enhancer	NN	O
from	IN	O
a	DT	O
eukaryotic	JJ	O
cell	NN	O
virus	NN	O
.	.	O
Examples	NNS	O
include	VBP	O
the	DT	O
SV40	NNP	O
enhancer	NN	O
on	IN	O
the	DT	O
late	JJ	O
side	NN	O
of	IN	O
the	DT	O
replication	NN	O
origin	NN	O
(	(	O
bp	IN	O
100-270	CD	O
)	)	O
,	,	O
the	DT	O
cytomegalovirus	NN	O
early	JJ	O
promoter	NN	O
enhancer	NN	O
,	,	O
the	DT	O
polyoma	NN	O
enhancer	NN	O
on	IN	O
the	DT	O
late	JJ	O
side	NN	O
of	IN	O
the	DT	O
replication	NN	O
origin	NN	O
,	,	O
and	CC	O
adenovirus	NN	O
enhancers	NNS	O
.	.	O
The	DT	O
enhancer	NN	O
may	MD	O
be	VB	O
spliced	VBN	O
into	IN	O
the	DT	O
vector	NN	O
at	IN	O
a	DT	O
position	NN	O
5′	CD	O
or	CC	O
3′	CD	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
coding	VBG	O
sequence	NN	O
,	,	O
but	CC	O
is	VBZ	O
preferably	RB	O
located	VBN	O
at	IN	O
a	DT	O
site	NN	O
5′	CD	O
from	IN	O
the	DT	O
promoter	NN	O
.	.	O
Expression	NN	O
vectors	NNS	O
used	VBN	O
in	IN	O
eukaryotic	JJ	O
host	NN	O
cells	NNS	O
(	(	O
yeast	NN	O
,	,	O
fungi	NNS	O
,	,	O
insect	NN	O
,	,	O
plant	NN	O
,	,	O
animal	NN	O
,	,	O
human	JJ	O
,	,	O
or	CC	O
nucleated	JJ	O
cells	NNS	O
from	IN	O
other	JJ	O
multicellular	JJ	O
organisms	NNS	O
)	)	O
will	MD	O
also	RB	O
contain	VB	O
sequences	NNS	O
necessary	JJ	O
for	IN	O
the	DT	O
termination	NN	O
of	IN	O
transcription	NN	O
and	CC	O
for	IN	O
stabilizing	VBG	O
the	DT	O
mRNA	NN	O
.	.	O
Such	JJ	O
sequences	NNS	O
are	VBP	O
commonly	RB	O
available	JJ	O
from	IN	O
the	DT	O
5′	CD	O
and	CC	O
,	,	O
occasionally	RB	O
3′	CD	O
,	,	O
untranslated	JJ	O
regions	NNS	O
of	IN	O
eukaryotic	JJ	O
or	CC	O
viral	JJ	O
DNAs	NNP	O
or	CC	O
cDNAs	NN	O
.	.	O
These	DT	O
regions	NNS	O
contain	VBP	O
nucleotide	JJ	O
segments	NNS	O
transcribed	VBD	O
as	IN	O
polyadenylated	JJ	O
fragments	NNS	O
in	IN	O
the	DT	O
untranslated	JJ	O
portion	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
Still	RB	O
other	JJ	O
methods	NNS	O
,	,	O
vectors	NNS	O
,	,	O
and	CC	O
host	NN	O
cells	NNS	O
suitable	JJ	O
for	IN	O
adaptation	NN	O
to	TO	O
the	DT	O
synthesis	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
in	IN	O
recombinant	JJ	O
vertebrate	NN	O
cell	NN	O
culture	NN	O
are	VBP	O
described	VBN	O
in	IN	O
Gething	VBG	B
et	NN	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
293:620-625	CD	I
(	(	I
1981	CD	I
)	)	I
;	:	O
Mantei	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
281:40-46	CD	I
(	(	I
1979	CD	I
)	)	I
;	:	O
EP	NNP	O
117,060	CD	O
;	:	O
and	CC	O
EP	NNP	O
117,058	CD	O
.	.	O
4	CD	O
.	.	O
Detecting	VBG	O
Gene	NNP	O
Amplification/Expression	NNP	O
Gene	NNP	O
amplification	NN	O
and/or	NNS	O
expression	NN	O
may	MD	O
be	VB	O
measured	VBN	O
in	IN	O
a	DT	O
sample	NN	O
directly	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
conventional	JJ	O
Southern	NNP	O
blotting	NN	O
,	,	O
Northern	NNP	O
blotting	VBG	O
to	TO	O
quantitate	VB	O
the	DT	O
transcription	NN	O
of	IN	O
mRNA	NN	O
[	NNP	O
Thomas	NNP	B
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
77:5201-5205	NNP	I
(	(	I
1980	CD	I
)	)	I
]	NN	O
,	,	O
dot	NN	O
blotting	NN	O
(	(	O
DNA	NNP	O
analysis	NN	O
)	)	O
,	,	O
or	CC	O
in	IN	O
situ	JJ	O
hybridization	NN	O
,	,	O
using	VBG	O
an	DT	O
appropriately	RB	O
labeled	JJ	O
probe	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
sequences	NNS	O
provided	VBD	O
herein	NN	O
.	.	O
Alternatively	RB	O
,	,	O
antibodies	NNS	O
may	MD	O
be	VB	O
employed	VBN	O
that	IN	O
can	MD	O
recognize	VB	O
specific	JJ	O
duplexes	NNS	O
,	,	O
including	VBG	O
DNA	NN	O
duplexes	NNS	O
,	,	O
RNA	NNP	O
duplexes	NNS	O
,	,	O
and	CC	O
DNA-RNA	NNP	O
hybrid	JJ	O
duplexes	NNS	O
or	CC	O
DNA-protein	NNP	O
duplexes	NNS	O
.	.	O
The	DT	O
antibodies	NNS	O
in	IN	O
turn	NN	O
may	MD	O
be	VB	O
labeled	VBN	O
and	CC	O
the	DT	O
assay	NN	O
may	MD	O
be	VB	O
carried	VBN	O
out	IN	O
where	WRB	O
the	DT	O
duplex	NN	O
is	VBZ	O
bound	VBN	O
to	TO	O
a	DT	O
surface	NN	O
,	,	O
so	IN	O
that	DT	O
upon	IN	O
the	DT	O
formation	NN	O
of	IN	O
duplex	NN	O
on	IN	O
the	DT	O
surface	NN	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
antibody	NN	O
bound	NN	O
to	TO	O
the	DT	O
duplex	NN	O
can	MD	O
be	VB	O
detected	VBN	O
.	.	O
Gene	NNP	O
expression	NN	O
,	,	O
alternatively	RB	O
,	,	O
may	MD	O
be	VB	O
measured	VBN	O
by	IN	O
immunological	JJ	O
methods	NNS	O
,	,	O
such	JJ	O
as	IN	O
immunohistochemical	JJ	O
staining	NN	O
of	IN	O
cells	NNS	O
or	CC	O
tissue	NN	O
sections	NNS	O
and	CC	O
assay	NN	O
of	IN	O
cell	NN	O
culture	NN	O
or	CC	O
body	NN	O
fluids	NNS	O
,	,	O
to	TO	O
quantitate	VB	O
directly	RB	O
the	DT	O
expression	NN	O
of	IN	O
gene	NN	O
product	NN	O
.	.	O
Antibodies	NNS	O
useful	JJ	O
for	IN	O
immunohistochemical	JJ	O
staining	NN	O
and/or	NNS	O
assay	VBP	O
of	IN	O
sample	JJ	O
fluids	NNS	O
may	MD	O
be	VB	O
either	CC	O
monoclonal	JJ	O
or	CC	O
polyclonal	JJ	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
prepared	VBN	O
in	IN	O
any	DT	O
mammal	NN	O
.	.	O
Conveniently	RB	O
,	,	O
the	DT	O
antibodies	NNS	O
may	MD	O
be	VB	O
prepared	VBN	O
against	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
or	CC	O
against	IN	O
a	DT	O
synthetic	JJ	O
peptide	NN	O
based	VBN	O
on	IN	O
the	DT	O
DNA	NN	O
sequences	NNS	O
provided	VBD	O
herein	NN	O
or	CC	O
against	IN	O
exogenous	JJ	O
sequence	NN	O
fused	VBD	O
to	TO	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
DNA	NNP	O
and	CC	O
encoding	VBG	O
a	DT	O
specific	JJ	O
antibody	NN	O
epitope	NN	O
.	.	O
5	CD	O
.	.	O
Purification	NN	O
of	IN	O
Polypeptide	NNP	O
Forms	NNP	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
may	MD	O
be	VB	O
recovered	VBN	O
from	IN	O
culture	NN	O
medium	NN	O
or	CC	O
from	IN	O
host	NN	O
cell	NN	O
lysates	VBZ	O
.	.	O
If	IN	O
membrane-bound	NN	O
,	,	O
it	PRP	O
can	MD	O
be	VB	O
released	VBN	O
from	IN	O
the	DT	O
membrane	NN	O
using	VBG	O
a	DT	O
suitable	JJ	O
detergent	NN	O
solution	NN	O
(	(	O
e.g	NN	O
.	.	O
Triton-X	NNP	O
100	CD	O
)	)	O
or	CC	O
by	IN	O
enzymatic	JJ	O
cleavage	NN	O
.	.	O
Cells	NNS	O
employed	VBN	O
in	IN	O
expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
can	MD	O
be	VB	O
disrupted	VBN	O
by	IN	O
various	JJ	O
physical	JJ	O
or	CC	O
chemical	NN	O
means	NNS	O
,	,	O
such	JJ	O
as	IN	O
freeze-thaw	JJ	O
cycling	NN	O
,	,	O
sonication	NN	O
,	,	O
mechanical	JJ	O
disruption	NN	O
,	,	O
or	CC	O
cell	NN	O
lysing	VBG	O
agents	NNS	O
.	.	O
It	PRP	O
may	MD	O
be	VB	O
desired	VBN	O
to	TO	O
purify	VB	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
from	IN	O
recombinant	NN	O
cell	NN	O
proteins	VBZ	O
or	CC	O
polypeptides	NNS	O
.	.	O
The	DT	O
following	JJ	O
procedures	NNS	O
are	VBP	O
exemplary	JJ	O
of	IN	O
suitable	JJ	O
purification	NN	O
procedures	NNS	O
:	:	O
by	IN	O
fractionation	NN	O
on	IN	O
an	DT	O
ion-exchange	JJ	O
column	NN	O
;	:	O
ethanol	CC	O
precipitation	NN	O
;	:	O
reverse	VB	O
phase	NN	O
HPLC	NNP	O
;	:	O
chromatography	NN	O
on	IN	O
silica	NN	O
or	CC	O
on	IN	O
a	DT	O
cation-exchange	JJ	O
resin	NN	O
such	JJ	O
as	IN	O
DEAE	NNP	O
;	:	O
chromatofocusing	VBG	O
;	:	O
SDS-PAGE	NNP	O
;	:	O
ammonium	NN	O
sulfate	NN	O
precipitation	NN	O
;	:	O
gel	CC	O
filtration	NN	O
using	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Sephadex	NNP	O
G-75	NNP	O
;	:	O
protein	VBZ	O
A	DT	O
Sepharose	NNP	O
columns	NN	O
to	TO	O
remove	VB	O
contaminants	NNS	O
such	JJ	O
as	IN	O
IgG	NNP	O
;	:	O
and	CC	O
metal	NN	O
chelating	VBG	O
columns	NN	O
to	TO	O
bind	VB	O
epitope-tagged	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Various	JJ	O
methods	NNS	O
of	IN	O
protein	JJ	O
purification	NN	O
may	MD	O
be	VB	O
employed	VBN	O
and	CC	O
such	JJ	O
methods	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
described	NN	O
for	IN	O
example	NN	O
in	IN	O
Deutscher	NNP	B
,	,	I
Methods	NNP	I
in	IN	I
Enzymology	NNP	I
,	,	I
182	CD	I
(	(	I
1990	CD	I
)	)	I
;	:	O
Scopes	NNP	B
,	,	I
Protein	NNP	I
Purification	NNP	I
:	:	I
Principles	NNS	I
and	CC	I
Practice	NNP	I
,	,	I
Springer-Verlag	NNP	I
,	,	I
New	NNP	I
York	NNP	I
(	(	I
1982	CD	I
)	)	I
.	.	O
The	DT	O
purification	NN	O
step	NN	O
(	(	O
s	PRP	O
)	)	O
selected	VBN	O
will	MD	O
depend	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
on	IN	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
production	NN	O
process	NN	O
used	VBN	O
and	CC	O
the	DT	O
particular	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
produced	VBD	O
.	.	O
E.	NNP	O
Uses	VBZ	O
for	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
;	:	O
PRO10096	NNP	O
;	:	O
PRO21384	NNP	O
;	:	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
Polypeptides	NNP	O
Nucleotide	NNP	O
sequences	NNS	O
(	(	O
or	CC	O
their	PRP$	O
complement	NN	O
)	)	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
have	VBP	O
various	JJ	O
applications	NNS	O
in	IN	O
the	DT	O
art	NN	O
of	IN	O
molecular	JJ	O
biology	NN	O
,	,	O
including	VBG	O
uses	NNS	O
as	IN	O
hybridization	NN	O
probes	NNS	O
,	,	O
in	IN	O
chromosome	NN	O
and	CC	O
gene	NN	O
mapping	NN	O
and	CC	O
in	IN	O
the	DT	O
generation	NN	O
of	IN	O
anti-sense	JJ	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
nucleic	JJ	O
acid	NN	O
will	MD	O
also	RB	O
be	VB	O
useful	JJ	O
for	IN	O
the	DT	O
preparation	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
by	IN	O
the	DT	O
recombinant	NN	O
techniques	NNS	O
described	VBN	O
herein	RB	O
.	.	O
The	DT	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
,	,	O
or	CC	O
portions	NNS	O
thereof	NNS	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
hybridization	NN	O
probes	NNS	O
for	IN	O
a	DT	O
cDNA	NN	O
library	NN	O
to	TO	O
isolate	VB	O
the	DT	O
full-length	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
cDNA	NN	O
or	CC	O
to	TO	O
isolate	VB	O
still	RB	O
other	JJ	O
cDNAs	NN	O
(	(	O
for	IN	O
instance	NN	O
,	,	O
those	DT	O
encoding	VBG	O
naturally-occurring	JJ	O
variants	NNS	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
or	CC	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
from	IN	O
other	JJ	O
species	NNS	O
)	)	O
which	WDT	O
have	VBP	O
a	DT	O
desired	VBN	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
sequence	NN	O
disclosed	VBD	O
herein	NN	O
.	.	O
Optionally	RB	O
,	,	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
probes	NNS	O
will	MD	O
be	VB	O
about	RB	O
20	CD	O
to	TO	O
about	IN	O
50	CD	O
bases	NNS	O
.	.	O
The	DT	O
hybridization	NN	O
probes	NNS	O
may	MD	O
be	VB	O
derived	VBN	O
from	IN	O
at	IN	O
least	JJS	O
partially	RB	O
novel	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
full	JJ	O
length	NN	O
native	JJ	O
nucleotide	JJ	O
sequence	NN	O
wherein	VBD	O
those	DT	O
regions	NNS	O
may	MD	O
be	VB	O
determined	VBN	O
without	IN	O
undue	JJ	O
experimentation	NN	O
or	CC	O
from	IN	O
genomic	JJ	O
sequences	NNS	O
including	VBG	O
promoters	NNS	O
,	,	O
enhancer	JJ	O
elements	NNS	O
and	CC	O
introns	NNS	O
of	IN	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
.	.	O
By	IN	O
way	NN	O
of	IN	O
example	NN	O
,	,	O
a	DT	O
screening	NN	O
method	NN	O
will	MD	O
comprise	VB	O
isolating	VBG	O
the	DT	O
coding	VBG	O
region	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
using	VBG	O
the	DT	O
known	VBN	O
DNA	NNP	O
sequence	NN	O
to	TO	O
synthesize	VB	O
a	DT	O
selected	JJ	O
probe	NN	O
of	IN	O
about	IN	O
40	CD	O
bases	NNS	O
.	.	O
Hybridization	NNP	O
probes	NNS	O
may	MD	O
be	VB	O
labeled	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
labels	NNS	O
,	,	O
including	VBG	O
radionucleotides	NNS	O
such	JJ	O
as	IN	O
32P	CD	O
or	CC	O
35S	CD	O
,	,	O
or	CC	O
enzymatic	JJ	O
labels	NNS	O
such	JJ	O
as	IN	O
alkaline	JJ	O
phosphatase	NN	O
coupled	VBN	O
to	TO	O
the	DT	O
probe	NN	O
via	IN	O
avidin/biotin	JJ	O
coupling	VBG	O
systems	NNS	O
.	.	O
Labeled	VBN	O
probes	NNS	O
having	VBG	O
a	DT	O
sequence	NN	O
complementary	NN	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
screen	JJ	O
libraries	NNS	O
of	IN	O
human	JJ	O
cDNA	NN	O
,	,	O
genomic	JJ	O
DNA	NN	O
or	CC	O
mRNA	NN	O
to	TO	O
determine	VB	O
which	WDT	O
members	NNS	O
of	IN	O
such	JJ	O
libraries	NNS	O
the	DT	O
probe	NN	O
hybridizes	VBZ	O
to	TO	O
.	.	O
Hybridization	NN	O
techniques	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
further	JJ	O
detail	NN	O
in	IN	O
the	DT	O
Examples	NNP	O
below	IN	O
.	.	O
Any	DT	O
EST	NNP	O
sequences	NNS	O
disclosed	VBD	O
in	IN	O
the	DT	O
present	JJ	O
application	NN	O
may	MD	O
similarly	RB	O
be	VB	O
employed	VBN	O
as	IN	O
probes	NNS	O
,	,	O
using	VBG	O
the	DT	O
methods	NNS	O
disclosed	VBD	O
herein	NN	O
.	.	O
Other	JJ	O
useful	JJ	O
fragments	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
nucleic	JJ	O
acids	NNS	O
include	VBP	O
antisense	NN	O
or	CC	O
sense	NN	O
oligonucleotides	NNS	O
comprising	VBG	O
a	DT	O
singe-stranded	JJ	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
(	(	O
either	CC	O
RNA	NNP	O
or	CC	O
DNA	NNP	O
)	)	O
capable	NN	O
of	IN	O
binding	VBG	O
to	TO	O
target	VB	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
mRNA	NN	O
(	(	O
sense	NN	O
)	)	O
or	CC	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
DNA	NNP	O
(	(	O
antisense	NN	O
)	)	O
sequences	NNS	O
.	.	O
Antisense	NNP	O
or	CC	O
sense	NN	O
oligonucleotides	NNS	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
comprise	VB	O
a	DT	O
fragment	NN	O
of	IN	O
the	DT	O
coding	VBG	O
region	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
DNA	NNP	O
.	.	O
Such	JJ	O
a	DT	O
fragment	NN	O
generally	RB	O
comprises	VBZ	O
at	IN	O
least	JJS	O
about	IN	O
14	CD	O
nucleotides	NNS	O
,	,	O
preferably	RB	O
from	IN	O
about	RB	O
14	CD	O
to	TO	O
30	CD	O
nucleotides	NNS	O
.	.	O
The	DT	O
ability	NN	O
to	TO	O
derive	VB	O
an	DT	O
antisense	NN	O
or	CC	O
a	DT	O
sense	NN	O
oligonucleotide	NN	O
,	,	O
based	VBN	O
upon	IN	O
a	DT	O
cDNA	NN	O
sequence	NN	O
encoding	VBG	O
a	DT	O
given	VBN	O
protein	NN	O
is	VBZ	O
described	VBN	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Stein	NNP	B
and	CC	I
Cohen	NNP	I
(	(	I
Cancer	NNP	I
Res	NNP	I
.	.	I
48:2659	CD	I
,	,	I
1988	CD	I
)	)	I
and	CC	O
van	JJ	B
der	NN	I
Krol	NNP	I
et	VBZ	I
al	NN	I
.	.	I
(	(	I
BioTechniques	NNS	I
6:958	CD	I
,	,	I
1988	CD	I
)	)	I
.	.	O
Binding	NNP	O
of	IN	O
antisense	NN	O
or	CC	O
sense	NN	O
oligonucleotides	NNS	O
to	TO	O
target	VB	O
nucleic	JJ	O
acid	JJ	O
sequences	NNS	O
results	NNS	O
in	IN	O
the	DT	O
formation	NN	O
of	IN	O
duplexes	NNS	O
that	WDT	O
block	VBP	O
transcription	NN	O
or	CC	O
translation	NN	O
of	IN	O
the	DT	O
target	NN	O
sequence	NN	O
by	IN	O
one	CD	O
of	IN	O
several	JJ	O
means	NNS	O
,	,	O
including	VBG	O
enhanced	JJ	O
degradation	NN	O
of	IN	O
the	DT	O
duplexes	NNS	O
,	,	O
premature	JJ	O
termination	NN	O
of	IN	O
transcription	NN	O
or	CC	O
translation	NN	O
,	,	O
or	CC	O
by	IN	O
other	JJ	O
means	NNS	O
.	.	O
The	DT	O
antisense	NN	O
oligonucleotides	VBZ	O
thus	RB	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
block	VB	O
expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
.	.	O
Antisense	NNP	O
or	CC	O
sense	NN	O
oligonucleotides	IN	O
further	JJ	O
comprise	NN	O
oligonucleotides	NNS	O
having	VBG	O
modified	VBN	O
sugar-phosphodiester	JJ	O
backbones	NNS	O
(	(	O
or	CC	O
other	JJ	O
sugar	NN	O
linkages	NNS	O
,	,	O
such	JJ	O
as	IN	O
those	DT	O
described	VBN	O
in	IN	O
WO	NNP	O
91/06629	CD	O
)	)	O
and	CC	O
wherein	$	O
such	JJ	O
sugar	NN	O
linkages	NNS	O
are	VBP	O
resistant	JJ	O
to	TO	O
endogenous	JJ	O
nucleases	NNS	O
.	.	O
Such	JJ	O
oligonucleotides	NNS	O
with	IN	O
resistant	JJ	O
sugar	NN	O
linkages	NNS	O
are	VBP	O
stable	JJ	O
in	IN	O
vivo	NN	O
(	(	O
i.e.	FW	O
,	,	O
capable	JJ	O
of	IN	O
resisting	VBG	O
enzymatic	JJ	O
degradation	NN	O
)	)	O
but	CC	O
retain	VBP	O
sequence	JJ	O
specificity	NN	O
to	TO	O
be	VB	O
able	JJ	O
to	TO	O
bind	VB	O
to	TO	O
target	VB	O
nucleotide	JJ	O
sequences	NNS	O
.	.	O
Other	JJ	O
examples	NNS	O
of	IN	O
sense	NN	O
or	CC	O
antisense	NN	O
oligonucleotides	NNS	O
include	VBP	O
those	DT	O
oligonucleotides	NNS	O
which	WDT	O
are	VBP	O
covalently	RB	O
linked	VBN	O
to	TO	O
organic	JJ	O
moieties	NNS	O
,	,	O
such	JJ	O
as	IN	O
those	DT	O
described	VBN	O
in	IN	O
WO	NNP	O
90/10048	CD	O
,	,	O
and	CC	O
other	JJ	O
moieties	NNS	O
that	WDT	O
increases	VBZ	O
affinity	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
for	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
,	,	O
such	JJ	O
as	IN	O
poly-	JJ	O
(	(	O
L-lysine	NNP	O
)	)	O
.	.	O
Further	RB	O
still	RB	O
,	,	O
intercalating	VBG	O
agents	NNS	O
,	,	O
such	JJ	O
as	IN	O
ellipticine	NN	O
,	,	O
and	CC	O
alkylating	VBG	O
agents	NNS	O
or	CC	O
metal	NN	O
complexes	NNS	O
may	MD	O
be	VB	O
attached	VBN	O
to	TO	O
sense	VB	O
or	CC	O
antisense	VB	O
oligonucleotides	NNS	O
to	TO	O
modify	VB	O
binding	VBG	O
specificities	NNS	O
of	IN	O
the	DT	O
antisense	NN	O
or	CC	O
sense	NN	O
oligonucleotide	NN	O
for	IN	O
the	DT	O
target	NN	O
nucleotide	JJ	O
sequence	NN	O
.	.	O
Antisense	NNP	O
or	CC	O
sense	NN	O
oligonucleotides	NNS	O
may	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
a	DT	O
cell	NN	O
containing	VBG	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
by	IN	O
any	DT	O
gene	NN	O
transfer	NN	O
method	NN	O
,	,	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
CaPO4-mediated	JJ	O
DNA	NNP	O
transfection	NN	O
,	,	O
electroporation	NN	O
,	,	O
or	CC	O
by	IN	O
using	VBG	O
gene	NN	O
transfer	NN	O
vectors	NNS	O
such	JJ	O
as	IN	O
Epstein-Barr	NNP	O
virus	NN	O
.	.	O
In	IN	O
a	DT	O
preferred	JJ	O
procedure	NN	O
,	,	O
an	DT	O
antisense	NN	O
or	CC	O
sense	NN	O
oligonucleotide	NN	O
is	VBZ	O
inserted	VBN	O
into	IN	O
a	DT	O
suitable	JJ	O
retroviral	JJ	O
vector	NN	O
.	.	O
A	DT	O
cell	NN	O
containing	VBG	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
is	VBZ	O
contacted	VBN	O
with	IN	O
the	DT	O
recombinant	JJ	O
retroviral	JJ	O
vector	NN	O
,	,	O
either	RB	O
in	IN	O
vivo	NN	O
or	CC	O
ex	NN	O
vivo	NN	O
.	.	O
Suitable	JJ	O
retroviral	JJ	O
vectors	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
those	DT	O
derived	VBN	O
from	IN	O
the	DT	O
murine	NN	O
retrovirus	NN	O
M-MuLV	NNP	O
,	,	O
N2	NNP	O
(	(	O
a	DT	O
retrovirus	NN	O
derived	VBN	O
from	IN	O
M-MuLV	NNP	O
)	)	O
,	,	O
or	CC	O
the	DT	O
double	JJ	O
copy	NN	O
vectors	NNS	O
designated	VBD	O
DCT5A	NNP	O
,	,	O
DCT5B	NNP	O
and	CC	O
DCT5C	NNP	O
(	(	O
see	VB	O
WO	NNP	O
90/13641	CD	O
)	)	O
.	.	O
Sense	NN	O
or	CC	O
antisense	NN	O
oligonucleotides	NNS	O
also	RB	O
may	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
a	DT	O
cell	NN	O
containing	VBG	O
the	DT	O
target	NN	O
nucleotide	JJ	O
sequence	NN	O
by	IN	O
formation	NN	O
of	IN	O
a	DT	O
conjugate	NN	O
with	IN	O
a	DT	O
ligand	NN	O
binding	NN	O
molecule	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
WO	NNP	O
91/04753	CD	O
.	.	O
Suitable	JJ	O
ligand	NN	O
binding	VBG	O
molecules	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
cell	VB	O
surface	NN	O
receptors	NNS	O
,	,	O
growth	NN	O
factors	NNS	O
,	,	O
other	JJ	O
cytokines	NNS	O
,	,	O
or	CC	O
other	JJ	O
ligands	NNS	O
that	WDT	O
bind	VBP	O
to	TO	O
cell	VB	O
surface	NN	O
receptors	NNS	O
.	.	O
Preferably	RB	O
,	,	O
conjugation	NN	O
of	IN	O
the	DT	O
ligand	NN	O
binding	VBG	O
molecule	NN	O
does	VBZ	O
not	RB	O
substantially	RB	O
interfere	VB	O
with	IN	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
ligand	NN	O
binding	VBG	O
molecule	NN	O
to	TO	O
bind	VB	O
to	TO	O
its	PRP$	O
corresponding	VBG	O
molecule	NN	O
or	CC	O
receptor	NN	O
,	,	O
or	CC	O
block	VB	O
entry	NN	O
of	IN	O
the	DT	O
sense	NN	O
or	CC	O
antisense	JJ	O
oligonucleotide	NN	O
or	CC	O
its	PRP$	O
conjugated	JJ	O
version	NN	O
into	IN	O
the	DT	O
cell	NN	O
.	.	O
Alternatively	RB	O
,	,	O
a	DT	O
sense	NN	O
or	CC	O
an	DT	O
antisense	JJ	O
oligonucleotide	NN	O
may	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
a	DT	O
cell	NN	O
containing	VBG	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
by	IN	O
formation	NN	O
of	IN	O
an	DT	O
oligonucleotide-lipid	JJ	O
complex	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
WO	NNP	O
90/10448	CD	O
.	.	O
The	DT	O
sense	NN	O
or	CC	O
antisense	JJ	O
oligonucleotide-lipid	JJ	O
complex	NN	O
is	VBZ	O
preferably	RB	O
dissociated	VBN	O
within	IN	O
the	DT	O
cell	NN	O
by	IN	O
an	DT	O
endogenous	JJ	O
lipase	NN	O
.	.	O
Antisense	NNP	O
or	CC	O
sense	NN	O
RNA	NNPS	O
or	CC	O
DNA	NNP	O
molecules	NNS	O
are	VBP	O
generally	RB	O
at	IN	O
least	JJS	O
about	IN	O
5	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
10	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
15	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
20	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
25	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
30	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
35	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
40	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
45	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
50	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
55	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
60	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
65	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
70	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
75	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
80	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
85	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
90	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
95	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
about	RB	O
100	CD	O
bases	NNS	O
in	IN	O
length	NN	O
,	,	O
or	CC	O
more	JJR	O
.	.	O
The	DT	O
probes	NNS	O
may	MD	O
also	RB	O
be	VB	O
employed	VBN	O
in	IN	O
PCR	NNP	O
techniques	NNS	O
to	TO	O
generate	VB	O
a	DT	O
pool	NN	O
of	IN	O
sequences	NNS	O
for	IN	O
identification	NN	O
of	IN	O
closely	RB	O
related	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
coding	VBG	O
sequences	NNS	O
.	.	O
Nucleotide	NNP	O
sequences	VBZ	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
construct	VB	O
hybridization	NN	O
probes	NNS	O
for	IN	O
mapping	VBG	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
that	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
for	IN	O
the	DT	O
genetic	JJ	O
analysis	NN	O
of	IN	O
individuals	NNS	O
with	IN	O
genetic	JJ	O
disorders	NNS	O
.	.	O
The	DT	O
nucleotide	JJ	O
sequences	NNS	O
provided	VBD	O
herein	NN	O
may	MD	O
be	VB	O
mapped	VBN	O
to	TO	O
a	DT	O
chromosome	NN	O
and	CC	O
specific	JJ	O
regions	NNS	O
of	IN	O
a	DT	O
chromosome	NN	O
using	VBG	O
known	VBN	O
techniques	NNS	O
,	,	O
such	JJ	O
as	IN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
,	,	O
linkage	NN	O
analysis	NN	O
against	IN	O
known	VBN	O
chromosomal	JJ	O
markers	NNS	O
,	,	O
and	CC	O
hybridization	NN	O
screening	VBG	O
with	IN	O
libraries	NNS	O
.	.	O
When	WRB	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
encode	VBP	O
a	DT	O
protein	NN	O
which	WDT	O
binds	VBZ	O
to	TO	O
another	DT	O
protein	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
where	WRB	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
is	VBZ	O
a	DT	O
receptor	NN	O
)	)	O
,	,	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
assays	NNS	O
to	TO	O
identify	VB	O
the	DT	O
other	JJ	O
proteins	NNS	O
or	CC	O
molecules	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
binding	NN	O
interaction	NN	O
.	.	O
By	IN	O
such	JJ	O
methods	NNS	O
,	,	O
inhibitors	NNS	O
of	IN	O
the	DT	O
receptor/ligand	NN	O
binding	VBG	O
interaction	NN	O
can	MD	O
be	VB	O
identified	VBN	O
.	.	O
Proteins	NNS	O
involved	VBN	O
in	IN	O
such	JJ	O
binding	JJ	O
interactions	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
screen	VB	O
for	IN	O
peptide	NN	O
or	CC	O
small	JJ	O
molecule	NN	O
inhibitors	NNS	O
or	CC	O
agonists	NNS	O
of	IN	O
the	DT	O
binding	NN	O
interaction	NN	O
.	.	O
Also	RB	O
,	,	O
the	DT	O
receptor	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
isolate	VB	O
correlative	JJ	O
ligand	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
Screening	VBG	O
assays	NNS	O
can	MD	O
be	VB	O
designed	VBN	O
to	TO	O
find	VB	O
lead	JJ	O
compounds	NNS	O
that	WDT	O
mimic	VBP	O
the	DT	O
biological	JJ	O
activity	NN	O
of	IN	O
a	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
or	CC	O
a	DT	O
receptor	NN	O
for	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
Such	JJ	O
screening	NN	O
assays	NNS	O
will	MD	O
include	VB	O
assays	NNS	O
amenable	JJ	O
to	TO	O
high-throughput	JJ	O
screening	NN	O
of	IN	O
chemical	NN	O
libraries	NNS	O
,	,	O
making	VBG	O
them	PRP	O
particularly	RB	O
suitable	JJ	O
for	IN	O
identifying	VBG	O
small	JJ	O
molecule	JJ	O
drug	NN	O
candidates	NNS	O
.	.	O
Small	JJ	O
molecules	NNS	O
contemplated	VBN	O
include	VBP	O
synthetic	JJ	O
organic	JJ	O
or	CC	O
inorganic	JJ	O
compounds	NNS	O
.	.	O
The	DT	O
assays	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
formats	NNS	O
,	,	O
including	VBG	O
protein-protein	JJ	O
binding	NN	O
assays	NNS	O
,	,	O
biochemical	JJ	O
screening	NN	O
assays	NNS	O
,	,	O
immunoassays	NNS	O
and	CC	O
cell	NN	O
based	VBN	O
assays	NNS	O
,	,	O
which	WDT	O
are	VBP	O
well	RB	O
characterized	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Nucleic	NNP	O
acids	NNS	O
which	WDT	O
encode	VBP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
or	CC	O
its	PRP$	O
modified	JJ	O
forms	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
generate	VB	O
either	DT	O
transgenic	JJ	O
animals	NNS	O
or	CC	O
“	VB	O
knock	NN	O
out	IN	O
”	NN	O
animals	NNS	O
which	WDT	O
,	,	O
in	IN	O
turn	NN	O
,	,	O
are	VBP	O
useful	JJ	O
in	IN	O
the	DT	O
development	NN	O
and	CC	O
screening	NN	O
of	IN	O
therapeutically	RB	O
useful	JJ	O
reagents	NNS	O
.	.	O
A	DT	O
transgenic	JJ	O
animal	NN	O
(	(	O
e.g.	JJ	O
,	,	O
a	DT	O
mouse	NN	O
or	CC	O
rat	NN	O
)	)	O
is	VBZ	O
an	DT	O
animal	JJ	O
having	VBG	O
cells	NNS	O
that	WDT	O
contain	VBP	O
a	DT	O
transgene	NN	O
,	,	O
which	WDT	O
transgene	NN	O
was	VBD	O
introduced	VBN	O
into	IN	O
the	DT	O
animal	NN	O
or	CC	O
an	DT	O
ancestor	NN	O
of	IN	O
the	DT	O
animal	NN	O
at	IN	O
a	DT	O
prenatal	NN	O
,	,	O
e.g.	NN	O
,	,	O
an	DT	O
embryonic	JJ	O
stage	NN	O
.	.	O
A	DT	O
transgene	NN	O
is	VBZ	O
a	DT	O
DNA	NN	O
which	WDT	O
is	VBZ	O
integrated	VBN	O
into	IN	O
the	DT	O
genome	NN	O
of	IN	O
a	DT	O
cell	NN	O
from	IN	O
which	WDT	O
a	DT	O
transgenic	NN	O
animal	NN	O
develops	NNS	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
cDNA	NN	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
clone	VB	O
genomic	JJ	O
DNA	NNP	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
in	IN	O
accordance	NN	O
with	IN	O
established	VBN	O
techniques	NNS	O
and	CC	O
the	DT	O
genomic	JJ	O
sequences	NNS	O
used	VBN	O
to	TO	O
generate	VB	O
transgenic	JJ	O
animals	NNS	O
that	WDT	O
contain	VBP	O
cells	NNS	O
which	WDT	O
express	VBP	O
DNA	NNP	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
Any	DT	O
technique	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
introduce	VB	O
a	DT	O
target	NN	O
gene	NN	O
transgene	NN	O
into	IN	O
animals	NNS	O
to	TO	O
produce	VB	O
the	DT	O
founder	NN	O
lines	NNS	O
of	IN	O
transgenic	JJ	O
animals	NNS	O
.	.	O
Such	JJ	O
techniques	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
pronuclear	VB	O
microinjection	NN	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,873,191	CD	O
,	,	O
4,736,866	CD	O
and	CC	O
4,870,009	CD	O
)	)	O
;	:	O
retrovirus	NN	O
mediated	VBD	O
gene	NN	O
transfer	NN	O
into	IN	O
germ	JJ	O
lines	NNS	O
(	(	O
Van	NNP	B
der	NN	I
Putten	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
USA	NNP	I
,	,	I
82:6148-6152	CD	I
(	(	I
1985	CD	I
)	)	I
)	)	O
;	:	O
gene	NN	O
targeting	VBG	O
in	IN	O
embryonic	JJ	O
stem	NN	O
cells	NNS	O
(	(	O
Thompson	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
,	,	I
56:313-321	NNP	I
(	(	I
1989	CD	I
)	)	I
)	)	O
;	:	O
nonspecific	JJ	O
insertional	JJ	O
inactivation	NN	O
using	VBG	O
a	DT	O
gene	NN	O
trap	NN	O
vector	NN	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,436,707	CD	O
)	)	O
;	:	O
electroporation	NN	O
of	IN	O
embryos	NN	O
(	(	O
Lo	NNP	B
,	,	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
3:1803-1814	NNP	I
(	(	I
1983	CD	I
)	)	I
)	)	O
;	:	O
and	CC	O
sperm-mediated	JJ	O
gene	NN	O
transfer	NN	O
(	(	O
Lavitrano	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
,	,	I
57:717-723	NNP	I
(	(	I
1989	CD	I
)	)	I
)	)	O
;	:	O
etc	FW	O
.	.	O
Typically	RB	O
,	,	O
particular	JJ	O
cells	NNS	O
would	MD	O
be	VB	O
targeted	VBN	O
for	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
transgene	JJ	O
incorporation	NN	O
with	IN	O
tissue-specific	JJ	O
enhancers	NNS	O
.	.	O
Transgenic	JJ	O
animals	NNS	O
that	WDT	O
include	VBP	O
a	DT	O
copy	NN	O
of	IN	O
a	DT	O
transgene	NN	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
introduced	VBD	O
into	IN	O
the	DT	O
germ	JJ	O
line	NN	O
of	IN	O
the	DT	O
animal	NN	O
at	IN	O
an	DT	O
embryonic	JJ	O
stage	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
increased	JJ	O
expression	NN	O
of	IN	O
DNA	NNP	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
Such	JJ	O
animals	NNS	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
tester	NN	O
animals	NNS	O
for	IN	O
reagents	NNS	O
thought	VBN	O
to	TO	O
confer	VB	O
protection	NN	O
from	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
pathological	JJ	O
conditions	NNS	O
associated	VBN	O
with	IN	O
its	PRP$	O
overexpression	NN	O
.	.	O
In	IN	O
accordance	NN	O
with	IN	O
this	DT	O
facet	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
an	DT	O
animal	NN	O
is	VBZ	O
treated	VBN	O
with	IN	O
the	DT	O
reagent	NN	O
and	CC	O
a	DT	O
reduced	JJ	O
incidence	NN	O
of	IN	O
the	DT	O
pathological	JJ	O
condition	NN	O
,	,	O
compared	VBN	O
to	TO	O
untreated	JJ	O
animals	NNS	O
bearing	VBG	O
the	DT	O
transgene	NN	O
,	,	O
would	MD	O
indicate	VB	O
a	DT	O
potential	JJ	O
therapeutic	JJ	O
intervention	NN	O
for	IN	O
the	DT	O
pathological	JJ	O
condition	NN	O
.	.	O
Alternatively	RB	O
,	,	O
non-human	JJ	O
homologues	NNS	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
construct	VB	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
“	NNP	O
knock	VB	O
out	RP	O
”	NNP	O
animal	NN	O
which	WDT	O
has	VBZ	O
a	DT	O
defective	JJ	O
or	CC	O
altered	JJ	O
gene	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
proteins	VBZ	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
homologous	JJ	O
recombination	NN	O
between	IN	O
the	DT	O
endogenous	JJ	O
gene	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
and	CC	O
altered	JJ	O
genomic	JJ	O
DNA	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
introduced	VBD	O
into	IN	O
an	DT	O
embryonic	JJ	O
stem	NN	O
cell	NN	O
of	IN	O
the	DT	O
animal	NN	O
.	.	O
Preferably	RB	O
the	DT	O
knock	NN	O
out	RP	O
animal	NN	O
is	VBZ	O
a	DT	O
mammal	NN	O
.	.	O
More	RBR	O
preferably	RB	O
,	,	O
the	DT	O
mammal	NN	O
is	VBZ	O
a	DT	O
rodent	NN	O
such	JJ	O
as	IN	O
a	DT	O
rat	NN	O
or	CC	O
mouse	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
cDNA	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
clone	VB	O
genomic	JJ	O
DNA	NNP	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
in	IN	O
accordance	NN	O
with	IN	O
established	VBN	O
techniques	NNS	O
.	.	O
A	DT	O
portion	NN	O
of	IN	O
the	DT	O
genomic	JJ	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
can	MD	O
be	VB	O
deleted	VBN	O
or	CC	O
replaced	VBN	O
with	IN	O
another	DT	O
gene	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
gene	NN	O
encoding	VBG	O
a	DT	O
selectable	JJ	O
marker	NN	O
which	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
monitor	VB	O
integration	NN	O
.	.	O
Typically	RB	O
,	,	O
several	JJ	O
kilobases	NNS	O
of	IN	O
unaltered	JJ	O
flanking	NN	O
DNA	NN	O
(	(	O
both	DT	O
at	IN	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
ends	NNS	O
)	)	O
are	VBP	O
included	VBN	O
in	IN	O
the	DT	O
vector	NN	O
[	NNP	O
see	NN	O
e.g.	NN	O
,	,	O
Thomas	NNP	B
and	CC	I
Capecchi	NNP	I
,	,	I
Cell	NNP	I
,	,	I
51:503	CD	I
(	(	I
1987	CD	I
)	)	I
for	IN	O
a	DT	O
description	NN	O
of	IN	O
homologous	JJ	O
recombination	NN	O
vectors	NNS	O
]	VBP	O
.	.	O
The	DT	O
vector	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
an	DT	O
embryonic	JJ	O
stem	NN	O
cell	NN	O
line	NN	O
(	(	O
e.g.	NN	O
,	,	O
by	IN	O
electroporation	NN	O
)	)	O
and	CC	O
cells	NNS	O
in	IN	O
which	WDT	O
the	DT	O
introduced	VBN	O
DNA	NNP	O
has	VBZ	O
homologously	RB	O
recombined	VBN	O
with	IN	O
the	DT	O
endogenous	JJ	O
DNA	NN	O
are	VBP	O
selected	VBN	O
[	NNP	O
see	VBP	O
e.g.	RB	O
,	,	O
Li	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
,	,	I
69:915	CD	I
(	(	I
1992	CD	I
)	)	I
]	NN	O
.	.	O
The	DT	O
selected	VBN	O
cells	NNS	O
are	VBP	O
then	RB	O
injected	VBN	O
into	IN	O
a	DT	O
blastocyst	NN	O
of	IN	O
an	DT	O
animal	NN	O
(	(	O
e.g.	JJ	O
,	,	O
a	DT	O
mouse	NN	O
or	CC	O
rat	NN	O
)	)	O
to	TO	O
form	VB	O
aggregation	NN	O
chimeras	NNS	O
[	VBP	O
see	VB	O
e.g.	JJ	O
,	,	O
Bradley	NNP	B
,	,	I
in	IN	I
Teratocarcinomas	NNP	I
and	CC	I
Embryonic	NNP	I
Stem	NNP	I
Cells	NNP	I
:	:	I
A	DT	I
Practical	NNP	I
Approach	NNP	I
,	,	I
E.	NNP	I
J.	NNP	I
Robertson	NNP	I
,	,	I
ed	NN	I
.	.	I
(	(	I
IRL	NNP	I
,	,	I
Oxford	NNP	I
,	,	I
1987	CD	I
)	)	I
,	,	I
pp	NN	I
.	.	I
113-152	JJ	I
]	NN	O
.	.	O
A	DT	O
chimeric	JJ	O
embryo	NN	O
can	MD	O
then	RB	O
be	VB	O
implanted	VBN	O
into	IN	O
a	DT	O
suitable	JJ	O
pseudopregnant	JJ	O
female	NN	O
foster	NN	O
animal	NN	O
and	CC	O
the	DT	O
embryo	NN	O
brought	VBD	O
to	TO	O
term	NN	O
to	TO	O
create	VB	O
a	DT	O
“	JJ	O
knock	NN	O
out	RP	O
”	NNP	O
animal	NN	O
.	.	O
Progeny	NNP	O
harboring	VBG	O
the	DT	O
homologously	RB	O
recombined	VBN	O
DNA	NNP	O
in	IN	O
their	PRP$	O
germ	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
standard	JJ	O
techniques	NNS	O
and	CC	O
used	VBN	O
to	TO	O
breed	VB	O
animals	NNS	O
in	IN	O
which	WDT	O
all	DT	O
cells	NNS	O
of	IN	O
the	DT	O
animal	NN	O
contain	VBP	O
the	DT	O
homologously	RB	O
recombined	VBN	O
DNA	NNP	O
.	.	O
Knockout	IN	O
animals	NNS	O
can	MD	O
be	VB	O
characterized	VBN	O
for	IN	O
instance	NN	O
,	,	O
for	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
defend	VB	O
against	IN	O
certain	JJ	O
pathological	JJ	O
conditions	NNS	O
and	CC	O
for	IN	O
their	PRP$	O
development	NN	O
of	IN	O
pathological	JJ	O
conditions	NNS	O
due	JJ	O
to	TO	O
absence	NN	O
of	IN	O
the	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
knockout	IN	O
mice	NNS	O
can	MD	O
be	VB	O
highly	RB	O
informative	JJ	O
in	IN	O
the	DT	O
discovery	NN	O
of	IN	O
gene	NN	O
function	NN	O
and	CC	O
pharmaceutical	JJ	O
utility	NN	O
for	IN	O
a	DT	O
drug	NN	O
target	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
the	DT	O
determination	NN	O
of	IN	O
the	DT	O
potential	JJ	O
on-target	JJ	O
side	NN	O
effects	NNS	O
associated	VBN	O
with	IN	O
a	DT	O
given	VBN	O
target	NN	O
.	.	O
Gene	NNP	O
function	NN	O
and	CC	O
physiology	NN	O
are	VBP	O
so	RB	O
well	RB	O
conserved	VBN	O
between	IN	O
mice	NNS	O
and	CC	O
humans.	NN	O
,	,	O
since	IN	O
they	PRP	O
are	VBP	O
both	DT	O
mammals	NNS	O
and	CC	O
contain	VB	O
similar	JJ	O
numbers	NNS	O
of	IN	O
genes	NNS	O
,	,	O
which	WDT	O
are	VBP	O
highly	RB	O
conserved	VBN	O
between	IN	O
the	DT	O
species	NNS	O
.	.	O
It	PRP	O
has	VBZ	O
recently	RB	O
been	VBN	O
well	RB	O
documented	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
that	IN	O
98	CD	O
%	NN	O
of	IN	O
genes	NNS	O
on	IN	O
mouse	NN	O
chromosome	NN	O
16	CD	O
have	VBP	O
a	DT	O
human	JJ	O
ortholog	NN	O
(	(	O
Mural	NNP	B
et	RB	I
al.	RB	I
,	,	I
Science	NNP	I
296:1661-71	CD	I
(	(	I
2002	CD	I
)	)	I
)	)	O
.	.	O
Although	IN	O
gene	NN	O
targeting	VBG	O
in	IN	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
has	VBZ	O
enabled	VBN	O
the	DT	O
construction	NN	O
of	IN	O
mice	NN	O
with	IN	O
null	JJ	O
mutations	NNS	O
in	IN	O
many	JJ	O
genes	NNS	O
associated	VBN	O
with	IN	O
human	JJ	O
disease	NN	O
,	,	O
not	RB	O
all	DT	O
genetic	JJ	O
diseases	NNS	O
are	VBP	O
attributable	JJ	O
to	TO	O
null	JJ	O
mutations	NNS	O
.	.	O
One	CD	O
can	MD	O
design	VB	O
valuable	JJ	O
mouse	NN	O
models	NNS	O
of	IN	O
human	JJ	O
diseases	NNS	O
by	IN	O
establishing	VBG	O
a	DT	O
method	NN	O
for	IN	O
gene	NN	O
replacement	NN	O
(	(	O
knock-in	NN	O
)	)	O
which	WDT	O
will	MD	O
disrupt	VB	O
the	DT	O
mouse	NN	O
locus	NN	O
and	CC	O
introduce	VB	O
a	DT	O
human	JJ	O
counterpart	NN	O
with	IN	O
mutation	NN	O
,	,	O
Subsequently	RB	O
one	CD	O
can	MD	O
conduct	VB	O
in	IN	O
vivo	JJ	O
drug	NN	O
studies	NNS	O
targeting	VBG	O
the	DT	O
human	JJ	O
protein	NN	O
(	(	O
Kitamoto	NNP	B
et	RB	I
.	.	I
Al.	NNP	I
,	,	I
Biochemical	NNP	I
and	CC	I
Biophysical	NNP	I
Res	NNP	I
.	.	I
Commun.	NNP	I
,	,	I
222:742-47	CD	I
(	(	I
1996	CD	I
)	)	I
)	)	O
.	.	O
Nucleic	NNP	O
acid	NN	O
encoding	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
in	IN	O
gene	NN	O
therapy	NN	O
.	.	O
In	IN	O
gene	NN	O
therapy	NN	O
applications	NNS	O
,	,	O
genes	NNS	O
are	VBP	O
introduced	VBN	O
into	IN	O
cells	NNS	O
in	IN	O
order	NN	O
to	TO	O
achieve	VB	O
in	IN	O
vivo	JJ	O
synthesis	NN	O
of	IN	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
genetic	JJ	O
product	NN	O
,	,	O
for	IN	O
example	NN	O
for	IN	O
replacement	NN	O
of	IN	O
a	DT	O
defective	JJ	O
gene	NN	O
.	.	O
“	JJ	O
Gene	NNP	O
therapy	NN	O
”	NNP	O
includes	VBZ	O
both	DT	O
conventional	JJ	O
gene	NN	O
therapy	NN	O
where	WRB	O
a	DT	O
lasting	JJ	O
effect	NN	O
is	VBZ	O
achieved	VBN	O
by	IN	O
a	DT	O
single	JJ	O
treatment	NN	O
,	,	O
and	CC	O
the	DT	O
administration	NN	O
of	IN	O
gene	NN	O
therapeutic	JJ	O
agents	NNS	O
,	,	O
which	WDT	O
involves	VBZ	O
the	DT	O
one	CD	O
time	NN	O
or	CC	O
repeated	VBN	O
administration	NN	O
of	IN	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
DNA	NNP	O
or	CC	O
mRNA	NN	O
.	.	O
Antisense	NNP	O
RNAs	NNP	O
and	CC	O
DNAs	NNP	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
for	IN	O
blocking	VBG	O
the	DT	O
expression	NN	O
of	IN	O
certain	JJ	O
genes	NNS	O
in	IN	O
vivo	NN	O
.	.	O
It	PRP	O
has	VBZ	O
already	RB	O
been	VBN	O
shown	VBN	O
that	IN	O
short	JJ	O
antisense	NN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
imported	VBN	O
into	IN	O
cells	NNS	O
where	WRB	O
they	PRP	O
act	VBP	O
as	IN	O
inhibitors	NNS	O
,	,	O
despite	IN	O
their	PRP$	O
low	JJ	O
intracellular	JJ	O
concentrations	NNS	O
caused	VBN	O
by	IN	O
their	PRP$	O
restricted	VBN	O
uptake	NN	O
by	IN	O
the	DT	O
cell	NN	O
membrane	NN	O
.	.	O
(	(	O
Zamecnik	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
83:4143-4146	CD	I
[	NN	I
1986	CD	I
]	NN	I
)	)	O
.	.	O
The	DT	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
modified	VBN	O
to	TO	O
enhance	VB	O
their	PRP$	O
uptake	NN	O
,	,	O
e.g	NN	O
.	.	O
by	IN	O
substituting	VBG	O
their	PRP$	O
negatively	RB	O
charged	VBN	O
phosphodiester	NN	O
groups	NNS	O
by	IN	O
uncharged	JJ	O
groups	NNS	O
.	.	O
There	EX	O
are	VBP	O
a	DT	O
variety	NN	O
of	IN	O
techniques	NNS	O
available	JJ	O
for	IN	O
introducing	VBG	O
nucleic	JJ	O
acids	NNS	O
into	IN	O
viable	JJ	O
cells	NNS	O
.	.	O
The	DT	O
techniques	NNS	O
vary	VBP	O
depending	VBG	O
upon	IN	O
whether	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
transferred	VBN	O
into	IN	O
cultured	JJ	O
cells	NNS	O
in	IN	O
vitro	NN	O
,	,	O
or	CC	O
in	IN	O
vivo	NN	O
in	IN	O
the	DT	O
cells	NNS	O
of	IN	O
the	DT	O
intended	JJ	O
host	NN	O
.	.	O
Techniques	NNS	O
suitable	JJ	O
for	IN	O
the	DT	O
transfer	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
into	IN	O
mammalian	JJ	O
cells	NNS	O
in	IN	O
vitro	JJ	O
include	VBP	O
the	DT	O
use	NN	O
of	IN	O
liposomes	NNS	O
,	,	O
electroporation	NN	O
,	,	O
microinjection	NN	O
,	,	O
cell	NN	O
fusion	NN	O
,	,	O
DEAE-dextran	NNP	O
,	,	O
the	DT	O
calcium	NN	O
phosphate	NN	O
precipitation	NN	O
method	NN	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
currently	RB	O
preferred	VBN	O
in	IN	O
vivo	NN	O
gene	NN	O
transfer	NN	O
techniques	NNS	O
include	VBP	O
transfection	NN	O
with	IN	O
viral	JJ	O
(	(	O
typically	RB	O
retroviral	JJ	O
)	)	O
vectors	NNS	O
and	CC	O
viral	JJ	O
coat	NN	O
protein-liposome	NN	O
mediated	VBN	O
transfection	NN	O
(	(	O
Dzau	NNP	B
et	RB	I
al.	RB	I
,	,	I
Trends	NNS	I
in	IN	I
Biotechnology	NNP	I
11	CD	I
,	,	I
205-210	CD	I
[	NN	I
1993	CD	I
]	NN	I
)	)	O
.	.	O
In	IN	O
some	DT	O
situations	NNS	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
provide	VB	O
the	DT	O
nucleic	JJ	O
acid	NN	O
source	NN	O
with	IN	O
an	DT	O
agent	NN	O
that	WDT	O
targets	VBZ	O
the	DT	O
target	NN	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
antibody	NN	O
specific	NN	O
for	IN	O
a	DT	O
cell	NN	O
surface	NN	O
membrane	NN	O
protein	NN	O
or	CC	O
the	DT	O
target	NN	O
cell	NN	O
,	,	O
a	DT	O
ligand	NN	O
for	IN	O
a	DT	O
receptor	NN	O
on	IN	O
the	DT	O
target	NN	O
cell	NN	O
,	,	O
etc	FW	O
.	.	O
Where	WRB	O
liposomes	NNS	O
are	VBP	O
employed	VBN	O
,	,	O
proteins	VBZ	O
which	WDT	O
bind	NN	O
to	TO	O
a	DT	O
cell	NN	O
surface	NN	O
membrane	NN	O
protein	NN	O
associated	VBN	O
with	IN	O
endocytosis	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
targeting	VBG	O
and/or	NN	O
to	TO	O
facilitate	VB	O
uptake	NN	O
,	,	O
e.g	NN	O
.	.	O
capsid	NN	O
proteins	NNS	O
or	CC	O
fragments	NNS	O
thereof	VBP	O
tropic	NN	O
for	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
type	NN	O
,	,	O
antibodies	NNS	O
for	IN	O
proteins	NNS	O
which	WDT	O
undergo	VBP	O
internalization	NN	O
in	IN	O
cycling	NN	O
,	,	O
proteins	VBZ	O
that	IN	O
target	NN	O
intracellular	JJ	O
localization	NN	O
and	CC	O
enhance	VB	O
intracellular	JJ	O
half-life	NN	O
.	.	O
The	DT	O
technique	NN	O
of	IN	O
receptor-mediated	JJ	O
endocytosis	NN	O
is	VBZ	O
described	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
Wu	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
262	CD	I
,	,	I
4429-4432	CD	I
(	(	I
1987	CD	I
)	)	I
;	:	O
and	CC	O
Wagner	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
87	CD	I
,	,	I
3410-3414	CD	I
(	(	I
1990	CD	I
)	)	I
.	.	O
For	IN	O
review	NN	O
of	IN	O
gene	NN	O
marking	NN	O
and	CC	O
gene	NN	O
therapy	NN	O
protocols	NNS	O
see	VBP	O
Anderson	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
256	CD	I
,	,	I
808-813	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
described	VBD	O
herein	NN	O
may	MD	O
also	RB	O
be	VB	O
employed	VBN	O
as	IN	O
molecular	JJ	O
weight	NN	O
markers	NNS	O
for	IN	O
protein	JJ	O
electrophoresis	NN	O
purposes	NNS	O
and	CC	O
the	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	JJ	O
sequences	NNS	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
recombinantly	RB	O
expressing	VBG	O
those	DT	O
markers	NNS	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
or	CC	O
fragments	NNS	O
thereof	JJ	O
described	VBN	O
herein	NNS	O
are	VBP	O
useful	JJ	O
for	IN	O
chromosome	NN	O
identification	NN	O
.	.	O
In	IN	O
this	DT	O
regard	NN	O
,	,	O
there	EX	O
exists	VBZ	O
an	DT	O
ongoing	VBG	O
need	NN	O
to	TO	O
identify	VB	O
new	JJ	O
chromosome	NN	O
markers	NNS	O
,	,	O
since	IN	O
relatively	RB	O
few	JJ	O
chromosome	NN	O
marking	VBG	O
reagents	NNS	O
,	,	O
based	VBN	O
upon	IN	O
actual	JJ	O
sequence	NN	O
data	NNS	O
are	VBP	O
presently	RB	O
available	JJ	O
.	.	O
Each	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
chromosome	NN	O
marker	NN	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
and	CC	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
diagnostically	RB	O
for	IN	O
tissue	NN	O
typing	NN	O
,	,	O
wherein	VBP	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
differentially	RB	O
expressed	VBN	O
in	IN	O
one	CD	O
tissue	NN	O
as	IN	O
compared	VBN	O
to	TO	O
another	DT	O
,	,	O
preferably	RB	O
in	IN	O
a	DT	O
diseased	JJ	O
tissue	NN	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
normal	JJ	O
tissue	NN	O
of	IN	O
the	DT	O
same	JJ	O
tissue	NN	O
type	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
will	MD	O
find	VB	O
use	NN	O
for	IN	O
generating	VBG	O
probes	NNS	O
for	IN	O
PCR	NNP	O
,	,	O
Northern	NNP	O
analysis	NN	O
,	,	O
Southern	JJ	O
analysis	NN	O
and	CC	O
Western	JJ	O
analysis	NN	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
described	VBD	O
herein	NN	O
may	MD	O
also	RB	O
be	VB	O
employed	VBN	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
formulated	VBN	O
according	VBG	O
to	TO	O
known	VBN	O
methods	NNS	O
to	TO	O
prepare	VB	O
pharmaceutically	RB	O
useful	JJ	O
compositions	NNS	O
,	,	O
whereby	VBP	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
product	NN	O
hereof	NN	O
is	VBZ	O
combined	VBN	O
in	IN	O
admixture	NN	O
with	IN	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
vehicle	NN	O
.	.	O
Therapeutic	JJ	O
formulations	NNS	O
are	VBP	O
prepared	JJ	O
for	IN	O
storage	NN	O
by	IN	O
mixing	VBG	O
the	DT	O
active	JJ	O
ingredient	NN	O
having	VBG	O
the	DT	O
desired	JJ	O
degree	NN	O
of	IN	O
purity	NN	O
with	IN	O
optional	JJ	O
physiologically	RB	O
acceptable	JJ	O
carriers	NNS	O
,	,	O
excipients	NNS	O
or	CC	O
stabilizers	NNS	O
(	(	O
Remington	NNP	B
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
16th	CD	I
edition	NN	I
,	,	I
Osol	NNP	I
,	,	I
A.	NNP	I
Ed	NNP	I
.	.	I
(	(	I
1980	CD	I
)	)	I
)	)	O
,	,	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
lyophilized	JJ	O
formulations	NNS	O
or	CC	O
aqueous	JJ	O
solutions	NNS	O
.	.	O
Acceptable	JJ	O
carriers	NNS	O
,	,	O
excipients	NNS	O
or	CC	O
stabilizers	NNS	O
are	VBP	O
nontoxic	JJ	O
to	TO	O
recipients	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
and	CC	O
concentrations	NNS	O
employed	VBN	O
,	,	O
and	CC	O
include	VBP	O
buffers	NNS	O
such	JJ	O
as	IN	O
phosphate	NN	O
,	,	O
citrate	NN	O
and	CC	O
other	JJ	O
organic	JJ	O
acids	NNS	O
;	:	O
antioxidants	NNS	O
including	VBG	O
ascorbic	JJ	O
acid	NN	O
;	:	O
low	JJ	O
molecular	JJ	O
weight	NN	O
(	(	O
less	JJR	O
than	IN	O
about	RB	O
10	CD	O
residues	NNS	O
)	)	O
polypeptides	NNS	O
;	:	O
proteins	NNS	O
,	,	O
such	JJ	O
as	IN	O
serum	NN	O
albumin	NN	O
,	,	O
gelatin	NN	O
or	CC	O
immunoglobulins	NNS	O
;	:	O
hydrophilic	JJ	O
polymers	NNS	O
such	JJ	O
as	IN	O
polyvinylpyrrolidone	NN	O
,	,	O
amino	JJ	O
acids	NNS	O
such	JJ	O
as	IN	O
glycine	NN	O
,	,	O
glutamine	NN	O
,	,	O
asparagine	NN	O
,	,	O
arginine	NN	O
or	CC	O
lysine	NN	O
;	:	O
monosaccharides	NNS	O
,	,	O
disaccharides	NNS	O
and	CC	O
other	JJ	O
carbohydrates	NNS	O
including	VBG	O
glucose	NN	O
,	,	O
mannose	VB	O
,	,	O
or	CC	O
dextrins	NNS	O
;	:	O
chelating	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
EDTA	NNP	O
;	:	O
sugar	NN	O
alcohols	NNS	O
such	JJ	O
as	IN	O
mannitol	NN	O
or	CC	O
sorbitol	NN	O
;	:	O
salt-forming	JJ	O
counterions	NNS	O
such	JJ	O
as	IN	O
sodium	NN	O
;	:	O
and/or	CC	O
nonionic	JJ	O
surfactants	NNS	O
such	JJ	O
as	IN	O
TWEEN™	NNP	O
,	,	O
PLURONICS™	NNP	O
or	CC	O
PEG	NNP	O
.	.	O
The	DT	O
formulations	NNS	O
to	TO	O
be	VB	O
used	VBN	O
for	IN	O
in	IN	O
vivo	JJ	O
administration	NN	O
must	MD	O
be	VB	O
sterile	JJ	O
.	.	O
This	DT	O
is	VBZ	O
readily	RB	O
accomplished	VBN	O
by	IN	O
filtration	NN	O
through	IN	O
sterile	JJ	O
filtration	NN	O
membranes	NNS	O
,	,	O
prior	RB	O
to	TO	O
or	CC	O
following	VBG	O
lyophilization	NN	O
and	CC	O
reconstitution	NN	O
.	.	O
Therapeutic	JJ	O
compositions	NNS	O
herein	VBP	O
generally	RB	O
are	VBP	O
placed	VBN	O
into	IN	O
a	DT	O
container	NN	O
having	VBG	O
a	DT	O
sterile	JJ	O
access	NN	O
port	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
an	DT	O
intravenous	JJ	O
solution	NN	O
bag	NN	O
or	CC	O
vial	JJ	O
having	VBG	O
a	DT	O
stopper	NN	O
pierceable	NN	O
by	IN	O
a	DT	O
hypodermic	JJ	O
injection	NN	O
needle	NN	O
.	.	O
The	DT	O
route	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
in	IN	O
accord	NN	O
with	IN	O
known	VBN	O
methods	NNS	O
,	,	O
e.g	NN	O
.	.	O
injection	NN	O
or	CC	O
infusion	NN	O
by	IN	O
intravenous	JJ	O
,	,	O
intraperitoneal	JJ	O
,	,	O
intracerebral	JJ	O
,	,	O
intramuscular	JJ	O
,	,	O
intraocular	JJ	O
,	,	O
intraarterial	JJ	O
or	CC	O
intralesional	JJ	O
routes	NNS	O
,	,	O
topical	JJ	O
administration	NN	O
,	,	O
or	CC	O
by	IN	O
sustained	JJ	O
release	NN	O
systems	NNS	O
.	.	O
Dosages	NNS	O
and	CC	O
desired	VBN	O
drug	NN	O
concentrations	NNS	O
of	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
the	DT	O
particular	JJ	O
use	NN	O
envisioned	VBD	O
.	.	O
The	DT	O
determination	NN	O
of	IN	O
the	DT	O
appropriate	JJ	O
dosage	NN	O
or	CC	O
route	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
well	RB	O
within	IN	O
the	DT	O
skill	NN	O
of	IN	O
an	DT	O
ordinary	JJ	O
physician	NN	O
.	.	O
Animal	JJ	O
experiments	NNS	O
provide	VBP	O
reliable	JJ	O
guidance	NN	O
for	IN	O
the	DT	O
determination	NN	O
of	IN	O
effective	JJ	O
doses	NNS	O
for	IN	O
human	JJ	O
therapy	NN	O
.	.	O
Interspecies	NNS	O
scaling	VBG	O
of	IN	O
effective	JJ	O
doses	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
following	VBG	O
the	DT	O
principles	NNS	O
laid	VBD	O
down	RB	O
by	IN	O
Mordenti	NNP	B
,	,	I
J.	NNP	I
and	CC	I
Chappell	NNP	I
,	,	I
W.	NNP	I
“	VBZ	I
The	DT	I
use	NN	I
of	IN	I
interspecies	NNS	I
scaling	VBG	I
in	IN	I
toxicokinetics	NNS	I
”	VBP	I
In	IN	I
Toxicokinetics	NNP	I
and	CC	I
New	NNP	I
Drug	NNP	I
Development	NNP	I
,	,	I
Yacobi	NNP	I
et	FW	I
al.	NN	I
,	,	I
Eds.	NNP	I
,	,	I
Pergamon	NNP	I
Press	NNP	I
,	,	I
New	NNP	I
York	NNP	I
1989	CD	I
,	,	I
pp	NN	I
.	.	I
42-96	JJ	I
.	.	O
When	WRB	O
in	IN	O
vivo	JJ	O
administration	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
agonist	NN	O
or	CC	O
antagonist	NN	O
thereof	NN	O
is	VBZ	O
employed	VBN	O
,	,	O
normal	JJ	O
dosage	NN	O
amounts	NNS	O
may	MD	O
vary	VB	O
from	IN	O
about	RB	O
10	CD	O
ng/kg	NNS	O
to	TO	O
up	RB	O
to	TO	O
100	CD	O
mg/kg	NN	O
of	IN	O
mammal	JJ	O
body	NN	O
weight	VBD	O
or	CC	O
more	JJR	O
per	IN	O
day	NN	O
,	,	O
preferably	RB	O
about	IN	O
1	CD	O
μg/kg/day	NN	O
to	TO	O
10	CD	O
mg/kg/day	NN	O
,	,	O
depending	VBG	O
upon	IN	O
the	DT	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O
Guidance	NN	O
as	IN	O
to	TO	O
particular	JJ	O
dosages	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
delivery	NN	O
is	VBZ	O
provided	VBN	O
in	IN	O
the	DT	O
literature	NN	O
;	:	O
see	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,657,760	CD	O
;	:	O
5,206,344	CD	O
;	:	O
or	CC	O
5,225,212	CD	O
.	.	O
It	PRP	O
is	VBZ	O
anticipated	VBN	O
that	IN	O
different	JJ	O
formulations	NNS	O
will	MD	O
be	VB	O
effective	JJ	O
for	IN	O
different	JJ	O
treatment	NN	O
compounds	NNS	O
and	CC	O
different	JJ	O
disorders	NNS	O
,	,	O
that	DT	O
administration	NN	O
targeting	VBG	O
one	CD	O
organ	NN	O
or	CC	O
tissue	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
may	MD	O
necessitate	VB	O
delivery	NN	O
in	IN	O
a	DT	O
manner	NN	O
different	JJ	O
from	IN	O
that	DT	O
to	TO	O
another	DT	O
organ	NN	O
or	CC	O
tissue	NN	O
.	.	O
Where	WRB	O
sustained-release	JJ	O
administration	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
desired	VBN	O
in	IN	O
a	DT	O
formulation	NN	O
with	IN	O
release	NN	O
characteristics	NNS	O
suitable	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
any	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
requiring	VBG	O
administration	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
microencapsulation	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
contemplated	VBN	O
.	.	O
Microencapsulation	NN	O
of	IN	O
recombinant	JJ	O
proteins	NNS	O
for	IN	O
sustained	JJ	O
release	NN	O
has	VBZ	O
been	VBN	O
successfully	RB	O
performed	VBN	O
with	IN	O
human	JJ	O
growth	NN	O
hormone	NN	O
(	(	O
rhGH	NN	O
)	)	O
,	,	O
interferon-	JJ	O
(	(	O
rhIFN-	JJ	O
)	)	O
,	,	O
interleukin-2	JJ	O
,	,	O
and	CC	O
MN	NNP	O
rgp120	NN	O
.	.	O
Johnson	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Med.	NNP	I
,	,	I
2:795-799	CD	I
(	(	I
1996	CD	I
)	)	I
;	:	O
Yasuda	NNP	B
,	,	I
Biomed	NNP	I
.	.	I
Ther.	NNP	I
,	,	I
27:1221-1223	CD	I
(	(	I
1993	CD	I
)	)	I
;	:	O
Hora	NNP	B
et	FW	I
al.	NN	I
,	,	I
Bio/Technology	NNP	I
,	,	I
8:755-758	CD	I
(	(	I
1990	CD	I
)	)	I
;	:	O
Cleland	NNP	B
,	,	I
“	NNP	I
Design	NNP	I
and	CC	I
Production	NNP	I
of	IN	I
Single	NNP	I
Immunization	NNP	I
Vaccines	NNP	I
Using	NNP	I
Polylactide	NNP	I
Polyglycolide	NNP	I
Microsphere	NNP	I
Systems	NNP	I
,	,	I
”	NNP	I
in	IN	I
Vaccine	NNP	I
Design	NNP	I
:	:	I
The	DT	I
Subunit	NNP	I
and	CC	I
Adjuvant	NNP	I
Approach	NNP	I
,	,	I
Powell	NNP	I
and	CC	I
Newman	NNP	I
,	,	I
eds	NNS	I
,	,	I
(	(	I
Plenum	NNP	I
Press	NNP	I
:	:	I
New	NNP	I
York	NNP	I
,	,	I
1995	CD	I
)	)	I
,	,	I
pp	NN	I
.	.	I
439-462	JJ	I
;	:	O
WO	NNP	O
97/03692	CD	O
,	,	O
WO	NNP	O
96/40072	CD	O
,	,	O
WO	NNP	O
96/07399	CD	O
;	:	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,654,010	CD	O
.	.	O
The	DT	O
sustained-release	JJ	O
formulations	NNS	O
of	IN	O
these	DT	O
proteins	NNS	O
were	VBD	O
developed	VBN	O
using	VBG	O
poly-lactic-coglycolic	JJ	O
acid	NN	O
(	(	O
PLGA	NNP	O
)	)	O
polymer	NN	O
due	JJ	O
to	TO	O
its	PRP$	O
biocompatibility	NN	O
and	CC	O
wide	JJ	O
range	NN	O
of	IN	O
biodegradable	JJ	O
properties	NNS	O
.	.	O
The	DT	O
degradation	NN	O
products	NNS	O
of	IN	O
PLGA	NNP	O
,	,	O
lactic	JJ	O
and	CC	O
glycolic	JJ	O
acids	NNS	O
,	,	O
can	MD	O
be	VB	O
cleared	VBN	O
quickly	RB	O
within	IN	O
the	DT	O
human	JJ	O
body	NN	O
.	.	O
Moreover	RB	O
,	,	O
the	DT	O
degradability	NN	O
of	IN	O
this	DT	O
polymer	NN	O
can	MD	O
be	VB	O
adjusted	VBN	O
from	IN	O
months	NNS	O
to	TO	O
years	NNS	O
depending	VBG	O
on	IN	O
its	PRP$	O
molecular	JJ	O
weight	NN	O
and	CC	O
composition	NN	O
.	.	O
Lewis	NNP	B
,	,	I
“	NNP	I
Controlled	NNP	I
release	NN	I
of	IN	I
bioactive	JJ	I
agents	NNS	I
from	IN	I
lactide/glycolide	JJ	I
polymer	NN	I
,	,	I
”	NN	I
in	IN	I
:	:	I
M.	NNP	I
Chasin	NNP	I
and	CC	I
R.	NNP	I
Langer	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
Biodegradable	JJ	I
Polymers	NNPS	I
as	IN	I
Drug	NNP	I
Delivery	NNP	I
Systems	NNP	I
(	(	I
Marcel	NNP	I
Dekker	NNP	I
:	:	I
New	NNP	I
York	NNP	I
,	,	I
1990	CD	I
)	)	I
,	,	I
pp	NN	I
.	.	I
1-41	JJ	I
.	.	O
This	DT	O
invention	NN	O
encompasses	VBZ	O
methods	NNS	O
of	IN	O
screening	VBG	O
compounds	NNS	O
to	TO	O
identify	VB	O
those	DT	O
that	WDT	O
mimic	VBP	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
(	(	O
agonists	NNS	O
)	)	O
or	CC	O
prevent	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
(	(	O
antagonists	NNS	O
)	)	O
.	.	O
Agonists	NNS	O
that	WDT	O
mimic	VBP	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
would	MD	O
be	VB	O
especially	RB	O
valuable	JJ	O
therapeutically	RB	O
in	IN	O
those	DT	O
instances	NNS	O
where	WRB	O
a	DT	O
negative	JJ	O
phenotype	NN	O
is	VBZ	O
observed	VBN	O
based	VBN	O
on	IN	O
findings	NNS	O
with	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Antagonists	NNS	O
that	WDT	O
prevent	VBP	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
would	MD	O
be	VB	O
especially	RB	O
valuable	JJ	O
therapeutically	RB	O
in	IN	O
those	DT	O
instances	NNS	O
where	WRB	O
a	DT	O
positive	JJ	O
phenotype	NN	O
is	VBZ	O
observed	VBN	O
based	VBN	O
upon	IN	O
observations	NNS	O
with	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
knockout	NN	O
animal	NN	O
.	.	O
Screening	VBG	O
assays	NNS	O
for	IN	O
antagonist	JJ	O
drug	NN	O
candidates	NNS	O
are	VBP	O
designed	VBN	O
to	TO	O
identify	VB	O
compounds	NNS	O
that	WDT	O
bind	VBP	O
or	CC	O
complex	JJ	O
with	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
encoded	VBD	O
by	IN	O
the	DT	O
genes	NNS	O
identified	VBN	O
herein	NN	O
,	,	O
or	CC	O
otherwise	RB	O
interfere	RB	O
with	IN	O
the	DT	O
interaction	NN	O
of	IN	O
the	DT	O
encoded	JJ	O
polypeptide	NN	O
with	IN	O
other	JJ	O
cellular	JJ	O
proteins	NNS	O
.	.	O
Such	JJ	O
screening	NN	O
assays	NNS	O
will	MD	O
include	VB	O
assays	NNS	O
amenable	JJ	O
to	TO	O
high-throughput	JJ	O
screening	NN	O
of	IN	O
chemical	NN	O
libraries	NNS	O
,	,	O
making	VBG	O
them	PRP	O
particularly	RB	O
suitable	JJ	O
for	IN	O
identifying	VBG	O
small	JJ	O
molecule	JJ	O
drug	NN	O
candidates	NNS	O
.	.	O
The	DT	O
assays	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
formats	NNS	O
,	,	O
including	VBG	O
protein-protein	JJ	O
binding	NN	O
assays	NNS	O
,	,	O
biochemical	JJ	O
screening	NN	O
assays	NNS	O
,	,	O
immunoassays	NNS	O
,	,	O
and	CC	O
cell-based	JJ	O
assays	NNS	O
,	,	O
which	WDT	O
are	VBP	O
well	RB	O
characterized	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
All	DT	O
assays	NNS	O
for	IN	O
antagonists	NNS	O
are	VBP	O
common	JJ	O
in	IN	O
that	DT	O
they	PRP	O
call	VBP	O
for	IN	O
contacting	VBG	O
the	DT	O
drug	NN	O
candidate	NN	O
with	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
encoded	VBD	O
by	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
identified	VBN	O
herein	JJ	O
under	IN	O
conditions	NNS	O
and	CC	O
for	IN	O
a	DT	O
time	NN	O
sufficient	NN	O
to	TO	O
allow	VB	O
these	DT	O
two	CD	O
components	NNS	O
to	TO	O
interact	VB	O
.	.	O
In	IN	O
binding	VBG	O
assays	NNS	O
,	,	O
the	DT	O
interaction	NN	O
is	VBZ	O
binding	VBG	O
and	CC	O
the	DT	O
complex	NN	O
formed	VBD	O
can	MD	O
be	VB	O
isolated	VBN	O
or	CC	O
detected	VBN	O
in	IN	O
the	DT	O
reaction	NN	O
mixture	NN	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
encoded	VBD	O
by	IN	O
the	DT	O
gene	NN	O
identified	VBD	O
herein	CD	O
or	CC	O
the	DT	O
drug	NN	O
candidate	NN	O
is	VBZ	O
immobilized	VBN	O
on	IN	O
a	DT	O
solid	JJ	O
phase	NN	O
,	,	O
e.g.	NN	O
,	,	O
on	IN	O
a	DT	O
microtiter	NN	O
plate	NN	O
,	,	O
by	IN	O
covalent	NN	O
or	CC	O
non-covalent	JJ	O
attachments	NNS	O
.	.	O
Non-covalent	JJ	O
attachment	NN	O
generally	RB	O
is	VBZ	O
accomplished	VBN	O
by	IN	O
coating	VBG	O
the	DT	O
solid	JJ	O
surface	NN	O
with	IN	O
a	DT	O
solution	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
drying	NN	O
.	.	O
Alternatively	RB	O
,	,	O
an	DT	O
immobilized	JJ	O
antibody	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
,	,	O
specific	NN	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
to	TO	O
be	VB	O
immobilized	VBN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
anchor	VB	O
it	PRP	O
to	TO	O
a	DT	O
solid	JJ	O
surface	NN	O
.	.	O
The	DT	O
assay	NN	O
is	VBZ	O
performed	VBN	O
by	IN	O
adding	VBG	O
the	DT	O
non-immobilized	JJ	O
component	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
labeled	VBN	O
by	IN	O
a	DT	O
detectable	JJ	O
label	NN	O
,	,	O
to	TO	O
the	DT	O
immobilized	JJ	O
component	NN	O
,	,	O
e.g.	NN	O
,	,	O
the	DT	O
coated	JJ	O
surface	NN	O
containing	VBG	O
the	DT	O
anchored	JJ	O
component	NN	O
.	.	O
When	WRB	O
the	DT	O
reaction	NN	O
is	VBZ	O
complete	JJ	O
,	,	O
the	DT	O
non-reacted	JJ	O
components	NNS	O
are	VBP	O
removed	VBN	O
,	,	O
e.g.	NN	O
,	,	O
by	IN	O
washing	VBG	O
,	,	O
and	CC	O
complexes	NNS	O
anchored	VBN	O
on	IN	O
the	DT	O
solid	JJ	O
surface	NN	O
are	VBP	O
detected	VBN	O
.	.	O
When	WRB	O
the	DT	O
originally	RB	O
non-immobilized	JJ	O
component	NN	O
carries	VBZ	O
a	DT	O
detectable	JJ	O
label	NN	O
,	,	O
the	DT	O
detection	NN	O
of	IN	O
label	NN	O
immobilized	VBN	O
on	IN	O
the	DT	O
surface	NN	O
indicates	VBZ	O
that	IN	O
complexing	VBG	O
occurred	VBD	O
.	.	O
Where	WRB	O
the	DT	O
originally	RB	O
non-immobilized	JJ	O
component	NN	O
does	VBZ	O
not	RB	O
carry	VB	O
a	DT	O
label	NN	O
,	,	O
complexing	VBG	O
can	MD	O
be	VB	O
detected	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
using	VBG	O
a	DT	O
labeled	VBN	O
antibody	NN	O
specifically	RB	O
binding	VBG	O
the	DT	O
immobilized	JJ	O
complex	NN	O
.	.	O
If	IN	O
the	DT	O
candidate	NN	O
compound	NN	O
interacts	VBZ	O
with	IN	O
but	CC	O
does	VBZ	O
not	RB	O
bind	VB	O
to	TO	O
a	DT	O
particular	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
encoded	VBD	O
by	IN	O
a	DT	O
gene	NN	O
identified	VBN	O
herein	CD	O
,	,	O
its	PRP$	O
interaction	NN	O
with	IN	O
that	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
assayed	VBN	O
by	IN	O
methods	NNS	O
well	RB	O
known	VBN	O
for	IN	O
detecting	VBG	O
protein-protein	JJ	O
interactions	NNS	O
.	.	O
Such	JJ	O
assays	NNS	O
include	VBP	O
traditional	JJ	O
approaches	NNS	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
e.g.	UH	O
,	,	O
cross-linking	JJ	O
,	,	O
co-immunoprecipitation	NN	O
,	,	O
and	CC	O
co-purification	NN	O
through	IN	O
gradients	NNS	O
or	CC	O
chromatographic	JJ	O
columns	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
protein-protein	JJ	O
interactions	NNS	O
can	MD	O
be	VB	O
monitored	VBN	O
by	IN	O
using	VBG	O
a	DT	O
yeast-based	JJ	O
genetic	JJ	O
system	NN	O
described	VBN	O
by	IN	O
Fields	NNS	B
and	CC	I
co-workers	NNS	I
(	(	I
Fields	NNS	I
and	CC	I
Song	NNP	I
,	,	I
Nature	NNP	I
(	(	I
London	NNP	I
)	)	I
,	,	I
340:245-246	JJ	I
(	(	I
1989	CD	I
)	)	I
;	:	O
Chien	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
88:9578-9582	CD	I
(	(	I
1991	CD	I
)	)	I
)	)	O
as	IN	O
disclosed	VBN	O
by	IN	O
Chevray	NNP	B
and	CC	I
Nathans	NNPS	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
89	CD	I
:	:	I
5789-5793	JJ	I
(	(	I
1991	CD	I
)	)	I
.	.	O
Many	JJ	O
transcriptional	JJ	O
activators	NNS	O
,	,	O
such	JJ	O
as	IN	O
yeast	NN	O
GAL4	NNP	O
,	,	O
consist	NN	O
of	IN	O
two	CD	O
physically	RB	O
discrete	JJ	O
modular	NN	O
domains	NNS	O
,	,	O
one	CD	O
acting	NN	O
as	IN	O
the	DT	O
DNA-binding	NNP	O
domain	NN	O
,	,	O
the	DT	O
other	JJ	O
one	CD	O
functioning	NN	O
as	IN	O
the	DT	O
transcription-activation	NN	O
domain	NN	O
.	.	O
The	DT	O
yeast	JJS	O
expression	NN	O
system	NN	O
described	VBN	O
in	IN	O
the	DT	O
foregoing	NN	O
publications	NNS	O
(	(	O
generally	RB	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
“	NNP	O
two-hybrid	JJ	O
system	NN	O
”	NNP	O
)	)	O
takes	VBZ	O
advantage	NN	O
of	IN	O
this	DT	O
property	NN	O
,	,	O
and	CC	O
employs	VBZ	O
two	CD	O
hybrid	JJ	O
proteins	NNS	O
,	,	O
one	CD	O
in	IN	O
which	WDT	O
the	DT	O
target	NN	O
protein	NN	O
is	VBZ	O
fused	VBN	O
to	TO	O
the	DT	O
DNA-binding	NNP	O
domain	NN	O
of	IN	O
GAL4	NNP	O
,	,	O
and	CC	O
another	DT	O
,	,	O
in	IN	O
which	WDT	O
candidate	NN	O
activating	NN	O
proteins	NNS	O
are	VBP	O
fused	VBN	O
to	TO	O
the	DT	O
activation	NN	O
domain	NN	O
.	.	O
The	DT	O
expression	NN	O
of	IN	O
a	DT	O
GAL1-lacZ	NNP	O
reporter	NN	O
gene	NN	O
under	IN	O
control	NN	O
of	IN	O
a	DT	O
GAL4-activated	JJ	O
promoter	NN	O
depends	VBZ	O
on	IN	O
reconstitution	NN	O
of	IN	O
GAL4	NNP	O
activity	NN	O
via	IN	O
protein-protein	JJ	O
interaction	NN	O
.	.	O
Colonies	NNS	O
containing	VBG	O
interacting	VBG	O
polypeptides	NNS	O
are	VBP	O
detected	VBN	O
with	IN	O
a	DT	O
chromogenic	JJ	O
substrate	NN	O
for	IN	O
β-galactosidase	NN	O
.	.	O
A	DT	O
complete	JJ	O
kit	NN	O
(	(	O
MATCHMAKER™	NNP	O
)	)	O
for	IN	O
identifying	VBG	O
protein-protein	JJ	O
interactions	NNS	O
between	IN	O
two	CD	O
specific	JJ	O
proteins	NNS	O
using	VBG	O
the	DT	O
two-hybrid	JJ	O
technique	NN	O
is	VBZ	O
commercially	RB	O
available	JJ	O
from	IN	O
Clontech	NNP	O
.	.	O
This	DT	O
system	NN	O
can	MD	O
also	RB	O
be	VB	O
extended	VBN	O
to	TO	O
map	VB	O
protein	NN	O
domains	NNS	O
involved	VBN	O
in	IN	O
specific	JJ	O
protein	NN	O
interactions	NNS	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
pinpoint	VB	O
amino	NN	O
acid	NN	O
residues	NNS	O
that	WDT	O
are	VBP	O
crucial	JJ	O
for	IN	O
these	DT	O
interactions	NNS	O
.	.	O
Compounds	NNS	O
that	WDT	O
interfere	VBP	O
with	IN	O
the	DT	O
interaction	NN	O
of	IN	O
a	DT	O
gene	NN	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
identified	VBD	O
herein	NN	O
and	CC	O
other	JJ	O
intra-	JJ	O
or	CC	O
extracellular	JJ	O
components	NNS	O
can	MD	O
be	VB	O
tested	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
usually	RB	O
a	DT	O
reaction	NN	O
mixture	NN	O
is	VBZ	O
prepared	JJ	O
containing	VBG	O
the	DT	O
product	NN	O
of	IN	O
the	DT	O
gene	NN	O
and	CC	O
the	DT	O
intra-	JJ	O
or	CC	O
extracellular	JJ	O
component	NN	O
under	IN	O
conditions	NNS	O
and	CC	O
for	IN	O
a	DT	O
time	NN	O
allowing	VBG	O
for	IN	O
the	DT	O
interaction	NN	O
and	CC	O
binding	NN	O
of	IN	O
the	DT	O
two	CD	O
products	NNS	O
.	.	O
To	TO	O
test	VB	O
the	DT	O
ability	NN	O
of	IN	O
a	DT	O
candidate	NN	O
compound	NN	O
to	TO	O
inhibit	VB	O
binding	NN	O
,	,	O
the	DT	O
reaction	NN	O
is	VBZ	O
run	VBN	O
in	IN	O
the	DT	O
absence	NN	O
and	CC	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
test	NN	O
compound	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
a	DT	O
placebo	NN	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
a	DT	O
third	JJ	O
reaction	NN	O
mixture	NN	O
,	,	O
to	TO	O
serve	VB	O
as	IN	O
positive	JJ	O
control	NN	O
.	.	O
The	DT	O
binding	NN	O
(	(	O
complex	JJ	O
formation	NN	O
)	)	O
between	IN	O
the	DT	O
test	NN	O
compound	NN	O
and	CC	O
the	DT	O
intra-	JJ	O
or	CC	O
extracellular	JJ	O
component	NN	O
present	NN	O
in	IN	O
the	DT	O
mixture	NN	O
is	VBZ	O
monitored	VBN	O
as	IN	O
described	JJ	O
hereinabove	NN	O
.	.	O
The	DT	O
formation	NN	O
of	IN	O
a	DT	O
complex	NN	O
in	IN	O
the	DT	O
control	NN	O
reaction	NN	O
(	(	O
s	JJ	O
)	)	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
reaction	NN	O
mixture	NN	O
containing	VBG	O
the	DT	O
test	NN	O
compound	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
test	NN	O
compound	NN	O
interferes	VBZ	O
with	IN	O
the	DT	O
interaction	NN	O
of	IN	O
the	DT	O
test	NN	O
compound	NN	O
and	CC	O
its	PRP$	O
reaction	NN	O
partner	NN	O
.	.	O
To	TO	O
assay	VB	O
for	IN	O
antagonists	NNS	O
,	,	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
a	DT	O
cell	NN	O
along	IN	O
with	IN	O
the	DT	O
compound	NN	O
to	TO	O
be	VB	O
screened	VBN	O
for	IN	O
a	DT	O
particular	JJ	O
activity	NN	O
and	CC	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
compound	NN	O
to	TO	O
inhibit	VB	O
the	DT	O
activity	NN	O
of	IN	O
interest	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
indicates	VBZ	O
that	IN	O
the	DT	O
compound	NN	O
is	VBZ	O
an	DT	O
antagonist	NN	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Alternatively	RB	O
,	,	O
antagonists	NNS	O
may	MD	O
be	VB	O
detected	VBN	O
by	IN	O
combining	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
a	DT	O
potential	JJ	O
antagonist	NN	O
with	IN	O
membrane-bound	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
receptors	NNS	O
or	CC	O
recombinant	JJ	O
receptors	NNS	O
under	IN	O
appropriate	JJ	O
conditions	NNS	O
for	IN	O
a	DT	O
competitive	JJ	O
inhibition	NN	O
assay	NN	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
can	MD	O
be	VB	O
labeled	VBN	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
radioactivity	NN	O
,	,	O
such	JJ	O
that	IN	O
the	DT	O
number	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
molecules	NNS	O
bound	IN	O
to	TO	O
the	DT	O
receptor	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
potential	JJ	O
antagonist	NN	O
.	.	O
The	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
receptor	NN	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
numerous	JJ	O
methods	NNS	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
ligand	VBP	O
panning	VBG	O
and	CC	O
FACS	NNP	O
sorting	NN	O
.	.	O
Coligan	NNP	B
et	CC	I
al.	RB	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Immun.	NNP	I
,	,	I
1	CD	I
(	(	I
2	CD	I
)	)	I
:	:	I
Chapter	NN	I
5	CD	I
(	(	I
1991	CD	I
)	)	I
.	.	O
Preferably	RB	O
,	,	O
expression	NN	O
cloning	NN	O
is	VBZ	O
employed	VBN	O
wherein	RB	O
polyadenylated	JJ	O
RNA	NNP	O
is	VBZ	O
prepared	VBN	O
from	IN	O
a	DT	O
cell	NN	O
responsive	NN	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
a	DT	O
cDNA	NN	O
library	NN	O
created	VBD	O
from	IN	O
this	DT	O
RNA	NNP	O
is	VBZ	O
divided	VBN	O
into	IN	O
pools	NNS	O
and	CC	O
used	VBN	O
to	TO	O
transfect	VB	O
COS	NNP	O
cells	NNS	O
or	CC	O
other	JJ	O
cells	NNS	O
that	WDT	O
are	VBP	O
not	RB	O
responsive	JJ	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Transfected	VBN	O
cells	NNS	O
that	WDT	O
are	VBP	O
grown	VBN	O
on	IN	O
glass	NN	O
slides	NNS	O
are	VBP	O
exposed	VBN	O
to	TO	O
labeled	VBN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
can	MD	O
be	VB	O
labeled	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
means	NNS	O
including	VBG	O
iodination	NN	O
or	CC	O
inclusion	NN	O
of	IN	O
a	DT	O
recognition	NN	O
site	NN	O
for	IN	O
a	DT	O
site-specific	JJ	O
protein	NN	O
kinase	NN	O
.	.	O
Following	VBG	O
fixation	NN	O
and	CC	O
incubation	NN	O
,	,	O
the	DT	O
slides	NNS	O
are	VBP	O
subjected	VBN	O
to	TO	O
autoradiographic	JJ	O
analysis	NN	O
.	.	O
Positive	JJ	O
pools	NNS	O
are	VBP	O
identified	VBN	O
and	CC	O
sub-pools	NNS	O
are	VBP	O
prepared	JJ	O
and	CC	O
re-transfected	JJ	O
using	VBG	O
an	DT	O
interactive	JJ	O
sub-pooling	NN	O
and	CC	O
re-screening	JJ	O
process	NN	O
,	,	O
eventually	RB	O
yielding	VBG	O
a	DT	O
single	JJ	O
clone	NN	O
that	WDT	O
encodes	VBZ	O
the	DT	O
putative	JJ	O
receptor	NN	O
.	.	O
As	IN	O
an	DT	O
alternative	JJ	O
approach	NN	O
for	IN	O
receptor	NN	O
identification	NN	O
,	,	O
the	DT	O
labeled	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
can	MD	O
be	VB	O
photoaffinity-linked	JJ	O
with	IN	O
cell	NN	O
membrane	NN	O
or	CC	O
extract	JJ	O
preparations	NNS	O
that	WDT	O
express	VBP	O
the	DT	O
receptor	NN	O
molecule	NN	O
.	.	O
Cross-linked	JJ	O
material	NN	O
is	VBZ	O
resolved	VBN	O
by	IN	O
PAGE	NNP	O
and	CC	O
exposed	VBN	O
to	TO	O
X-ray	JJ	O
film	NN	O
.	.	O
The	DT	O
labeled	VBN	O
complex	NN	O
containing	VBG	O
the	DT	O
receptor	NN	O
can	MD	O
be	VB	O
excised	VBN	O
,	,	O
resolved	VBN	O
into	IN	O
peptide	NN	O
fragments	NNS	O
,	,	O
and	CC	O
subjected	VBN	O
to	TO	O
protein	VB	O
micro-sequencing	NN	O
.	.	O
The	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
obtained	VBN	O
from	IN	O
micro-sequencing	NN	O
would	MD	O
be	VB	O
used	VBN	O
to	TO	O
design	VB	O
a	DT	O
set	NN	O
of	IN	O
degenerate	JJ	O
oligonucleotide	NN	O
probes	NNS	O
to	TO	O
screen	VB	O
a	DT	O
cDNA	NN	O
library	NN	O
to	TO	O
identify	VB	O
the	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
putative	JJ	O
receptor	NN	O
.	.	O
Another	DT	O
approach	NN	O
in	IN	O
assessing	VBG	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
antagonist	NN	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
would	MD	O
be	VB	O
administering	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
antagonist	VBP	O
to	TO	O
a	DT	O
wild-type	JJ	O
mouse	NN	O
in	IN	O
order	NN	O
to	TO	O
mimic	VB	O
a	DT	O
known	VBN	O
knockout	NN	O
phenotype	NN	O
.	.	O
Thus	RB	O
,	,	O
one	CD	O
would	MD	O
initially	RB	O
knockout	VB	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
of	IN	O
interest	NN	O
and	CC	O
observe	VB	O
the	DT	O
resultant	JJ	O
phenotype	NN	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
knocking	VBG	O
out	RP	O
or	CC	O
disrupting	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
.	.	O
Subsequently	RB	O
,	,	O
one	CD	O
could	MD	O
then	RB	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
antagonist	NN	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
by	IN	O
administering	VBG	O
an	DT	O
antagonist	NN	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
to	TO	O
a	DT	O
wild-type	JJ	O
mouse	NN	O
.	.	O
An	DT	O
effective	JJ	O
antagonist	NN	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
mimic	VB	O
the	DT	O
phenotypic	NN	O
effect	NN	O
that	WDT	O
was	VBD	O
initially	RB	O
observed	VBN	O
in	IN	O
the	DT	O
knockout	NN	O
animal	NN	O
.	.	O
Likewise	RB	O
,	,	O
one	CD	O
could	MD	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
agonist	NN	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
by	IN	O
administering	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
agonist	VBP	O
to	TO	O
a	DT	O
non-human	JJ	O
transgenic	NN	O
mouse	NN	O
in	IN	O
order	NN	O
to	TO	O
ameliorate	VB	O
a	DT	O
known	JJ	O
negative	JJ	O
knockout	NN	O
phenotype	NN	O
.	.	O
Thus	RB	O
,	,	O
one	CD	O
would	MD	O
initially	RB	O
knockout	VB	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
of	IN	O
interest	NN	O
and	CC	O
observe	VB	O
the	DT	O
resultant	JJ	O
phenotype	NN	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
knocking	VBG	O
out	RP	O
or	CC	O
disrupting	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
gene	NN	O
.	.	O
Subsequently	RB	O
,	,	O
one	CD	O
could	MD	O
then	RB	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
agonist	NN	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
by	IN	O
administering	VBG	O
an	DT	O
agonist	NN	O
to	TO	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
to	TO	O
a	DT	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
mouse	NN	O
.	.	O
An	DT	O
effective	JJ	O
agonist	NN	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
ameliorate	VB	O
the	DT	O
negative	JJ	O
phenotypic	NN	O
effect	NN	O
that	WDT	O
was	VBD	O
initially	RB	O
observed	VBN	O
in	IN	O
the	DT	O
knockout	NN	O
animal	NN	O
In	IN	O
another	DT	O
assay	NN	O
for	IN	O
antagonists	NNS	O
,	,	O
mammalian	JJ	O
cells	NNS	O
or	CC	O
a	DT	O
membrane	JJ	O
preparation	NN	O
expressing	VBG	O
the	DT	O
receptor	NN	O
would	MD	O
be	VB	O
incubated	VBN	O
with	IN	O
a	DT	O
labeled	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
candidate	NN	O
compound	NN	O
.	.	O
The	DT	O
ability	NN	O
of	IN	O
the	DT	O
compound	NN	O
to	TO	O
enhance	VB	O
or	CC	O
block	VB	O
this	DT	O
interaction	NN	O
could	MD	O
then	RB	O
be	VB	O
measured	VBN	O
.	.	O
More	RBR	O
specific	JJ	O
examples	NNS	O
of	IN	O
potential	JJ	O
antagonists	NNS	O
include	VBP	O
an	DT	O
oligonucleotide	NN	O
that	WDT	O
binds	VBZ	O
to	TO	O
the	DT	O
fusions	NNS	O
of	IN	O
immunoglobulin	NN	O
with	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
and	CC	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
antibodies	NNS	O
including	VBG	O
,	,	O
without	IN	O
limitation	NN	O
,	,	O
poly-	JJ	O
and	CC	O
monoclonal	JJ	O
antibodies	NNS	O
and	CC	O
antibody	NN	O
fragments	NNS	O
,	,	O
single-chain	JJ	O
antibodies	NNS	O
,	,	O
anti-idiotypic	JJ	O
antibodies	NNS	O
,	,	O
and	CC	O
chimeric	NN	O
or	CC	O
humanized	JJ	O
versions	NNS	O
of	IN	O
such	JJ	O
antibodies	NNS	O
or	CC	O
fragments	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
human	JJ	O
antibodies	NNS	O
and	CC	O
antibody	NN	O
fragments	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
a	DT	O
potential	JJ	O
antagonist	NN	O
may	MD	O
be	VB	O
a	DT	O
closely	RB	O
related	JJ	O
protein	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
mutated	JJ	O
form	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
that	WDT	O
recognizes	VBZ	O
the	DT	O
receptor	NN	O
but	CC	O
imparts	VBZ	O
no	DT	O
effect	NN	O
,	,	O
thereby	RB	O
competitively	RB	O
inhibiting	VBG	O
the	DT	O
action	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Another	DT	O
potential	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
antagonist	NN	O
is	VBZ	O
an	DT	O
antisense	JJ	O
RNA	NNP	O
or	CC	O
DNA	NNP	O
construct	NN	O
prepared	VBD	O
using	VBG	O
antisense	JJ	O
technology	NN	O
,	,	O
where	WRB	O
,	,	O
e.g.	NN	O
,	,	O
an	DT	O
antisense	JJ	O
RNA	NNP	O
or	CC	O
DNA	NNP	O
molecule	NN	O
acts	NNS	O
to	TO	O
block	VB	O
directly	RB	O
the	DT	O
translation	NN	O
of	IN	O
mRNA	NN	O
by	IN	O
hybridizing	VBG	O
to	TO	O
targeted	VBN	O
mRNA	NN	O
and	CC	O
preventing	VBG	O
protein	JJ	O
translation	NN	O
.	.	O
Antisense	NNP	O
technology	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
control	VB	O
gene	NN	O
expression	NN	O
through	IN	O
triple-helix	JJ	O
formation	NN	O
or	CC	O
antisense	JJ	O
DNA	NN	O
or	CC	O
RNA	NNP	O
,	,	O
both	DT	O
of	IN	O
which	WDT	O
methods	NNS	O
are	VBP	O
based	VBN	O
on	IN	O
binding	NN	O
of	IN	O
a	DT	O
polynucleotide	NN	O
to	TO	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
5′	CD	O
coding	VBG	O
portion	NN	O
of	IN	O
the	DT	O
polynucleotide	NN	O
sequence	NN	O
,	,	O
which	WDT	O
encodes	VBZ	O
the	DT	O
mature	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
herein	NN	O
,	,	O
is	VBZ	O
used	VBN	O
to	TO	O
design	VB	O
an	DT	O
antisense	NN	O
RNA	NNP	O
oligonucleotide	NN	O
of	IN	O
from	IN	O
about	IN	O
10	CD	O
to	TO	O
40	CD	O
base	NN	O
pairs	NNS	O
in	IN	O
length	NN	O
.	.	O
A	DT	O
DNA	NNP	O
oligonucleotide	NN	O
is	VBZ	O
designed	VBN	O
to	TO	O
be	VB	O
complementary	JJ	O
to	TO	O
a	DT	O
region	NN	O
of	IN	O
the	DT	O
gene	NN	O
involved	VBN	O
in	IN	O
transcription	NN	O
(	(	O
triple	JJ	O
helix—see	NN	O
Lee	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nucl	NNP	I
.	.	I
Acids	NNP	I
Res.	NNP	I
,	,	I
6:3073	CD	I
(	(	I
1979	CD	I
)	)	I
;	:	O
Cooney	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
241	CD	I
:	:	I
456	CD	I
(	(	I
1988	CD	I
)	)	I
;	:	O
Dervan	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
251:1360	CD	I
(	(	I
1991	CD	I
)	)	I
)	)	O
,	,	O
thereby	RB	O
preventing	VBG	O
transcription	NN	O
and	CC	O
the	DT	O
production	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
The	DT	O
antisense	NN	O
RNA	NNP	O
oligonucleotide	RB	O
hybridizes	VBZ	O
to	TO	O
the	DT	O
mRNA	NN	O
in	IN	O
vivo	NN	O
and	CC	O
blocks	NNS	O
translation	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
molecule	NN	O
into	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
(	(	O
antisense—Okano	NN	B
,	,	I
Neurochem.	NNP	I
,	,	I
56:560	CD	I
(	(	I
1991	CD	I
)	)	I
;	:	O
Oligodeoxynucleotides	CC	B
as	IN	I
Antisense	NNP	I
Inhibitors	NNP	I
of	IN	I
Gene	NNP	I
Expression	NNP	I
(	(	I
CRC	NNP	I
Press	NNP	I
:	:	I
Boca	NNP	I
Raton	NNP	I
,	,	I
Fla.	NNP	I
,	,	I
1988	CD	I
)	)	I
.	.	O
The	DT	O
oligonucleotides	NNS	O
described	VBN	O
above	IN	O
can	MD	O
also	RB	O
be	VB	O
delivered	VBN	O
to	TO	O
cells	NNS	O
such	JJ	O
that	IN	O
the	DT	O
antisense	NN	O
RNA	NNP	O
or	CC	O
DNA	NNP	O
may	MD	O
be	VB	O
expressed	VBN	O
in	IN	O
vivo	NN	O
to	TO	O
inhibit	VB	O
production	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
When	WRB	O
antisense	NN	O
DNA	NN	O
is	VBZ	O
used	VBN	O
,	,	O
oligodeoxyribonucleotides	VBZ	O
derived	VBN	O
from	IN	O
the	DT	O
translation-initiation	NN	O
site	NN	O
,	,	O
e.g.	NN	O
,	,	O
between	IN	O
about	IN	O
−10	NNP	O
and	CC	O
+10	NNP	O
positions	NNS	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
nucleotide	JJ	O
sequence	NN	O
,	,	O
are	VBP	O
preferred	VBN	O
.	.	O
Potential	JJ	O
antagonists	NNS	O
include	VBP	O
small	JJ	O
molecules	NNS	O
that	WDT	O
bind	VBP	O
to	TO	O
the	DT	O
active	JJ	O
site	NN	O
,	,	O
the	DT	O
receptor	NN	O
binding	VBG	O
site	NN	O
,	,	O
or	CC	O
growth	NN	O
factor	NN	O
or	CC	O
other	JJ	O
relevant	JJ	O
binding	VBG	O
site	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
thereby	RB	O
blocking	VBG	O
the	DT	O
normal	JJ	O
biological	JJ	O
activity	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Examples	NNS	O
of	IN	O
small	JJ	O
molecules	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
small	JJ	O
peptides	NNS	O
or	CC	O
peptide-like	JJ	O
molecules	NNS	O
,	,	O
preferably	RB	O
soluble	JJ	O
peptides	NNS	O
,	,	O
and	CC	O
synthetic	JJ	O
non-peptidyl	JJ	O
organic	NN	O
or	CC	O
inorganic	JJ	O
compounds	NNS	O
.	.	O
Ribozymes	NNS	O
are	VBP	O
enzymatic	JJ	O
RNA	NNP	O
molecules	NNS	O
capable	JJ	O
of	IN	O
catalyzing	VBG	O
the	DT	O
specific	JJ	O
cleavage	NN	O
of	IN	O
RNA	NNP	O
.	.	O
Ribozymes	NNP	O
act	NN	O
by	IN	O
sequence-specific	JJ	O
hybridization	NN	O
to	TO	O
the	DT	O
complementary	JJ	O
target	NN	O
RNA	NNP	O
,	,	O
followed	VBN	O
by	IN	O
endonucleolytic	JJ	O
cleavage	NN	O
.	.	O
Specific	JJ	O
ribozyme	NN	O
cleavage	NN	O
sites	NNS	O
within	IN	O
a	DT	O
potential	JJ	O
RNA	NNP	O
target	NN	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
known	VBN	O
techniques	NNS	O
.	.	O
For	IN	O
further	JJ	O
details	NNS	O
see	VBP	O
,	,	O
e.g.	FW	O
,	,	O
Rossi	NNP	B
,	,	I
Current	NNP	I
Biology	NNP	I
,	,	I
4:469-471	CD	I
(	(	I
1994	CD	I
)	)	I
,	,	O
and	CC	O
PCT	NNP	O
publication	NN	O
No	NNP	O
.	.	O
WO	$	O
97/33551	CD	O
(	(	O
published	VBN	O
Sep.	NNP	O
18	CD	O
,	,	O
1997	CD	O
)	)	O
.	.	O
Nucleic	NNP	O
acid	NN	O
molecules	NNS	O
in	IN	O
triple-helix	JJ	O
formation	NN	O
used	VBN	O
to	TO	O
inhibit	VB	O
transcription	NN	O
should	MD	O
be	VB	O
single-stranded	JJ	O
and	CC	O
composed	VBN	O
of	IN	O
deoxynucleotides	NNS	O
.	.	O
The	DT	O
base	JJ	O
composition	NN	O
of	IN	O
these	DT	O
oligonucleotides	NNS	O
is	VBZ	O
designed	VBN	O
such	JJ	O
that	IN	O
it	PRP	O
promotes	VBZ	O
triple-helix	JJ	O
formation	NN	O
via	IN	O
Hoogsteen	NNP	O
base-pairing	NN	O
rules	NNS	O
,	,	O
which	WDT	O
generally	RB	O
require	VBP	O
sizeable	JJ	O
stretches	NNS	O
of	IN	O
purines	NNS	O
or	CC	O
pyrimidines	NNS	O
on	IN	O
one	CD	O
strand	NN	O
of	IN	O
a	DT	O
duplex	NN	O
.	.	O
For	IN	O
further	JJ	O
details	NNS	O
see	VBP	O
,	,	O
e.g.	FW	O
,	,	O
PCT	NNP	O
publication	NN	O
No	NNP	O
.	.	O
WO	NNP	O
97/33551	CD	O
,	,	O
supra	NN	O
.	.	O
These	DT	O
small	JJ	O
molecules	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
any	DT	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
screening	NN	O
assays	NNS	O
discussed	VBN	O
hereinabove	VB	O
and/or	NN	O
by	IN	O
any	DT	O
other	JJ	O
screening	NN	O
techniques	NNS	O
well	RB	O
known	VBN	O
for	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Diagnostic	JJ	O
and	CC	O
therapeutic	JJ	O
uses	NNS	O
of	IN	O
the	DT	O
herein	NN	O
disclosed	VBD	O
molecules	NNS	O
may	MD	O
also	RB	O
be	VB	O
based	VBN	O
upon	IN	O
the	DT	O
positive	JJ	O
functional	JJ	O
assay	NN	O
hits	NNS	O
disclosed	VBN	O
and	CC	O
described	VBN	O
below	IN	O
.	.	O
F.	NNP	O
Anti-PRO227	NNP	O
,	,	O
Anti-PRO233	NNP	O
,	,	O
Anti-PRO238	NNP	O
,	,	O
Anti-PRO1328	NNP	O
,	,	O
Anti-PRO4342	NNP	O
,	,	O
Anti-PRO7423	NNP	O
;	:	O
Anti-PRO10096	NNP	O
;	:	O
Anti-PRO21384	NNP	O
;	:	O
Anti-PRO353	NNP	O
or	CC	O
Anti-PRO1885	NNP	O
Antibodies	NNPS	O
The	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
which	WDT	O
may	MD	O
find	VB	O
use	NN	O
herein	NN	O
as	IN	O
therapeutic	JJ	O
and/or	NN	O
diagnostic	JJ	O
agents	NNS	O
.	.	O
Exemplary	JJ	O
antibodies	NNS	O
include	VBP	O
polyclonal	JJ	O
,	,	O
monoclonal	JJ	O
,	,	O
humanized	VBN	O
,	,	O
bispecific	NN	O
,	,	O
and	CC	O
heteroconjugate	NN	O
antibodies	NNS	O
.	.	O
1	CD	O
.	.	O
Polyclonal	JJ	O
Antibodies	NNP	O
Polyclonal	NNP	O
antibodies	NNS	O
are	VBP	O
preferably	RB	O
raised	VBN	O
in	IN	O
animals	NNS	O
by	IN	O
multiple	JJ	O
subcutaneous	JJ	O
(	(	O
sc	NN	O
)	)	O
or	CC	O
intraperitoneal	NN	O
(	(	O
ip	NN	O
)	)	O
injections	NNS	O
of	IN	O
the	DT	O
relevant	JJ	O
antigen	NN	O
and	CC	O
an	DT	O
adjuvant	NN	O
.	.	O
It	PRP	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
conjugate	VB	O
the	DT	O
relevant	JJ	O
antigen	NN	O
(	(	O
especially	RB	O
when	WRB	O
synthetic	JJ	O
peptides	NNS	O
are	VBP	O
used	VBN	O
)	)	O
to	TO	O
a	DT	O
protein	NN	O
that	WDT	O
is	VBZ	O
immunogenic	JJ	O
in	IN	O
the	DT	O
species	NNS	O
to	TO	O
be	VB	O
immunized	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
antigen	NN	O
can	MD	O
be	VB	O
conjugated	VBN	O
to	TO	O
keyhole	VB	O
limpet	NN	O
hemocyanin	NN	O
(	(	O
KLH	NNP	O
)	)	O
,	,	O
serum	JJ	O
albumin	NN	O
,	,	O
bovine	NN	O
thyroglobulin	NN	O
,	,	O
or	CC	O
soybean	NN	O
trypsin	NN	O
inhibitor	NN	O
,	,	O
using	VBG	O
a	DT	O
bifunctional	JJ	O
or	CC	O
derivatizing	VBG	O
agent	NN	O
,	,	O
e.g.	NN	O
,	,	O
maleimidobenzoyl	JJ	O
sulfosuccinimide	NN	O
ester	NN	O
(	(	O
conjugation	NN	O
through	IN	O
cysteine	NN	O
residues	NNS	O
)	)	O
,	,	O
N-hydroxysuccinimide	NNP	O
(	(	O
through	IN	O
lysine	NN	O
residues	NNS	O
)	)	O
,	,	O
glutaraldehyde	UH	O
,	,	O
succinic	JJ	O
anhydride	NN	O
,	,	O
SOCl2	NNP	O
,	,	O
or	CC	O
R1N═C═NR	NNP	O
,	,	O
where	WRB	O
R	NNP	O
and	CC	O
R1	NNP	O
are	VBP	O
different	JJ	O
alkyl	JJ	O
groups	NNS	O
.	.	O
Animals	NNS	O
are	VBP	O
immunized	VBN	O
against	IN	O
the	DT	O
antigen	NN	O
,	,	O
immunogenic	JJ	O
conjugates	NNS	O
,	,	O
or	CC	O
derivatives	NNS	O
by	IN	O
combining	VBG	O
,	,	O
e.g.	NN	O
,	,	O
100	CD	O
μg	NN	O
or	CC	O
5	CD	O
μg	NN	O
of	IN	O
the	DT	O
protein	NN	O
or	CC	O
conjugate	NN	O
(	(	O
for	IN	O
rabbits	NNS	O
or	CC	O
mice	NN	O
,	,	O
respectively	RB	O
)	)	O
with	IN	O
3	CD	O
volumes	NNS	O
of	IN	O
Freund	NNP	O
's	POS	O
complete	JJ	O
adjuvant	NN	O
and	CC	O
injecting	VBG	O
the	DT	O
solution	NN	O
intradermally	RB	O
at	IN	O
multiple	JJ	O
sites	NNS	O
.	.	O
One	CD	O
month	NN	O
later	RB	O
,	,	O
the	DT	O
animals	NNS	O
are	VBP	O
boosted	VBN	O
with	IN	O
⅕	NN	O
to	TO	O
1/10	CD	O
the	DT	O
original	JJ	O
amount	NN	O
of	IN	O
peptide	NN	O
or	CC	O
conjugate	NN	O
in	IN	O
Freund	NNP	O
's	POS	O
complete	JJ	O
adjuvant	NN	O
by	IN	O
subcutaneous	JJ	O
injection	NN	O
at	IN	O
multiple	JJ	O
sites	NNS	O
.	.	O
Seven	RB	O
to	TO	O
14	CD	O
days	NNS	O
later	RB	O
,	,	O
the	DT	O
animals	NNS	O
are	VBP	O
bled	VBN	O
and	CC	O
the	DT	O
serum	NN	O
is	VBZ	O
assayed	VBN	O
for	IN	O
antibody	NN	O
titer	NN	O
.	.	O
Animals	NNS	O
are	VBP	O
boosted	VBN	O
until	IN	O
the	DT	O
titer	NN	O
plateaus	NN	O
.	.	O
Conjugates	NNS	O
also	RB	O
can	MD	O
be	VB	O
made	VBN	O
in	IN	O
recombinant	JJ	O
cell	NN	O
culture	NN	O
as	IN	O
protein	NN	O
fusions	NNS	O
.	.	O
Also	RB	O
,	,	O
aggregating	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
alum	NN	O
are	VBP	O
suitably	RB	O
used	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
immune	JJ	O
response	NN	O
.	.	O
2	CD	O
.	.	O
Monoclonal	JJ	O
Antibodies	NNP	O
Monoclonal	NNP	O
antibodies	NNS	O
may	MD	O
be	VB	O
made	VBN	O
using	VBG	O
the	DT	O
hybridoma	NN	O
method	NN	O
first	RB	O
described	VBN	O
by	IN	O
Kohler	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
256:495	CD	I
(	(	I
1975	CD	I
)	)	I
,	,	O
or	CC	O
may	MD	O
be	VB	O
made	VBN	O
by	IN	O
recombinant	JJ	O
DNA	NNP	O
methods	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,816,567	CD	O
)	)	O
.	.	O
In	IN	O
the	DT	O
hybridoma	NN	O
method	NN	O
,	,	O
a	DT	O
mouse	NN	O
or	CC	O
other	JJ	O
appropriate	JJ	O
host	NN	O
animal	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
hamster	NN	O
,	,	O
is	VBZ	O
immunized	VBN	O
as	IN	O
described	VBN	O
above	IN	O
to	TO	O
elicit	VB	O
lymphocytes	NNS	O
that	IN	O
produce	VBP	O
or	CC	O
are	VBP	O
capable	JJ	O
of	IN	O
producing	VBG	O
antibodies	NNS	O
that	WDT	O
will	MD	O
specifically	RB	O
bind	VB	O
to	TO	O
the	DT	O
protein	NN	O
used	VBN	O
for	IN	O
immunization	NN	O
.	.	O
Alternatively	RB	O
,	,	O
lymphocytes	NNS	O
may	MD	O
be	VB	O
immunized	VBN	O
in	IN	O
vitro	NN	O
.	.	O
After	IN	O
immunization	NN	O
,	,	O
lymphocytes	NNS	O
are	VBP	O
isolated	VBN	O
and	CC	O
then	RB	O
fused	VBD	O
with	IN	O
a	DT	O
myeloma	NN	O
cell	NN	O
line	NN	O
using	VBG	O
a	DT	O
suitable	JJ	O
fusing	NN	O
agent	NN	O
,	,	O
such	JJ	O
as	IN	O
polyethylene	NN	O
glycol	NN	O
,	,	O
to	TO	O
form	VB	O
a	DT	O
hybridoma	NN	O
cell	NN	O
(	(	O
Goding	NNP	B
,	,	I
Monoclonal	NNP	I
Antibodies	NNPS	I
:	:	I
Principles	NNS	I
and	CC	I
Practice	NNP	I
,	,	I
pp	NN	I
.	.	I
59-103	JJ	I
(	(	I
Academic	NNP	I
Press	NNP	I
,	,	I
1986	CD	I
)	)	I
)	)	O
.	.	O
The	DT	O
hybridoma	NN	O
cells	NNS	O
thus	RB	O
prepared	VBN	O
are	VBP	O
seeded	VBN	O
and	CC	O
grown	VBN	O
in	IN	O
a	DT	O
suitable	JJ	O
culture	NN	O
medium	NN	O
which	WDT	O
medium	NN	O
preferably	RB	O
contains	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
substances	NNS	O
that	WDT	O
inhibit	VBP	O
the	DT	O
growth	NN	O
or	CC	O
survival	NN	O
of	IN	O
the	DT	O
unfused	JJ	O
,	,	O
parental	JJ	O
myeloma	NN	O
cells	NNS	O
(	(	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
fusion	NN	O
partner	NN	O
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
if	IN	O
the	DT	O
parental	JJ	O
myeloma	NN	O
cells	NNS	O
lack	VBP	O
the	DT	O
enzyme	NN	O
hypoxanthine	NN	O
guanine	NN	O
phosphoribosyl	NN	O
transferase	NN	O
(	(	O
HGPRT	NNP	O
or	CC	O
HPRT	NNP	O
)	)	O
,	,	O
the	DT	O
selective	JJ	O
culture	NN	O
medium	NN	O
for	IN	O
the	DT	O
hybridomas	NN	O
typically	RB	O
will	MD	O
include	VB	O
hypoxanthine	NN	O
,	,	O
aminopterin	NN	O
,	,	O
and	CC	O
thymidine	NN	O
(	(	O
HAT	NNP	O
medium	NN	O
)	)	O
,	,	O
which	WDT	O
substances	VBZ	O
prevent	VBP	O
the	DT	O
growth	NN	O
of	IN	O
HGPRT-deficient	NNP	O
cells	NNS	O
.	.	O
Preferred	JJ	O
fusion	NN	O
partner	NN	O
myeloma	NN	O
cells	NNS	O
are	VBP	O
those	DT	O
that	IN	O
fuse	VBP	O
efficiently	RB	O
,	,	O
support	NN	O
stable	JJ	O
high-level	JJ	O
production	NN	O
of	IN	O
antibody	NN	O
by	IN	O
the	DT	O
selected	VBN	O
antibody-producing	NN	O
cells	NNS	O
,	,	O
and	CC	O
are	VBP	O
sensitive	JJ	O
to	TO	O
a	DT	O
selective	JJ	O
medium	NN	O
that	WDT	O
selects	VBZ	O
against	IN	O
the	DT	O
unfused	JJ	O
parental	JJ	O
cells	NNS	O
.	.	O
Preferred	NNP	O
myeloma	NN	O
cell	NN	O
lines	NNS	O
are	VBP	O
murine	JJ	O
myeloma	NN	O
lines	NNS	O
,	,	O
such	JJ	O
as	IN	O
those	DT	O
derived	VBN	O
from	IN	O
MOPC-21	NNP	O
and	CC	O
MPC-11	NNP	O
mouse	NN	O
tumors	NNS	O
available	JJ	O
from	IN	O
the	DT	O
Salk	NNP	O
Institute	NNP	O
Cell	NNP	O
Distribution	NNP	O
Center	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
USA	NNP	O
,	,	O
and	CC	O
SP-2	NNP	O
and	CC	O
derivatives	NNS	O
e.g.	VBP	O
,	,	O
X63-Ag8-653	JJ	O
cells	NNS	O
available	JJ	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
,	,	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
,	,	O
USA	NNP	O
.	.	O
Human	NNP	O
myeloma	NN	O
and	CC	O
mouse-human	JJ	O
heteromyeloma	NN	O
cell	NN	O
lines	NNS	O
also	RB	O
have	VBP	O
been	VBN	O
described	VBN	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
human	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
(	(	O
Kozbor	NNP	B
,	,	I
J	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
133:3001	CD	I
(	(	I
1984	CD	I
)	)	I
;	:	O
and	CC	O
Brodeur	NNP	B
et	FW	I
al.	NN	I
,	,	I
Monoclonal	NNP	I
Antibody	NNP	I
Production	NNP	I
Techniques	NNP	I
and	CC	I
Applications	NNP	I
,	,	I
pp	NN	I
.	.	I
51-63	JJ	I
(	(	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
1987	CD	I
)	)	I
)	)	O
.	.	O
Culture	NN	O
medium	NN	O
in	IN	O
which	WDT	O
hybridoma	NN	O
cells	NNS	O
are	VBP	O
growing	VBG	O
is	VBZ	O
assayed	VBN	O
for	IN	O
production	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
antigen	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
binding	VBG	O
specificity	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
produced	VBN	O
by	IN	O
hybridoma	NN	O
cells	NNS	O
is	VBZ	O
determined	VBN	O
by	IN	O
immunoprecipitation	NN	O
or	CC	O
by	IN	O
an	DT	O
in	IN	O
vitro	NN	O
binding	NN	O
assay	NN	O
,	,	O
such	JJ	O
as	IN	O
radioimmunoassay	NN	O
(	(	O
RIA	NNP	O
)	)	O
or	CC	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
.	.	O
The	DT	O
binding	VBG	O
affinity	NN	O
of	IN	O
the	DT	O
monoclonal	JJ	O
antibody	NN	O
can	MD	O
,	,	O
for	IN	O
example	NN	O
,	,	O
be	VB	O
determined	VBN	O
by	IN	O
the	DT	O
Scatchard	NNP	O
analysis	NN	O
described	VBN	O
in	IN	O
Munson	NNP	B
et	CC	I
al.	NN	I
,	,	I
Anal	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
107:220	CD	I
(	(	I
1980	CD	I
)	)	I
.	.	O
Once	RB	O
hybridoma	JJ	O
cells	NNS	O
that	WDT	O
produce	VBP	O
antibodies	NNS	O
of	IN	O
the	DT	O
desired	JJ	O
specificity	NN	O
,	,	O
affinity	NN	O
,	,	O
and/or	JJ	O
activity	NN	O
are	VBP	O
identified	VBN	O
,	,	O
the	DT	O
clones	NNS	O
may	MD	O
be	VB	O
subcloned	VBN	O
by	IN	O
limiting	VBG	O
dilution	NN	O
procedures	NNS	O
and	CC	O
grown	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
(	(	O
Goding	VBG	B
,	,	I
Monoclonal	JJ	I
Antibodies	NNS	I
:	:	I
Principles	NNS	I
and	CC	I
Practice	NNP	I
,	,	I
pp	NN	I
.	.	I
59-103	JJ	I
(	(	I
Academic	NNP	I
Press	NNP	I
,	,	I
1986	CD	I
)	)	I
)	)	O
.	.	O
Suitable	JJ	O
culture	NN	O
media	NNS	O
for	IN	O
this	DT	O
purpose	JJ	O
include	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
D-MEM	NNP	O
or	CC	O
RPMI-1640	NNP	O
medium	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
hybridoma	NN	O
cells	NNS	O
may	MD	O
be	VB	O
grown	VBN	O
in	IN	O
vivo	NN	O
as	IN	O
ascites	NNS	O
tumors	NNS	O
in	IN	O
an	DT	O
animal	JJ	O
e.g	NN	O
.	.	O
by	IN	O
i.p	NN	O
.	.	O
injection	NN	O
of	IN	O
the	DT	O
cells	NNS	O
into	IN	O
mice	NN	O
.	.	O
The	DT	O
monoclonal	JJ	O
antibodies	NNS	O
secreted	VBN	O
by	IN	O
the	DT	O
subclones	NNS	O
are	VBP	O
suitably	RB	O
separated	VBN	O
from	IN	O
the	DT	O
culture	NN	O
medium	NN	O
,	,	O
ascites	VBZ	O
fluid	NN	O
,	,	O
or	CC	O
serum	NN	O
by	IN	O
conventional	JJ	O
antibody	NN	O
purification	NN	O
procedures	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
affinity	NN	O
chromatography	NN	O
(	(	O
e.g.	NN	O
,	,	O
using	VBG	O
protein	RP	O
A	DT	O
or	CC	O
protein	JJ	O
G-Sepharose	JJ	O
)	)	O
or	CC	O
ion-exchange	JJ	O
chromatography	NN	O
,	,	O
hydroxylapatite	JJ	O
chromatography	NN	O
,	,	O
gel	JJ	O
electrophoresis	NN	O
,	,	O
dialysis	NN	O
,	,	O
etc	FW	O
.	.	O
DNA	NN	O
encoding	VBG	O
the	DT	O
monoclonal	JJ	O
antibodies	NNS	O
is	VBZ	O
readily	RB	O
isolated	VBN	O
and	CC	O
sequenced	VBN	O
using	VBG	O
conventional	JJ	O
procedures	NNS	O
(	(	O
e.g.	NN	O
,	,	O
by	IN	O
using	VBG	O
oligonucleotide	JJ	O
probes	NNS	O
that	WDT	O
are	VBP	O
capable	JJ	O
of	IN	O
binding	VBG	O
specifically	RB	O
to	TO	O
genes	NNS	O
encoding	VBG	O
the	DT	O
heavy	JJ	O
and	CC	O
light	JJ	O
chains	NNS	O
of	IN	O
murine	NN	O
antibodies	NNS	O
)	)	O
.	.	O
The	DT	O
hybridoma	NN	O
cells	NNS	O
serve	VBP	O
as	IN	O
a	DT	O
preferred	JJ	O
source	NN	O
of	IN	O
such	JJ	O
DNA	NNP	O
.	.	O
Once	RB	O
isolated	VBN	O
,	,	O
the	DT	O
DNA	NN	O
may	MD	O
be	VB	O
placed	VBN	O
into	IN	O
expression	NN	O
vectors	NNS	O
,	,	O
which	WDT	O
are	VBP	O
then	RB	O
transfected	VBN	O
into	IN	O
host	NN	O
cells	NNS	O
such	JJ	O
as	IN	O
E.	NNP	O
coli	VBP	O
cells	NNS	O
,	,	O
simian	JJ	O
COS	NNP	O
cells	NNS	O
,	,	O
Chinese	JJ	O
Hamster	NNP	O
Ovary	NNP	O
(	(	O
CHO	NNP	O
)	)	O
cells	NNS	O
,	,	O
or	CC	O
myeloma	NN	O
cells	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
otherwise	RB	O
produce	VB	O
antibody	NN	O
protein	NN	O
,	,	O
to	TO	O
obtain	VB	O
the	DT	O
synthesis	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
in	IN	O
the	DT	O
recombinant	NN	O
host	NN	O
cells	NNS	O
.	.	O
Review	NNP	O
articles	NNS	O
on	IN	O
recombinant	JJ	O
expression	NN	O
in	IN	O
bacteria	NNS	O
of	IN	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
antibody	NN	O
include	VBP	O
Skerra	NNP	B
et	FW	I
al.	NN	I
,	,	I
Curr	NNP	I
.	.	I
Opinion	NN	I
in	IN	I
Immunol.	NNP	I
,	,	I
5:256-262	NNP	I
(	(	I
1993	CD	I
)	)	I
and	CC	O
Plückthun	NNP	B
,	,	I
Immunol	NNP	I
.	.	I
Revs	NNP	I
.	.	I
130:151-188	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
Monoclonal	JJ	O
antibodies	NNS	O
or	CC	O
antibody	NN	O
fragments	NNS	O
can	MD	O
be	VB	O
isolated	VBN	O
from	IN	O
antibody	JJ	O
phage	NN	O
libraries	NNS	O
generated	VBD	O
using	VBG	O
the	DT	O
techniques	NNS	O
described	VBN	O
in	IN	O
McCafferty	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
348:552-554	NNP	I
(	(	I
1990	CD	I
)	)	I
.	.	O
Clackson	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
352:624-628	NNP	I
(	(	I
1991	CD	I
)	)	I
and	CC	O
Marks	NNP	B
et	VBP	I
al.	NN	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
222:581-597	CD	I
(	(	I
1991	CD	I
)	)	I
describe	VB	O
the	DT	O
isolation	NN	O
of	IN	O
murine	NN	O
and	CC	O
human	JJ	O
antibodies	NNS	O
,	,	O
respectively	RB	O
,	,	O
using	VBG	O
phage	NN	O
libraries	NNS	O
.	.	O
Subsequent	JJ	O
publications	NNS	O
describe	VBP	O
the	DT	O
production	NN	O
of	IN	O
high	JJ	O
affinity	NN	O
(	(	O
nM	JJ	O
range	NN	O
)	)	O
human	NN	O
antibodies	NNS	O
by	IN	O
chain	NN	O
shuffling	NN	O
(	(	O
Marks	NNP	B
et	RB	I
al.	RB	I
,	,	I
Bio/Technology	NNP	I
,	,	I
10:779-783	CD	I
(	(	I
1992	CD	I
)	)	I
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
combinatorial	JJ	O
infection	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
recombination	NN	O
as	IN	O
a	DT	O
strategy	NN	O
for	IN	O
constructing	VBG	O
very	RB	O
large	JJ	O
phage	NN	O
libraries	NNS	O
(	(	O
Waterhouse	NNP	B
et	VBZ	I
al.	RB	I
,	,	I
Nuc	NNP	I
.	.	I
Acids	NNS	I
.	.	I
Res	NNP	I
.	.	I
21:2265-2266	CD	I
(	(	I
1993	CD	I
)	)	I
)	)	O
.	.	O
Thus	RB	O
,	,	O
these	DT	O
techniques	NNS	O
are	VBP	O
viable	JJ	O
alternatives	NNS	O
to	TO	O
traditional	JJ	O
monoclonal	JJ	O
antibody	NN	O
hybridoma	NN	O
techniques	NNS	O
for	IN	O
isolation	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
.	.	O
The	DT	O
DNA	NN	O
that	WDT	O
encodes	VBZ	O
the	DT	O
antibody	NN	O
may	MD	O
be	VB	O
modified	VBN	O
to	TO	O
produce	VB	O
chimeric	JJ	O
or	CC	O
fusion	NN	O
antibody	NN	O
polypeptides	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
substituting	VBG	O
human	JJ	O
heavy	JJ	O
chain	NN	O
and	CC	O
light	NN	O
chain	NN	O
constant	JJ	O
domain	NN	O
(	(	O
CH	NNP	O
and	CC	O
CL	NNP	O
)	)	O
sequences	NNS	O
for	IN	O
the	DT	O
homologous	JJ	O
murine	NN	O
sequences	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,816,567	CD	O
;	:	O
and	CC	O
Morrison	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
81:6851	CD	I
(	(	I
1984	CD	I
)	)	I
)	)	O
,	,	O
or	CC	O
by	IN	O
fusing	VBG	O
the	DT	O
immunoglobulin	NN	O
coding	VBG	O
sequence	NN	O
with	IN	O
all	DT	O
or	CC	O
part	NN	O
of	IN	O
the	DT	O
coding	NN	O
sequence	NN	O
for	IN	O
a	DT	O
non-immunoglobulin	JJ	O
polypeptide	NN	O
(	(	O
heterologous	JJ	O
polypeptide	NN	O
)	)	O
.	.	O
The	DT	O
non-immunoglobulin	JJ	O
polypeptide	NN	O
sequences	NNS	O
can	MD	O
substitute	VB	O
for	IN	O
the	DT	O
constant	JJ	O
domains	NNS	O
of	IN	O
an	DT	O
antibody	NN	O
,	,	O
or	CC	O
they	PRP	O
are	VBP	O
substituted	VBN	O
for	IN	O
the	DT	O
variable	JJ	O
domains	NNS	O
of	IN	O
one	CD	O
antigen-combining	JJ	O
site	NN	O
of	IN	O
an	DT	O
antibody	NN	O
to	TO	O
create	VB	O
a	DT	O
chimeric	JJ	O
bivalent	NN	O
antibody	NN	O
comprising	VBG	O
one	CD	O
antigen-combining	JJ	O
site	NN	O
having	VBG	O
specificity	NN	O
for	IN	O
an	DT	O
antigen	NN	O
and	CC	O
another	DT	O
antigen-combining	JJ	O
site	NN	O
having	VBG	O
specificity	NN	O
for	IN	O
a	DT	O
different	JJ	O
antigen	NN	O
.	.	O
3	CD	O
.	.	O
Human	NNP	O
and	CC	O
Humanized	NNP	O
Antibodies	NNPS	O
The	DT	O
anti-PRO227	NN	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
further	RB	O
comprise	VB	O
humanized	JJ	O
antibodies	NNS	O
or	CC	O
human	JJ	O
antibodies	NNS	O
.	.	O
Humanized	VBN	O
forms	NNS	O
of	IN	O
non-human	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
murine	NN	O
)	)	O
antibodies	NNS	O
are	VBP	O
chimeric	JJ	O
immunoglobulins	NNS	O
,	,	O
immunoglobulin	NN	O
chains	NNS	O
or	CC	O
fragments	NNS	O
thereof	JJ	O
(	(	O
such	JJ	O
as	IN	O
Fv	NNP	O
,	,	O
Fab	NNP	O
,	,	O
Fab′	NNP	O
,	,	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
or	CC	O
other	JJ	O
antigen-binding	JJ	O
subsequences	NNS	O
of	IN	O
antibodies	NNS	O
)	)	O
which	WDT	O
contain	VBP	O
minimal	JJ	O
sequence	NN	O
derived	VBN	O
from	IN	O
non-human	JJ	O
immunoglobulin	NN	O
.	.	O
Humanized	VBN	O
antibodies	NNS	O
include	VBP	O
human	JJ	O
immunoglobulins	NNS	O
(	(	O
recipient	VB	O
antibody	NN	O
)	)	O
in	IN	O
which	WDT	O
residues	VBP	O
from	IN	O
a	DT	O
complementary	JJ	O
determining	NN	O
region	NN	O
(	(	O
CDR	NNP	O
)	)	O
of	IN	O
the	DT	O
recipient	NN	O
are	VBP	O
replaced	VBN	O
by	IN	O
residues	NNS	O
from	IN	O
a	DT	O
CDR	NNP	O
of	IN	O
a	DT	O
non-human	JJ	O
species	NNS	O
(	(	O
donor	VB	O
antibody	NN	O
)	)	O
such	JJ	O
as	IN	O
mouse	NN	O
,	,	O
rat	NN	O
or	CC	O
rabbit	NN	O
having	VBG	O
the	DT	O
desired	JJ	O
specificity	NN	O
,	,	O
affinity	NN	O
and	CC	O
capacity	NN	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
Fv	NNP	O
framework	NN	O
residues	NNS	O
of	IN	O
the	DT	O
human	JJ	O
immunoglobulin	NN	O
are	VBP	O
replaced	VBN	O
by	IN	O
corresponding	VBG	O
non-human	JJ	O
residues	NNS	O
.	.	O
Humanized	VBN	O
antibodies	NNS	O
may	MD	O
also	RB	O
comprise	VB	O
residues	NNS	O
which	WDT	O
are	VBP	O
found	VBN	O
neither	RB	O
in	IN	O
the	DT	O
recipient	NN	O
antibody	NN	O
nor	CC	O
in	IN	O
the	DT	O
imported	JJ	O
CDR	NNP	O
or	CC	O
framework	NN	O
sequences	NNS	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
humanized	VBN	O
antibody	NN	O
will	MD	O
comprise	VB	O
substantially	RB	O
all	DT	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
,	,	O
and	CC	O
typically	RB	O
two	CD	O
,	,	O
variable	JJ	O
domains	NNS	O
,	,	O
in	IN	O
which	WDT	O
all	DT	O
or	CC	O
substantially	RB	O
all	DT	O
of	IN	O
the	DT	O
CDR	NNP	O
regions	NNS	O
correspond	NN	O
to	TO	O
those	DT	O
of	IN	O
a	DT	O
non-human	JJ	O
immunoglobulin	NN	O
and	CC	O
all	DT	O
or	CC	O
substantially	RB	O
all	DT	O
of	IN	O
the	DT	O
FR	NNP	O
regions	NNS	O
are	VBP	O
those	DT	O
of	IN	O
a	DT	O
human	JJ	O
immunoglobulin	NN	O
consensus	NN	O
sequence	NN	O
.	.	O
The	DT	O
humanized	VBN	O
antibody	NN	O
optimally	RB	O
also	RB	O
will	MD	O
comprise	VB	O
at	IN	O
least	JJS	O
a	DT	O
portion	NN	O
of	IN	O
an	DT	O
immunoglobulin	NN	O
constant	JJ	O
region	NN	O
(	(	O
Fc	NNP	O
)	)	O
,	,	O
typically	RB	O
that	IN	O
of	IN	O
a	DT	O
human	JJ	O
immunoglobulin	NN	O
[	NNP	O
Jones	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
321:522-525	NNP	I
(	(	I
1986	CD	I
)	)	I
;	:	O
Riechmann	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
332:323-329	NNP	I
(	(	I
1988	CD	I
)	)	I
;	:	O
and	CC	O
Presta	NNP	B
,	,	I
Curr	NNP	I
.	.	I
Op	NNP	I
.	.	I
Struct	NN	I
.	.	I
Biol.	NNP	I
,	,	I
2:593-596	CD	I
(	(	I
1992	CD	I
)	)	I
]	NN	O
.	.	O
Methods	NNS	O
for	IN	O
humanizing	VBG	O
non-human	JJ	O
antibodies	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Generally	RB	O
,	,	O
a	DT	O
humanized	VBN	O
antibody	NN	O
has	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	NN	O
residues	NNS	O
introduced	VBN	O
into	IN	O
it	PRP	O
from	IN	O
a	DT	O
source	NN	O
which	WDT	O
is	VBZ	O
non-human	JJ	O
.	.	O
These	DT	O
non-human	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
are	VBP	O
often	RB	O
referred	VBN	O
to	TO	O
as	IN	O
“	JJ	O
import	NN	O
”	NN	O
residues	NNS	O
,	,	O
which	WDT	O
are	VBP	O
typically	RB	O
taken	VBN	O
from	IN	O
an	DT	O
“	JJ	O
import	NN	O
”	NNP	O
variable	JJ	O
domain	NN	O
.	.	O
Humanization	NN	O
can	MD	O
be	VB	O
essentially	RB	O
performed	VBN	O
following	VBG	O
the	DT	O
method	NN	O
of	IN	O
Winter	NNP	O
and	CC	O
co-workers	NNS	O
[	NNP	O
Jones	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
321:522-525	NNP	I
(	(	I
1986	CD	I
)	)	I
;	:	O
Riechmann	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
332:323-327	NNP	I
(	(	I
1988	CD	I
)	)	I
;	:	O
Verhoeyen	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
239:1534-1536	CD	I
(	(	I
1988	CD	I
)	)	I
]	NN	O
,	,	O
by	IN	O
substituting	VBG	O
rodent	NN	O
CDRs	NNP	O
or	CC	O
CDR	NNP	O
sequences	NNS	O
for	IN	O
the	DT	O
corresponding	JJ	O
sequences	NNS	O
of	IN	O
a	DT	O
human	JJ	O
antibody	NN	O
.	.	O
Accordingly	RB	O
,	,	O
such	JJ	O
“	FW	O
humanized	VBN	O
”	NN	O
antibodies	NNS	O
are	VBP	O
chimeric	JJ	O
antibodies	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,816,567	CD	O
)	)	O
,	,	O
wherein	WP	O
substantially	RB	O
less	JJR	O
than	IN	O
an	DT	O
intact	JJ	O
human	JJ	O
variable	NN	O
domain	NN	O
has	VBZ	O
been	VBN	O
substituted	VBN	O
by	IN	O
the	DT	O
corresponding	JJ	O
sequence	NN	O
from	IN	O
a	DT	O
non-human	JJ	O
species	NNS	O
.	.	O
In	IN	O
practice	NN	O
,	,	O
humanized	VBN	O
antibodies	NNS	O
are	VBP	O
typically	RB	O
human	JJ	O
antibodies	NNS	O
in	IN	O
which	WDT	O
some	DT	O
CDR	NNP	O
residues	NNS	O
and	CC	O
possibly	RB	O
some	DT	O
FR	NNP	O
residues	NNS	O
are	VBP	O
substituted	VBN	O
by	IN	O
residues	NNS	O
from	IN	O
analogous	JJ	O
sites	NNS	O
in	IN	O
rodent	JJ	O
antibodies	NNS	O
.	.	O
The	DT	O
choice	NN	O
of	IN	O
human	JJ	O
variable	JJ	O
domains	NNS	O
,	,	O
both	DT	O
light	JJ	O
and	CC	O
heavy	JJ	O
,	,	O
to	TO	O
be	VB	O
used	VBN	O
in	IN	O
making	VBG	O
the	DT	O
humanized	JJ	O
antibodies	NNS	O
is	VBZ	O
very	RB	O
important	JJ	O
to	TO	O
reduce	VB	O
antigenicity	NN	O
and	CC	O
HAMA	NNP	O
response	NN	O
(	(	O
human	JJ	O
anti-mouse	NN	O
antibody	NN	O
)	)	O
when	WRB	O
the	DT	O
antibody	NN	O
is	VBZ	O
intended	VBN	O
for	IN	O
human	JJ	O
therapeutic	JJ	O
use	NN	O
.	.	O
According	VBG	O
to	TO	O
the	DT	O
so-called	JJ	O
“	JJ	O
best-fit	JJ	O
”	NN	O
method	NN	O
,	,	O
the	DT	O
sequence	NN	O
of	IN	O
the	DT	O
variable	JJ	O
domain	NN	O
of	IN	O
a	DT	O
rodent	NN	O
antibody	NN	O
is	VBZ	O
screened	VBN	O
against	IN	O
the	DT	O
entire	JJ	O
library	NN	O
of	IN	O
known	VBN	O
human	JJ	O
variable	JJ	O
domain	NN	O
sequences	NNS	O
.	.	O
The	DT	O
human	JJ	O
V	NNP	O
domain	NN	O
sequence	NN	O
which	WDT	O
is	VBZ	O
closest	JJS	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
rodent	NN	O
is	VBZ	O
identified	VBN	O
and	CC	O
the	DT	O
human	JJ	O
framework	NN	O
region	NN	O
(	(	O
FR	NNP	O
)	)	O
within	IN	O
it	PRP	O
accepted	VBD	O
for	IN	O
the	DT	O
humanized	VBN	O
antibody	NN	O
(	(	O
Sims	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
151:2296	CD	I
(	(	I
1993	CD	I
)	)	I
;	:	O
Chothia	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
196:901	CD	I
(	(	I
1987	CD	I
)	)	I
)	)	O
.	.	O
Another	DT	O
method	NN	O
uses	VBZ	O
a	DT	O
particular	JJ	O
framework	NN	O
region	NN	O
derived	VBN	O
from	IN	O
the	DT	O
consensus	NN	O
sequence	NN	O
of	IN	O
all	DT	O
human	JJ	O
antibodies	NNS	O
of	IN	O
a	DT	O
particular	JJ	O
subgroup	NN	O
of	IN	O
light	NN	O
or	CC	O
heavy	JJ	O
chains	NNS	O
.	.	O
The	DT	O
same	JJ	O
framework	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
several	JJ	O
different	JJ	O
humanized	VBN	O
antibodies	NNS	O
(	(	O
Carter	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
89:4285	CD	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Presta	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
151:2623	CD	I
(	(	I
1993	CD	I
)	)	I
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
further	RBR	O
important	JJ	O
that	IN	O
antibodies	NNS	O
be	VB	O
humanized	VBN	O
with	IN	O
retention	NN	O
of	IN	O
high	JJ	O
binding	NN	O
affinity	NN	O
for	IN	O
the	DT	O
antigen	NN	O
and	CC	O
other	JJ	O
favorable	JJ	O
biological	JJ	O
properties	NNS	O
.	.	O
To	TO	O
achieve	VB	O
this	DT	O
goal	NN	O
,	,	O
according	VBG	O
to	TO	O
a	DT	O
preferred	JJ	O
method	NN	O
,	,	O
humanized	VBN	O
antibodies	NNS	O
are	VBP	O
prepared	VBN	O
by	IN	O
a	DT	O
process	NN	O
of	IN	O
analysis	NN	O
of	IN	O
the	DT	O
parental	JJ	O
sequences	NNS	O
and	CC	O
various	JJ	O
conceptual	JJ	O
humanized	VBN	O
products	NNS	O
using	VBG	O
three-dimensional	JJ	O
models	NNS	O
of	IN	O
the	DT	O
parental	NN	O
and	CC	O
humanized	JJ	O
sequences	NNS	O
.	.	O
Three-dimensional	JJ	O
immunoglobulin	NN	O
models	NNS	O
are	VBP	O
commonly	RB	O
available	JJ	O
and	CC	O
are	VBP	O
familiar	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Computer	NNP	O
programs	NNS	O
are	VBP	O
available	JJ	O
which	WDT	O
illustrate	NN	O
and	CC	O
display	NN	O
probable	JJ	O
three-dimensional	JJ	O
conformational	JJ	O
structures	NNS	O
of	IN	O
selected	VBN	O
candidate	NN	O
immunoglobulin	NN	O
sequences	NNS	O
.	.	O
Inspection	NN	O
of	IN	O
these	DT	O
displays	NNS	O
permits	VBP	O
analysis	NN	O
of	IN	O
the	DT	O
likely	JJ	O
role	NN	O
of	IN	O
the	DT	O
residues	NNS	O
in	IN	O
the	DT	O
functioning	NN	O
of	IN	O
the	DT	O
candidate	NN	O
immunoglobulin	NN	O
sequence	NN	O
,	,	O
i.e.	FW	O
,	,	O
the	DT	O
analysis	NN	O
of	IN	O
residues	NNS	O
that	WDT	O
influence	VBP	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
candidate	NN	O
immunoglobulin	NN	O
to	TO	O
bind	VB	O
its	PRP$	O
antigen	NN	O
.	.	O
In	IN	O
this	DT	O
way	NN	O
,	,	O
FR	NNP	O
residues	NNS	O
can	MD	O
be	VB	O
selected	VBN	O
and	CC	O
combined	VBN	O
from	IN	O
the	DT	O
recipient	NN	O
and	CC	O
import	NN	O
sequences	NNS	O
so	RB	O
that	IN	O
the	DT	O
desired	VBN	O
antibody	NN	O
characteristic	JJ	O
,	,	O
such	JJ	O
as	IN	O
increased	JJ	O
affinity	NN	O
for	IN	O
the	DT	O
target	NN	O
antigen	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
is	VBZ	O
achieved	VBN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
hypervariable	JJ	O
region	NN	O
residues	NNS	O
are	VBP	O
directly	RB	O
and	CC	O
most	JJS	O
substantially	RB	O
involved	VBN	O
in	IN	O
influencing	VBG	O
antigen	NN	O
binding	NN	O
.	.	O
Various	JJ	O
forms	NNS	O
of	IN	O
a	DT	O
humanized	JJ	O
anti-PRO227	NN	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
are	VBP	O
contemplated	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
humanized	VBN	O
antibody	NN	O
may	MD	O
be	VB	O
an	DT	O
antibody	NN	O
fragment	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
Fab	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
optionally	RB	O
conjugated	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
cytotoxic	JJ	O
agent	NN	O
(	(	O
s	NN	O
)	)	O
in	IN	O
order	NN	O
to	TO	O
generate	VB	O
an	DT	O
immunoconjugate	NN	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
humanized	VBN	O
antibody	NN	O
may	MD	O
be	VB	O
an	DT	O
intact	JJ	O
antibody	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
intact	JJ	O
IgG1	NNP	O
antibody	NN	O
.	.	O
As	IN	O
an	DT	O
alternative	NN	O
to	TO	O
humanization	NN	O
,	,	O
human	JJ	O
antibodies	NNS	O
can	MD	O
be	VB	O
generated	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
it	PRP	O
is	VBZ	O
now	RB	O
possible	JJ	O
to	TO	O
produce	VB	O
transgenic	JJ	O
animals	NNS	O
(	(	O
e.g.	NN	O
,	,	O
mice	NN	O
)	)	O
that	WDT	O
are	VBP	O
capable	JJ	O
,	,	O
upon	JJ	O
immunization	NN	O
,	,	O
of	IN	O
producing	VBG	O
a	DT	O
full	JJ	O
repertoire	NN	O
of	IN	O
human	JJ	O
antibodies	NNS	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
endogenous	JJ	O
immunoglobulin	NN	O
production	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
it	PRP	O
has	VBZ	O
been	VBN	O
described	VBN	O
that	IN	O
the	DT	O
homozygous	JJ	O
deletion	NN	O
of	IN	O
the	DT	O
antibody	NN	O
heavy-chain	JJ	O
joining	NN	O
region	NN	O
(	(	O
JH	NNP	O
)	)	O
gene	NN	O
in	IN	O
chimeric	JJ	O
and	CC	O
germ-line	JJ	O
mutant	JJ	O
mice	NN	O
results	NNS	O
in	IN	O
complete	JJ	O
inhibition	NN	O
of	IN	O
endogenous	JJ	O
antibody	NN	O
production	NN	O
.	.	O
Transfer	NN	O
of	IN	O
the	DT	O
human	JJ	O
germ-line	JJ	O
immunoglobulin	NN	O
gene	NN	O
array	NN	O
into	IN	O
such	JJ	O
germ-line	JJ	O
mutant	NN	O
mice	NN	O
will	MD	O
result	VB	O
in	IN	O
the	DT	O
production	NN	O
of	IN	O
human	JJ	O
antibodies	NNS	O
upon	IN	O
antigen	NN	O
challenge	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Jakobovits	NNP	B
et	CC	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
90:2551	CD	I
(	(	I
1993	CD	I
)	)	I
;	:	O
Jakobovits	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
362:255-258	NNP	I
(	(	I
1993	CD	I
)	)	I
;	:	O
Bruggemann	NNP	B
et	FW	I
al.	NN	I
,	,	I
Year	NN	I
in	IN	I
Immuno	NNP	I
.	.	I
7:33	CD	I
(	(	I
1993	CD	I
)	)	I
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,545,806	CD	O
,	,	O
5,569,825	CD	O
,	,	O
5,591,669	CD	O
(	(	O
all	DT	O
of	IN	O
GenPharm	NNP	O
)	)	O
;	:	O
5,545,807	CD	O
;	:	O
and	CC	O
WO	NNP	O
97/17852	CD	O
.	.	O
Alternatively	RB	O
,	,	O
phage	NN	O
display	NN	O
technology	NN	O
(	(	O
McCafferty	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nature	NNP	I
348:552-553	CD	I
[	NN	I
1990	CD	I
]	NN	I
)	)	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
produce	VB	O
human	JJ	O
antibodies	NNS	O
and	CC	O
antibody	NN	O
fragments	NNS	O
in	IN	O
vitro	NN	O
,	,	O
from	IN	O
immunoglobulin	NN	O
variable	NN	O
(	(	O
V	NNP	O
)	)	O
domain	VBP	O
gene	NN	O
repertoires	NNS	O
from	IN	O
unimmunized	JJ	O
donors	NNS	O
.	.	O
According	VBG	O
to	TO	O
this	DT	O
technique	NN	O
,	,	O
antibody	NN	O
V	NNP	O
domain	NN	O
genes	NNS	O
are	VBP	O
cloned	VBN	O
in-frame	JJ	O
into	IN	O
either	CC	O
a	DT	O
major	JJ	O
or	CC	O
minor	JJ	O
coat	NN	O
protein	NN	O
gene	NN	O
of	IN	O
a	DT	O
filamentous	JJ	O
bacteriophage	NN	O
,	,	O
such	JJ	O
as	IN	O
M13	NNP	O
or	CC	O
fd	NN	O
,	,	O
and	CC	O
displayed	VBD	O
as	IN	O
functional	JJ	O
antibody	NN	O
fragments	NNS	O
on	IN	O
the	DT	O
surface	NN	O
of	IN	O
the	DT	O
phage	NN	O
particle	NN	O
.	.	O
Because	IN	O
the	DT	O
filamentous	JJ	O
particle	NN	O
contains	VBZ	O
a	DT	O
single-stranded	JJ	O
DNA	NNP	O
copy	NN	O
of	IN	O
the	DT	O
phage	NN	O
genome	NN	O
,	,	O
selections	NNS	O
based	VBN	O
on	IN	O
the	DT	O
functional	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
antibody	NN	O
also	RB	O
result	NN	O
in	IN	O
selection	NN	O
of	IN	O
the	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
antibody	NN	O
exhibiting	VBG	O
those	DT	O
properties	NNS	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
phage	NN	O
mimics	VBD	O
some	DT	O
of	IN	O
the	DT	O
properties	NNS	O
of	IN	O
the	DT	O
B-cell	NNP	O
.	.	O
Phage	NN	O
display	NN	O
can	MD	O
be	VB	O
performed	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
formats	NNS	O
,	,	O
reviewed	VBN	O
in	IN	O
,	,	O
e.g.	NN	O
,	,	O
Johnson	NNP	B
,	,	I
Kevin	NNP	I
S	NNP	I
,	,	I
and	CC	I
Chiswell	NNP	I
,	,	I
David	NNP	I
J.	NNP	I
,	,	I
Current	NNP	I
Opinion	NNP	I
in	IN	I
Structural	NNP	I
Biology	NNP	I
3:564-571	CD	I
(	(	I
1993	CD	I
)	)	I
.	.	O
Several	JJ	O
sources	NNS	O
of	IN	O
V-gene	NNP	O
segments	NNS	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
phage	NN	O
display	NN	O
.	.	O
Clackson	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
352:624-628	NNP	I
(	(	I
1991	CD	I
)	)	I
isolated	VBD	O
a	DT	O
diverse	JJ	O
array	NN	O
of	IN	O
anti-oxazolone	JJ	O
antibodies	NNS	O
from	IN	O
a	DT	O
small	JJ	O
random	JJ	O
combinatorial	JJ	O
library	NN	O
of	IN	O
V	NNP	O
genes	NNS	O
derived	VBN	O
from	IN	O
the	DT	O
spleens	NNS	O
of	IN	O
immunized	JJ	O
mice	NN	O
.	.	O
A	DT	O
repertoire	NN	O
of	IN	O
V	NNP	O
genes	NNS	O
from	IN	O
unimmunized	JJ	O
human	JJ	O
donors	NNS	O
can	MD	O
be	VB	O
constructed	VBN	O
and	CC	O
antibodies	NNS	O
to	TO	O
a	DT	O
diverse	JJ	O
array	NN	O
of	IN	O
antigens	NNS	O
(	(	O
including	VBG	O
self-antigens	NNS	O
)	)	O
can	MD	O
be	VB	O
isolated	VBN	O
essentially	RB	O
following	VBG	O
the	DT	O
techniques	NNS	O
described	VBN	O
by	IN	O
Marks	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol	NNP	I
.	.	I
222:581-597	CD	I
(	(	I
1991	CD	I
)	)	I
,	,	O
or	CC	O
Griffith	NNP	B
et	CC	I
al.	NN	I
,	,	I
EMBO	NNP	I
J	NNP	I
.	.	I
12:725-734	CD	I
(	(	I
1993	CD	I
)	)	I
.	.	O
See	NNP	O
,	,	O
also	RB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,565,332	CD	O
and	CC	O
5,573,905	CD	O
.	.	O
As	IN	O
discussed	VBN	O
above	IN	O
,	,	O
human	JJ	O
antibodies	NNS	O
may	MD	O
also	RB	O
be	VB	O
generated	VBN	O
by	IN	O
in	IN	O
vitro	NN	O
activated	VBN	O
B	NNP	O
cells	NNS	O
(	(	O
see	VB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,567,610	CD	O
and	CC	O
5,229,275	CD	O
)	)	O
.	.	O
4	CD	O
.	.	O
Antibody	NN	O
Fragments	NNS	O
In	IN	O
certain	JJ	O
circumstances	NNS	O
there	EX	O
are	VBP	O
advantages	NNS	O
of	IN	O
using	VBG	O
antibody	NN	O
fragments	NNS	O
,	,	O
rather	RB	O
than	IN	O
whole	JJ	O
antibodies	NNS	O
.	.	O
The	DT	O
smaller	JJR	O
size	NN	O
of	IN	O
the	DT	O
fragments	NNS	O
allows	VBZ	O
for	IN	O
rapid	JJ	O
clearance	NN	O
,	,	O
and	CC	O
may	MD	O
lead	VB	O
to	TO	O
improved	JJ	O
access	NN	O
to	TO	O
solid	JJ	O
tumors	NNS	O
.	.	O
Various	JJ	O
techniques	NNS	O
have	VBP	O
been	VBN	O
developed	VBN	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
antibody	NN	O
fragments	NNS	O
.	.	O
Traditionally	RB	O
,	,	O
these	DT	O
fragments	NNS	O
were	VBD	O
derived	VBN	O
via	IN	O
proteolytic	JJ	O
digestion	NN	O
of	IN	O
intact	JJ	O
antibodies	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Morimoto	NNP	B
et	FW	I
al.	NN	I
,	,	I
Journal	NNP	I
of	IN	I
Biochemical	NNP	I
and	CC	I
Biophysical	NNP	I
Methods	NNP	I
24:107-117	CD	I
(	(	I
1992	CD	I
)	)	I
;	:	O
and	CC	O
Brennan	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
229:81	CD	I
(	(	I
1985	CD	I
)	)	I
)	)	O
.	.	O
However	RB	O
,	,	O
these	DT	O
fragments	NNS	O
can	MD	O
now	RB	O
be	VB	O
produced	VBN	O
directly	RB	O
by	IN	O
recombinant	JJ	O
host	NN	O
cells	NNS	O
.	.	O
Fab	NNP	O
,	,	O
Fv	NNP	O
and	CC	O
ScFv	NNP	O
antibody	NN	O
fragments	NNS	O
can	MD	O
all	DT	O
be	VB	O
expressed	VBN	O
in	IN	O
and	CC	O
secreted	VBD	O
from	IN	O
E.	NNP	O
coli	NNS	O
,	,	O
thus	RB	O
allowing	VBG	O
the	DT	O
facile	JJ	O
production	NN	O
of	IN	O
large	JJ	O
amounts	NNS	O
of	IN	O
these	DT	O
fragments	NNS	O
.	.	O
Antibody	NN	O
fragments	NNS	O
can	MD	O
be	VB	O
isolated	VBN	O
from	IN	O
the	DT	O
antibody	NN	O
phage	NN	O
libraries	NNS	O
discussed	VBN	O
above	IN	O
.	.	O
Alternatively	RB	O
,	,	O
Fab′-SH	JJ	O
fragments	NNS	O
can	MD	O
be	VB	O
directly	RB	O
recovered	VBN	O
from	IN	O
E.	NNP	O
coli	NNS	O
and	CC	O
chemically	RB	O
coupled	VBN	O
to	TO	O
form	VB	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
fragments	NNS	O
(	(	O
Carter	NNP	B
et	RB	I
al.	RB	I
,	,	I
Bio/Technology	NNP	I
10:163-167	CD	I
(	(	I
1992	CD	I
)	)	I
)	)	O
.	.	O
According	VBG	O
to	TO	O
another	DT	O
approach	NN	O
,	,	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
fragments	NNS	O
can	MD	O
be	VB	O
isolated	VBN	O
directly	RB	O
from	IN	O
recombinant	JJ	O
host	NN	O
cell	NN	O
culture	NN	O
.	.	O
Fab	NNP	O
and	CC	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
fragment	JJ	O
with	IN	O
increased	VBN	O
in	IN	O
vivo	JJ	O
half-life	JJ	O
comprising	VBG	O
a	DT	O
salvage	NN	O
receptor	NN	O
binding	VBG	O
epitope	NN	O
residues	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,869,046	CD	O
.	.	O
Other	JJ	O
techniques	NNS	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
antibody	NN	O
fragments	NNS	O
will	MD	O
be	VB	O
apparent	JJ	O
to	TO	O
the	DT	O
skilled	JJ	O
practitioner	NN	O
.	.	O
The	DT	O
antibody	NN	O
of	IN	O
choice	NN	O
is	VBZ	O
a	DT	O
single	JJ	O
chain	NN	O
Fv	NNP	O
fragment	NN	O
(	(	O
scFv	NN	O
)	)	O
.	.	O
See	NNP	O
WO	NNP	O
93/16185	CD	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,571,894	CD	O
;	:	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,587,458	CD	O
.	.	O
Fv	NNP	O
and	CC	O
sFv	NN	O
are	VBP	O
the	DT	O
only	JJ	O
species	NNS	O
with	IN	O
intact	JJ	O
combining	VBG	O
sites	NNS	O
that	WDT	O
are	VBP	O
devoid	JJ	O
of	IN	O
constant	JJ	O
regions	NNS	O
;	:	O
thus	RB	O
,	,	O
they	PRP	O
are	VBP	O
suitable	JJ	O
for	IN	O
reduced	JJ	O
nonspecific	JJ	O
binding	NN	O
during	IN	O
in	IN	O
vivo	NN	O
use	NN	O
.	.	O
sFv	JJ	O
fusion	NN	O
proteins	NNS	O
may	MD	O
be	VB	O
constructed	VBN	O
to	TO	O
yield	VB	O
fusion	NN	O
of	IN	O
an	DT	O
effector	NN	O
protein	NN	O
at	IN	O
either	CC	O
the	DT	O
amino	NN	O
or	CC	O
the	DT	O
carboxy	JJ	O
terminus	NN	O
of	IN	O
an	DT	O
sFv	NN	O
.	.	O
See	VB	O
Antibody	NNP	B
Engineering	NNP	I
,	,	I
ed	NN	I
.	.	I
Borrebaeck	NNP	I
,	,	I
supra	NN	I
.	.	O
The	DT	O
antibody	NN	O
fragment	NN	O
may	MD	O
also	RB	O
be	VB	O
a	DT	O
“	JJ	O
linear	JJ	O
antibody	NN	O
”	NNP	O
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,641,870	CD	O
for	IN	O
example	NN	O
.	.	O
Such	JJ	O
linear	JJ	O
antibody	NN	O
fragments	NNS	O
may	MD	O
be	VB	O
monospecific	JJ	O
or	CC	O
bispecific	NN	O
.	.	O
5	CD	O
.	.	O
Bispecific	NNP	O
Antibodies	NNP	O
Bispecific	NNP	O
antibodies	NNS	O
are	VBP	O
antibodies	NNS	O
that	WDT	O
have	VBP	O
binding	VBG	O
specificities	NNS	O
for	IN	O
at	IN	O
least	JJS	O
two	CD	O
different	JJ	O
epitopes	NNS	O
.	.	O
Exemplary	NNP	O
bispecific	NN	O
antibodies	NNS	O
may	MD	O
bind	VB	O
to	TO	O
two	CD	O
different	JJ	O
epitopes	NNS	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
protein	CC	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
Other	JJ	O
such	JJ	O
antibodies	NNS	O
may	MD	O
combine	VB	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
binding	VBG	O
site	NN	O
with	IN	O
a	DT	O
binding	NN	O
site	NN	O
for	IN	O
another	DT	O
protein	NN	O
.	.	O
Alternatively	RB	O
,	,	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
arm	NN	O
may	MD	O
be	VB	O
combined	VBN	O
with	IN	O
an	DT	O
arm	NN	O
which	WDT	O
binds	VBZ	O
to	TO	O
a	DT	O
triggering	VBG	O
molecule	NN	O
on	IN	O
a	DT	O
leukocyte	NN	O
such	JJ	O
as	IN	O
a	DT	O
T-cell	NNP	O
receptor	NN	O
molecule	NN	O
(	(	O
e.g	NN	O
.	.	O
CD3	NNP	O
)	)	O
,	,	O
or	CC	O
Fc	NNP	O
receptors	NNS	O
for	IN	O
IgG	NNP	O
(	(	O
FcγR	NNP	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
FcγRI	NNP	O
(	(	O
CD64	NNP	O
)	)	O
,	,	O
FcγRII	NNP	O
(	(	O
CD32	NNP	O
)	)	O
and	CC	O
FcγRIII	NNP	O
(	(	O
CD16	NNP	O
)	)	O
,	,	O
so	RB	O
as	IN	O
to	TO	O
focus	VB	O
and	CC	O
localize	VB	O
cellular	JJ	O
defense	NN	O
mechanisms	NN	O
to	TO	O
the	DT	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-expressing	NNP	O
cell	NN	O
.	.	O
Bispecific	NNP	O
antibodies	NNS	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
localize	VB	O
cytotoxic	JJ	O
agents	NNS	O
to	TO	O
cells	NNS	O
which	WDT	O
express	VBP	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
These	DT	O
antibodies	NNS	O
possess	VBP	O
a	DT	O
PRO227-	JJ	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-binding	NNP	O
arm	NN	O
and	CC	O
an	DT	O
arm	NN	O
which	WDT	O
binds	VBZ	O
the	DT	O
cytotoxic	NN	O
agent	NN	O
(	(	O
e.g.	UH	O
,	,	O
saporin	JJ	O
,	,	O
anti-interferon-α	JJ	O
,	,	O
vinca	JJ	O
alkaloid	NN	O
,	,	O
ricin	VB	O
A	NNP	O
chain	NN	O
,	,	O
methotrexate	NN	O
or	CC	O
radioactive	JJ	O
isotope	NN	O
hapten	NN	O
)	)	O
.	.	O
Bispecific	NNP	O
antibodies	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
full	JJ	O
length	NN	O
antibodies	NNS	O
or	CC	O
antibody	NN	O
fragments	NNS	O
(	(	O
e.g.	NN	O
,	,	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
bispecific	JJ	O
antibodies	NNS	O
)	)	O
.	.	O
WO	$	O
96/16673	CD	O
describes	VBZ	O
a	DT	O
bispecific	JJ	O
anti-ErbB2/anti-FcγRIII	JJ	O
antibody	NN	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,837,234	CD	O
discloses	VBZ	O
a	DT	O
bispecific	JJ	O
anti-ErbB2/anti-FcγRI	JJ	O
antibody	NN	O
.	.	O
A	DT	O
bispecific	JJ	O
anti-ErbB2/Fcα	JJ	O
antibody	NN	O
is	VBZ	O
shown	VBN	O
in	IN	O
WO98/02463	NNP	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,821,337	CD	O
teaches	NNS	O
a	DT	O
bispecific	JJ	O
anti-ErbB2/anti-CD3	JJ	O
antibody	NN	O
.	.	O
Methods	NNS	O
for	IN	O
making	VBG	O
bispecific	JJ	O
antibodies	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Traditional	JJ	O
production	NN	O
of	IN	O
full	JJ	O
length	NN	O
bispecific	NN	O
antibodies	NNS	O
is	VBZ	O
based	VBN	O
on	IN	O
the	DT	O
co-expression	NN	O
of	IN	O
two	CD	O
immunoglobulin	JJ	O
heavy	JJ	O
chain-light	NN	O
chain	NN	O
pairs	NNS	O
,	,	O
where	WRB	O
the	DT	O
two	CD	O
chains	NNS	O
have	VBP	O
different	JJ	O
specificities	NNS	O
(	(	O
Millstein	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nature	NNP	I
305:537-539	CD	I
(	(	I
1983	CD	I
)	)	I
)	)	O
.	.	O
Because	IN	O
of	IN	O
the	DT	O
random	JJ	O
assortment	NN	O
of	IN	O
immunoglobulin	NN	O
heavy	JJ	O
and	CC	O
light	JJ	O
chains	NNS	O
,	,	O
these	DT	O
hybridomas	NNS	O
(	(	O
quadromas	NN	O
)	)	O
produce	VBP	O
a	DT	O
potential	JJ	O
mixture	NN	O
of	IN	O
10	CD	O
different	JJ	O
antibody	NN	O
molecules	NNS	O
,	,	O
of	IN	O
which	WDT	O
only	RB	O
one	CD	O
has	VBZ	O
the	DT	O
correct	JJ	O
bispecific	NN	O
structure	NN	O
.	.	O
Purification	NN	O
of	IN	O
the	DT	O
correct	JJ	O
molecule	NN	O
,	,	O
which	WDT	O
is	VBZ	O
usually	RB	O
done	VBN	O
by	IN	O
affinity	NN	O
chromatography	NN	O
steps	NNS	O
,	,	O
is	VBZ	O
rather	RB	O
cumbersome	JJ	O
,	,	O
and	CC	O
the	DT	O
product	NN	O
yields	NNS	O
are	VBP	O
low	JJ	O
.	.	O
Similar	JJ	O
procedures	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
WO	NNP	O
93/08829	CD	O
,	,	O
and	CC	O
in	IN	O
Traunecker	NNP	B
et	CC	I
al.	NN	I
,	,	I
EMBO	NNP	I
J	NNP	I
.	.	I
10:3655-3659	CD	I
(	(	I
1991	CD	I
)	)	I
.	.	O
According	VBG	O
to	TO	O
a	DT	O
different	JJ	O
approach	NN	O
,	,	O
antibody	NN	O
variable	JJ	O
domains	NNS	O
with	IN	O
the	DT	O
desired	JJ	O
binding	NN	O
specificity	NN	O
(	(	O
antibody-antigen	JJ	O
combining	NN	O
sites	NNS	O
)	)	O
are	VBP	O
fused	VBN	O
to	TO	O
immunoglobulin	VB	O
constant	JJ	O
domain	NN	O
sequences	NNS	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
fusion	NN	O
is	VBZ	O
with	IN	O
an	DT	O
Ig	NNP	O
heavy	NN	O
chain	NN	O
constant	JJ	O
domain	NN	O
,	,	O
comprising	VBG	O
at	IN	O
least	JJS	O
part	NN	O
of	IN	O
the	DT	O
hinge	NN	O
,	,	O
CH2	NNP	O
,	,	O
and	CC	O
CH3	NNP	O
regions	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
preferred	VBN	O
to	TO	O
have	VB	O
the	DT	O
first	JJ	O
heavy-chain	NN	O
constant	JJ	O
region	NN	O
(	(	O
CH1	NNP	O
)	)	O
containing	VBG	O
the	DT	O
site	NN	O
necessary	JJ	O
for	IN	O
light	NN	O
chain	NN	O
bonding	NN	O
,	,	O
present	JJ	O
in	IN	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
fusions	NNS	O
.	.	O
DNAs	NNP	O
encoding	VBG	O
the	DT	O
immunoglobulin	NN	O
heavy	NN	O
chain	NN	O
fusions	NNS	O
and	CC	O
,	,	O
if	IN	O
desired	VBN	O
,	,	O
the	DT	O
immunoglobulin	NN	O
light	NN	O
chain	NN	O
,	,	O
are	VBP	O
inserted	VBN	O
into	IN	O
separate	JJ	O
expression	NN	O
vectors	NNS	O
,	,	O
and	CC	O
are	VBP	O
co-transfected	VBN	O
into	IN	O
a	DT	O
suitable	JJ	O
host	NN	O
cell	NN	O
.	.	O
This	DT	O
provides	VBZ	O
for	IN	O
greater	JJR	O
flexibility	NN	O
in	IN	O
adjusting	VBG	O
the	DT	O
mutual	JJ	O
proportions	NNS	O
of	IN	O
the	DT	O
three	CD	O
polypeptide	NN	O
fragments	NNS	O
when	WRB	O
unequal	JJ	O
ratios	NNS	O
of	IN	O
the	DT	O
three	CD	O
polypeptide	NN	O
chains	NNS	O
used	VBN	O
in	IN	O
the	DT	O
construction	NN	O
provide	IN	O
the	DT	O
optimum	JJ	O
yield	NN	O
of	IN	O
the	DT	O
desired	VBN	O
bispecific	NN	O
antibody	NN	O
.	.	O
It	PRP	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
possible	JJ	O
to	TO	O
insert	VB	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
two	CD	O
or	CC	O
all	DT	O
three	CD	O
polypeptide	NN	O
chains	NNS	O
into	IN	O
a	DT	O
single	JJ	O
expression	NN	O
vector	NN	O
when	WRB	O
the	DT	O
expression	NN	O
of	IN	O
at	IN	O
least	JJS	O
two	CD	O
polypeptide	NN	O
chains	NNS	O
in	IN	O
equal	JJ	O
ratios	NNS	O
results	NNS	O
in	IN	O
high	JJ	O
yields	NNS	O
or	CC	O
when	WRB	O
the	DT	O
ratios	NNS	O
have	VBP	O
no	DT	O
significant	JJ	O
affect	NN	O
on	IN	O
the	DT	O
yield	NN	O
of	IN	O
the	DT	O
desired	VBN	O
chain	NN	O
combination	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
bispecific	JJ	O
antibodies	NNS	O
which	WDT	O
are	VBP	O
composed	VBN	O
of	IN	O
a	DT	O
hybrid	JJ	O
immunoglobulin	NN	O
heavy	NN	O
chain	NN	O
with	IN	O
a	DT	O
first	JJ	O
binding	NN	O
specificity	NN	O
in	IN	O
one	CD	O
arm	NN	O
,	,	O
and	CC	O
a	DT	O
hybrid	JJ	O
immunoglobulin	JJ	O
heavy	JJ	O
chain-light	NN	O
chain	NN	O
pair	NN	O
(	(	O
providing	VBG	O
a	DT	O
second	JJ	O
binding	NN	O
specificity	NN	O
)	)	O
in	IN	O
the	DT	O
other	JJ	O
arm	NN	O
.	.	O
It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
this	DT	O
asymmetric	JJ	O
structure	NN	O
facilitates	VBZ	O
the	DT	O
separation	NN	O
of	IN	O
the	DT	O
desired	VBN	O
bispecific	NN	O
compound	NN	O
from	IN	O
unwanted	JJ	O
immunoglobulin	NN	O
chain	NN	O
combinations	NNS	O
,	,	O
as	IN	O
the	DT	O
presence	NN	O
of	IN	O
an	DT	O
immunoglobulin	NN	O
light	NN	O
chain	NN	O
in	IN	O
only	RB	O
one	CD	O
half	NN	O
of	IN	O
the	DT	O
bispecific	JJ	O
molecule	NN	O
provides	VBZ	O
for	IN	O
a	DT	O
facile	JJ	O
way	NN	O
of	IN	O
separation	NN	O
.	.	O
This	DT	O
approach	NN	O
is	VBZ	O
disclosed	VBN	O
in	IN	O
WO	NNP	O
94/04690	CD	O
.	.	O
For	IN	O
further	JJ	O
details	NNS	O
of	IN	O
generating	VBG	O
bispecific	JJ	O
antibodies	NNS	O
see	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Suresh	NNP	B
et	FW	I
al.	NN	I
,	,	I
Methods	NNP	I
in	IN	I
Enzymology	NNP	I
121:210	CD	I
(	(	I
1986	CD	I
)	)	I
.	.	O
According	VBG	O
to	TO	O
another	DT	O
approach	NN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,731,168	CD	O
,	,	O
the	DT	O
interface	NN	O
between	IN	O
a	DT	O
pair	NN	O
of	IN	O
antibody	NN	O
molecules	NNS	O
can	MD	O
be	VB	O
engineered	VBN	O
to	TO	O
maximize	VB	O
the	DT	O
percentage	NN	O
of	IN	O
heterodimers	NNS	O
which	WDT	O
are	VBP	O
recovered	VBN	O
from	IN	O
recombinant	NN	O
cell	NN	O
culture	NN	O
.	.	O
The	DT	O
preferred	JJ	O
interface	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
a	DT	O
part	NN	O
of	IN	O
the	DT	O
CH3	NNP	O
domain	NN	O
.	.	O
In	IN	O
this	DT	O
method	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
small	JJ	O
amino	NN	O
acid	JJ	O
side	NN	O
chains	NNS	O
from	IN	O
the	DT	O
interface	NN	O
of	IN	O
the	DT	O
first	JJ	O
antibody	NN	O
molecule	NN	O
are	VBP	O
replaced	VBN	O
with	IN	O
larger	JJR	O
side	NN	O
chains	NNS	O
(	(	O
e.g.	NN	O
,	,	O
tyrosine	NN	O
or	CC	O
tryptophan	NN	O
)	)	O
.	.	O
Compensatory	NNP	O
“	NNP	O
cavities	VBZ	O
”	NNP	O
of	IN	O
identical	JJ	O
or	CC	O
similar	JJ	O
size	NN	O
to	TO	O
the	DT	O
large	JJ	O
side	NN	O
chain	NN	O
(	(	O
s	NN	O
)	)	O
are	VBP	O
created	VBN	O
on	IN	O
the	DT	O
interface	NN	O
of	IN	O
the	DT	O
second	JJ	O
antibody	NN	O
molecule	NN	O
by	IN	O
replacing	VBG	O
large	JJ	O
amino	NN	O
acid	JJ	O
side	NN	O
chains	NNS	O
with	IN	O
smaller	JJR	O
ones	NNS	O
(	(	O
e.g.	NN	O
,	,	O
alanine	NN	O
or	CC	O
threonine	NN	O
)	)	O
.	.	O
This	DT	O
provides	VBZ	O
a	DT	O
mechanism	NN	O
for	IN	O
increasing	VBG	O
the	DT	O
yield	NN	O
of	IN	O
the	DT	O
heterodimer	NN	O
over	IN	O
other	JJ	O
unwanted	JJ	O
end-products	NNS	O
such	JJ	O
as	IN	O
homodimers	NNS	O
.	.	O
Bispecific	NNP	O
antibodies	NNS	O
include	VBP	O
cross-linked	JJ	O
or	CC	O
“	JJ	O
heteroconjugate	NN	O
”	NN	O
antibodies	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
one	CD	O
of	IN	O
the	DT	O
antibodies	NNS	O
in	IN	O
the	DT	O
heteroconjugate	NN	O
can	MD	O
be	VB	O
coupled	VBN	O
to	TO	O
avidin	VB	O
,	,	O
the	DT	O
other	JJ	O
to	TO	O
biotin	VB	O
.	.	O
Such	JJ	O
antibodies	NNS	O
have	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
been	VBN	O
proposed	VBN	O
to	TO	O
target	VB	O
immune	JJ	O
system	NN	O
cells	NNS	O
to	TO	O
unwanted	JJ	O
cells	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,676,980	CD	O
)	)	O
,	,	O
and	CC	O
for	IN	O
treatment	NN	O
of	IN	O
HIV	NNP	O
infection	NN	O
(	(	O
WO	NNP	O
91/00360	CD	O
,	,	O
WO	NNP	O
92/200373	CD	O
,	,	O
and	CC	O
EP	NNP	O
03089	CD	O
)	)	O
.	.	O
Heteroconjugate	NNP	O
antibodies	NNS	O
may	MD	O
be	VB	O
made	VBN	O
using	VBG	O
any	DT	O
convenient	JJ	O
cross-linking	JJ	O
methods	NNS	O
.	.	O
Suitable	JJ	O
cross-linking	JJ	O
agents	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
and	CC	O
are	VBP	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,676,980	CD	O
,	,	O
along	IN	O
with	IN	O
a	DT	O
number	NN	O
of	IN	O
cross-linking	JJ	O
techniques	NNS	O
.	.	O
Techniques	NNS	O
for	IN	O
generating	VBG	O
bispecific	JJ	O
antibodies	NNS	O
from	IN	O
antibody	NN	O
fragments	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
described	VBN	O
in	IN	O
the	DT	O
literature	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
bispecific	JJ	O
antibodies	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
using	VBG	O
chemical	JJ	O
linkage	NN	O
.	.	O
Brennan	NNP	B
et	CC	I
al.	NN	I
,	,	I
Science	NNP	I
229:81	CD	I
(	(	I
1985	CD	I
)	)	I
describe	VB	O
a	DT	O
procedure	NN	O
wherein	NN	O
intact	JJ	O
antibodies	NNS	O
are	VBP	O
proteolytically	RB	O
cleaved	VBN	O
to	TO	O
generate	VB	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
fragments	NNS	O
.	.	O
These	DT	O
fragments	NNS	O
are	VBP	O
reduced	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
dithiol	NN	O
complexing	VBG	O
agent	NN	O
,	,	O
sodium	NN	O
arsenite	RB	O
,	,	O
to	TO	O
stabilize	VB	O
vicinal	JJ	O
dithiols	NNS	O
and	CC	O
prevent	NN	O
intermolecular	JJ	O
disulfide	NN	O
formation	NN	O
.	.	O
The	DT	O
Fab′	NNP	O
fragments	NNS	O
generated	VBD	O
are	VBP	O
then	RB	O
converted	VBN	O
to	TO	O
thionitrobenzoate	VB	O
(	(	O
TNB	NNP	O
)	)	O
derivatives	NNS	O
.	.	O
One	CD	O
of	IN	O
the	DT	O
Fab′-TNB	NNP	O
derivatives	NNS	O
is	VBZ	O
then	RB	O
reconverted	VBN	O
to	TO	O
the	DT	O
Fab′-thiol	NNP	O
by	IN	O
reduction	NN	O
with	IN	O
mercaptoethylamine	NN	O
and	CC	O
is	VBZ	O
mixed	JJ	O
with	IN	O
an	DT	O
equimolar	JJ	O
amount	NN	O
of	IN	O
the	DT	O
other	JJ	O
Fab′-TNB	NNP	O
derivative	NN	O
to	TO	O
form	VB	O
the	DT	O
bispecific	NN	O
antibody	NN	O
.	.	O
The	DT	O
bispecific	NN	O
antibodies	NNS	O
produced	VBD	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
agents	NNS	O
for	IN	O
the	DT	O
selective	JJ	O
immobilization	NN	O
of	IN	O
enzymes	NNS	O
.	.	O
Recent	JJ	O
progress	NN	O
has	VBZ	O
facilitated	VBN	O
the	DT	O
direct	JJ	O
recovery	NN	O
of	IN	O
Fab′-SH	NNP	O
fragments	NNS	O
from	IN	O
E.	NNP	O
coli	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
chemically	RB	O
coupled	VBN	O
to	TO	O
form	VB	O
bispecific	JJ	O
antibodies	NNS	O
.	.	O
Shalaby	NNP	B
et	CC	I
al.	NN	I
,	,	I
J.	NNP	I
Exp	NNP	I
.	.	I
Med	NNP	I
.	.	I
175	CD	I
:	:	I
217-225	CD	I
(	(	I
1992	CD	I
)	)	I
describe	VB	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
fully	RB	O
humanized	VBN	O
bispecific	NN	O
antibody	NN	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
molecule	NN	O
.	.	O
Each	DT	O
Fab′	NNP	O
fragment	NN	O
was	VBD	O
separately	RB	O
secreted	VBN	O
from	IN	O
E.	NNP	O
coli	NNS	O
and	CC	O
subjected	VBN	O
to	TO	O
directed	VB	O
chemical	NN	O
coupling	NN	O
in	IN	O
vitro	NN	O
to	TO	O
form	VB	O
the	DT	O
bispecific	NN	O
antibody	NN	O
.	.	O
The	DT	O
bispecific	NN	O
antibody	NN	O
thus	RB	O
formed	VBN	O
was	VBD	O
able	JJ	O
to	TO	O
bind	VB	O
to	TO	O
cells	NNS	O
overexpressing	VBG	O
the	DT	O
ErbB2	NNP	O
receptor	NN	O
and	CC	O
normal	JJ	O
human	JJ	O
T	NNP	O
cells	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
trigger	NN	O
the	DT	O
lytic	JJ	O
activity	NN	O
of	IN	O
human	JJ	O
cytotoxic	NN	O
lymphocytes	NNS	O
against	IN	O
human	JJ	O
breast	NN	O
tumor	NN	O
targets	NNS	O
.	.	O
Various	JJ	O
techniques	NNS	O
for	IN	O
making	VBG	O
and	CC	O
isolating	VBG	O
bispecific	NN	O
antibody	NN	O
fragments	NNS	O
directly	RB	O
from	IN	O
recombinant	NN	O
cell	NN	O
culture	NN	O
have	VBP	O
also	RB	O
been	VBN	O
described	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
bispecific	NN	O
antibodies	NNS	O
have	VBP	O
been	VBN	O
produced	VBN	O
using	VBG	O
leucine	JJ	O
zippers	NNS	O
.	.	O
Kostelny	NNP	B
et	CC	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
148	CD	I
(	(	I
5	CD	I
)	)	I
:1547-1553	NN	I
(	(	I
1992	CD	I
)	)	I
.	.	O
The	DT	O
leucine	JJ	O
zipper	NN	O
peptides	NNS	O
from	IN	O
the	DT	O
Fos	NNP	O
and	CC	O
Jun	NNP	O
proteins	NNS	O
were	VBD	O
linked	VBN	O
to	TO	O
the	DT	O
Fab′	NNP	O
portions	NNS	O
of	IN	O
two	CD	O
different	JJ	O
antibodies	NNS	O
by	IN	O
gene	NN	O
fusion	NN	O
.	.	O
The	DT	O
antibody	NN	O
homodimers	NNS	O
were	VBD	O
reduced	VBN	O
at	IN	O
the	DT	O
hinge	NN	O
region	NN	O
to	TO	O
form	VB	O
monomers	NNS	O
and	CC	O
then	RB	O
re-oxidized	JJ	O
to	TO	O
form	VB	O
the	DT	O
antibody	NN	O
heterodimers	NNS	O
.	.	O
This	DT	O
method	NN	O
can	MD	O
also	RB	O
be	VB	O
utilized	VBN	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
antibody	NN	O
homodimers	NNS	O
.	.	O
The	DT	O
“	NNP	O
diabody	NN	O
”	NNP	O
technology	NN	O
described	VBN	O
by	IN	O
Hollinger	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
90:6444-6448	CD	I
(	(	I
1993	CD	I
)	)	I
has	VBZ	O
provided	VBN	O
an	DT	O
alternative	JJ	O
mechanism	NN	O
for	IN	O
making	VBG	O
bispecific	JJ	O
antibody	NN	O
fragments	NNS	O
.	.	O
The	DT	O
fragments	NNS	O
comprise	VBP	O
a	DT	O
VH	NNP	O
connected	VBN	O
to	TO	O
a	DT	O
VL	NNP	O
by	IN	O
a	DT	O
linker	NN	O
which	WDT	O
is	VBZ	O
too	RB	O
short	JJ	O
to	TO	O
allow	VB	O
pairing	VBG	O
between	IN	O
the	DT	O
two	CD	O
domains	NNS	O
on	IN	O
the	DT	O
same	JJ	O
chain	NN	O
.	.	O
Accordingly	RB	O
,	,	O
the	DT	O
VH	NNP	O
and	CC	O
VL	NNP	O
domains	NNS	O
of	IN	O
one	CD	O
fragment	NN	O
are	VBP	O
forced	VBN	O
to	TO	O
pair	VB	O
with	IN	O
the	DT	O
complementary	JJ	O
VL	NNP	O
and	CC	O
VH	NNP	O
domains	NNS	O
of	IN	O
another	DT	O
fragment	NN	O
,	,	O
thereby	RB	O
forming	VBG	O
two	CD	O
antigen-binding	JJ	O
sites	NNS	O
.	.	O
Another	DT	O
strategy	NN	O
for	IN	O
making	VBG	O
bispecific	JJ	O
antibody	NN	O
fragments	NNS	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
single-chain	JJ	O
Fv	NNP	O
(	(	O
sFv	NN	O
)	)	O
dimers	NNS	O
has	VBZ	O
also	RB	O
been	VBN	O
reported	VBN	O
.	.	O
See	VB	O
Gruber	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Immunol.	NNP	I
,	,	I
152:5368	CD	I
(	(	I
1994	CD	I
)	)	I
.	.	O
Antibodies	NNS	O
with	IN	O
more	JJR	O
than	IN	O
two	CD	O
valencies	NNS	O
are	VBP	O
contemplated	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
trispecific	JJ	O
antibodies	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
.	.	O
Tutt	NNP	B
et	CC	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
147:60	CD	I
(	(	I
1991	CD	I
)	)	I
.	.	O
6	CD	O
.	.	O
Heteroconjugate	NNP	O
Antibodies	NNP	O
Heteroconjugate	NNP	O
antibodies	NNS	O
are	VBP	O
also	RB	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Heteroconjugate	NNP	O
antibodies	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
two	CD	O
covalently	RB	O
joined	VBD	O
antibodies	NNS	O
.	.	O
Such	JJ	O
antibodies	NNS	O
have	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
been	VBN	O
proposed	VBN	O
to	TO	O
target	VB	O
immune	JJ	O
system	NN	O
cells	NNS	O
to	TO	O
unwanted	JJ	O
cells	NNS	O
[	JJ	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,676,980	CD	O
]	NN	O
,	,	O
and	CC	O
for	IN	O
treatment	NN	O
of	IN	O
HIV	NNP	O
infection	NN	O
[	NNP	O
WO	NNP	O
91/00360	CD	O
;	:	O
WO	NNP	O
92/200373	CD	O
;	:	O
EP	NNP	O
03089	CD	O
]	NN	O
.	.	O
It	PRP	O
is	VBZ	O
contemplated	VBN	O
that	IN	O
the	DT	O
antibodies	NNS	O
may	MD	O
be	VB	O
prepared	VBN	O
in	IN	O
vitro	JJ	O
using	VBG	O
known	VBN	O
methods	NNS	O
in	IN	O
synthetic	JJ	O
protein	NN	O
chemistry	NN	O
,	,	O
including	VBG	O
those	DT	O
involving	VBG	O
crosslinking	VBG	O
agents	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
immunotoxins	NNS	O
may	MD	O
be	VB	O
constructed	VBN	O
using	VBG	O
a	DT	O
disulfide	JJ	O
exchange	NN	O
reaction	NN	O
or	CC	O
by	IN	O
forming	VBG	O
a	DT	O
thioether	NN	O
bond	NN	O
.	.	O
Examples	NNS	O
of	IN	O
suitable	JJ	O
reagents	NNS	O
for	IN	O
this	DT	O
purpose	JJ	O
include	VBP	O
iminothiolate	JJ	O
and	CC	O
methyl-4-mercaptobutyrimidate	JJ	O
and	CC	O
those	DT	O
disclosed	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,676,980	CD	O
.	.	O
7	CD	O
.	.	O
Multivalent	NNP	O
Antibodies	VBZ	O
A	NNP	O
multivalent	NN	O
antibody	NN	O
may	MD	O
be	VB	O
internalized	VBN	O
(	(	O
and/or	JJ	O
catabolized	VBN	O
)	)	O
faster	RBR	O
than	IN	O
a	DT	O
bivalent	NN	O
antibody	NN	O
by	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
an	DT	O
antigen	NN	O
to	TO	O
which	WDT	O
the	DT	O
antibodies	NNS	O
bind	VBP	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
multivalent	JJ	O
antibodies	NNS	O
(	(	O
which	WDT	O
are	VBP	O
other	JJ	O
than	IN	O
of	IN	O
the	DT	O
IgM	NNP	O
class	NN	O
)	)	O
with	IN	O
three	CD	O
or	CC	O
more	JJR	O
antigen	JJ	O
binding	NN	O
sites	NNS	O
(	(	O
e.g	NN	O
.	.	O
tetravalent	JJ	O
antibodies	NNS	O
)	)	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
readily	RB	O
produced	VBN	O
by	IN	O
recombinant	JJ	O
expression	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
polypeptide	NN	O
chains	NNS	O
of	IN	O
the	DT	O
antibody	NN	O
.	.	O
The	DT	O
multivalent	NN	O
antibody	NN	O
can	MD	O
comprise	VB	O
a	DT	O
dimerization	NN	O
domain	NN	O
and	CC	O
three	CD	O
or	CC	O
more	JJR	O
antigen	JJ	O
binding	NN	O
sites	NNS	O
.	.	O
The	DT	O
preferred	JJ	O
dimerization	NN	O
domain	NN	O
comprises	NNS	O
(	(	O
or	CC	O
consists	VBZ	O
of	IN	O
)	)	O
an	DT	O
Fc	JJ	O
region	NN	O
or	CC	O
a	DT	O
hinge	JJ	O
region	NN	O
.	.	O
In	IN	O
this	DT	O
scenario	NN	O
,	,	O
the	DT	O
antibody	NN	O
will	MD	O
comprise	VB	O
an	DT	O
Fc	NNP	O
region	NN	O
and	CC	O
three	CD	O
or	CC	O
more	JJR	O
antigen	JJ	O
binding	NN	O
sites	VBZ	O
amino-terminal	JJ	O
to	TO	O
the	DT	O
Fc	NNP	O
region	NN	O
.	.	O
The	DT	O
preferred	JJ	O
multivalent	NN	O
antibody	NN	O
herein	NN	O
comprises	VBZ	O
(	(	O
or	CC	O
consists	VBZ	O
of	IN	O
)	)	O
three	CD	O
to	TO	O
about	IN	O
eight	CD	O
,	,	O
but	CC	O
preferably	RB	O
four	CD	O
,	,	O
antigen	NN	O
binding	NN	O
sites	NNS	O
.	.	O
The	DT	O
multivalent	NN	O
antibody	NN	O
comprises	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
polypeptide	NN	O
chain	NN	O
(	(	O
and	CC	O
preferably	RB	O
two	CD	O
polypeptide	NN	O
chains	NNS	O
)	)	O
,	,	O
wherein	VBD	O
the	DT	O
polypeptide	NN	O
chain	NN	O
(	(	O
s	PRP	O
)	)	O
comprise	VBP	O
two	CD	O
or	CC	O
more	JJR	O
variable	JJ	O
domains	NNS	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
the	DT	O
polypeptide	NN	O
chain	NN	O
(	(	O
s	PRP	O
)	)	O
may	MD	O
comprise	VB	O
VD1-	NNP	O
(	(	O
X1	NNP	O
)	)	O
n-VD2-	NN	O
(	(	O
X2	NNP	O
)	)	O
n-Fc	NN	O
,	,	O
wherein	NN	O
VD1	NNP	O
is	VBZ	O
a	DT	O
first	JJ	O
variable	JJ	O
domain	NN	O
,	,	O
VD2	NNP	O
is	VBZ	O
a	DT	O
second	JJ	O
variable	JJ	O
domain	NN	O
,	,	O
Fc	NNP	O
is	VBZ	O
one	CD	O
polypeptide	NN	O
chain	NN	O
of	IN	O
an	DT	O
Fc	NNP	O
region	NN	O
,	,	O
X1	NNP	O
and	CC	O
X2	NNP	O
represent	VBP	O
an	DT	O
amino	NN	O
acid	NN	O
or	CC	O
polypeptide	NN	O
,	,	O
and	CC	O
n	NN	O
is	VBZ	O
0	CD	O
or	CC	O
1	CD	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
the	DT	O
polypeptide	NN	O
chain	NN	O
(	(	O
s	PRP	O
)	)	O
may	MD	O
comprise	VB	O
:	:	O
VH-CH1-flexible	JJ	O
linker-VH-CH1-Fc	JJ	O
region	NN	O
chain	NN	O
;	:	O
or	CC	O
VH-CH1-VH-CH1-Fc	JJ	O
region	NN	O
chain	NN	O
.	.	O
The	DT	O
multivalent	NN	O
antibody	NN	O
herein	NN	O
preferably	RB	O
further	JJ	O
comprises	NNS	O
at	IN	O
least	JJS	O
two	CD	O
(	(	O
and	CC	O
preferably	RB	O
four	CD	O
)	)	O
light	NN	O
chain	NN	O
variable	JJ	O
domain	NN	O
polypeptides	NNS	O
.	.	O
The	DT	O
multivalent	NN	O
antibody	NN	O
herein	NN	O
may	MD	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
comprise	NN	O
from	IN	O
about	RB	O
two	CD	O
to	TO	O
about	IN	O
eight	CD	O
light	NN	O
chain	NN	O
variable	JJ	O
domain	NN	O
polypeptides	NNS	O
.	.	O
The	DT	O
light	NN	O
chain	NN	O
variable	JJ	O
domain	NN	O
polypeptides	NNS	O
contemplated	VBD	O
here	RB	O
comprise	VB	O
a	DT	O
light	NN	O
chain	NN	O
variable	JJ	O
domain	NN	O
and	CC	O
,	,	O
optionally	RB	O
,	,	O
further	JJ	O
comprise	NN	O
a	DT	O
CL	NNP	O
domain	NN	O
.	.	O
8	CD	O
.	.	O
Effector	NNP	O
Function	NNP	O
Engineering	NNP	O
It	PRP	O
may	MD	O
be	VB	O
desirable	JJ	O
to	TO	O
modify	VB	O
the	DT	O
antibody	NN	O
of	IN	O
the	DT	O
invention	NN	O
with	IN	O
respect	NN	O
to	TO	O
effector	VB	O
function	NN	O
,	,	O
e.g.	NN	O
,	,	O
so	RB	O
as	IN	O
to	TO	O
enhance	VB	O
antigen-dependent	JJ	O
cell-mediated	JJ	O
cyotoxicity	NN	O
(	(	O
ADCC	NNP	O
)	)	O
and/or	VBP	O
complement	JJ	O
dependent	JJ	O
cytotoxicity	NN	O
(	(	O
CDC	NNP	O
)	)	O
of	IN	O
the	DT	O
antibody	NN	O
.	.	O
This	DT	O
may	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
introducing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	NN	O
substitutions	NNS	O
in	IN	O
an	DT	O
Fc	NNP	O
region	NN	O
of	IN	O
the	DT	O
antibody	NN	O
.	.	O
Alternatively	RB	O
or	CC	O
additionally	RB	O
,	,	O
cysteine	NN	O
residue	NN	O
(	(	O
s	PRP	O
)	)	O
may	MD	O
be	VB	O
introduced	VBN	O
in	IN	O
the	DT	O
Fc	NNP	O
region	NN	O
,	,	O
thereby	RB	O
allowing	VBG	O
interchain	JJ	O
disulfide	JJ	O
bond	NN	O
formation	NN	O
in	IN	O
this	DT	O
region	NN	O
.	.	O
The	DT	O
homodimeric	JJ	O
antibody	NN	O
thus	RB	O
generated	VBD	O
may	MD	O
have	VB	O
improved	VBN	O
internalization	NN	O
capability	NN	O
and/or	NN	O
increased	VBD	O
complement-mediated	JJ	O
cell	NN	O
killing	VBG	O
and	CC	O
antibody-dependent	JJ	O
cellular	JJ	O
cytotoxicity	NN	O
(	(	O
ADCC	NNP	O
)	)	O
.	.	O
See	VB	O
Caron	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Exp	NNP	I
Med	NNP	I
.	.	I
176:1191-1195	CD	I
(	(	I
1992	CD	I
)	)	I
and	CC	O
Shopes	NNP	B
,	,	I
B.	NNP	I
J.	NNP	I
Immunol	NNP	I
.	.	I
148:2918-2922	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
Homodimeric	JJ	O
antibodies	NNS	O
with	IN	O
enhanced	JJ	O
anti-tumor	JJ	O
activity	NN	O
may	MD	O
also	RB	O
be	VB	O
prepared	VBN	O
using	VBG	O
heterobifunctional	JJ	O
cross-linkers	NNS	O
as	IN	O
described	VBN	O
in	IN	O
Wolff	NNP	B
et	CC	I
al.	NN	I
,	,	I
Cancer	NNP	I
Research	NNP	I
53:2560-2565	CD	I
(	(	I
1993	CD	I
)	)	I
.	.	O
Alternatively	RB	O
,	,	O
an	DT	O
antibody	NN	O
can	MD	O
be	VB	O
engineered	VBN	O
which	WDT	O
has	VBZ	O
dual	JJ	O
Fc	NNP	O
regions	NNS	O
and	CC	O
may	MD	O
thereby	RB	O
have	VB	O
enhanced	VBN	O
complement	JJ	O
lysis	NN	O
and	CC	O
ADCC	NNP	O
capabilities	NNS	O
.	.	O
See	VB	O
Stevenson	NNP	B
et	FW	I
al.	NN	I
,	,	I
Anti-Cancer	NNP	I
Drug	NNP	I
Design	NNP	I
3:219-230	CD	I
(	(	I
1989	CD	I
)	)	I
.	.	O
To	TO	O
increase	VB	O
the	DT	O
serum	NN	O
half	JJ	O
life	NN	O
of	IN	O
the	DT	O
antibody	NN	O
,	,	O
one	CD	O
may	MD	O
incorporate	VB	O
a	DT	O
salvage	NN	O
receptor	NN	O
binding	VBG	O
epitope	NN	O
into	IN	O
the	DT	O
antibody	NN	O
(	(	O
especially	RB	O
an	DT	O
antibody	NN	O
fragment	NN	O
)	)	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,739,277	CD	O
,	,	O
for	IN	O
example	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
salvage	NN	O
receptor	NN	O
binding	VBG	O
epitope	NN	O
”	NN	O
refers	NNS	O
to	TO	O
an	DT	O
epitope	NN	O
of	IN	O
the	DT	O
Fc	NNP	O
region	NN	O
of	IN	O
an	DT	O
IgG	NNP	O
molecule	NN	O
(	(	O
e.g.	JJ	O
,	,	O
IgG1	NNP	O
,	,	O
IgG2	NNP	O
,	,	O
IgG3	NNP	O
,	,	O
or	CC	O
IgG4	NNP	O
)	)	O
that	WDT	O
is	VBZ	O
responsible	JJ	O
for	IN	O
increasing	VBG	O
the	DT	O
in	IN	O
vivo	JJ	O
serum	JJ	O
half-life	NN	O
of	IN	O
the	DT	O
IgG	NNP	O
molecule	NN	O
.	.	O
9	CD	O
.	.	O
Immunoconjugates	VBZ	O
The	DT	O
invention	NN	O
also	RB	O
pertains	VBZ	O
to	TO	O
immunoconjugates	VB	O
comprising	VBG	O
an	DT	O
antibody	NN	O
conjugated	VBD	O
to	TO	O
a	DT	O
cytotoxic	JJ	O
agent	NN	O
such	JJ	O
as	IN	O
a	DT	O
chemotherapeutic	JJ	O
agent	NN	O
,	,	O
a	DT	O
growth	NN	O
inhibitory	NN	O
agent	NN	O
,	,	O
a	DT	O
toxin	NN	O
(	(	O
e.g.	NN	O
,	,	O
an	DT	O
enzymatically	RB	O
active	JJ	O
toxin	NN	O
of	IN	O
bacterial	JJ	O
,	,	O
fungal	JJ	O
,	,	O
plant	NN	O
,	,	O
or	CC	O
animal	JJ	O
origin	NN	O
,	,	O
or	CC	O
fragments	NNS	O
thereof	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
radioactive	JJ	O
isotope	NN	O
(	(	O
i.e.	FW	O
,	,	O
a	DT	O
radioconjugate	NN	O
)	)	O
.	.	O
Chemotherapeutic	JJ	O
agents	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
generation	NN	O
of	IN	O
such	JJ	O
immunoconjugates	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
above	IN	O
.	.	O
Enzymatically	RB	O
active	JJ	O
toxins	NNS	O
and	CC	O
fragments	NNS	O
thereof	VBP	O
that	IN	O
can	MD	O
be	VB	O
used	VBN	O
include	VBP	O
diphtheria	NNS	O
A	NNP	O
chain	NN	O
,	,	O
nonbinding	VBG	O
active	JJ	O
fragments	NNS	O
of	IN	O
diphtheria	NN	O
toxin	NN	O
,	,	O
exotoxin	VBZ	O
A	NNP	O
chain	NN	O
(	(	O
from	IN	O
Pseudomonas	NNP	O
aeruginosa	NN	O
)	)	O
,	,	O
ricin	VBZ	O
A	NNP	O
chain	NN	O
,	,	O
abrin	VBZ	O
A	NNP	O
chain	NN	O
,	,	O
modeccin	VBZ	O
A	NNP	O
chain	NN	O
,	,	O
alpha-sarcin	JJ	O
,	,	O
Aleurites	NNP	O
fordii	VBP	O
proteins	NNS	O
,	,	O
dianthin	JJ	O
proteins	NNS	O
,	,	O
Phytolaca	NNP	O
americana	NN	O
proteins	NNS	O
(	(	O
PAPI	NNP	O
,	,	O
PAPII	NNP	O
,	,	O
and	CC	O
PAP-S	NNP	O
)	)	O
,	,	O
momordica	JJ	O
charantia	NN	O
inhibitor	NN	O
,	,	O
curcin	NN	O
,	,	O
crotin	NN	O
,	,	O
sapaonaria	NN	O
officinalis	NN	O
inhibitor	NN	O
,	,	O
gelonin	NN	O
,	,	O
mitogellin	NN	O
,	,	O
restrictocin	NN	O
,	,	O
phenomycin	NN	O
,	,	O
enomycin	NN	O
,	,	O
and	CC	O
the	DT	O
tricothecenes	NNS	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
radionuclides	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
radioconjugated	JJ	O
antibodies	NNS	O
.	.	O
Examples	NNS	O
include	VBP	O
212Bi	CD	O
,	,	O
131I	CD	O
,	,	O
131In	CD	O
,	,	O
90Y	CD	O
,	,	O
and	CC	O
186Re	CD	O
.	.	O
Conjugates	NNS	O
of	IN	O
the	DT	O
antibody	NN	O
and	CC	O
cytotoxic	NN	O
agent	NN	O
are	VBP	O
made	VBN	O
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
bifunctional	JJ	O
protein-coupling	JJ	O
agents	NNS	O
such	JJ	O
as	IN	O
N-succinimidyl-3-	NNP	O
(	(	O
2-pyridyldithiol	JJ	O
)	)	O
propionate	NN	O
(	(	O
SPDP	NNP	O
)	)	O
,	,	O
iminothiolane	NN	O
(	(	O
TT	NNP	O
)	)	O
,	,	O
bifunctional	JJ	O
derivatives	NNS	O
of	IN	O
imidoesters	NNS	O
(	(	O
such	JJ	O
as	IN	O
dimethyl	JJ	O
adipimidate	NN	O
HCL	NNP	O
)	)	O
,	,	O
active	JJ	O
esters	NNS	O
(	(	O
such	JJ	O
as	IN	O
disuccinimidyl	JJ	O
suberate	NN	O
)	)	O
,	,	O
aldehydes	NNS	O
(	(	O
such	JJ	O
as	IN	O
glutareldehyde	NN	O
)	)	O
,	,	O
bis-azido	JJ	O
compounds	NNS	O
(	(	O
such	JJ	O
as	IN	O
bis	NN	O
(	(	O
p-azidobenzoyl	JJ	O
)	)	O
hexanediamine	NN	O
)	)	O
,	,	O
bis-diazonium	JJ	O
derivatives	NNS	O
(	(	O
such	JJ	O
as	IN	O
bis-	JJ	O
(	(	O
p-diazoniumbenzoyl	JJ	O
)	)	O
-ethylenediamine	NN	O
)	)	O
,	,	O
diisocyanates	VBZ	O
(	(	O
such	JJ	O
as	IN	O
tolyene	JJ	O
2,6-diisocyanate	JJ	O
)	)	O
,	,	O
and	CC	O
bis-active	JJ	O
fluorine	NN	O
compounds	NNS	O
(	(	O
such	JJ	O
as	IN	O
1,5-difluoro-2,4-dinitrobenzene	JJ	O
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
ricin	NN	O
immunotoxin	NN	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Vitetta	NNP	B
et	CC	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
238	CD	I
:	:	I
1098	CD	I
(	(	I
1987	CD	I
)	)	I
.	.	O
Carbon-14-labeled	JJ	O
1-isothiocyanatobenzyl-3-methyldiethylene	JJ	O
triaminepentaacetic	JJ	O
acid	NN	O
(	(	O
MX-DTPA	NNP	O
)	)	O
is	VBZ	O
an	DT	O
exemplary	JJ	O
chelating	NN	O
agent	NN	O
for	IN	O
conjugation	NN	O
of	IN	O
radionucleotide	NN	O
to	TO	O
the	DT	O
antibody	NN	O
.	.	O
See	VB	O
WO94/11026	NNP	O
.	.	O
Conjugates	NNS	O
of	IN	O
an	DT	O
antibody	NN	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
small	JJ	O
molecule	NN	O
toxins	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
calicheamicin	NN	O
,	,	O
maytansinoids	NNS	O
,	,	O
a	DT	O
trichothene	NN	O
,	,	O
and	CC	O
CC1065	NNP	O
,	,	O
and	CC	O
the	DT	O
derivatives	NNS	O
of	IN	O
these	DT	O
toxins	NNS	O
that	WDT	O
have	VBP	O
toxin	VBN	O
activity	NN	O
,	,	O
are	VBP	O
also	RB	O
contemplated	VBN	O
herein	NN	O
.	.	O
Maytansine	NNP	O
and	CC	O
Maytansinoids	NNP	O
The	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
(	(	O
full	JJ	O
length	NN	O
or	CC	O
fragments	NNS	O
)	)	O
which	WDT	O
is	VBZ	O
conjugated	VBN	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
maytansinoid	JJ	O
molecules	NNS	O
.	.	O
Maytansinoids	NNS	O
are	VBP	O
mitototic	JJ	O
inhibitors	NNS	O
which	WDT	O
act	VBP	O
by	IN	O
inhibiting	VBG	O
tubulin	JJ	O
polymerization	NN	O
.	.	O
Maytansine	NNP	O
was	VBD	O
first	RB	O
isolated	VBN	O
from	IN	O
the	DT	O
east	JJ	O
African	JJ	O
shrub	NN	O
Maytenus	NNP	O
serrata	NN	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
3,896,111	CD	O
)	)	O
.	.	O
Subsequently	RB	O
,	,	O
it	PRP	O
was	VBD	O
discovered	VBN	O
that	IN	O
certain	JJ	O
microbes	NNS	O
also	RB	O
produce	VBP	O
maytansinoids	NNS	O
,	,	O
such	JJ	O
as	IN	O
maytansinol	NNS	O
and	CC	O
C-3	NNP	O
maytansinol	NN	O
esters	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,151,042	CD	O
)	)	O
.	.	O
Synthetic	JJ	O
maytansinol	NN	O
and	CC	O
derivatives	NNS	O
and	CC	O
analogues	NNS	O
thereof	NNS	O
are	VBP	O
disclosed	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,137,230	CD	O
;	:	O
4,248,870	CD	O
;	:	O
4,256,746	CD	O
;	:	O
4,260,608	CD	O
;	:	O
4,265,814	CD	O
;	:	O
4,294,757	CD	O
;	:	O
4,307,016	CD	O
;	:	O
4,308,268	CD	O
;	:	O
4,308,269	CD	O
;	:	O
4,309,428	CD	O
;	:	O
4,313,946	CD	O
;	:	O
4,315,929	CD	O
;	:	O
4,317,821	CD	O
;	:	O
4,322,348	CD	O
;	:	O
4,331,598	CD	O
;	:	O
4,361,650	CD	O
;	:	O
4,364,866	CD	O
;	:	O
4,424,219	CD	O
;	:	O
4,450,254	CD	O
;	:	O
4,362,663	CD	O
;	:	O
and	CC	O
4,371,533	CD	O
,	,	O
the	DT	O
disclosures	NNS	O
of	IN	O
which	WDT	O
are	VBP	O
hereby	RB	O
expressly	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Maytansinoid-Antibody	NN	O
Conjugates	NNS	O
In	IN	O
an	DT	O
attempt	NN	O
to	TO	O
improve	VB	O
their	PRP$	O
therapeutic	JJ	O
index	NN	O
,	,	O
maytansine	NN	O
and	CC	O
maytansinoids	NNS	O
have	VBP	O
been	VBN	O
conjugated	VBN	O
to	TO	O
antibodies	NNS	O
specifically	RB	O
binding	VBG	O
to	TO	O
tumor	VB	O
cell	NN	O
antigens	NNS	O
.	.	O
Immunoconjugates	NNS	O
containing	VBG	O
maytansinoids	NNS	O
and	CC	O
their	PRP$	O
therapeutic	JJ	O
use	NN	O
are	VBP	O
disclosed	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,208,020	CD	O
,	,	O
5,416,064	CD	O
and	CC	O
European	JJ	O
Patent	NNP	O
EP	NNP	O
0	CD	O
425	CD	O
235	CD	O
B1	NNP	O
,	,	O
the	DT	O
disclosures	NNS	O
of	IN	O
which	WDT	O
are	VBP	O
hereby	RB	O
expressly	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Liu	NNP	B
et	CC	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
93:8618-8623	CD	I
(	(	I
1996	CD	I
)	)	I
described	VBN	O
immunoconjugates	VBZ	O
comprising	VBG	O
a	DT	O
maytansinoid	NN	O
designated	VBN	O
DM1	NNP	O
linked	VBD	O
to	TO	O
the	DT	O
monoclonal	JJ	O
antibody	NN	O
C242	NNP	O
directed	VBD	O
against	IN	O
human	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O
The	DT	O
conjugate	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
highly	RB	O
cytotoxic	JJ	O
towards	NNS	O
cultured	VBN	O
colon	NN	O
cancer	NN	O
cells	NNS	O
,	,	O
and	CC	O
showed	VBD	O
antitumor	NN	O
activity	NN	O
in	IN	O
an	DT	O
in	IN	O
vivo	JJ	O
tumor	NN	O
growth	NN	O
assay	VBP	O
.	.	O
Chari	NNP	B
et	CC	I
al.	NN	I
,	,	I
Cancer	NNP	I
Research	NNP	I
52:127-131	CD	I
(	(	I
1992	CD	I
)	)	I
describe	NN	O
immunoconjugates	NNS	O
in	IN	O
which	WDT	O
a	DT	O
maytansinoid	NN	O
was	VBD	O
conjugated	VBN	O
via	IN	O
a	DT	O
disulfide	JJ	O
linker	NN	O
to	TO	O
the	DT	O
murine	NN	O
antibody	NN	O
A7	NNP	O
binding	NN	O
to	TO	O
an	DT	O
antigen	NN	O
on	IN	O
human	JJ	O
colon	NN	O
cancer	NN	O
cell	NN	O
lines	NNS	O
,	,	O
or	CC	O
to	TO	O
another	DT	O
murine	NN	O
monoclonal	NN	O
antibody	NN	O
TA.1	NNP	O
that	WDT	O
binds	VBZ	O
the	DT	O
HER-2/neu	NNP	O
oncogene	NN	O
.	.	O
The	DT	O
cytotoxicity	NN	O
of	IN	O
the	DT	O
TA.1-maytansonoid	JJ	O
conjugate	NN	O
was	VBD	O
tested	VBN	O
in	IN	O
vitro	NN	O
on	IN	O
the	DT	O
human	JJ	O
breast	NN	O
cancer	NN	O
cell	NN	O
line	NN	O
SK-BR-3	NNP	O
,	,	O
which	WDT	O
expresses	VBZ	O
3×105	CD	O
HER-2	JJ	O
surface	NN	O
antigens	NNS	O
per	IN	O
cell	NN	O
.	.	O
The	DT	O
drug	NN	O
conjugate	NN	O
achieved	VBD	O
a	DT	O
degree	NN	O
of	IN	O
cytotoxicity	NN	O
similar	JJ	O
to	TO	O
the	DT	O
free	JJ	O
maytansonid	NN	O
drug	NN	O
,	,	O
which	WDT	O
could	MD	O
be	VB	O
increased	VBN	O
by	IN	O
increasing	VBG	O
the	DT	O
number	NN	O
of	IN	O
maytansinoid	JJ	O
molecules	NNS	O
per	IN	O
antibody	NN	O
molecule	NN	O
.	.	O
The	DT	O
A7-maytansinoid	JJ	O
conjugate	NN	O
showed	VBD	O
low	JJ	O
systemic	JJ	O
cytotoxicity	NN	O
in	IN	O
mice	NN	O
.	.	O
Anti-PRO227	NNP	O
,	,	O
Anti-PRO233	NNP	O
,	,	O
Anti-PRO238	NNP	O
,	,	O
Anti-PRO1328	NNP	O
,	,	O
Anti-PRO4342	NNP	O
,	,	O
Anti-PRO7423	NNP	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
Anti-PRO1885	JJ	O
Antibody-Maytansinoid	JJ	O
Conjugates	NNP	O
(	(	O
Immunoconjugates	NNP	O
)	)	O
Anti-PRO227	NNP	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody-maytansinoid	JJ	O
conjugates	NNS	O
are	VBP	O
prepared	VBN	O
by	IN	O
chemically	RB	O
linking	VBG	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
to	TO	O
a	DT	O
maytansinoid	NN	O
molecule	NN	O
without	IN	O
significantly	RB	O
diminishing	VBG	O
the	DT	O
biological	JJ	O
activity	NN	O
of	IN	O
either	CC	O
the	DT	O
antibody	NN	O
or	CC	O
the	DT	O
maytansinoid	JJ	O
molecule	NN	O
.	.	O
An	DT	O
average	NN	O
of	IN	O
3-4	JJ	O
maytansinoid	NN	O
molecules	NNS	O
conjugated	VBN	O
per	IN	O
antibody	NN	O
molecule	NN	O
has	VBZ	O
shown	VBN	O
efficacy	NN	O
in	IN	O
enhancing	VBG	O
cytotoxicity	NN	O
of	IN	O
target	NN	O
cells	NNS	O
without	IN	O
negatively	RB	O
affecting	VBG	O
the	DT	O
function	NN	O
or	CC	O
solubility	NN	O
of	IN	O
the	DT	O
antibody	NN	O
,	,	O
although	IN	O
even	RB	O
one	CD	O
molecule	NN	O
of	IN	O
toxin/antibody	NN	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
enhance	VB	O
cytotoxicity	NN	O
over	IN	O
the	DT	O
use	NN	O
of	IN	O
naked	JJ	O
antibody	NN	O
.	.	O
Maytansinoids	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
can	MD	O
be	VB	O
synthesized	VBN	O
by	IN	O
known	VBN	O
techniques	NNS	O
or	CC	O
isolated	VBN	O
from	IN	O
natural	JJ	O
sources	NNS	O
.	.	O
Suitable	JJ	O
maytansinoids	NNS	O
are	VBP	O
disclosed	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,208,020	CD	O
and	CC	O
in	IN	O
the	DT	O
other	JJ	O
patents	NNS	O
and	CC	O
nonpatent	JJ	O
publications	NNS	O
referred	VBD	O
to	TO	O
hereinabove	VB	O
.	.	O
Preferred	JJ	O
maytansinoids	NNS	O
are	VBP	O
maytansinol	JJ	O
and	CC	O
maytansinol	JJ	O
analogues	NNS	O
modified	VBN	O
in	IN	O
the	DT	O
aromatic	JJ	O
ring	NN	O
or	CC	O
at	IN	O
other	JJ	O
positions	NNS	O
of	IN	O
the	DT	O
maytansinol	NN	O
molecule	NN	O
,	,	O
such	JJ	O
as	IN	O
various	JJ	O
maytansinol	NN	O
esters	NNS	O
.	.	O
There	EX	O
are	VBP	O
many	JJ	O
linking	VBG	O
groups	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
making	VBG	O
antibody-maytansinoid	JJ	O
conjugates	NNS	O
,	,	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
those	DT	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,208,020	CD	O
or	CC	O
EP	NNP	O
Patent	NNP	O
0	CD	O
425	CD	O
235	CD	O
B1	NNP	O
,	,	O
and	CC	O
Chari	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Cancer	NNP	I
Research	NNP	I
52:127-131	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
The	DT	O
linking	VBG	O
groups	NNS	O
include	VBP	O
disulfide	JJ	O
groups	NNS	O
,	,	O
thioether	RB	O
groups	NNS	O
,	,	O
acid	VBP	O
labile	JJ	O
groups	NNS	O
,	,	O
photolabile	NN	O
groups	NNS	O
,	,	O
peptidase	NN	O
labile	NN	O
groups	NNS	O
,	,	O
or	CC	O
esterase	VB	O
labile	JJ	O
groups	NNS	O
,	,	O
as	IN	O
disclosed	VBN	O
in	IN	O
the	DT	O
above-identified	JJ	O
patents	NNS	O
,	,	O
disulfide	NN	O
and	CC	O
thioether	NN	O
groups	NNS	O
being	VBG	O
preferred	VBN	O
.	.	O
Conjugates	NNS	O
of	IN	O
the	DT	O
antibody	NN	O
and	CC	O
maytansinoid	NN	O
may	MD	O
be	VB	O
made	VBN	O
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
bifunctional	JJ	O
protein	NN	O
coupling	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
N-succinimidyl-3-	NNP	O
(	(	O
2-pyridyldithio	CD	O
)	)	O
propionate	NN	O
(	(	O
SPDP	NNP	O
)	)	O
,	,	O
succinimidyl-4-	JJ	O
(	(	O
N-maleimidomethyl	NNP	O
)	)	O
cyclohexane-1-carboxylate	NN	O
,	,	O
iminothiolane	NN	O
(	(	O
IT	NNP	O
)	)	O
,	,	O
bifunctional	JJ	O
derivatives	NNS	O
of	IN	O
imidoesters	NNS	O
(	(	O
such	JJ	O
as	IN	O
dimethyl	JJ	O
adipimidate	NN	O
HCL	NNP	O
)	)	O
,	,	O
active	JJ	O
esters	NNS	O
(	(	O
such	JJ	O
as	IN	O
disuccinimidyl	JJ	O
suberate	NN	O
)	)	O
,	,	O
aldehydes	NNS	O
(	(	O
such	JJ	O
as	IN	O
glutareldehyde	NN	O
)	)	O
,	,	O
bis-azido	JJ	O
compounds	NNS	O
(	(	O
such	JJ	O
as	IN	O
bis	NN	O
(	(	O
p-azidobenzoyl	JJ	O
)	)	O
hexanediamine	NN	O
)	)	O
,	,	O
bis-diazonium	JJ	O
derivatives	NNS	O
(	(	O
such	JJ	O
as	IN	O
bis-	JJ	O
(	(	O
p-diazoniumbenzoyl	JJ	O
)	)	O
-ethylenediamine	NN	O
)	)	O
,	,	O
diisocyanates	VBZ	O
(	(	O
such	JJ	O
as	IN	O
toluene	JJ	O
2,6-diisocyanate	JJ	O
)	)	O
,	,	O
and	CC	O
bis-active	JJ	O
fluorine	NN	O
compounds	NNS	O
(	(	O
such	JJ	O
as	IN	O
1,5-difluoro-2,4-dinitrobenzene	JJ	O
)	)	O
.	.	O
Particularly	RB	O
preferred	JJ	O
coupling	VBG	O
agents	NNS	O
include	VBP	O
N-succinimidyl-3-	NNP	O
(	(	O
2-pyridyldithio	CD	O
)	)	O
propionate	NN	O
(	(	O
SPDP	NNP	O
)	)	O
(	(	O
Carlsson	NNP	B
et	RB	I
al.	RB	I
,	,	I
Biochem	NNP	I
.	.	I
J	NNP	I
.	.	I
173:723-737	CD	I
[	JJ	I
1978	CD	I
]	NN	I
)	)	O
and	CC	O
N-succinimidyl-4-	NNP	O
(	(	O
2-pyridylthio	CD	O
)	)	O
pentanoate	NN	O
(	(	O
SPP	NNP	O
)	)	O
to	TO	O
provide	VB	O
for	IN	O
a	DT	O
disulfide	JJ	O
linkage	NN	O
.	.	O
The	DT	O
linker	NN	O
may	MD	O
be	VB	O
attached	VBN	O
to	TO	O
the	DT	O
maytansinoid	NN	O
molecule	NN	O
at	IN	O
various	JJ	O
positions	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
type	NN	O
of	IN	O
the	DT	O
link	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
ester	JJ	O
linkage	NN	O
may	MD	O
be	VB	O
formed	VBN	O
by	IN	O
reaction	NN	O
with	IN	O
a	DT	O
hydroxyl	NN	O
group	NN	O
using	VBG	O
conventional	JJ	O
coupling	NN	O
techniques	NNS	O
.	.	O
The	DT	O
reaction	NN	O
may	MD	O
occur	VB	O
at	IN	O
the	DT	O
C-3	NNP	O
position	NN	O
having	VBG	O
a	DT	O
hydroxyl	NN	O
group	NN	O
,	,	O
the	DT	O
C-14	NNP	O
position	NN	O
modified	VBD	O
with	IN	O
hyrdoxymethyl	NN	O
,	,	O
the	DT	O
C-15	NNP	O
position	NN	O
modified	VBD	O
with	IN	O
a	DT	O
hydroxyl	NN	O
group	NN	O
,	,	O
and	CC	O
the	DT	O
C-20	NNP	O
position	NN	O
having	VBG	O
a	DT	O
hydroxyl	NN	O
group	NN	O
.	.	O
The	DT	O
linkage	NN	O
is	VBZ	O
formed	VBN	O
at	IN	O
the	DT	O
C-3	NNP	O
position	NN	O
of	IN	O
maytansinol	NN	O
or	CC	O
a	DT	O
maytansinol	JJ	O
analogue	NN	O
.	.	O
Calicheamicin	NNP	O
Another	DT	O
immunoconjugate	NN	O
of	IN	O
interest	NN	O
comprises	NNS	O
an	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
conjugated	VBD	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
calicheamicin	JJ	O
molecules	NNS	O
.	.	O
The	DT	O
calicheamicin	JJ	O
family	NN	O
of	IN	O
antibiotics	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
producing	VBG	O
double-stranded	JJ	O
DNA	NNP	O
breaks	NNS	O
at	IN	O
sub-picomolar	JJ	O
concentrations	NNS	O
.	.	O
For	IN	O
the	DT	O
preparation	NN	O
of	IN	O
conjugates	NNS	O
of	IN	O
the	DT	O
calicheamicin	NN	O
family	NN	O
,	,	O
see	VBP	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,712,374	CD	O
,	,	O
5,714,586	CD	O
,	,	O
5,739,116	CD	O
,	,	O
5,767,285	CD	O
,	,	O
5,770,701	CD	O
,	,	O
5,770,710	CD	O
,	,	O
5,773,001	CD	O
,	,	O
5,877,296	CD	O
(	(	O
all	DT	O
to	TO	O
American	NNP	O
Cyanamid	NNP	O
Company	NNP	O
)	)	O
.	.	O
Structural	JJ	O
analogues	NNS	O
of	IN	O
calicheamicin	NN	O
which	WDT	O
may	MD	O
be	VB	O
used	VBN	O
include	NN	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
γ1	NNP	O
I	PRP	O
,	,	O
α2	''	O
I	PRP	O
,	,	O
α3	''	O
I	PRP	O
,	,	O
N-acetyl-γ1	NNP	O
I	PRP	O
,	,	O
PSAG	NNP	O
and	CC	O
θI	$	O
1	CD	O
(	(	O
Hinman	NNP	B
et	VBZ	I
al.	RB	I
,	,	I
Cancer	NNP	I
Research	NNP	I
53:3336-3342	CD	I
(	(	I
1993	CD	I
)	)	I
,	,	O
Lode	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cancer	NNP	I
Research	NNP	I
58:2925-2928	CD	I
(	(	I
1998	CD	I
)	)	I
and	CC	O
the	DT	O
aforementioned	JJ	O
U.S.	NNP	O
patents	NNS	O
to	TO	O
American	NNP	O
Cyanamid	NNP	O
)	)	O
.	.	O
Another	DT	O
anti-tumor	JJ	O
drug	NN	O
that	IN	O
the	DT	O
antibody	NN	O
can	MD	O
be	VB	O
conjugated	VBN	O
is	VBZ	O
QFA	NNP	O
which	WDT	O
is	VBZ	O
an	DT	O
antifolate	NN	O
.	.	O
Both	DT	O
calicheamicin	NN	O
and	CC	O
QFA	NNP	O
have	VBP	O
intracellular	JJ	O
sites	NNS	O
of	IN	O
action	NN	O
and	CC	O
do	VBP	O
not	RB	O
readily	RB	O
cross	VB	O
the	DT	O
plasma	NN	O
membrane	NN	O
.	.	O
Therefore	RB	O
,	,	O
cellular	JJ	O
uptake	NN	O
of	IN	O
these	DT	O
agents	NNS	O
through	IN	O
antibody	NN	O
mediated	VBN	O
internalization	NN	O
greatly	RB	O
enhances	VBZ	O
their	PRP$	O
cytotoxic	JJ	O
effects	NNS	O
.	.	O
Other	JJ	O
Cytotoxic	NNP	O
Agents	NNP	O
Other	JJ	O
antitumor	NN	O
agents	NNS	O
that	WDT	O
can	MD	O
be	VB	O
conjugated	VBN	O
to	TO	O
the	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
BCNU	NNP	O
,	,	O
streptozoicin	NN	O
,	,	O
vincristine	NN	O
and	CC	O
5-fluorouracil	JJ	O
,	,	O
the	DT	O
family	NN	O
of	IN	O
agents	NNS	O
known	VBN	O
collectively	RB	O
LL-E33288	NNP	O
complex	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,053,394	CD	O
,	,	O
5,770,710	CD	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
esperamicins	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,877,296	CD	O
)	)	O
.	.	O
Enzymatically	RB	O
active	JJ	O
toxins	NNS	O
and	CC	O
fragments	NNS	O
thereof	IN	O
which	WDT	O
can	MD	O
be	VB	O
used	VBN	O
include	VBP	O
diphtheria	NNS	O
A	NNP	O
chain	NN	O
,	,	O
nonbinding	VBG	O
active	JJ	O
fragments	NNS	O
of	IN	O
diphtheria	NN	O
toxin	NN	O
,	,	O
exotoxin	VBZ	O
A	NNP	O
chain	NN	O
(	(	O
from	IN	O
Pseudomonas	NNP	O
aeruginosa	NN	O
)	)	O
,	,	O
ricin	VBZ	O
A	NNP	O
chain	NN	O
,	,	O
abrin	VBZ	O
A	NNP	O
chain	NN	O
,	,	O
modeccin	VBZ	O
A	NNP	O
chain	NN	O
,	,	O
alpha-sarcin	JJ	O
,	,	O
Aleurites	NNP	O
fordii	VBP	O
proteins	NNS	O
,	,	O
dianthin	JJ	O
proteins	NNS	O
,	,	O
Phytolaca	NNP	O
americana	NN	O
proteins	NNS	O
(	(	O
PAPI	NNP	O
,	,	O
PAPII	NNP	O
,	,	O
and	CC	O
PAP-S	NNP	O
)	)	O
,	,	O
momordica	JJ	O
charantia	NN	O
inhibitor	NN	O
,	,	O
curcin	NN	O
,	,	O
crotin	NN	O
,	,	O
sapaonaria	NN	O
officinalis	NN	O
inhibitor	NN	O
,	,	O
gelonin	NN	O
,	,	O
mitogellin	NN	O
,	,	O
restrictocin	NN	O
,	,	O
phenomycin	NN	O
,	,	O
enomycin	NN	O
and	CC	O
the	DT	O
tricothecenes	NNS	O
.	.	O
See	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
WO	NNP	O
93/21232	CD	O
published	VBN	O
Oct.	NNP	O
28	CD	O
,	,	O
1993	CD	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
contemplates	VBZ	O
an	DT	O
immunoconjugate	NN	O
formed	VBD	O
between	IN	O
an	DT	O
antibody	NN	O
and	CC	O
a	DT	O
compound	NN	O
with	IN	O
nucleolytic	JJ	O
activity	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
ribonuclease	NN	O
or	CC	O
a	DT	O
DNA	JJ	O
endonuclease	NN	O
such	JJ	O
as	IN	O
a	DT	O
deoxyribonuclease	NN	O
;	:	O
DNase	NNP	O
)	)	O
.	.	O
For	IN	O
selective	JJ	O
destruction	NN	O
of	IN	O
the	DT	O
tumor	NN	O
,	,	O
the	DT	O
antibody	NN	O
may	MD	O
comprise	VB	O
a	DT	O
highly	RB	O
radioactive	JJ	O
atom	NN	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
radioactive	JJ	O
isotopes	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
radioconjugated	JJ	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
.	.	O
Examples	NNS	O
include	VBP	O
At211	NNP	O
,	,	O
I131	NNP	O
,	,	O
I125	NNP	O
,	,	O
Y90	NNP	O
,	,	O
Re186	NNP	O
,	,	O
Re188	NNP	O
,	,	O
Sm153	NNP	O
,	,	O
Bi212	NNP	O
,	,	O
P32	NNP	O
,	,	O
Pb212	NNP	O
and	CC	O
radioactive	JJ	O
isotopes	NNS	O
of	IN	O
Lu	NNP	O
.	.	O
When	WRB	O
the	DT	O
conjugate	NN	O
is	VBZ	O
used	VBN	O
for	IN	O
diagnosis	NN	O
,	,	O
it	PRP	O
may	MD	O
comprise	VB	O
a	DT	O
radioactive	JJ	O
atom	NN	O
for	IN	O
scintigraphic	JJ	O
studies	NNS	O
,	,	O
for	IN	O
example	NN	O
tc99m	NN	O
or	CC	O
I123	NNP	O
,	,	O
or	CC	O
a	DT	O
spin	JJ	O
label	NN	O
for	IN	O
nuclear	JJ	O
magnetic	JJ	O
resonance	NN	O
(	(	O
NMR	NNP	O
)	)	O
imaging	NN	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
,	,	O
mri	NN	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
iodine-123	NN	O
again	RB	O
,	,	O
iodine-131	JJ	O
,	,	O
indium-111	JJ	O
,	,	O
fluorine-19	JJ	O
,	,	O
carbon-13	JJ	O
,	,	O
nitrogen-15	JJ	O
,	,	O
oxygen-17	JJ	O
,	,	O
gadolinium	NN	O
,	,	O
manganese	JJ	O
or	CC	O
iron	NN	O
.	.	O
The	DT	O
radio-	NN	O
or	CC	O
other	JJ	O
labels	NNS	O
may	MD	O
be	VB	O
incorporated	VBN	O
in	IN	O
the	DT	O
conjugate	NN	O
in	IN	O
known	JJ	O
ways	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
peptide	NN	O
may	MD	O
be	VB	O
biosynthesized	VBN	O
or	CC	O
may	MD	O
be	VB	O
synthesized	VBN	O
by	IN	O
chemical	NN	O
amino	NN	O
acid	JJ	O
synthesis	NN	O
using	VBG	O
suitable	JJ	O
amino	NN	O
acid	NN	O
precursors	NNS	O
involving	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
fluorine-19	NN	O
in	IN	O
place	NN	O
of	IN	O
hydrogen	NN	O
.	.	O
Labels	NNS	O
such	JJ	O
as	IN	O
tc99m	NN	O
or	CC	O
I123	NNP	O
,	,	O
Re186	NNP	O
,	,	O
Re188	NNP	O
and	CC	O
In111	NNP	O
can	MD	O
be	VB	O
attached	VBN	O
via	IN	O
a	DT	O
cysteine	NN	O
residue	NN	O
in	IN	O
the	DT	O
peptide	NN	O
.	.	O
Yttrium-90	NN	O
can	MD	O
be	VB	O
attached	VBN	O
via	IN	O
a	DT	O
lysine	NN	O
residue	NN	O
.	.	O
The	DT	O
IODOGEN	NNP	O
method	NN	O
(	(	O
Fraker	NNP	B
et	VBZ	I
al	NN	I
(	(	I
1978	CD	I
)	)	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun	NNP	I
.	.	I
80	CD	I
:	:	I
49-57	JJ	I
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
incorporate	VB	O
iodine-123	NN	O
.	.	O
“	JJ	B
Monoclonal	NNP	I
Antibodies	NNPS	I
in	IN	I
Immunoscintigraphy	NNP	I
”	NNP	I
(	(	I
Chatal	NNP	I
,	,	I
CRC	NNP	I
Press	NNP	I
1989	CD	I
)	)	I
describes	VBZ	O
other	JJ	O
methods	NNS	O
in	IN	O
detail	NN	O
.	.	O
Conjugates	NNS	O
of	IN	O
the	DT	O
antibody	NN	O
and	CC	O
cytotoxic	JJ	O
agent	NN	O
may	MD	O
be	VB	O
made	VBN	O
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
bifunctional	JJ	O
protein	NN	O
coupling	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
N-succinimidyl-3-	NNP	O
(	(	O
2-pyridyldithio	CD	O
)	)	O
propionate	NN	O
(	(	O
SPDP	NNP	O
)	)	O
,	,	O
succinimidyl-4-	JJ	O
(	(	O
N-maleimidomethyl	NNP	O
)	)	O
cyclohexane-1-carboxylate	NN	O
,	,	O
iminothiolane	NN	O
(	(	O
IT	NNP	O
)	)	O
,	,	O
bifunctional	JJ	O
derivatives	NNS	O
of	IN	O
imidoesters	NNS	O
(	(	O
such	JJ	O
as	IN	O
dimethyl	JJ	O
adipimidate	NN	O
HCL	NNP	O
)	)	O
,	,	O
active	JJ	O
esters	NNS	O
(	(	O
such	JJ	O
as	IN	O
disuccinimidyl	JJ	O
suberate	NN	O
)	)	O
,	,	O
aldehydes	NNS	O
(	(	O
such	JJ	O
as	IN	O
glutareldehyde	NN	O
)	)	O
,	,	O
bis-azido	JJ	O
compounds	NNS	O
(	(	O
such	JJ	O
as	IN	O
bis	NN	O
(	(	O
p-azidobenzoyl	JJ	O
)	)	O
hexanediamine	NN	O
)	)	O
,	,	O
bis-diazonium	JJ	O
derivatives	NNS	O
(	(	O
such	JJ	O
as	IN	O
bis-	JJ	O
(	(	O
p-diazoniumbenzoyl	JJ	O
)	)	O
-ethylenediamine	NN	O
)	)	O
,	,	O
diisocyanates	VBZ	O
(	(	O
such	JJ	O
as	IN	O
tolyene	JJ	O
2,6-diisocyanate	JJ	O
)	)	O
,	,	O
and	CC	O
bis-active	JJ	O
fluorine	NN	O
compounds	NNS	O
(	(	O
such	JJ	O
as	IN	O
1,5-difluoro-2,4-dinitrobenzene	JJ	O
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
ricin	NN	O
immunotoxin	NN	O
can	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Vitetta	NNP	B
et	CC	I
al.	NN	I
,	,	I
Science	NNP	I
238:1098	CD	I
(	(	I
1987	CD	I
)	)	I
.	.	O
Carbon-14-labeled	JJ	O
1-isothiocyanatobenzyl-3-methyldiethylene	JJ	O
triaminepentaacetic	JJ	O
acid	NN	O
(	(	O
MX-DTPA	NNP	O
)	)	O
is	VBZ	O
an	DT	O
exemplary	JJ	O
chelating	NN	O
agent	NN	O
for	IN	O
conjugation	NN	O
of	IN	O
radionucleotide	NN	O
to	TO	O
the	DT	O
antibody	NN	O
.	.	O
See	VB	O
WO94/11026	NNP	O
.	.	O
The	DT	O
linker	NN	O
may	MD	O
be	VB	O
a	DT	O
“	JJ	O
cleavable	JJ	O
linker	NN	O
”	NNP	O
facilitating	VBG	O
release	NN	O
of	IN	O
the	DT	O
cytotoxic	JJ	O
drug	NN	O
in	IN	O
the	DT	O
cell	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
acid-labile	JJ	O
linker	NN	O
,	,	O
peptidase-sensitive	JJ	O
linker	NN	O
,	,	O
photolabile	NN	O
linker	NN	O
,	,	O
dimethyl	JJ	O
linker	NN	O
or	CC	O
disulfide-containing	JJ	O
linker	NN	O
(	(	O
Chari	NNP	B
et	RB	I
al.	RB	I
,	,	I
Cancer	NNP	I
Research	NNP	I
52:127-131	CD	I
(	(	I
1992	CD	I
)	)	I
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,208,020	CD	O
)	)	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O
Alternatively	RB	O
,	,	O
a	DT	O
fusion	NN	O
protein	NN	O
comprising	VBG	O
the	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
and	CC	O
cytotoxic	JJ	O
agent	NN	O
may	MD	O
be	VB	O
made	VBN	O
,	,	O
e.g.	VB	O
,	,	O
by	IN	O
recombinant	JJ	O
techniques	NNS	O
or	CC	O
peptide	JJ	O
synthesis	NN	O
.	.	O
The	DT	O
length	NN	O
of	IN	O
DNA	NNP	O
may	MD	O
comprise	VB	O
respective	JJ	O
regions	NNS	O
encoding	VBG	O
the	DT	O
two	CD	O
portions	NNS	O
of	IN	O
the	DT	O
conjugate	NN	O
either	CC	O
adjacent	JJ	O
one	CD	O
another	DT	O
or	CC	O
separated	VBN	O
by	IN	O
a	DT	O
region	NN	O
encoding	VBG	O
a	DT	O
linker	NN	O
peptide	NN	O
which	WDT	O
does	VBZ	O
not	RB	O
destroy	VB	O
the	DT	O
desired	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
conjugate	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
that	IN	O
the	DT	O
antibody	NN	O
may	MD	O
be	VB	O
conjugated	VBN	O
to	TO	O
a	DT	O
“	JJ	O
receptor	NN	O
”	NNP	O
(	(	O
such	JJ	O
streptavidin	NN	O
)	)	O
for	IN	O
utilization	NN	O
in	IN	O
tumor	NN	O
pre-targeting	NN	O
wherein	IN	O
the	DT	O
antibody-receptor	JJ	O
conjugate	NN	O
is	VBZ	O
administered	VBN	O
to	TO	O
the	DT	O
patient	NN	O
,	,	O
followed	VBN	O
by	IN	O
removal	NN	O
of	IN	O
unbound	JJ	O
conjugate	NN	O
from	IN	O
the	DT	O
circulation	NN	O
using	VBG	O
a	DT	O
clearing	NN	O
agent	NN	O
and	CC	O
then	RB	O
administration	NN	O
of	IN	O
a	DT	O
“	JJ	O
ligand	NN	O
”	NNP	O
(	(	O
e.g.	NN	O
,	,	O
avidin	NN	O
)	)	O
which	WDT	O
is	VBZ	O
conjugated	VBN	O
to	TO	O
a	DT	O
cytotoxic	NN	O
agent	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
radionucleotide	NN	O
)	)	O
.	.	O
10	CD	O
.	.	O
Immunoliposomes	VBZ	O
The	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
disclosed	VBN	O
herein	NN	O
may	MD	O
also	RB	O
be	VB	O
formulated	VBN	O
as	IN	O
immunoliposomes	NNS	O
.	.	O
A	DT	O
“	JJ	O
liposome	NN	O
”	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
vesicle	NN	O
composed	VBN	O
of	IN	O
various	JJ	O
types	NNS	O
of	IN	O
lipids	NNS	O
,	,	O
phospholipids	NNS	O
and/or	VBP	O
surfactant	JJ	O
which	WDT	O
is	VBZ	O
useful	JJ	O
for	IN	O
delivery	NN	O
of	IN	O
a	DT	O
drug	NN	O
to	TO	O
a	DT	O
mammal	NN	O
.	.	O
The	DT	O
components	NNS	O
of	IN	O
the	DT	O
liposome	NN	O
are	VBP	O
commonly	RB	O
arranged	VBN	O
in	IN	O
a	DT	O
bilayer	NN	O
formation	NN	O
,	,	O
similar	JJ	O
to	TO	O
the	DT	O
lipid	JJ	O
arrangement	NN	O
of	IN	O
biological	JJ	O
membranes	NNS	O
.	.	O
Liposomes	NNS	O
containing	VBG	O
the	DT	O
antibody	NN	O
are	VBP	O
prepared	VBN	O
by	IN	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
such	JJ	O
as	IN	O
described	NNS	O
in	IN	O
Epstein	NNP	B
et	CC	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
82:3688	CD	I
(	(	I
1985	CD	I
)	)	I
;	:	O
Hwang	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
77:4030	CD	I
(	(	I
1980	CD	I
)	)	I
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,485,045	CD	O
and	CC	O
4,544,545	CD	O
;	:	O
and	CC	O
WO97/38731	NNP	O
published	VBD	O
Oct.	NNP	O
23	CD	O
,	,	O
1997	CD	O
.	.	O
Liposomes	NNS	O
with	IN	O
enhanced	JJ	O
circulation	NN	O
time	NN	O
are	VBP	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,013,556	CD	O
.	.	O
Particularly	RB	O
useful	JJ	O
liposomes	NNS	O
can	MD	O
be	VB	O
generated	VBN	O
by	IN	O
the	DT	O
reverse	NN	O
phase	NN	O
evaporation	NN	O
method	NN	O
with	IN	O
a	DT	O
lipid	JJ	O
composition	NN	O
comprising	VBG	O
phosphatidylcholine	NN	O
,	,	O
cholesterol	NN	O
and	CC	O
PEG-derivatized	JJ	O
phosphatidylethanolamine	NN	O
(	(	O
PEG-PE	NNP	O
)	)	O
.	.	O
Liposomes	NNS	O
are	VBP	O
extruded	VBN	O
through	IN	O
filters	NNS	O
of	IN	O
defined	VBN	O
pore	NN	O
size	NN	O
to	TO	O
yield	VB	O
liposomes	RB	O
with	IN	O
the	DT	O
desired	JJ	O
diameter	NN	O
.	.	O
Fab′	NNP	O
fragments	NNS	O
of	IN	O
the	DT	O
antibody	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
conjugated	VBN	O
to	TO	O
the	DT	O
liposomes	NNS	O
as	IN	O
described	VBN	O
in	IN	O
Martin	NNP	B
et	CC	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
257:286-288	CD	I
(	(	I
1982	CD	I
)	)	I
via	IN	O
a	DT	O
disulfide	JJ	O
interchange	NN	O
reaction	NN	O
.	.	O
A	DT	O
chemotherapeutic	JJ	O
agent	NN	O
is	VBZ	O
optionally	RB	O
contained	VBN	O
within	IN	O
the	DT	O
liposome	NN	O
.	.	O
See	VB	O
Gabizon	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
National	NNP	I
Cancer	NNP	I
Inst	NNP	I
.	.	I
81	CD	I
(	(	I
19	CD	I
)	)	I
:1484	NN	I
(	(	I
1989	CD	I
)	)	I
.	.	O
11	CD	O
.	.	O
Pharmaceutical	JJ	O
Compositions	NNS	O
of	IN	O
Antibodies	NNP	O
Antibodies	NNP	O
specifically	RB	O
binding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
identified	VBD	O
herein	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
molecules	NNS	O
identified	VBN	O
by	IN	O
the	DT	O
screening	NN	O
assays	NNS	O
disclosed	VBD	O
hereinbefore	RB	O
,	,	O
can	MD	O
be	VB	O
administered	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
various	JJ	O
disorders	NNS	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
.	.	O
If	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
intracellular	JJ	O
and	CC	O
whole	JJ	O
antibodies	NNS	O
are	VBP	O
used	VBN	O
as	IN	O
inhibitors	NNS	O
,	,	O
internalizing	VBG	O
antibodies	NNS	O
are	VBP	O
preferred	VBN	O
.	.	O
However	RB	O
,	,	O
lipofections	NNS	O
or	CC	O
liposomes	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
deliver	VB	O
the	DT	O
antibody	NN	O
,	,	O
or	CC	O
an	DT	O
antibody	NN	O
fragment	NN	O
,	,	O
into	IN	O
cells	NNS	O
.	.	O
Where	WRB	O
antibody	NN	O
fragments	NNS	O
are	VBP	O
used	VBN	O
,	,	O
the	DT	O
smallest	JJS	O
inhibitory	JJ	O
fragment	NN	O
that	WDT	O
specifically	RB	O
binds	VBZ	O
to	TO	O
the	DT	O
binding	VBG	O
domain	NN	O
of	IN	O
the	DT	O
target	NN	O
protein	NN	O
is	VBZ	O
preferred	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
based	VBN	O
upon	IN	O
the	DT	O
variable-region	NN	O
sequences	NNS	O
of	IN	O
an	DT	O
antibody	NN	O
,	,	O
peptide	IN	O
molecules	NNS	O
can	MD	O
be	VB	O
designed	VBN	O
that	IN	O
retain	VBP	O
the	DT	O
ability	NN	O
to	TO	O
bind	VB	O
the	DT	O
target	NN	O
protein	NN	O
sequence	NN	O
.	.	O
Such	JJ	O
peptides	NNS	O
can	MD	O
be	VB	O
synthesized	VBN	O
chemically	RB	O
and/or	RB	O
produced	VBN	O
by	IN	O
recombinant	JJ	O
DNA	NNP	O
technology	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Marasco	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
90	CD	I
:	:	I
7889-7893	CD	I
(	(	I
1993	CD	I
)	)	I
.	.	O
The	DT	O
formulation	NN	O
herein	NN	O
may	MD	O
also	RB	O
contain	VB	O
more	JJR	O
than	IN	O
one	CD	O
active	JJ	O
compound	NN	O
as	IN	O
necessary	JJ	O
for	IN	O
the	DT	O
particular	JJ	O
indication	NN	O
being	VBG	O
treated	VBN	O
,	,	O
preferably	RB	O
those	DT	O
with	IN	O
complementary	JJ	O
activities	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
adversely	RB	O
affect	JJ	O
each	DT	O
other	JJ	O
.	.	O
Alternatively	RB	O
,	,	O
or	CC	O
in	IN	O
addition	NN	O
,	,	O
the	DT	O
composition	NN	O
may	MD	O
comprise	VB	O
an	DT	O
agent	NN	O
that	WDT	O
enhances	VBZ	O
its	PRP$	O
function	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
cytotoxic	NN	O
agent	NN	O
,	,	O
cytokine	NN	O
,	,	O
chemotherapeutic	JJ	O
agent	NN	O
,	,	O
or	CC	O
growth-inhibitory	JJ	O
agent	NN	O
.	.	O
Such	JJ	O
molecules	NNS	O
are	VBP	O
suitably	RB	O
present	JJ	O
in	IN	O
combination	NN	O
in	IN	O
amounts	NNS	O
that	WDT	O
are	VBP	O
effective	JJ	O
for	IN	O
the	DT	O
purpose	NN	O
intended	VBN	O
.	.	O
The	DT	O
active	JJ	O
ingredients	NNS	O
may	MD	O
also	RB	O
be	VB	O
entrapped	VBN	O
in	IN	O
microcapsules	NNS	O
prepared	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
coacervation	NN	O
techniques	NNS	O
or	CC	O
by	IN	O
interfacial	JJ	O
polymerization	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
hydroxymethylcellulose	VB	O
or	CC	O
gelatin-microcapsules	NNS	O
and	CC	O
poly-	NN	O
(	(	O
methylmethacylate	NN	O
)	)	O
microcapsules	NNS	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
colloidal	JJ	O
drug	NN	O
delivery	NN	O
systems	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
liposomes	RB	O
,	,	O
albumin	JJ	O
microspheres	NNS	O
,	,	O
microemulsions	NNS	O
,	,	O
nano-particles	NNS	O
,	,	O
and	CC	O
nanocapsules	NNS	O
)	)	O
or	CC	O
in	IN	O
macroemulsions	NNS	O
.	.	O
Such	JJ	O
techniques	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
Remington	NNP	O
's	POS	O
Pharmaceutical	NNP	O
Sciences	NNPS	O
,	,	O
supra	NN	O
.	.	O
The	DT	O
formulations	NNS	O
to	TO	O
be	VB	O
used	VBN	O
for	IN	O
in	IN	O
vivo	JJ	O
administration	NN	O
must	MD	O
be	VB	O
sterile	JJ	O
.	.	O
This	DT	O
is	VBZ	O
readily	RB	O
accomplished	VBN	O
by	IN	O
filtration	NN	O
through	IN	O
sterile	JJ	O
filtration	NN	O
membranes	NNS	O
.	.	O
Sustained-release	JJ	O
preparations	NNS	O
may	MD	O
be	VB	O
prepared	VBN	O
.	.	O
Suitable	JJ	O
examples	NNS	O
of	IN	O
sustained-release	JJ	O
preparations	NNS	O
include	VBP	O
semipermeable	JJ	O
matrices	NNS	O
of	IN	O
solid	JJ	O
hydrophobic	NN	O
polymers	NNS	O
containing	VBG	O
the	DT	O
antibody	NN	O
,	,	O
which	WDT	O
matrices	NNS	O
are	VBP	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
shaped	JJ	O
articles	NNS	O
,	,	O
e.g.	NN	O
,	,	O
films	NNS	O
,	,	O
or	CC	O
microcapsules	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
sustained-release	JJ	O
matrices	NNS	O
include	VBP	O
polyesters	NNS	O
,	,	O
hydrogels	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
poly	NN	O
(	(	O
2-hydroxyethyl-methacrylate	JJ	O
)	)	O
,	,	O
or	CC	O
poly	NN	O
(	(	O
vinylalcohol	NN	O
)	)	O
)	)	O
,	,	O
polylactides	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
3,773,919	CD	O
)	)	O
,	,	O
copolymers	NNS	O
of	IN	O
L-glutamic	NNP	O
acid	NN	O
and	CC	O
γ	JJ	O
ethyl-L-glutamate	JJ	O
,	,	O
non-degradable	JJ	O
ethylene-vinyl	JJ	O
acetate	NN	O
,	,	O
degradable	JJ	O
lactic	JJ	O
acid-glycolic	JJ	O
acid	NN	O
copolymers	NNS	O
such	JJ	O
as	IN	O
the	DT	O
LUPRON	NNP	O
DEPOT™	NNP	O
(	(	O
injectable	JJ	O
microspheres	NNS	O
composed	VBN	O
of	IN	O
lactic	JJ	O
acid-glycolic	JJ	O
acid	NN	O
copolymer	NN	O
and	CC	O
leuprolide	JJ	O
acetate	NN	O
)	)	O
,	,	O
and	CC	O
poly-D-	NN	O
(	(	O
−	NNP	O
)	)	O
-3-hydroxybutyric	JJ	O
acid	NN	O
.	.	O
While	IN	O
polymers	NNS	O
such	JJ	O
as	IN	O
ethylene-vinyl	JJ	O
acetate	NN	O
and	CC	O
lactic	JJ	O
acid-glycolic	JJ	O
acid	NN	O
enable	JJ	O
release	NN	O
of	IN	O
molecules	NNS	O
for	IN	O
over	IN	O
100	CD	O
days	NNS	O
,	,	O
certain	JJ	O
hydrogels	NNS	O
release	VBP	O
proteins	NNS	O
for	IN	O
shorter	JJR	O
time	NN	O
periods	NNS	O
.	.	O
When	WRB	O
encapsulated	JJ	O
antibodies	NNS	O
remain	VBP	O
in	IN	O
the	DT	O
body	NN	O
for	IN	O
a	DT	O
long	JJ	O
time	NN	O
,	,	O
they	PRP	O
may	MD	O
denature	VB	O
or	CC	O
aggregate	VB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
exposure	NN	O
to	TO	O
moisture	VB	O
at	IN	O
37°	CD	O
C.	NNP	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
loss	NN	O
of	IN	O
biological	JJ	O
activity	NN	O
and	CC	O
possible	JJ	O
changes	NNS	O
in	IN	O
immunogenicity	NN	O
.	.	O
Rational	JJ	O
strategies	NNS	O
can	MD	O
be	VB	O
devised	VBN	O
for	IN	O
stabilization	NN	O
depending	VBG	O
on	IN	O
the	DT	O
mechanism	NN	O
involved	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
if	IN	O
the	DT	O
aggregation	NN	O
mechanism	NN	O
is	VBZ	O
discovered	VBN	O
to	TO	O
be	VB	O
intermolecular	JJ	O
S—S	NNP	O
bond	NN	O
formation	NN	O
through	IN	O
thio-disulfide	JJ	O
interchange	NN	O
,	,	O
stabilization	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
modifying	VBG	O
sulfhydryl	NN	O
residues	NNS	O
,	,	O
lyophilizing	VBG	O
from	IN	O
acidic	JJ	O
solutions	NNS	O
,	,	O
controlling	VBG	O
moisture	NN	O
content	NN	O
,	,	O
using	VBG	O
appropriate	JJ	O
additives	NNS	O
,	,	O
and	CC	O
developing	VBG	O
specific	JJ	O
polymer	NN	O
matrix	NN	O
compositions	NNS	O
.	.	O
G.	NNP	O
Uses	VBZ	O
for	IN	O
Anti-PRO227	NNP	O
,	,	O
Anti-PRO233	NNP	O
,	,	O
Anti-PRO238	NNP	O
,	,	O
Anti-PRO1328	NNP	O
,	,	O
Anti-PRO4342	NNP	O
,	,	O
Anti-PRO7423	NNP	O
;	:	O
Anti-PRO10096	NNP	O
;	:	O
Anti-PRO21384	NNP	O
;	:	O
Anti-PRO353	NNP	O
or	CC	O
Anti-PRO1885	NNP	O
Antibodies	NNPS	O
The	DT	O
anti-PRO227	NN	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
various	JJ	O
therapeutic	JJ	O
and/or	NN	O
diagnostic	JJ	O
utilities	NNS	O
for	IN	O
a	DT	O
neurological	JJ	O
disorder	NN	O
;	:	O
a	DT	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder	NN	O
;	:	O
an	DT	O
immunological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
oncological	JJ	O
disorder	NN	O
;	:	O
an	DT	O
embryonic	JJ	O
developmental	NN	O
disorder	NN	O
or	CC	O
lethality	NN	O
,	,	O
or	CC	O
a	DT	O
metabolic	JJ	O
abnormality	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
diagnostic	JJ	O
assays	NNS	O
for	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
,	,	O
e.g.	NN	O
,	,	O
detecting	VBG	O
its	PRP$	O
expression	NN	O
(	(	O
and	CC	O
in	IN	O
some	DT	O
cases	NNS	O
,	,	O
differential	JJ	O
expression	NN	O
)	)	O
in	IN	O
specific	JJ	O
cells	NNS	O
,	,	O
tissues	NNS	O
,	,	O
or	CC	O
serum	NN	O
.	.	O
Various	JJ	O
diagnostic	JJ	O
assay	NN	O
techniques	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
may	MD	O
be	VB	O
used	VBN	O
,	,	O
such	JJ	O
as	IN	O
competitive	JJ	O
binding	NN	O
assays	NNS	O
,	,	O
direct	JJ	O
or	CC	O
indirect	JJ	O
sandwich	NN	O
assays	NNS	O
and	CC	O
immunoprecipitation	NN	O
assays	NNS	O
conducted	VBN	O
in	IN	O
either	DT	O
heterogeneous	JJ	O
or	CC	O
homogeneous	JJ	O
phases	NNS	O
[	VBP	O
Zola	NNP	B
,	,	I
Monoclonal	NNP	I
Antibodies	NNPS	I
:	:	I
A	DT	I
Manual	NNP	I
of	IN	I
Techniques	NNP	I
,	,	I
CRC	NNP	I
Press	NNP	I
,	,	I
Inc.	NNP	I
(	(	I
1987	CD	I
)	)	I
pp	NN	I
.	.	I
147-158	JJ	I
]	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
used	VBN	O
in	IN	O
the	DT	O
diagnostic	JJ	O
assays	NNS	O
can	MD	O
be	VB	O
labeled	VBN	O
with	IN	O
a	DT	O
detectable	JJ	O
moiety	NN	O
.	.	O
The	DT	O
detectable	JJ	O
moiety	NN	O
should	MD	O
be	VB	O
capable	JJ	O
of	IN	O
producing	VBG	O
,	,	O
either	DT	O
directly	RB	O
or	CC	O
indirectly	RB	O
,	,	O
a	DT	O
detectable	JJ	O
signal	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
detectable	JJ	O
moiety	NN	O
may	MD	O
be	VB	O
a	DT	O
radioisotope	NN	O
,	,	O
such	JJ	O
as	IN	O
3H	CD	O
,	,	O
14C	CD	O
,	,	O
32P	CD	O
,	,	O
35S	CD	O
,	,	O
or	CC	O
125I	CD	O
,	,	O
a	DT	O
fluorescent	NN	O
or	CC	O
chemiluminescent	NN	O
compound	NN	O
,	,	O
such	JJ	O
as	IN	O
fluorescein	JJ	O
isothiocyanate	NN	O
,	,	O
rhodamine	NN	O
,	,	O
or	CC	O
luciferin	NN	O
,	,	O
or	CC	O
an	DT	O
enzyme	NN	O
,	,	O
such	JJ	O
as	IN	O
alkaline	JJ	O
phosphatase	NN	O
,	,	O
beta-galactosidase	NN	O
or	CC	O
horseradish	JJ	O
peroxidase	NN	O
.	.	O
Any	DT	O
method	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
conjugating	VBG	O
the	DT	O
antibody	NN	O
to	TO	O
the	DT	O
detectable	JJ	O
moiety	NN	O
may	MD	O
be	VB	O
employed	VBN	O
,	,	O
including	VBG	O
those	DT	O
methods	NNS	O
described	VBN	O
by	IN	O
Hunter	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
144:945	CD	I
(	(	I
1962	CD	I
)	)	I
;	:	O
David	NNP	B
et	FW	I
al.	NN	I
,	,	I
Biochemistry	NNP	I
,	,	I
13:1014	CD	I
(	(	I
1974	CD	I
)	)	I
;	:	O
Pain	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
Meth.	NNP	I
,	,	I
40:219	CD	I
(	(	I
1981	CD	I
)	)	I
;	:	O
and	CC	O
Nygren	NNP	B
,	,	I
J.	NNP	I
Histochem	NNP	I
.	.	I
and	CC	I
Cytochem.	NNP	I
,	,	I
30:407	CD	I
(	(	I
1982	CD	I
)	)	I
.	.	O
Anti-PRO227	NNP	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
also	RB	O
are	VBP	O
useful	JJ	O
for	IN	O
the	DT	O
affinity	NN	O
purification	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
from	IN	O
recombinant	NN	O
cell	NN	O
culture	NN	O
or	CC	O
natural	JJ	O
sources	NNS	O
.	.	O
In	IN	O
this	DT	O
process	NN	O
,	,	O
the	DT	O
antibodies	NNS	O
against	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
are	VBP	O
immobilized	VBN	O
on	IN	O
a	DT	O
suitable	JJ	O
support	NN	O
,	,	O
such	PDT	O
a	DT	O
Sephadex	NNP	O
resin	NN	O
or	CC	O
filter	JJ	O
paper	NN	O
,	,	O
using	VBG	O
methods	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
immobilized	JJ	O
antibody	NN	O
then	RB	O
is	VBZ	O
contacted	VBN	O
with	IN	O
a	DT	O
sample	NN	O
containing	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
to	TO	O
be	VB	O
purified	VBN	O
,	,	O
and	CC	O
thereafter	RB	O
the	DT	O
support	NN	O
is	VBZ	O
washed	VBN	O
with	IN	O
a	DT	O
suitable	JJ	O
solvent	NN	O
that	WDT	O
will	MD	O
remove	VB	O
substantially	RB	O
all	PDT	O
the	DT	O
material	NN	O
in	IN	O
the	DT	O
sample	NN	O
except	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
which	WDT	O
is	VBZ	O
bound	VBN	O
to	TO	O
the	DT	O
immobilized	VBN	O
antibody	NN	O
.	.	O
Finally	RB	O
,	,	O
the	DT	O
support	NN	O
is	VBZ	O
washed	VBN	O
with	IN	O
another	DT	O
suitable	JJ	O
solvent	NN	O
that	WDT	O
will	MD	O
release	VB	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
from	IN	O
the	DT	O
antibody	NN	O
.	.	O
The	DT	O
following	JJ	O
examples	NNS	O
are	VBP	O
offered	VBN	O
for	IN	O
illustrative	JJ	O
purposes	NNS	O
only	RB	O
,	,	O
and	CC	O
are	VBP	O
not	RB	O
intended	VBN	O
to	TO	O
limit	VB	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
in	IN	O
any	DT	O
way	NN	O
.	.	O
All	DT	O
patent	NN	O
and	CC	O
literature	NN	O
references	NNS	O
cited	VBD	O
in	IN	O
the	DT	O
present	JJ	O
specification	NN	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
.	.	O
EXAMPLES	NNP	O
Commercially	NNP	O
available	JJ	O
reagents	NNS	O
referred	VBD	O
to	TO	O
in	IN	O
the	DT	O
examples	NNS	O
were	VBD	O
used	VBN	O
according	VBG	O
to	TO	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
unless	IN	O
otherwise	RB	O
indicated	VBN	O
.	.	O
The	DT	O
source	NN	O
of	IN	O
those	DT	O
cells	NNS	O
identified	VBN	O
in	IN	O
the	DT	O
following	JJ	O
examples	NNS	O
,	,	O
and	CC	O
throughout	IN	O
the	DT	O
specification	NN	O
,	,	O
by	IN	O
ATCC	NNP	O
accession	NN	O
numbers	NNS	O
is	VBZ	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
,	,	O
Manassas	NNP	O
,	,	O
Va	NNP	O
.	.	O
Example	RB	O
1	CD	O
Extracellular	JJ	O
Domain	NNP	O
Homology	NNP	O
Screening	NNP	O
to	TO	O
Identify	NNP	O
Novel	NNP	O
Polypeptides	NNP	O
and	CC	O
cDNA	NN	O
Encoding	NNP	O
Therefor	NNP	O
The	DT	O
extracellular	JJ	O
domain	NN	O
(	(	O
ECD	NNP	O
)	)	O
sequences	NNS	O
(	(	O
including	VBG	O
the	DT	O
secretion	NN	O
signal	JJ	O
sequence	NN	O
,	,	O
if	IN	O
any	DT	O
)	)	O
from	IN	O
about	IN	O
950	CD	O
known	NNS	O
secreted	VBD	O
proteins	NNS	O
from	IN	O
the	DT	O
Swiss-Prot	NNP	O
public	JJ	O
database	NN	O
were	VBD	O
used	VBN	O
to	TO	O
search	VB	O
EST	NNP	O
databases	NNS	O
.	.	O
The	DT	O
EST	NNP	O
databases	NNS	O
included	VBD	O
public	JJ	O
databases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
Dayhoff	NNP	O
,	,	O
GenBank	NNP	O
)	)	O
,	,	O
and	CC	O
proprietary	JJ	O
databases	NNS	O
(	(	O
e.g	NN	O
.	.	O
LIFESEQ™	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
The	DT	O
search	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
computer	NN	O
program	NN	O
BLAST	NNP	O
or	CC	O
BLAST-2	NNP	O
(	(	O
Altschul	NNP	B
et	RB	I
al.	RB	I
,	,	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
,	,	I
266:460-480	CD	I
(	(	I
1996	CD	I
)	)	I
)	)	O
as	IN	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
ECD	NNP	O
protein	NN	O
sequences	NNS	O
to	TO	O
a	DT	O
6	CD	O
frame	NN	O
translation	NN	O
of	IN	O
the	DT	O
EST	NNP	O
sequences	NNS	O
.	.	O
Those	DT	O
comparisons	NNS	O
with	IN	O
a	DT	O
BLAST	NNP	O
score	NN	O
of	IN	O
70	CD	O
(	(	O
or	CC	O
in	IN	O
some	DT	O
cases	NNS	O
90	CD	O
)	)	O
or	CC	O
greater	JJR	O
that	WDT	O
did	VBD	O
not	RB	O
encode	VB	O
known	JJ	O
proteins	NNS	O
were	VBD	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
into	IN	O
consensus	NN	O
DNA	NNP	O
sequences	VBZ	O
with	IN	O
the	DT	O
program	NN	O
“	NNP	O
phrap	NN	O
”	NNP	O
(	(	O
Phil	NNP	O
Green	NNP	O
,	,	O
University	NNP	O
of	IN	O
Washington	NNP	O
,	,	O
Seattle	NNP	O
,	,	O
Wash.	NNP	O
)	)	O
.	.	O
Using	VBG	O
this	DT	O
extracellular	JJ	O
domain	NN	O
homology	NN	O
screen	NN	O
,	,	O
consensus	NN	O
DNA	NN	O
sequences	NNS	O
were	VBD	O
assembled	VBN	O
relative	JJ	O
to	TO	O
the	DT	O
other	JJ	O
identified	JJ	O
EST	NNP	O
sequences	NNS	O
using	VBG	O
phrap	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
consensus	NN	O
DNA	NNP	O
sequences	NNS	O
obtained	VBN	O
were	VBD	O
often	RB	O
(	(	O
but	CC	O
not	RB	O
always	RB	O
)	)	O
extended	VBD	O
using	VBG	O
repeated	JJ	O
cycles	NNS	O
of	IN	O
BLAST	NNP	O
or	CC	O
BLAST-2	NNP	O
and	CC	O
phrap	NN	O
to	TO	O
extend	VB	O
the	DT	O
consensus	NN	O
sequence	NN	O
as	RB	O
far	RB	O
as	IN	O
possible	JJ	O
using	VBG	O
the	DT	O
sources	NNS	O
of	IN	O
EST	NNP	O
sequences	NNS	O
discussed	VBN	O
above	IN	O
.	.	O
Based	VBN	O
upon	IN	O
the	DT	O
consensus	NN	O
sequences	NNS	O
obtained	VBD	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
oligonucleotides	NNS	O
were	VBD	O
then	RB	O
synthesized	VBN	O
and	CC	O
used	VBN	O
to	TO	O
identify	VB	O
by	IN	O
PCR	NNP	O
a	DT	O
cDNA	NN	O
library	NN	O
that	WDT	O
contained	VBD	O
the	DT	O
sequence	NN	O
of	IN	O
interest	NN	O
and	CC	O
for	IN	O
use	NN	O
as	IN	O
probes	NNS	O
to	TO	O
isolate	VB	O
a	DT	O
clone	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
coding	NN	O
sequence	NN	O
for	IN	O
a	DT	O
PRO	NNP	O
polypeptide	NN	O
.	.	O
Forward	NNP	O
and	CC	O
reverse	VB	O
PCR	NNP	O
primers	NNS	O
generally	RB	O
range	VBP	O
from	IN	O
20	CD	O
to	TO	O
30	CD	O
nucleotides	NNS	O
and	CC	O
are	VBP	O
often	RB	O
designed	VBN	O
to	TO	O
give	VB	O
a	DT	O
PCR	NNP	O
product	NN	O
of	IN	O
about	IN	O
100-1000	CD	O
bp	NN	O
in	IN	O
length	NN	O
.	.	O
The	DT	O
probe	NN	O
sequences	NNS	O
are	VBP	O
typically	RB	O
40-55	JJ	O
bp	NN	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
additional	JJ	O
oligonucleotides	NNS	O
are	VBP	O
synthesized	VBN	O
when	WRB	O
the	DT	O
consensus	NN	O
sequence	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
about	IN	O
1-1.5	JJ	O
kbp	NN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
,	,	O
as	IN	O
per	IN	O
Ausubel	NNP	B
et	FW	I
al.	NN	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	O
with	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pair	NN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
gene	NN	O
of	IN	O
interest	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
primer	NN	O
pairs	NNS	O
.	.	O
The	DT	O
cDNA	NN	O
libraries	NNS	O
used	VBN	O
to	TO	O
isolate	VB	O
the	DT	O
cDNA	NN	O
clones	NNS	O
were	VBD	O
constructed	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
using	VBG	O
commercially	RB	O
available	JJ	O
reagents	NNS	O
such	JJ	O
as	IN	O
those	DT	O
from	IN	O
Invitrogen	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif	NNP	O
.	.	O
The	DT	O
cDNA	NN	O
was	VBD	O
primed	VBN	O
with	IN	O
oligo	JJ	O
dT	NN	O
containing	VBG	O
a	DT	O
NotI	NNP	O
site	NN	O
,	,	O
linked	VBN	O
with	IN	O
blunt	NN	O
to	TO	O
SalI	NNP	O
hemikinased	VBD	O
adaptors	NNS	O
,	,	O
cleaved	VBN	O
with	IN	O
NotI	NNP	O
,	,	O
sized	VBD	O
appropriately	RB	O
by	IN	O
gel	JJ	O
electrophoresis	NN	O
,	,	O
and	CC	O
cloned	VBD	O
in	IN	O
a	DT	O
defined	JJ	O
orientation	NN	O
into	IN	O
a	DT	O
suitable	JJ	O
cloning	NN	O
vector	NN	O
(	(	O
such	JJ	O
as	IN	O
pRKB	NN	O
or	CC	O
pRKD	NN	O
;	:	O
pRK5B	NN	O
is	VBZ	O
a	DT	O
precursor	NN	O
of	IN	O
pRK5D	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
contain	VB	O
the	DT	O
SfiI	NNP	O
site	NN	O
;	:	O
see	VB	O
,	,	O
Holmes	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
253:1278-1280	CD	I
(	(	I
1991	CD	I
)	)	I
)	)	O
in	IN	O
the	DT	O
unique	JJ	O
XhoI	NNP	O
and	CC	O
NotI	NNP	O
sites	NNS	O
.	.	O
Example	RB	O
2	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNS	O
by	IN	O
Amylase	NNP	O
Screening	NNP	O
1	CD	O
.	.	O
Preparation	NN	O
of	IN	O
Oligo	NNP	O
dT	NN	O
Primed	NNP	O
cDNA	NN	O
Library	NNP	O
mRNA	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
a	DT	O
human	JJ	O
tissue	NN	O
of	IN	O
interest	NN	O
using	VBG	O
reagents	NNS	O
and	CC	O
protocols	NNS	O
from	IN	O
Invitrogen	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
(	(	O
Fast	NNP	O
Track	NNP	O
2	CD	O
)	)	O
.	.	O
This	DT	O
RNA	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
generate	VB	O
an	DT	O
oligo	JJ	O
dT	NN	O
primed	VBD	O
cDNA	JJ	O
library	NN	O
in	IN	O
the	DT	O
vector	NN	O
pRK5D	NN	O
using	VBG	O
reagents	NNS	O
and	CC	O
protocols	NNS	O
from	IN	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Gaithersburg	NNP	O
,	,	O
Md	NNP	O
.	.	O
(	(	O
Super	NNP	O
Script	NNP	O
Plasmid	NNP	O
System	NNP	O
)	)	O
.	.	O
In	IN	O
this	DT	O
procedure	NN	O
,	,	O
the	DT	O
double	NN	O
stranded	VBD	O
cDNA	NN	O
was	VBD	O
sized	VBN	O
to	TO	O
greater	JJR	O
than	IN	O
1000	CD	O
bp	NN	O
and	CC	O
the	DT	O
SalI/NotI	NNP	O
linkered	VBD	O
cDNA	NN	O
was	VBD	O
cloned	VBN	O
into	IN	O
XhoI/NotI	NNP	O
cleaved	VBD	O
vector	NN	O
.	.	O
pRK5D	NN	O
is	VBZ	O
a	DT	O
cloning	VBG	O
vector	NN	O
that	WDT	O
has	VBZ	O
an	DT	O
sp6	JJ	O
transcription	NN	O
initiation	NN	O
site	NN	O
followed	VBN	O
by	IN	O
an	DT	O
SfiI	NNP	O
restriction	NN	O
enzyme	NN	O
site	NN	O
preceding	VBG	O
the	DT	O
XhoI/NotI	NNP	O
cDNA	NN	O
cloning	VBG	O
sites	NNS	O
.	.	O
2	CD	O
.	.	O
Preparation	NN	O
of	IN	O
Random	NNP	O
Primed	NNP	O
cDNA	NN	O
Library	NNP	O
A	NNP	O
secondary	JJ	O
cDNA	NN	O
library	NN	O
was	VBD	O
generated	VBN	O
in	IN	O
order	NN	O
to	TO	O
preferentially	RB	O
represent	VB	O
the	DT	O
5′	CD	O
ends	NNS	O
of	IN	O
the	DT	O
primary	JJ	O
cDNA	NN	O
clones	NNS	O
.	.	O
Sp6	NNP	O
RNA	NNP	O
was	VBD	O
generated	VBN	O
from	IN	O
the	DT	O
primary	JJ	O
library	NN	O
(	(	O
described	VBN	O
above	IN	O
)	)	O
,	,	O
and	CC	O
this	DT	O
RNA	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
generate	VB	O
a	DT	O
random	NN	O
primed	VBN	O
cDNA	JJ	O
library	NN	O
in	IN	O
the	DT	O
vector	NN	O
pSST-AMY.0	JJ	O
using	VBG	O
reagents	NNS	O
and	CC	O
protocols	NNS	O
from	IN	O
Life	NNP	O
Technologies	NNPS	O
(	(	O
Super	NNP	O
Script	NNP	O
Plasmid	NNP	O
System	NNP	O
,	,	O
referenced	VBN	O
above	IN	O
)	)	O
.	.	O
In	IN	O
this	DT	O
procedure	NN	O
the	DT	O
double	NN	O
stranded	VBD	O
cDNA	NN	O
was	VBD	O
sized	VBN	O
to	TO	O
500-1000	CD	O
bp	NN	O
,	,	O
linkered	VBN	O
with	IN	O
blunt	NN	O
to	TO	O
NotI	NNP	O
adaptors	NNS	O
,	,	O
cleaved	VBN	O
with	IN	O
SfiI	NNP	O
,	,	O
and	CC	O
cloned	VBD	O
into	IN	O
SfiI/NotI	NNP	O
cleaved	VBD	O
vector	NN	O
.	.	O
pSST-AMY.0	NN	O
is	VBZ	O
a	DT	O
cloning	VBG	O
vector	NN	O
that	WDT	O
has	VBZ	O
a	DT	O
yeast	NN	O
alcohol	NN	O
dehydrogenase	NN	O
promoter	NN	O
preceding	VBG	O
the	DT	O
cDNA	NN	O
cloning	VBG	O
sites	NNS	O
and	CC	O
the	DT	O
mouse	NN	O
amylase	NN	O
sequence	NN	O
(	(	O
the	DT	O
mature	NN	O
sequence	NN	O
without	IN	O
the	DT	O
secretion	NN	O
signal	NN	O
)	)	O
followed	VBN	O
by	IN	O
the	DT	O
yeast	NN	O
alcohol	NN	O
dehydrogenase	NN	O
terminator	NN	O
,	,	O
after	IN	O
the	DT	O
cloning	NN	O
sites	NNS	O
.	.	O
Thus	RB	O
,	,	O
cDNAs	NN	O
cloned	VBD	O
into	IN	O
this	DT	O
vector	NN	O
that	WDT	O
are	VBP	O
fused	VBN	O
in	IN	O
frame	NN	O
with	IN	O
amylase	JJ	O
sequence	NN	O
will	MD	O
lead	VB	O
to	TO	O
the	DT	O
secretion	NN	O
of	IN	O
amylase	NN	O
from	IN	O
appropriately	RB	O
transfected	VBN	O
yeast	NN	O
colonies	NNS	O
.	.	O
3	CD	O
.	.	O
Transformation	NN	O
and	CC	O
Detection	NNP	O
DNA	NNP	O
from	IN	O
the	DT	O
library	JJ	O
described	NN	O
in	IN	O
paragraph	NN	O
2	CD	O
above	NN	O
was	VBD	O
chilled	VBN	O
on	IN	O
ice	NN	O
to	TO	O
which	WDT	O
was	VBD	O
added	VBN	O
electrocompetent	JJ	O
DH10B	NNP	O
bacteria	NN	O
(	(	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
20	CD	O
ml	NN	O
)	)	O
.	.	O
The	DT	O
bacteria	NN	O
and	CC	O
vector	NN	O
mixture	NN	O
was	VBD	O
then	RB	O
electroporated	VBN	O
as	IN	O
recommended	VBN	O
by	IN	O
the	DT	O
manufacturer	NN	O
.	.	O
Subsequently	RB	O
,	,	O
SOC	NNP	O
media	NNS	O
(	(	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
1	CD	O
ml	NN	O
)	)	O
was	VBD	O
added	VBN	O
and	CC	O
the	DT	O
mixture	NN	O
was	VBD	O
incubated	VBN	O
at	IN	O
37°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
minutes	NNS	O
.	.	O
The	DT	O
transformants	NNS	O
were	VBD	O
then	RB	O
plated	VBN	O
onto	IN	O
20	CD	O
standard	JJ	O
150	CD	O
mm	NN	O
LB	NNP	O
plates	VBZ	O
containing	VBG	O
ampicillin	NN	O
and	CC	O
incubated	VBN	O
for	IN	O
16	CD	O
hours	NNS	O
(	(	O
37°	CD	O
C.	NNP	O
)	)	O
.	.	O
Positive	JJ	O
colonies	NNS	O
were	VBD	O
scraped	VBN	O
off	RP	O
the	DT	O
plates	NNS	O
and	CC	O
the	DT	O
DNA	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
bacterial	JJ	O
pellet	NN	O
using	VBG	O
standard	JJ	O
protocols	NNS	O
,	,	O
e.g	NN	O
.	.	O
CsCl-gradient	NN	O
.	.	O
The	DT	O
purified	JJ	O
DNA	NN	O
was	VBD	O
then	RB	O
carried	VBN	O
on	IN	O
to	TO	O
the	DT	O
yeast	NN	O
protocols	NNS	O
below	IN	O
.	.	O
The	DT	O
yeast	NN	O
methods	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
categories	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
Transformation	NN	O
of	IN	O
yeast	NN	O
with	IN	O
the	DT	O
plasmid/cDNA	NN	O
combined	VBD	O
vector	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
Detection	NN	O
and	CC	O
isolation	NN	O
of	IN	O
yeast	NN	O
clones	NNS	O
secreting	VBG	O
amylase	NN	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
PCR	NNP	O
amplification	NN	O
of	IN	O
the	DT	O
insert	NN	O
directly	RB	O
from	IN	O
the	DT	O
yeast	NN	O
colony	NN	O
and	CC	O
purification	NN	O
of	IN	O
the	DT	O
DNA	NN	O
for	IN	O
sequencing	VBG	O
and	CC	O
further	JJ	O
analysis	NN	O
.	.	O
The	DT	O
yeast	NN	O
strain	NN	O
used	VBN	O
was	VBD	O
HD56-5A	NNP	O
(	(	O
ATCC-90785	NNP	O
)	)	O
.	.	O
This	DT	O
strain	NN	O
has	VBZ	O
the	DT	O
following	JJ	O
genotype	NN	O
:	:	O
MAT	NNP	O
alpha	NN	O
,	,	O
ura3-52	JJ	O
,	,	O
leu2-3	JJ	O
,	,	O
leu2-112	JJ	O
,	,	O
his3-11	JJ	O
,	,	O
his3-15	JJ	O
,	,	O
MAL+	NNP	O
,	,	O
SUC+	NNP	O
,	,	O
GAL+	NNP	O
.	.	O
Preferably	RB	O
,	,	O
yeast	JJ	O
mutants	NNS	O
can	MD	O
be	VB	O
employed	VBN	O
that	DT	O
have	VBP	O
deficient	JJ	O
post-translational	JJ	O
pathways	NNS	O
.	.	O
Such	JJ	O
mutants	NNS	O
may	MD	O
have	VB	O
translocation	NN	O
deficient	NN	O
alleles	NNS	O
in	IN	O
sec71	NN	O
,	,	O
sec72	NN	O
,	,	O
sec62	NN	O
,	,	O
with	IN	O
truncated	JJ	O
sec71	NN	O
being	VBG	O
most	JJS	O
preferred	VBN	O
.	.	O
Alternatively	RB	O
,	,	O
antagonists	NNS	O
(	(	O
including	VBG	O
antisense	NN	O
nucleotides	NNS	O
and/or	VBP	O
ligands	NNS	O
)	)	O
which	WDT	O
interfere	RB	O
with	IN	O
the	DT	O
normal	JJ	O
operation	NN	O
of	IN	O
these	DT	O
genes	NNS	O
,	,	O
other	JJ	O
proteins	NNS	O
implicated	VBN	O
in	IN	O
this	DT	O
post	NN	O
translation	NN	O
pathway	NN	O
(	(	O
e.g.	JJ	O
,	,	O
SEC61p	NNP	O
,	,	O
SEC72p	NNP	O
,	,	O
SEC62p	NNP	O
,	,	O
SEC63p	NNP	O
,	,	O
TDJ1p	NNP	O
or	CC	O
SSA1p-4p	NNP	O
)	)	O
or	CC	O
the	DT	O
complex	JJ	O
formation	NN	O
of	IN	O
these	DT	O
proteins	NNS	O
may	MD	O
also	RB	O
be	VB	O
preferably	RB	O
employed	VBN	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
amylase-expressing	JJ	O
yeast	NN	O
.	.	O
Transformation	NN	O
was	VBD	O
performed	VBN	O
based	VBN	O
on	IN	O
the	DT	O
protocol	NN	O
outlined	VBN	O
by	IN	O
Gietz	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nucl	NNP	I
.	.	I
Acid	NNP	I
.	.	I
Res.	NNP	I
,	,	I
20:1425	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
Transformed	NNP	O
cells	NNS	O
were	VBD	O
then	RB	O
inoculated	VBN	O
from	IN	O
agar	NN	O
into	IN	O
YEPD	NNP	O
complex	JJ	O
media	NNS	O
broth	NN	O
(	(	O
100	CD	O
ml	NN	O
)	)	O
and	CC	O
grown	JJ	O
overnight	NN	O
at	IN	O
30°	CD	O
C.	NNP	O
The	DT	O
YEPD	NNP	O
broth	NN	O
was	VBD	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Kaiser	NNP	B
et	CC	I
al.	NN	I
,	,	I
Methods	NNP	I
in	IN	I
Yeast	NNP	I
Genetics	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Press	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
p.	VBZ	I
207	CD	I
(	(	I
1994	CD	I
)	)	I
.	.	O
The	DT	O
overnight	JJ	O
culture	NN	O
was	VBD	O
then	RB	O
diluted	VBN	O
to	TO	O
about	IN	O
2×106	CD	O
cells/ml	NN	O
(	(	O
approx	NN	O
.	.	O
OD600=0.1	NNP	O
)	)	O
into	IN	O
fresh	JJ	O
YEPD	NNP	O
broth	NN	O
(	(	O
500	CD	O
ml	NN	O
)	)	O
and	CC	O
regrown	VBN	O
to	TO	O
1×107	CD	O
cells/ml	NN	O
(	(	O
approx	NN	O
.	.	O
OD600=0.4-0.5	NNP	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
then	RB	O
harvested	VBN	O
and	CC	O
prepared	VBN	O
for	IN	O
transformation	NN	O
by	IN	O
transfer	NN	O
into	IN	O
GS3	NNP	O
rotor	NN	O
bottles	NNS	O
in	IN	O
a	DT	O
Sorval	NNP	O
GS3	NNP	O
rotor	NN	O
at	IN	O
5,000	CD	O
rpm	NN	O
for	IN	O
5	CD	O
minutes	NNS	O
,	,	O
the	DT	O
supernatant	NN	O
discarded	VBD	O
,	,	O
and	CC	O
then	RB	O
resuspended	VBD	O
into	IN	O
sterile	JJ	O
water	NN	O
,	,	O
and	CC	O
centrifuged	VBD	O
again	RB	O
in	IN	O
50	CD	O
ml	JJ	O
falcon	NN	O
tubes	NNS	O
at	IN	O
3,500	CD	O
rpm	NN	O
in	IN	O
a	DT	O
Beckman	NNP	O
GS-6KR	NNP	O
centrifuge	NN	O
.	.	O
The	DT	O
supernatant	NN	O
was	VBD	O
discarded	VBN	O
and	CC	O
the	DT	O
cells	NNS	O
were	VBD	O
subsequently	RB	O
washed	VBN	O
with	IN	O
LiAc/TE	NNP	O
(	(	O
10	CD	O
ml	NN	O
,	,	O
10	CD	O
mM	NN	O
Tris-HCl	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
pH	NN	O
7.5	CD	O
,	,	O
100	CD	O
mM	NN	O
Li2OOCCH3	NNP	O
)	)	O
,	,	O
and	CC	O
resuspended	VBD	O
into	IN	O
LiAc/TE	NNP	O
(	(	O
2.5	CD	O
ml	NN	O
)	)	O
.	.	O
Transformation	NN	O
took	VBD	O
place	NN	O
by	IN	O
mixing	VBG	O
the	DT	O
prepared	JJ	O
cells	NNS	O
(	(	O
100	CD	O
μl	NN	O
)	)	O
with	IN	O
freshly	RB	O
denatured	VBN	O
single	JJ	O
stranded	VBD	O
salmon	JJ	O
testes	NNS	O
DNA	NNP	O
(	(	O
Lofstrand	NNP	O
Labs	NNP	O
,	,	O
Gaithersburg	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
and	CC	O
transforming	VBG	O
DNA	NNP	O
(	(	O
1	CD	O
μg	NN	O
,	,	O
vol	NN	O
.	.	O
<	RB	O
10	CD	O
μl	NN	O
)	)	O
in	IN	O
microfuge	NN	O
tubes	NNS	O
.	.	O
The	DT	O
mixture	NN	O
was	VBD	O
mixed	JJ	O
briefly	NN	O
by	IN	O
vortexing	VBG	O
,	,	O
then	RB	O
40	CD	O
%	NN	O
PEG/TE	NNP	O
(	(	O
600	CD	O
μl	NN	O
,	,	O
40	CD	O
%	NN	O
polyethylene	JJ	O
glycol-4000	NN	O
,	,	O
10	CD	O
mM	NN	O
Tris-HCl	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
100	CD	O
mM	NN	O
Li2OOCCH3	NNP	O
,	,	O
pH	RB	O
7.5	CD	O
)	)	O
was	VBD	O
added	VBN	O
.	.	O
This	DT	O
mixture	NN	O
was	VBD	O
gently	RB	O
mixed	JJ	O
and	CC	O
incubated	VBN	O
at	IN	O
30°	CD	O
C.	NNP	O
while	IN	O
agitating	VBG	O
for	IN	O
30	CD	O
minutes	NNS	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
then	RB	O
heat	NN	O
shocked	VBD	O
at	IN	O
42°	CD	O
C.	NNP	O
for	IN	O
15	CD	O
minutes	NNS	O
,	,	O
and	CC	O
the	DT	O
reaction	NN	O
vessel	NN	O
centrifuged	VBN	O
in	IN	O
a	DT	O
microfuge	NN	O
at	IN	O
12,000	CD	O
rpm	NN	O
for	IN	O
5-10	JJ	O
seconds	NNS	O
,	,	O
decanted	VBN	O
and	CC	O
resuspended	VBN	O
into	IN	O
TE	NNP	O
(	(	O
500	CD	O
μl	NN	O
,	,	O
10	CD	O
mM	NN	O
Tris-HCl	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
pH	VBZ	O
7.5	CD	O
)	)	O
followed	VBN	O
by	IN	O
recentrifugation	NN	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
then	RB	O
diluted	VBN	O
into	IN	O
TE	NNP	O
(	(	O
1	CD	O
ml	NN	O
)	)	O
and	CC	O
aliquots	NNS	O
(	(	O
200	CD	O
μl	NN	O
)	)	O
were	VBD	O
spread	VBN	O
onto	IN	O
the	DT	O
selective	JJ	O
media	NNS	O
previously	RB	O
prepared	VBN	O
in	IN	O
150	CD	O
mm	JJ	O
growth	NN	O
plates	NNS	O
(	(	O
VWR	NNP	O
)	)	O
.	.	O
Alternatively	RB	O
,	,	O
instead	RB	O
of	IN	O
multiple	JJ	O
small	JJ	O
reactions	NNS	O
,	,	O
the	DT	O
transformation	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
a	DT	O
single	JJ	O
,	,	O
large	JJ	O
scale	NN	O
reaction	NN	O
,	,	O
wherein	JJ	O
reagent	NN	O
amounts	NNS	O
were	VBD	O
scaled	VBN	O
up	RP	O
accordingly	RB	O
.	.	O
The	DT	O
selective	JJ	O
media	NNS	O
used	VBN	O
was	VBD	O
a	DT	O
synthetic	JJ	O
complete	JJ	O
dextrose	NN	O
agar	NN	O
lacking	VBG	O
uracil	JJ	O
(	(	O
SCD-Ura	NNP	O
)	)	O
prepared	VBD	O
as	IN	O
described	VBN	O
in	IN	O
Kaiser	NNP	B
et	CC	I
al.	NN	I
,	,	I
Methods	NNP	I
in	IN	I
Yeast	NNP	I
Genetics	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Press	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
p.	VBZ	I
208-210	CD	I
(	(	I
1994	CD	I
)	)	I
.	.	O
Transformants	NNS	O
were	VBD	O
grown	VBN	O
at	IN	O
30°	CD	O
C.	NNP	O
for	IN	O
2-3	JJ	O
days	NNS	O
.	.	O
The	DT	O
detection	NN	O
of	IN	O
colonies	NNS	O
secreting	VBG	O
amylase	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
including	VBG	O
red	JJ	O
starch	NN	O
in	IN	O
the	DT	O
selective	JJ	O
growth	NN	O
media	NNS	O
.	.	O
Starch	NN	O
was	VBD	O
coupled	VBN	O
to	TO	O
the	DT	O
red	JJ	O
dye	NN	O
(	(	O
Reactive	JJ	O
Red-120	NNP	O
,	,	O
Sigma	NNP	O
)	)	O
as	IN	O
per	IN	O
the	DT	O
procedure	NN	O
described	VBN	O
by	IN	O
Biely	NNP	B
et	FW	I
al.	NN	I
,	,	I
Anal	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
172:176-179	CD	I
(	(	I
1988	CD	I
)	)	I
.	.	O
The	DT	O
coupled	VBN	O
starch	NN	O
was	VBD	O
incorporated	VBN	O
into	IN	O
the	DT	O
SCD-Ura	NNP	O
agar	NN	O
plates	NNS	O
at	IN	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
0.15	CD	O
%	NN	O
(	(	O
w/v	NN	O
)	)	O
,	,	O
and	CC	O
was	VBD	O
buffered	VBN	O
with	IN	O
potassium	NN	O
phosphate	NN	O
to	TO	O
a	DT	O
pH	NN	O
of	IN	O
7.0	CD	O
(	(	O
50-100	JJ	O
mM	NN	O
final	JJ	O
concentration	NN	O
)	)	O
.	.	O
The	DT	O
positive	JJ	O
colonies	NNS	O
were	VBD	O
picked	VBN	O
and	CC	O
streaked	VBN	O
across	IN	O
fresh	JJ	O
selective	JJ	O
media	NNS	O
(	(	O
onto	IN	O
150	CD	O
mm	NNS	O
plates	NNS	O
)	)	O
in	IN	O
order	NN	O
to	TO	O
obtain	VB	O
well	RB	O
isolated	JJ	O
and	CC	O
identifiable	JJ	O
single	JJ	O
colonies	NNS	O
.	.	O
Well	RB	O
isolated	JJ	O
single	JJ	O
colonies	NNS	O
positive	JJ	O
for	IN	O
amylase	JJ	O
secretion	NN	O
were	VBD	O
detected	VBN	O
by	IN	O
direct	JJ	O
incorporation	NN	O
of	IN	O
red	JJ	O
starch	NN	O
into	IN	O
buffered	VBN	O
SCD-Ura	NNP	O
agar	NN	O
.	.	O
Positive	JJ	O
colonies	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
break	VB	O
down	RP	O
starch	NN	O
resulting	VBG	O
in	IN	O
a	DT	O
clear	JJ	O
halo	NN	O
around	IN	O
the	DT	O
positive	JJ	O
colony	NN	O
visualized	VBN	O
directly	RB	O
.	.	O
4	CD	O
.	.	O
Isolation	NN	O
of	IN	O
DNA	NN	O
by	IN	O
PCR	NNP	O
Amplification	NNP	O
When	WRB	O
a	DT	O
positive	JJ	O
colony	NN	O
was	VBD	O
isolated	VBN	O
,	,	O
a	DT	O
portion	NN	O
of	IN	O
it	PRP	O
was	VBD	O
picked	VBN	O
by	IN	O
a	DT	O
toothpick	NN	O
and	CC	O
diluted	VBD	O
into	IN	O
sterile	JJ	O
water	NN	O
(	(	O
30	CD	O
μl	NN	O
)	)	O
in	IN	O
a	DT	O
96	CD	O
well	RB	O
plate	NN	O
.	.	O
At	IN	O
this	DT	O
time	NN	O
,	,	O
the	DT	O
positive	JJ	O
colonies	NNS	O
were	VBD	O
either	RB	O
frozen	JJ	O
and	CC	O
stored	VBD	O
for	IN	O
subsequent	JJ	O
analysis	NN	O
or	CC	O
immediately	RB	O
amplified	VBN	O
.	.	O
An	DT	O
aliquot	NN	O
of	IN	O
cells	NNS	O
(	(	O
5	CD	O
μl	NN	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
template	NN	O
for	IN	O
the	DT	O
PCR	NNP	O
reaction	NN	O
in	IN	O
a	DT	O
25	CD	O
μl	NN	O
volume	NN	O
containing	VBG	O
0.5	CD	O
μl	JJ	O
Klentaq	NNP	O
(	(	O
Clontech	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
;	:	O
4.0	CD	O
μl	$	O
10	CD	O
mM	NN	O
dNTP	NN	O
's	POS	O
(	(	O
Perkin	NNP	O
Elmer-Cetus	NNP	O
)	)	O
;	:	O
2.5	CD	O
μl	NN	O
Kentaq	NNP	O
buffer	NN	O
(	(	O
Clontech	NNP	O
)	)	O
;	:	O
0.25	CD	O
μl	FW	O
forward	RB	O
oligo	VBZ	O
1	CD	O
;	:	O
0.25	CD	O
μl	JJ	O
reverse	NN	O
oligo	NN	O
2	CD	O
;	:	O
12.5	CD	O
μl	NN	O
distilled	JJ	O
water	NN	O
.	.	O
The	DT	O
sequence	NN	O
of	IN	O
the	DT	O
forward	NN	O
oligonucleotide	IN	O
1	CD	O
was	VBD	O
:	:	O
The	DT	O
sequence	NN	O
of	IN	O
reverse	JJ	O
oligonucleotide	IN	O
2	CD	O
was	VBD	O
:	:	O
PCR	NN	O
was	VBD	O
then	RB	O
performed	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
The	DT	O
underlined	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
oligonucleotides	NNS	O
annealed	VBD	O
to	TO	O
the	DT	O
ADH	NNP	O
promoter	NN	O
region	NN	O
and	CC	O
the	DT	O
amylase	JJ	O
region	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
amplified	VBD	O
a	DT	O
307	CD	O
bp	JJ	O
region	NN	O
from	IN	O
vector	NN	O
pSST-AMY.0	NN	O
when	WRB	O
no	DT	O
insert	NN	O
was	VBD	O
present	JJ	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
first	JJ	O
18	CD	O
nucleotides	NNS	O
of	IN	O
the	DT	O
5′	CD	O
end	NN	O
of	IN	O
these	DT	O
oligonucleotides	NNS	O
contained	VBD	O
annealing	VBG	O
sites	NNS	O
for	IN	O
the	DT	O
sequencing	NN	O
primers	NNS	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
total	JJ	O
product	NN	O
of	IN	O
the	DT	O
PCR	NNP	O
reaction	NN	O
from	IN	O
an	DT	O
empty	JJ	O
vector	NN	O
was	VBD	O
343	CD	O
bp	NN	O
.	.	O
However	RB	O
,	,	O
signal	JJ	O
sequence-fused	JJ	O
cDNA	NN	O
resulted	VBD	O
in	IN	O
considerably	RB	O
longer	RBR	O
nucleotide	JJ	O
sequences	NNS	O
.	.	O
Following	VBG	O
the	DT	O
PCR	NNP	O
,	,	O
an	DT	O
aliquot	NN	O
of	IN	O
the	DT	O
reaction	NN	O
(	(	O
5	CD	O
μl	NN	O
)	)	O
was	VBD	O
examined	VBN	O
by	IN	O
agarose	JJ	O
gel	JJ	O
electrophoresis	NN	O
in	IN	O
a	DT	O
1	CD	O
%	NN	O
agarose	JJ	O
gel	NN	O
using	VBG	O
a	DT	O
Tris-Borate-EDTA	NNP	O
(	(	O
TBE	NNP	O
)	)	O
buffering	VBG	O
system	NN	O
as	IN	O
described	VBN	O
by	IN	O
Sambrook	NNP	O
et	FW	O
al.	NN	O
,	,	O
supra	NN	O
.	.	O
Clones	NNS	O
resulting	VBG	O
in	IN	O
a	DT	O
single	JJ	O
strong	JJ	O
PCR	NNP	O
product	NN	O
larger	JJR	O
than	IN	O
400	CD	O
bp	NNS	O
were	VBD	O
further	RB	O
analyzed	VBN	O
by	IN	O
DNA	NNP	O
sequencing	VBG	O
after	IN	O
purification	NN	O
with	IN	O
a	DT	O
96	CD	O
Qiaquick	NNP	O
PCR	NNP	O
clean-up	JJ	O
column	NN	O
(	(	O
Qiagen	NNP	O
Inc.	NNP	O
,	,	O
Chatsworth	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Example	RB	O
3	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Using	NNP	O
Signal	NNP	O
Algorithm	NNP	O
Analysis	NNP	O
Various	NNP	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
were	VBD	O
identified	VBN	O
by	IN	O
applying	VBG	O
a	DT	O
proprietary	JJ	O
signal	NN	O
sequence	NN	O
finding	VBG	O
algorithm	NNS	O
developed	VBN	O
by	IN	O
Genentech	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
South	NNP	O
San	NNP	O
Francisco	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
upon	NN	O
ESTs	NNP	O
as	RB	O
well	RB	O
as	IN	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
EST	NN	O
fragments	NNS	O
from	IN	O
public	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
GenBank	NNP	O
)	)	O
and/or	VBP	O
private	JJ	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
databases	VBZ	O
.	.	O
The	DT	O
signal	JJ	O
sequence	NN	O
algorithm	NN	O
computes	VBZ	O
a	DT	O
secretion	NN	O
signal	NN	O
score	NN	O
based	VBN	O
on	IN	O
the	DT	O
character	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
nucleotides	NNS	O
surrounding	VBG	O
the	DT	O
first	JJ	O
and	CC	O
optionally	RB	O
the	DT	O
second	JJ	O
methionine	NN	O
codon	NN	O
(	(	O
s	NN	O
)	)	O
(	(	O
ATG	NNP	O
)	)	O
at	IN	O
the	DT	O
5′-end	NN	O
of	IN	O
the	DT	O
sequence	NN	O
or	CC	O
sequence	NN	O
fragment	NN	O
under	IN	O
consideration	NN	O
.	.	O
The	DT	O
nucleotides	NNS	O
following	VBG	O
the	DT	O
first	JJ	O
ATG	NNP	O
must	MD	O
code	VB	O
for	IN	O
at	IN	O
least	JJS	O
35	CD	O
unambiguous	JJ	O
amino	NN	O
acids	NNS	O
without	IN	O
any	DT	O
stop	JJ	O
codons	NNS	O
.	.	O
If	IN	O
the	DT	O
first	JJ	O
ATG	NNP	O
has	VBZ	O
the	DT	O
required	VBN	O
amino	NN	O
acids	NNS	O
,	,	O
the	DT	O
second	NN	O
is	VBZ	O
not	RB	O
examined	VBN	O
.	.	O
If	IN	O
neither	DT	O
meets	VBZ	O
the	DT	O
requirement	NN	O
,	,	O
the	DT	O
candidate	NN	O
sequence	NN	O
is	VBZ	O
not	RB	O
scored	VBN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
EST	NNP	O
sequence	NN	O
contains	VBZ	O
an	DT	O
authentic	JJ	O
signal	NN	O
sequence	NN	O
,	,	O
the	DT	O
DNA	NN	O
and	CC	O
corresponding	VBG	O
amino	NN	O
acid	NN	O
sequences	NNS	O
surrounding	VBG	O
the	DT	O
ATG	NNP	O
codon	NN	O
are	VBP	O
scored	VBN	O
using	VBG	O
a	DT	O
set	NN	O
of	IN	O
seven	CD	O
sensors	NNS	O
(	(	O
evaluation	NN	O
parameters	NNS	O
)	)	O
known	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
secretion	NN	O
signals	NNS	O
.	.	O
Use	NN	O
of	IN	O
this	DT	O
algorithm	NN	O
resulted	VBD	O
in	IN	O
the	DT	O
identification	NN	O
of	IN	O
numerous	JJ	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
.	.	O
Using	VBG	O
the	DT	O
techniques	NNS	O
described	VBN	O
in	IN	O
Examples	NNP	O
1	CD	O
to	TO	O
3	CD	O
above	IN	O
,	,	O
numerous	JJ	O
full-length	JJ	O
cDNA	NN	O
clones	NNS	O
were	VBD	O
identified	VBN	O
as	IN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
as	IN	O
disclosed	JJ	O
herein	NN	O
.	.	O
These	DT	O
cDNAs	NNS	O
were	VBD	O
then	RB	O
deposited	VBN	O
under	IN	O
the	DT	O
terms	NNS	O
of	IN	O
the	DT	O
Budapest	NNP	O
Treaty	NN	O
with	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
,	,	O
10801	CD	O
University	NNP	O
Blvd.	NNP	O
,	,	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
20110-2209	CD	O
,	,	O
USA	NNP	O
(	(	O
ATCC	NNP	O
)	)	O
as	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
7	CD	O
below	IN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
DNA108809	NNP	O
(	(	O
UNQ2964	NNP	O
)	)	O
,	,	O
was	VBD	O
identified	VBN	O
from	IN	O
GenBank	NNP	O
accession	NN	O
no	DT	O
.	.	O
:	:	O
AJ010588	NN	O
.	.	O
These	DT	O
deposits	NNS	O
were	VBD	O
made	VBN	O
under	IN	O
the	DT	O
provisions	NNS	O
of	IN	O
the	DT	O
Budapest	NNP	O
Treaty	NNP	O
on	IN	O
the	DT	O
International	NNP	O
Recognition	NNP	O
of	IN	O
the	DT	O
Deposit	NNP	O
of	IN	O
Microorganisms	NNP	O
for	IN	O
the	DT	O
Purpose	NNP	O
of	IN	O
Patent	NNP	O
Procedure	NNP	O
and	CC	O
the	DT	O
Regulations	NNPS	O
thereunder	NN	O
(	(	O
Budapest	NNP	O
Treaty	NNP	O
)	)	O
.	.	O
This	DT	O
assures	VBZ	O
maintenance	NN	O
of	IN	O
a	DT	O
viable	JJ	O
culture	NN	O
of	IN	O
the	DT	O
deposit	NN	O
for	IN	O
30	CD	O
years	NNS	O
from	IN	O
the	DT	O
date	NN	O
of	IN	O
deposit	NN	O
.	.	O
The	DT	O
deposits	NNS	O
will	MD	O
be	VB	O
made	VBN	O
available	JJ	O
by	IN	O
ATCC	NNP	O
under	IN	O
the	DT	O
terms	NNS	O
of	IN	O
the	DT	O
Budapest	NNP	O
Treaty	NNP	O
,	,	O
and	CC	O
subject	JJ	O
to	TO	O
an	DT	O
agreement	NN	O
between	IN	O
Genentech	NNP	O
,	,	O
Inc.	NNP	O
and	CC	O
ATCC	NNP	O
,	,	O
which	WDT	O
assures	VBZ	O
permanent	JJ	O
and	CC	O
unrestricted	JJ	O
availability	NN	O
of	IN	O
the	DT	O
progeny	NN	O
of	IN	O
the	DT	O
culture	NN	O
of	IN	O
the	DT	O
deposit	NN	O
to	TO	O
the	DT	O
public	JJ	O
upon	JJ	O
issuance	NN	O
of	IN	O
the	DT	O
pertinent	JJ	O
U.S.	NNP	O
patent	NN	O
or	CC	O
upon	IN	O
laying	VBG	O
open	JJ	O
to	TO	O
the	DT	O
public	NN	O
of	IN	O
any	DT	O
U.S.	NNP	O
or	CC	O
foreign	JJ	O
patent	NN	O
application	NN	O
,	,	O
whichever	WDT	O
comes	VBZ	O
first	RB	O
,	,	O
and	CC	O
assures	VBZ	O
availability	NN	O
of	IN	O
the	DT	O
progeny	NN	O
to	TO	O
one	CD	O
determined	VBN	O
by	IN	O
the	DT	O
U.S.	NNP	O
Commissioner	NNP	O
of	IN	O
Patents	NNP	O
and	CC	O
Trademarks	NNP	O
to	TO	O
be	VB	O
entitled	VBN	O
thereto	RB	O
according	VBG	O
to	TO	O
35	CD	O
USC	NNP	O
§122	NN	O
and	CC	O
the	DT	O
Commissioner	NNP	O
's	POS	O
rules	NNS	O
pursuant	VBP	O
thereto	NN	O
(	(	O
including	VBG	O
37	CD	O
CFR	NNP	O
§1.14	NN	O
with	IN	O
particular	JJ	O
reference	NN	O
to	TO	O
886	CD	O
OG	NNP	O
638	CD	O
)	)	O
.	.	O
The	DT	O
assignee	NN	O
of	IN	O
the	DT	O
present	JJ	O
application	NN	O
has	VBZ	O
agreed	VBN	O
that	IN	O
if	IN	O
a	DT	O
culture	NN	O
of	IN	O
the	DT	O
materials	NNS	O
on	IN	O
deposit	NN	O
should	MD	O
die	VB	O
or	CC	O
be	VB	O
lost	VBN	O
or	CC	O
destroyed	VBN	O
when	WRB	O
cultivated	VBN	O
under	IN	O
suitable	JJ	O
conditions	NNS	O
,	,	O
the	DT	O
materials	NNS	O
will	MD	O
be	VB	O
promptly	RB	O
replaced	VBN	O
on	IN	O
notification	NN	O
with	IN	O
another	DT	O
of	IN	O
the	DT	O
same	JJ	O
.	.	O
Availability	NN	O
of	IN	O
the	DT	O
deposited	JJ	O
material	NN	O
is	VBZ	O
not	RB	O
to	TO	O
be	VB	O
construed	VBN	O
as	IN	O
a	DT	O
license	NN	O
to	TO	O
practice	NN	O
the	DT	O
invention	NN	O
in	IN	O
contravention	NN	O
of	IN	O
the	DT	O
rights	NNS	O
granted	VBN	O
under	IN	O
the	DT	O
authority	NN	O
of	IN	O
any	DT	O
government	NN	O
in	IN	O
accordance	NN	O
with	IN	O
its	PRP$	O
patent	NN	O
laws	NNS	O
.	.	O
Example	RB	O
4	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO227	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ201	NNP	O
)	)	O
The	DT	O
extracellular	JJ	O
domain	NN	O
(	(	O
ECD	NNP	O
)	)	O
sequences	NNS	O
(	(	O
including	VBG	O
the	DT	O
secretion	NN	O
signal	NN	O
,	,	O
if	IN	O
any	DT	O
)	)	O
of	IN	O
from	IN	O
about	IN	O
950	CD	O
known	NNS	O
secreted	VBD	O
proteins	NNS	O
from	IN	O
the	DT	O
Swiss-Prot	NNP	O
public	JJ	O
protein	NN	O
database	NN	O
were	VBD	O
used	VBN	O
to	TO	O
search	VB	O
expressed	JJ	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
databases	VBZ	O
.	.	O
The	DT	O
EST	NNP	O
databases	NNS	O
included	VBD	O
public	JJ	O
EST	NNP	O
databases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
GenBank	NNP	O
)	)	O
and	CC	O
a	DT	O
proprietary	JJ	O
EST	NNP	O
DNA	NN	O
database	NN	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
The	DT	O
search	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
computer	NN	O
program	NN	O
BLAST	NNP	O
or	CC	O
BLAST2	NNP	O
(	(	O
Altshul	NNP	B
et	RB	I
al.	RB	I
,	,	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
266:460-480	CD	I
(	(	I
1996	CD	I
)	)	I
)	)	O
as	IN	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
ECD	NNP	O
protein	NN	O
sequences	NNS	O
to	TO	O
a	DT	O
6	CD	O
frame	NN	O
translation	NN	O
of	IN	O
the	DT	O
EST	NNP	O
sequence	NN	O
.	.	O
Those	DT	O
comparisons	NNS	O
resulting	VBG	O
in	IN	O
a	DT	O
BLAST	NNP	O
score	NN	O
of	IN	O
70	CD	O
(	(	O
or	CC	O
in	IN	O
some	DT	O
cases	NNS	O
90	CD	O
)	)	O
or	CC	O
greater	JJR	O
that	WDT	O
did	VBD	O
not	RB	O
encode	VB	O
known	JJ	O
proteins	NNS	O
were	VBD	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
into	IN	O
consensus	NN	O
DNA	NNP	O
sequences	VBZ	O
with	IN	O
the	DT	O
program	NN	O
“	NNP	O
phrap	NN	O
”	NNP	O
(	(	O
Phil	NNP	O
Green	NNP	O
,	,	O
University	NNP	O
of	IN	O
Washington	NNP	O
,	,	O
Seattle	NNP	O
,	,	O
Wash.	NNP	O
)	)	O
.	.	O
A	DT	O
consensus	NN	O
DNA	NNP	O
sequence	NN	O
encoding	VBG	O
PRO227	NNP	O
was	VBD	O
assembled	VBN	O
relative	JJ	O
to	TO	O
the	DT	O
other	JJ	O
identified	JJ	O
EST	NNP	O
sequences	NNS	O
,	,	O
wherein	VBP	O
the	DT	O
consensus	NN	O
sequence	NN	O
was	VBD	O
designated	VBN	O
herein	RB	O
as	IN	O
DNA28740	NNP	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
DNA28740	NNP	O
consensus	NN	O
sequence	NN	O
,	,	O
oligonucleotides	NNS	O
were	VBD	O
synthesized	VBN	O
to	TO	O
identify	VB	O
by	IN	O
PCR	NNP	O
a	DT	O
cDNA	NN	O
library	NN	O
that	WDT	O
contained	VBD	O
the	DT	O
sequence	NN	O
of	IN	O
interest	NN	O
and	CC	O
for	IN	O
use	NN	O
as	IN	O
probes	NNS	O
to	TO	O
isolate	VB	O
a	DT	O
clone	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
coding	NN	O
sequence	NN	O
for	IN	O
PRO227	NNP	O
.	.	O
A	DT	O
pair	NN	O
of	IN	O
PCR	NNP	O
primers	NNS	O
(	(	O
forward	RB	O
and	CC	O
reverse	VB	O
)	)	O
were	VBD	O
synthesized	VBN	O
:	:	O
Additionally	RB	O
,	,	O
a	DT	O
synthetic	JJ	O
oligonucleotide	NN	O
hybridization	NN	O
probe	NN	O
was	VBD	O
constructed	VBN	O
from	IN	O
the	DT	O
consensus	NN	O
DNA28740	NNP	O
sequence	NN	O
which	WDT	O
had	VBD	O
the	DT	O
following	JJ	O
nucleotide	JJ	O
sequence	NN	O
:	:	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
source	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
with	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pair	NN	O
identified	VBN	O
above	IN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
PRO227	NNP	O
gene	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
PCR	NNP	O
primers	NNS	O
.	.	O
RNA	NNP	O
for	IN	O
construction	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
libraries	NNS	O
was	VBD	O
isolated	VBN	O
from	IN	O
human	JJ	O
fetal	JJ	O
lung	NN	O
tissue	NN	O
.	.	O
The	DT	O
cDNA	NN	O
libraries	NNS	O
used	VBN	O
to	TO	O
isolate	VB	O
the	DT	O
cDNA	NN	O
clones	NNS	O
were	VBD	O
constructed	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
using	VBG	O
commercially	RB	O
available	JJ	O
reagents	NNS	O
such	JJ	O
as	IN	O
those	DT	O
from	IN	O
Invitrogen	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif	NNP	O
.	.	O
The	DT	O
cDNA	NN	O
was	VBD	O
primed	VBN	O
with	IN	O
oligo	JJ	O
dT	NN	O
containing	VBG	O
a	DT	O
NotI	NNP	O
site	NN	O
,	,	O
linked	VBN	O
with	IN	O
blunt	NN	O
to	TO	O
SalI	NNP	O
hemikinased	VBD	O
adaptors	NNS	O
,	,	O
cleaved	VBN	O
with	IN	O
NotI	NNP	O
,	,	O
sized	VBD	O
appropriately	RB	O
by	IN	O
gel	JJ	O
electrophoresis	NN	O
,	,	O
and	CC	O
cloned	VBD	O
in	IN	O
a	DT	O
defined	JJ	O
orientation	NN	O
into	IN	O
a	DT	O
suitable	JJ	O
cloning	NN	O
vector	NN	O
(	(	O
such	JJ	O
as	IN	O
pRKB	NN	O
or	CC	O
pRKD	NN	O
;	:	O
pRK5B	NN	O
is	VBZ	O
a	DT	O
precursor	NN	O
of	IN	O
pRK5D	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
contain	VB	O
the	DT	O
SfiI	NNP	O
site	NN	O
;	:	O
see	VB	O
,	,	O
Holmes	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
253:1278-1280	CD	I
(	(	I
1991	CD	I
)	)	I
)	)	O
in	IN	O
the	DT	O
unique	JJ	O
XhoI	NNP	O
and	CC	O
NotI	NNP	O
sites	NNS	O
.	.	O
DNA	NN	O
sequencing	NN	O
of	IN	O
the	DT	O
clones	NNS	O
isolated	VBD	O
as	IN	O
described	VBN	O
above	IN	O
gave	VBD	O
the	DT	O
full-length	JJ	O
DNA	NNP	O
sequence	NN	O
for	IN	O
PRO227	NNP	O
[	NNP	O
herein	RB	O
designated	VBD	O
as	IN	O
UNQ201	NNP	O
(	(	O
DNA33786-1132	NNP	O
)	)	O
and	CC	O
the	DT	O
derived	JJ	O
protein	NN	O
sequence	NN	O
for	IN	O
PRO227	NNP	O
.	.	O
The	DT	O
entire	JJ	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
UNQ201	NNP	O
(	(	O
DNA33786-1132	NNP	O
)	)	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
.	.	O
Clone	NN	O
UNQ201	NNP	O
(	(	O
DNA33786-1132	NNP	O
)	)	O
contains	VBZ	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
117-119	JJ	O
and	CC	O
ending	VBG	O
at	IN	O
the	DT	O
stop	NN	O
codon	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
1989-1991	JJ	O
(	(	O
FIG	NNP	O
.	.	O
1	CD	O
,	,	O
the	DT	O
initiation	NN	O
and	CC	O
stop	VB	O
codons	NNS	O
are	VBP	O
bold	JJ	O
and	CC	O
underlined	JJ	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
is	VBZ	O
620	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
2	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
.	.	O
Clone	NN	O
UNQ201	NNP	O
(	(	O
DNA33786-1132	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
deposited	VBN	O
with	IN	O
ATCC	NNP	O
on	IN	O
Sep.	NNP	O
16	CD	O
,	,	O
1997	CD	O
and	CC	O
is	VBZ	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
209253	CD	O
.	.	O
Example	RB	O
5	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO233	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ207	NNP	O
)	)	O
The	DT	O
extracellular	JJ	O
domain	NN	O
(	(	O
ECD	NNP	O
)	)	O
sequences	NNS	O
(	(	O
including	VBG	O
the	DT	O
secretion	NN	O
signal	NN	O
,	,	O
if	IN	O
any	DT	O
)	)	O
of	IN	O
from	IN	O
about	IN	O
950	CD	O
known	NNS	O
secreted	VBD	O
proteins	NNS	O
from	IN	O
the	DT	O
Swiss-Prot	NNP	O
public	JJ	O
protein	NN	O
database	NN	O
were	VBD	O
used	VBN	O
to	TO	O
search	VB	O
expressed	JJ	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
databases	VBZ	O
.	.	O
The	DT	O
EST	NNP	O
databases	NNS	O
included	VBD	O
public	JJ	O
EST	NNP	O
databases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
GenBank	NNP	O
)	)	O
and	CC	O
a	DT	O
proprietary	JJ	O
EST	NNP	O
DNA	NN	O
database	NN	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
The	DT	O
search	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
computer	NN	O
program	NN	O
BLAST	NNP	O
or	CC	O
BLAST2	NNP	O
(	(	O
Altshul	NNP	B
et	RB	I
al.	RB	I
,	,	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
266:460-480	CD	I
(	(	I
1996	CD	I
)	)	I
)	)	O
as	IN	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
ECD	NNP	O
protein	NN	O
sequences	NNS	O
to	TO	O
a	DT	O
6	CD	O
frame	NN	O
translation	NN	O
of	IN	O
the	DT	O
EST	NNP	O
sequence	NN	O
.	.	O
Those	DT	O
comparisons	NNS	O
resulting	VBG	O
in	IN	O
a	DT	O
BLAST	NNP	O
score	NN	O
of	IN	O
70	CD	O
(	(	O
or	CC	O
in	IN	O
some	DT	O
cases	NNS	O
90	CD	O
)	)	O
or	CC	O
greater	JJR	O
that	WDT	O
did	VBD	O
not	RB	O
encode	VB	O
known	JJ	O
proteins	NNS	O
were	VBD	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
into	IN	O
consensus	NN	O
DNA	NNP	O
sequences	NNS	O
.	.	O
An	DT	O
expressed	JJ	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
was	VBD	O
identified	VBN	O
by	IN	O
the	DT	O
EST	NNP	O
database	NN	O
search	NN	O
and	CC	O
a	DT	O
consensus	NN	O
DNA	NNP	O
sequence	NN	O
was	VBD	O
assembled	VBN	O
relative	JJ	O
to	TO	O
other	JJ	O
EST	NNP	O
sequences	NNS	O
using	VBG	O
phrap	NN	O
(	(	O
Phil	NNP	O
Green	NNP	O
,	,	O
University	NNP	O
of	IN	O
Washington	NNP	O
,	,	O
Seattle	NNP	O
,	,	O
Wash.	NNP	O
)	)	O
.	.	O
This	DT	O
consensus	NN	O
sequence	NN	O
is	VBZ	O
herein	RB	O
designated	VBN	O
“	NNP	O
Consen0821	NNP	O
”	NNP	O
,	,	O
which	WDT	O
was	VBD	O
used	VBN	O
to	TO	O
derive	VB	O
the	DT	O
final	JJ	O
consensus	NN	O
sequence	NN	O
,	,	O
“	NNP	O
DNA30945	NNP	O
”	NNP	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
DNA30945	NNP	O
consensus	NN	O
sequence	NN	O
,	,	O
oligonucleotides	NNS	O
were	VBD	O
synthesized	VBN	O
:	:	O
1	CD	O
)	)	O
to	TO	O
identify	VB	O
by	IN	O
PCR	NNP	O
a	DT	O
cDNA	NN	O
library	NN	O
that	WDT	O
contained	VBD	O
the	DT	O
sequence	NN	O
of	IN	O
interest	NN	O
,	,	O
and	CC	O
2	CD	O
)	)	O
for	IN	O
use	NN	O
as	IN	O
probes	NNS	O
to	TO	O
isolate	VB	O
a	DT	O
clone	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
coding	NN	O
sequence	NN	O
for	IN	O
PRO233	NNP	O
.	.	O
Forward	NNP	O
and	CC	O
reverse	VB	O
PCR	NNP	O
primers	NNS	O
generally	RB	O
range	VBP	O
from	IN	O
20	CD	O
to	TO	O
30	CD	O
nucleotides	NNS	O
and	CC	O
are	VBP	O
often	RB	O
designed	VBN	O
to	TO	O
give	VB	O
a	DT	O
PCR	NNP	O
product	NN	O
of	IN	O
about	IN	O
100-1000	CD	O
bp	NN	O
in	IN	O
length	NN	O
.	.	O
The	DT	O
probe	NN	O
sequences	NNS	O
are	VBP	O
typically	RB	O
40-55	JJ	O
bp	NN	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
additional	JJ	O
oligonucleotides	NNS	O
are	VBP	O
synthesized	VBN	O
when	WRB	O
the	DT	O
consensus	NN	O
sequence	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
about	IN	O
1-1.5	JJ	O
kbp	NN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
,	,	O
as	IN	O
ber	NN	O
Ausubel	NNP	B
et	CC	I
al.	RB	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	O
with	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pair	NN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
gene	NN	O
of	IN	O
interest	NN	O
by	IN	O
the	DT	O
in	IN	O
vivo	NN	O
cloning	NN	O
procedure	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
primer	NN	O
pairs	NNS	O
.	.	O
Forward	NNP	O
and	CC	O
reverse	VB	O
PCR	NNP	O
primers	NNS	O
were	VBD	O
synthesized	VBN	O
:	:	O
Additionally	RB	O
,	,	O
a	DT	O
synthetic	JJ	O
oligonucleotide	NN	O
hybridization	NN	O
probe	NN	O
was	VBD	O
constructed	VBN	O
from	IN	O
the	DT	O
consensus	NN	O
DNA30945	NNP	O
sequence	NN	O
which	WDT	O
had	VBD	O
the	DT	O
following	JJ	O
nucleotide	JJ	O
sequence	NN	O
:	:	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
source	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
with	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pair	NN	O
identified	VBN	O
above	IN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
PRO233	NNP	O
gene	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
.	.	O
RNA	NNP	O
for	IN	O
construction	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
libraries	NNS	O
was	VBD	O
isolated	VBN	O
from	IN	O
human	JJ	O
fetal	JJ	O
brain	NN	O
tissue	NN	O
.	.	O
The	DT	O
cDNA	NN	O
libraries	NNS	O
used	VBN	O
to	TO	O
isolate	VB	O
the	DT	O
cDNA	NN	O
clones	NNS	O
were	VBD	O
constructed	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
using	VBG	O
commercially	RB	O
available	JJ	O
reagents	NNS	O
such	JJ	O
as	IN	O
those	DT	O
from	IN	O
Invitrogen	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif	NNP	O
.	.	O
The	DT	O
cDNA	NN	O
was	VBD	O
primed	VBN	O
with	IN	O
oligo	JJ	O
dT	NN	O
containing	VBG	O
a	DT	O
NotI	NNP	O
site	NN	O
,	,	O
linked	VBN	O
with	IN	O
blunt	NN	O
to	TO	O
SalI	NNP	O
hemikinased	VBD	O
adaptors	NNS	O
,	,	O
cleaved	VBN	O
with	IN	O
NotI	NNP	O
,	,	O
sized	VBD	O
appropriately	RB	O
by	IN	O
gel	JJ	O
electrophoresis	NN	O
,	,	O
and	CC	O
cloned	VBD	O
in	IN	O
a	DT	O
defined	JJ	O
orientation	NN	O
into	IN	O
a	DT	O
suitable	JJ	O
cloning	NN	O
vector	NN	O
(	(	O
such	JJ	O
as	IN	O
pRKB	NN	O
or	CC	O
pRKD	NN	O
;	:	O
pRK5B	NN	O
is	VBZ	O
a	DT	O
precursor	NN	O
of	IN	O
pRK5D	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
contain	VB	O
the	DT	O
SfiI	NNP	O
site	NN	O
;	:	O
see	VB	O
,	,	O
Holmes	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
253:1278-1280	CD	I
(	(	I
1991	CD	I
)	)	I
)	)	O
in	IN	O
the	DT	O
unique	JJ	O
XhoI	NNP	O
and	CC	O
NotI	NNP	O
sites	NNS	O
.	.	O
DNA	NN	O
sequencing	NN	O
of	IN	O
the	DT	O
clones	NNS	O
isolated	VBD	O
as	IN	O
described	VBN	O
above	IN	O
gave	VBD	O
the	DT	O
full-length	JJ	O
DNA	NNP	O
sequence	NN	O
for	IN	O
PRO233	NNP	O
[	NNP	O
herein	RB	O
designated	VBD	O
as	IN	O
UNQ207	NNP	O
(	(	O
DNA34436-1238	NNP	O
)	)	O
]	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
and	CC	O
the	DT	O
derived	JJ	O
protein	NN	O
sequence	NN	O
for	IN	O
PRO233	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
.	.	O
The	DT	O
entire	JJ	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
UNQ207	NNP	O
(	(	O
DNA34436-1238	NNP	O
)	)	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
3	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
.	.	O
Clone	NN	O
UNQ207	NNP	O
(	(	O
DNA34436-1238	NNP	O
)	)	O
contains	VBZ	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
101-103	JJ	O
and	CC	O
ending	VBG	O
at	IN	O
the	DT	O
stop	NN	O
codon	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
1001-1003	JJ	O
(	(	O
FIG	NNP	O
.	.	O
3	LS	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
is	VBZ	O
300	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
4	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
.	.	O
The	DT	O
full-length	JJ	O
PRO233	NNP	O
protein	NN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
4	CD	O
has	VBZ	O
an	DT	O
estimated	VBN	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
32964	CD	O
and	CC	O
a	DT	O
pI	NN	O
of	IN	O
about	IN	O
9.52	CD	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
regions	NNS	O
of	IN	O
interest	NN	O
including	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
and	CC	O
a	DT	O
putative	JJ	O
oxidoreductase	NN	O
active	JJ	O
site	NN	O
,	,	O
are	VBP	O
designated	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
4	CD	O
.	.	O
Clone	NN	O
UNQ207	NNP	O
(	(	O
DNA34436-1238	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
deposited	VBN	O
with	IN	O
ATCC	NNP	O
on	IN	O
Dec.	NNP	O
10	CD	O
,	,	O
1997	CD	O
and	CC	O
is	VBZ	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
209523	CD	O
.	.	O
Analysis	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
PRO233	NNP	O
polypeptide	NN	O
suggests	VBZ	O
that	IN	O
portions	NNS	O
of	IN	O
it	PRP	O
possess	JJ	O
significant	JJ	O
homology	NN	O
to	TO	O
reductase	VB	O
proteins	NNS	O
,	,	O
thereby	RB	O
indicating	VBG	O
that	IN	O
PRO233	NNP	O
may	MD	O
be	VB	O
a	DT	O
novel	JJ	O
reductase	NN	O
.	.	O
Example	RB	O
6	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO238	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ212	NNP	O
)	)	O
A	NNP	O
consensus	NN	O
DNA	NNP	O
sequence	NN	O
was	VBD	O
assembled	VBN	O
relative	JJ	O
to	TO	O
other	JJ	O
EST	NNP	O
sequences	NNS	O
using	VBG	O
phrap	NN	O
as	IN	O
described	VBN	O
above	IN	O
in	IN	O
Example	NNP	O
1	CD	O
.	.	O
This	DT	O
consensus	NN	O
sequence	NN	O
is	VBZ	O
herein	RB	O
designated	VBN	O
DNA30908	NNP	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
DNA30908	NNP	O
consensus	NN	O
sequence	NN	O
,	,	O
oligonucleotides	NNS	O
were	VBD	O
synthesized	VBN	O
:	:	O
1	CD	O
)	)	O
to	TO	O
identify	VB	O
by	IN	O
PCR	NNP	O
a	DT	O
cDNA	NN	O
library	NN	O
that	WDT	O
contained	VBD	O
the	DT	O
sequence	NN	O
of	IN	O
interest	NN	O
,	,	O
and	CC	O
2	CD	O
)	)	O
for	IN	O
use	NN	O
as	IN	O
probes	NNS	O
to	TO	O
isolate	VB	O
a	DT	O
clone	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
coding	NN	O
sequence	NN	O
for	IN	O
PRO238	NNP	O
.	.	O
PCR	NNP	O
primers	NNS	O
(	(	O
forward	RB	O
and	CC	O
reverse	VB	O
)	)	O
were	VBD	O
synthesized	VBN	O
:	:	O
Additionally	RB	O
,	,	O
a	DT	O
synthetic	JJ	O
oligonucleotide	NN	O
hybridization	NN	O
probe	NN	O
was	VBD	O
constructed	VBN	O
from	IN	O
the	DT	O
consensus	NN	O
DNA30908	NNP	O
sequence	NN	O
which	WDT	O
had	VBD	O
the	DT	O
following	JJ	O
nucleotide	JJ	O
sequence	NN	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
source	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
with	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pair	NN	O
identified	VBN	O
above	IN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
PRO238	NNP	O
gene	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
PCR	NNP	O
primers	NNS	O
.	.	O
RNA	NNP	O
for	IN	O
construction	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
libraries	NNS	O
was	VBD	O
isolated	VBN	O
from	IN	O
human	JJ	O
fetal	JJ	O
liver	NN	O
tissue	NN	O
.	.	O
DNA	NN	O
sequencing	NN	O
of	IN	O
the	DT	O
clones	NNS	O
isolated	VBD	O
as	IN	O
described	VBN	O
above	IN	O
gave	VBD	O
the	DT	O
full-length	JJ	O
DNA	NNP	O
sequence	NN	O
for	IN	O
DNA35600-1162	NNP	O
and	CC	O
the	DT	O
derived	JJ	O
protein	NN	O
sequence	NN	O
for	IN	O
PRO238	NNP	O
.	.	O
The	DT	O
entire	JJ	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
DNA35600-1162	NNP	O
(	(	O
UNQ212	NNP	O
)	)	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
5	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
)	)	O
.	.	O
Clone	NNP	O
DNA35600-1162	NNP	O
contains	VBZ	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
134-136	JJ	O
and	CC	O
ending	VBG	O
prior	RB	O
to	TO	O
the	DT	O
stop	NN	O
codon	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
1064-1066	JJ	O
(	(	O
FIG	NNP	O
.	.	O
5	CD	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
is	VBZ	O
310	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
6	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:6	NNP	O
)	)	O
.	.	O
Clone	NNP	O
DNA35600-1162	NNP	O
has	VBZ	O
been	VBN	O
deposited	VBN	O
with	IN	O
ATCC	NNP	O
on	IN	O
Oct.	NNP	O
16	CD	O
,	,	O
1997	CD	O
and	CC	O
is	VBZ	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
ATCC	$	O
209370	CD	O
.	.	O
Analysis	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
PRO238	NNP	O
polypeptide	NN	O
suggests	VBZ	O
that	IN	O
portions	NNS	O
of	IN	O
it	PRP	O
possess	JJ	O
significant	JJ	O
homology	NN	O
to	TO	O
reductase	VB	O
,	,	O
particularly	RB	O
oxidoreductase	NN	O
,	,	O
thereby	RB	O
indicating	VBG	O
that	IN	O
PRO238	NNP	O
may	MD	O
be	VB	O
a	DT	O
novel	JJ	O
reductase	NN	O
.	.	O
Example	RB	O
7	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO1328	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ688	NNP	O
)	)	O
DNA66658-1584	NNP	O
was	VBD	O
identified	VBN	O
by	IN	O
applying	VBG	O
a	DT	O
proprietary	JJ	O
signal	NN	O
sequence	NN	O
finding	VBG	O
algorithm	NNS	O
developed	VBN	O
by	IN	O
Genentech	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
South	NNP	O
San	NNP	O
Francisco	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
upon	NN	O
ESTs	NNP	O
as	RB	O
well	RB	O
as	IN	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
EST	NN	O
fragments	NNS	O
from	IN	O
public	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
GenBank	NNP	O
)	)	O
and/or	VBP	O
private	JJ	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
databases	VBZ	O
.	.	O
The	DT	O
signal	JJ	O
sequence	NN	O
algorithm	NN	O
computes	VBZ	O
a	DT	O
secretion	NN	O
signal	NN	O
score	NN	O
based	VBN	O
on	IN	O
the	DT	O
character	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
nucleotides	NNS	O
surrounding	VBG	O
the	DT	O
first	JJ	O
and	CC	O
optionally	RB	O
the	DT	O
second	JJ	O
methionine	NN	O
codon	NN	O
(	(	O
s	NN	O
)	)	O
(	(	O
ATG	NNP	O
)	)	O
at	IN	O
the	DT	O
5′-end	NN	O
of	IN	O
the	DT	O
sequence	NN	O
or	CC	O
sequence	NN	O
fragment	NN	O
under	IN	O
consideration	NN	O
.	.	O
The	DT	O
nucleotides	NNS	O
following	VBG	O
the	DT	O
first	JJ	O
ATG	NNP	O
must	MD	O
code	VB	O
for	IN	O
at	IN	O
least	JJS	O
35	CD	O
unambiguous	JJ	O
amino	NN	O
acids	NNS	O
without	IN	O
any	DT	O
stop	JJ	O
codons	NNS	O
.	.	O
If	IN	O
the	DT	O
first	JJ	O
ATG	NNP	O
has	VBZ	O
the	DT	O
required	VBN	O
amino	NN	O
acids	NNS	O
,	,	O
the	DT	O
second	NN	O
is	VBZ	O
not	RB	O
examined	VBN	O
.	.	O
If	IN	O
neither	DT	O
meets	VBZ	O
the	DT	O
requirement	NN	O
,	,	O
the	DT	O
candidate	NN	O
sequence	NN	O
is	VBZ	O
not	RB	O
scored	VBN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
EST	NNP	O
sequence	NN	O
contains	VBZ	O
an	DT	O
authentic	JJ	O
signal	NN	O
sequence	NN	O
,	,	O
the	DT	O
DNA	NN	O
and	CC	O
corresponding	VBG	O
amino	NN	O
acid	NN	O
sequences	NNS	O
surrounding	VBG	O
the	DT	O
ATG	NNP	O
codon	NN	O
are	VBP	O
scored	VBN	O
using	VBG	O
a	DT	O
set	NN	O
of	IN	O
seven	CD	O
sensors	NNS	O
(	(	O
evaluation	NN	O
parameters	NNS	O
)	)	O
known	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
secretion	NN	O
signals	NNS	O
.	.	O
Use	NNP	O
of	IN	O
the	DT	O
above	JJ	O
described	VBD	O
signal	JJ	O
sequence	NN	O
algorithm	NN	O
allowed	VBD	O
identification	NN	O
of	IN	O
an	DT	O
EST	NNP	O
cluster	NN	O
sequence	NN	O
from	IN	O
the	DT	O
Incyte	NNP	O
database	NN	O
,	,	O
designated	VBN	O
Incyte	NNP	O
EST	NNP	O
cluster	NN	O
sequence	NN	O
no	DT	O
.	.	O
40671	CD	O
.	.	O
This	DT	O
EST	NNP	O
cluster	NN	O
sequence	NN	O
was	VBD	O
then	RB	O
compared	VBN	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
expressed	JJ	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
databases	VBZ	O
which	WDT	O
included	VBD	O
public	JJ	O
EST	NNP	O
databases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
GenBank	NNP	O
)	)	O
and	CC	O
a	DT	O
proprietary	JJ	O
EST	NNP	O
DNA	NN	O
database	NN	O
(	(	O
Lifeseq®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
to	TO	O
identify	VB	O
existing	VBG	O
homologies	NNS	O
.	.	O
The	DT	O
homology	NN	O
search	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
computer	NN	O
program	NN	O
BLAST	NNP	O
or	CC	O
BLAST2	NNP	O
(	(	O
Altshul	NNP	B
et	RB	I
al.	RB	I
,	,	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
266:460-480	CD	I
(	(	I
1996	CD	I
)	)	I
)	)	O
.	.	O
Those	DT	O
comparisons	NNS	O
resulting	VBG	O
in	IN	O
a	DT	O
BLAST	NNP	O
score	NN	O
of	IN	O
70	CD	O
(	(	O
or	CC	O
in	IN	O
some	DT	O
cases	NNS	O
90	CD	O
)	)	O
or	CC	O
greater	JJR	O
that	WDT	O
did	VBD	O
not	RB	O
encode	VB	O
known	JJ	O
proteins	NNS	O
were	VBD	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
into	IN	O
a	DT	O
consensus	NN	O
DNA	NNP	O
sequence	NN	O
with	IN	O
the	DT	O
program	NN	O
“	NNP	O
phrap	NN	O
”	NNP	O
(	(	O
Phil	NNP	O
Green	NNP	O
,	,	O
University	NNP	O
of	IN	O
Washington	NNP	O
,	,	O
Seattle	NNP	O
,	,	O
Wash.	NNP	O
)	)	O
.	.	O
The	DT	O
consensus	NN	O
sequence	NN	O
is	VBZ	O
herein	RB	O
designated	VBN	O
DNA56749	NNP	O
.	.	O
Proprietary	JJ	O
Genentech	NNP	O
EST	NNP	O
sequences	NNS	O
were	VBD	O
used	VBN	O
in	IN	O
the	DT	O
assembly	NN	O
.	.	O
In	IN	O
light	NN	O
of	IN	O
the	DT	O
sequence	NN	O
homology	NN	O
between	IN	O
the	DT	O
DNA56749	NNP	O
sequence	NN	O
and	CC	O
the	DT	O
Incyte	NNP	O
EST	NNP	O
clone	NN	O
no	DT	O
.	.	O
4111192	CD	O
,	,	O
the	DT	O
Incyte	NNP	O
EST	NNP	O
clone	NN	O
no	DT	O
.	.	O
4111192	CD	O
was	VBD	O
purchased	VBN	O
and	CC	O
the	DT	O
cDNA	NN	O
insert	NN	O
was	VBD	O
obtained	VBN	O
and	CC	O
sequenced	VBN	O
.	.	O
The	DT	O
sequence	NN	O
of	IN	O
this	DT	O
cDNA	NN	O
insert	NN	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
7	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
)	)	O
and	CC	O
is	VBZ	O
herein	RB	O
designated	VBN	O
as	IN	O
DNA66658-1584	NNP	O
.	.	O
Clone	NN	O
UNQ688	NNP	O
(	(	O
DNA66658-1584	NNP	O
)	)	O
contains	VBZ	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
9-11	CD	O
and	CC	O
ending	VBG	O
at	IN	O
the	DT	O
stop	NN	O
codon	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
780-782	JJ	O
(	(	O
FIG	NNP	O
.	.	O
7	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
is	VBZ	O
257	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
8	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
.	.	O
The	DT	O
full-length	JJ	O
PRO1328	NNP	O
protein	NN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
8	CD	O
has	VBZ	O
an	DT	O
estimated	VBN	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
28,472	CD	O
daltons	NNS	O
and	CC	O
a	DT	O
pI	NN	O
of	IN	O
about	IN	O
9.33	CD	O
.	.	O
Analysis	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
PRO1328	NNP	O
sequence	NN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
8	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
evidences	VBZ	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
a	DT	O
signal	JJ	O
peptide	NN	O
from	IN	O
about	IN	O
amino	NN	O
acid	NN	O
1	CD	O
to	TO	O
about	IN	O
amino	NN	O
acid	NN	O
19	CD	O
,	,	O
transmembrane	NN	O
domains	NNS	O
from	IN	O
about	IN	O
amino	NN	O
acid	NN	O
32	CD	O
to	TO	O
about	IN	O
amino	NN	O
acid	NN	O
51	CD	O
,	,	O
from	IN	O
about	IN	O
amino	NN	O
acid	NN	O
119	CD	O
to	TO	O
about	IN	O
amino	NN	O
acid	NN	O
138	CD	O
,	,	O
from	IN	O
about	IN	O
amino	NN	O
acid	NN	O
152	CD	O
to	TO	O
about	IN	O
amino	NN	O
acid	NN	O
169	CD	O
and	CC	O
from	IN	O
about	IN	O
amino	NN	O
acid	NN	O
216	CD	O
to	TO	O
about	IN	O
amino	NN	O
acid	NN	O
235	CD	O
,	,	O
a	DT	O
glycosaminoglycan	JJ	O
attachment	NN	O
site	NN	O
from	IN	O
about	IN	O
amino	NN	O
acid	NN	O
120	CD	O
to	TO	O
about	IN	O
amino	NN	O
acid	NN	O
123	CD	O
and	CC	O
sodium/neurotransmitter	JJR	O
symporter	NN	O
family	NN	O
protein	NN	O
homology	NN	O
block	NN	O
from	IN	O
about	IN	O
amino	NN	O
acid	NN	O
31	CD	O
to	TO	O
about	IN	O
amino	NN	O
acid	NN	O
65	CD	O
.	.	O
Clone	NN	O
UNQ688	NNP	O
(	(	O
DNA66658-1584	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
deposited	VBN	O
with	IN	O
ATCC	NNP	O
on	IN	O
Sep.	NNP	O
15	CD	O
,	,	O
1998	CD	O
and	CC	O
is	VBZ	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
203229	CD	O
.	.	O
An	DT	O
analysis	NN	O
of	IN	O
the	DT	O
Dayhoff	NNP	O
database	NN	O
(	(	O
version	NN	O
35.45	CD	O
SwissProt	NNP	O
35	CD	O
)	)	O
,	,	O
using	VBG	O
a	DT	O
WU-BLAST2	JJ	O
sequence	NN	O
alignment	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
PRO1328	NNP	O
amino	NN	O
acid	NN	O
sequence	NN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
8	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
,	,	O
evidenced	VBD	O
significant	JJ	O
homology	NN	O
between	IN	O
the	DT	O
PRO1328	NNP	O
amino	NN	O
acid	NN	O
sequence	NN	O
and	CC	O
the	DT	O
following	JJ	O
Dayhoff	NNP	O
sequences	NNS	O
:	:	O
CEVF36H2L—2	NNP	O
,	,	O
TIP2_TOBAC	NNP	O
,	,	O
AB009466—16	NNP	O
,	,	O
ATU39485—1	NNP	O
,	,	O
P_R60153	NNP	O
,	,	O
P_R77082	NNP	O
,	,	O
S73351	NNP	O
,	,	O
C69392	NNP	O
,	,	O
LEU95008—1	NNP	O
and	CC	O
E64667	NNP	O
.	.	O
Example	RB	O
8	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO4342	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ1896	NNP	O
)	)	O
A	NNP	O
expressed	VBN	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
DNA	NNP	O
database	NN	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
was	VBD	O
searched	VBN	O
with	IN	O
human	JJ	O
interleukin-1	JJ	O
receptor	NN	O
antagonist	NN	O
(	(	O
hIL-1Ra	JJ	O
)	)	O
sequence	NN	O
,	,	O
and	CC	O
the	DT	O
EST	NNP	O
,	,	O
designated	VBD	O
5120028	CD	O
was	VBD	O
identified	VBN	O
,	,	O
which	WDT	O
showed	VBD	O
homology	NN	O
with	IN	O
the	DT	O
hIL-1Ra	JJ	O
known	JJ	O
protein	NN	O
.	.	O
EST	NNP	O
clone	NN	O
5120028	CD	O
was	VBD	O
purchased	VBN	O
from	IN	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
(	(	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
and	CC	O
the	DT	O
cDNA	NN	O
insert	NN	O
was	VBD	O
obtained	VBN	O
and	CC	O
sequenced	VBN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
The	DT	O
entire	JJ	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
clone	NN	O
5120028	CD	O
,	,	O
designated	VBN	O
UNQ1896	NNP	O
(	(	O
DNA96787-2534-1	NNP	O
)	)	O
,	,	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
9	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
.	.	O
Clone	NN	O
UNQ1896	NNP	O
(	(	O
DNA96787-2534-1	NNP	O
)	)	O
contains	VBZ	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
1-3	JJ	O
,	,	O
and	CC	O
a	DT	O
stop	JJ	O
codon	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
466-468	JJ	O
(	(	O
FIG	NNP	O
.	.	O
9	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
(	(	O
hIL-1Ra3	JJ	O
)	)	O
is	VBZ	O
155	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
10	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
)	)	O
.	.	O
The	DT	O
putative	JJ	O
signal	NN	O
sequence	NN	O
extends	VBZ	O
from	IN	O
amino	JJ	O
acid	JJ	O
positions	NNS	O
1-33	NNS	O
.	.	O
Putative	JJ	O
N-myristoylation	NN	O
sites	NNS	O
are	VBP	O
located	VBN	O
at	IN	O
amino	JJ	O
acid	JJ	O
positions	NNS	O
29-34	JJ	O
,	,	O
60-65	JJ	O
,	,	O
63-68	JJ	O
,	,	O
73-78	JJ	O
,	,	O
91-96	JJ	O
and	CC	O
106-111	JJ	O
.	.	O
An	DT	O
interleukin-1-like	JJ	O
sequence	NN	O
is	VBZ	O
located	VBN	O
at	IN	O
amino	JJ	O
acid	JJ	O
positions	NNS	O
111-131	NNS	O
.	.	O
Clone	NN	O
DNA96787	NNP	O
(	(	O
designated	VBN	O
as	IN	O
DNA96787-2534-1	NNP	O
)	)	O
was	VBD	O
deposited	VBN	O
with	IN	O
ATCC	NNP	O
on	IN	O
Jan.	NNP	O
12	CD	O
,	,	O
1999	CD	O
and	CC	O
was	VBD	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
203589	CD	O
.	.	O
The	DT	O
full	JJ	O
length	NN	O
hIL-1Ra3	JJ	O
protein	NN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
10	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
)	)	O
has	VBZ	O
an	DT	O
estimated	VBN	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
16,961	CD	O
daltons	NNS	O
and	CC	O
a	DT	O
pI	NN	O
of	IN	O
about	IN	O
4.9	CD	O
.	.	O
Based	VBN	O
on	IN	O
a	DT	O
BLAST	NNP	O
and	CC	O
FastA	NNP	O
sequence	NN	O
alignment	NN	O
analysis	NN	O
(	(	O
using	VBG	O
the	DT	O
ALIGN	NNP	O
computer	NN	O
program	NN	O
)	)	O
of	IN	O
the	DT	O
full-length	JJ	O
sequence	NN	O
,	,	O
hIL-1Ra3	JJ	O
shows	NNS	O
significant	JJ	O
amino	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
hicIL-1Ra	JJ	O
and	CC	O
hIL-1Ra	JJ	O
proteins	NNS	O
.	.	O
Example	RB	O
9	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO10096	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ3099	NNP	O
)	)	O
DNA125185-2806	NNP	O
(	(	O
UNQ3099	NNP	O
)	)	O
was	VBD	O
identified	VBN	O
by	IN	O
applying	VBG	O
a	DT	O
proprietary	JJ	O
signal	NN	O
sequence	NN	O
finding	VBG	O
algorithm	NNS	O
developed	VBN	O
by	IN	O
Genentech	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
South	NNP	O
San	NNP	O
Francisco	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
upon	NN	O
ESTs	NNP	O
as	RB	O
well	RB	O
as	IN	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
EST	NN	O
fragments	NNS	O
from	IN	O
public	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
GenBank	NNP	O
)	)	O
and/or	VBP	O
private	JJ	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
databases	VBZ	O
.	.	O
The	DT	O
signal	JJ	O
sequence	NN	O
algorithm	NN	O
computes	VBZ	O
a	DT	O
secretion	NN	O
signal	NN	O
score	NN	O
based	VBN	O
on	IN	O
the	DT	O
character	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
nucleotides	NNS	O
surrounding	VBG	O
the	DT	O
first	JJ	O
and	CC	O
optionally	RB	O
the	DT	O
second	JJ	O
methionine	NN	O
codon	NN	O
(	(	O
s	NN	O
)	)	O
(	(	O
ATG	NNP	O
)	)	O
at	IN	O
the	DT	O
5′-end	NN	O
of	IN	O
the	DT	O
sequence	NN	O
or	CC	O
sequence	NN	O
fragment	NN	O
under	IN	O
consideration	NN	O
.	.	O
The	DT	O
nucleotides	NNS	O
following	VBG	O
the	DT	O
first	JJ	O
ATG	NNP	O
must	MD	O
code	VB	O
for	IN	O
at	IN	O
least	JJS	O
35	CD	O
unambiguous	JJ	O
amino	NN	O
acids	NNS	O
without	IN	O
any	DT	O
stop	JJ	O
codons	NNS	O
.	.	O
If	IN	O
the	DT	O
first	JJ	O
ATG	NNP	O
has	VBZ	O
the	DT	O
required	VBN	O
amino	NN	O
acids	NNS	O
,	,	O
the	DT	O
second	NN	O
is	VBZ	O
not	RB	O
examined	VBN	O
.	.	O
If	IN	O
neither	DT	O
meets	VBZ	O
the	DT	O
requirement	NN	O
,	,	O
the	DT	O
candidate	NN	O
sequence	NN	O
is	VBZ	O
not	RB	O
scored	VBN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
EST	NNP	O
sequence	NN	O
contains	VBZ	O
an	DT	O
authentic	JJ	O
signal	NN	O
sequence	NN	O
,	,	O
the	DT	O
DNA	NN	O
and	CC	O
corresponding	VBG	O
amino	NN	O
acid	NN	O
sequences	NNS	O
surrounding	VBG	O
the	DT	O
ATG	NNP	O
codon	NN	O
are	VBP	O
scored	VBN	O
using	VBG	O
a	DT	O
set	NN	O
of	IN	O
seven	CD	O
sensors	NNS	O
(	(	O
evaluation	NN	O
parameters	NNS	O
)	)	O
known	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
secretion	NN	O
signals	NNS	O
.	.	O
Use	NNP	O
of	IN	O
the	DT	O
above	JJ	O
described	VBD	O
signal	JJ	O
sequence	NN	O
algorithm	NN	O
allowed	VBD	O
identification	NN	O
of	IN	O
an	DT	O
EST	NNP	O
cluster	NN	O
sequence	NN	O
from	IN	O
the	DT	O
Incyte	NNP	O
database	NN	O
,	,	O
designated	VBN	O
herein	NN	O
as	IN	O
5086173H1	CD	O
.	.	O
This	DT	O
EST	NNP	O
cluster	NN	O
sequence	NN	O
was	VBD	O
then	RB	O
compared	VBN	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
expressed	JJ	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
databases	VBZ	O
which	WDT	O
included	VBD	O
public	JJ	O
EST	NNP	O
databases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
GenBank	NNP	O
)	)	O
and	CC	O
a	DT	O
proprietary	JJ	O
EST	NNP	O
DNA	NN	O
database	NN	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
to	TO	O
identify	VB	O
existing	VBG	O
homologies	NNS	O
.	.	O
The	DT	O
homology	NN	O
search	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
computer	NN	O
program	NN	O
BLAST	NNP	O
or	CC	O
BLAST2	NNP	O
(	(	O
Altshul	NNP	B
et	RB	I
al.	RB	I
,	,	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
266:460-480	CD	I
(	(	I
1996	CD	I
)	)	I
)	)	O
.	.	O
Those	DT	O
comparisons	NNS	O
resulting	VBG	O
in	IN	O
a	DT	O
BLAST	NNP	O
score	NN	O
of	IN	O
70	CD	O
(	(	O
or	CC	O
in	IN	O
some	DT	O
cases	NNS	O
90	CD	O
)	)	O
or	CC	O
greater	JJR	O
that	WDT	O
did	VBD	O
not	RB	O
encode	VB	O
known	JJ	O
proteins	NNS	O
were	VBD	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
into	IN	O
a	DT	O
consensus	NN	O
DNA	NNP	O
sequence	NN	O
with	IN	O
the	DT	O
program	NN	O
“	NNP	B
phrap	NN	I
”	NNP	I
(	(	I
Phil	NNP	I
Green	NNP	I
,	,	I
University	NNP	I
of	IN	I
Washington	NNP	I
,	,	I
Seattle	NNP	I
,	,	I
Wash.	NNP	I
)	)	I
.	.	O
The	DT	O
consensus	NN	O
sequence	NN	O
obtained	VBN	O
therefrom	NN	O
is	VBZ	O
herein	RB	O
designated	VBN	O
DNA110880	NNP	O
.	.	O
In	IN	O
light	NN	O
of	IN	O
an	DT	O
observed	JJ	O
sequence	NN	O
homology	NN	O
between	IN	O
the	DT	O
DNA110880	NNP	O
sequence	NN	O
and	CC	O
an	DT	O
EST	NNP	O
sequence	NN	O
encompassed	VBD	O
within	IN	O
clone	NN	O
no	DT	O
.	.	O
5088384	CD	O
from	IN	O
the	DT	O
Incyte	NNP	O
database	NN	O
,	,	O
clone	NN	O
no	DT	O
.	.	O
5088384	CD	O
was	VBD	O
purchased	VBN	O
and	CC	O
the	DT	O
cDNA	NN	O
insert	NN	O
was	VBD	O
obtained	VBN	O
and	CC	O
sequenced	VBN	O
.	.	O
It	PRP	O
was	VBD	O
found	VBN	O
herein	NN	O
that	IN	O
that	DT	O
cDNA	NN	O
insert	NN	O
encoded	VBD	O
a	DT	O
full-length	JJ	O
protein	NN	O
.	.	O
The	DT	O
sequence	NN	O
of	IN	O
this	DT	O
cDNA	NN	O
insert	NN	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
13	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:13	NNP	O
)	)	O
and	CC	O
is	VBZ	O
herein	RB	O
designated	VBN	O
as	IN	O
DNA125185-2806	NNP	O
.	.	O
Clone	NNP	O
DNA125185-2806	NNP	O
[	NNP	O
UNQ3099	NNP	O
]	NNP	O
contains	VBZ	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
58-60	JJ	O
and	CC	O
ending	VBG	O
at	IN	O
the	DT	O
stop	NN	O
codon	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
595-597	JJ	O
(	(	O
FIG	NNP	O
.	.	O
13	CD	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
is	VBZ	O
179	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
14	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:14	NNP	O
)	)	O
.	.	O
The	DT	O
full-length	JJ	O
PRO10096	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:14	NNP	O
)	)	O
protein	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
14	CD	O
has	VBZ	O
an	DT	O
estimated	VBN	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
20,011	CD	O
daltons	NNS	O
and	CC	O
a	DT	O
pI	NN	O
of	IN	O
about	IN	O
8.10	CD	O
.	.	O
Analysis	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
PRO10096	NNP	O
sequence	NN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
14	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:14	NNP	O
)	)	O
evidences	VBZ	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
important	JJ	O
polypeptide	NN	O
domains	NNS	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
14	CD	O
,	,	O
wherein	VBD	O
the	DT	O
locations	NNS	O
given	VBN	O
for	IN	O
those	DT	O
important	JJ	O
polypeptide	NN	O
domains	NNS	O
are	VBP	O
approximate	JJ	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Clone	NNP	O
DNA125185-2806	NNP	O
has	VBZ	O
been	VBN	O
deposited	VBN	O
with	IN	O
ATCC	NNP	O
on	IN	O
Dec.	NNP	O
7	CD	O
,	,	O
1999	CD	O
and	CC	O
is	VBZ	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
PTA-1031	NNP	O
.	.	O
Example	RB	O
10	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO21384	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ6368	NNP	O
)	)	O
The	DT	O
extracellular	JJ	O
domain	NN	O
(	(	O
ECD	NNP	O
)	)	O
sequences	NNS	O
(	(	O
including	VBG	O
the	DT	O
secretion	NN	O
signal	NN	O
,	,	O
if	IN	O
any	DT	O
)	)	O
of	IN	O
from	IN	O
about	IN	O
950	CD	O
known	NNS	O
secreted	VBD	O
proteins	NNS	O
from	IN	O
the	DT	O
Swiss-Prot	NNP	O
public	JJ	O
protein	NN	O
database	NN	O
were	VBD	O
used	VBN	O
to	TO	O
search	VB	O
expressed	JJ	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
databases	VBZ	O
.	.	O
The	DT	O
EST	NNP	O
databases	NNS	O
included	VBD	O
public	JJ	O
EST	NNP	O
databases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
GenBank	NNP	O
)	)	O
and	CC	O
a	DT	O
proprietary	JJ	O
EST	NNP	O
DNA	NN	O
database	NN	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
The	DT	O
search	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
computer	NN	O
program	NN	O
BLAST	NNP	O
or	CC	O
BLAST2	NNP	O
(	(	O
Altshul	NNP	B
et	RB	I
al.	RB	I
,	,	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
266:460-480	CD	I
(	(	I
1996	CD	I
)	)	I
)	)	O
as	IN	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
ECD	NNP	O
protein	NN	O
sequences	NNS	O
to	TO	O
a	DT	O
6	CD	O
frame	NN	O
translation	NN	O
of	IN	O
the	DT	O
EST	NNP	O
sequence	NN	O
.	.	O
Those	DT	O
comparisons	NNS	O
resulting	VBG	O
in	IN	O
a	DT	O
BLAST	NNP	O
score	NN	O
of	IN	O
70	CD	O
(	(	O
or	CC	O
in	IN	O
some	DT	O
cases	NNS	O
90	CD	O
)	)	O
or	CC	O
greater	JJR	O
that	WDT	O
did	VBD	O
not	RB	O
encode	VB	O
known	JJ	O
proteins	NNS	O
were	VBD	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
into	IN	O
consensus	NN	O
DNA	NNP	O
sequences	NNS	O
.	.	O
An	DT	O
expressed	JJ	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
was	VBD	O
identified	VBN	O
by	IN	O
the	DT	O
EST	NNP	O
database	NN	O
search	NN	O
and	CC	O
a	DT	O
consensus	NN	O
DNA	NNP	O
sequence	NN	O
was	VBD	O
assembled	VBN	O
relative	JJ	O
to	TO	O
other	JJ	O
EST	NNP	O
sequences	NNS	O
using	VBG	O
phrap	NN	O
(	(	O
Phil	NNP	O
Green	NNP	O
,	,	O
University	NNP	O
of	IN	O
Washington	NNP	O
,	,	O
Seattle	NNP	O
,	,	O
Wash.	NNP	O
)	)	O
.	.	O
This	DT	O
consensus	NN	O
sequence	NN	O
is	VBZ	O
herein	RB	O
designated	VBN	O
“	NNP	O
Consen0821	NNP	O
”	NNP	O
,	,	O
which	WDT	O
was	VBD	O
used	VBN	O
to	TO	O
derive	VB	O
the	DT	O
final	JJ	O
consensus	NN	O
sequence	NN	O
,	,	O
“	NNP	O
DNA172257	NNP	O
”	NNP	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
DNA172257	NNP	O
consensus	NN	O
sequence	NN	O
,	,	O
oligonucleotides	NNS	O
were	VBD	O
synthesized	VBN	O
:	:	O
1	CD	O
)	)	O
to	TO	O
identify	VB	O
by	IN	O
PCR	NNP	O
a	DT	O
cDNA	NN	O
library	NN	O
that	WDT	O
contained	VBD	O
the	DT	O
sequence	NN	O
of	IN	O
interest	NN	O
,	,	O
and	CC	O
2	CD	O
)	)	O
for	IN	O
use	NN	O
as	IN	O
probes	NNS	O
to	TO	O
isolate	VB	O
a	DT	O
clone	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
coding	NN	O
sequence	NN	O
for	IN	O
PRO233	NNP	O
.	.	O
Forward	NNP	O
and	CC	O
reverse	VB	O
PCR	NNP	O
primers	NNS	O
generally	RB	O
range	VBP	O
from	IN	O
20	CD	O
to	TO	O
30	CD	O
nucleotides	NNS	O
and	CC	O
are	VBP	O
often	RB	O
designed	VBN	O
to	TO	O
give	VB	O
a	DT	O
PCR	NNP	O
product	NN	O
of	IN	O
about	IN	O
100-1000	CD	O
bp	NN	O
in	IN	O
length	NN	O
.	.	O
The	DT	O
probe	NN	O
sequences	NNS	O
are	VBP	O
typically	RB	O
40-55	JJ	O
bp	NN	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
additional	JJ	O
oligonucleotides	NNS	O
are	VBP	O
synthesized	VBN	O
when	WRB	O
the	DT	O
consensus	NN	O
sequence	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
about	IN	O
1-1.5	JJ	O
kbp	NN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
,	,	O
as	IN	O
ber	NN	O
Ausubel	NNP	B
et	CC	I
al.	RB	I
,	,	I
Current	NNP	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	O
with	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pair	NN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
gene	NN	O
of	IN	O
interest	NN	O
by	IN	O
the	DT	O
in	IN	O
vivo	NN	O
cloning	NN	O
procedure	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
primer	NN	O
pairs	NNS	O
.	.	O
Forward	NNP	O
and	CC	O
reverse	VB	O
PCR	NNP	O
primers	NNS	O
were	VBD	O
synthesized	VBN	O
:	:	O
Additionally	RB	O
,	,	O
a	DT	O
synthetic	JJ	O
oligonucleotide	NN	O
hybridization	NN	O
probe	NN	O
was	VBD	O
constructed	VBN	O
from	IN	O
the	DT	O
consensus	NN	O
DNA172257	NNP	O
sequence	NN	O
which	WDT	O
had	VBD	O
the	DT	O
following	JJ	O
nucleotide	JJ	O
sequence	NN	O
:	:	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
source	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
with	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pair	NN	O
identified	VBN	O
above	IN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
PRO21384	NNP	O
gene	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
.	.	O
RNA	NNP	O
for	IN	O
construction	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
libraries	NNS	O
was	VBD	O
isolated	VBN	O
from	IN	O
a	DT	O
mixture	NN	O
of	IN	O
human	JJ	O
tissues	NNS	O
.	.	O
The	DT	O
cDNA	NN	O
libraries	NNS	O
used	VBN	O
to	TO	O
isolate	VB	O
the	DT	O
cDNA	NN	O
clones	NNS	O
were	VBD	O
constructed	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
using	VBG	O
commercially	RB	O
available	JJ	O
reagents	NNS	O
such	JJ	O
as	IN	O
those	DT	O
from	IN	O
Invitrogen	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif	NNP	O
.	.	O
The	DT	O
cDNA	NN	O
was	VBD	O
primed	VBN	O
with	IN	O
oligo	JJ	O
dT	NN	O
containing	VBG	O
a	DT	O
NotI	NNP	O
site	NN	O
,	,	O
linked	VBN	O
with	IN	O
blunt	NN	O
to	TO	O
SalI	NNP	O
hemikinased	VBD	O
adaptors	NNS	O
,	,	O
cleaved	VBN	O
with	IN	O
NotI	NNP	O
,	,	O
sized	VBD	O
appropriately	RB	O
by	IN	O
gel	JJ	O
electrophoresis	NN	O
,	,	O
and	CC	O
cloned	VBD	O
in	IN	O
a	DT	O
defined	JJ	O
orientation	NN	O
into	IN	O
a	DT	O
suitable	JJ	O
cloning	NN	O
vector	NN	O
(	(	O
such	JJ	O
as	IN	O
pRKB	NN	O
or	CC	O
pRKD	NN	O
;	:	O
pRK5B	NN	O
is	VBZ	O
a	DT	O
precursor	NN	O
of	IN	O
pRK5D	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
contain	VB	O
the	DT	O
SfiI	NNP	O
site	NN	O
;	:	O
see	VB	O
,	,	O
Holmes	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
253:1278-1280	CD	I
(	(	I
1991	CD	I
)	)	I
)	)	O
in	IN	O
the	DT	O
unique	JJ	O
XhoI	NNP	O
and	CC	O
NotI	NNP	O
sites	NNS	O
.	.	O
DNA	NN	O
sequencing	NN	O
of	IN	O
the	DT	O
clones	NNS	O
isolated	VBD	O
as	IN	O
described	VBN	O
above	IN	O
gave	VBD	O
the	DT	O
full-length	JJ	O
DNA	NNP	O
sequence	NN	O
of	IN	O
PRO21384	NNP	O
[	NNP	O
herein	RB	O
designated	VBD	O
as	IN	O
UNQ6368	NNP	O
(	(	O
DNA177313-2982	NNP	O
)	)	O
]	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
)	)	O
and	CC	O
the	DT	O
derived	JJ	O
protein	NN	O
sequence	NN	O
of	IN	O
PRO21384	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:16	NNP	O
)	)	O
.	.	O
The	DT	O
entire	JJ	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
UNQ6368	NNP	O
(	(	O
DNA177313-2982	NNP	O
)	)	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
15	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
)	)	O
.	.	O
Clone	NN	O
UNQ6368	NNP	O
(	(	O
DNA177313-2982	NNP	O
)	)	O
contains	VBZ	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
93-95	CD	O
and	CC	O
ending	VBG	O
at	IN	O
the	DT	O
stop	NN	O
codon	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
1939-1941	JJ	O
(	(	O
FIG	NNP	O
.	.	O
15	CD	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
is	VBZ	O
582	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
16	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:16	NNP	O
)	)	O
.	.	O
The	DT	O
full-length	JJ	O
PRO21384	NNP	O
protein	NN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
16	CD	O
has	VBZ	O
an	DT	O
estimated	VBN	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
66605	CD	O
daltons	NNS	O
and	CC	O
a	DT	O
pI	NN	O
of	IN	O
about	IN	O
8.14	CD	O
.	.	O
Clone	NN	O
UNQ6368	NNP	O
(	(	O
DNA177313-2982	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
deposited	VBN	O
with	IN	O
ATCC	NNP	O
on	IN	O
Jul	NNP	O
.	.	O
19	CD	O
,	,	O
2000	CD	O
and	CC	O
is	VBZ	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
PTA-2251	NNP	O
.	.	O
Analysis	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
PRO21384	NNP	O
polypeptide	NN	O
evidenced	VBD	O
sequence	NN	O
identity	NN	O
between	IN	O
the	DT	O
PRO21384	NNP	O
amino	NN	O
acid	NN	O
sequence	NN	O
and	CC	O
the	DT	O
following	JJ	O
Dayhoff	NNP	O
sequences	NNS	O
:	:	O
P_R10545	NNP	O
,	,	O
IL6B_MOUSE	NNP	O
,	,	O
GCSR_HUMAN	NNP	O
,	,	O
LIFR_HUMAN	NNP	O
,	,	O
HSU64198—1	NNP	O
,	,	O
P_R85912	NNP	O
,	,	O
P_W70848	NNP	O
,	,	O
P_Y29779	NNP	O
,	,	O
P_Y17825	NNP	O
and	CC	O
P_W70839	NNP	O
.	.	O
Example	RB	O
11	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO353	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ310	NNP	O
)	)	O
A	NNP	O
consensus	NN	O
DNA	NNP	O
sequence	NN	O
was	VBD	O
assembled	VBN	O
relative	JJ	O
to	TO	O
other	JJ	O
EST	NNP	O
sequences	NNS	O
using	VBG	O
phrap	NN	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
1	CD	O
above	IN	O
.	.	O
This	DT	O
consensus	NN	O
sequences	VBZ	O
is	VBZ	O
herein	RB	O
designated	VBN	O
DNA36363	NNP	O
.	.	O
The	DT	O
consensus	NN	O
DNA	NNP	O
sequence	NN	O
was	VBD	O
extended	VBN	O
using	VBG	O
repeated	JJ	O
cycles	NNS	O
of	IN	O
BLAST	NNP	O
and	CC	O
phrap	NN	O
to	TO	O
extend	VB	O
the	DT	O
consensus	NN	O
sequence	NN	O
as	RB	O
far	RB	O
as	IN	O
possible	JJ	O
using	VBG	O
the	DT	O
sources	NNS	O
of	IN	O
EST	NNP	O
sequences	NNS	O
discussed	VBN	O
above	IN	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
DNA36363	NNP	O
consensus	NN	O
sequence	NN	O
,	,	O
oligonucleotides	NNS	O
were	VBD	O
synthesized	VBN	O
:	:	O
1	CD	O
)	)	O
to	TO	O
identify	VB	O
by	IN	O
PCR	NNP	O
a	DT	O
cDNA	NN	O
library	NN	O
that	WDT	O
contained	VBD	O
the	DT	O
sequence	NN	O
of	IN	O
interest	NN	O
,	,	O
and	CC	O
2	CD	O
)	)	O
for	IN	O
use	NN	O
as	IN	O
probes	NNS	O
to	TO	O
isolate	VB	O
a	DT	O
clone	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
coding	NN	O
sequence	NN	O
for	IN	O
PRO353	NNP	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
DNA36363	NNP	O
consensus	NN	O
sequence	NN	O
,	,	O
forward	RB	O
and	CC	O
reverse	VB	O
PCR	NNP	O
primers	NNS	O
were	VBD	O
synthesized	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
Additionally	RB	O
,	,	O
a	DT	O
synthetic	JJ	O
oligonucleotide	NN	O
hybridization	NN	O
probe	NN	O
was	VBD	O
constructed	VBN	O
from	IN	O
the	DT	O
DNA36363	NNP	O
consensus	NN	O
sequence	NN	O
which	WDT	O
had	VBD	O
the	DT	O
following	JJ	O
nucleotide	JJ	O
sequence	NN	O
:	:	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
source	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
with	IN	O
one	CD	O
of	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pairs	NNS	O
identified	VBN	O
above	IN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
PRO353	NNP	O
gene	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
PCR	NNP	O
primers	NNS	O
.	.	O
RNA	NNP	O
for	IN	O
construction	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
libraries	NNS	O
was	VBD	O
isolated	VBN	O
from	IN	O
human	JJ	O
fetal	JJ	O
kidney	NN	O
tissue	NN	O
.	.	O
DNA	NN	O
sequencing	NN	O
of	IN	O
the	DT	O
clones	NNS	O
isolated	VBD	O
as	IN	O
described	VBN	O
above	IN	O
gave	VBD	O
the	DT	O
full-length	JJ	O
DNA	NNP	O
sequence	NN	O
for	IN	O
PRO353	NNP	O
[	NNP	O
herein	RB	O
designated	VBD	O
as	IN	O
DNA41234-1242-1	NNP	O
]	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
)	)	O
and	CC	O
the	DT	O
derived	JJ	O
protein	NN	O
sequence	NN	O
for	IN	O
PRO353	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:18	NNP	O
)	)	O
.	.	O
The	DT	O
entire	JJ	O
nucleotide	JJ	O
sequence	NN	O
of	IN	O
DNA41234-1242-1	NNP	O
[	NNP	O
UNQ310	NNP	O
]	NNP	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
17	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
)	)	O
.	.	O
Clone	NNP	O
DNA41234-1242-1	NNP	O
contains	VBZ	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
305-307	JJ	O
and	CC	O
ending	VBG	O
at	IN	O
the	DT	O
stop	NN	O
codon	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
1148-1150	JJ	O
(	(	O
FIG	NNP	O
.	.	O
17	CD	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
is	VBZ	O
281	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
18	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:18	NNP	O
)	)	O
.	.	O
Important	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
encoded	VBN	O
by	IN	O
PRO353	NNP	O
include	VBP	O
the	DT	O
signal	JJ	O
peptide	NN	O
,	,	O
corresponding	VBG	O
to	TO	O
amino	VB	O
acids	NNS	O
1-26	CD	O
,	,	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
mature	NN	O
protein	NN	O
at	IN	O
amino	NN	O
acid	JJ	O
position	NN	O
27	CD	O
,	,	O
a	DT	O
potential	JJ	O
N-glycosylation	NN	O
site	NN	O
,	,	O
corresponding	VBG	O
to	TO	O
amino	VB	O
acids	NNS	O
93-98	CD	O
and	CC	O
a	DT	O
region	NN	O
which	WDT	O
has	VBZ	O
homology	NN	O
to	TO	O
a	DT	O
30	CD	O
kd	NN	O
adipocyte	JJ	O
complement-related	JJ	O
protein	NN	O
precursor	NN	O
,	,	O
corresponding	VBG	O
to	TO	O
amino	VB	O
acids	JJ	O
99-281	CD	O
.	.	O
Clone	NNP	O
DNA41234-1242-1	NNP	O
has	VBZ	O
been	VBN	O
deposited	VBN	O
with	IN	O
the	DT	O
ATCC	NNP	O
and	CC	O
is	VBZ	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
ATCC	$	O
209618	CD	O
on	IN	O
Feb.	NNP	O
5	CD	O
,	,	O
1998	CD	O
.	.	O
Analysis	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
PRO353	NNP	O
polypeptides	NNS	O
suggests	VBZ	O
that	IN	O
portions	NNS	O
of	IN	O
them	PRP	O
possess	VBP	O
significant	JJ	O
homology	NN	O
to	TO	O
portions	NNS	O
of	IN	O
human	JJ	O
and	CC	O
murine	JJ	O
complement	NN	O
proteins	NNS	O
,	,	O
thereby	RB	O
indicating	VBG	O
that	IN	O
PRO353	NNP	O
may	MD	O
be	VB	O
a	DT	O
novel	JJ	O
complement	NN	O
protein	NN	O
.	.	O
Example	RB	O
12	CD	O
Isolation	NNP	O
of	IN	O
cDNA	NN	O
Clones	NNP	O
Encoding	NNP	O
Human	NNP	O
PRO1885	NNP	O
Polypeptides	NNP	O
(	(	O
UNQ868	NNP	O
)	)	O
by	IN	O
Amylase	NNP	O
Screening	NNP	O
1	CD	O
.	.	O
Preparation	NN	O
of	IN	O
Oligo	NNP	O
dT	NN	O
Primed	NNP	O
cDNA	NN	O
Library	NNP	O
mRNA	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
a	DT	O
human	JJ	O
tissue	NN	O
of	IN	O
interest	NN	O
using	VBG	O
reagents	NNS	O
and	CC	O
protocols	NNS	O
from	IN	O
Invitrogen	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
(	(	O
Fast	NNP	O
Track	NNP	O
2	CD	O
)	)	O
.	.	O
This	DT	O
RNA	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
generate	VB	O
an	DT	O
oligo	JJ	O
dT	NN	O
primed	VBD	O
cDNA	JJ	O
library	NN	O
in	IN	O
the	DT	O
vector	NN	O
pRK5D	NN	O
using	VBG	O
reagents	NNS	O
and	CC	O
protocols	NNS	O
from	IN	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Gaithersburg	NNP	O
,	,	O
Md	NNP	O
.	.	O
(	(	O
Super	NNP	O
Script	NNP	O
Plasmid	NNP	O
System	NNP	O
)	)	O
.	.	O
In	IN	O
this	DT	O
procedure	NN	O
,	,	O
the	DT	O
double	NN	O
stranded	VBD	O
cDNA	NN	O
was	VBD	O
sized	VBN	O
to	TO	O
greater	JJR	O
than	IN	O
1000	CD	O
bp	NN	O
and	CC	O
the	DT	O
SalI/NotI	NNP	O
linkered	VBD	O
cDNA	NN	O
was	VBD	O
cloned	VBN	O
into	IN	O
XhoI/NotI	NNP	O
cleaved	VBD	O
vector	NN	O
.	.	O
pRK5D	NN	O
is	VBZ	O
a	DT	O
cloning	VBG	O
vector	NN	O
that	WDT	O
has	VBZ	O
an	DT	O
sp6	JJ	O
transcription	NN	O
initiation	NN	O
site	NN	O
followed	VBN	O
by	IN	O
an	DT	O
SfiI	NNP	O
restriction	NN	O
enzyme	NN	O
site	NN	O
preceding	VBG	O
the	DT	O
XhoI/NotI	NNP	O
cDNA	NN	O
cloning	VBG	O
sites	NNS	O
.	.	O
2	CD	O
.	.	O
Preparation	NN	O
of	IN	O
Random	NNP	O
Primed	NNP	O
cDNA	NN	O
Library	NNP	O
A	NNP	O
secondary	JJ	O
cDNA	NN	O
library	NN	O
was	VBD	O
generated	VBN	O
in	IN	O
order	NN	O
to	TO	O
preferentially	RB	O
represent	VB	O
the	DT	O
5′	CD	O
ends	NNS	O
of	IN	O
the	DT	O
primary	JJ	O
cDNA	NN	O
clones	NNS	O
.	.	O
Sp6	NNP	O
RNA	NNP	O
was	VBD	O
generated	VBN	O
from	IN	O
the	DT	O
primary	JJ	O
library	NN	O
(	(	O
described	VBN	O
above	IN	O
)	)	O
,	,	O
and	CC	O
this	DT	O
RNA	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
generate	VB	O
a	DT	O
random	NN	O
primed	VBN	O
cDNA	JJ	O
library	NN	O
in	IN	O
the	DT	O
vector	NN	O
pSST-AMY.0	JJ	O
using	VBG	O
reagents	NNS	O
and	CC	O
protocols	NNS	O
from	IN	O
Life	NNP	O
Technologies	NNPS	O
(	(	O
Super	NNP	O
Script	NNP	O
Plasmid	NNP	O
System	NNP	O
,	,	O
referenced	VBN	O
above	IN	O
)	)	O
.	.	O
In	IN	O
this	DT	O
procedure	NN	O
the	DT	O
double	NN	O
stranded	VBD	O
cDNA	NN	O
was	VBD	O
sized	VBN	O
to	TO	O
500-1000	CD	O
bp	NN	O
,	,	O
linkered	VBN	O
with	IN	O
blunt	NN	O
to	TO	O
NotI	NNP	O
adaptors	NNS	O
,	,	O
cleaved	VBN	O
with	IN	O
SfiI	NNP	O
,	,	O
and	CC	O
cloned	VBD	O
into	IN	O
SfiI/NotI	NNP	O
cleaved	VBD	O
vector	NN	O
.	.	O
pSST-AMY.0	NN	O
is	VBZ	O
a	DT	O
cloning	VBG	O
vector	NN	O
that	WDT	O
has	VBZ	O
a	DT	O
yeast	NN	O
alcohol	NN	O
dehydrogenase	NN	O
promoter	NN	O
preceding	VBG	O
the	DT	O
cDNA	NN	O
cloning	VBG	O
sites	NNS	O
and	CC	O
the	DT	O
mouse	NN	O
amylase	NN	O
sequence	NN	O
(	(	O
the	DT	O
mature	NN	O
sequence	NN	O
without	IN	O
the	DT	O
secretion	NN	O
signal	NN	O
)	)	O
followed	VBN	O
by	IN	O
the	DT	O
yeast	NN	O
alcohol	NN	O
dehydrogenase	NN	O
terminator	NN	O
,	,	O
after	IN	O
the	DT	O
cloning	NN	O
sites	NNS	O
.	.	O
Thus	RB	O
,	,	O
cDNAs	NN	O
cloned	VBD	O
into	IN	O
this	DT	O
vector	NN	O
that	WDT	O
are	VBP	O
fused	VBN	O
in	IN	O
frame	NN	O
with	IN	O
amylase	JJ	O
sequence	NN	O
will	MD	O
lead	VB	O
to	TO	O
the	DT	O
secretion	NN	O
of	IN	O
amylase	NN	O
from	IN	O
appropriately	RB	O
transfected	VBN	O
yeast	NN	O
colonies	NNS	O
.	.	O
3	CD	O
.	.	O
Transformation	NN	O
and	CC	O
Detection	NNP	O
DNA	NNP	O
from	IN	O
the	DT	O
library	JJ	O
described	NN	O
in	IN	O
paragraph	NN	O
2	CD	O
above	NN	O
was	VBD	O
chilled	VBN	O
on	IN	O
ice	NN	O
to	TO	O
which	WDT	O
was	VBD	O
added	VBN	O
electrocompetent	JJ	O
DH10B	NNP	O
bacteria	NN	O
(	(	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
20	CD	O
ml	NN	O
)	)	O
.	.	O
The	DT	O
bacteria	NN	O
and	CC	O
vector	NN	O
mixture	NN	O
was	VBD	O
then	RB	O
electroporated	VBN	O
as	IN	O
recommended	VBN	O
by	IN	O
the	DT	O
manufacturer	NN	O
.	.	O
Subsequently	RB	O
,	,	O
SOC	NNP	O
media	NNS	O
(	(	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
1	CD	O
ml	NN	O
)	)	O
was	VBD	O
added	VBN	O
and	CC	O
the	DT	O
mixture	NN	O
was	VBD	O
incubated	VBN	O
at	IN	O
37°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
minutes	NNS	O
.	.	O
The	DT	O
transformants	NNS	O
were	VBD	O
then	RB	O
plated	VBN	O
onto	IN	O
20	CD	O
standard	JJ	O
150	CD	O
mm	NN	O
LB	NNP	O
plates	VBZ	O
containing	VBG	O
ampicillin	NN	O
and	CC	O
incubated	VBN	O
for	IN	O
16	CD	O
hours	NNS	O
(	(	O
37°	CD	O
C.	NNP	O
)	)	O
.	.	O
Positive	JJ	O
colonies	NNS	O
were	VBD	O
scraped	VBN	O
off	RP	O
the	DT	O
plates	NNS	O
and	CC	O
the	DT	O
DNA	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
bacterial	JJ	O
pellet	NN	O
using	VBG	O
standard	JJ	O
protocols	NNS	O
,	,	O
e.g	NN	O
.	.	O
CsCl-gradient	NN	O
.	.	O
The	DT	O
purified	JJ	O
DNA	NN	O
was	VBD	O
then	RB	O
carried	VBN	O
on	IN	O
to	TO	O
the	DT	O
yeast	NN	O
protocols	NNS	O
below	IN	O
.	.	O
The	DT	O
yeast	NN	O
methods	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
categories	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
Transformation	NN	O
of	IN	O
yeast	NN	O
with	IN	O
the	DT	O
plasmid/cDNA	NN	O
combined	VBD	O
vector	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
Detection	NN	O
and	CC	O
isolation	NN	O
of	IN	O
yeast	NN	O
clones	NNS	O
secreting	VBG	O
amylase	NN	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
PCR	NNP	O
amplification	NN	O
of	IN	O
the	DT	O
insert	NN	O
directly	RB	O
from	IN	O
the	DT	O
yeast	NN	O
colony	NN	O
and	CC	O
purification	NN	O
of	IN	O
the	DT	O
DNA	NN	O
for	IN	O
sequencing	VBG	O
and	CC	O
further	JJ	O
analysis	NN	O
.	.	O
The	DT	O
yeast	NN	O
strain	NN	O
used	VBN	O
was	VBD	O
HD56-5A	NNP	O
(	(	O
ATCC-90785	NNP	O
)	)	O
.	.	O
This	DT	O
strain	NN	O
has	VBZ	O
the	DT	O
following	JJ	O
genotype	NN	O
:	:	O
MAT	NNP	O
alpha	NN	O
,	,	O
ura3-52	JJ	O
,	,	O
leu2-3	JJ	O
,	,	O
leu2-112	JJ	O
,	,	O
his3-11	JJ	O
,	,	O
his3-15	JJ	O
,	,	O
MAL+	NNP	O
,	,	O
SUC+	NNP	O
,	,	O
GAL+	NNP	O
.	.	O
Preferably	RB	O
,	,	O
yeast	JJ	O
mutants	NNS	O
can	MD	O
be	VB	O
employed	VBN	O
that	DT	O
have	VBP	O
deficient	JJ	O
post-translational	JJ	O
pathways	NNS	O
.	.	O
Such	JJ	O
mutants	NNS	O
may	MD	O
have	VB	O
translocation	NN	O
deficient	NN	O
alleles	NNS	O
in	IN	O
sec71	NN	O
,	,	O
sec72	NN	O
,	,	O
sec62	NN	O
,	,	O
with	IN	O
truncated	JJ	O
sec71	NN	O
being	VBG	O
most	JJS	O
preferred	VBN	O
.	.	O
Alternatively	RB	O
,	,	O
antagonists	NNS	O
(	(	O
including	VBG	O
antisense	NN	O
nucleotides	NNS	O
and/or	VBP	O
ligands	NNS	O
)	)	O
which	WDT	O
interfere	RB	O
with	IN	O
the	DT	O
normal	JJ	O
operation	NN	O
of	IN	O
these	DT	O
genes	NNS	O
,	,	O
other	JJ	O
proteins	NNS	O
implicated	VBN	O
in	IN	O
this	DT	O
post	NN	O
translation	NN	O
pathway	NN	O
(	(	O
e.g.	JJ	O
,	,	O
SEC61p	NNP	O
,	,	O
SEC72p	NNP	O
,	,	O
SEC62p	NNP	O
,	,	O
SEC63p	NNP	O
,	,	O
TDJ1p	NNP	O
or	CC	O
SSA1p-4p	NNP	O
)	)	O
or	CC	O
the	DT	O
complex	JJ	O
formation	NN	O
of	IN	O
these	DT	O
proteins	NNS	O
may	MD	O
also	RB	O
be	VB	O
preferably	RB	O
employed	VBN	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
amylase-expressing	JJ	O
yeast	NN	O
.	.	O
Transformation	NN	O
was	VBD	O
performed	VBN	O
based	VBN	O
on	IN	O
the	DT	O
protocol	NN	O
outlined	VBN	O
by	IN	O
Gietz	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nucl	NNP	I
.	.	I
Acid	NNP	I
.	.	I
Res.	NNP	I
,	,	I
20:1425	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
Transformed	NNP	O
cells	NNS	O
were	VBD	O
then	RB	O
inoculated	VBN	O
from	IN	O
agar	NN	O
into	IN	O
YEPD	NNP	O
complex	JJ	O
media	NNS	O
broth	NN	O
(	(	O
100	CD	O
ml	NN	O
)	)	O
and	CC	O
grown	JJ	O
overnight	NN	O
at	IN	O
30°	CD	O
C.	NNP	O
The	DT	O
YEPD	NNP	O
broth	NN	O
was	VBD	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Kaiser	NNP	B
et	CC	I
al.	NN	I
,	,	I
Methods	NNP	I
in	IN	I
Yeast	NNP	I
Genetics	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Press	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
p.	VBZ	I
207	CD	I
(	(	I
1994	CD	I
)	)	I
.	.	O
The	DT	O
overnight	JJ	O
culture	NN	O
was	VBD	O
then	RB	O
diluted	VBN	O
to	TO	O
about	IN	O
2×106	CD	O
cells/ml	NN	O
(	(	O
approx	NN	O
.	.	O
OD600=0.1	NNP	O
)	)	O
into	IN	O
fresh	JJ	O
YEPD	NNP	O
broth	NN	O
(	(	O
500	CD	O
ml	NN	O
)	)	O
and	CC	O
regrown	VBN	O
to	TO	O
1×107	CD	O
cells/ml	NN	O
(	(	O
approx	NN	O
.	.	O
OD600=0.4-0.5	NNP	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
then	RB	O
harvested	VBN	O
and	CC	O
prepared	VBN	O
for	IN	O
transformation	NN	O
by	IN	O
transfer	NN	O
into	IN	O
GS3	NNP	O
rotor	NN	O
bottles	NNS	O
in	IN	O
a	DT	O
Sorval	NNP	O
GS3	NNP	O
rotor	NN	O
at	IN	O
5,000	CD	O
rpm	NN	O
for	IN	O
5	CD	O
minutes	NNS	O
,	,	O
the	DT	O
supernatant	NN	O
discarded	VBD	O
,	,	O
and	CC	O
then	RB	O
resuspended	VBD	O
into	IN	O
sterile	JJ	O
water	NN	O
,	,	O
and	CC	O
centrifuged	VBD	O
again	RB	O
in	IN	O
50	CD	O
ml	JJ	O
falcon	NN	O
tubes	NNS	O
at	IN	O
3,500	CD	O
rpm	NN	O
in	IN	O
a	DT	O
Beckman	NNP	O
GS-6KR	NNP	O
centrifuge	NN	O
.	.	O
The	DT	O
supernatant	NN	O
was	VBD	O
discarded	VBN	O
and	CC	O
the	DT	O
cells	NNS	O
were	VBD	O
subsequently	RB	O
washed	VBN	O
with	IN	O
LiAc/TE	NNP	O
(	(	O
10	CD	O
ml	NN	O
,	,	O
10	CD	O
mM	NN	O
Tris-HCl	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
pH	NN	O
7.5	CD	O
,	,	O
100	CD	O
mM	NN	O
Li2OOCCH3	NNP	O
)	)	O
,	,	O
and	CC	O
resuspended	VBD	O
into	IN	O
LiAc/TE	NNP	O
(	(	O
2.5	CD	O
ml	NN	O
)	)	O
.	.	O
Transformation	NN	O
took	VBD	O
place	NN	O
by	IN	O
mixing	VBG	O
the	DT	O
prepared	JJ	O
cells	NNS	O
(	(	O
100	CD	O
μl	NN	O
)	)	O
with	IN	O
freshly	RB	O
denatured	VBN	O
single	JJ	O
stranded	VBD	O
salmon	JJ	O
testes	NNS	O
DNA	NNP	O
(	(	O
Lofstrand	NNP	O
Labs	NNP	O
,	,	O
Gaithersburg	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
and	CC	O
transforming	VBG	O
DNA	NNP	O
(	(	O
1	CD	O
μg	NN	O
,	,	O
vol	NN	O
.	.	O
<	RB	O
10	CD	O
μl	NN	O
)	)	O
in	IN	O
microfuge	NN	O
tubes	NNS	O
.	.	O
The	DT	O
mixture	NN	O
was	VBD	O
mixed	JJ	O
briefly	NN	O
by	IN	O
vortexing	VBG	O
,	,	O
then	RB	O
40	CD	O
%	NN	O
PEG/TE	NNP	O
(	(	O
600	CD	O
μl	NN	O
,	,	O
40	CD	O
%	NN	O
polyethylene	JJ	O
glycol-4000	NN	O
,	,	O
10	CD	O
mM	NN	O
Tris-HCl	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
100	CD	O
mM	NN	O
Li2OOCCH3	NNP	O
,	,	O
pH	RB	O
7.5	CD	O
)	)	O
was	VBD	O
added	VBN	O
.	.	O
This	DT	O
mixture	NN	O
was	VBD	O
gently	RB	O
mixed	JJ	O
and	CC	O
incubated	VBN	O
at	IN	O
30°	CD	O
C.	NNP	O
while	IN	O
agitating	VBG	O
for	IN	O
30	CD	O
minutes	NNS	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
then	RB	O
heat	NN	O
shocked	VBD	O
at	IN	O
42°	CD	O
C.	NNP	O
for	IN	O
15	CD	O
minutes	NNS	O
,	,	O
and	CC	O
the	DT	O
reaction	NN	O
vessel	NN	O
centrifuged	VBN	O
in	IN	O
a	DT	O
microfuge	NN	O
at	IN	O
12,000	CD	O
rpm	NN	O
for	IN	O
5-10	JJ	O
seconds	NNS	O
,	,	O
decanted	VBN	O
and	CC	O
resuspended	VBN	O
into	IN	O
TE	NNP	O
(	(	O
500	CD	O
μl	NN	O
,	,	O
10	CD	O
mM	NN	O
Tris-HCl	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
pH	VBZ	O
7.5	CD	O
)	)	O
followed	VBN	O
by	IN	O
recentrifugation	NN	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
then	RB	O
diluted	VBN	O
into	IN	O
TE	NNP	O
(	(	O
1	CD	O
ml	NN	O
)	)	O
and	CC	O
aliquots	NNS	O
(	(	O
200	CD	O
μl	NN	O
)	)	O
were	VBD	O
spread	VBN	O
onto	IN	O
the	DT	O
selective	JJ	O
media	NNS	O
previously	RB	O
prepared	VBN	O
in	IN	O
150	CD	O
mm	JJ	O
growth	NN	O
plates	NNS	O
(	(	O
VWR	NNP	O
)	)	O
.	.	O
Alternatively	RB	O
,	,	O
instead	RB	O
of	IN	O
multiple	JJ	O
small	JJ	O
reactions	NNS	O
,	,	O
the	DT	O
transformation	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
a	DT	O
single	JJ	O
,	,	O
large	JJ	O
scale	NN	O
reaction	NN	O
,	,	O
wherein	JJ	O
reagent	NN	O
amounts	NNS	O
were	VBD	O
scaled	VBN	O
up	RP	O
accordingly	RB	O
.	.	O
The	DT	O
selective	JJ	O
media	NNS	O
used	VBN	O
was	VBD	O
a	DT	O
synthetic	JJ	O
complete	JJ	O
dextrose	NN	O
agar	NN	O
lacking	VBG	O
uracil	JJ	O
(	(	O
SCD-Ura	NNP	O
)	)	O
prepared	VBD	O
as	IN	O
described	VBN	O
in	IN	O
Kaiser	NNP	B
et	CC	I
al.	NN	I
,	,	I
Methods	NNP	I
in	IN	I
Yeast	NNP	I
Genetics	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Press	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
p.	VBZ	I
208-210	CD	I
(	(	I
1994	CD	I
)	)	I
.	.	O
Transformants	NNS	O
were	VBD	O
grown	VBN	O
at	IN	O
30°	CD	O
C.	NNP	O
for	IN	O
2-3	JJ	O
days	NNS	O
.	.	O
The	DT	O
detection	NN	O
of	IN	O
colonies	NNS	O
secreting	VBG	O
amylase	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
including	VBG	O
red	JJ	O
starch	NN	O
in	IN	O
the	DT	O
selective	JJ	O
growth	NN	O
media	NNS	O
.	.	O
Starch	NN	O
was	VBD	O
coupled	VBN	O
to	TO	O
the	DT	O
red	JJ	O
dye	NN	O
(	(	O
Reactive	JJ	O
Red-120	NNP	O
,	,	O
Sigma	NNP	O
)	)	O
as	IN	O
per	IN	O
the	DT	O
procedure	NN	O
described	VBN	O
by	IN	O
Biely	NNP	B
et	FW	I
al.	NN	I
,	,	I
Anal	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
172:176-179	CD	I
(	(	I
1988	CD	I
)	)	I
.	.	O
The	DT	O
coupled	VBN	O
starch	NN	O
was	VBD	O
incorporated	VBN	O
into	IN	O
the	DT	O
SCD-Ura	NNP	O
agar	NN	O
plates	NNS	O
at	IN	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
0.15	CD	O
%	NN	O
(	(	O
w/v	NN	O
)	)	O
,	,	O
and	CC	O
was	VBD	O
buffered	VBN	O
with	IN	O
potassium	NN	O
phosphate	NN	O
to	TO	O
a	DT	O
pH	NN	O
of	IN	O
7.0	CD	O
(	(	O
50-100	JJ	O
mM	NN	O
final	JJ	O
concentration	NN	O
)	)	O
.	.	O
The	DT	O
positive	JJ	O
colonies	NNS	O
were	VBD	O
picked	VBN	O
and	CC	O
streaked	VBN	O
across	IN	O
fresh	JJ	O
selective	JJ	O
media	NNS	O
(	(	O
onto	IN	O
150	CD	O
mm	NNS	O
plates	NNS	O
)	)	O
in	IN	O
order	NN	O
to	TO	O
obtain	VB	O
well	RB	O
isolated	JJ	O
and	CC	O
identifiable	JJ	O
single	JJ	O
colonies	NNS	O
.	.	O
Well	RB	O
isolated	JJ	O
single	JJ	O
colonies	NNS	O
positive	JJ	O
for	IN	O
amylase	JJ	O
secretion	NN	O
were	VBD	O
detected	VBN	O
by	IN	O
direct	JJ	O
incorporation	NN	O
of	IN	O
red	JJ	O
starch	NN	O
into	IN	O
buffered	VBN	O
SCD-Ura	NNP	O
agar	NN	O
.	.	O
Positive	JJ	O
colonies	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
break	VB	O
down	RP	O
starch	NN	O
resulting	VBG	O
in	IN	O
a	DT	O
clear	JJ	O
halo	NN	O
around	IN	O
the	DT	O
positive	JJ	O
colony	NN	O
visualized	VBN	O
directly	RB	O
.	.	O
4	CD	O
.	.	O
Isolation	NN	O
of	IN	O
DNA	NN	O
by	IN	O
PCR	NNP	O
Amplification	NNP	O
When	WRB	O
a	DT	O
positive	JJ	O
colony	NN	O
was	VBD	O
isolated	VBN	O
,	,	O
a	DT	O
portion	NN	O
of	IN	O
it	PRP	O
was	VBD	O
picked	VBN	O
by	IN	O
a	DT	O
toothpick	NN	O
and	CC	O
diluted	VBD	O
into	IN	O
sterile	JJ	O
water	NN	O
(	(	O
30	CD	O
μl	NN	O
)	)	O
in	IN	O
a	DT	O
96	CD	O
well	RB	O
plate	NN	O
.	.	O
At	IN	O
this	DT	O
time	NN	O
,	,	O
the	DT	O
positive	JJ	O
colonies	NNS	O
were	VBD	O
either	RB	O
frozen	JJ	O
and	CC	O
stored	VBD	O
for	IN	O
subsequent	JJ	O
analysis	NN	O
or	CC	O
immediately	RB	O
amplified	VBN	O
.	.	O
An	DT	O
aliquot	NN	O
of	IN	O
cells	NNS	O
(	(	O
5	CD	O
μl	NN	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
template	NN	O
for	IN	O
the	DT	O
PCR	NNP	O
reaction	NN	O
in	IN	O
a	DT	O
25	CD	O
μl	NN	O
volume	NN	O
containing	VBG	O
0.5	CD	O
μl	JJ	O
Klentaq	NNP	O
(	(	O
Clontech	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
;	:	O
4.0	CD	O
μl	$	O
10	CD	O
mM	NN	O
dNTP	NN	O
's	POS	O
(	(	O
Perkin	NNP	O
Elmer-Cetus	NNP	O
)	)	O
;	:	O
2.5	CD	O
μl	NN	O
Kentaq	NNP	O
buffer	NN	O
(	(	O
Clontech	NNP	O
)	)	O
;	:	O
0.25	CD	O
μl	FW	O
forward	RB	O
oligo	VBZ	O
1	CD	O
;	:	O
0.25	CD	O
μl	JJ	O
reverse	NN	O
oligo	NN	O
2	CD	O
;	:	O
12.5	CD	O
μl	NN	O
distilled	JJ	O
water	NN	O
.	.	O
The	DT	O
sequence	NN	O
of	IN	O
the	DT	O
forward	NN	O
oligonucleotide	IN	O
1	CD	O
was	VBD	O
:	:	O
The	DT	O
sequence	NN	O
of	IN	O
reverse	JJ	O
oligonucleotide	IN	O
2	CD	O
was	VBD	O
:	:	O
PCR	NN	O
was	VBD	O
then	RB	O
performed	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
The	DT	O
underlined	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
oligonucleotides	NNS	O
annealed	VBD	O
to	TO	O
the	DT	O
ADH	NNP	O
promoter	NN	O
region	NN	O
and	CC	O
the	DT	O
amylase	JJ	O
region	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
amplified	VBD	O
a	DT	O
307	CD	O
bp	JJ	O
region	NN	O
from	IN	O
vector	NN	O
pSST-AMY.0	NN	O
when	WRB	O
no	DT	O
insert	NN	O
was	VBD	O
present	JJ	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
first	JJ	O
18	CD	O
nucleotides	NNS	O
of	IN	O
the	DT	O
5′	CD	O
end	NN	O
of	IN	O
these	DT	O
oligonucleotides	NNS	O
contained	VBD	O
annealing	VBG	O
sites	NNS	O
for	IN	O
the	DT	O
sequencing	NN	O
primers	NNS	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
total	JJ	O
product	NN	O
of	IN	O
the	DT	O
PCR	NNP	O
reaction	NN	O
from	IN	O
an	DT	O
empty	JJ	O
vector	NN	O
was	VBD	O
343	CD	O
bp	NN	O
.	.	O
However	RB	O
,	,	O
signal	JJ	O
sequence-fused	JJ	O
cDNA	NN	O
resulted	VBD	O
in	IN	O
considerably	RB	O
longer	RBR	O
nucleotide	JJ	O
sequences	NNS	O
.	.	O
Following	VBG	O
the	DT	O
PCR	NNP	O
,	,	O
an	DT	O
aliquot	NN	O
of	IN	O
the	DT	O
reaction	NN	O
(	(	O
5	CD	O
μl	NN	O
)	)	O
was	VBD	O
examined	VBN	O
by	IN	O
agarose	JJ	O
gel	JJ	O
electrophoresis	NN	O
in	IN	O
a	DT	O
1	CD	O
%	NN	O
agarose	JJ	O
gel	NN	O
using	VBG	O
a	DT	O
Tris-Borate-EDTA	NNP	O
(	(	O
TBE	NNP	O
)	)	O
buffering	VBG	O
system	NN	O
as	IN	O
described	VBN	O
by	IN	O
Sambrook	NNP	O
et	FW	O
al.	NN	O
,	,	O
supra	NN	O
.	.	O
Clones	NNS	O
resulting	VBG	O
in	IN	O
a	DT	O
single	JJ	O
strong	JJ	O
PCR	NNP	O
product	NN	O
larger	JJR	O
than	IN	O
400	CD	O
bp	NNS	O
were	VBD	O
further	RB	O
analyzed	VBN	O
by	IN	O
DNA	NNP	O
sequencing	VBG	O
after	IN	O
purification	NN	O
with	IN	O
a	DT	O
96	CD	O
Qiaquick	NNP	O
PCR	NNP	O
clean-up	JJ	O
column	NN	O
(	(	O
Qiagen	NNP	O
Inc.	NNP	O
,	,	O
Chatsworth	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
5	CD	O
.	.	O
Identification	NN	O
of	IN	O
Full-Length	NNP	O
Clone	NNP	O
A	NNP	O
cDNA	NN	O
sequence	NN	O
was	VBD	O
isolated	VBN	O
in	IN	O
the	DT	O
above	JJ	O
screen	NN	O
and	CC	O
compared	VBN	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
expressed	JJ	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
databases	VBZ	O
which	WDT	O
included	VBD	O
public	JJ	O
EST	NNP	O
databases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
GenBank	NNP	O
,	,	O
Merck/Wash	NNP	O
.	.	O
U	NNP	O
.	.	O
)	)	O
And	CC	O
a	DT	O
proprietary	JJ	O
EST	NNP	O
DNA	NN	O
database	NN	O
(	(	O
LIFESEQ®	NNP	O
,	,	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
to	TO	O
identify	VB	O
existing	VBG	O
homologies	NNS	O
.	.	O
The	DT	O
homology	NN	O
search	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
computer	NN	O
program	NN	O
BLAST	NNP	O
or	CC	O
BLAST2	NNP	O
(	(	O
Altshul	NNP	B
et	RB	I
al.	RB	I
,	,	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
266:460-480	CD	I
(	(	I
1996	CD	I
)	)	I
)	)	O
.	.	O
Those	DT	O
comparisons	NNS	O
resulting	VBG	O
in	IN	O
a	DT	O
BLAST	NNP	O
score	NN	O
of	IN	O
70	CD	O
(	(	O
or	CC	O
in	IN	O
some	DT	O
cases	NNS	O
90	CD	O
)	)	O
or	CC	O
greater	JJR	O
that	WDT	O
did	VBD	O
not	RB	O
encode	VB	O
known	JJ	O
proteins	NNS	O
were	VBD	O
clustered	VBN	O
and	CC	O
assembled	VBN	O
into	IN	O
consensus	NN	O
DNA	NNP	O
sequences	VBZ	O
with	IN	O
the	DT	O
program	NN	O
“	NNP	O
phrap	NN	O
”	NNP	O
(	(	O
Phil	NNP	O
Green	NNP	O
,	,	O
University	NNP	O
of	IN	O
Washington	NNP	O
,	,	O
Seattle	NNP	O
Wash.	NNP	O
)	)	O
.	.	O
The	DT	O
consensus	NN	O
sequence	NN	O
obtained	VBN	O
is	VBZ	O
herein	JJ	O
designated	VBN	O
:	:	O
“	JJ	O
DNA76621	NNP	O
”	NNP	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
DNA76621	NNP	O
sequence	NN	O
,	,	O
oligonucleotide	IN	O
probes	NNS	O
were	VBD	O
generated	VBN	O
and	CC	O
used	VBN	O
to	TO	O
screen	VB	O
a	DT	O
human	JJ	O
testis	NN	O
library	NN	O
prepared	VBD	O
as	IN	O
described	VBN	O
in	IN	O
paragraph	NN	O
1	CD	O
above	IN	O
.	.	O
The	DT	O
cloning	NN	O
vector	NN	O
was	VBD	O
pRK5B	JJ	O
(	(	O
pRK5B	NN	O
is	VBZ	O
a	DT	O
precursors	NNS	O
of	IN	O
pRK5D	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
contain	VB	O
the	DT	O
SfiI	NNP	O
site	NN	O
;	:	O
see	VB	O
Holmes	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
253:1278-1280	CD	I
(	(	I
1991	CD	I
)	)	I
)	)	O
,	,	O
and	CC	O
the	DT	O
cDNA	NN	O
size	NN	O
cut	NN	O
was	VBD	O
less	JJR	O
than	IN	O
2800	CD	O
bp	NN	O
.	.	O
PCR	NNP	O
primers	NNS	O
(	(	O
forward	RB	O
and	CC	O
reverse	VB	O
)	)	O
were	VBD	O
synthesized	VBN	O
:	:	O
Additionally	RB	O
,	,	O
a	DT	O
synthetic	JJ	O
oligonucleotide	NN	O
hybridization	NN	O
probe	NN	O
was	VBD	O
constructed	VBN	O
fro	PDT	O
the	DT	O
DNA76621	NNP	O
sequence	NN	O
which	WDT	O
had	VBD	O
the	DT	O
following	JJ	O
nucleotide	JJ	O
sequence	NN	O
:	:	O
In	IN	O
order	NN	O
to	TO	O
screen	VB	O
several	JJ	O
libraries	NNS	O
for	IN	O
a	DT	O
full-length	JJ	O
clone	NN	O
,	,	O
DNA	NN	O
from	IN	O
the	DT	O
libraries	NNS	O
was	VBD	O
screened	VBN	O
by	IN	O
PCR	NNP	O
amplification	NN	O
with	IN	O
the	DT	O
PCR	NNP	O
primer	NN	O
pair	NN	O
identified	VBN	O
above	IN	O
.	.	O
A	DT	O
positive	JJ	O
library	NN	O
was	VBD	O
then	RB	O
used	VBN	O
to	TO	O
isolate	VB	O
clones	NNS	O
encoding	VBG	O
the	DT	O
PRO1885	NNP	O
gene	NN	O
using	VBG	O
the	DT	O
probe	NN	O
oligonucleotide	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
PCR	NNP	O
primers	NNS	O
.	.	O
A	DT	O
full-length	JJ	O
clone	NN	O
was	VBD	O
identified	VBN	O
(	(	O
designated	VBN	O
DNA79302-2521	NNP	O
)	)	O
that	WDT	O
contained	VBD	O
a	DT	O
single	JJ	O
open	JJ	O
reading	NN	O
frame	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
translational	JJ	O
initiation	NN	O
site	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
40-42	JJ	O
,	,	O
and	CC	O
a	DT	O
stop	JJ	O
signal	NN	O
at	IN	O
nucleotide	JJ	O
positions	NNS	O
1705-1707	JJ	O
(	(	O
FIG	NNP	O
.	.	O
19	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:19	NNP	O
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
polypeptide	NN	O
precursor	NN	O
is	VBZ	O
555	CD	O
amino	JJ	O
acids	NNS	O
long	RB	O
(	(	O
FIG	NNP	O
.	.	O
20	CD	O
;	:	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
)	)	O
and	CC	O
has	VBZ	O
a	DT	O
calculated	JJ	O
molecular	JJ	O
weight	NN	O
of	IN	O
approximately	RB	O
63913	CD	O
daltons	NNS	O
and	CC	O
an	DT	O
estimated	JJ	O
pI	NN	O
of	IN	O
approximately	RB	O
4.99	CD	O
.	.	O
Clone	CD	O
DNA79302-2521	NNP	O
(	(	O
UNQ868	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
deposited	VBN	O
with	IN	O
the	DT	O
ATCC	NNP	O
and	CC	O
is	VBZ	O
assigned	VBN	O
ATCC	NNP	O
deposit	NN	O
no	DT	O
.	.	O
203545	CD	O
on	IN	O
Dec.	NNP	O
22	CD	O
,	,	O
1998	CD	O
.	.	O
An	DT	O
analysis	NN	O
of	IN	O
the	DT	O
Dayhoff	NNP	O
database	NN	O
(	(	O
version	NN	O
35.45	CD	O
Swiss	JJ	O
Prot	NNP	O
35	CD	O
)	)	O
,	,	O
using	VBG	O
a	DT	O
WU-BLAST2	JJ	O
sequence	NN	O
alignment	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
sequence	NN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
20	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:20	NNP	O
)	)	O
;	:	O
evidenced	VBN	O
sequence	NN	O
identity	NN	O
between	IN	O
the	DT	O
PRO1885	NNP	O
amino	NN	O
acid	NN	O
sequence	NN	O
and	CC	O
the	DT	O
following	JJ	O
Dayhoff	NNP	O
sequences	NNS	O
:	:	O
A31567—1	NNP	O
,	,	O
P_R10426	NNP	O
,	,	O
ACE_HUMAN	NNP	O
,	,	O
P_R04111	NNP	O
,	,	O
A00914—1	NNP	O
,	,	O
ACE_DROME	NNP	O
,	,	O
P_R70013	NNP	O
,	,	O
S81361—1	NNP	O
,	,	O
S57157	NNP	O
and	CC	O
P_R65207	NNP	O
.	.	O
Example	RB	O
13	CD	O
Generation	NNP	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
Gene	NNP	O
Disruptions	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
,	,	O
disruptions	NNS	O
in	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
genes	NNS	O
were	VBD	O
produced	VBN	O
by	IN	O
homologous	JJ	O
recombination	NN	O
.	.	O
Specifically	RB	O
,	,	O
transgenic	JJ	O
mice	NN	O
comprising	VBG	O
disruptions	NNS	O
in	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
genes	NNS	O
(	(	O
i.e.	NN	O
,	,	O
knockout	IN	O
mice	NNS	O
)	)	O
were	VBD	O
created	VBN	O
by	IN	O
either	DT	O
gene	NN	O
targeting	VBG	O
or	CC	O
gene	NN	O
trapping	NN	O
.	.	O
Mutations	NNS	O
were	VBD	O
confirmed	VBN	O
by	IN	O
southern	JJ	O
blot	NN	O
analysis	NN	O
to	TO	O
confirm	VB	O
correct	JJ	O
targeting	VBG	O
on	IN	O
both	CC	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
ends	NNS	O
.	.	O
Gene-specific	JJ	O
genotyping	NN	O
was	VBD	O
also	RB	O
performed	VBN	O
by	IN	O
genomic	JJ	O
PCR	NNP	O
to	TO	O
confirm	VB	O
the	DT	O
loss	NN	O
of	IN	O
the	DT	O
endogenous	JJ	O
native	JJ	O
transcript	NN	O
as	IN	O
demonstrated	VBN	O
by	IN	O
RT-PCR	NNP	O
using	VBG	O
primers	NNS	O
that	WDT	O
anneal	VBP	O
to	TO	O
exons	NNS	O
flanking	VBG	O
the	DT	O
site	NN	O
of	IN	O
insertion	NN	O
.	.	O
Targeting	VBG	O
vectors	NNS	O
were	VBD	O
electroporated	VBN	O
into	IN	O
129	CD	O
strain	NN	O
ES	NNP	O
cells	NNS	O
and	CC	O
targeted	VBN	O
clones	NNS	O
were	VBD	O
identified	VBN	O
.	.	O
Targeted	VBN	O
clones	NNS	O
were	VBD	O
microinjected	VBN	O
into	IN	O
host	NN	O
blastocysts	NNS	O
to	TO	O
produce	VB	O
chimeras	NNS	O
.	.	O
Chimeras	NNS	O
were	VBD	O
bred	VBN	O
with	IN	O
C57	NNP	O
animals	NNS	O
to	TO	O
produce	VB	O
F1	NNP	O
heterozygotes	NNS	O
.	.	O
Heterozygotes	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
produce	VB	O
F2	NNP	O
wildtype	NN	O
,	,	O
heterozygote	NN	O
and	CC	O
homozygote	NN	O
cohorts	NNS	O
which	WDT	O
were	VBD	O
used	VBN	O
for	IN	O
phenotypic	NN	O
analysis	NN	O
.	.	O
Rarely	RB	O
,	,	O
if	IN	O
not	RB	O
enough	JJ	O
F1	NNP	O
heterozygotes	NNS	O
were	VBD	O
produced	VBN	O
,	,	O
the	DT	O
F1	NNP	O
hets	NNS	O
were	VBD	O
bred	VBN	O
to	TO	O
wildtype	VB	O
C57	NNP	O
mice	NN	O
to	TO	O
produce	VB	O
sufficient	JJ	O
heterozygotes	NNS	O
to	TO	O
breed	VB	O
for	IN	O
cohorts	NNS	O
to	TO	O
be	VB	O
analyzed	VBN	O
for	IN	O
a	DT	O
phenotype	NN	O
.	.	O
All	DT	O
phenotypic	NN	O
analysis	NN	O
was	VBD	O
performed	VBN	O
from	IN	O
12-16	JJ	O
weeks	NNS	O
after	IN	O
birth	NN	O
.	.	O
Overall	JJ	O
Summary	NNP	O
of	IN	O
Results	NNP	O
:	:	O
A	DT	O
.	.	O
Generation	NN	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA33786-1132	NNP	O
(	(	O
UNQ201	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO227	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA33786-1132	NNP	O
(	(	O
UNQ201	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
NM—181074	NN	O
:	:	O
or	CC	O
Mus	NNP	O
musculus	CC	O
RIKEN	NNP	O
cDNA	VBP	O
4930471K13	CD	O
gene	NN	O
(	(	O
4930471K13Rik	CD	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—851419	NN	O
or	CC	O
Mus	NNP	O
musculus	CC	O
RIKEN	NNP	O
cDNA	VBP	O
4930471K13	CD	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
BC011057	NNP	O
or	CC	O
homo	NN	O
sapiens	JJ	O
hypothetical	JJ	O
protein	NN	O
FLJ14594	NNP	O
(	(	O
cDNA	VB	O
clone	NN	O
MGC:17422	NNP	O
IMAGE	NNP	O
:	:	O
4214343	CD	O
)	)	O
;	:	O
the	DT	O
human	JJ	O
protein	NN	O
sequence	NN	O
corresponds	NNS	O
to	TO	O
reference	VB	O
:	:	O
AAH11057	NNP	O
or	CC	O
Homo	NNP	O
sapiens	JJ	O
hypothetical	JJ	O
protein	NN	O
FLJ14594	NNP	O
.	.	O
Mutation	NNP	O
Specific	NNP	O
Information	NNP	O
corresponds	VBZ	O
to	TO	O
Homologous	NNP	O
Recombination	NNP	O
(	(	O
standard	NN	O
)	)	O
wherein	NN	O
Exon	NNP	O
2	CD	O
was	VBD	O
targeted	VBN	O
(	(	O
NM—181074	NNP	O
)	)	O
.	.	O
The	DT	O
targeted	VBN	O
mouse	NN	O
gene	NN	O
is	VBZ	O
represented	VBN	O
by	IN	O
NCBI	NNP	O
accession	NN	O
NM—181074	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
an	DT	O
ortholog	NN	O
of	IN	O
human	JJ	O
hypothetical	JJ	O
protein	NN	O
FLJ14594	NNP	O
.	.	O
FLJ14594	NNP	O
has	VBZ	O
features	NNS	O
consistent	JJ	O
with	IN	O
a	DT	O
type	NN	O
I	PRP	O
plasma	VBP	O
membrane	JJ	O
protein	NN	O
;	:	O
contains	VBZ	O
leucine-rich	JJ	O
repeats	NNS	O
,	,	O
an	DT	O
immunoglobulin	NN	O
(	(	O
Ig	NNP	O
)	)	O
-like	NN	O
domain	NN	O
,	,	O
a	DT	O
transmembrane	NN	O
segment	NN	O
,	,	O
and	CC	O
possibly	RB	O
a	DT	O
short	JJ	O
cytoplasmic	JJ	O
C	NNP	O
terminus	NN	O
.	.	O
The	DT	O
hypothetical	JJ	O
protein	NN	O
belongs	NNS	O
to	TO	O
a	DT	O
gene	NN	O
family	NN	O
comprised	VBN	O
of	IN	O
three	CD	O
members	NNS	O
,	,	O
all	DT	O
having	VBG	O
no	DT	O
known	VBN	O
function	NN	O
(	(	O
EnsEMBL	NNP	O
protein	VBP	O
family	NN	O
ENSF00000002632	NNP	O
)	)	O
.	.	O
Both	DT	O
leucine-rich	JJ	O
repeats	NNS	O
and	CC	O
Ig-like	JJ	O
domains	NNS	O
are	VBP	O
usually	RB	O
involved	VBN	O
in	IN	O
protein-protein	JJ	O
interactions	NNS	O
and	CC	O
found	VBN	O
in	IN	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
proteins	NNS	O
(	(	O
Pfam	NNP	O
PF00560	NNP	O
and	CC	O
PF00047	NNP	O
)	)	O
.	.	O
The	DT	O
domain	NN	O
organization	NN	O
and	CC	O
predicted	VBD	O
cell	NN	O
location	NN	O
(	(	O
plasma	JJ	O
membrane	NN	O
)	)	O
of	IN	O
this	DT	O
hypothetical	JJ	O
protein	NN	O
suggests	VBZ	O
that	IN	O
it	PRP	O
may	MD	O
function	VB	O
as	IN	O
a	DT	O
cell	NN	O
adhesion	NN	O
molecule	NN	O
,	,	O
receptor	NN	O
,	,	O
or	CC	O
ligand	NN	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
progeny	NN	O
.	.	O
On	IN	O
rare	JJ	O
occasions	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
very	RB	O
few	JJ	O
F1	NNP	O
mice	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
chimera	NN	O
,	,	O
F1	NNP	O
heterozygous	JJ	O
mice	NNS	O
were	VBD	O
crossed	VBN	O
to	TO	O
129SvEvBrd/C57	CD	O
hybrid	JJ	O
mice	NN	O
to	TO	O
yield	VB	O
additional	JJ	O
heterozygous	JJ	O
animals	NNS	O
for	IN	O
the	DT	O
intercross	NN	O
to	TO	O
generate	VB	O
the	DT	O
F2	NNP	O
mice	NN	O
.	.	O
Expression	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
and	CC	O
in	IN	O
all	DT	O
13	CD	O
adult	NNS	O
tissue	NN	O
samples	NNS	O
tested	VBN	O
by	IN	O
RT-PCR	NNP	O
,	,	O
except	IN	O
bone	NN	O
,	,	O
small	JJ	O
intestine	NN	O
and	CC	O
colon	NN	O
,	,	O
and	CC	O
adipose	RB	O
.	.	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
Phenotypic	NNP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
mice	NN	O
from	IN	O
this	DT	O
generation	NN	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
1	CD	O
.	.	O
Overall	JJ	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
Disrupted	VBN	O
Gene	NNP	O
:	:	O
DNA33786-1132	NNP	O
(	(	O
UNQ201	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
:	:	O
Mutation	NN	O
of	IN	O
the	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
ortholog	NN	O
of	IN	O
human	JJ	O
hypothetical	JJ	O
protein	NN	O
FLJ14594	NNP	O
(	(	O
FLJ14594	NNP	O
)	)	O
resulted	VBD	O
in	IN	O
growth	NN	O
retardation	NN	O
in	IN	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
.	.	O
The	DT	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
were	VBD	O
smaller	JJR	O
than	IN	O
their	PRP$	O
wild-type	JJ	O
littermates	NNS	O
,	,	O
exhibiting	VBG	O
decreased	VBN	O
mean	JJ	O
body	NN	O
length	NN	O
,	,	O
total	JJ	O
tissue	NN	O
mass	NN	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
.	.	O
The	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
also	RB	O
exhibited	VBD	O
a	DT	O
decreased	JJ	O
bone	NN	O
mineral-related	JJ	O
measurements	NNS	O
.	.	O
Both	DT	O
serum	JJ	O
cholesterol	NN	O
and	CC	O
triglycerides	NNS	O
were	VBD	O
elevated	VBN	O
in	IN	O
(	(	O
−/−	NN	O
)	)	O
mutant	NN	O
mice	NN	O
.	.	O
Gene	NNP	O
disruption	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
blot	NN	O
.	.	O
(	(	O
b	NN	O
)	)	O
Bone	FW	O
Metabolism	NN	O
:	:	O
Radiology	NNP	O
Phenotypic	NNP	O
Analysis	NNP	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
bone	NN	O
metabolism	NN	O
,	,	O
targets	NNS	O
were	VBD	O
identified	VBN	O
herein	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
arthritis	NN	O
,	,	O
osteoporosis	NN	O
,	,	O
osteopenia	NN	O
and	CC	O
osteopetrosis	NN	O
as	RB	O
well	RB	O
as	IN	O
identifying	VBG	O
targets	NNS	O
that	WDT	O
promote	VBP	O
bone	NN	O
healing	NN	O
.	.	O
Tests	NNS	O
included	VBD	O
:	:	O
DEXA	NNP	O
for	IN	O
measurement	NN	O
of	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
on	IN	O
femur	NN	O
and	CC	O
vertebra	NN	O
MicroCT	NNP	O
for	IN	O
very	RB	O
high	JJ	O
resolution	NN	O
and	CC	O
very	RB	O
high	JJ	O
sensitivity	NN	O
measurements	NNS	O
of	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
for	IN	O
both	DT	O
trabecular	JJ	O
and	CC	O
cortical	JJ	O
bone	NN	O
.	.	O
Dexa	NNP	O
Analysis—Test	NNP	O
Description	NN	O
:	:	O
Procedure	NN	O
:	:	O
A	DT	O
cohort	NN	O
of	IN	O
4	CD	O
wild	JJ	O
type	NN	O
,	,	O
4	CD	O
heterozygotes	NNS	O
and	CC	O
8	CD	O
homozygotes	NNS	O
were	VBD	O
tested	VBN	O
in	IN	O
this	DT	O
assay	NN	O
.	.	O
Dual	NNP	O
Energy	NNP	O
X-ray	JJ	O
Absorptiometry	NNP	O
(	(	O
DEXA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
used	VBN	O
successfully	RB	O
to	TO	O
identify	VB	O
changes	NNS	O
in	IN	O
bone	NN	O
.	.	O
Anesthetized	VBN	O
animals	NNS	O
were	VBD	O
examined	VBN	O
and	CC	O
bone	JJ	O
mineral	NN	O
content	NN	O
(	(	O
BMC	NNP	O
)	)	O
,	,	O
BMC/LBM	NNP	O
ratios	NNS	O
,	,	O
volumetric	JJ	O
bone	NN	O
mineral	JJ	O
density	NN	O
(	(	O
vBMD	NN	O
)	)	O
,	,	O
total	JJ	O
body	NN	O
BMD	NNP	O
,	,	O
femur	NN	O
BMD	NNP	O
and	CC	O
vertebra	JJ	O
BMD	NNP	O
were	VBD	O
measured	VBN	O
.	.	O
The	DT	O
mouse	NN	O
was	VBD	O
anesthetized	VBN	O
by	IN	O
intraperitoneal	JJ	O
injection	NN	O
of	IN	O
Avertin	NNP	O
(	(	O
1.25	CD	O
%	NN	O
2,2,2	CD	O
,	,	O
-tribromoethanol	NNP	O
,	,	O
20	CD	O
ml/kg	NN	O
body	NN	O
weight	NN	O
)	)	O
,	,	O
body	NN	O
length	NN	O
and	CC	O
weight	NN	O
were	VBD	O
measured	VBN	O
,	,	O
and	CC	O
then	RB	O
the	DT	O
mouse	NN	O
was	VBD	O
placed	VBN	O
in	IN	O
a	DT	O
prone	NN	O
position	NN	O
on	IN	O
the	DT	O
platform	NN	O
of	IN	O
the	DT	O
PIXImus™	NNP	O
Densitometer	NNP	O
(	(	O
Lunar	NNP	O
Inc.	NNP	O
)	)	O
for	IN	O
a	DT	O
DEXA	NNP	O
scan	NN	O
.	.	O
Using	VBG	O
Lunar	NNP	O
PIXImus	NNP	O
software	NN	O
,	,	O
the	DT	O
bone	NN	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
and	CC	O
fat	JJ	O
composition	NN	O
(	(	O
%	NN	O
fat	NN	O
)	)	O
and	CC	O
total	JJ	O
tissue	NN	O
mass	NN	O
(	(	O
TTM	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
in	IN	O
the	DT	O
regions	NNS	O
of	IN	O
interest	NN	O
(	(	O
ROI	NNP	O
)	)	O
[	NNP	O
i.e.	NN	O
,	,	O
whole	JJ	O
body	NN	O
,	,	O
vertebrae	NN	O
,	,	O
and	CC	O
both	DT	O
femurs	NNS	O
]	VBP	O
.	.	O
DEXA	JJ	O
Results	NNS	O
:	:	O
Both	DT	O
the	DT	O
male	NN	O
and	CC	O
female	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
exhibited	VBD	O
decreased	JJ	O
mean	JJ	O
total	JJ	O
tissue	NN	O
mass	NN	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
and	CC	O
the	DT	O
historical	JJ	O
means	NNS	O
.	.	O
These	DT	O
mutant	JJ	O
mice	NN	O
also	RB	O
exhibited	VBD	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
bone	JJ	O
mineral	JJ	O
density	NN	O
in	IN	O
total	JJ	O
body	NN	O
,	,	O
femur	NN	O
,	,	O
and	CC	O
vertebrae	NN	O
.	.	O
Bone	NNP	O
microCT	NN	O
Analysis	NN	O
:	:	O
Procedure	NN	O
:	:	O
MicroCT	NNP	O
was	VBD	O
also	RB	O
used	VBN	O
to	TO	O
get	VB	O
very	RB	O
sensitive	JJ	O
measurements	NNS	O
of	IN	O
BMD	NNP	O
.	.	O
One	CD	O
vertebra	NN	O
and	CC	O
1	CD	O
femur	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
a	DT	O
cohort	NN	O
of	IN	O
4	CD	O
wild	JJ	O
type	NN	O
and	CC	O
8	CD	O
homozygous	JJ	O
mice	NN	O
.	.	O
Measurements	NNS	O
were	VBD	O
taken	VBN	O
of	IN	O
lumbar	NN	O
5	CD	O
veterbra	NN	O
traebecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
traebecular	JJ	O
thickness	NN	O
,	,	O
connectivity	NN	O
density	NN	O
and	CC	O
midshaft	NN	O
femur	NN	O
total	JJ	O
bone	NN	O
area	NN	O
and	CC	O
cortical	JJ	O
thickness	NN	O
.	.	O
The	DT	O
μCT40	NN	O
scans	NNS	O
provided	VBD	O
detailed	JJ	O
information	NN	O
on	IN	O
bone	NN	O
mass	NN	O
and	CC	O
architecture	NN	O
.	.	O
Multiple	JJ	O
bones	NNS	O
were	VBD	O
placed	VBN	O
into	IN	O
sample	JJ	O
holders	NNS	O
and	CC	O
scanned	VBD	O
automatically	RB	O
.	.	O
Instrument	NNP	O
software	NN	O
was	VBD	O
used	VBN	O
to	TO	O
select	VB	O
regions	NNS	O
of	IN	O
interest	NN	O
for	IN	O
analysis	NN	O
.	.	O
Trabecular	JJ	O
bone	NN	O
parameters	NNS	O
were	VBD	O
analyzed	VBN	O
in	IN	O
the	DT	O
fifth	JJ	O
lumbar	NN	O
vertebrae	NN	O
(	(	O
LV5	NNP	O
)	)	O
at	IN	O
16	CD	O
micrometer	NN	O
resolution	NN	O
and	CC	O
cortical	JJ	O
bone	NN	O
parameters	NNS	O
were	VBD	O
analyzed	VBN	O
in	IN	O
the	DT	O
femur	NN	O
midshaft	NN	O
at	IN	O
a	DT	O
resolution	NN	O
of	IN	O
20	CD	O
micrometers	NNS	O
.	.	O
Micro-CT	JJ	O
Analysis	NN	O
Results	NNS	O
:	:	O
The	DT	O
male	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
exhibited	VBD	O
decreased	JJ	O
mean	JJ	O
vertebral	JJ	O
trabecular	JJ	O
bone	NN	O
volume	NN	O
,	,	O
thickness	NN	O
,	,	O
and	CC	O
connectivity	NN	O
density	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
and	CC	O
the	DT	O
historical	JJ	O
means	NNS	O
.	.	O
These	DT	O
mutants	NNS	O
also	RB	O
exhibited	VBD	O
decreased	JJ	O
mean	JJ	O
femoral	JJ	O
mid-shaft	NN	O
cortical	JJ	O
thickness	NN	O
and	CC	O
cross-sectional	JJ	O
area	NN	O
.	.	O
[	NNS	O
Analyzed	NNP	O
wt/het/hom	NN	O
:	:	O
4/4/8	CD	O
]	IN	O
Body	NN	O
Measurements	NNS	O
:	:	O
A	DT	O
measurement	NN	O
of	IN	O
length	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
approximately	RB	O
16	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
.	.	O
The	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
exhibited	VBD	O
a	DT	O
decreased	JJ	O
weight	NN	O
gain	NN	O
and	CC	O
decreased	JJ	O
mean	NN	O
body	NN	O
length	NN	O
,	,	O
decreased	VBD	O
total	JJ	O
tissue	NN	O
mass	NN	O
and	CC	O
decreased	JJ	O
lean	JJ	O
body	NN	O
mass	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
and	CC	O
the	DT	O
historical	JJ	O
mean	NN	O
.	.	O
These	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
knockout	NN	O
mutant	JJ	O
male	JJ	O
mice	NN	O
deficient	NN	O
in	IN	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO227	NNP	O
polypeptides	NNS	O
exhibit	VBP	O
growth	NN	O
retardation	NN	O
as	RB	O
well	RB	O
as	IN	O
abnormal	JJ	O
bone	NN	O
metabolism	NN	O
with	IN	O
significant	JJ	O
bone	NN	O
loss	NN	O
characterized	VBN	O
by	IN	O
a	DT	O
decrease	NN	O
in	IN	O
bone	NN	O
mass	NN	O
with	IN	O
decreased	JJ	O
density	NN	O
and	CC	O
possibly	RB	O
fragility	NN	O
leading	VBG	O
to	TO	O
bone	VB	O
fractures	NNS	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
the	DT	O
observed	JJ	O
bone	NN	O
metabolism	NN	O
abnormalities	NNS	O
,	,	O
these	DT	O
studies	NNS	O
indicated	VBD	O
that	IN	O
(	(	O
−/−	NNP	O
)	)	O
mutant	NN	O
mice	NN	O
also	RB	O
showed	VBD	O
signs	NNS	O
of	IN	O
growth	NN	O
retardation	NN	O
.	.	O
The	DT	O
bony	NN	O
changes	NNS	O
may	MD	O
be	VB	O
a	DT	O
result	NN	O
of	IN	O
the	DT	O
decreased	VBN	O
body	NN	O
size	NN	O
and	CC	O
mass	NN	O
of	IN	O
these	DT	O
mice	NNS	O
as	IN	O
suggested	VBN	O
by	IN	O
the	DT	O
fact	NN	O
that	IN	O
the	DT	O
gene	NN	O
is	VBZ	O
not	RB	O
expressed	VBN	O
in	IN	O
the	DT	O
bone	NN	O
.	.	O
Such	JJ	O
growth	NN	O
disorders	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
the	DT	O
phenotype	NN	O
or	CC	O
physiological	JJ	O
condition	NN	O
associated	VBN	O
with	IN	O
tissue	NN	O
wasting	VBG	O
diseases	NNS	O
such	JJ	O
as	IN	O
diabetes	NNS	O
or	CC	O
cachexia	NN	O
.	.	O
Thus	RB	O
,	,	O
PRO227	NNP	O
polypeptides	VBZ	O
or	CC	O
agonists	NNS	O
thereof	RP	O
would	MD	O
be	VB	O
useful	JJ	O
for	IN	O
treating	VBG	O
diabetes	NNS	O
or	CC	O
cachexia	NN	O
.	.	O
No	DT	O
hypercalcemia	NN	O
,	,	O
or	CC	O
hyperglycemia	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
blood	NN	O
chemistry	NN	O
tests	NNS	O
to	TO	O
suggest	VB	O
renal	JJ	O
,	,	O
parathyroid	JJ	O
,	,	O
or	CC	O
adrenal	JJ	O
dysfunction	NN	O
that	WDT	O
might	MD	O
be	VB	O
related	VBN	O
to	TO	O
the	DT	O
decrease	NN	O
in	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
seen	VBN	O
on	IN	O
the	DT	O
Dexa	NNP	O
scan	NN	O
.	.	O
However	RB	O
,	,	O
the	DT	O
(	(	O
+/−	NN	O
)	)	O
and	CC	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
showed	VBD	O
more	JJR	O
wide	JJ	O
variation	NN	O
in	IN	O
their	PRP$	O
alkaline	JJ	O
phosphatase	NN	O
levels	NNS	O
.	.	O
Although	IN	O
the	DT	O
PRO227	NNP	O
encoding	VBG	O
gene	NN	O
is	VBZ	O
not	RB	O
expressed	VBN	O
in	IN	O
the	DT	O
bone	NN	O
,	,	O
the	DT	O
secondary	JJ	O
affects	NNS	O
caused	VBN	O
by	IN	O
growth	NN	O
retardation	NN	O
suggests	VBZ	O
that	IN	O
PRO227	NNP	O
would	MD	O
be	VB	O
important	JJ	O
for	IN	O
maintaining	VBG	O
bone	NN	O
homeostasis	NN	O
and	CC	O
bone	NN	O
healing	NN	O
or	CC	O
would	MD	O
be	VB	O
useful	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
arthritis	NN	O
or	CC	O
osteoporosis	NN	O
;	:	O
whereas	JJ	O
antagonists	NNS	O
to	TO	O
PRO227	NNP	O
or	CC	O
its	PRP$	O
encoding	JJ	O
gene	NN	O
would	MD	O
lead	VB	O
to	TO	O
abnormal	JJ	O
or	CC	O
pathological	JJ	O
bone	NN	O
disorders	NNS	O
including	VBG	O
inflammatory	JJ	O
diseases	NNS	O
associated	VBN	O
with	IN	O
abnormal	JJ	O
bone	NN	O
metabolism	NN	O
such	JJ	O
as	IN	O
arthritis	NN	O
.	.	O
[	NNS	O
Analyzed	NNP	O
wt/het/hom	NN	O
:	:	O
14/29/17	CD	O
]	NN	O
(	(	O
c	NN	O
)	)	O
Phenotypic	NNP	O
Analysis	NN	O
:	:	O
Cardiology	NN	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
cardiovascular	JJ	O
biology	NN	O
,	,	O
targets	NNS	O
were	VBD	O
identified	VBN	O
herein	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
,	,	O
atherosclerosis	NN	O
,	,	O
heart	NN	O
failure	NN	O
,	,	O
stroke	NN	O
,	,	O
various	JJ	O
coronary	JJ	O
artery	NN	O
diseases	NNS	O
,	,	O
dyslipidemias	NNS	O
such	JJ	O
as	IN	O
high	JJ	O
cholesterol	NN	O
(	(	O
hypercholesterolemia	NN	O
)	)	O
and	CC	O
elevated	VBN	O
serum	NN	O
triglycerides	NNS	O
(	(	O
hypertriglyceridemia	NN	O
)	)	O
,	,	O
diabetes	VBZ	O
,	,	O
cancer	NN	O
and/or	NN	O
obesity	NN	O
.	.	O
The	DT	O
phenotypic	NN	O
tests	NNS	O
in	IN	O
this	DT	O
instance	NN	O
included	VBD	O
the	DT	O
measurement	NN	O
of	IN	O
serum	NN	O
cholesterol	NN	O
and	CC	O
triglycerides	NNS	O
Blood	NNP	O
Lipids	NNP	O
Procedure	NN	O
:	:	O
A	DT	O
cohort	NN	O
of	IN	O
4	CD	O
wild	JJ	O
type	NN	O
,	,	O
4	CD	O
heterozygotes	NNS	O
and	CC	O
8	CD	O
homozygotes	NNS	O
were	VBD	O
tested	VBN	O
in	IN	O
this	DT	O
assay	NN	O
.	.	O
High	JJ	O
cholesterol	NN	O
and	CC	O
elevated	VBD	O
triglyceride	NN	O
levels	NNS	O
are	VBP	O
recognized	VBN	O
risk	NN	O
factors	NNS	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O
Measuring	VBG	O
blood	NN	O
lipids	NNS	O
allowed	VBD	O
finding	NN	O
of	IN	O
the	DT	O
biological	JJ	O
switches	NNS	O
that	WDT	O
regulate	VBP	O
blood	NN	O
lipid	JJ	O
levels	NNS	O
and	CC	O
that	DT	O
upon	JJ	O
inhibition	NN	O
would	MD	O
lead	VB	O
to	TO	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
risk	NN	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O
Cholesterol	NN	O
measurements	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O
The	DT	O
COBAS	NNP	O
Integra	NNP	O
400	CD	O
(	(	O
mfr	NN	O
:	:	O
Roche	NNP	O
)	)	O
was	VBD	O
used	VBN	O
for	IN	O
running	VBG	O
blood	NN	O
chemistry	NN	O
tests	NNS	O
on	IN	O
mice	NNS	O
.	.	O
Results	NNS	O
:	:	O
Both	DT	O
heterozygous	JJ	O
(	(	O
+/−	NNP	O
)	)	O
and	CC	O
homozygous	JJ	O
(	(	O
−/−	NNP	O
)	)	O
mutant	NN	O
mice	NN	O
exhibited	VBD	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
and	CC	O
triglyceride	NN	O
levels	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
and	CC	O
the	DT	O
historical	JJ	O
mean	NN	O
.	.	O
(	(	O
Analyzed	JJ	O
wt/het/hom	NN	O
:	:	O
4/4/8	CD	O
)	)	O
Thus	RB	O
,	,	O
mutant	JJ	O
mice	NN	O
deficient	NN	O
in	IN	O
the	DT	O
PRO227	NNP	O
gene	NN	O
can	MD	O
serve	VB	O
as	IN	O
a	DT	O
model	NN	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O
PRO227	NNP	O
or	CC	O
its	PRP$	O
encoding	JJ	O
gene	NN	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
regulating	VBG	O
blood	NN	O
lipids	NNS	O
and	CC	O
in	IN	O
particular	JJ	O
maintaining	VBG	O
normal	JJ	O
cholesterol	NN	O
and	CC	O
triglyceride	NN	O
levels	NNS	O
.	.	O
Thus	RB	O
PRO227	NNP	O
polypeptides	NNS	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
such	JJ	O
cardiovascular	JJ	O
diseases	NNS	O
as	IN	O
:	:	O
hypertension	NN	O
,	,	O
atherosclerosis	NN	O
,	,	O
heart	NN	O
failure	NN	O
,	,	O
stroke	NN	O
,	,	O
various	JJ	O
coronary	JJ	O
artery	NN	O
diseases	VBZ	O
and/or	JJ	O
diabetes	NNS	O
.	.	O
B	NNP	O
.	.	O
Generation	NN	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA34436-1238	NNP	O
(	(	O
UNQ207	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO233	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA34436-1238	NNP	O
(	(	O
UNQ207	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
NM—053262	NN	O
:	:	O
or	CC	O
Mus	NNP	O
musculus	JJ	O
retinal	JJ	O
short-chain	JJ	O
dehydrogenase/reductase	NN	O
2	CD	O
gene	NN	O
;	:	O
protein	CC	O
reference	NN	O
:	:	O
NP—444492	NN	O
or	CC	O
Mus	NNP	O
musculus	JJ	O
retinal	JJ	O
short-chain	JJ	O
dehydrogenase/reductase	NN	O
2	CD	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
BQ927122	NNP	O
(	(	O
AGENCOURT—8802906	NNP	O
NIH_MGC—40	NNP	O
Homo	NNP	O
sapiens	VBZ	O
cDNA	NN	O
clone	NN	O
IMAGE	NN	O
:	:	O
638241	CD	O
)	)	O
;	:	O
the	DT	O
human	JJ	O
protein	NN	O
sequence	NN	O
corresponds	NNS	O
to	TO	O
reference	VB	O
:	:	O
AAH21673	NNP	O
or	CC	O
Homo	NNP	O
sapiens	JJ	O
retinal	JJ	O
short-chain	JJ	O
dehydrogenase/reductase	NN	O
2	CD	O
.	.	O
Mutation	NNP	O
Specific	NNP	O
Information	NNP	O
corresponds	VBZ	O
to	TO	O
retroviral	VB	O
insertion	NN	O
(	(	O
OST	NNP	O
)	)	O
.	.	O
Retroviral	JJ	O
insertion	NN	O
disrupted	VBD	O
the	DT	O
gene	NN	O
prior	RB	O
to	TO	O
the	DT	O
exon	NN	O
encoding	VBG	O
amino	JJ	O
acid	JJ	O
55	CD	O
in	IN	O
a	DT	O
protein	NN	O
of	IN	O
298	CD	O
amino	JJ	O
acids	NNS	O
(	(	O
NCBI	NNP	O
accession	NN	O
number	NN	O
NP—444492	NNP	O
)	)	O
.	.	O
The	DT	O
disrupted	VBN	O
mouse	NN	O
gene	NN	O
is	VBZ	O
retinal	JJ	O
short-chain	JJ	O
dehydrogenase/reductase	NN	O
2	CD	O
(	(	O
retsdr2	NN	O
)	)	O
,	,	O
ortholog	NN	O
of	IN	O
human	JJ	O
RETSDR2	NNP	O
.	.	O
Aliases	NNS	O
include	VBP	O
SDR2	NNP	O
,	,	O
Pan1b	NNP	O
,	,	O
RetSDR2	NNP	O
,	,	O
Hsd17b11	NNP	O
,	,	O
hydroxysteroid	NN	O
(	(	O
17-beta	JJ	O
)	)	O
dehydrogenase	NN	O
11	CD	O
,	,	O
retinal	JJ	O
short-chain	JJ	O
dehydrogenase/reductase	NN	O
SDR2	NNP	O
,	,	O
17-BETA-HSD11	JJ	O
,	,	O
17betaHSD11	CD	O
,	,	O
17-BETA-HSDXI	JJ	O
,	,	O
and	CC	O
17-beta-hydroxysteroid	JJ	O
dehydrogenase	NN	O
type	NN	O
XI	NN	O
.	.	O
RETSDR2	NNP	O
converts	VBZ	O
5	CD	O
alpha-androstane-3	JJ	O
alpha	NN	O
,	,	O
17	CD	O
beta-diol	NN	O
(	(	O
a	DT	O
metabolite	NN	O
of	IN	O
dihydrostestosterone	NN	O
)	)	O
into	IN	O
androsterone	NN	O
,	,	O
such	JJ	O
activity	NN	O
being	VBG	O
first	JJ	O
documented	VBN	O
in	IN	O
lung	NN	O
(	(	O
Brereton	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Endocrinol.	NNP	I
,	,	I
171	CD	I
(	(	I
1-2	JJ	I
)	)	I
:	:	I
111-7	JJ	I
(	(	I
2001	CD	I
)	)	I
)	)	O
though	IN	O
expression	NN	O
of	IN	O
the	DT	O
gene	NN	O
is	VBZ	O
reported	VBN	O
in	IN	O
other	JJ	O
tissues	NNS	O
.	.	O
Overall	JJ	O
,	,	O
RETSDR2	NNP	O
is	VBZ	O
well	RB	O
expressed	VBN	O
in	IN	O
cells	NNS	O
involved	VBN	O
with	IN	O
steroidogeneisis	NN	O
and	CC	O
the	DT	O
enzyme	NN	O
is	VBZ	O
proposed	VBN	O
to	TO	O
have	VB	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
androgen	NN	O
metabolism	NN	O
(	(	O
Li	NNP	B
et	RB	I
al.	RB	I
,	,	I
Endocr	NNP	I
.	.	I
Res.	NNP	I
,	,	I
24	CD	I
(	(	I
3-4	JJ	I
)	)	I
:663-7	NN	I
(	(	I
1998	CD	I
)	)	I
;	:	O
Chai	NNP	B
et	FW	I
al.	NN	I
,	,	I
Endocrinology	NNP	I
,	,	I
144	CD	I
(	(	I
5	CD	I
)	)	I
:2084-91	NN	I
(	(	I
2003	CD	I
)	)	I
)	)	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
wild-type	JJ	O
expression	NN	O
panel	NN	O
resulted	VBD	O
in	IN	O
the	DT	O
following	JJ	O
observation	NN	O
:	:	O
expression	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
and	CC	O
,	,	O
among	IN	O
the	DT	O
13	CD	O
adult	NN	O
tissue	NN	O
samples	NNS	O
tested	VBN	O
by	IN	O
RT-PCR	NNP	O
,	,	O
in	IN	O
bone	NN	O
,	,	O
skin	FW	O
fibroblast	NN	O
,	,	O
adipose	RB	O
,	,	O
and	CC	O
tail	NN	O
.	.	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
progeny	NN	O
.	.	O
On	IN	O
rare	JJ	O
occasions	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
very	RB	O
few	JJ	O
F1	NNP	O
mice	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
chimera	NN	O
,	,	O
F1	NNP	O
heterozygous	JJ	O
mice	NNS	O
were	VBD	O
crossed	VBN	O
to	TO	O
129SvEvBrd/C57	CD	O
hybrid	JJ	O
mice	NN	O
to	TO	O
yield	VB	O
additional	JJ	O
heterozygous	JJ	O
animals	NNS	O
for	IN	O
the	DT	O
intercross	NN	O
to	TO	O
generate	VB	O
the	DT	O
F2	NNP	O
mice	NN	O
.	.	O
The	DT	O
wild-type	JJ	O
expression	NN	O
panel	NN	O
showed	VBD	O
that	IN	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
gene	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
and	CC	O
,	,	O
among	IN	O
the	DT	O
13	CD	O
adult	NN	O
tissue	NN	O
samples	NNS	O
tested	VBN	O
by	IN	O
RT-PCR	NNP	O
,	,	O
in	IN	O
brain	NN	O
,	,	O
spinal	JJ	O
cord	NN	O
,	,	O
thymus	NN	O
,	,	O
bone	NN	O
,	,	O
and	CC	O
adipose	RB	O
.	.	O
RT-PCR	JJ	O
analysis	NN	O
revealed	VBD	O
that	IN	O
the	DT	O
transcript	NN	O
was	VBD	O
absent	JJ	O
in	IN	O
the	DT	O
(	(	O
−/−	NN	O
)	)	O
mouse	NN	O
analyzed	VBN	O
.	.	O
Phenotypic	NNP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
mice	NN	O
from	IN	O
this	DT	O
generation	NN	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
1	CD	O
.	.	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
Disrupted	VBN	O
Gene	NNP	O
:	:	O
DNA34436-1238	NNP	O
(	(	O
UNQ207	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
:	:	O
Mutation	NN	O
of	IN	O
the	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
ortholog	NN	O
of	IN	O
human	JJ	O
retinal	JJ	O
short-chain	NN	O
dehydrogenase/reductase	NN	O
2	CD	O
(	(	O
RETSDR2	NNP	O
)	)	O
resulted	VBD	O
in	IN	O
a	DT	O
2½	CD	O
fold	NN	O
increased	VBD	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
exhibited	VBD	O
consistent	JJ	O
alterations	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
,	,	O
but	CC	O
no	DT	O
effects	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
thymus	NN	O
or	CC	O
spleen	NN	O
.	.	O
Lymph	NNP	O
node	NN	O
FACS	NNP	O
showed	VBD	O
trends	NNS	O
in	IN	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
certain	JJ	O
cell	NN	O
types	NNS	O
.	.	O
RT-PCR	JJ	O
analyses	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
transcript	NN	O
was	VBD	O
absent	JJ	O
in	IN	O
the	DT	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
.	.	O
(	(	O
b	NN	O
)	)	O
Immunology	NNP	O
Phenotypic	NNP	O
Analysis	NNP	O
Immune	NNP	O
related	VBN	O
and	CC	O
inflammatory	JJ	O
diseases	NNS	O
are	VBP	O
the	DT	O
manifestation	NN	O
or	CC	O
consequence	NN	O
of	IN	O
fairly	RB	O
complex	JJ	O
,	,	O
often	RB	O
multiple	JJ	O
interconnected	JJ	O
biological	NN	O
pathways	NNS	O
which	WDT	O
in	IN	O
normal	JJ	O
physiology	NN	O
are	VBP	O
critical	JJ	O
to	TO	O
respond	VB	O
to	TO	O
insult	VB	O
or	CC	O
injury	VB	O
,	,	O
initiate	VB	O
repair	NN	O
from	IN	O
insult	NN	O
or	CC	O
injury	NN	O
,	,	O
and	CC	O
mount	VB	O
innate	NN	O
and	CC	O
acquired	VBD	O
defense	NN	O
against	IN	O
foreign	JJ	O
organisms	NNS	O
.	.	O
Disease	NNP	O
or	CC	O
pathology	NN	O
occurs	NNS	O
when	WRB	O
these	DT	O
normal	JJ	O
physiological	JJ	O
pathways	NNS	O
cause	VBP	O
additional	JJ	O
insult	NN	O
or	CC	O
injury	NN	O
either	CC	O
as	IN	O
directly	RB	O
related	VBN	O
to	TO	O
the	DT	O
intensity	NN	O
of	IN	O
the	DT	O
response	NN	O
,	,	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
abnormal	JJ	O
regulation	NN	O
or	CC	O
excessive	JJ	O
stimulation	NN	O
,	,	O
as	IN	O
a	DT	O
reaction	NN	O
to	TO	O
self	VB	O
,	,	O
or	CC	O
as	IN	O
a	DT	O
combination	NN	O
of	IN	O
these	DT	O
.	.	O
Though	IN	O
the	DT	O
genesis	NN	O
of	IN	O
these	DT	O
diseases	NNS	O
often	RB	O
involves	VBZ	O
multistep	NNS	O
pathways	NNS	O
and	CC	O
often	RB	O
multiple	JJ	O
different	JJ	O
biological	JJ	O
systems/pathways	NNS	O
,	,	O
intervention	NN	O
at	IN	O
critical	JJ	O
points	NNS	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
these	DT	O
pathways	NNS	O
can	MD	O
have	VB	O
an	DT	O
ameliorative	JJ	O
or	CC	O
therapeutic	JJ	O
effect	NN	O
.	.	O
Therapeutic	JJ	O
intervention	NN	O
can	MD	O
occur	VB	O
by	IN	O
either	DT	O
antagonism	NN	O
of	IN	O
a	DT	O
detrimental	JJ	O
process/pathway	NN	O
or	CC	O
stimulation	NN	O
of	IN	O
a	DT	O
beneficial	JJ	O
process/pathway	NN	O
.	.	O
T	NNP	O
lymphocytes	VBZ	O
(	(	O
T	NNP	O
cells	NNS	O
)	)	O
are	VBP	O
an	DT	O
important	JJ	O
component	NN	O
of	IN	O
a	DT	O
mammalian	JJ	O
immune	NN	O
response	NN	O
.	.	O
T	NNP	O
cells	NNS	O
recognize	VBP	O
antigens	NNS	O
which	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
self-molecule	NN	O
encoded	VBN	O
by	IN	O
genes	NNS	O
within	IN	O
the	DT	O
major	JJ	O
histocompatibility	NN	O
complex	NN	O
(	(	O
MHC	NNP	O
)	)	O
.	.	O
The	DT	O
antigen	NN	O
may	MD	O
be	VB	O
displayed	VBN	O
together	RB	O
with	IN	O
MHC	NNP	O
molecules	NNS	O
on	IN	O
the	DT	O
surface	NN	O
of	IN	O
antigen	NN	O
presenting	VBG	O
cells	NNS	O
,	,	O
virus	NN	O
infected	VBD	O
cells	NNS	O
,	,	O
cancer	NN	O
cells	NNS	O
,	,	O
grafts	NNS	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
T	NNP	O
cell	NN	O
system	NN	O
eliminates	VBZ	O
these	DT	O
altered	JJ	O
cells	NNS	O
which	WDT	O
pose	VBP	O
a	DT	O
health	NN	O
threat	NN	O
to	TO	O
the	DT	O
host	NN	O
mammal	JJ	O
T	NNP	O
cells	NNS	O
include	VBP	O
helper	JJ	O
T	NNP	O
cells	NNS	O
and	CC	O
cytotoxic	NN	O
T	NNP	O
cells	NNS	O
.	.	O
Helper	NNP	O
T	NNP	O
cells	NNS	O
proliferate	VBP	O
extensively	RB	O
following	VBG	O
recognition	NN	O
of	IN	O
an	DT	O
antigen-MHC	JJ	O
complex	NN	O
on	IN	O
an	DT	O
antigen	NN	O
presenting	NN	O
cell	NN	O
.	.	O
Helper	NNP	O
T	NNP	O
cells	NNS	O
also	RB	O
secrete	VBP	O
a	DT	O
variety	NN	O
of	IN	O
cytokines	NNS	O
,	,	O
i.e.	FW	O
,	,	O
lymphokines	NNS	O
,	,	O
which	WDT	O
play	VBP	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
the	DT	O
activation	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
,	,	O
cytotoxic	NN	O
T	NNP	O
cells	NNS	O
and	CC	O
a	DT	O
variety	NN	O
of	IN	O
other	JJ	O
cells	NNS	O
which	WDT	O
participate	VBP	O
in	IN	O
the	DT	O
immune	JJ	O
response	NN	O
.	.	O
In	IN	O
many	JJ	O
immune	JJ	O
responses	NNS	O
,	,	O
inflammatory	JJ	O
cells	NNS	O
infiltrate	VBP	O
the	DT	O
site	NN	O
of	IN	O
injury	NN	O
or	CC	O
infection	NN	O
.	.	O
The	DT	O
migrating	NN	O
cells	NNS	O
may	MD	O
be	VB	O
neutrophilic	JJ	O
,	,	O
eosinophilic	JJ	O
,	,	O
monocytic	JJ	O
or	CC	O
lymphocytic	JJ	O
as	IN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
histologic	JJ	O
examination	NN	O
of	IN	O
the	DT	O
affected	JJ	O
tissues	NNS	O
.	.	O
Current	JJ	B
Protocols	NNP	I
in	IN	I
Immunology	NNP	I
,	,	I
ed	NN	I
.	.	I
John	NNP	I
E.	NNP	I
Coligan	NNP	I
,	,	I
1994	CD	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc	NNP	I
.	.	O
Many	JJ	O
immune	NNS	O
related	JJ	O
diseases	NNS	O
are	VBP	O
known	VBN	O
and	CC	O
have	VBP	O
been	VBN	O
extensively	RB	O
studied	VBN	O
.	.	O
Such	JJ	O
diseases	NNS	O
include	VBP	O
immune-mediated	JJ	O
inflammatory	JJ	O
diseases	NNS	O
(	(	O
such	JJ	O
as	IN	O
rheumatoid	JJ	O
arthritis	NN	O
,	,	O
immune	NN	O
mediated	VBD	O
renal	JJ	O
disease	NN	O
,	,	O
hepatobiliary	JJ	O
diseases	NNS	O
,	,	O
inflammatory	NN	O
bowel	NN	O
disease	NN	O
(	(	O
IBD	NNP	O
)	)	O
,	,	O
psoriasis	NN	O
,	,	O
and	CC	O
asthma	NN	O
)	)	O
,	,	O
non-immune-mediated	JJ	O
inflammatory	NN	O
diseases	NNS	O
,	,	O
infectious	JJ	O
diseases	NNS	O
,	,	O
immunodeficiency	NN	O
diseases	NNS	O
,	,	O
neoplasia	NN	O
,	,	O
and	CC	O
graft	NN	O
rejection	NN	O
,	,	O
etc	FW	O
.	.	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
immunology	NN	O
,	,	O
targets	NNS	O
were	VBD	O
identified	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
inflammation	NN	O
and	CC	O
inflammatory	NN	O
disorders	NNS	O
.	.	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
immunology	NN	O
,	,	O
targets	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
herein	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
inflammation	NN	O
and	CC	O
inflammatory	NN	O
disorders	NNS	O
.	.	O
Immune	NNP	O
related	JJ	O
diseases	NNS	O
,	,	O
in	IN	O
one	CD	O
instance	NN	O
,	,	O
could	MD	O
be	VB	O
treated	VBN	O
by	IN	O
suppressing	VBG	O
the	DT	O
immune	JJ	O
response	NN	O
.	.	O
Using	VBG	O
neutralizing	VBG	O
antibodies	NNS	O
that	WDT	O
inhibit	VBP	O
molecules	NNS	O
having	VBG	O
immune	JJ	O
stimulatory	JJ	O
activity	NN	O
would	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
immune-mediated	JJ	O
and	CC	O
inflammatory	JJ	O
diseases	NNS	O
.	.	O
Molecules	NNS	O
which	WDT	O
inhibit	VBP	O
the	DT	O
immune	JJ	O
response	NN	O
can	MD	O
be	VB	O
utilized	VBN	O
(	(	O
proteins	NNS	O
directly	RB	O
or	CC	O
via	IN	O
the	DT	O
use	NN	O
of	IN	O
antibody	NN	O
agonists	NNS	O
)	)	O
to	TO	O
inhibit	VB	O
the	DT	O
immune	JJ	O
response	NN	O
and	CC	O
thus	RB	O
ameliorate	VB	O
immune	NN	O
related	JJ	O
disease	NN	O
.	.	O
The	DT	O
following	JJ	O
tests	NNS	O
were	VBD	O
performed	VBN	O
:	:	O
Flourescence-Activated	JJ	O
Cell-Sorting	NNP	O
(	(	O
FACS	NNP	O
)	)	O
Analysis/Tissue	NNP	O
Specific	NNP	O
FACS	NNP	O
Analysis	NNP	O
Procedure	NN	O
:	:	O
FACS	NNP	O
analysis	NN	O
of	IN	O
immune	NN	O
cell	NN	O
composition	NN	O
from	IN	O
peripheral	JJ	O
blood	NN	O
was	VBD	O
performed	VBN	O
including	VBG	O
analysis	NN	O
of	IN	O
CD4	NNP	O
,	,	O
CD8	NNP	O
and	CC	O
T	NNP	O
cell	NN	O
receptors	NNS	O
to	TO	O
evaluate	VB	O
T	NNP	O
lymphocytes	NNS	O
,	,	O
CD19	NNP	O
for	IN	O
B	NNP	O
lymphocytes	NNS	O
,	,	O
CD45	NNP	O
as	IN	O
a	DT	O
leukocyte	NN	O
marker	NN	O
and	CC	O
pan	NN	O
NK	NNP	O
for	IN	O
natural	JJ	O
killer	NN	O
cells	NNS	O
.	.	O
The	DT	O
FACS	NNP	O
analysis	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
2	CD	O
wild	JJ	O
type	NN	O
and	CC	O
6	CD	O
homozygous	JJ	O
mice	NN	O
and	CC	O
included	VBD	O
cells	NNS	O
derived	VBN	O
from	IN	O
thymus	NN	O
,	,	O
spleen	NN	O
,	,	O
bone	NN	O
marrow	NN	O
and	CC	O
lymph	JJ	O
node	NN	O
.	.	O
In	IN	O
these	DT	O
studies	NNS	O
,	,	O
analyzed	JJ	O
cells	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
thymus	NN	O
,	,	O
peripheral	JJ	O
blood	NN	O
,	,	O
spleen	NN	O
,	,	O
bone	NN	O
marrow	NN	O
and	CC	O
lymph	NN	O
nodes	NNS	O
.	.	O
Flow	NNP	O
cytometry	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
relative	JJ	O
proportions	NNS	O
of	IN	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
positive	JJ	O
T	NNP	O
cells	NNS	O
,	,	O
B	NNP	O
cells	NNS	O
,	,	O
NK	NNP	O
cells	NNS	O
and	CC	O
monocytes	NNS	O
in	IN	O
the	DT	O
mononuclear	NN	O
cell	NN	O
population	NN	O
.	.	O
A	DT	O
Becton-Dickinson	NNP	O
FACSCalibur	NNP	O
3-laser	CD	O
FACS	NNP	O
machine	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
immune	JJ	O
status	NN	O
.	.	O
For	IN	O
Phenotypic	NNP	O
Assays	NNP	O
and	CC	O
Screening	NNP	O
,	,	O
this	DT	O
machine	NN	O
records	NNS	O
CD4+/CD8−	NNP	O
,	,	O
CD8+/CD4−	NNP	O
,	,	O
NK	NNP	O
,	,	O
B	NNP	O
cell	NN	O
and	CC	O
monocyte	NN	O
numbers	NNS	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
CD4+/CD8+	NNP	O
ratio	NN	O
.	.	O
The	DT	O
mononuclear	NN	O
cell	NN	O
profile	NN	O
was	VBD	O
derived	VBN	O
by	IN	O
staining	VBG	O
a	DT	O
single	JJ	O
sample	NN	O
of	IN	O
lysed	JJ	O
peripheral	JJ	O
blood	NN	O
from	IN	O
each	DT	O
mouse	NN	O
with	IN	O
a	DT	O
panel	NN	O
of	IN	O
six	CD	O
lineage-specific	JJ	O
antibodies	NNS	O
:	:	O
CD45	NNP	O
PerCP	NNP	O
,	,	O
anti-TCRb	JJ	O
APC	NNP	O
,	,	O
CD4	NNP	O
PE	NNP	O
,	,	O
CD8	NNP	O
FITC	NNP	O
,	,	O
pan-NK	JJ	O
PE	NNP	O
,	,	O
and	CC	O
CD19	NNP	O
FITC	NNP	O
.	.	O
The	DT	O
two	CD	O
FITC	NNP	O
and	CC	O
PE	NNP	O
labeled	VBD	O
antibodies	NNS	O
stain	VBP	O
mutually	RB	O
exclusive	JJ	O
cell	NN	O
types	NNS	O
.	.	O
The	DT	O
samples	NNS	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
a	DT	O
Becton	NNP	O
Dickinson	NNP	O
FACSCalibur	NNP	O
flow	NN	O
cytometer	NN	O
with	IN	O
CellQuest	NNP	O
software	NN	O
.	.	O
Results	NNS	O
:	:	O
Tissue	NNP	O
specific	JJ	O
FACS	NNP	O
analysis	NN	O
gave	VBD	O
the	DT	O
following	JJ	O
results	NNS	O
:	:	O
The	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
exhibited	VBD	O
a	DT	O
2½	CD	O
fold	JJ	O
increase	NN	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
(	(	O
+/+	NN	O
)	)	O
littermates	VBZ	O
and	CC	O
the	DT	O
historical	JJ	O
mean	NN	O
.	.	O
Lymph	NNP	O
node	CC	O
FACS	NNP	O
analysis	NN	O
showed	VBD	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
certain	JJ	O
cell	NN	O
types	NNS	O
(	(	O
TcR+	NNP	O
cells	NNS	O
;	:	O
CD19+	NNP	O
cells	NNS	O
;	:	O
and	CC	O
GR1-cells	NNP	O
)	)	O
.	.	O
In	IN	O
summary	JJ	O
,	,	O
tissue	NN	O
specific	JJ	O
FACS	NNP	O
analysis	NN	O
indicate	NN	O
that	IN	O
knockout	NN	O
mice	NN	O
deficient	NN	O
in	IN	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO233	NNP	O
polypeptides	NNS	O
exhibit	VBP	O
immunological	JJ	O
abnormalities	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
wild-type	JJ	O
littermates	NNS	O
.	.	O
The	DT	O
mutant	JJ	O
mice	NN	O
exhibited	VBD	O
an	DT	O
abnormal	JJ	O
immune	NN	O
cell	NN	O
composition	NN	O
and	CC	O
tissue	NN	O
specific	JJ	O
FACS	NNP	O
analysis	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
inhibitors	NNS	O
or	CC	O
antagonists	NNS	O
to	TO	O
PRO233	NNP	O
polypeptides	NNS	O
would	MD	O
stimulate	VB	O
the	DT	O
immune	NN	O
system	NN	O
(	(	O
such	JJ	O
as	IN	O
T	NNP	O
cell	NN	O
proliferation	NN	O
)	)	O
and	CC	O
would	MD	O
find	VB	O
utility	NN	O
in	IN	O
the	DT	O
cases	NNS	O
wherein	VBP	O
this	DT	O
effect	NN	O
would	MD	O
be	VB	O
beneficial	JJ	O
to	TO	O
the	DT	O
individual	NN	O
such	JJ	O
as	IN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
leukemia	NN	O
,	,	O
and	CC	O
other	JJ	O
types	NNS	O
of	IN	O
cancer	NN	O
,	,	O
and	CC	O
in	IN	O
immunocompromised	JJ	O
patients	NNS	O
,	,	O
such	JJ	O
as	IN	O
AIDS	NNP	O
sufferers	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
PRO233	NNP	O
polypeptides	VBZ	O
or	CC	O
agonists	NNS	O
thereof	RB	O
would	MD	O
inhibit	VB	O
the	DT	O
immune	JJ	O
response	NN	O
and	CC	O
would	MD	O
be	VB	O
useful	JJ	O
candidates	NNS	O
for	IN	O
suppressing	VBG	O
harmful	JJ	O
immune	JJ	O
responses	NNS	O
,	,	O
e.g	NN	O
.	.	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
graft	NN	O
rejection	NN	O
or	CC	O
graft-versus-host	NN	O
diseases	NNS	O
.	.	O
C.	NNP	O
Generation	NNP	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA35600-1162	NNP	O
(	(	O
UNQ212	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO238	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA35600-1162	NNP	O
(	(	O
UNQ212	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
NM—145428	NN	O
:	:	O
or	CC	O
Mus	NNP	O
musculus	CC	O
similar	JJ	O
to	TO	O
DKFZP566O084	NNP	O
protein	NN	O
(	(	O
LOC216820	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—663403	NN	O
or	CC	O
Mus	NNP	O
musculus	CC	O
similar	JJ	O
to	TO	O
DKFZP566O084	NNP	O
protein	NN	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
NM—015510	NN	O
or	CC	O
DKFZP566O084	NNP	O
protein	JJ	O
gene	NN	O
;	:	O
the	DT	O
human	JJ	O
protein	NN	O
sequence	NN	O
corresponds	NNS	O
to	TO	O
reference	VB	O
:	:	O
NP—056325	NNP	O
or	CC	O
Homo	NNP	O
sapiens	JJ	O
DKFZP566O084	NNP	O
protein	NN	O
.	.	O
Mutation	NNP	O
Specific	NNP	O
Information	NNP	O
corresponds	VBZ	O
to	TO	O
retroviral	VB	O
insertion	NN	O
(	(	O
OST	NNP	O
)	)	O
.	.	O
Retroviral	JJ	O
insertion	NN	O
disrupted	VBD	O
the	DT	O
gene	NN	O
prior	RB	O
to	TO	O
the	DT	O
exon	NN	O
encoding	VBG	O
amino	JJ	O
acid	JJ	O
18	CD	O
in	IN	O
a	DT	O
protein	NN	O
of	IN	O
323	CD	O
amino	JJ	O
acids	NNS	O
(	(	O
NCBI	NNP	O
accession	NN	O
number	NN	O
NP—663403	NNP	O
)	)	O
.	.	O
The	DT	O
gene	NN	O
of	IN	O
interest	NN	O
is	VBZ	O
represented	VBN	O
by	IN	O
NCBI	NNP	O
accession	NN	O
NM—145428	NNP	O
,	,	O
ortholog	NN	O
of	IN	O
human	JJ	O
DKFZP566O084	NNP	O
protein	NN	O
.	.	O
Aliases	NNS	O
include	VBP	O
cDNA	JJ	O
sequence	NN	O
BC003479	NNP	O
,	,	O
LOC216820	NNP	O
,	,	O
CGI-93	NNP	O
and	CC	O
MGC8916	NNP	O
.	.	O
DKFZp566O084	NNP	O
is	VBZ	O
a	DT	O
hypothetical	JJ	O
protein	NN	O
containing	VBG	O
a	DT	O
short	JJ	O
chain	NN	O
dehydrogenase	NN	O
domain	NN	O
(	(	O
Pfam	NNP	O
PF00106	NNP	O
)	)	O
.	.	O
Typically	RB	O
,	,	O
such	JJ	O
proteins	NNS	O
are	VBP	O
NAD-	JJ	O
or	CC	O
NADP-dependent	JJ	O
oxidoreductases	NNS	O
.	.	O
A	DT	O
signal	JJ	O
peptide	NN	O
is	VBZ	O
predicted	VBN	O
at	IN	O
the	DT	O
N-terminus	NNP	O
,	,	O
and	CC	O
ProtComp	NNP	O
(	(	O
Softberry	NNP	O
,	,	O
Inc.	NNP	O
Mount	NNP	O
Kisco	NNP	O
,	,	O
N.Y.	NNP	O
)	)	O
software	NN	O
analysis	NN	O
indicates	VBZ	O
the	DT	O
protein	NN	O
may	MD	O
be	VB	O
targeted	VBN	O
to	TO	O
the	DT	O
mitochondrion	NN	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
progeny	NN	O
.	.	O
On	IN	O
rare	JJ	O
occasions	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
very	RB	O
few	JJ	O
F1	NNP	O
mice	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
chimera	NN	O
,	,	O
F1	NNP	O
heterozygous	JJ	O
mice	NNS	O
were	VBD	O
crossed	VBN	O
to	TO	O
129SvEvBrd/C57	CD	O
hybrid	JJ	O
mice	NN	O
to	TO	O
yield	VB	O
additional	JJ	O
heterozygous	JJ	O
animals	NNS	O
for	IN	O
the	DT	O
intercross	NN	O
to	TO	O
generate	VB	O
the	DT	O
F2	NNP	O
mice	NN	O
.	.	O
In	IN	O
the	DT	O
wild-type	JJ	O
animals	NNS	O
,	,	O
expression	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
and	CC	O
in	IN	O
all	DT	O
19	CD	O
adult	NNS	O
tissue	NN	O
samples	NNS	O
tested	VBN	O
by	IN	O
RT-PCR	NNP	O
,	,	O
except	IN	O
asthmatic	JJ	O
lung	NN	O
,	,	O
skeletal	JJ	O
muscle	NN	O
,	,	O
and	CC	O
adipose	JJ	O
tissue	NN	O
.	.	O
Genetic	NNP	O
data	NNS	O
indicate	NN	O
that	IN	O
this	DT	O
retroviral	JJ	O
insertion	NN	O
resulted	VBD	O
in	IN	O
lethality	NN	O
of	IN	O
the	DT	O
homozygous	JJ	O
mutants	NNS	O
.	.	O
Due	JJ	O
to	TO	O
lethality	NN	O
,	,	O
transcript	JJ	O
expression	NN	O
analysis	NN	O
was	VBD	O
not	RB	O
performed	VBN	O
.	.	O
It	PRP	O
is	VBZ	O
not	RB	O
clear	JJ	O
when	WRB	O
lethality	NN	O
occurs	VBZ	O
but	CC	O
by	IN	O
three	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
all	DT	O
of	IN	O
the	DT	O
(	(	O
−/−	NN	O
)	)	O
mutant	NN	O
mice	NN	O
were	VBD	O
dead	JJ	O
.	.	O
Discussion	NN	O
Related	VBN	O
to	TO	O
Embryonic	NNP	O
Developmental	NNP	O
Abnormality	NNP	O
of	IN	O
Lethality	NNP	O
:	:	O
Embryonic	JJ	O
lethality	NN	O
in	IN	O
knockout	NN	O
mice	NNS	O
usually	RB	O
results	NNS	O
from	IN	O
various	JJ	O
serious	JJ	O
developmental	NN	O
problems	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
neurodegenerative	JJ	O
diseases	NNS	O
,	,	O
angiogenic	JJ	O
disorders	NNS	O
,	,	O
inflammatory	NN	O
diseases	NNS	O
,	,	O
or	CC	O
where	WRB	O
the	DT	O
gene/protein	NN	O
has	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
basic	JJ	O
cell	NN	O
signaling	VBG	O
processes	NNS	O
in	IN	O
many	JJ	O
cell	NN	O
types	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
embryonic	JJ	O
lethals	NNS	O
are	VBP	O
useful	JJ	O
as	IN	O
potential	JJ	O
cancer	NN	O
models	NNS	O
.	.	O
Likewise	RB	O
,	,	O
the	DT	O
corresponding	VBG	O
heterozygous	JJ	O
(	(	O
+/−	NNP	O
)	)	O
mutant	NN	O
animals	NNS	O
are	VBP	O
particularly	RB	O
useful	JJ	O
when	WRB	O
they	PRP	O
exhibit	VBP	O
a	DT	O
phenotype	NN	O
and/or	NN	O
a	DT	O
pathology	NN	O
report	NN	O
which	WDT	O
reveals	VBZ	O
highly	RB	O
informative	JJ	O
clues	NNS	O
as	IN	O
to	TO	O
the	DT	O
function	NN	O
of	IN	O
the	DT	O
knocked-out	JJ	O
gene	NN	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
EPO	NNP	O
knockout	NN	O
animals	NNS	O
were	VBD	O
embryonic	JJ	O
lethals	NNS	O
,	,	O
but	CC	O
the	DT	O
pathology	NN	O
reports	NNS	O
on	IN	O
the	DT	O
embryos	NN	O
showed	VBD	O
a	DT	O
profound	JJ	O
lack	NN	O
of	IN	O
RBCs	NNP	O
.	.	O
In	IN	O
the	DT	O
instant	JJ	O
example	NN	O
,	,	O
PRO238	NNP	O
mutant	NN	O
mice	NN	O
showed	VBD	O
serious	JJ	O
and	CC	O
multiple	JJ	O
physiological	JJ	O
abnormalities	NNS	O
involving	VBG	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
(	(	O
GI	NNP	O
)	)	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
1	CD	O
.	.	O
Overall	JJ	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
Disrupted	VBN	O
Gene	NNP	O
:	:	O
DNA35600-1162	NNP	O
(	(	O
UNQ212	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
:	:	O
Multiple	JJ	O
histological	JJ	O
defects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
KO	NNP	O
mice	NN	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
Necropsy	NNP	O
revealed	VBD	O
that	IN	O
the	DT	O
13	CD	O
day-old	JJ	O
homozygous	JJ	O
mutants	NNS	O
exhibited	VBD	O
numerous	JJ	O
lesions	NNS	O
,	,	O
including	VBG	O
megaesophagus	NN	O
and	CC	O
hypoplasia	NN	O
of	IN	O
the	DT	O
glandular	JJ	O
stomach	NN	O
.	.	O
Three	CD	O
fourths	NNS	O
of	IN	O
the	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
exhibited	VBD	O
thymic	JJ	O
atrophy	NN	O
,	,	O
lymphoid	JJ	O
depletion	NN	O
,	,	O
and	CC	O
muscle	NN	O
degeneration	NN	O
.	.	O
Exophthalmus	NNP	O
was	VBD	O
present	VBN	O
in	IN	O
most	JJS	O
homozygotes	NNS	O
.	.	O
Homozygous	JJ	O
mutant	JJ	O
mice	NN	O
resulted	VBD	O
in	IN	O
embryonic	JJ	O
lethality	NN	O
by	IN	O
three	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
.	.	O
Thus	RB	O
,	,	O
PRO238	NNP	O
polypeptides	VBZ	O
or	CC	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO238	NNP	O
must	MD	O
be	VB	O
essential	JJ	O
for	IN	O
embryonic	JJ	O
development	NN	O
.	.	O
(	(	O
b	NN	O
)	)	O
Pathology	NNP	O
Analysis	NNP	O
Multiple	NNP	O
histological	JJ	O
defects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
KO	NNP	O
mice	NN	O
involving	VBG	O
GI	NNP	O
,	,	O
hematopoietic	JJ	O
,	,	O
respiratory	NN	O
,	,	O
neuromuscular	JJ	O
,	,	O
and	CC	O
reproductive	JJ	O
systems	NNS	O
.	.	O
Necropsy	NNP	O
revealed	VBD	O
that	IN	O
the	DT	O
13	CD	O
day-old	JJ	O
homozygous	JJ	O
mutants	NNS	O
exhibited	VBD	O
numerous	JJ	O
lesions	NNS	O
,	,	O
including	VBG	O
megaesophagus	NN	O
and	CC	O
hypoplasia	NN	O
of	IN	O
the	DT	O
glandular	JJ	O
stomach	NN	O
.	.	O
Three	CD	O
fourths	NNS	O
of	IN	O
the	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
exhibited	VBD	O
thymic	JJ	O
atrophy	NN	O
,	,	O
lymphoid	JJ	O
depletion	NN	O
,	,	O
and	CC	O
muscle	NN	O
degeneration	NN	O
.	.	O
Exophthalmus	NNP	O
was	VBD	O
present	VBN	O
in	IN	O
most	JJS	O
homozygotes	NNS	O
.	.	O
In	IN	O
the	DT	O
GI	NNP	O
tract	NN	O
,	,	O
esophageal	JJ	O
dilatation	NN	O
with	IN	O
multifocal	JJ	O
hyperkeratosis	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
gastric	JJ	O
hypoplasia	NN	O
was	VBD	O
observed	VBN	O
with	IN	O
significantly	RB	O
reduced	VBN	O
parietal	JJ	O
cells	NNS	O
and	CC	O
chief	JJ	O
cells	NNS	O
.	.	O
These	DT	O
KO	NNP	O
mice	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
stressed	VBN	O
with	IN	O
thymic	JJ	O
atrophy/necrosis	NN	O
and/or	NN	O
splenic	JJ	O
lymphoid	JJ	O
depletion	NN	O
.	.	O
Increased	VBN	O
hematopoiesis	NN	O
was	VBD	O
also	RB	O
noted	VBN	O
in	IN	O
bone	NN	O
marrow	NN	O
,	,	O
liver	RB	O
,	,	O
spleen	JJ	O
and	CC	O
thymus	NN	O
.	.	O
Aspiration	NNP	O
pneumonia	NN	O
was	VBD	O
found	VBN	O
in	IN	O
several	JJ	O
mice	NNS	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
esophageal	VB	O
dysfunction	NN	O
.	.	O
Other	JJ	O
findings	NNS	O
included	VBD	O
seminiferous	JJ	O
tubule	NN	O
necrosis	NN	O
,	,	O
multifocal	JJ	O
vacuolation	NN	O
in	IN	O
brain	NN	O
,	,	O
focal	JJ	O
muscular	JJ	O
degeneration	NN	O
,	,	O
and	CC	O
diffuse	VB	O
degeneration	NN	O
in	IN	O
the	DT	O
Harderia	NNP	O
gland	NN	O
.	.	O
All	PDT	O
the	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
died	VBN	O
by	IN	O
three	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
.	.	O
As	IN	O
summarized	VBN	O
above	IN	O
,	,	O
embryonic	JJ	O
lethality	NN	O
in	IN	O
knockout	NN	O
mice	NNS	O
usually	RB	O
results	NNS	O
from	IN	O
various	JJ	O
serious	JJ	O
developmental	NN	O
problems	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
neurodegenerative	JJ	O
diseases	NNS	O
,	,	O
angiogenic	JJ	O
disorders	NNS	O
,	,	O
inflammatory	NN	O
diseases	NNS	O
,	,	O
or	CC	O
where	WRB	O
the	DT	O
gene/protein	NN	O
has	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
basic	JJ	O
cell	NN	O
signaling	VBG	O
processes	NNS	O
in	IN	O
many	JJ	O
cell	NN	O
types	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
embryonic	JJ	O
lethals	NNS	O
are	VBP	O
useful	JJ	O
as	IN	O
potential	JJ	O
cancer	NN	O
models	NNS	O
.	.	O
In	IN	O
the	DT	O
instant	JJ	O
example	NN	O
,	,	O
it	PRP	O
is	VBZ	O
likely	JJ	O
that	IN	O
antagonists	VBZ	O
to	TO	O
PRO238	VB	O
or	CC	O
its	PRP$	O
encoding	JJ	O
gene	NN	O
results	NNS	O
in	IN	O
serious	JJ	O
disorders	NNS	O
of	IN	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
and	CC	O
could	MD	O
lead	VB	O
to	TO	O
such	JJ	O
disorders	NNS	O
as	IN	O
stomach	NN	O
or	CC	O
esophageal	JJ	O
cancer	NN	O
.	.	O
Likewise	RB	O
,	,	O
PRO238	NNP	O
or	CC	O
agonists	NNS	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gastrointestinal	JJ	O
disorders	NNS	O
including	VBG	O
cancer	NN	O
.	.	O
D.	NNP	O
Generation	NNP	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA66658-1584	NNP	O
(	(	O
UNQ688	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO1328	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA66658-1584	NNP	O
(	(	O
UNQ688	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
NM—026674	NN	O
or	CC	O
Mus	NNP	O
musculus	CC	O
RIKEN	NNP	O
cDNA	VBP	O
0610008A10	CD	O
gene	NN	O
(	(	O
0610008A10Rik	CD	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
BAB22004	NNP	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
NM—031301	NN	O
or	CC	O
Homo	NNP	O
sapiens	NNS	O
which	WDT	O
is	VBZ	O
likely	JJ	O
the	DT	O
ortholog	NN	O
of	IN	O
C.	NNP	O
elegans	NNS	O
anterior	JJ	O
pharynx	VBP	O
defective	JJ	O
1B	CD	O
(	(	O
APH-1B	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
AAH20905	NNP	O
or	CC	O
hypothetical	JJ	O
protein	NN	O
DKFZp564D0372	NNP	O
[	NNP	O
Homo	NNP	O
sapiens	VBZ	O
]	NNP	O
.	.	O
Mutation	NNP	O
Specific	NNP	O
Information	NNP	O
corresponds	VBZ	O
to	TO	O
homologous	JJ	O
recombination	NN	O
(	(	O
conditional	JJ	O
)	)	O
(	(	O
codon	$	O
2	CD	O
was	VBD	O
targeted	VBN	O
)	)	O
.	.	O
The	DT	O
mouse	NN	O
gene	NN	O
targeted	VBN	O
is	VBZ	O
represented	VBN	O
by	IN	O
RIKEN	NNP	O
cDNA	NN	O
0610008A10	CD	O
,	,	O
which	WDT	O
is	VBZ	O
orthologous	JJ	O
to	TO	O
human	JJ	O
anterior	JJ	O
pharynx	NN	O
defective	JJ	O
1B-like	JJ	O
(	(	O
PSFL	NNP	O
)	)	O
.	.	O
Aliases	NNS	O
include	VBP	O
presenilin	JJ	O
stabilization	NN	O
factor-like	NN	O
and	CC	O
APH-1B	NNP	O
.	.	O
PSFL	NNP	O
consists	VBZ	O
of	IN	O
a	DT	O
signal	JJ	O
peptide	NN	O
sequence	NN	O
and	CC	O
six	CD	O
or	CC	O
seven	CD	O
transmembrane	NN	O
spanning	VBG	O
segments	NNS	O
.	.	O
The	DT	O
protein	NN	O
is	VBZ	O
predicted	VBN	O
to	TO	O
be	VB	O
located	VBN	O
at	IN	O
the	DT	O
plasma	NN	O
membrane	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
ProtComp	NNP	O
analysis	NN	O
(	(	O
Softberry	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Mount	NNP	O
Kisco	NNP	O
,	,	O
N.Y.	NNP	O
,	,	O
2003	CD	O
)	)	O
.	.	O
PSFL	NNP	O
interacts	VBZ	O
with	IN	O
presenilin	JJ	O
enhancer	NN	O
2	CD	O
,	,	O
nicastrin	NN	O
,	,	O
and	CC	O
presenilin	NN	O
.	.	O
PSFL	NNP	O
is	VBZ	O
required	VBN	O
for	IN	O
the	DT	O
activity	NN	O
and	CC	O
accumulation	NN	O
of	IN	O
gamma-secretase	NN	O
,	,	O
which	WDT	O
is	VBZ	O
involved	VBN	O
in	IN	O
Notch	NNP	O
and	CC	O
beta-amyloid	JJ	O
precursor	NN	O
protein	NN	O
signaling	VBG	O
.	.	O
Notch	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
developmental	JJ	O
cell	NN	O
fate	NN	O
,	,	O
and	CC	O
beta-amyloid	JJ	O
precursor	NN	O
protein	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
gene	NN	O
expression	NN	O
and	CC	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
progeny	NN	O
.	.	O
On	IN	O
rare	JJ	O
occasions	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
very	RB	O
few	JJ	O
F1	NNP	O
mice	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
chimera	NN	O
,	,	O
F1	NNP	O
heterozygous	JJ	O
mice	NNS	O
were	VBD	O
crossed	VBN	O
to	TO	O
129SvEvBrd/C57	CD	O
hybrid	JJ	O
mice	NN	O
to	TO	O
yield	VB	O
additional	JJ	O
heterozygous	JJ	O
animals	NNS	O
for	IN	O
the	DT	O
intercross	NN	O
to	TO	O
generate	VB	O
the	DT	O
F2	NNP	O
mice	NN	O
.	.	O
Level	NN	O
I	PRP	O
phenotypic	VBP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
mice	NN	O
from	IN	O
this	DT	O
generation	NN	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
Wild-type	JJ	O
expression	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
and	CC	O
in	IN	O
all	DT	O
13	CD	O
adult	NNS	O
tissue	NN	O
samples	NNS	O
tested	VBN	O
by	IN	O
RT-PCR	NNP	O
,	,	O
except	IN	O
tail	NN	O
.	.	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
1	CD	O
.	.	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
Disrupted	VBN	O
Gene	NNP	O
:	:	O
DNA66658-1584	NNP	O
(	(	O
UNQ688	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
The	DT	O
male	NN	O
and	CC	O
female	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
exhibited	VBD	O
increased	JJ	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
levels	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
and	CC	O
the	DT	O
historical	JJ	O
means	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
abnormalities	NNS	O
in	IN	O
the	DT	O
urinalysis	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
homozygous	JJ	O
mice	NN	O
.	.	O
(	(	O
b	NN	O
)	)	O
Phenotypic	NNP	O
Analysis	NN	O
:	:	O
Cardiology	NN	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
cardiovascular	JJ	O
biology	NN	O
,	,	O
targets	NNS	O
were	VBD	O
identified	VBN	O
herein	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
,	,	O
atherosclerosis	NN	O
,	,	O
heart	NN	O
failure	NN	O
,	,	O
stroke	NN	O
,	,	O
various	JJ	O
coronary	JJ	O
artery	NN	O
diseases	NNS	O
,	,	O
dyslipidemias	NNS	O
such	JJ	O
as	IN	O
high	JJ	O
cholesterol	NN	O
(	(	O
hypercholesterolemia	NN	O
)	)	O
and	CC	O
elevated	VBN	O
serum	NN	O
triglycerides	NNS	O
(	(	O
hypertriglyceridemia	NN	O
)	)	O
,	,	O
cancer	NN	O
and/or	NN	O
obesity	NN	O
.	.	O
The	DT	O
phenotypic	NN	O
tests	NNS	O
included	VBD	O
the	DT	O
measurement	NN	O
of	IN	O
serum	NN	O
cholesterol	NN	O
and	CC	O
triglycerides	NNS	O
.	.	O
Blood	NNP	O
Lipids	NNP	O
Procedure	NN	O
:	:	O
A	DT	O
cohort	NN	O
of	IN	O
4	CD	O
wild	JJ	O
type	NN	O
,	,	O
4	CD	O
heterozygotes	NNS	O
and	CC	O
8	CD	O
homozygotes	NNS	O
were	VBD	O
tested	VBN	O
in	IN	O
this	DT	O
assay	NN	O
.	.	O
High	JJ	O
cholesterol	NN	O
levels	NNS	O
are	VBP	O
recognized	VBN	O
risk	NN	O
factors	NNS	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O
Measuring	VBG	O
blood	NN	O
lipids	NNS	O
allowed	VBD	O
finding	NN	O
of	IN	O
the	DT	O
biological	JJ	O
switches	NNS	O
that	WDT	O
regulate	VBP	O
blood	NN	O
lipid	JJ	O
levels	NNS	O
and	CC	O
that	DT	O
upon	JJ	O
inhibition	NN	O
would	MD	O
lead	VB	O
to	TO	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
risk	NN	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O
Cholesterol	NN	O
measurements	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O
The	DT	O
COBAS	NNP	O
Integra	NNP	O
400	CD	O
(	(	O
mfr	NN	O
:	:	O
Roche	NNP	O
)	)	O
was	VBD	O
used	VBN	O
for	IN	O
running	VBG	O
blood	NN	O
chemistry	NN	O
tests	NNS	O
on	IN	O
mice	NNS	O
.	.	O
Results	NNS	O
:	:	O
As	IN	O
summarized	VBN	O
above	IN	O
,	,	O
the	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
exhibited	VBD	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
(	(	O
compared	VBN	O
to	TO	O
normal	JJ	O
levels	NNS	O
)	)	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
and	CC	O
the	DT	O
historical	JJ	O
mean	NN	O
.	.	O
No	DT	O
change	NN	O
in	IN	O
triglycerides	NNS	O
was	VBD	O
observed	VBN	O
.	.	O
(	(	O
Analyzed	JJ	O
Wt/Het/Hom	NNP	O
:	:	O
4/4/8	CD	O
)	)	O
Thus	RB	O
,	,	O
mutant	JJ	O
mice	NN	O
deficient	NN	O
in	IN	O
the	DT	O
PRO1328	NNP	O
can	MD	O
serve	VB	O
as	IN	O
a	DT	O
model	NN	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O
PRO1328	NNP	O
or	CC	O
its	PRP$	O
encoding	JJ	O
gene	NN	O
would	MD	O
be	VB	O
useful	JJ	O
for	IN	O
regulating	VBG	O
blood	NN	O
lipids	NNS	O
and	CC	O
in	IN	O
particular	JJ	O
maintaining	VBG	O
normal	JJ	O
cholesterol	NN	O
and	CC	O
triglyceride	NN	O
levels	NNS	O
.	.	O
Thus	RB	O
,	,	O
PRO1328	NNP	O
polypeptides	NNS	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
such	JJ	O
cardiovascular	JJ	O
diseases	NNS	O
as	IN	O
:	:	O
hypertension	NN	O
,	,	O
atherosclerosis	NN	O
,	,	O
heart	NN	O
failure	NN	O
,	,	O
stroke	NN	O
,	,	O
various	JJ	O
coronary	JJ	O
artery	NN	O
diseases	NNS	O
,	,	O
and/or	JJ	O
obesity	NN	O
or	CC	O
diabetes	NNS	O
.	.	O
Urinalysis	NN	O
:	:	O
Test	JJS	O
Description	NN	O
:	:	O
The	DT	O
routine	JJ	O
urinalysis	NN	O
is	VBZ	O
a	DT	O
screening	JJ	O
test	NN	O
done	VBN	O
to	TO	O
provide	VB	O
a	DT	O
general	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
renal/urinary	JJ	O
system	NN	O
.	.	O
The	DT	O
characteristics	NNS	O
for	IN	O
which	WDT	O
urine	NN	O
is	VBZ	O
routinely	RB	O
examined	JJ	O
includes	VBZ	O
tests	NNS	O
for	IN	O
protein	NN	O
,	,	O
glucose	NN	O
,	,	O
ketones	NNS	O
,	,	O
blood	NN	O
,	,	O
bilirubin	NN	O
,	,	O
urobilinogen	NN	O
,	,	O
nitrate	NN	O
and	CC	O
leukocyte	JJ	O
esterase	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
pH	NN	O
and	CC	O
specific	JJ	O
gravity	NN	O
.	.	O
The	DT	O
histograms	NN	O
show	VBP	O
9	CD	O
measurements	NNS	O
grouped	VBN	O
by	IN	O
genotype	NN	O
:	:	O
Leukocyte	NNP	O
,	,	O
nitrate	NN	O
,	,	O
protein	NN	O
,	,	O
glucose	NN	O
,	,	O
osmolality	NN	O
,	,	O
ketone	NN	O
,	,	O
urobilinogen	NN	O
,	,	O
bilirubin	NN	O
,	,	O
blood	NN	O
.	.	O
Results	NNS	O
:	:	O
The	DT	O
(	(	O
−/−	NN	O
)	)	O
mutant	NN	O
mice	NN	O
showed	VBD	O
abnormalities	NNS	O
in	IN	O
the	DT	O
urinalysis	NN	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Elevated	JJ	O
levels	NNS	O
of	IN	O
urobilinogen	NN	O
,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
were	VBD	O
observed	VBN	O
.	.	O
The	DT	O
presence	NN	O
of	IN	O
ketones	NNS	O
in	IN	O
the	DT	O
urine	NN	O
is	VBZ	O
indicative	JJ	O
of	IN	O
an	DT	O
abnormal	JJ	O
lipid	JJ	O
metabolism	NN	O
or	CC	O
dyslipidemia	NN	O
which	WDT	O
may	MD	O
be	VB	O
an	DT	O
early	JJ	O
sign	NN	O
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
diabetes	NNS	O
.	.	O
E.	NNP	O
Generation	NNP	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA96787-2534-1	NNP	O
(	(	O
UNQ1896	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO4342	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA96787-2534-1	NNP	O
(	(	O
UNQ1896	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
NM—019451	NN	O
or	CC	O
Mus	NNP	O
musculus	CC	O
interleukin	JJ	O
1	CD	O
family	NN	O
,	,	O
member	NN	O
5	CD	O
(	(	O
delta	NN	O
)	)	O
(	(	O
Il1f5	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—062324	NN	O
or	CC	O
interleukin	VB	O
1	CD	O
family	NN	O
,	,	O
member	NN	O
5	CD	O
;	:	O
interleukin	JJ	O
1	CD	O
receptor	NN	O
antagonist	NN	O
homolog	NN	O
1	CD	O
[	NN	O
Mus	NNP	O
musculus	CC	O
]	NNP	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
NM—012275	NN	O
or	CC	O
Homo	NN	O
sapiens	NNS	O
interleukin	VBP	O
1	CD	O
family	NN	O
,	,	O
member	NN	O
5	CD	O
(	(	O
delta	NN	O
)	)	O
(	(	O
IL1F5	NNP	O
)	)	O
,	,	O
transcript	JJ	O
variant	JJ	O
1	CD	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—036407	NN	O
or	CC	O
interleukin	VB	O
1	CD	O
family	NN	O
,	,	O
member	NN	O
5	CD	O
;	:	O
interleukin-1	JJ	O
receptor	NN	O
antagonist	NN	O
homolog	NN	O
1	CD	O
;	:	O
interleukin	JJ	O
1	CD	O
,	,	O
delta	NN	O
;	:	O
interleukin-1-like	JJ	O
protein	NN	O
1	CD	O
;	:	O
family	NN	O
of	IN	O
interleukin	JJ	O
1-delta	JJ	O
;	:	O
interleukin-1	JJ	O
HY1	NNP	O
;	:	O
IL-1ra	NNP	O
homolog	NN	O
;	:	O
IL-1	NNP	O
related	VBD	O
protein	RB	O
3	CD	O
[	JJ	O
Homo	NNP	O
sapiens	VBZ	O
]	NNP	O
.	.	O
Mutation	NNP	O
Specific	NNP	O
Information	NNP	O
corresponds	VBZ	O
to	TO	O
homologous	JJ	O
recombination	NN	O
(	(	O
standard	NN	O
)	)	O
(	(	O
exons	$	O
3	CD	O
,	,	O
4	CD	O
and	CC	O
5	CD	O
were	VBD	O
targeted—AK014576	VBN	O
)	)	O
.	.	O
The	DT	O
disrupted	VBN	O
mouse	NN	O
gene	NN	O
is	VBZ	O
an	DT	O
interleukin	JJ	O
1	CD	O
family	NN	O
,	,	O
member	NN	O
5	CD	O
(	(	O
delta	NN	O
)	)	O
(	(	O
Il1f5	NNP	O
)	)	O
,	,	O
ortholog	NN	O
of	IN	O
human	JJ	O
interleukin	FW	O
1	CD	O
family	NN	O
,	,	O
member	NN	O
5	CD	O
(	(	O
delta	NN	O
)	)	O
(	(	O
IL1F5	NNP	O
)	)	O
.	.	O
Aliases	NNS	O
include	VBP	O
IL-1H3	NNP	O
,	,	O
IL1HY1	NNP	O
,	,	O
FIL1delta	NNP	O
,	,	O
interleukin	VBZ	O
1	CD	O
receptor	NN	O
antagonist	NN	O
homolog	NN	O
1	CD	O
,	,	O
FIL1	NNP	O
,	,	O
FIL1D	NNP	O
,	,	O
IL1L1	NNP	O
,	,	O
IL1RP3	NNP	O
,	,	O
MGC29840	NNP	O
,	,	O
IL-1ra	NNP	O
homolog	NN	O
,	,	O
interleukin-1	JJ	O
HY1	NNP	O
,	,	O
IL-1	NNP	O
related	VBD	O
protein	RB	O
3	CD	O
,	,	O
interleukin-1-like	JJ	O
protein	NN	O
1	CD	O
,	,	O
family	NN	O
of	IN	O
interleukin	JJ	O
1-delta	JJ	O
,	,	O
and	CC	O
interleukin-1	JJ	O
receptor	NN	O
antagonist	NN	O
homolog	NN	O
1	CD	O
.	.	O
IL1F5	NNP	O
,	,	O
a	DT	O
member	NN	O
of	IN	O
the	DT	O
interleukin	JJ	O
1	CD	O
cytokine	JJ	O
family	NN	O
,	,	O
specifically	RB	O
inhibits	VBZ	O
activation	NN	O
of	IN	O
nuclear	JJ	O
factor-kappaB	JJ	O
by	IN	O
IL1F6	NNP	O
(	(	O
interleukin	JJ	O
1	CD	O
family	NN	O
,	,	O
member	NN	O
6	CD	O
[	NN	O
epsilon	NN	O
]	NN	O
;	:	O
(	(	O
Debets	NNPS	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
167	CD	I
(	(	I
3	CD	I
)	)	I
:1440-6	NN	I
(	(	I
2001	CD	I
)	)	I
)	)	O
.	.	O
However	RB	O
,	,	O
IL1F5	NNP	O
does	VBZ	O
not	RB	O
have	VB	O
antagonist	NN	O
activities	NNS	O
associated	VBN	O
with	IN	O
its	PRP$	O
close	JJ	O
paralog	NN	O
,	,	O
IL1RN	NNP	O
(	(	O
interleukin	JJ	O
1	CD	O
receptor	NN	O
antagonist	NN	O
;	:	O
(	(	O
Barton	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Eur	NNP	I
J	NNP	I
Immunol	NNP	I
30	CD	I
(	(	I
11	CD	I
)	)	I
:3299-308	NN	I
(	(	I
2000	CD	I
)	)	I
)	)	O
.	.	O
Allelic	JJ	O
variation	NN	O
in	IN	O
IL1F5	NNP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
as	IN	O
a	DT	O
predisposing	NN	O
factor	NN	O
in	IN	O
some	DT	O
forms	NNS	O
of	IN	O
severe	JJ	O
alopecia	NN	O
areata	NN	O
(	(	O
Tazi-Ahnini	NNP	B
et	FW	I
al.	NN	I
,	,	I
Eur	NNP	I
J	NNP	I
Immunogenet	NNP	I
29	CD	I
(	(	I
1	CD	I
)	)	I
:25-30	NN	I
(	(	I
2002	CD	I
)	)	I
)	)	O
.	.	O
By	IN	O
similarity	NN	O
with	IN	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
interleukin	JJ	O
1	CD	O
family	NN	O
,	,	O
an	DT	O
extracellular	JJ	O
location	NN	O
is	VBZ	O
inferred	VBN	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
progeny	NN	O
.	.	O
On	IN	O
rare	JJ	O
occasions	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
very	RB	O
few	JJ	O
F1	NNP	O
mice	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
chimera	NN	O
,	,	O
F1	NNP	O
heterozygous	JJ	O
mice	NNS	O
were	VBD	O
crossed	VBN	O
to	TO	O
129SvEvBrd/C57	CD	O
hybrid	JJ	O
mice	NN	O
to	TO	O
yield	VB	O
additional	JJ	O
heterozygous	JJ	O
animals	NNS	O
for	IN	O
the	DT	O
intercross	NN	O
to	TO	O
generate	VB	O
the	DT	O
F2	NNP	O
mice	NN	O
.	.	O
Level	NN	O
I	PRP	O
phenotypic	VBP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
mice	NN	O
from	IN	O
this	DT	O
generation	NN	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
Wild-type	JJ	O
expression	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
and	CC	O
in	IN	O
all	DT	O
13	CD	O
adult	NN	O
samples	NNS	O
tested	VBN	O
by	IN	O
RT-PCR	NNP	O
,	,	O
except	IN	O
lung	NN	O
,	,	O
liver	NN	O
,	,	O
skeletal	JJ	O
muscle	NN	O
,	,	O
bone	NN	O
,	,	O
and	CC	O
heart	NN	O
.	.	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
1	CD	O
.	.	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
disrupted	VBN	O
gene	NN	O
:	:	O
DNA96787-2534-1	NNP	O
(	(	O
UNQ1896	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
The	DT	O
female	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
exhibited	VBD	O
increased	JJ	O
activity	NN	O
during	IN	O
home-cage	NN	O
activity	NN	O
testing	VBG	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
wild-type	JJ	O
littermates	NNS	O
and	CC	O
the	DT	O
historical	JJ	O
means	NNS	O
.	.	O
Whiskers	NNS	O
were	VBD	O
absent	VBN	O
on	IN	O
most	JJS	O
homozygotes	NNS	O
,	,	O
with	IN	O
bald	JJ	O
patches	NNS	O
on	IN	O
the	DT	O
snouts	NNS	O
.	.	O
There	EX	O
was	VBD	O
moderate	JJ	O
degeneration	NN	O
of	IN	O
the	DT	O
seminiferous	JJ	O
tubules	NNS	O
in	IN	O
the	DT	O
male	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
examined	VBD	O
.	.	O
(	(	O
b	NN	O
)	)	O
Phenotypic	NNP	O
Analysis	NN	O
:	:	O
CNS/Neurology	NN	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
neurology	NN	O
,	,	O
analysis	NN	O
focused	VBD	O
herein	NN	O
on	IN	O
identifying	VBG	O
in	IN	O
vivo	NN	O
validated	VBN	O
targets	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
neurological	JJ	O
and	CC	O
psychiatric	JJ	O
disorders	NNS	O
including	VBG	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Neurological	JJ	O
disorders	NNS	O
include	VBP	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	NN	O
disorders	NNS	O
,	,	O
mild	NN	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
Procedure	NN	O
:	:	O
Behavioral	JJ	O
screens	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
cohort	NN	O
of	IN	O
4	CD	O
wild	JJ	O
type	NN	O
,	,	O
4	CD	O
heterozygous	JJ	O
and	CC	O
8	CD	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
.	.	O
All	DT	O
behavioral	JJ	O
tests	NNS	O
were	VBD	O
done	VBN	O
between	IN	O
12	CD	O
and	CC	O
16	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
unless	IN	O
reduced	VBN	O
viability	NN	O
necessitates	NNS	O
earlier	RBR	O
testing	VBG	O
.	.	O
These	DT	O
tests	NNS	O
included	VBD	O
measurements	NNS	O
of	IN	O
circadian	JJ	O
rhythms	NN	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
functional	JJ	O
observational	JJ	O
battery	NN	O
(	(	O
FOB	NNP	O
)	)	O
to	TO	O
measure	VB	O
anxiety	NN	O
,	,	O
or	CC	O
activity	NN	O
levels	NNS	O
.	.	O
Circadian	JJ	O
Test	NNP	O
Description	NN	O
:	:	O
Female	JJ	O
mice	NNS	O
are	VBP	O
individually	RB	O
housed	VBN	O
at	IN	O
4	CD	O
pm	NN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
testing	VBG	O
in	IN	O
48.2	CD	O
cm×26.5	NN	O
cm	NN	O
home	NN	O
cages	NNS	O
and	CC	O
administered	VBN	O
food	NN	O
and	CC	O
water	NN	O
ad	NN	O
libitum	NN	O
.	.	O
Animals	NNS	O
are	VBP	O
exposed	VBN	O
to	TO	O
a	DT	O
12-hour	JJ	O
light/dark	NN	O
cycle	NN	O
with	IN	O
lights	NNS	O
turning	VBG	O
on	IN	O
at	IN	O
7	CD	O
am	VBP	O
and	CC	O
turning	VBG	O
off	RP	O
at	IN	O
7	CD	O
pm	NN	O
.	.	O
The	DT	O
system	NN	O
software	NN	O
records	VBZ	O
the	DT	O
number	NN	O
of	IN	O
beam	NN	O
interruptions	NNS	O
caused	VBN	O
by	IN	O
the	DT	O
animal	NN	O
's	POS	O
movements	NNS	O
,	,	O
with	IN	O
beam	NN	O
breaks	NNS	O
automatically	RB	O
divided	VBD	O
into	IN	O
ambulations	NNS	O
.	.	O
Activity	NN	O
is	VBZ	O
recorded	VBN	O
in	IN	O
60	CD	O
,	,	O
one-hour	JJ	O
intervals	NNS	O
during	IN	O
the	DT	O
three-day	JJ	O
test	NN	O
.	.	O
Data	NNP	O
generated	VBD	O
are	VBP	O
displayed	VBN	O
by	IN	O
median	JJ	O
activity	NN	O
levels	NNS	O
recorded	VBN	O
for	IN	O
each	DT	O
hour	NN	O
(	(	O
circadian	JJ	O
rhythm	NN	O
)	)	O
and	CC	O
median	JJ	O
total	NN	O
activity	NN	O
during	IN	O
each	DT	O
light/dark	NN	O
cycle	NN	O
(	(	O
locomotor	JJ	O
activity	NN	O
)	)	O
over	IN	O
the	DT	O
three-day	JJ	O
testing	NN	O
period	NN	O
.	.	O
Results	NNS	O
:	:	O
The	DT	O
female	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
exhibited	VBD	O
increased	JJ	O
ambulatory	NN	O
counts	NNS	O
during	IN	O
the	DT	O
12	CD	O
hour	NN	O
habituation	NN	O
and	CC	O
both	DT	O
dark	JJ	O
phases	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
and	CC	O
the	DT	O
historical	JJ	O
means	NNS	O
.	.	O
These	DT	O
results	NNS	O
are	VBP	O
indicative	JJ	O
of	IN	O
increased	JJ	O
anxiety	NN	O
of	IN	O
the	DT	O
(	(	O
−/−	NN	O
)	)	O
mutant	NN	O
mice	NN	O
.	.	O
Functional	NNP	O
Observational	NNP	O
Battery	NNP	O
(	(	O
FOB	NNP	O
)	)	O
Test	NN	O
:	:	O
Test	NN	O
Description	NN	O
The	DT	O
FOB	NNP	O
is	VBZ	O
a	DT	O
series	NN	O
of	IN	O
situations	NNS	O
applied	VBN	O
to	TO	O
the	DT	O
animal	NN	O
to	TO	O
determine	VB	O
gross	JJ	O
sensory	NN	O
and	CC	O
motor	NN	O
deficits	NNS	O
.	.	O
A	DT	O
subset	NN	O
of	IN	O
tests	NNS	O
from	IN	O
the	DT	O
Irwin	NNP	O
neurological	JJ	O
screen	NN	O
that	WDT	O
evaluates	VBZ	O
gross	JJ	O
neurological	JJ	O
function	NN	O
is	VBZ	O
used	VBN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
short-duration	NN	O
,	,	O
tactile	NN	O
,	,	O
olfactory	NN	O
,	,	O
and	CC	O
visual	JJ	O
stimuli	NNS	O
are	VBP	O
applied	VBN	O
to	TO	O
the	DT	O
animal	NN	O
to	TO	O
determine	VB	O
their	PRP$	O
ability	NN	O
to	TO	O
detect	VB	O
and	CC	O
respond	VB	O
normally	RB	O
.	.	O
These	DT	O
simple	JJ	O
tests	NNS	O
take	VBP	O
approximately	RB	O
10	CD	O
minutes	NNS	O
and	CC	O
the	DT	O
mouse	NN	O
is	VBZ	O
returned	VBN	O
to	TO	O
its	PRP$	O
home	NN	O
cage	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
testing	VBG	O
.	.	O
Results	NNS	O
:	:	O
Whiskers	NNS	O
were	VBD	O
absent	VBN	O
on	IN	O
most	JJS	O
homozygotes	NNS	O
with	IN	O
bald	JJ	O
patches	NNS	O
on	IN	O
the	DT	O
snout	NN	O
.	.	O
This	DT	O
finding	NN	O
is	VBZ	O
indicative	JJ	O
of	IN	O
an	DT	O
increased	VBN	O
anxiety	NN	O
level	NN	O
of	IN	O
the	DT	O
mutant	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
negative	JJ	O
phenotype	NN	O
of	IN	O
alopecia	NN	O
(	(	O
baldness	NN	O
)	)	O
was	VBD	O
observed	VBN	O
.	.	O
Thus	RB	O
,	,	O
antagonists	NNS	O
to	TO	O
PRO4342	NNP	O
would	MD	O
be	VB	O
a	DT	O
causative	JJ	O
factor	NN	O
for	IN	O
alopecia	NN	O
(	(	O
baldness	NN	O
)	)	O
.	.	O
In	IN	O
this	DT	O
regard	NN	O
,	,	O
PRO4342	NNP	O
or	CC	O
agonists	NNS	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
balding	NN	O
or	CC	O
premature	JJ	O
hair	NN	O
loss	NN	O
.	.	O
In	IN	O
summary	JJ	O
,	,	O
both	PDT	O
the	DT	O
circadian	JJ	O
rhythm	NN	O
testing	NN	O
and	CC	O
functional	JJ	O
observational	JJ	O
battery	NN	O
tests	NNS	O
indicated	VBD	O
an	DT	O
increased	VBN	O
anxiety	NN	O
behavior	NN	O
pattern	NN	O
for	IN	O
the	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
.	.	O
Thus	RB	O
,	,	O
knockout	IN	O
mice	RB	O
demonstrated	VBD	O
a	DT	O
phenotype	JJ	O
consistent	NN	O
with	IN	O
“	NNP	O
anxiety	NN	O
disorders	NNS	O
”	VBP	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
or	CC	O
cyclothymic	JJ	O
disorder	NN	O
.	.	O
In	IN	O
view	NN	O
of	IN	O
these	DT	O
findings	NNS	O
,	,	O
PRO4342	NNP	O
or	CC	O
agonists	NNS	O
thereof	RP	O
would	MD	O
be	VB	O
useful	JJ	O
for	IN	O
treating	VBG	O
such	JJ	O
neurological	JJ	O
anxiety	NN	O
disorders	NNS	O
.	.	O
(	(	O
c	NN	O
)	)	O
Pathology	NNP	O
Microscopic	NNP	O
observations	NNS	O
on	IN	O
the	DT	O
two	CD	O
male	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
examined	VBD	O
exhibited	VBD	O
a	DT	O
moderate	JJ	O
degeneration	NN	O
of	IN	O
the	DT	O
seminiferous	JJ	O
tubules	NNS	O
.	.	O
This	DT	O
negative	JJ	O
phenotype	NN	O
suggests	VBZ	O
that	IN	O
antagonists	NNS	O
to	TO	O
PRO4342	NNP	O
may	MD	O
lead	VB	O
to	TO	O
reproductive	JJ	O
disorders	NNS	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
PRO4342	NNP	O
or	CC	O
agonists	NNS	O
thereof	RP	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
prevention	NN	O
or	CC	O
treatment	NN	O
of	IN	O
such	JJ	O
reproductive	JJ	O
disorders	NNS	O
.	.	O
F.	NNP	O
Generation	NNP	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA108809	NNP	O
(	(	O
UNQ2964	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO7423	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA108809	NNP	O
(	(	O
UNQ2964	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
AJ245857	NNP	O
or	CC	O
Mus	NNP	O
musculus	CC	O
mRNA	NN	O
for	IN	O
carbonic	JJ	O
anhydrase	NN	O
(	(	O
MN/CA9	NNP	O
gene	NN	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—647466	NN	O
or	CC	O
carbonic	JJ	O
anhydrase	NN	O
9	CD	O
[	NN	O
Mus	NNP	O
musculus	CC	O
]	NNP	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
BC014950	NNP	O
or	CC	O
Homo	NNP	O
sapiens	NNS	O
,	,	O
carbonic	JJ	O
anhydrase	NN	O
IX	NNP	O
,	,	O
clone	NN	O
MGC:22967	NNP	O
IMAGE:4865275	NNP	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—001207	NN	O
or	CC	O
carbonic	JJ	O
anhydrase	NN	O
IX	NNP	O
precursor	NN	O
;	:	O
RCC-associated	JJ	O
protein	NN	O
G250	NNP	O
;	:	O
carbonic	JJ	O
dehydratase	NN	O
[	NNP	O
Homo	NNP	O
sapiens	VBZ	O
]	NNP	O
.	.	O
Mutation	NNP	O
type	NN	O
corresponds	NNS	O
to	TO	O
Homologous	NNP	O
Recombination	NNP	O
(	(	O
standard	NN	O
)	)	O
.	.	O
Coding	VBG	O
exons	NNS	O
1	CD	O
through	IN	O
6	CD	O
were	VBD	O
targeted	VBN	O
(	(	O
NM—139305	NNP	O
)	)	O
.	.	O
The	DT	O
disrupted	VBN	O
mouse	NN	O
gene	NN	O
is	VBZ	O
carbonic	JJ	O
anhydrase	NN	O
9	CD	O
(	(	O
Car9	NNP	O
)	)	O
,	,	O
ortholog	NN	O
of	IN	O
human	JJ	O
carbonic	JJ	O
anhydrase	NN	O
9	CD	O
(	(	O
CA9	NNP	O
)	)	O
.	.	O
Aliases	NNS	O
include	VBP	O
CAIX	NNP	O
,	,	O
MN/CA9	NNP	O
,	,	O
MN	NNP	O
,	,	O
membrane	NN	O
antigen	NN	O
MN	NNP	O
,	,	O
carbonic	JJ	O
dehydratase	NN	O
,	,	O
and	CC	O
RCC-associated	JJ	O
protein	NN	O
G250	NNP	O
.	.	O
Carbonic	JJ	O
anhydrases	NNS	O
(	(	O
CAs	NNP	O
)	)	O
are	VBP	O
a	DT	O
large	JJ	O
group	NN	O
of	IN	O
enzymes	NNS	O
involved	VBN	O
in	IN	O
numerous	JJ	O
physiological	JJ	O
functions	NNS	O
such	JJ	O
as	IN	O
respiration	NN	O
,	,	O
bone	NN	O
resorption	NN	O
,	,	O
and	CC	O
the	DT	O
formation	NN	O
of	IN	O
saliva	NN	O
,	,	O
etc	FW	O
.	.	O
Three	CD	O
major	JJ	O
families	NNS	O
of	IN	O
CAs	NNP	O
are	VBP	O
known	VBN	O
;	:	O
alpha	NN	O
,	,	O
beta	NN	O
,	,	O
and	CC	O
gamma	NN	O
CA9	NNP	O
,	,	O
an	DT	O
alpha	JJ	O
family	NN	O
member	NN	O
,	,	O
binds	VBZ	O
zinc	NN	O
and	CC	O
DNA	NNP	O
,	,	O
and	CC	O
has	VBZ	O
some	DT	O
similarity	NN	O
with	IN	O
transcription	NN	O
factors	NNS	O
(	(	O
Pastorek	NNP	B
et	RB	I
al	RB	I
,	,	I
Oncogene	NNP	I
9	CD	I
(	(	I
10	CD	I
)	)	I
:2877-88	NN	I
(	(	I
1994	CD	I
)	)	I
)	)	O
.	.	O
CA9	NNP	O
expression	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
marker	NN	O
for	IN	O
certain	JJ	O
aggressive	JJ	O
tumors	NNS	O
(	(	O
Potter	NNP	B
and	CC	I
Harris	NNP	I
,	,	I
Br	NNP	I
J	NNP	I
Cancer	NNP	I
89	CD	I
(	(	I
1	CD	I
)	)	I
:2-7	NN	I
(	(	I
2003	CD	I
)	)	I
,	,	O
and	CC	O
its	PRP$	O
expression	NN	O
is	VBZ	O
induced	VBN	O
by	IN	O
hypoxia	NN	O
(	(	O
Olive	JJ	B
et	NN	I
al	NN	I
,	,	I
Cancer	NNP	I
Res	NNP	I
61	CD	I
(	(	I
24	CD	I
)	)	I
:8924-9	NN	I
(	(	I
2001	CD	I
)	)	I
)	)	O
.	.	O
CA9	NNP	O
is	VBZ	O
reported	VBN	O
to	TO	O
reside	VB	O
in	IN	O
the	DT	O
plasma	NN	O
membrane	NN	O
,	,	O
cytoplasm	NN	O
or	CC	O
extracellular	JJ	O
spaces	NNS	O
(	(	O
Ivanov	NNP	B
et	RB	I
al	RB	I
,	,	I
Am	NNP	I
J	NNP	I
Pathol	NNP	I
158	CD	I
(	(	I
3	CD	I
)	)	I
:905-19	NN	I
(	(	I
2001	CD	I
)	)	I
;	:	O
Zavada	NNP	B
et	FW	I
al.	NN	I
,	,	I
Br	NNP	I
J	NNP	I
Cancer	NNP	I
89	CD	I
(	(	I
6	CD	I
)	)	I
:1067-71	NN	I
(	(	I
2003	CD	I
)	)	I
)	)	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
progeny	NN	O
.	.	O
On	IN	O
rare	JJ	O
occasions	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
very	RB	O
few	JJ	O
F1	NNP	O
mice	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
chimera	NN	O
,	,	O
F1	NNP	O
heterozygous	JJ	O
mice	NNS	O
were	VBD	O
crossed	VBN	O
to	TO	O
129SvEvBrd/C57	CD	O
hybrid	JJ	O
mice	NN	O
to	TO	O
yield	VB	O
additional	JJ	O
heterozygous	JJ	O
animals	NNS	O
for	IN	O
the	DT	O
intercross	NN	O
to	TO	O
generate	VB	O
the	DT	O
F2	NNP	O
mice	NN	O
.	.	O
In	IN	O
the	DT	O
wild-type	JJ	O
animals	NNS	O
,	,	O
expression	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
and	CC	O
in	IN	O
all	DT	O
13	CD	O
adult	NN	O
tissues	NNS	O
samples	NNS	O
tested	VBN	O
by	IN	O
RT-PCR	NNP	O
,	,	O
except	IN	O
thymus	NN	O
,	,	O
liver	RB	O
,	,	O
testis	NN	O
,	,	O
bone	NN	O
,	,	O
heart	NN	O
,	,	O
adipose	RB	O
,	,	O
and	CC	O
blood	NN	O
.	.	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
1	CD	O
.	.	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
Disrupted	VBN	O
Gene	NNP	O
:	:	O
DNA108809	NNP	O
(	(	O
UNQ2964	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
The	DT	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
exhibited	VBD	O
an	DT	O
increased	VBN	O
ability	NN	O
to	TO	O
respond	VB	O
to	TO	O
an	DT	O
inflammatory	JJ	O
response	NN	O
after	IN	O
a	DT	O
zymosan	JJ	O
challenge	NN	O
.	.	O
(	(	O
b	NN	O
)	)	O
Immunology	NNP	O
Phenotypic	NNP	O
Analysis	NNP	O
Immune	NNP	O
related	VBN	O
and	CC	O
inflammatory	JJ	O
diseases	NNS	O
are	VBP	O
the	DT	O
manifestation	NN	O
or	CC	O
consequence	NN	O
of	IN	O
fairly	RB	O
complex	JJ	O
,	,	O
often	RB	O
multiple	JJ	O
interconnected	JJ	O
biological	NN	O
pathways	NNS	O
which	WDT	O
in	IN	O
normal	JJ	O
physiology	NN	O
are	VBP	O
critical	JJ	O
to	TO	O
respond	VB	O
to	TO	O
insult	VB	O
or	CC	O
injury	VB	O
,	,	O
initiate	VB	O
repair	NN	O
from	IN	O
insult	NN	O
or	CC	O
injury	NN	O
,	,	O
and	CC	O
mount	VB	O
innate	NN	O
and	CC	O
acquired	VBD	O
defense	NN	O
against	IN	O
foreign	JJ	O
organisms	NNS	O
.	.	O
Disease	NNP	O
or	CC	O
pathology	NN	O
occurs	NNS	O
when	WRB	O
these	DT	O
normal	JJ	O
physiological	JJ	O
pathways	NNS	O
cause	VBP	O
additional	JJ	O
insult	NN	O
or	CC	O
injury	NN	O
either	CC	O
as	IN	O
directly	RB	O
related	VBN	O
to	TO	O
the	DT	O
intensity	NN	O
of	IN	O
the	DT	O
response	NN	O
,	,	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
abnormal	JJ	O
regulation	NN	O
or	CC	O
excessive	JJ	O
stimulation	NN	O
,	,	O
as	IN	O
a	DT	O
reaction	NN	O
to	TO	O
self	VB	O
,	,	O
or	CC	O
as	IN	O
a	DT	O
combination	NN	O
of	IN	O
these	DT	O
.	.	O
Though	IN	O
the	DT	O
genesis	NN	O
of	IN	O
these	DT	O
diseases	NNS	O
often	RB	O
involves	VBZ	O
multistep	NNS	O
pathways	NNS	O
and	CC	O
often	RB	O
multiple	JJ	O
different	JJ	O
biological	JJ	O
systems/pathways	NNS	O
,	,	O
intervention	NN	O
at	IN	O
critical	JJ	O
points	NNS	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
these	DT	O
pathways	NNS	O
can	MD	O
have	VB	O
an	DT	O
ameliorative	JJ	O
or	CC	O
therapeutic	JJ	O
effect	NN	O
.	.	O
Therapeutic	JJ	O
intervention	NN	O
can	MD	O
occur	VB	O
by	IN	O
either	DT	O
antagonism	NN	O
of	IN	O
a	DT	O
detrimental	JJ	O
process/pathway	NN	O
or	CC	O
stimulation	NN	O
of	IN	O
a	DT	O
beneficial	JJ	O
process/pathway	NN	O
.	.	O
T	NNP	O
lymphocytes	VBZ	O
(	(	O
T	NNP	O
cells	NNS	O
)	)	O
are	VBP	O
an	DT	O
important	JJ	O
component	NN	O
of	IN	O
a	DT	O
mammalian	JJ	O
immune	NN	O
response	NN	O
.	.	O
T	NNP	O
cells	NNS	O
recognize	VBP	O
antigens	NNS	O
which	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
self-molecule	NN	O
encoded	VBN	O
by	IN	O
genes	NNS	O
within	IN	O
the	DT	O
major	JJ	O
histocompatibility	NN	O
complex	NN	O
(	(	O
MHC	NNP	O
)	)	O
.	.	O
The	DT	O
antigen	NN	O
may	MD	O
be	VB	O
displayed	VBN	O
together	RB	O
with	IN	O
MHC	NNP	O
molecules	NNS	O
on	IN	O
the	DT	O
surface	NN	O
of	IN	O
antigen	NN	O
presenting	VBG	O
cells	NNS	O
,	,	O
virus	NN	O
infected	VBD	O
cells	NNS	O
,	,	O
cancer	NN	O
cells	NNS	O
,	,	O
grafts	NNS	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
T	NNP	O
cell	NN	O
system	NN	O
eliminates	VBZ	O
these	DT	O
altered	JJ	O
cells	NNS	O
which	WDT	O
pose	VBP	O
a	DT	O
health	NN	O
threat	NN	O
to	TO	O
the	DT	O
host	NN	O
mammal	JJ	O
T	NNP	O
cells	NNS	O
include	VBP	O
helper	JJ	O
T	NNP	O
cells	NNS	O
and	CC	O
cytotoxic	NN	O
T	NNP	O
cells	NNS	O
.	.	O
Helper	NNP	O
T	NNP	O
cells	NNS	O
proliferate	VBP	O
extensively	RB	O
following	VBG	O
recognition	NN	O
of	IN	O
an	DT	O
antigen-MHC	JJ	O
complex	NN	O
on	IN	O
an	DT	O
antigen	NN	O
presenting	NN	O
cell	NN	O
.	.	O
Helper	NNP	O
T	NNP	O
cells	NNS	O
also	RB	O
secrete	VBP	O
a	DT	O
variety	NN	O
of	IN	O
cytokines	NNS	O
,	,	O
i.e.	FW	O
,	,	O
lymphokines	NNS	O
,	,	O
which	WDT	O
play	VBP	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
the	DT	O
activation	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
,	,	O
cytotoxic	NN	O
T	NNP	O
cells	NNS	O
and	CC	O
a	DT	O
variety	NN	O
of	IN	O
other	JJ	O
cells	NNS	O
which	WDT	O
participate	VBP	O
in	IN	O
the	DT	O
immune	JJ	O
response	NN	O
.	.	O
In	IN	O
many	JJ	O
immune	JJ	O
responses	NNS	O
,	,	O
inflammatory	JJ	O
cells	NNS	O
infiltrate	VBP	O
the	DT	O
site	NN	O
of	IN	O
injury	NN	O
or	CC	O
infection	NN	O
.	.	O
The	DT	O
migrating	NN	O
cells	NNS	O
may	MD	O
be	VB	O
neutrophilic	JJ	O
,	,	O
eosinophilic	JJ	O
,	,	O
monocytic	JJ	O
or	CC	O
lymphocytic	JJ	O
as	IN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
histologic	JJ	O
examination	NN	O
of	IN	O
the	DT	O
affected	JJ	O
tissues	NNS	O
.	.	O
Current	JJ	B
Protocols	NNP	I
in	IN	I
Immunology	NNP	I
,	,	I
ed	NN	I
.	.	I
John	NNP	I
E.	NNP	I
Coligan	NNP	I
,	,	I
1994	CD	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc	NNP	I
.	.	O
Many	JJ	O
immune	NNS	O
related	JJ	O
diseases	NNS	O
are	VBP	O
known	VBN	O
and	CC	O
have	VBP	O
been	VBN	O
extensively	RB	O
studied	VBN	O
.	.	O
Such	JJ	O
diseases	NNS	O
include	VBP	O
immune-mediated	JJ	O
inflammatory	JJ	O
diseases	NNS	O
(	(	O
such	JJ	O
as	IN	O
rheumatoid	JJ	O
arthritis	NN	O
,	,	O
immune	NN	O
mediated	VBD	O
renal	JJ	O
disease	NN	O
,	,	O
hepatobiliary	JJ	O
diseases	NNS	O
,	,	O
inflammatory	NN	O
bowel	NN	O
disease	NN	O
(	(	O
IBD	NNP	O
)	)	O
,	,	O
psoriasis	NN	O
,	,	O
and	CC	O
asthma	NN	O
)	)	O
,	,	O
non-immune-mediated	JJ	O
inflammatory	NN	O
diseases	NNS	O
,	,	O
infectious	JJ	O
diseases	NNS	O
,	,	O
immunodeficiency	NN	O
diseases	NNS	O
,	,	O
neoplasia	NN	O
,	,	O
and	CC	O
graft	NN	O
rejection	NN	O
,	,	O
etc	FW	O
.	.	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
immunology	NN	O
,	,	O
targets	NNS	O
were	VBD	O
identified	VBN	O
herein	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
inflammation	NN	O
and	CC	O
inflammatory	NN	O
disorders	NNS	O
.	.	O
Immune	NNP	O
related	JJ	O
diseases	NNS	O
could	MD	O
be	VB	O
treated	VBN	O
by	IN	O
suppressing	VBG	O
the	DT	O
immune	JJ	O
response	NN	O
.	.	O
Using	VBG	O
neutralizing	VBG	O
antibodies	NNS	O
that	WDT	O
inhibit	VBP	O
molecules	NNS	O
having	VBG	O
immune	JJ	O
stimulatory	JJ	O
activity	NN	O
would	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
immune-mediated	JJ	O
and	CC	O
inflammatory	JJ	O
diseases	NNS	O
.	.	O
Molecules	NNS	O
which	WDT	O
inhibit	VBP	O
the	DT	O
immune	JJ	O
response	NN	O
can	MD	O
be	VB	O
utilized	VBN	O
(	(	O
proteins	NNS	O
directly	RB	O
or	CC	O
via	IN	O
the	DT	O
use	NN	O
of	IN	O
antibody	NN	O
agonists	NNS	O
)	)	O
to	TO	O
inhibit	VB	O
the	DT	O
immune	JJ	O
response	NN	O
and	CC	O
thus	RB	O
ameliorate	VB	O
immune	NN	O
related	JJ	O
disease	NN	O
.	.	O
The	DT	O
following	JJ	O
test	NN	O
was	VBD	O
performed	VBN	O
:	:	O
Zymosan	JJ	O
Challenge	NNP	O
Assay—Peritoneal	NNP	O
Inflammation	NNP	O
:	:	O
Procedure	NN	O
:	:	O
A	DT	O
cohort	NN	O
of	IN	O
1	CD	O
wild	JJ	O
type	NN	O
and	CC	O
2	CD	O
homozygous	JJ	O
mutants	NNS	O
were	VBD	O
used	VBN	O
in	IN	O
this	DT	O
assay	NN	O
.	.	O
Peritoneal	NNP	O
leukocyte	JJ	O
recruitment	NN	O
assays	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
identify	VB	O
targets	NNS	O
that	WDT	O
may	MD	O
regulate	VB	O
the	DT	O
inflammatory	JJ	O
component	NN	O
of	IN	O
atherosclerosis	NN	O
.	.	O
These	DT	O
assays	NNS	O
detect	VBP	O
abnormalities	NNS	O
in	IN	O
immune	NN	O
cell	NN	O
recruitment	NN	O
to	TO	O
a	DT	O
site	NN	O
of	IN	O
inflammation	NN	O
.	.	O
Zymosan	NNP	O
(	(	O
an	DT	O
agent	NN	O
which	WDT	O
induces	VBZ	O
inflammation	NN	O
)	)	O
was	VBD	O
injected	VBN	O
into	IN	O
the	DT	O
intraperitoneal	JJ	O
cavity	NN	O
and	CC	O
fluid	NN	O
was	VBD	O
later	RB	O
removed	VBN	O
and	CC	O
measurements	NNS	O
were	VBD	O
taken	VBN	O
of	IN	O
total	JJ	O
WBC	NNP	O
counts	NNS	O
,	,	O
neutrophil/monocyte	JJ	O
ratio	NN	O
and	CC	O
percent	NN	O
granulocytes	NNS	O
,	,	O
monocytes	NNS	O
,	,	O
lymphocytes	NNS	O
and	CC	O
eosinophils	NNS	O
in	IN	O
the	DT	O
ip	NN	O
fluid	NN	O
.	.	O
Results	NNS	O
:	:	O
The	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
exhibited	VBD	O
a	DT	O
notably	RB	O
increased	JJ	O
total	JJ	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
after	IN	O
zymosan	JJ	O
challenge	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
(	(	O
+/+	NN	O
)	)	O
littermate	NN	O
and	CC	O
the	DT	O
historical	JJ	O
range	NN	O
,	,	O
suggestive	NN	O
of	IN	O
an	DT	O
increased	VBN	O
response	NN	O
to	TO	O
an	DT	O
inflammatory	JJ	O
stimulus	NN	O
in	IN	O
these	DT	O
mutants	NNS	O
.	.	O
In	IN	O
summary	JJ	O
,	,	O
the	DT	O
zymosan	NN	O
challenge	NN	O
studies	NNS	O
indicate	VBP	O
that	IN	O
knockout	NN	O
mice	NN	O
deficient	NN	O
in	IN	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO7423	NNP	O
polypeptides	NNS	O
exhibit	VBP	O
a	DT	O
proinflammatory	NN	O
response	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
wild-type	JJ	O
littermates	NNS	O
.	.	O
Thus	RB	O
,	,	O
antagonists	NNS	O
of	IN	O
PRO7423	NNP	O
polypeptides	NNS	O
would	MD	O
stimulate	VB	O
the	DT	O
immune	NN	O
system	NN	O
(	(	O
such	JJ	O
as	IN	O
T	NNP	O
cell	NN	O
proliferation	NN	O
)	)	O
and	CC	O
would	MD	O
find	VB	O
utility	NN	O
in	IN	O
the	DT	O
cases	NNS	O
wherein	VBP	O
this	DT	O
effect	NN	O
would	MD	O
be	VB	O
beneficial	JJ	O
to	TO	O
the	DT	O
individual	NN	O
such	JJ	O
as	IN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
leukemia	NN	O
,	,	O
and	CC	O
other	JJ	O
types	NNS	O
of	IN	O
cancer	NN	O
,	,	O
and	CC	O
in	IN	O
immunocompromised	JJ	O
patients	NNS	O
,	,	O
such	JJ	O
as	IN	O
AIDS	NNP	O
sufferers	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
PRO7423	NNP	O
polypeptides	VBZ	O
or	CC	O
agonists	NNS	O
thereto	NN	O
would	MD	O
inhibit	VB	O
the	DT	O
immune	JJ	O
response	NN	O
and	CC	O
would	MD	O
be	VB	O
useful	JJ	O
candidates	NNS	O
for	IN	O
suppressing	VBG	O
harmful	JJ	O
immune	JJ	O
responses	NNS	O
,	,	O
e.g	NN	O
.	.	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
graft	NN	O
rejection	NN	O
or	CC	O
graft-versus-host	NN	O
diseases	NNS	O
.	.	O
G.	NNP	O
Generation	NNP	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA125185-2806	NNP	O
(	(	O
UNQ3099	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO10096	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA125185-2806	NNP	O
(	(	O
UNQ3099	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
NM—016971	NN	O
or	CC	O
Mus	NNP	O
musculus	CC	O
interleukin	JJ	O
22	CD	O
(	(	O
Il122	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—058667	NN	O
or	CC	O
interleukin	JJ	O
22	CD	O
;	:	O
interleukin	JJ	O
10-related	JJ	O
T	NNP	O
cell-derived	JJ	O
inducible	JJ	O
factor	NN	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
NM—020525	NN	O
or	CC	O
Homo	NN	O
sapiens	NNS	O
interleukin	VBP	O
22	CD	O
(	(	O
IL22	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—065386	NN	O
or	CC	O
IL-10-related	JJ	O
T-cell-derived	JJ	O
inducible	JJ	O
factor	NN	O
;	:	O
interleukin	CC	O
21	CD	O
[	JJ	O
Homo	NNP	O
sapiens	VBZ	O
]	NNP	O
.	.	O
Mutation	NNP	O
type	NN	O
corresponds	NNS	O
to	TO	O
Homologous	NNP	O
Recombination	NNP	O
(	(	O
conditional	JJ	O
)	)	O
.	.	O
Coding	VBG	O
exons	NNS	O
1	CD	O
through	IN	O
4	CD	O
were	VBD	O
targeted	VBN	O
(	(	O
NM—016971	NNP	O
)	)	O
.	.	O
The	DT	O
gene	NN	O
of	IN	O
interest	NN	O
is	VBZ	O
interleukin	JJ	O
22	CD	O
(	(	O
IL22	NNP	O
)	)	O
,	,	O
ortholog	NN	O
of	IN	O
human	JJ	O
IL22	NNP	O
.	.	O
Aliases	NNS	O
include	VBP	O
IL-22	NNP	O
,	,	O
ILtif	NNP	O
,	,	O
IL-TIF	NNP	O
,	,	O
interleukin	JJ	O
10-related	JJ	O
T	NNP	O
cell-derived	JJ	O
inducible	JJ	O
factor	NN	O
,	,	O
interleukin	JJ	O
21	CD	O
,	,	O
IL21	NNP	O
,	,	O
TIFa	NNP	O
,	,	O
IL-21	NNP	O
,	,	O
ILTIF	NNP	O
,	,	O
IL-IL-D110	NNP	O
,	,	O
zcytol8	NN	O
,	,	O
and	CC	O
TIFIL-23	NNP	O
.	.	O
IL22	NNP	O
,	,	O
a	DT	O
homolog	NN	O
of	IN	O
IL-10	NNP	O
,	,	O
is	VBZ	O
a	DT	O
cytokine	NN	O
that	WDT	O
binds	VBZ	O
to	TO	O
and	CC	O
signals	NNS	O
through	IN	O
the	DT	O
class	NN	O
II	NNP	O
cytokine	NN	O
receptor	NN	O
heterodimer	VBD	O
IL-22RA1/CRF2-4	NNP	O
(	(	O
Xu	NNP	B
et	RB	I
al	RB	I
,	,	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
98	CD	I
(	(	I
17	CD	I
)	)	I
:9511-6	NN	I
(	(	I
2001	CD	I
)	)	I
)	)	O
.	.	O
IL22	NNP	O
triggers	NNS	O
all	DT	O
three	CD	O
major	JJ	O
mitogen-activated	JJ	O
protein	NN	O
kinase	NN	O
pathways	NNS	O
(	(	O
Lejeune	NNP	B
et	RB	I
al	RB	I
,	,	I
J	NNP	I
Biol	NNP	I
Chem	NNP	I
277	CD	I
(	(	I
37	CD	I
)	)	I
:33676-82	NN	I
(	(	I
2002	CD	I
)	)	I
)	)	O
,	,	O
activating	VBG	O
signal	JJ	O
transducer	NN	O
and	CC	O
activator	NN	O
of	IN	O
transcription	NN	O
(	(	O
STAT	NNP	O
)	)	O
1	CD	O
STAT3	NNP	O
,	,	O
and	CC	O
STAT5	NNP	O
(	(	O
Xie	NNP	B
et	RB	I
al	RB	I
,	,	I
J	NNP	I
Biol	NNP	I
Chem	NNP	I
275	CD	I
(	(	I
40	CD	I
)	)	I
:31335-9	NN	I
(	(	I
2000	CD	I
)	)	I
)	)	O
.	.	O
T	NNP	O
cells	NNS	O
and	CC	O
mast	NN	O
cells	NNS	O
produce	VBP	O
IL22	NNP	O
to	TO	O
induce	VB	O
acute-phase	JJ	O
reactants	NNS	O
in	IN	O
other	JJ	O
tissues	NNS	O
,	,	O
suggesting	VBG	O
IL22	NNP	O
is	VBZ	O
involved	VBN	O
in	IN	O
inflammation	NN	O
(	(	O
Xu	NNP	B
et	RB	I
al	RB	I
,	,	I
2001	CD	I
supra	NN	I
)	)	O
.	.	O
Moreover	RB	O
,	,	O
IL22	NNP	O
modulates	VBZ	O
IL-4	JJ	O
production	NN	O
from	IN	O
Th2T	NNP	O
cells	NNS	O
(	(	O
Xie	NNP	B
et	RB	I
al	RB	I
,	,	I
2000	CD	I
supra	NN	I
)	)	O
.	.	O
The	DT	O
cytokine	NN	O
receptor	NN	O
IL22RA2	NNP	O
is	VBZ	O
a	DT	O
naturally	RB	O
occurring	VBG	O
antagonist	NN	O
of	IN	O
IL22	NNP	O
and	CC	O
may	MD	O
be	VB	O
an	DT	O
important	JJ	O
regulator	NN	O
of	IN	O
IL22	NNP	O
in	IN	O
the	DT	O
immune	JJ	O
response	NN	O
(	(	O
Xu	NNP	B
et	RB	I
al	RB	I
,	,	I
2001	CD	I
supra	NN	I
)	)	O
.	.	O
The	DT	O
interleukin	JJ	O
10	CD	O
family	NN	O
of	IN	O
cytokines	NNS	O
have	VBP	O
been	VBN	O
the	DT	O
subject	NN	O
of	IN	O
several	JJ	O
reviews	NNS	O
(	(	O
Wolk	NNP	B
et	RB	I
al.	RB	I
,	,	I
J	NNP	I
Immunol	NNP	I
168	CD	I
(	(	I
11	CD	I
)	)	I
:5397-402	NN	I
(	(	I
2002	CD	I
)	)	I
;	:	O
Kotenko	NNP	B
,	,	I
S.	NNP	I
V.	NNP	I
,	,	I
Cytokine	NNP	I
Growth	NNP	I
Factor	NNP	I
Rev	NNP	I
13	CD	I
(	(	I
3	CD	I
)	)	I
:223-40	NN	I
(	(	I
2003	CD	I
)	)	I
;	:	O
Conti	NNP	B
et	FW	I
al.	NN	I
,	,	I
Immunol	NNP	I
Lett	NNP	I
88	CD	I
(	(	I
3	CD	I
)	)	I
:171-4	NN	I
(	(	I
2003	CD	I
)	)	I
)	)	O
and	CC	O
a	DT	O
crystal	JJ	O
structure	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
for	IN	O
IL22	NNP	O
(	(	O
Nagem	NNP	B
et	RB	I
al.	RB	I
,	,	I
Structure	NNP	I
(	(	I
Camb	NNP	I
)	)	I
10	CD	I
(	(	I
8	CD	I
)	)	I
:1051-62	NN	I
(	(	I
2002	CD	I
)	)	I
)	)	O
.	.	O
Interpreting	VBG	O
the	DT	O
literature	NN	O
is	VBZ	O
done	VBN	O
with	IN	O
caution	NN	O
because	IN	O
two	CD	O
of	IN	O
the	DT	O
aliases	NNS	O
encountered	VBD	O
for	IN	O
IL22	NNP	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
refer	VB	O
to	TO	O
other	JJ	O
genes	NNS	O
;	:	O
IL-21	NNP	O
is	VBZ	O
an	DT	O
synonym	NN	O
for	IN	O
interleukin	JJ	O
21	CD	O
(	(	O
LocusLink	NNP	O
50616	CD	O
)	)	O
,	,	O
and	CC	O
IL-22	NNP	O
is	VBZ	O
an	DT	O
alias	NN	O
for	IN	O
interleukin	JJ	O
17D	CD	O
(	(	O
LocusLink	NNP	O
53342	CD	O
)	)	O
.	.	O
Current	JJ	O
knowledge	NN	O
of	IN	O
IL-22	NNP	O
suggests	VBZ	O
it	PRP	O
can	MD	O
induce	VB	O
a	DT	O
variety	NN	O
of	IN	O
“	NNP	O
acute	JJ	O
phase	NN	O
”	NNP	O
proteins	VBZ	O
including	VBG	O
serum	JJ	O
amyloid	NN	O
A	NNP	O
,	,	O
PAP1	NNP	O
,	,	O
osteopontin	NN	O
,	,	O
alpha1-antichymotrypsin	NN	O
,	,	O
and	CC	O
haptoglobin	NN	O
,	,	O
and	CC	O
S100A8	NNP	O
,	,	O
MMP-3	NNP	O
,	,	O
and	CC	O
mucins	NNS	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
are	VBP	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
are	VBP	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
are	VBP	O
crossed	VBN	O
to	TO	O
hybrid	VB	O
129SvEvBrd/C57	CD	O
Cre	NNP	O
homozygous	JJ	O
mice	NN	O
to	TO	O
generate	VB	O
mice	NN	O
carrying	VBG	O
both	CC	O
the	DT	O
mutant	NN	O
and	CC	O
Cre	NNP	O
alleles	NNS	O
(	(	O
compound	NN	O
heterozygous	JJ	O
mice	NN	O
)	)	O
.	.	O
The	DT	O
male	NN	O
compound	NN	O
heterozygous	JJ	O
mice	NNS	O
are	VBP	O
then	RB	O
crossed	VBN	O
to	TO	O
hybrid	VB	O
129SvEvBrd/C57	CD	O
F1	NNP	O
mice	NN	O
,	,	O
derived	VBN	O
from	IN	O
crossing	VBG	O
129SvEvBrd	CD	O
mice	NN	O
to	TO	O
C57BL/6J	NNP	O
mice	NN	O
,	,	O
to	TO	O
generate	VB	O
heterozygous	JJ	O
Cre-excised	JJ	O
animals	NNS	O
.	.	O
Finally	RB	O
,	,	O
these	DT	O
progeny	NNS	O
are	VBP	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
wild-type	JJ	O
,	,	O
Cre-excised	JJ	O
heterozygous	JJ	O
,	,	O
and	CC	O
Cre-excised	JJ	O
homozygous	JJ	O
mice	NN	O
.	.	O
Level	NN	O
I	PRP	O
phenotypic	VBP	O
analysis	NN	O
is	VBZ	O
performed	VBN	O
on	IN	O
mice	NN	O
from	IN	O
this	DT	O
generation	NN	O
.	.	O
1	CD	O
.	.	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
disrupted	VBN	O
gene	NN	O
:	:	O
DNA125185-2806	NNP	O
(	(	O
UNQ3099	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
:	:	O
Mutation	NN	O
of	IN	O
the	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
ortholog	NN	O
of	IN	O
human	JJ	O
interleukin	FW	O
22	CD	O
(	(	O
IL22	NNP	O
)	)	O
resulted	VBD	O
in	IN	O
anxiety-related	JJ	O
phenotypes	NNS	O
and	CC	O
an	DT	O
abnormal	JJ	O
exploratory	NN	O
response	NN	O
in	IN	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
.	.	O
Females	NNS	O
showed	VBD	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
in	IN	O
open	JJ	O
field	NN	O
testing	VBG	O
.	.	O
The	DT	O
(	(	O
−/−	NN	O
)	)	O
mice	NN	O
also	RB	O
exhibited	VBD	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
CD4	NNP	O
cells	NNS	O
and	CC	O
a	DT	O
decreased	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
the	DT	O
peripheral	JJ	O
blood	NN	O
.	.	O
Gene	NNP	O
disruption	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
blot	NN	O
.	.	O
(	(	O
b	NN	O
)	)	O
Immunology	NNP	O
Phenotypic	NNP	O
Analysis	NNP	O
Immune	NNP	O
related	VBN	O
and	CC	O
inflammatory	JJ	O
diseases	NNS	O
are	VBP	O
the	DT	O
manifestation	NN	O
or	CC	O
consequence	NN	O
of	IN	O
fairly	RB	O
complex	JJ	O
,	,	O
often	RB	O
multiple	JJ	O
interconnected	JJ	O
biological	NN	O
pathways	NNS	O
which	WDT	O
in	IN	O
normal	JJ	O
physiology	NN	O
are	VBP	O
critical	JJ	O
to	TO	O
respond	VB	O
to	TO	O
insult	VB	O
or	CC	O
injury	VB	O
,	,	O
initiate	VB	O
repair	NN	O
from	IN	O
insult	NN	O
or	CC	O
injury	NN	O
,	,	O
and	CC	O
mount	VB	O
innate	NN	O
and	CC	O
acquired	VBD	O
defense	NN	O
against	IN	O
foreign	JJ	O
organisms	NNS	O
.	.	O
Disease	NNP	O
or	CC	O
pathology	NN	O
occurs	NNS	O
when	WRB	O
these	DT	O
normal	JJ	O
physiological	JJ	O
pathways	NNS	O
cause	VBP	O
additional	JJ	O
insult	NN	O
or	CC	O
injury	NN	O
either	CC	O
as	IN	O
directly	RB	O
related	VBN	O
to	TO	O
the	DT	O
intensity	NN	O
of	IN	O
the	DT	O
response	NN	O
,	,	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
abnormal	JJ	O
regulation	NN	O
or	CC	O
excessive	JJ	O
stimulation	NN	O
,	,	O
as	IN	O
a	DT	O
reaction	NN	O
to	TO	O
self	VB	O
,	,	O
or	CC	O
as	IN	O
a	DT	O
combination	NN	O
of	IN	O
these	DT	O
.	.	O
Though	IN	O
the	DT	O
genesis	NN	O
of	IN	O
these	DT	O
diseases	NNS	O
often	RB	O
involves	VBZ	O
multistep	NNS	O
pathways	NNS	O
and	CC	O
often	RB	O
multiple	JJ	O
different	JJ	O
biological	JJ	O
systems/pathways	NNS	O
,	,	O
intervention	NN	O
at	IN	O
critical	JJ	O
points	NNS	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
these	DT	O
pathways	NNS	O
can	MD	O
have	VB	O
an	DT	O
ameliorative	JJ	O
or	CC	O
therapeutic	JJ	O
effect	NN	O
.	.	O
Therapeutic	JJ	O
intervention	NN	O
can	MD	O
occur	VB	O
by	IN	O
either	DT	O
antagonism	NN	O
of	IN	O
a	DT	O
detrimental	JJ	O
process/pathway	NN	O
or	CC	O
stimulation	NN	O
of	IN	O
a	DT	O
beneficial	JJ	O
process/pathway	NN	O
.	.	O
T	NNP	O
lymphocytes	VBZ	O
(	(	O
T	NNP	O
cells	NNS	O
)	)	O
are	VBP	O
an	DT	O
important	JJ	O
component	NN	O
of	IN	O
a	DT	O
mammalian	JJ	O
immune	NN	O
response	NN	O
.	.	O
T	NNP	O
cells	NNS	O
recognize	VBP	O
antigens	NNS	O
which	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
self-molecule	NN	O
encoded	VBN	O
by	IN	O
genes	NNS	O
within	IN	O
the	DT	O
major	JJ	O
histocompatibility	NN	O
complex	NN	O
(	(	O
MHC	NNP	O
)	)	O
.	.	O
The	DT	O
antigen	NN	O
may	MD	O
be	VB	O
displayed	VBN	O
together	RB	O
with	IN	O
MHC	NNP	O
molecules	NNS	O
on	IN	O
the	DT	O
surface	NN	O
of	IN	O
antigen	NN	O
presenting	VBG	O
cells	NNS	O
,	,	O
virus	NN	O
infected	VBD	O
cells	NNS	O
,	,	O
cancer	NN	O
cells	NNS	O
,	,	O
grafts	NNS	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
T	NNP	O
cell	NN	O
system	NN	O
eliminates	VBZ	O
these	DT	O
altered	JJ	O
cells	NNS	O
which	WDT	O
pose	VBP	O
a	DT	O
health	NN	O
threat	NN	O
to	TO	O
the	DT	O
host	NN	O
mammal	JJ	O
T	NNP	O
cells	NNS	O
include	VBP	O
helper	JJ	O
T	NNP	O
cells	NNS	O
and	CC	O
cytotoxic	NN	O
T	NNP	O
cells	NNS	O
.	.	O
Helper	NNP	O
T	NNP	O
cells	NNS	O
proliferate	VBP	O
extensively	RB	O
following	VBG	O
recognition	NN	O
of	IN	O
an	DT	O
antigen-MHC	JJ	O
complex	NN	O
on	IN	O
an	DT	O
antigen	NN	O
presenting	NN	O
cell	NN	O
.	.	O
Helper	NNP	O
T	NNP	O
cells	NNS	O
also	RB	O
secrete	VBP	O
a	DT	O
variety	NN	O
of	IN	O
cytokines	NNS	O
,	,	O
i.e.	FW	O
,	,	O
lymphokines	NNS	O
,	,	O
which	WDT	O
play	VBP	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
the	DT	O
activation	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
,	,	O
cytotoxic	NN	O
T	NNP	O
cells	NNS	O
and	CC	O
a	DT	O
variety	NN	O
of	IN	O
other	JJ	O
cells	NNS	O
which	WDT	O
participate	VBP	O
in	IN	O
the	DT	O
immune	JJ	O
response	NN	O
.	.	O
In	IN	O
many	JJ	O
immune	JJ	O
responses	NNS	O
,	,	O
inflammatory	JJ	O
cells	NNS	O
infiltrate	VBP	O
the	DT	O
site	NN	O
of	IN	O
injury	NN	O
or	CC	O
infection	NN	O
.	.	O
The	DT	O
migrating	NN	O
cells	NNS	O
may	MD	O
be	VB	O
neutrophilic	JJ	O
,	,	O
eosinophilic	JJ	O
,	,	O
monocytic	JJ	O
or	CC	O
lymphocytic	JJ	O
as	IN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
histologic	JJ	O
examination	NN	O
of	IN	O
the	DT	O
affected	JJ	O
tissues	NNS	O
.	.	O
Current	JJ	B
Protocols	NNP	I
in	IN	I
Immunology	NNP	I
,	,	I
ed	NN	I
.	.	I
John	NNP	I
E.	NNP	I
Coligan	NNP	I
,	,	I
1994	CD	I
,	,	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc	NNP	I
.	.	O
Many	JJ	O
immune	NNS	O
related	JJ	O
diseases	NNS	O
are	VBP	O
known	VBN	O
and	CC	O
have	VBP	O
been	VBN	O
extensively	RB	O
studied	VBN	O
.	.	O
Such	JJ	O
diseases	NNS	O
include	VBP	O
immune-mediated	JJ	O
inflammatory	JJ	O
diseases	NNS	O
(	(	O
such	JJ	O
as	IN	O
rheumatoid	JJ	O
arthritis	NN	O
,	,	O
immune	NN	O
mediated	VBD	O
renal	JJ	O
disease	NN	O
,	,	O
hepatobiliary	JJ	O
diseases	NNS	O
,	,	O
inflammatory	NN	O
bowel	NN	O
disease	NN	O
(	(	O
IBD	NNP	O
)	)	O
,	,	O
psoriasis	NN	O
,	,	O
and	CC	O
asthma	NN	O
)	)	O
,	,	O
non-immune-mediated	JJ	O
inflammatory	NN	O
diseases	NNS	O
,	,	O
infectious	JJ	O
diseases	NNS	O
,	,	O
immunodeficiency	NN	O
diseases	NNS	O
,	,	O
neoplasia	NN	O
,	,	O
and	CC	O
graft	NN	O
rejection	NN	O
,	,	O
etc	FW	O
.	.	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
immunology	NN	O
,	,	O
targets	NNS	O
were	VBD	O
identified	VBN	O
herein	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
inflammation	NN	O
and	CC	O
inflammatory	NN	O
disorders	NNS	O
.	.	O
Immune	NNP	O
related	JJ	O
diseases	NNS	O
could	MD	O
be	VB	O
treated	VBN	O
by	IN	O
suppressing	VBG	O
the	DT	O
immune	JJ	O
response	NN	O
.	.	O
Using	VBG	O
neutralizing	VBG	O
antibodies	NNS	O
that	WDT	O
inhibit	VBP	O
molecules	NNS	O
having	VBG	O
immune	JJ	O
stimulatory	JJ	O
activity	NN	O
would	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
immune-mediated	JJ	O
and	CC	O
inflammatory	JJ	O
diseases	NNS	O
.	.	O
Molecules	NNS	O
which	WDT	O
inhibit	VBP	O
the	DT	O
immune	JJ	O
response	NN	O
can	MD	O
be	VB	O
utilized	VBN	O
(	(	O
proteins	NNS	O
directly	RB	O
or	CC	O
via	IN	O
the	DT	O
use	NN	O
of	IN	O
antibody	NN	O
agonists	NNS	O
)	)	O
to	TO	O
inhibit	VB	O
the	DT	O
immune	JJ	O
response	NN	O
and	CC	O
thus	RB	O
ameliorate	VB	O
immune	NN	O
related	JJ	O
disease	NN	O
.	.	O
The	DT	O
following	JJ	O
tests	NNS	O
were	VBD	O
performed	VBN	O
:	:	O
Flourescence-Activated	JJ	O
Cell-Sorting	NNP	O
(	(	O
FACS	NNP	O
)	)	O
Analysis	NNP	O
Procedure	NN	O
:	:	O
FACS	NNP	O
analysis	NN	O
of	IN	O
immune	NN	O
cell	NN	O
composition	NN	O
from	IN	O
peripheral	JJ	O
blood	NN	O
was	VBD	O
performed	VBN	O
including	VBG	O
CD4	NNP	O
,	,	O
CD8	NNP	O
and	CC	O
T	NNP	O
cell	NN	O
receptor	NN	O
to	TO	O
evaluate	VB	O
T	NNP	O
lymphocytes	NNS	O
,	,	O
CD19	NNP	O
for	IN	O
B	NNP	O
lymphocytes	NNS	O
,	,	O
CD45	NNP	O
as	IN	O
a	DT	O
leukocyte	NN	O
marker	NN	O
and	CC	O
pan	NN	O
NK	NNP	O
for	IN	O
natural	JJ	O
killer	NN	O
cells	NNS	O
.	.	O
The	DT	O
FACS	NNP	O
analysis	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
6	CD	O
wild	JJ	O
type	NN	O
and	CC	O
8	CD	O
homozygous	JJ	O
mice	NN	O
and	CC	O
included	VBD	O
cells	NNS	O
derived	VBN	O
from	IN	O
thymus	NN	O
,	,	O
spleen	NN	O
,	,	O
bone	NN	O
marrow	NN	O
and	CC	O
lymph	JJ	O
node	NN	O
.	.	O
In	IN	O
these	DT	O
studies	NNS	O
,	,	O
analyzed	JJ	O
cells	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
thymus	NN	O
,	,	O
peripheral	JJ	O
blood	NN	O
,	,	O
spleen	NN	O
,	,	O
bone	NN	O
marrow	NN	O
and	CC	O
lymph	NN	O
nodes	NNS	O
.	.	O
Flow	NNP	O
cytometry	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
relative	JJ	O
proportions	NNS	O
of	IN	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
positive	JJ	O
T	NNP	O
cells	NNS	O
,	,	O
B	NNP	O
cells	NNS	O
,	,	O
NK	NNP	O
cells	NNS	O
and	CC	O
monocytes	NNS	O
in	IN	O
the	DT	O
mononuclear	NN	O
cell	NN	O
population	NN	O
.	.	O
A	DT	O
Becton-Dickinson	NNP	O
FACSCalibur	NNP	O
3-laser	CD	O
FACS	NNP	O
machine	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
immune	JJ	O
status	NN	O
.	.	O
For	IN	O
Phenotypic	NNP	O
Assays	NNP	O
and	CC	O
Screening	NNP	O
,	,	O
this	DT	O
machine	NN	O
records	NNS	O
CD4+/CD8−	NNP	O
,	,	O
CD8+/CD4−	NNP	O
,	,	O
NK	NNP	O
,	,	O
B	NNP	O
cell	NN	O
and	CC	O
monocyte	NN	O
numbers	NNS	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
CD4+/CD8+	NNP	O
ratio	NN	O
.	.	O
The	DT	O
mononuclear	NN	O
cell	NN	O
profile	NN	O
was	VBD	O
derived	VBN	O
by	IN	O
staining	VBG	O
a	DT	O
single	JJ	O
sample	NN	O
of	IN	O
lysed	JJ	O
peripheral	JJ	O
blood	NN	O
from	IN	O
each	DT	O
mouse	NN	O
with	IN	O
a	DT	O
panel	NN	O
of	IN	O
six	CD	O
lineage-specific	JJ	O
antibodies	NNS	O
:	:	O
CD45	NNP	O
PerCP	NNP	O
,	,	O
anti-TCRb	JJ	O
APC	NNP	O
,	,	O
CD4	NNP	O
PE	NNP	O
,	,	O
CD8	NNP	O
FITC	NNP	O
,	,	O
pan-NK	JJ	O
PE	NNP	O
,	,	O
and	CC	O
CD19	NNP	O
FITC	NNP	O
.	.	O
The	DT	O
two	CD	O
FITC	NNP	O
and	CC	O
PE	NNP	O
labeled	VBD	O
antibodies	NNS	O
stain	VBP	O
mutually	RB	O
exclusive	JJ	O
cell	NN	O
types	NNS	O
.	.	O
The	DT	O
samples	NNS	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
a	DT	O
Becton	NNP	O
Dickinson	NNP	O
FACSCalibur	NNP	O
flow	NN	O
cytometer	NN	O
with	IN	O
CellQuest	NNP	O
software	NN	O
.	.	O
Results	NNS	O
:	:	O
The	DT	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
exhibited	VBD	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
and	CC	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
wild-type	JJ	O
littermates	NNS	O
.	.	O
In	IN	O
summary	JJ	O
,	,	O
FACS	NNP	O
analysis	NN	O
of	IN	O
immune	NN	O
cell	NN	O
composition	NN	O
from	IN	O
peripheral	JJ	O
blood	NN	O
indicates	VBZ	O
that	IN	O
knockout	NN	O
mice	NN	O
exhibit	NN	O
immunological	JJ	O
differences	NNS	O
with	IN	O
respect	NN	O
to	TO	O
CD4	NNP	O
cells	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
wild-type	JJ	O
littermates	NNS	O
.	.	O
Thus	RB	O
,	,	O
antagonists	NNS	O
of	IN	O
PRO10096	NNP	O
polypeptides	NNS	O
or	CC	O
its	PRP$	O
encoding	JJ	O
gene	NN	O
would	MD	O
elicit	VB	O
increased	JJ	O
levels	NNS	O
of	IN	O
CD4	NNP	O
.	.	O
The	DT	O
co-receptor	NN	O
CD4	NNP	O
molecule	NN	O
cooperates	NNS	O
with	IN	O
the	DT	O
T-cell	NNP	O
receptor	NN	O
which	WDT	O
differentially	RB	O
recognizes	VBZ	O
MHC	NNP	O
class	NN	O
II	NNP	O
molecules	NNS	O
in	IN	O
the	DT	O
antigen	NN	O
recognition	NN	O
process	NN	O
.	.	O
(	(	O
c	NN	O
)	)	O
Phenotypic	NNP	O
Analysis	NN	O
:	:	O
CNS/Neurology	NN	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
neurology	NN	O
,	,	O
analysis	NN	O
focused	VBD	O
herein	NN	O
on	IN	O
identifying	VBG	O
in	IN	O
vivo	NN	O
validated	VBN	O
targets	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
neurological	JJ	O
and	CC	O
psychiatric	JJ	O
disorders	NNS	O
including	VBG	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Neurological	JJ	O
disorders	NNS	O
include	VBP	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	NN	O
disorders	NNS	O
,	,	O
mild	NN	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
Procedure	NN	O
:	:	O
Behavioral	JJ	O
screens	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
cohort	NN	O
of	IN	O
4	CD	O
wild	JJ	O
type	NN	O
,	,	O
4	CD	O
heterozygous	JJ	O
and	CC	O
8	CD	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
.	.	O
All	DT	O
behavioral	JJ	O
tests	NNS	O
were	VBD	O
done	VBN	O
between	IN	O
12	CD	O
and	CC	O
16	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
unless	IN	O
reduced	VBN	O
viability	NN	O
necessitates	NNS	O
earlier	RBR	O
testing	VBG	O
.	.	O
These	DT	O
tests	NNS	O
included	VBD	O
open	JJ	O
field	NN	O
to	TO	O
measure	VB	O
anxiety	NN	O
,	,	O
activity	NN	O
levels	NNS	O
and	CC	O
exploration	NN	O
.	.	O
Open	JJ	O
Field	NNP	O
Test	NNP	O
:	:	O
Several	JJ	O
targets	NNS	O
of	IN	O
known	VBN	O
drugs	NNS	O
have	VBP	O
exhibited	VBN	O
phenotypes	NNS	O
in	IN	O
the	DT	O
open	JJ	O
field	NN	O
test	NN	O
.	.	O
These	DT	O
include	VBP	O
knockouts	NNS	O
of	IN	O
the	DT	O
serotonin	NN	O
transporter	NN	O
,	,	O
the	DT	O
dopamine	NN	O
transporter	NN	O
(	(	O
Giros	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nature	NNP	I
.	.	I
1996	CD	I
Feb.	NNP	I
15	CD	I
;	:	I
379	CD	I
(	(	I
6566	CD	I
)	)	I
:606-12	NN	I
)	)	O
,	,	O
and	CC	O
the	DT	O
GABA	NNP	O
receptor	NN	O
(	(	O
Homanics	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
.	.	I
1997	CD	I
Apr	NNP	I
.	.	I
15	CD	I
;	:	I
94	CD	I
(	(	I
8	CD	I
)	)	I
:4143-8	NN	I
)	)	O
.	.	O
An	DT	O
automated	JJ	O
open-field	JJ	O
assay	NN	O
was	VBD	O
customized	VBN	O
to	TO	O
address	VB	O
changes	NNS	O
related	VBN	O
to	TO	O
affective	JJ	O
state	NN	O
and	CC	O
exploratory	NN	O
patterns	NNS	O
related	VBN	O
to	TO	O
learning	VBG	O
.	.	O
First	RB	O
,	,	O
the	DT	O
field	NN	O
(	(	O
40×40	CD	O
cm	NN	O
)	)	O
was	VBD	O
selected	VBN	O
to	TO	O
be	VB	O
relatively	RB	O
large	JJ	O
for	IN	O
a	DT	O
mouse	NN	O
,	,	O
thus	RB	O
designed	VBN	O
to	TO	O
pick	VB	O
up	RP	O
changes	NNS	O
in	IN	O
locomotor	NN	O
activity	NN	O
associated	VBN	O
with	IN	O
exploration	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
there	EX	O
were	VBD	O
4	CD	O
holes	NNS	O
in	IN	O
the	DT	O
floor	NN	O
to	TO	O
allow	VB	O
for	IN	O
nose-poking	JJ	O
,	,	O
an	DT	O
activity	NN	O
specifically	RB	O
related	VBN	O
to	TO	O
exploration	NN	O
.	.	O
Several	JJ	O
factors	NNS	O
were	VBD	O
also	RB	O
designed	VBN	O
to	TO	O
heighten	VB	O
the	DT	O
affective	JJ	O
state	NN	O
associated	VBN	O
with	IN	O
this	DT	O
test	NN	O
.	.	O
The	DT	O
open-field	JJ	O
test	NN	O
is	VBZ	O
the	DT	O
first	JJ	O
experimental	JJ	O
procedure	NN	O
in	IN	O
which	WDT	O
the	DT	O
mice	NN	O
are	VBP	O
tested	VBN	O
,	,	O
and	CC	O
the	DT	O
measurements	NNS	O
that	WDT	O
were	VBD	O
taken	VBN	O
were	VBD	O
the	DT	O
subjects	NNS	O
'	POS	O
first	JJ	O
experience	NN	O
with	IN	O
the	DT	O
chamber	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
open-field	NN	O
was	VBD	O
brightly	RB	O
lit	VBN	O
.	.	O
All	PDT	O
these	DT	O
factors	NNS	O
will	MD	O
heighten	VB	O
the	DT	O
natural	JJ	O
anxiety	NN	O
associated	VBN	O
with	IN	O
novel	NN	O
and	CC	O
open	JJ	O
spaces	NNS	O
.	.	O
The	DT	O
pattern	NN	O
and	CC	O
extent	NN	O
of	IN	O
exploratory	NN	O
activity	NN	O
,	,	O
and	CC	O
especially	RB	O
the	DT	O
center-to-total	JJ	O
distance	NN	O
traveled	VBD	O
ratio	NN	O
,	,	O
may	MD	O
then	RB	O
be	VB	O
able	JJ	O
to	TO	O
discern	VB	O
changes	NNS	O
related	VBN	O
to	TO	O
susceptibility	NN	O
to	TO	O
anxiety	NN	O
or	CC	O
depression	NN	O
.	.	O
A	DT	O
large	JJ	O
arena	NN	O
(	(	O
40	CD	O
cm×40	NN	O
cm	NN	O
,	,	O
VersaMax	NNP	O
animal	NN	O
activity	NN	O
monitoring	VBG	O
system	NN	O
from	IN	O
AccuScan	JJ	O
Instruments	NNS	O
)	)	O
with	IN	O
infrared	JJ	O
beams	NNS	O
at	IN	O
three	CD	O
different	JJ	O
levels	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
record	VB	O
rearing	NN	O
,	,	O
hole	NN	O
poke	NN	O
,	,	O
and	CC	O
locomotor	NN	O
activity	NN	O
.	.	O
The	DT	O
animal	NN	O
was	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
center	NN	O
and	CC	O
its	PRP$	O
activity	NN	O
was	VBD	O
measured	VBN	O
for	IN	O
20	CD	O
minutes	NNS	O
.	.	O
Data	NNS	O
from	IN	O
this	DT	O
test	NN	O
was	VBD	O
analyzed	VBN	O
in	IN	O
five	CD	O
,	,	O
4-minute	JJ	O
intervals	NNS	O
.	.	O
The	DT	O
total	JJ	O
distance	NN	O
traveled	VBD	O
(	(	O
cm	NN	O
)	)	O
,	,	O
vertical	JJ	O
movement	NN	O
number	NN	O
(	(	O
rearing	VBG	O
)	)	O
,	,	O
number	NN	O
of	IN	O
hole	JJ	O
pokes	NNS	O
,	,	O
and	CC	O
the	DT	O
center	NN	O
to	TO	O
total	JJ	O
distance	NN	O
ratio	NN	O
were	VBD	O
recorded	VBN	O
.	.	O
The	DT	O
propensity	NN	O
for	IN	O
mice	NN	O
to	TO	O
exhibit	VB	O
normal	JJ	O
habituation	NN	O
responses	NNS	O
to	TO	O
a	DT	O
novel	JJ	O
environment	NN	O
is	VBZ	O
assessed	VBN	O
by	IN	O
determining	VBG	O
the	DT	O
overall	JJ	O
change	NN	O
in	IN	O
their	PRP$	O
horizontal	JJ	O
locomotor	NN	O
activity	NN	O
across	IN	O
the	DT	O
5	CD	O
time	NN	O
intervals	NNS	O
.	.	O
This	DT	O
calculated	VBD	O
slope	NN	O
of	IN	O
the	DT	O
change	NN	O
in	IN	O
activity	NN	O
over	IN	O
time	NN	O
is	VBZ	O
determined	VBN	O
using	VBG	O
normalized	VBN	O
,	,	O
rather	RB	O
than	IN	O
absolute	VB	O
,	,	O
total	JJ	O
distance	NN	O
traveled	VBD	O
.	.	O
The	DT	O
slope	NN	O
is	VBZ	O
determined	VBN	O
from	IN	O
the	DT	O
regression	NN	O
line	NN	O
through	IN	O
the	DT	O
normalized	JJ	O
activity	NN	O
at	IN	O
each	DT	O
of	IN	O
the	DT	O
5	CD	O
time	NN	O
intervals	NNS	O
.	.	O
Normal	JJ	O
habituation	NN	O
is	VBZ	O
represented	VBN	O
by	IN	O
a	DT	O
negative	JJ	O
slope	NN	O
value	NN	O
.	.	O
Results	NNS	O
:	:	O
A	DT	O
notable	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
The	DT	O
female	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
exhibited	VBD	O
a	DT	O
decreased	JJ	O
median	JJ	O
sum	NN	O
time	NN	O
in	IN	O
the	DT	O
center	NN	O
area	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
.	.	O
This	DT	O
type	NN	O
of	IN	O
behavior	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
an	DT	O
increased	VBN	O
anxiety	NN	O
like	IN	O
response	NN	O
.	.	O
Knockout	NNP	O
mice	NN	O
demonstrated	VBD	O
a	DT	O
phenotype	JJ	O
consistent	NN	O
with	IN	O
anxiety	NN	O
related	VBN	O
disorders	NNS	O
which	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
and/or	JJ	O
bipolar	NN	O
disorders	NNS	O
;	:	O
hyperactivity	NN	O
;	:	O
sensory	JJ	O
disorders	NNS	O
;	:	O
obsessive-compulsive	JJ	O
disorders	NNS	O
,	,	O
schizophrenia	NN	O
or	CC	O
a	DT	O
paranoid	JJ	O
personality	NN	O
.	.	O
Thus	RB	O
,	,	O
PRO10096	NNP	O
polypeptides	VBZ	O
or	CC	O
agonists	NNS	O
thereof	RP	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
such	JJ	O
neurological	JJ	O
disorders	NNS	O
or	CC	O
the	DT	O
amelioration	NN	O
of	IN	O
the	DT	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
anxiety	NN	O
disorders	NNS	O
.	.	O
H.	NNP	O
Generation	NNP	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA177313-2982	NNP	O
(	(	O
UNQ6368	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO21384	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA177313-2982	NNP	O
(	(	O
UNQ6368	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
NM—139299	NN	O
or	CC	O
Mus	NNP	O
musculus	CC	O
gp130-like	JJ	O
monocyte	NN	O
receptor	NN	O
(	(	O
Glmr-pending	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—647460	NN	O
or	CC	O
gp130-like	JJ	O
monocyte	NN	O
receptor	NN	O
;	:	O
cytokine	JJ	O
receptor	NN	O
NR10	NNP	O
[	NNP	O
Mus	NNP	O
musculus	CC	O
]	NNP	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
NM—139017	NN	O
or	CC	O
Homo	NN	O
sapiens	JJ	O
gp130-like	JJ	O
monocyte	NN	O
receptor	NN	O
(	(	O
CRL3	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—620586	NN	O
or	CC	O
gp130-like	JJ	O
monocyte	NN	O
receptor	NN	O
;	:	O
soluble	JJ	O
type	NN	O
I	PRP	O
cytokine	VBP	O
receptor	NN	O
CRL3	NNP	O
[	NNP	O
Homo	NNP	O
sapiens	VBZ	O
]	NNP	O
.	.	O
Mutation	NNP	O
type	NN	O
corresponds	NNS	O
to	TO	O
Homologous	NNP	O
Recombination	NNP	O
(	(	O
standard	NN	O
)	)	O
.	.	O
Coding	VBG	O
exon	$	O
4	CD	O
was	VBD	O
targeted	VBN	O
.	.	O
The	DT	O
disrupted	VBN	O
mouse	NN	O
gene	NN	O
is	VBZ	O
Gp130-like	JJ	O
monocyte	NN	O
receptor	NN	O
(	(	O
Glmr	NNP	O
)	)	O
,	,	O
ortholog	NN	O
of	IN	O
human	JJ	O
gp130-like	JJ	O
monocyte	NN	O
receptor	NN	O
(	(	O
CRL3	NNP	O
)	)	O
.	.	O
Aliases	NNS	O
include	VBP	O
NR10	NNP	O
,	,	O
GLM-R	NNP	O
,	,	O
cytokine	NN	O
receptor	NN	O
NR10	NNP	O
,	,	O
GLMR	NNP	O
,	,	O
and	CC	O
soluble	JJ	O
type	NN	O
I	PRP	O
cytokine	VBP	O
receptor	NN	O
CRL3	NNP	O
.	.	O
CRL3	NNP	O
is	VBZ	O
a	DT	O
novel	JJ	O
type	NN	O
I	PRP	O
cytokine	VBP	O
receptor	NN	O
with	IN	O
homology	NN	O
to	TO	O
interleukin-6	JJ	O
receptor	NN	O
gp130	NN	O
and	CC	O
granulocyte	JJ	O
colony-stimulating	JJ	O
factor	NN	O
receptor	NN	O
.	.	O
CRL3	NNP	O
is	VBZ	O
expressed	VBN	O
on	IN	O
CD14-positive	NNP	O
cells	NNS	O
,	,	O
activates	VBZ	O
STAT3	NNP	O
and	CC	O
STAT5	NNP	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
involved	VBN	O
in	IN	O
monocyte	JJ	O
maturation	NN	O
and	CC	O
development	NN	O
.	.	O
Bioinformatic	JJ	O
analyses	NNS	O
indicate	VBP	O
the	DT	O
receptor	NN	O
has	VBZ	O
a	DT	O
signal	JJ	O
peptide	NN	O
sequence	NN	O
,	,	O
a	DT	O
large	JJ	O
extracellular	JJ	O
domain	NN	O
,	,	O
and	CC	O
a	DT	O
cytoplasmic	JJ	O
signaling	NN	O
domain	NN	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
progeny	NN	O
.	.	O
On	IN	O
rare	JJ	O
occasions	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
very	RB	O
few	JJ	O
F1	NNP	O
mice	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
chimera	NN	O
,	,	O
F1	NNP	O
heterozygous	JJ	O
mice	NNS	O
were	VBD	O
crossed	VBN	O
to	TO	O
129SvEvBrd/C57	CD	O
hybrid	JJ	O
mice	NN	O
to	TO	O
yield	VB	O
additional	JJ	O
heterozygous	JJ	O
animals	NNS	O
for	IN	O
the	DT	O
intercross	NN	O
to	TO	O
generate	VB	O
the	DT	O
F2	NNP	O
mice	NN	O
.	.	O
Level	NN	O
I	PRP	O
phenotypic	VBP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
mice	NN	O
from	IN	O
this	DT	O
generation	NN	O
as	IN	O
shown	VBN	O
below	IN	O
.	.	O
Wild-type	JJ	O
expression	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
detected	VBN	O
all	DT	O
13	CD	O
adult	NNS	O
tissue	NN	O
samples	NNS	O
tested	VBN	O
by	IN	O
RT-PCR	NNP	O
,	,	O
except	IN	O
liver	NN	O
,	,	O
testis	NN	O
,	,	O
small	JJ	O
intestine	NN	O
and	CC	O
colon	NN	O
,	,	O
heart	NN	O
,	,	O
and	CC	O
tail	NN	O
.	.	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
1	CD	O
.	.	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
Disrupted	VBN	O
Gene	NNP	O
:	:	O
DNA177313-2982	NNP	O
(	(	O
UNQ6368	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
:	:	O
The	DT	O
male	NN	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
exhibited	VBD	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
wild-type	JJ	O
littermates	NNS	O
and	CC	O
the	DT	O
historical	JJ	O
mean	NN	O
.	.	O
No	DT	O
other	JJ	O
notable	JJ	O
phenotype	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
.	.	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
(	(	O
b	NN	O
)	)	O
Phenotypic	NNP	O
Analysis	NN	O
:	:	O
CNS/Neurology	NN	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
neurology	NN	O
,	,	O
analysis	NN	O
focused	VBD	O
herein	NN	O
on	IN	O
identifying	VBG	O
in	IN	O
vivo	NN	O
validated	VBN	O
targets	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
neurological	JJ	O
and	CC	O
psychiatric	JJ	O
disorders	NNS	O
including	VBG	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders	NNS	O
.	.	O
Neurological	JJ	O
disorders	NNS	O
include	VBP	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hyperactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	NN	O
disorders	NNS	O
,	,	O
mild	NN	O
to	TO	O
moderate	VB	O
anxiety	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition	NN	O
,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorder	NN	O
,	,	O
panic	JJ	O
attack	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia	NN	O
,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia	NN	O
,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
,	,	O
social	JJ	O
phobia	NN	O
,	,	O
social	JJ	O
anxiety	NN	O
,	,	O
autism	NN	O
,	,	O
specific	JJ	O
phobia	NN	O
,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder	NN	O
,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
agoraphobia	NN	O
,	,	O
monopolar	JJ	O
disorders	NNS	O
,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II	NNP	O
,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
cyclothymic	JJ	O
disorder	NN	O
,	,	O
depressive	JJ	O
disorder	NN	O
,	,	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
substance-induced	JJ	O
mood	NN	O
disorder	NN	O
,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy	VB	O
,	,	O
learning	VBG	O
disorders/disabilities	NNS	O
,	,	O
cerebral	JJ	O
palsy	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types	NNS	O
:	:	O
paranoid	NN	O
,	,	O
antisocial	JJ	O
,	,	O
avoidant	JJ	O
behavior	NN	O
,	,	O
borderline	JJ	O
personality	NN	O
disorders	NNS	O
,	,	O
dependent	NN	O
,	,	O
histronic	JJ	O
,	,	O
narcissistic	JJ	O
,	,	O
obsessive-compulsive	JJ	O
,	,	O
schizoid	JJ	O
,	,	O
and	CC	O
schizotypal	NN	O
.	.	O
Procedure	NN	O
:	:	O
Behavioral	JJ	O
screens	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
cohort	NN	O
of	IN	O
4	CD	O
wild	JJ	O
type	NN	O
,	,	O
4	CD	O
heterozygous	JJ	O
and	CC	O
8	CD	O
homozygous	JJ	O
mutant	JJ	O
mice	NN	O
.	.	O
All	DT	O
behavioral	JJ	O
tests	NNS	O
were	VBD	O
done	VBN	O
between	IN	O
12	CD	O
and	CC	O
16	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
unless	IN	O
reduced	VBN	O
viability	NN	O
necessitates	NNS	O
earlier	RBR	O
testing	VBG	O
.	.	O
These	DT	O
tests	NNS	O
included	VBD	O
open	JJ	O
field	NN	O
to	TO	O
measure	VB	O
anxiety	NN	O
,	,	O
activity	NN	O
levels	NNS	O
and	CC	O
exploration	NN	O
.	.	O
Open	JJ	O
Field	NNP	O
Test	NNP	O
:	:	O
Several	JJ	O
targets	NNS	O
of	IN	O
known	VBN	O
drugs	NNS	O
have	VBP	O
exhibited	VBN	O
phenotypes	NNS	O
in	IN	O
the	DT	O
open	JJ	O
field	NN	O
test	NN	O
.	.	O
These	DT	O
include	VBP	O
knockouts	NNS	O
of	IN	O
the	DT	O
serotonin	NN	O
transporter	NN	O
,	,	O
the	DT	O
dopamine	NN	O
transporter	NN	O
(	(	O
Giros	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nature	NNP	I
.	.	I
1996	CD	I
Feb.	NNP	I
15	CD	I
;	:	I
379	CD	I
(	(	I
6566	CD	I
)	)	I
:606-12	NN	I
)	)	O
,	,	O
and	CC	O
the	DT	O
GABA	NNP	O
receptor	NN	O
(	(	O
Homanics	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
.	.	I
1997	CD	I
Apr	NNP	I
.	.	I
15	CD	I
;	:	I
94	CD	I
(	(	I
8	CD	I
)	)	I
:4143-8	NN	I
)	)	O
.	.	O
An	DT	O
automated	JJ	O
open-field	JJ	O
assay	NN	O
was	VBD	O
customized	VBN	O
to	TO	O
address	VB	O
changes	NNS	O
related	VBN	O
to	TO	O
affective	JJ	O
state	NN	O
and	CC	O
exploratory	NN	O
patterns	NNS	O
related	VBN	O
to	TO	O
learning	VBG	O
.	.	O
First	RB	O
,	,	O
the	DT	O
field	NN	O
(	(	O
40×40	CD	O
cm	NN	O
)	)	O
was	VBD	O
selected	VBN	O
to	TO	O
be	VB	O
relatively	RB	O
large	JJ	O
for	IN	O
a	DT	O
mouse	NN	O
,	,	O
thus	RB	O
designed	VBN	O
to	TO	O
pick	VB	O
up	RP	O
changes	NNS	O
in	IN	O
locomotor	NN	O
activity	NN	O
associated	VBN	O
with	IN	O
exploration	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
there	EX	O
were	VBD	O
4	CD	O
holes	NNS	O
in	IN	O
the	DT	O
floor	NN	O
to	TO	O
allow	VB	O
for	IN	O
nose-poking	JJ	O
,	,	O
an	DT	O
activity	NN	O
specifically	RB	O
related	VBN	O
to	TO	O
exploration	NN	O
.	.	O
Several	JJ	O
factors	NNS	O
were	VBD	O
also	RB	O
designed	VBN	O
to	TO	O
heighten	VB	O
the	DT	O
affective	JJ	O
state	NN	O
associated	VBN	O
with	IN	O
this	DT	O
test	NN	O
.	.	O
The	DT	O
open-field	JJ	O
test	NN	O
is	VBZ	O
the	DT	O
first	JJ	O
experimental	JJ	O
procedure	NN	O
in	IN	O
which	WDT	O
the	DT	O
mice	NN	O
are	VBP	O
tested	VBN	O
,	,	O
and	CC	O
the	DT	O
measurements	NNS	O
that	WDT	O
were	VBD	O
taken	VBN	O
were	VBD	O
the	DT	O
subjects	NNS	O
'	POS	O
first	JJ	O
experience	NN	O
with	IN	O
the	DT	O
chamber	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
open-field	NN	O
was	VBD	O
brightly	RB	O
lit	VBN	O
.	.	O
All	PDT	O
these	DT	O
factors	NNS	O
will	MD	O
heighten	VB	O
the	DT	O
natural	JJ	O
anxiety	NN	O
associated	VBN	O
with	IN	O
novel	NN	O
and	CC	O
open	JJ	O
spaces	NNS	O
.	.	O
The	DT	O
pattern	NN	O
and	CC	O
extent	NN	O
of	IN	O
exploratory	NN	O
activity	NN	O
,	,	O
and	CC	O
especially	RB	O
the	DT	O
center-to-total	JJ	O
distance	NN	O
traveled	VBD	O
ratio	NN	O
,	,	O
may	MD	O
then	RB	O
be	VB	O
able	JJ	O
to	TO	O
discern	VB	O
changes	NNS	O
related	VBN	O
to	TO	O
susceptibility	NN	O
to	TO	O
anxiety	NN	O
or	CC	O
depression	NN	O
.	.	O
A	DT	O
large	JJ	O
arena	NN	O
(	(	O
40	CD	O
cm×40	NN	O
cm	NN	O
,	,	O
VersaMax	NNP	O
animal	NN	O
activity	NN	O
monitoring	VBG	O
system	NN	O
from	IN	O
AccuScan	JJ	O
Instruments	NNS	O
)	)	O
with	IN	O
infrared	JJ	O
beams	NNS	O
at	IN	O
three	CD	O
different	JJ	O
levels	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
record	VB	O
rearing	NN	O
,	,	O
hole	NN	O
poke	NN	O
,	,	O
and	CC	O
locomotor	NN	O
activity	NN	O
.	.	O
The	DT	O
animal	NN	O
was	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
center	NN	O
and	CC	O
its	PRP$	O
activity	NN	O
was	VBD	O
measured	VBN	O
for	IN	O
20	CD	O
minutes	NNS	O
.	.	O
Data	NNS	O
from	IN	O
this	DT	O
test	NN	O
was	VBD	O
analyzed	VBN	O
in	IN	O
five	CD	O
,	,	O
4-minute	JJ	O
intervals	NNS	O
.	.	O
The	DT	O
total	JJ	O
distance	NN	O
traveled	VBD	O
(	(	O
cm	NN	O
)	)	O
,	,	O
vertical	JJ	O
movement	NN	O
number	NN	O
(	(	O
rearing	VBG	O
)	)	O
,	,	O
number	NN	O
of	IN	O
hole	JJ	O
pokes	NNS	O
,	,	O
and	CC	O
the	DT	O
center	NN	O
to	TO	O
total	JJ	O
distance	NN	O
ratio	NN	O
were	VBD	O
recorded	VBN	O
.	.	O
The	DT	O
propensity	NN	O
for	IN	O
mice	NN	O
to	TO	O
exhibit	VB	O
normal	JJ	O
habituation	NN	O
responses	NNS	O
to	TO	O
a	DT	O
novel	JJ	O
environment	NN	O
is	VBZ	O
assessed	VBN	O
by	IN	O
determining	VBG	O
the	DT	O
overall	JJ	O
change	NN	O
in	IN	O
their	PRP$	O
horizontal	JJ	O
locomotor	NN	O
activity	NN	O
across	IN	O
the	DT	O
5	CD	O
time	NN	O
intervals	NNS	O
.	.	O
This	DT	O
calculated	VBD	O
slope	NN	O
of	IN	O
the	DT	O
change	NN	O
in	IN	O
activity	NN	O
over	IN	O
time	NN	O
is	VBZ	O
determined	VBN	O
using	VBG	O
normalized	VBN	O
,	,	O
rather	RB	O
than	IN	O
absolute	VB	O
,	,	O
total	JJ	O
distance	NN	O
traveled	VBD	O
.	.	O
The	DT	O
slope	NN	O
is	VBZ	O
determined	VBN	O
from	IN	O
the	DT	O
regression	NN	O
line	NN	O
through	IN	O
the	DT	O
normalized	JJ	O
activity	NN	O
at	IN	O
each	DT	O
of	IN	O
the	DT	O
5	CD	O
time	NN	O
intervals	NNS	O
.	.	O
Normal	JJ	O
habituation	NN	O
is	VBZ	O
represented	VBN	O
by	IN	O
a	DT	O
negative	JJ	O
slope	NN	O
value	NN	O
.	.	O
Results	NNS	O
:	:	O
A	DT	O
notable	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing	VBG	O
.	.	O
The	DT	O
male	NN	O
(	(	O
−/−	NNP	O
)	)	O
mice	NN	O
exhibited	VBD	O
an	DT	O
increased	JJ	O
median	JJ	O
sum	NN	O
time	NN	O
in	IN	O
the	DT	O
center	NN	O
area	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
gender-matched	JJ	O
(	(	O
+/+	NNP	O
)	)	O
littermates	VBZ	O
,	,	O
which	WDT	O
is	VBZ	O
indicative	JJ	O
of	IN	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
in	IN	O
the	DT	O
mutants	NNS	O
.	.	O
Thus	RB	O
,	,	O
male	NN	O
knockout	NN	O
mice	NN	O
demonstrated	VBD	O
a	DT	O
phenotype	JJ	O
consistent	NN	O
with	IN	O
depressive	JJ	O
disorders	NNS	O
,	,	O
including	VBG	O
depression	NN	O
,	,	O
generalized	VBN	O
anxiety	NN	O
disorders	NNS	O
,	,	O
attention	NN	O
deficit	NN	O
disorder	NN	O
,	,	O
sleep	JJ	O
disorder	NN	O
,	,	O
hypoactivity	NN	O
disorder	NN	O
,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder	NN	O
,	,	O
schizophrenia	NN	O
,	,	O
cognitive	JJ	O
disorders	NNS	O
,	,	O
hyperalgesia	NN	O
and/or	JJ	O
sensory	NN	O
disorders	NNS	O
.	.	O
Thus	RB	O
,	,	O
PRO21384	NNP	O
polypeptides	NNS	O
and	CC	O
agonists	NNS	O
thereof	NNS	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
or	CC	O
amelioration	NN	O
of	IN	O
the	DT	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
depressive	JJ	O
disorders	NNS	O
.	.	O
I	PRP	O
.	.	O
Generation	NN	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA41234-1242-1	NNP	O
(	(	O
UNQ310	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO353	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA41234-1242-1	NNP	O
(	(	O
UNQ310	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
NM—019959	NN	O
or	CC	O
Mus	NNP	O
musculus	CC	O
putative	JJ	O
secreted	VBN	O
protein	NN	O
ZSIG37	NNP	O
(	(	O
Zsig37	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
NP—064343	NN	O
or	CC	O
putative	JJ	O
secreted	VBN	O
protein	NN	O
ZSIG37	NNP	O
[	NNP	O
Mus	NNP	O
musculus	CC	O
]	NNP	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
AF232905	NNP	O
or	CC	O
Homo	NNP	O
sapiens	JJ	O
putative	JJ	O
GPCR	NNP	O
interacting	VBG	O
protein	NN	O
GIP	NNP	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
AAG44303	NNP	O
or	CC	O
putative	JJ	O
GPCR	NNP	O
interacting	VBG	O
protein	NN	O
GIP	NNP	O
[	NNP	O
Homo	NNP	O
sapiens	VBZ	O
]	NNP	O
.	.	O
Mutation	NNP	O
type	NN	O
corresponds	NNS	O
to	TO	O
Homologous	NNP	O
Recombination	NNP	O
(	(	O
standard	NN	O
)	)	O
.	.	O
Coding	VBG	O
exon	$	O
4	CD	O
was	VBD	O
targeted	VBN	O
(	(	O
NM—019959	NNP	O
)	)	O
.	.	O
The	DT	O
gene	NN	O
that	WDT	O
is	VBZ	O
mutated	VBN	O
in	IN	O
these	DT	O
animals	NNS	O
is	VBZ	O
represented	VBN	O
by	IN	O
mouse	NN	O
UniGene	NNP	O
cluster	NN	O
Mm.23845	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
the	DT	O
ortholog	NN	O
of	IN	O
human	JJ	O
cluster	NN	O
Hs.201398	NNP	O
(	(	O
C1QTNF1	NNP	O
)	)	O
.	.	O
C1QTNF1	NNP	O
encodes	VBZ	O
G	NNP	O
protein	NN	O
coupled	VBD	O
receptor	NN	O
interacting	VBG	O
protein	NN	O
[	NN	O
that	WDT	O
is	VBZ	O
]	JJ	O
complement-C1q	JJ	O
tumor	NN	O
necrosis	NN	O
factor-related	JJ	O
.	.	O
Alternate	NNP	O
names	NNS	O
include	VBP	O
GIP	NNP	O
,	,	O
CTRP1	NNP	O
,	,	O
ZSIG37	NNP	O
and	CC	O
FLJ90694	NNP	O
.	.	O
C1QTNF1	NNP	O
encodes	VBZ	O
several	JJ	O
distinct	JJ	O
domains	NNS	O
.	.	O
The	DT	O
N-terminus	NNP	O
contains	NNS	O
two	CD	O
overlapping	VBG	O
cysteine-rich	JJ	O
regions	NNS	O
characteristic	NN	O
of	IN	O
the	DT	O
TNFR/NGFR	NNP	O
motif	NN	O
Receptors	NNPS	O
in	IN	O
this	DT	O
family	NN	O
include	VBP	O
certain	JJ	O
tumor	JJ	O
necrosis	NN	O
factor	NN	O
receptors	NNS	O
and	CC	O
nerve	NN	O
growth	NN	O
factor	NN	O
receptors	NNS	O
.	.	O
The	DT	O
C-terminus	NNP	O
contains	VBZ	O
a	DT	O
C1q-like	JJ	O
domain	NN	O
,	,	O
a	DT	O
globular	JJ	O
domain	NN	O
found	VBD	O
in	IN	O
many	JJ	O
collagens	NNS	O
.	.	O
Overall	JJ	O
,	,	O
the	DT	O
protein	NN	O
has	VBZ	O
similarities	NNS	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
soluble	JJ	O
collagens	NNS	O
that	WDT	O
are	VBP	O
thought	VBN	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
defense	NN	O
processes	NNS	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
membrane	VBN	O
bound	NN	O
or	CC	O
secreted	VBN	O
(	(	O
by	IN	O
similarity	NN	O
)	)	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
were	VBD	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
were	VBD	O
intercrossed	VBN	O
to	TO	O
generate	VB	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
progeny	NN	O
.	.	O
On	IN	O
rare	JJ	O
occasions	NNS	O
,	,	O
for	IN	O
example	NN	O
when	WRB	O
very	RB	O
few	JJ	O
F1	NNP	O
mice	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
chimera	NN	O
,	,	O
F1	NNP	O
heterozygous	JJ	O
mice	NNS	O
were	VBD	O
crossed	VBN	O
to	TO	O
129SvEvBrd/C57	CD	O
hybrid	JJ	O
mice	NN	O
to	TO	O
yield	VB	O
additional	JJ	O
heterozygous	JJ	O
animals	NNS	O
for	IN	O
the	DT	O
intercross	NN	O
to	TO	O
generate	VB	O
the	DT	O
F2	NNP	O
mice	NN	O
.	.	O
Level	NN	O
I	PRP	O
phenotypic	VBP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
mice	NN	O
from	IN	O
this	DT	O
generation	NN	O
as	IN	O
shown	VBN	O
below	IN	O
.	.	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
1	CD	O
.	.	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
Disrupted	VBN	O
Gene	NNP	O
:	:	O
DNA41234-1242-1	NNP	O
(	(	O
UNQ310	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
:	:	O
Knockout	NNP	O
homozygous	JJ	O
(	(	O
−/−	NNP	O
)	)	O
and	CC	O
heterozygous	JJ	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
showed	VBD	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
both	DT	O
also	RB	O
showed	VBD	O
an	DT	O
increased	VBN	O
level	NN	O
of	IN	O
ketones	NNS	O
and	CC	O
proteins	NNS	O
in	IN	O
the	DT	O
urine	JJ	O
compared	VBN	O
with	IN	O
wild-type	JJ	O
littermates	NNS	O
and	CC	O
the	DT	O
historical	JJ	O
mean	NN	O
.	.	O
(	(	O
b	NN	O
)	)	O
Phenotypic	NNP	O
Analysis	NN	O
:	:	O
Metabolism—Blood	NNP	O
Chemistry	NNP	O
&	CC	O
Urinalysis	NNP	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
metabolism	NN	O
,	,	O
targets	NNS	O
may	MD	O
be	VB	O
identified	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetes	NNS	O
.	.	O
Blood	NNP	O
chemistry	NN	O
phenotypic	NN	O
analysis	NN	O
includes	VBZ	O
blood	NN	O
glucose	NN	O
measurements	NNS	O
as	RB	O
well	RB	O
as	IN	O
urinalysis	NN	O
to	TO	O
determine	VB	O
if	IN	O
protein	JJ	O
and/or	VBP	O
ketone	JJ	O
bodies	NNS	O
may	MD	O
be	VB	O
present	JJ	O
.	.	O
Abnormal	NNP	O
glucose	JJ	O
metabolism	NN	O
may	MD	O
indicate	VB	O
the	DT	O
following	JJ	O
disorders	NNS	O
or	CC	O
conditions	NNS	O
:	:	O
cachexia	NN	O
,	,	O
Diabetes	NNP	O
Type	NNP	O
1	CD	O
and	CC	O
Type	NNP	O
2	CD	O
,	,	O
Syndrome	NNP	O
X	NNP	O
,	,	O
and	CC	O
various	JJ	O
cardiovascular	JJ	O
diseases	NNS	O
.	.	O
The	DT	O
COBAS	NNP	O
Integra	NNP	O
400	CD	O
(	(	O
mfr	NN	O
:	:	O
Roche	NNP	O
)	)	O
was	VBD	O
used	VBN	O
for	IN	O
running	VBG	O
blood	NN	O
chemistry	NN	O
tests	NNS	O
on	IN	O
the	DT	O
mice	NN	O
.	.	O
The	DT	O
routine	JJ	O
urinalysis	NN	O
is	VBZ	O
a	DT	O
screening	JJ	O
test	NN	O
done	VBN	O
to	TO	O
provide	VB	O
a	DT	O
general	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
renal/urinary	JJ	O
system	NN	O
.	.	O
The	DT	O
characteristics	NNS	O
for	IN	O
which	WDT	O
urine	NN	O
is	VBZ	O
routinely	RB	O
examined	JJ	O
includes	VBZ	O
tests	NNS	O
for	IN	O
protein	NN	O
,	,	O
glucose	NN	O
,	,	O
ketones	NNS	O
,	,	O
blood	NN	O
,	,	O
bilirubin	NN	O
,	,	O
urobilinogen	NN	O
,	,	O
nitrate	NN	O
and	CC	O
leukocyte	JJ	O
esterase	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
pH	NN	O
and	CC	O
specific	JJ	O
gravity	NN	O
.	.	O
Results	NNS	O
:	:	O
Blood	NNP	O
chemistry	NN	O
and	CC	O
urinalysis	NN	O
tests	NNS	O
results	NNS	O
indicated	VBD	O
increased	JJ	O
levels	NNS	O
of	IN	O
glucose	NN	O
in	IN	O
the	DT	O
blood	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
presence	NN	O
of	IN	O
both	DT	O
protein	NN	O
and	CC	O
ketones	NNS	O
in	IN	O
the	DT	O
urine	NN	O
for	IN	O
homozygous	JJ	O
(	(	O
−/−	NNP	O
)	)	O
mutant	NN	O
mice	NN	O
and	CC	O
heterozygous	JJ	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
compared	VBN	O
with	IN	O
wild-type	JJ	O
littermates	NNS	O
and	CC	O
the	DT	O
historical	JJ	O
mean	NN	O
.	.	O
These	DT	O
results	NNS	O
suggest	VBP	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
diabetes	NNS	O
.	.	O
As	IN	O
such	JJ	O
,	,	O
PRO353	NNP	O
polypeptides	VBZ	O
and/or	VB	O
its	PRP$	O
encoding	VBG	O
gene	NN	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
maintaining	VBG	O
normal	JJ	O
glucose	JJ	O
metabolism	NN	O
.	.	O
J	NNP	O
.	.	O
Generation	NN	O
and	CC	O
Analysis	NNP	O
of	IN	O
Mice	NNP	O
Comprising	NNP	O
DNA79302-2521	NNP	O
(	(	O
UNQ868	NNP	O
)	)	O
Gene	NNP	O
Disruptions	NNP	O
In	IN	O
these	DT	O
knockout	NN	O
experiments	NNS	O
,	,	O
the	DT	O
gene	NN	O
encoding	VBG	O
PRO1885	NNP	O
polypeptides	NNS	O
(	(	O
designated	VBN	O
as	IN	O
DNA79302-2521	NNP	O
(	(	O
UNQ868	NNP	O
)	)	O
was	VBD	O
disrupted	VBN	O
.	.	O
The	DT	O
gene	NN	O
specific	JJ	O
information	NN	O
for	IN	O
these	DT	O
studies	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mutated	VBN	O
mouse	NN	O
gene	NN	O
corresponds	NNS	O
to	TO	O
nucleotide	JJ	O
reference	NN	O
:	:	O
AB053181	NNP	O
or	CC	O
Mus	NNP	O
musculus	CC	O
ACE2	NNP	O
mRNA	NN	O
for	IN	O
angiotensin-converting	JJ	O
enzyme-related	JJ	O
carboxypeptidase	NN	O
;	:	O
protein	CC	O
reference	NN	O
:	:	O
BAB40431	NNP	O
or	CC	O
angiotensin-converting	JJ	O
enzyme-related	JJ	O
carboxypeptidase	NN	O
[	NNP	O
Mus	NNP	O
musculus	CC	O
]	NNP	O
;	:	O
the	DT	O
human	JJ	O
gene	NN	O
sequence	NN	O
reference	NN	O
:	:	O
NM—021804	NN	O
or	CC	O
Homo	NN	O
sapiens	JJ	O
angiotensin	NN	O
I	PRP	O
converting	VBG	O
enzyme	JJ	O
(	(	O
peptidyl-dipeptidase	VB	O
A	NNP	O
)	)	O
2	CD	O
(	(	O
ACE2	NNP	O
)	)	O
;	:	O
protein	JJ	O
reference	NN	O
:	:	O
BAB40370	NNP	O
or	CC	O
ACE2	NNP	O
.	.	O
Mutation	NNP	O
type	NN	O
corresponds	NNS	O
to	TO	O
Homologous	NNP	O
Recombination	NNP	O
(	(	O
standard	NN	O
)	)	O
.	.	O
Coding	VBG	O
exon	$	O
1	CD	O
was	VBD	O
targeted	VBN	O
.	.	O
Mutation	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
X-linked	JJ	O
.	.	O
The	DT	O
gene	NN	O
that	WDT	O
is	VBZ	O
mutated	VBN	O
in	IN	O
these	DT	O
animals	NNS	O
is	VBZ	O
represented	VBN	O
by	IN	O
mouse	NN	O
UniGene	NNP	O
cluster	NN	O
Mm.13451	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
the	DT	O
ortholog	NN	O
of	IN	O
human	JJ	O
UniGene	NNP	O
cluster	NN	O
Hs.178098	NNP	O
(	(	O
ACE2	NNP	O
)	)	O
.	.	O
ACE2	NNP	O
encodes	VBZ	O
angiotensin	NN	O
I	PRP	O
converting	VBG	O
enzyme	JJ	O
(	(	O
peptidyl-dipeptidase	VB	O
A	NNP	O
)	)	O
2	CD	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
angiotensin-converting	JJ	O
enzyme-related	JJ	O
carboxypeptidase	NN	O
and	CC	O
ACEH	NNP	O
(	(	O
OMIM	NNP	O
300335	CD	O
)	)	O
.	.	O
The	DT	O
physiological	JJ	O
substrate	NN	O
for	IN	O
ACE2	NNP	O
is	VBZ	O
not	RB	O
precisely	RB	O
known	VBN	O
.	.	O
Unlike	IN	O
ACE	NNP	O
,	,	O
which	WDT	O
catalyzes	VBZ	O
the	DT	O
cleavage	NN	O
of	IN	O
the	DT	O
carboxy-terminal	JJ	O
dipeptide	NN	O
of	IN	O
biologically	RB	O
inactive	JJ	O
Ang1-10	NNP	O
to	TO	O
the	DT	O
potent	JJ	O
vasoconstrictor	NN	O
Ang1-8	NNP	O
,	,	O
ACE2	NNP	O
catalyzes	VBZ	O
the	DT	O
cleavage	NN	O
of	IN	O
the	DT	O
carboxy-terminal	JJ	O
residue	NN	O
of	IN	O
Ang1-10	NNP	O
to	TO	O
form	VB	O
Ang1-9	NNP	O
,	,	O
and	CC	O
the	DT	O
carboxy-terminal	JJ	O
residue	NN	O
of	IN	O
Ang1-8	NNP	O
to	TO	O
form	VB	O
Ang1-7	NNP	O
.	.	O
Moreover	RB	O
,	,	O
Ang1-8	NNP	O
is	VBZ	O
a	DT	O
400-fold	JJ	O
better	RBR	O
substrate	NN	O
than	IN	O
Ang1-10	NNP	O
.	.	O
ACE2	NNP	O
is	VBZ	O
not	RB	O
inhibited	VBN	O
by	IN	O
the	DT	O
ACE	NNP	O
inhibitors	NNS	O
linesopril	VBD	O
or	CC	O
captopril	NN	O
.	.	O
Male	JJ	O
ACE2	NNP	O
knockout	NN	O
mice	NN	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
but	CC	O
not	RB	O
3	CD	O
months	NNS	O
)	)	O
display	VBP	O
decreased	VBN	O
cardiac	JJ	O
contractility	NN	O
and	CC	O
decreased	VBD	O
blood	NN	O
pressure	NN	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
consequence	NN	O
of	IN	O
decreased	JJ	O
cardiac	JJ	O
function	NN	O
.	.	O
Apparently	RB	O
,	,	O
lack	NN	O
of	IN	O
ACE2	NNP	O
activity	NN	O
in	IN	O
ace2	JJ	O
null	JJ	O
mice	NN	O
locally	RB	O
elevates	VBZ	O
Ang1-8	NNP	O
and	CC	O
causes	VBZ	O
vasoconstriction	NN	O
of	IN	O
coronary	JJ	O
arteries	NNS	O
and	CC	O
hypoxia	NN	O
in	IN	O
cardiomyocytes	NNS	O
,	,	O
which	WDT	O
damages	NNS	O
cardiac	VBP	O
tissue	NN	O
and	CC	O
culminates	NNS	O
in	IN	O
heart	NN	O
dysfunction	NN	O
.	.	O
Targeted	VBN	O
or	CC	O
gene	NN	O
trap	JJ	O
mutations	NNS	O
are	VBP	O
generated	VBN	O
in	IN	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
are	VBP	O
bred	VBN	O
to	TO	O
C57BL/6J	NNP	O
albino	NN	O
mice	NN	O
to	TO	O
generate	VB	O
F1	NNP	O
female	JJ	O
heterozygous	JJ	O
animals	NNS	O
.	.	O
These	DT	O
progeny	NNS	O
are	VBP	O
crossed	VBN	O
to	TO	O
hybrid	VB	O
129SvEvBrd/C57	CD	O
F1	NNP	O
mice	NN	O
,	,	O
derived	VBN	O
from	IN	O
crossing	VBG	O
129SvEvBrd	CD	O
mice	NN	O
to	TO	O
C57BL/6J	NNP	O
mice	NN	O
,	,	O
to	TO	O
generate	VB	O
F1A	NNP	O
wild-type	NN	O
,	,	O
female	JJ	O
heterozygous	JJ	O
,	,	O
and	CC	O
male	JJ	O
hemizygous	JJ	O
mice	NN	O
.	.	O
Level	NN	O
I	PRP	O
phenotypic	VBP	O
analysis	NN	O
is	VBZ	O
performed	VBN	O
on	IN	O
mice	NN	O
from	IN	O
this	DT	O
generation	NN	O
.	.	O
Summary	NNP	O
of	IN	O
X-linked	JJ	O
Gene	NNP	O
Distributions	NNP	O
for	IN	O
Sex	NN	O
by	IN	O
Genotype	NNP	O
:	:	O
Disruption	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
Southern	NNP	O
hybridization	NN	O
analysis	NN	O
.	.	O
1	CD	O
.	.	O
Phenotypic	NNP	O
Analysis	NNP	O
(	(	O
for	IN	O
Disrupted	VBN	O
Gene	NNP	O
:	:	O
DNA79302-2521	NNP	O
(	(	O
UNQ868	NNP	O
)	)	O
(	(	O
a	DT	O
)	)	O
Overall	JJ	O
Phenotypic	NNP	O
Summary	NNP	O
:	:	O
This	DT	O
retroviral	JJ	O
insertion	NN	O
is	VBZ	O
in	IN	O
an	DT	O
X-linked	JJ	O
gene	NN	O
.	.	O
Only	RB	O
male	JJ	O
hemizygous	JJ	O
(	(	O
0/−	CD	O
)	)	O
and	CC	O
female	JJ	O
heterozygous	JJ	O
(	(	O
+/−	NNP	O
)	)	O
mice	NN	O
were	VBD	O
analyzed	VBN	O
,	,	O
whereas	IN	O
the	DT	O
wild-type	JJ	O
mice	NN	O
analyzed	VBN	O
were	VBD	O
both	DT	O
male	JJ	O
and	CC	O
female	JJ	O
.	.	O
General	JJ	O
Observations	NNPS	O
:	:	O
The	DT	O
female	NN	O
(	(	O
+/−	NNP	O
)	)	O
and	CC	O
male	NN	O
(	(	O
0/−	CD	O
)	)	O
albino	NN	O
mice	NN	O
had	VBD	O
yellow-tinted	JJ	O
coats	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
(	(	O
+/+	NN	O
)	)	O
albino	NN	O
littermates	NNS	O
.	.	O
[	NNS	O
Analyzed	NNP	O
wt/het/hom	NN	O
:	:	O
35/16/18	CD	O
]	NNS	O
Male	NNP	O
hemizygous	JJ	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
(	(	O
M-105	JJ	O
and	CC	O
M-112	NNP	O
)	)	O
exhibited	VBD	O
heterogeneous	JJ	O
retinal	JJ	O
backgrounds	NNS	O
with	IN	O
mild	JJ	O
depigmentation	NN	O
spots	NNS	O
,	,	O
which	WDT	O
indicates	VBZ	O
early	JJ	O
signs	NNS	O
of	IN	O
retinal	JJ	O
degeneration	NN	O
.	.	O
[	NNS	O
Analyzed	NNP	O
wt/het/hemi	NN	O
:	:	O
4/4/8	CD	O
]	NN	O
(	(	O
b	IN	O
Cardiovascular	NNP	O
Phenotypic	NNP	O
Analysis	NN	O
:	:	O
In	IN	O
the	DT	O
area	NN	O
of	IN	O
cardiovascular	JJ	O
biology	NN	O
,	,	O
phenotypic	NN	O
testing	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
identify	VB	O
potential	JJ	O
targets	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cardiovascular	NN	O
,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
.	.	O
One	CD	O
such	JJ	O
phenotypic	JJ	O
test	NN	O
included	VBD	O
optic	JJ	O
fundus	NN	O
photography	NN	O
and	CC	O
angiography	NN	O
to	TO	O
determine	VB	O
the	DT	O
retinal	JJ	O
arteriovenous	JJ	O
ratio	NN	O
(	(	O
A/V	NNP	O
ratio	NN	O
)	)	O
in	IN	O
order	NN	O
to	TO	O
flag	VB	O
various	JJ	O
eye	NN	O
abnormalities	NNS	O
.	.	O
An	DT	O
abnormal	JJ	O
A/V	NNP	O
ratio	NN	O
signals	NNS	O
such	JJ	O
systemic	JJ	O
diseases	NNS	O
or	CC	O
disorders	NNS	O
that	WDT	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
the	DT	O
vascular	JJ	O
disease	NN	O
of	IN	O
hypertension	NN	O
(	(	O
and	CC	O
any	DT	O
disease	NN	O
that	WDT	O
causes	VBZ	O
hypertension	NN	O
,	,	O
e.g	NN	O
.	.	O
atherosclerosis	NN	O
)	)	O
,	,	O
diabetes	VBZ	O
or	CC	O
other	JJ	O
ocular	JJ	O
diseases	NNS	O
corresponding	VBG	O
to	TO	O
ophthalmological	JJ	O
disorders	NNS	O
.	.	O
Such	JJ	O
eye	NN	O
abnormalities	NNS	O
may	MD	O
include	VB	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
the	DT	O
following	NN	O
:	:	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
various	JJ	O
retinopathies	NNS	O
,	,	O
restenosis	NN	O
,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion	NN	O
;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature	NN	O
,	,	O
retinitis	NN	O
pigmentosa	NN	O
,	,	O
macular	JJ	O
dystrophies	NNS	O
,	,	O
Stargardt	NNP	O
's	POS	O
disease	NN	O
,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness	NN	O
,	,	O
choroideremia	NN	O
,	,	O
gyrate	NN	O
atrophy	NN	O
,	,	O
Leber	NNP	O
's	POS	O
congenital	JJ	O
amaurosis	NN	O
,	,	O
retinoschisis	NN	O
disorders	NNS	O
,	,	O
Wagner	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Usher	NNP	O
syndromes	VBZ	O
,	,	O
Zellweger	NNP	O
syndrome	NN	O
,	,	O
Saldino-Mainzer	NNP	O
syndrome	NN	O
,	,	O
Senior-Loken	NNP	O
syndrome	NN	O
,	,	O
Bardet-Biedl	NNP	O
syndrome	NN	O
,	,	O
Alport	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alstom	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Cockayne	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia	NN	O
,	,	O
Flynn-Aird	NNP	O
syndrome	NN	O
,	,	O
Friedreich	NNP	O
ataxia	NN	O
,	,	O
Hallgren	NNP	O
syndrome	NN	O
,	,	O
Marshall	NNP	O
syndrome	NN	O
,	,	O
Albers-Schnoberg	NNP	O
disease	NN	O
,	,	O
Refsum	NNP	O
's	POS	O
disease	NN	O
,	,	O
Kearns-Sayre	NNP	O
syndrome	NN	O
,	,	O
Waardenburg	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Alagile	NNP	O
syndrome	NN	O
,	,	O
myotonic	JJ	O
dystrophy	NN	O
,	,	O
olivopontocerebellar	JJ	O
atrophy	NN	O
,	,	O
Pierre-Marie	NNP	O
dunsdrome	NN	O
,	,	O
Stickler	NNP	O
syndrome	NN	O
,	,	O
carotinemeia	NN	O
,	,	O
cystinosis	NN	O
,	,	O
Wolfram	NNP	O
syndrome	NN	O
,	,	O
Bassen-Kornzweig	NNP	O
syndrome	NN	O
,	,	O
abetalipoproteinemia	NN	O
,	,	O
incontinentia	NN	O
pigmenti	NN	O
,	,	O
Batten	NNP	O
's	POS	O
disease	NN	O
,	,	O
mucopolysaccharidoses	NNS	O
,	,	O
homocystinuria	NN	O
,	,	O
or	CC	O
mannosidosis	NN	O
.	.	O
Procedure	NN	O
:	:	O
Optic	JJ	O
fundus	NN	O
photography	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
conscious	JJ	O
animals	NNS	O
using	VBG	O
a	DT	O
Kowa	NNP	O
Genesis	NNP	O
small	JJ	O
animal	NN	O
fundus	NN	O
camera	NN	O
modified	VBD	O
according	VBG	O
to	TO	O
Hawes	NNP	O
and	CC	O
coauthors	NNS	O
(	(	O
Hawes	NNP	B
et	RB	I
al.	RB	I
,	,	I
1999	CD	I
Molecular	NNP	I
Vision	NNP	I
1999	CD	I
;	:	I
5:22	CD	I
)	)	O
.	.	O
Intra-peritoneal	JJ	O
injection	NN	O
of	IN	O
fluorescein	NN	O
permitted	VBD	O
the	DT	O
acquisition	NN	O
of	IN	O
direct	JJ	O
light	NN	O
fundus	NN	O
images	NNS	O
and	CC	O
fluorescent	JJ	O
angiograms	NNS	O
for	IN	O
each	DT	O
examination	NN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
direct	VB	O
ophthalmological	JJ	O
changes	NNS	O
,	,	O
this	DT	O
test	NN	O
can	MD	O
detect	VB	O
retinal	JJ	O
changes	NNS	O
associated	VBN	O
with	IN	O
systemic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
diabetes	NNS	O
and	CC	O
atherosclerosis	NN	O
or	CC	O
other	JJ	O
retinal	JJ	O
abnormalities	NNS	O
.	.	O
Pictures	NNS	O
were	VBD	O
provided	VBN	O
of	IN	O
the	DT	O
optic	JJ	O
fundus	NN	O
under	IN	O
normal	JJ	O
light	NN	O
.	.	O
The	DT	O
angiographic	JJ	O
pictures	NNS	O
allowed	VBN	O
examination	NN	O
of	IN	O
the	DT	O
arteries	NNS	O
and	CC	O
veins	NNS	O
of	IN	O
the	DT	O
eye	NN	O
.	.	O
In	IN	O
addition	NN	O
an	DT	O
artery	NN	O
to	TO	O
vein	VB	O
(	(	O
A/V	NNP	O
)	)	O
ratio	NN	O
was	VBD	O
determined	VBN	O
for	IN	O
the	DT	O
eye	NN	O
.	.	O
Ophthalmology	NNP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
generated	JJ	O
F2	NNP	O
wild	JJ	O
type	NN	O
,	,	O
heterozygous	JJ	O
,	,	O
and	CC	O
hemizygous	JJ	O
mutant	NN	O
progeny	NN	O
using	VBG	O
the	DT	O
protocol	NN	O
described	VBN	O
above	IN	O
.	.	O
Specifically	RB	O
,	,	O
the	DT	O
A/V	NNP	O
ratio	NN	O
was	VBD	O
measured	VBN	O
and	CC	O
calculated	VBN	O
according	VBG	O
to	TO	O
the	DT	O
fundus	NN	O
images	VBZ	O
with	IN	O
Kowa	NNP	O
COMIT+	NNP	O
software	NN	O
.	.	O
This	DT	O
test	NN	O
takes	VBZ	O
color	NN	O
photographs	NN	O
through	IN	O
a	DT	O
dilated	JJ	O
pupil	NN	O
:	:	O
the	DT	O
images	NNS	O
help	VBP	O
in	IN	O
detecting	NN	O
and	CC	O
classifying	VBG	O
many	JJ	O
diseases	NNS	O
.	.	O
The	DT	O
artery	NN	O
to	TO	O
vein	VB	O
ratio	NN	O
(	(	O
A/V	NNP	O
)	)	O
is	VBZ	O
the	DT	O
ratio	NN	O
of	IN	O
the	DT	O
artery	NN	O
diameter	NN	O
to	TO	O
the	DT	O
vein	NN	O
diameter	NN	O
(	(	O
measured	VBN	O
before	IN	O
the	DT	O
bifurcation	NN	O
of	IN	O
the	DT	O
vessels	NNS	O
)	)	O
.	.	O
Many	JJ	O
diseases	NNS	O
will	MD	O
influence	VB	O
the	DT	O
ratio	NN	O
,	,	O
i.e.	FW	O
,	,	O
diabetes	VBZ	O
,	,	O
cardiovascular	JJ	O
disorders	NNS	O
,	,	O
papilledema	NN	O
,	,	O
optic	JJ	O
atrophy	NN	O
or	CC	O
other	JJ	O
eye	NN	O
abnormalities	NNS	O
such	JJ	O
as	IN	O
retinal	JJ	O
degeneration	NN	O
(	(	O
known	VBN	O
as	IN	O
retinitis	NN	O
pigmentosa	NN	O
)	)	O
or	CC	O
retinal	JJ	O
dysplasia	NN	O
,	,	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness	NN	O
.	.	O
Thus	RB	O
,	,	O
phenotypic	NN	O
observations	NNS	O
which	WDT	O
result	VBP	O
in	IN	O
an	DT	O
increased	JJ	O
artery-to-vein	NN	O
ratio	NN	O
in	IN	O
homozygous	JJ	O
(	(	O
−/−	NNP	O
)	)	O
and	CC	O
heterozygous	JJ	O
(	(	O
+/−	NNP	O
)	)	O
mutant	NN	O
progeny	NN	O
compared	VBN	O
to	TO	O
wildtype	VB	O
(	(	O
+/+	NN	O
)	)	O
littermates	VBZ	O
would	MD	O
be	VB	O
indicative	JJ	O
of	IN	O
such	JJ	O
pathological	JJ	O
conditions	NNS	O
.	.	O
Results	NNS	O
:	:	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
male	NN	O
hemizygous	JJ	O
(	(	O
0/−	CD	O
)	)	O
mice	NN	O
(	(	O
M-105	JJ	O
and	CC	O
M-112	NNP	O
)	)	O
exhibited	VBD	O
heterogeneous	JJ	O
retinal	JJ	O
backgrounds	NNS	O
with	IN	O
mild	JJ	O
depigmentation	NN	O
spots	NNS	O
,	,	O
which	WDT	O
indicates	VBZ	O
early	JJ	O
signs	NNS	O
of	IN	O
retinal	JJ	O
degeneration	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
hemizygous	JJ	O
mice	NN	O
exhibited	VBD	O
an	DT	O
increased	VBN	O
mean	NN	O
artery-to-vein	NN	O
(	(	O
A/V	NNP	O
)	)	O
ratio	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
their	PRP$	O
(	(	O
+/+	NN	O
)	)	O
littermates	VBZ	O
indicative	JJ	O
of	IN	O
retinal	JJ	O
degeneration	NN	O
.	.	O
In	IN	O
summary	JJ	O
,	,	O
by	IN	O
knocking	VBG	O
out	RP	O
the	DT	O
gene	NN	O
identified	VBD	O
as	IN	O
DNA79302-2521	NNP	O
encoding	VBG	O
PRO1885	NNP	O
polypeptides	NNS	O
,	,	O
hemizygous	JJ	O
mutant	JJ	O
progeny	NN	O
exhibit	NN	O
phenotypes	NNS	O
which	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration	NN	O
.	.	O
Such	JJ	O
detected	VBD	O
retinal	JJ	O
changes	NNS	O
are	VBP	O
most	RBS	O
commonly	RB	O
associated	VBN	O
with	IN	O
cardiovascular	JJ	O
systemic	JJ	O
diseases	NNS	O
or	CC	O
disorders	NNS	O
that	WDT	O
are	VBP	O
related	VBN	O
to	TO	O
the	DT	O
vascular	JJ	O
disease	NN	O
of	IN	O
hypertension	NN	O
(	(	O
and/or	IN	O
any	DT	O
disease	NN	O
that	WDT	O
causes	VBZ	O
hypertension	NN	O
,	,	O
e.g	NN	O
.	.	O
atherosclerosis	NN	O
)	)	O
,	,	O
diabetes	VBZ	O
or	CC	O
other	JJ	O
ocular	JJ	O
diseases	NNS	O
corresponding	VBG	O
to	TO	O
ophthalmological	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
retinal	JJ	O
degeneration	NN	O
.	.	O
Thus	RB	O
,	,	O
antagonists	NNS	O
of	IN	O
PRO1885	NNP	O
encoding	VBG	O
genes	NNS	O
would	MD	O
lead	VB	O
to	TO	O
similar	JJ	O
pathological	JJ	O
retinal	NN	O
changes	NNS	O
,	,	O
whereas	JJ	O
agonists	NNS	O
would	MD	O
be	VB	O
useful	JJ	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
,	,	O
atherosclerosis	NN	O
or	CC	O
other	JJ	O
opthamological	JJ	O
disorders	NNS	O
including	VBG	O
retinal	JJ	O
degeneration	NN	O
and	CC	O
diseases	NNS	O
associated	VBN	O
with	IN	O
this	DT	O
condition	NN	O
(	(	O
as	IN	O
indicated	VBN	O
above	IN	O
)	)	O
.	.	O
Example	RB	O
14	CD	O
Use	NNP	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
as	IN	O
a	DT	O
Hybridization	NNP	O
Probe	NNP	O
The	DT	O
following	JJ	O
method	NN	O
describes	NNS	O
use	NN	O
of	IN	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
a	DT	O
hybridization	NN	O
probe	NN	O
.	.	O
DNA	NN	O
comprising	VBG	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
full-length	JJ	O
or	CC	O
mature	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
as	IN	O
disclosed	JJ	O
herein	NN	O
is	VBZ	O
employed	VBN	O
as	IN	O
a	DT	O
probe	NN	O
to	TO	O
screen	VB	O
for	IN	O
homologous	JJ	O
DNAs	NNP	O
(	(	O
such	JJ	O
as	IN	O
those	DT	O
encoding	VBG	O
naturally-occurring	JJ	O
variants	NNS	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
)	)	O
in	IN	O
human	JJ	O
tissue	NN	O
cDNA	NN	O
libraries	NNS	O
or	CC	O
human	JJ	O
tissue	NN	O
genomic	JJ	O
libraries	NNS	O
.	.	O
Hybridization	NN	O
and	CC	O
washing	NN	O
of	IN	O
filters	NNS	O
containing	VBG	O
either	CC	O
library	JJ	O
DNAs	NNP	O
is	VBZ	O
performed	VBN	O
under	IN	O
the	DT	O
following	JJ	O
high	JJ	O
stringency	NN	O
conditions	NNS	O
.	.	O
Hybridization	NN	O
of	IN	O
radiolabeled	JJ	O
PRO227-	NNP	O
,	,	O
PRO233-	NNP	O
,	,	O
PRO238-	NNP	O
,	,	O
PRO1328-	NNP	O
,	,	O
PRO4342-	NNP	O
,	,	O
PRO7423-	NNP	O
,	,	O
PRO10096-	NNP	O
,	,	O
PRO21384-	NNP	O
,	,	O
PRO353-	NNP	O
or	CC	O
PRO1885-derived	NNP	O
probe	NN	O
to	TO	O
the	DT	O
filters	NNS	O
is	VBZ	O
performed	VBN	O
in	IN	O
a	DT	O
solution	NN	O
of	IN	O
50	CD	O
%	NN	O
formamide	NN	O
,	,	O
5×SSC	CD	O
,	,	O
0.1	CD	O
%	NN	O
SDS	NNP	O
,	,	O
0.1	CD	O
%	NN	O
sodium	NN	O
pyrophosphate	NN	O
,	,	O
50	CD	O
mM	NN	O
sodium	NN	O
phosphate	NN	O
,	,	O
pH	NN	O
6.8	CD	O
,	,	O
2×Denhardt	CD	O
's	POS	O
solution	NN	O
,	,	O
and	CC	O
10	CD	O
%	NN	O
dextran	NN	O
sulfate	NN	O
at	IN	O
42°	CD	O
C.	NNP	O
for	IN	O
20	CD	O
hours	NNS	O
.	.	O
Washing	VBG	O
of	IN	O
the	DT	O
filters	NNS	O
is	VBZ	O
performed	VBN	O
in	IN	O
an	DT	O
aqueous	JJ	O
solution	NN	O
of	IN	O
0.1×SSC	CD	O
and	CC	O
0.1	CD	O
%	NN	O
SDS	NNP	O
at	IN	O
42°	CD	O
C.	NNP	O
DNAs	NNP	O
having	VBG	O
a	DT	O
desired	JJ	O
sequence	NN	O
identity	NN	O
with	IN	O
the	DT	O
DNA	NN	O
encoding	VBG	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
can	MD	O
then	RB	O
be	VB	O
identified	VBN	O
using	VBG	O
standard	JJ	O
techniques	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Example	RB	O
15	CD	O
Expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
in	IN	O
E.	NNP	O
coli	VBP	O
This	DT	O
example	NN	O
illustrates	VBZ	O
preparation	NN	O
of	IN	O
an	DT	O
unglycosylated	JJ	O
form	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
by	IN	O
recombinant	JJ	O
expression	NN	O
in	IN	O
E.	NNP	O
coli	NNS	O
.	.	O
The	DT	O
DNA	NNP	O
sequence	NN	O
encoding	VBG	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
initially	RB	O
amplified	JJ	O
using	VBG	O
selected	VBN	O
PCR	NNP	O
primers	NNS	O
.	.	O
The	DT	O
primers	NNS	O
should	MD	O
contain	VB	O
restriction	NN	O
enzyme	NN	O
sites	NNS	O
which	WDT	O
correspond	VBP	O
to	TO	O
the	DT	O
restriction	NN	O
enzyme	NN	O
sites	VBZ	O
on	IN	O
the	DT	O
selected	VBN	O
expression	NN	O
vector	NN	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
expression	NN	O
vectors	NNS	O
may	MD	O
be	VB	O
employed	VBN	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
a	DT	O
suitable	JJ	O
vector	NN	O
is	VBZ	O
pBR322	JJ	O
(	(	O
derived	VBN	O
from	IN	O
E.	NNP	O
coli	NNS	O
;	:	O
see	VB	O
Bolivar	NNP	B
et	FW	I
al.	NN	I
,	,	I
Gene	NNP	I
,	,	I
2:95	CD	I
(	(	I
1977	CD	I
)	)	I
)	)	O
which	WDT	O
contains	VBZ	O
genes	NNS	O
for	IN	O
ampicillin	NN	O
and	CC	O
tetracycline	NN	O
resistance	NN	O
.	.	O
The	DT	O
vector	NN	O
is	VBZ	O
digested	VBN	O
with	IN	O
restriction	NN	O
enzyme	NN	O
and	CC	O
dephosphorylated	VBN	O
.	.	O
The	DT	O
PCR	NNP	O
amplified	VBD	O
sequences	NNS	O
are	VBP	O
then	RB	O
ligated	VBN	O
into	IN	O
the	DT	O
vector	NN	O
.	.	O
The	DT	O
vector	NN	O
will	MD	O
preferably	RB	O
include	VB	O
sequences	NNS	O
which	WDT	O
encode	VBP	O
for	IN	O
an	DT	O
antibiotic	JJ	O
resistance	NN	O
gene	NN	O
,	,	O
a	DT	O
trp	NN	O
promoter	NN	O
,	,	O
a	DT	O
polyhis	JJ	O
leader	NN	O
(	(	O
including	VBG	O
the	DT	O
first	JJ	O
six	CD	O
STII	NNP	O
codons	NNS	O
,	,	O
polyhis	NN	O
sequence	NN	O
,	,	O
and	CC	O
enterokinase	JJ	O
cleavage	NN	O
site	NN	O
)	)	O
,	,	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
coding	VBG	O
region	NN	O
,	,	O
lambda	JJ	O
transcriptional	JJ	O
terminator	NN	O
,	,	O
and	CC	O
an	DT	O
argU	JJ	O
gene	NN	O
.	.	O
The	DT	O
ligation	NN	O
mixture	NN	O
is	VBZ	O
then	RB	O
used	VBN	O
to	TO	O
transform	VB	O
a	DT	O
selected	VBN	O
E.	NNP	O
coli	NNS	O
strain	VBP	O
using	VBG	O
the	DT	O
methods	NNS	O
described	VBN	O
in	IN	O
Sambrook	NNP	O
et	CC	O
al.	NN	O
,	,	O
supra	NN	O
.	.	O
Transformants	NNS	O
are	VBP	O
identified	VBN	O
by	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
grow	VB	O
on	IN	O
LB	NNP	O
plates	NNS	O
and	CC	O
antibiotic	JJ	O
resistant	NN	O
colonies	NNS	O
are	VBP	O
then	RB	O
selected	VBN	O
.	.	O
Plasmid	NNP	O
DNA	NNP	O
can	MD	O
be	VB	O
isolated	VBN	O
and	CC	O
confirmed	VBN	O
by	IN	O
restriction	NN	O
analysis	NN	O
and	CC	O
DNA	NNP	O
sequencing	NN	O
.	.	O
Selected	VBN	O
clones	NNS	O
can	MD	O
be	VB	O
grown	VBN	O
overnight	RB	O
in	IN	O
liquid	JJ	O
culture	NN	O
medium	NN	O
such	JJ	O
as	IN	O
LB	NNP	O
broth	CC	O
supplemented	VBN	O
with	IN	O
antibiotics	NNS	O
.	.	O
The	DT	O
overnight	JJ	O
culture	NN	O
may	MD	O
subsequently	RB	O
be	VB	O
used	VBN	O
to	TO	O
inoculate	VB	O
a	DT	O
larger	JJR	O
scale	JJ	O
culture	NN	O
.	.	O
The	DT	O
cells	NNS	O
are	VBP	O
then	RB	O
grown	VBN	O
to	TO	O
a	DT	O
desired	JJ	O
optical	JJ	O
density	NN	O
,	,	O
during	IN	O
which	WDT	O
the	DT	O
expression	NN	O
promoter	NN	O
is	VBZ	O
turned	VBN	O
on	IN	O
.	.	O
After	IN	O
culturing	VBG	O
the	DT	O
cells	NNS	O
for	IN	O
several	JJ	O
more	JJR	O
hours	NNS	O
,	,	O
the	DT	O
cells	NNS	O
can	MD	O
be	VB	O
harvested	VBN	O
by	IN	O
centrifugation	NN	O
.	.	O
The	DT	O
cell	NN	O
pellet	NN	O
obtained	VBN	O
by	IN	O
the	DT	O
centrifugation	NN	O
can	MD	O
be	VB	O
solubilized	VBN	O
using	VBG	O
various	JJ	O
agents	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
and	CC	O
the	DT	O
solubilized	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
protein	NN	O
can	MD	O
then	RB	O
be	VB	O
purified	VBN	O
using	VBG	O
a	DT	O
metal	NN	O
chelating	VBG	O
column	NN	O
under	IN	O
conditions	NNS	O
that	WDT	O
allow	VBP	O
tight	JJ	O
binding	NN	O
of	IN	O
the	DT	O
protein	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
may	MD	O
be	VB	O
expressed	VBN	O
in	IN	O
E.	NNP	O
coli	NNS	O
in	IN	O
a	DT	O
poly-His	JJ	O
tagged	JJ	O
form	NN	O
,	,	O
using	VBG	O
the	DT	O
following	JJ	O
procedure	NN	O
.	.	O
The	DT	O
DNA	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
is	VBZ	O
initially	RB	O
amplified	JJ	O
using	VBG	O
selected	VBN	O
PCR	NNP	O
primers	NNS	O
.	.	O
The	DT	O
primers	NNS	O
will	MD	O
contain	VB	O
restriction	NN	O
enzyme	NN	O
sites	NNS	O
which	WDT	O
correspond	VBP	O
to	TO	O
the	DT	O
restriction	NN	O
enzyme	NN	O
sites	VBZ	O
on	IN	O
the	DT	O
selected	VBN	O
expression	NN	O
vector	NN	O
,	,	O
and	CC	O
other	JJ	O
useful	JJ	O
sequences	NNS	O
providing	VBG	O
for	IN	O
efficient	JJ	O
and	CC	O
reliable	JJ	O
translation	NN	O
initiation	NN	O
,	,	O
rapid	JJ	O
purification	NN	O
on	IN	O
a	DT	O
metal	NN	O
chelation	NN	O
column	NN	O
,	,	O
and	CC	O
proteolytic	JJ	O
removal	NN	O
with	IN	O
enterokinase	NN	O
.	.	O
The	DT	O
PCR-amplified	NNP	O
,	,	O
poly-His	JJ	O
tagged	JJ	O
sequences	NNS	O
are	VBP	O
then	RB	O
ligated	VBN	O
into	IN	O
an	DT	O
expression	NN	O
vector	NN	O
,	,	O
which	WDT	O
is	VBZ	O
used	VBN	O
to	TO	O
transform	VB	O
an	DT	O
E.	NNP	O
coli	NNS	O
host	NN	O
based	VBN	O
on	IN	O
strain	NN	O
52	CD	O
(	(	O
W3110	NNP	O
fuhA	NN	O
(	(	O
tonA	NN	O
)	)	O
lon	NN	O
galE	NN	O
rpoHts	NN	O
(	(	O
htpRts	NN	O
)	)	O
clpP	NN	O
(	(	O
lacIq	NN	O
)	)	O
.	.	O
Transformants	NNS	O
are	VBP	O
first	JJ	O
grown	VBN	O
in	IN	O
LB	NNP	O
containing	VBG	O
50	CD	O
mg/ml	JJ	O
carbenicillin	NN	O
at	IN	O
30°	CD	O
C.	NNP	O
with	IN	O
shaking	VBG	O
until	IN	O
an	DT	O
O.D	NNP	O
.	.	O
600	CD	O
of	IN	O
3-5	JJ	O
is	VBZ	O
reached	VBN	O
.	.	O
Cultures	NNS	O
are	VBP	O
then	RB	O
diluted	VBN	O
50-100	JJ	O
fold	NN	O
into	IN	O
CRAP	NNP	O
media	NNS	O
(	(	O
prepared	VBN	O
by	IN	O
mixing	VBG	O
3.57	CD	O
g	NN	O
(	(	O
NH4	NNP	O
)	)	O
2SO4	CD	O
,	,	O
0.71	CD	O
g	NN	O
sodium	NN	O
citrate.2H20	NN	O
,	,	O
1.07	CD	O
g	NN	O
KCl	NNP	O
,	,	O
5.36	CD	O
g	NN	O
Difco	NNP	O
yeast	NNP	O
extract	NN	O
,	,	O
5.36	CD	O
g	NN	O
Sheffield	NNP	O
hycase	NN	O
SF	NNP	O
in	IN	O
500	CD	O
mL	JJ	O
water	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
110	CD	O
mM	NN	O
MPOS	NNP	O
,	,	O
pH	NN	O
7.3	CD	O
,	,	O
0.55	CD	O
%	NN	O
(	(	O
w/v	NN	O
)	)	O
glucose	NN	O
and	CC	O
7	CD	O
mM	NNS	O
MgSO4	NNP	O
)	)	O
and	CC	O
grown	VBN	O
for	IN	O
approximately	RB	O
20-30	JJ	O
hours	NNS	O
at	IN	O
30°	CD	O
C.	NNP	O
with	IN	O
shaking	NN	O
.	.	O
Samples	NNS	O
are	VBP	O
removed	VBN	O
to	TO	O
verify	VB	O
expression	NN	O
by	IN	O
SDS-PAGE	NNP	O
analysis	NN	O
,	,	O
and	CC	O
the	DT	O
bulk	JJ	O
culture	NN	O
is	VBZ	O
centrifuged	VBN	O
to	TO	O
pellet	VB	O
the	DT	O
cells	NNS	O
.	.	O
Cell	NNP	O
pellets	NNS	O
are	VBP	O
frozen	JJ	O
until	IN	O
purification	NN	O
and	CC	O
refolding	NN	O
.	.	O
E.	NNP	O
coli	NNS	O
paste	NN	O
from	IN	O
0.5	CD	O
to	TO	O
1	CD	O
L	NNP	O
fermentations	NNS	O
(	(	O
6-10	JJ	O
g	NN	O
pellets	NNS	O
)	)	O
is	VBZ	O
resuspended	VBN	O
in	IN	O
10	CD	O
volumes	NNS	O
(	(	O
w/v	NN	O
)	)	O
in	IN	O
7	CD	O
M	NNP	O
guanidine	NN	O
,	,	O
20	CD	O
mM	NN	O
Tris	NNP	O
,	,	O
pH	VBZ	O
8	CD	O
buffer	NN	O
.	.	O
Solid	JJ	O
sodium	NN	O
sulfite	NN	O
and	CC	O
sodium	NN	O
tetrathionate	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
make	VB	O
final	JJ	O
concentrations	NNS	O
of	IN	O
0.1M	CD	O
and	CC	O
0.02	CD	O
M	NNP	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
solution	NN	O
is	VBZ	O
stirred	VBN	O
overnight	RB	O
at	IN	O
4°	CD	O
C.	NNP	O
This	DT	O
step	NN	O
results	NNS	O
in	IN	O
a	DT	O
denatured	JJ	O
protein	NN	O
with	IN	O
all	DT	O
cysteine	NN	O
residues	NNS	O
blocked	VBN	O
by	IN	O
sulfitolization	NN	O
.	.	O
The	DT	O
solution	NN	O
is	VBZ	O
centrifuged	VBN	O
at	IN	O
40,000	CD	O
rpm	NN	O
in	IN	O
a	DT	O
Beckman	NNP	O
Ultracentifuge	NNP	O
for	IN	O
30	CD	O
min	NN	O
.	.	O
The	DT	O
supernatant	NN	O
is	VBZ	O
diluted	VBN	O
with	IN	O
3-5	JJ	O
volumes	NNS	O
of	IN	O
metal	NN	O
chelate	NN	O
column	NN	O
buffer	NN	O
(	(	O
6	CD	O
M	NNP	O
guanidine	NN	O
,	,	O
20	CD	O
mM	NN	O
Tris	NNP	O
,	,	O
pH	RB	O
7.4	CD	O
)	)	O
and	CC	O
filtered	VBN	O
through	IN	O
0.22	CD	O
micron	NN	O
filters	NNS	O
to	TO	O
clarify	VB	O
.	.	O
The	DT	O
clarified	JJ	O
extract	NN	O
is	VBZ	O
loaded	VBN	O
onto	IN	O
a	DT	O
5	CD	O
ml	NN	O
Qiagen	NNP	O
Ni-NTA	NNP	O
metal	NN	O
chelate	NN	O
column	NN	O
equilibrated	VBN	O
in	IN	O
the	DT	O
metal	NN	O
chelate	NN	O
column	NN	O
buffer	NN	O
.	.	O
The	DT	O
column	NN	O
is	VBZ	O
washed	VBN	O
with	IN	O
additional	JJ	O
buffer	NN	O
containing	VBG	O
50	CD	O
mM	JJ	O
imidazole	NN	O
(	(	O
Calbiochem	NNP	O
,	,	O
Utrol	NNP	O
grade	NN	O
)	)	O
,	,	O
pH	JJ	O
7.4	CD	O
.	.	O
The	DT	O
protein	NN	O
is	VBZ	O
eluted	VBN	O
with	IN	O
buffer	NN	O
containing	VBG	O
250	CD	O
mM	JJ	O
imidazole	NN	O
.	.	O
Fractions	NNS	O
containing	VBG	O
the	DT	O
desired	VBN	O
protein	NN	O
are	VBP	O
pooled	VBN	O
and	CC	O
stored	VBN	O
at	IN	O
4°	CD	O
C.	NNP	O
Protein	NNP	O
concentration	NN	O
is	VBZ	O
estimated	VBN	O
by	IN	O
its	PRP$	O
absorbance	NN	O
at	IN	O
280	CD	O
nm	NNS	O
using	VBG	O
the	DT	O
calculated	JJ	O
extinction	NN	O
coefficient	NN	O
based	VBN	O
on	IN	O
its	PRP$	O
amino	NN	O
acid	NN	O
sequence	NN	O
.	.	O
The	DT	O
proteins	NNS	O
are	VBP	O
refolded	VBN	O
by	IN	O
diluting	VBG	O
the	DT	O
sample	NN	O
slowly	RB	O
into	IN	O
freshly	RB	O
prepared	JJ	O
refolding	VBG	O
buffer	NN	O
consisting	NN	O
of	IN	O
:	:	O
20	CD	O
mM	NN	O
Tris	NNP	O
,	,	O
pH	NN	O
8.6	CD	O
,	,	O
0.3	CD	O
M	NNP	O
NaCl	NNP	O
,	,	O
2.5	CD	O
M	NNP	O
urea	NN	O
,	,	O
5	CD	O
mM	NN	O
cysteine	NN	O
,	,	O
20	CD	O
mM	NN	O
glycine	NN	O
and	CC	O
1	CD	O
mM	NN	O
EDTA	NNP	O
.	.	O
Refolding	VBG	O
volumes	NNS	O
are	VBP	O
chosen	VBN	O
so	RB	O
that	IN	O
the	DT	O
final	JJ	O
protein	NN	O
concentration	NN	O
is	VBZ	O
between	IN	O
50	CD	O
to	TO	O
100	CD	O
micrograms/ml	NNS	O
.	.	O
The	DT	O
refolding	VBG	O
solution	NN	O
is	VBZ	O
stirred	VBN	O
gently	RB	O
at	IN	O
4°	CD	O
C.	NNP	O
for	IN	O
12-36	JJ	O
hours	NNS	O
.	.	O
The	DT	O
refolding	VBG	O
reaction	NN	O
is	VBZ	O
quenched	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
TFA	NNP	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
0.4	CD	O
%	NN	O
(	(	O
pH	NN	O
of	IN	O
approximately	RB	O
3	CD	O
)	)	O
.	.	O
Before	IN	O
further	JJ	O
purification	NN	O
of	IN	O
the	DT	O
protein	NN	O
,	,	O
the	DT	O
solution	NN	O
is	VBZ	O
filtered	VBN	O
through	IN	O
a	DT	O
0.22	CD	O
micron	NN	O
filter	NN	O
and	CC	O
acetonitrile	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
2-10	CD	O
%	NN	O
final	JJ	O
concentration	NN	O
.	.	O
The	DT	O
refolded	JJ	O
protein	NN	O
is	VBZ	O
chromatographed	VBN	O
on	IN	O
a	DT	O
Poros	NNP	O
R1/H	NNP	O
reversed	VBD	O
phase	NN	O
column	NN	O
using	VBG	O
a	DT	O
mobile	JJ	O
buffer	NN	O
of	IN	O
0.1	CD	O
%	NN	O
TFA	NNP	O
with	IN	O
elution	NN	O
with	IN	O
a	DT	O
gradient	NN	O
of	IN	O
acetonitrile	NN	O
from	IN	O
10	CD	O
to	TO	O
80	CD	O
%	NN	O
.	.	O
Aliquots	NNS	O
of	IN	O
fractions	NNS	O
with	IN	O
A280	NNP	O
absorbance	NN	O
are	VBP	O
analyzed	VBN	O
on	IN	O
SDS	NNP	O
polyacrylamide	NN	O
gels	NNS	O
and	CC	O
fractions	NNS	O
containing	VBG	O
homogeneous	JJ	O
refolded	VBN	O
protein	NN	O
are	VBP	O
pooled	VBN	O
.	.	O
Generally	RB	O
,	,	O
the	DT	O
properly	RB	O
refolded	JJ	O
species	NNS	O
of	IN	O
most	JJS	O
proteins	NNS	O
are	VBP	O
eluted	VBN	O
at	IN	O
the	DT	O
lowest	JJS	O
concentrations	NNS	O
of	IN	O
acetonitrile	NN	O
since	IN	O
those	DT	O
species	NNS	O
are	VBP	O
the	DT	O
most	RBS	O
compact	JJ	O
with	IN	O
their	PRP$	O
hydrophobic	JJ	O
interiors	NNS	O
shielded	VBD	O
from	IN	O
interaction	NN	O
with	IN	O
the	DT	O
reversed	JJ	O
phase	NN	O
resin	NN	O
.	.	O
Aggregated	VBN	O
species	NNS	O
are	VBP	O
usually	RB	O
eluted	VBN	O
at	IN	O
higher	JJR	O
acetonitrile	NN	O
concentrations	NNS	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
resolving	VBG	O
misfolded	JJ	O
forms	NNS	O
of	IN	O
proteins	NNS	O
from	IN	O
the	DT	O
desired	JJ	O
form	NN	O
,	,	O
the	DT	O
reversed	JJ	O
phase	NN	O
step	NN	O
also	RB	O
removes	VBZ	O
endotoxin	NN	O
from	IN	O
the	DT	O
samples	NNS	O
.	.	O
Fractions	NNS	O
containing	VBG	O
the	DT	O
desired	VBN	O
folded	VBD	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
are	VBP	O
pooled	VBN	O
and	CC	O
the	DT	O
acetonitrile	NN	O
removed	VBD	O
using	VBG	O
a	DT	O
gentle	JJ	O
stream	NN	O
of	IN	O
nitrogen	NN	O
directed	VBN	O
at	IN	O
the	DT	O
solution	NN	O
.	.	O
Proteins	NNS	O
are	VBP	O
formulated	VBN	O
into	IN	O
20	CD	O
mM	NN	O
Hepes	NNP	O
,	,	O
pH	VBZ	O
6.8	CD	O
with	IN	O
0.14	CD	O
M	NNP	O
sodium	NN	O
chloride	NN	O
and	CC	O
4	CD	O
%	NN	O
mannitol	NN	O
by	IN	O
dialysis	NN	O
or	CC	O
by	IN	O
gel	JJ	O
filtration	NN	O
using	VBG	O
G25	NNP	O
Superfine	NNP	O
(	(	O
Pharmacia	NNP	O
)	)	O
resins	VBZ	O
equilibrated	VBN	O
in	IN	O
the	DT	O
formulation	NN	O
buffer	NN	O
and	CC	O
sterile	JJ	O
filtered	VBN	O
.	.	O
Example	RB	O
16	CD	O
Expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
in	IN	O
Mammalian	NNP	O
Cells	NNP	O
This	DT	O
example	NN	O
illustrates	VBZ	O
preparation	NN	O
of	IN	O
a	DT	O
potentially	RB	O
glycosylated	JJ	O
form	NN	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
by	IN	O
recombinant	JJ	O
expression	NN	O
in	IN	O
mammalian	JJ	O
cells	NNS	O
.	.	O
The	DT	O
vector	NN	O
,	,	O
pRK5	NN	O
(	(	O
see	VB	O
EP	NNP	O
307,247	CD	O
,	,	O
published	VBN	O
Mar	NNP	O
.	.	O
15	CD	O
,	,	O
1989	CD	O
)	)	O
,	,	O
is	VBZ	O
employed	VBN	O
as	IN	O
the	DT	O
expression	NN	O
vector	NN	O
.	.	O
Optionally	RB	O
,	,	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
DNA	NNP	O
is	VBZ	O
ligated	VBN	O
into	IN	O
pRK5	NN	O
with	IN	O
selected	VBN	O
restriction	NN	O
enzymes	VBZ	O
to	TO	O
allow	VB	O
insertion	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
DNA	NNP	O
using	VBG	O
ligation	NN	O
methods	NNS	O
such	JJ	O
as	IN	O
described	NNS	O
in	IN	O
Sambrook	NNP	O
et	CC	O
al.	NN	O
,	,	O
supra	NN	O
.	.	O
The	DT	O
resulting	VBG	O
vector	NN	O
is	VBZ	O
called	VBN	O
pRK5-PRO227	JJ	O
,	,	O
pRK5-pRK5-PRO233	JJ	O
,	,	O
pRK5-PRO238	JJ	O
,	,	O
pRK5-PRO1328	JJ	O
,	,	O
pRK5-PRO4342	JJ	O
,	,	O
pRK5-PRO7423	JJ	O
;	:	O
pRK5-PRO10096	JJ	O
;	:	O
pRK5-PRO21384	JJ	O
;	:	O
pRK5-PRO353	JJ	O
or	CC	O
pRK5-PRO1885	JJ	O
.	.	O
The	DT	O
selected	VBN	O
host	NN	O
cells	NNS	O
may	MD	O
be	VB	O
293	CD	O
cells	NNS	O
.	.	O
Human	JJ	O
293	CD	O
cells	NNS	O
(	(	O
ATCC	NNP	O
CCL	NNP	O
1573	CD	O
)	)	O
are	VBP	O
grown	VBN	O
to	TO	O
confluence	VB	O
in	IN	O
tissue	NN	O
culture	NN	O
plates	VBZ	O
in	IN	O
medium	NN	O
such	JJ	O
as	IN	O
DMEM	NNP	O
supplemented	VBD	O
with	IN	O
fetal	JJ	O
calf	NN	O
serum	NN	O
and	CC	O
optionally	RB	O
,	,	O
nutrient	JJ	O
components	NNS	O
and/or	JJ	O
antibiotics	NNS	O
.	.	O
About	IN	O
10	CD	O
μg	JJ	O
pRK5-PRO227	JJ	O
,	,	O
pRK5-pRK5-PRO233	JJ	O
,	,	O
pRK5-PRO238	JJ	O
,	,	O
pRK5-PRO1328	JJ	O
,	,	O
pRK5-PRO4342	JJ	O
,	,	O
pRK5-PRO7423	JJ	O
;	:	O
pRK5-PRO10096	JJ	O
;	:	O
pRK5-PRO21384	JJ	O
;	:	O
pRK5-PRO353	JJ	O
or	CC	O
pRK5-PRO1885	JJ	O
DNA	NN	O
is	VBZ	O
mixed	JJ	O
with	IN	O
about	IN	O
1	CD	O
μg	NNS	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
VA	NNP	O
RNA	NNP	O
gene	NN	O
[	NNP	O
Thimmappaya	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cell	NNP	I
,	,	I
31:543	CD	I
(	(	I
1982	CD	I
)	)	I
]	NN	O
and	CC	O
dissolved	VBN	O
in	IN	O
500	CD	O
μl	NN	O
of	IN	O
1	CD	O
mM	JJ	O
Tris-HCl	NNP	O
,	,	O
0.1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
0.227	CD	O
M	NNP	O
CaCl2	NNP	O
.	.	O
To	TO	O
this	DT	O
mixture	NN	O
is	VBZ	O
added	VBN	O
,	,	O
dropwise	NN	O
,	,	O
500	CD	O
μl	NN	O
of	IN	O
50	CD	O
mM	NNS	O
HEPES	NNP	O
(	(	O
pH	VB	O
7.35	CD	O
)	)	O
,	,	O
280	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
1.5	CD	O
mM	NN	O
NaPO4	NNP	O
,	,	O
and	CC	O
a	DT	O
precipitate	NN	O
is	VBZ	O
allowed	VBN	O
to	TO	O
form	VB	O
for	IN	O
10	CD	O
minutes	NNS	O
at	IN	O
25°	CD	O
C.	NNP	O
The	DT	O
precipitate	NN	O
is	VBZ	O
suspended	VBN	O
and	CC	O
added	VBN	O
to	TO	O
the	DT	O
293	CD	O
cells	NNS	O
and	CC	O
allowed	VBN	O
to	TO	O
settle	VB	O
for	IN	O
about	RB	O
four	CD	O
hours	NNS	O
at	IN	O
37°	CD	O
C.	NNP	O
The	DT	O
culture	NN	O
medium	NN	O
is	VBZ	O
aspirated	VBN	O
off	RB	O
and	CC	O
2	CD	O
ml	NN	O
of	IN	O
20	CD	O
%	NN	O
glycerol	NN	O
in	IN	O
PBS	NNP	O
is	VBZ	O
added	VBN	O
for	IN	O
30	CD	O
seconds	NNS	O
.	.	O
The	DT	O
293	CD	O
cells	NNS	O
are	VBP	O
then	RB	O
washed	VBN	O
with	IN	O
serum	JJ	O
free	JJ	O
medium	NN	O
,	,	O
fresh	JJ	O
medium	NN	O
is	VBZ	O
added	VBN	O
and	CC	O
the	DT	O
cells	NNS	O
are	VBP	O
incubated	VBN	O
for	IN	O
about	RB	O
5	CD	O
days	NNS	O
.	.	O
Approximately	RB	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
transfections	NNS	O
,	,	O
the	DT	O
culture	NN	O
medium	NN	O
is	VBZ	O
removed	VBN	O
and	CC	O
replaced	VBN	O
with	IN	O
culture	NN	O
medium	NN	O
(	(	O
alone	RB	O
)	)	O
or	CC	O
culture	NN	O
medium	NN	O
containing	VBG	O
200	CD	O
μCi/ml	JJ	O
35S-cysteine	JJ	O
and	CC	O
200	CD	O
μCi/ml	JJ	O
35S-methionine	JJ	O
.	.	O
After	IN	O
a	DT	O
12	CD	O
hour	NN	O
incubation	NN	O
,	,	O
the	DT	O
conditioned	JJ	O
medium	NN	O
is	VBZ	O
collected	VBN	O
,	,	O
concentrated	VBN	O
on	IN	O
a	DT	O
spin	NN	O
filter	NN	O
,	,	O
and	CC	O
loaded	VBD	O
onto	IN	O
a	DT	O
15	CD	O
%	NN	O
SDS	NNP	O
gel	NN	O
.	.	O
The	DT	O
processed	JJ	O
gel	NN	O
may	MD	O
be	VB	O
dried	VBN	O
and	CC	O
exposed	VBN	O
to	TO	O
film	NN	O
for	IN	O
a	DT	O
selected	JJ	O
period	NN	O
of	IN	O
time	NN	O
to	TO	O
reveal	VB	O
the	DT	O
presence	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
.	.	O
The	DT	O
cultures	NNS	O
containing	VBG	O
transfected	JJ	O
cells	NNS	O
may	MD	O
undergo	VB	O
further	JJ	O
incubation	NN	O
(	(	O
in	IN	O
serum	NN	O
free	JJ	O
medium	NN	O
)	)	O
and	CC	O
the	DT	O
medium	NN	O
is	VBZ	O
tested	VBN	O
in	IN	O
selected	VBN	O
bioassays	NNS	O
.	.	O
In	IN	O
an	DT	O
alternative	JJ	O
technique	NN	O
,	,	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
may	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
293	CD	O
cells	NNS	O
transiently	RB	O
using	VBG	O
the	DT	O
dextran	NN	O
sulfate	NN	O
method	NN	O
described	VBN	O
by	IN	O
Somparyrac	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
12:7575	CD	I
(	(	I
1981	CD	I
)	)	I
.	.	O
293	CD	O
cells	NNS	O
are	VBP	O
grown	VBN	O
to	TO	O
maximal	JJ	O
density	NN	O
in	IN	O
a	DT	O
spinner	NN	O
flask	NN	O
and	CC	O
700	CD	O
μg	JJ	O
pRK5-PRO227	JJ	O
,	,	O
pRK5-pRK5-PRO233	JJ	O
,	,	O
pRK5-PRO238	JJ	O
,	,	O
pRK5-PRO1328	JJ	O
,	,	O
pRK5-PRO4342	JJ	O
,	,	O
pRK5-PRO7423	JJ	O
;	:	O
pRK5-PRO10096	JJ	O
;	:	O
pRK5-PRO21384	JJ	O
;	:	O
pRK5-PRO353	JJ	O
or	CC	O
pRK5-PRO1885	JJ	O
DNA	NN	O
is	VBZ	O
added	VBN	O
.	.	O
The	DT	O
cells	NNS	O
are	VBP	O
first	RB	O
concentrated	VBN	O
from	IN	O
the	DT	O
spinner	NN	O
flask	NN	O
by	IN	O
centrifugation	NN	O
and	CC	O
washed	VBD	O
with	IN	O
PBS	NNP	O
.	.	O
The	DT	O
DNA-dextran	NNP	O
precipitate	NN	O
is	VBZ	O
incubated	VBN	O
on	IN	O
the	DT	O
cell	NN	O
pellet	NN	O
for	IN	O
four	CD	O
hours	NNS	O
.	.	O
The	DT	O
cells	NNS	O
are	VBP	O
treated	VBN	O
with	IN	O
20	CD	O
%	NN	O
glycerol	NN	O
for	IN	O
90	CD	O
seconds	NNS	O
,	,	O
washed	VBN	O
with	IN	O
tissue	NN	O
culture	NN	O
medium	NN	O
,	,	O
and	CC	O
re-introduced	JJ	O
into	IN	O
the	DT	O
spinner	NN	O
flask	NN	O
containing	VBG	O
tissue	NN	O
culture	NN	O
medium	NN	O
,	,	O
5	CD	O
μg/ml	JJ	O
bovine	NN	O
insulin	NN	O
and	CC	O
0.1	CD	O
μg/ml	JJ	O
bovine	NN	O
transferrin	NN	O
.	.	O
After	IN	O
about	RB	O
four	CD	O
days	NNS	O
,	,	O
the	DT	O
conditioned	JJ	O
media	NNS	O
is	VBZ	O
centrifuged	VBN	O
and	CC	O
filtered	VBN	O
to	TO	O
remove	VB	O
cells	NNS	O
and	CC	O
debris	NN	O
.	.	O
The	DT	O
sample	NN	O
containing	VBG	O
expressed	VBN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
then	RB	O
be	VB	O
concentrated	VBN	O
and	CC	O
purified	VBN	O
by	IN	O
any	DT	O
selected	VBN	O
method	NN	O
,	,	O
such	JJ	O
as	IN	O
dialysis	NN	O
and/or	NN	O
column	NN	O
chromatography	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
be	VB	O
expressed	VBN	O
in	IN	O
CHO	NNP	O
cells	NNS	O
.	.	O
The	DT	O
pRK5-PRO227	JJ	O
,	,	O
pRK5-pRK5-PRO233	JJ	O
,	,	O
pRK5-PRO238	JJ	O
,	,	O
pRK5-PRO1328	JJ	O
,	,	O
pRK5-PRO4342	JJ	O
,	,	O
pRK5-PRO7423	JJ	O
;	:	O
pRK5-PRO10096	JJ	O
;	:	O
pRK5-PRO21384	JJ	O
;	:	O
pRK5-PRO353	JJ	O
or	CC	O
pRK5-PRO1885	JJ	O
can	MD	O
be	VB	O
transfected	VBN	O
into	IN	O
CHO	NNP	O
cells	NNS	O
using	VBG	O
known	JJ	O
reagents	NNS	O
such	JJ	O
as	IN	O
CaPO4	NNP	O
or	CC	O
DEAE-dextran	NNP	O
.	.	O
As	IN	O
described	VBN	O
above	IN	O
,	,	O
the	DT	O
cell	NN	O
cultures	NNS	O
can	MD	O
be	VB	O
incubated	VBN	O
,	,	O
and	CC	O
the	DT	O
medium	NN	O
replaced	VBD	O
with	IN	O
culture	NN	O
medium	NN	O
(	(	O
alone	RB	O
)	)	O
or	CC	O
medium	NN	O
containing	VBG	O
a	DT	O
radiolabel	NN	O
such	JJ	O
as	IN	O
35S-methionine	JJ	O
.	.	O
After	IN	O
determining	VBG	O
the	DT	O
presence	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
culture	NN	O
medium	NN	O
may	MD	O
be	VB	O
replaced	VBN	O
with	IN	O
serum	JJ	O
free	JJ	O
medium	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
cultures	NNS	O
are	VBP	O
incubated	VBN	O
for	IN	O
about	RB	O
6	CD	O
days	NNS	O
,	,	O
and	CC	O
then	RB	O
the	DT	O
conditioned	JJ	O
medium	NN	O
is	VBZ	O
harvested	VBN	O
.	.	O
The	DT	O
medium	NN	O
containing	VBG	O
the	DT	O
expressed	VBN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
then	RB	O
be	VB	O
concentrated	VBN	O
and	CC	O
purified	VBN	O
by	IN	O
any	DT	O
selected	VBN	O
method	NN	O
.	.	O
Epitope-tagged	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
may	MD	O
also	RB	O
be	VB	O
expressed	VBN	O
in	IN	O
host	NN	O
CHO	NNP	O
cells	NNS	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
may	MD	O
be	VB	O
subcloned	VBN	O
out	IN	O
of	IN	O
the	DT	O
pRK5	NN	O
vector	NN	O
.	.	O
The	DT	O
subclone	NN	O
insert	NN	O
can	MD	O
undergo	VB	O
PCR	NNP	O
to	TO	O
fuse	VB	O
in	IN	O
frame	NN	O
with	IN	O
a	DT	O
selected	VBN	O
epitope	NN	O
tag	NN	O
such	JJ	O
as	IN	O
a	DT	O
poly-his	JJ	O
tag	NN	O
into	IN	O
a	DT	O
Baculovirus	NNP	O
expression	NN	O
vector	NN	O
.	.	O
The	DT	O
poly-his	JJ	O
tagged	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
insert	NN	O
can	MD	O
then	RB	O
be	VB	O
subcloned	VBN	O
into	IN	O
a	DT	O
SV40	NNP	O
driven	NN	O
vector	NN	O
containing	VBG	O
a	DT	O
selection	NN	O
marker	NN	O
such	JJ	O
as	IN	O
DHFR	NNP	O
for	IN	O
selection	NN	O
of	IN	O
stable	JJ	O
clones	NNS	O
.	.	O
Finally	RB	O
,	,	O
the	DT	O
CHO	NNP	O
cells	NNS	O
can	MD	O
be	VB	O
transfected	VBN	O
(	(	O
as	IN	O
described	VBN	O
above	IN	O
)	)	O
with	IN	O
the	DT	O
SV40	NNP	O
driven	NN	O
vector	NN	O
.	.	O
Labeling	VBG	O
may	MD	O
be	VB	O
performed	VBN	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
to	TO	O
verify	VB	O
expression	NN	O
.	.	O
The	DT	O
culture	NN	O
medium	NN	O
containing	VBG	O
the	DT	O
expressed	VBN	O
poly-His	NN	O
tagged	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
then	RB	O
be	VB	O
concentrated	VBN	O
and	CC	O
purified	VBN	O
by	IN	O
any	DT	O
selected	VBN	O
method	NN	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
Ni2+-chelate	NNP	O
affinity	NN	O
chromatography	NN	O
.	.	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
may	MD	O
also	RB	O
be	VB	O
expressed	VBN	O
in	IN	O
CHO	NNP	O
and/or	NN	O
COS	NNP	O
cells	NNS	O
by	IN	O
a	DT	O
transient	JJ	O
expression	NN	O
procedure	NN	O
or	CC	O
in	IN	O
CHO	NNP	O
cells	NNS	O
by	IN	O
another	DT	O
stable	JJ	O
expression	NN	O
procedure	NN	O
.	.	O
Stable	JJ	O
expression	NN	O
in	IN	O
CHO	NNP	O
cells	NNS	O
is	VBZ	O
performed	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
procedure	NN	O
.	.	O
The	DT	O
proteins	NNS	O
are	VBP	O
expressed	VBN	O
as	IN	O
an	DT	O
IgG	NNP	O
construct	NN	O
(	(	O
immunoadhesin	NN	O
)	)	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
the	DT	O
soluble	JJ	O
forms	NNS	O
(	(	O
e.g	NN	O
.	.	O
extracellular	JJ	O
domains	NNS	O
)	)	O
of	IN	O
the	DT	O
respective	JJ	O
proteins	NNS	O
are	VBP	O
fused	VBN	O
to	TO	O
an	DT	O
IgG1	NNP	O
constant	JJ	O
region	NN	O
sequence	NN	O
containing	VBG	O
the	DT	O
hinge	NN	O
,	,	O
CH2	NNP	O
and	CC	O
CH2	NNP	O
domains	NNS	O
and/or	VBP	O
is	VBZ	O
a	DT	O
poly-His	JJ	O
tagged	JJ	O
form	NN	O
.	.	O
Following	VBG	O
PCR	NNP	O
amplification	NN	O
,	,	O
the	DT	O
respective	JJ	O
DNAs	NNP	O
are	VBP	O
subcloned	VBN	O
in	IN	O
a	DT	O
CHO	NNP	O
expression	NN	O
vector	NN	O
using	VBG	O
standard	JJ	O
techniques	NNS	O
as	IN	O
described	VBN	O
in	IN	O
Ausubel	NNP	B
et	CC	I
al.	RB	I
,	,	I
Current	NNP	I
Protocols	NNP	I
of	IN	I
Molecular	NNP	I
Biology	NNP	I
,	,	I
Unit	NNP	I
3.16	CD	I
,	,	I
John	NNP	I
Wiley	NNP	I
and	CC	I
Sons	NNP	I
(	(	I
1997	CD	I
)	)	I
.	.	O
CHO	NNP	O
expression	NN	O
vectors	NNS	O
are	VBP	O
constructed	VBN	O
to	TO	O
have	VB	O
compatible	JJ	O
restriction	NN	O
sites	VBZ	O
5′	CD	O
and	CC	O
3′	CD	O
of	IN	O
the	DT	O
DNA	NN	O
of	IN	O
interest	NN	O
to	TO	O
allow	VB	O
the	DT	O
convenient	NN	O
shuttling	NN	O
of	IN	O
cDNA	NN	O
's	POS	O
.	.	O
The	DT	O
vector	NN	O
used	VBN	O
expression	NN	O
in	IN	O
CHO	NNP	O
cells	NNS	O
is	VBZ	O
as	IN	O
described	VBN	O
in	IN	O
Lucas	NNP	B
et	CC	I
al.	NN	I
,	,	I
Nucl	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
24:9	CD	I
(	(	I
1774-1779	CD	I
(	(	I
1996	CD	I
)	)	I
,	,	O
and	CC	O
uses	VBZ	O
the	DT	O
SV40	NNP	O
early	JJ	O
promoter/enhancer	NN	O
to	TO	O
drive	VB	O
expression	NN	O
of	IN	O
the	DT	O
cDNA	NN	O
of	IN	O
interest	NN	O
and	CC	O
dihydrofolate	JJ	O
reductase	NN	O
(	(	O
DHFR	NNP	O
)	)	O
.	.	O
DHFR	NNP	O
expression	NN	O
permits	VBZ	O
selection	NN	O
for	IN	O
stable	JJ	O
maintenance	NN	O
of	IN	O
the	DT	O
plasmid	NN	O
following	VBG	O
transfection	NN	O
.	.	O
Twelve	NNP	O
micrograms	NNS	O
of	IN	O
the	DT	O
desired	VBN	O
plasmid	NN	O
DNA	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
approximately	RB	O
10	CD	O
million	CD	O
CHO	NNP	O
cells	NNS	O
using	VBG	O
commercially	RB	O
available	JJ	O
transfection	NN	O
reagents	NNS	O
Superfect®	NNP	O
(	(	O
Qiagen	NNP	O
)	)	O
,	,	O
Dosper®	NNP	O
or	CC	O
Fugene®	NNP	O
(	(	O
Boehringer	NNP	O
Mannheim	NNP	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
are	VBP	O
grown	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Lucas	NNP	O
et	CC	O
al.	NN	O
,	,	O
supra	NN	O
.	.	O
Approximately	RB	O
3×107	CD	O
cells	NNS	O
are	VBP	O
frozen	VBN	O
in	IN	O
an	DT	O
ampule	NN	O
for	IN	O
further	JJ	O
growth	NN	O
and	CC	O
production	NN	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
The	DT	O
ampules	NNS	O
containing	VBG	O
the	DT	O
plasmid	NN	O
DNA	NNP	O
are	VBP	O
thawed	VBN	O
by	IN	O
placement	NN	O
into	IN	O
water	NN	O
bath	NN	O
and	CC	O
mixed	JJ	O
by	IN	O
vortexing	VBG	O
.	.	O
The	DT	O
contents	NNS	O
are	VBP	O
pipetted	VBN	O
into	IN	O
a	DT	O
centrifuge	NN	O
tube	NN	O
containing	VBG	O
10	CD	O
mLs	NN	O
of	IN	O
media	NNS	O
and	CC	O
centrifuged	VBN	O
at	IN	O
1000	CD	O
rpm	NN	O
for	IN	O
5	CD	O
minutes	NNS	O
.	.	O
The	DT	O
supernatant	NN	O
is	VBZ	O
aspirated	VBN	O
and	CC	O
the	DT	O
cells	NNS	O
are	VBP	O
resuspended	VBN	O
in	IN	O
10	CD	O
mL	NN	O
of	IN	O
selective	JJ	O
media	NNS	O
(	(	O
0.2	CD	O
μm	RB	O
filtered	VBN	O
PS20	NNP	O
with	IN	O
5	CD	O
%	NN	O
0.2	CD	O
μm	NN	O
diafiltered	VBD	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
are	VBP	O
then	RB	O
aliquoted	VBN	O
into	IN	O
a	DT	O
100	CD	O
mL	NN	O
spinner	NN	O
containing	VBG	O
90	CD	O
mL	NN	O
of	IN	O
selective	JJ	O
media	NNS	O
.	.	O
After	IN	O
1-2	JJ	O
days	NNS	O
,	,	O
the	DT	O
cells	NNS	O
are	VBP	O
transferred	VBN	O
into	IN	O
a	DT	O
250	CD	O
mL	NN	O
spinner	NN	O
filled	VBN	O
with	IN	O
150	CD	O
mL	NNS	O
selective	JJ	O
growth	NN	O
medium	NN	O
and	CC	O
incubated	VBN	O
at	IN	O
37°	CD	O
C.	NNP	O
After	IN	O
another	DT	O
2-3	JJ	O
days	NNS	O
,	,	O
250	CD	O
mL	NN	O
,	,	O
500	CD	O
mL	NN	O
and	CC	O
2000	CD	O
mL	NN	O
spinners	NNS	O
are	VBP	O
seeded	VBN	O
with	IN	O
3×105	CD	O
cells/mL	NNS	O
.	.	O
The	DT	O
cell	NN	O
media	NNS	O
is	VBZ	O
exchanged	VBN	O
with	IN	O
fresh	JJ	O
media	NNS	O
by	IN	O
centrifugation	NN	O
and	CC	O
resuspension	NN	O
in	IN	O
production	NN	O
medium	NN	O
.	.	O
Although	IN	O
any	DT	O
suitable	JJ	O
CHO	NNP	O
media	NNS	O
may	MD	O
be	VB	O
employed	VBN	O
,	,	O
a	DT	O
production	NN	O
medium	NN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,122,469	CD	O
,	,	O
issued	VBN	O
Jun	NNP	O
.	.	O
16	CD	O
,	,	O
1992	CD	O
may	MD	O
actually	RB	O
be	VB	O
used	VBN	O
.	.	O
A	DT	O
3L	CD	O
production	NN	O
spinner	NN	O
is	VBZ	O
seeded	VBN	O
at	IN	O
1.2×106	CD	O
cells/mL	NN	O
.	.	O
On	IN	O
day	NN	O
0	CD	O
,	,	O
the	DT	O
cell	NN	O
number	NN	O
pH	NN	O
ie	NN	O
determined	VBD	O
.	.	O
On	IN	O
day	NN	O
1	CD	O
,	,	O
the	DT	O
spinner	NN	O
is	VBZ	O
sampled	VBN	O
and	CC	O
sparging	VBG	O
with	IN	O
filtered	JJ	O
air	NN	O
is	VBZ	O
commenced	VBN	O
.	.	O
On	IN	O
day	NN	O
2	CD	O
,	,	O
the	DT	O
spinner	NN	O
is	VBZ	O
sampled	VBN	O
,	,	O
the	DT	O
temperature	NN	O
shifted	VBD	O
to	TO	O
33°	CD	O
C.	NNP	O
,	,	O
and	CC	O
30	CD	O
mL	NN	O
of	IN	O
500	CD	O
g/L	NNS	O
glucose	JJ	O
and	CC	O
0.6	CD	O
mL	NN	O
of	IN	O
10	CD	O
%	NN	O
antifoam	NN	O
(	(	O
e.g.	UH	O
,	,	O
35	CD	O
%	NN	O
polydimethylsiloxane	NN	O
emulsion	NN	O
,	,	O
Dow	NNP	O
Corning	NNP	O
365	CD	O
Medical	NNP	O
Grade	NNP	O
Emulsion	NNP	O
)	)	O
taken	VBN	O
.	.	O
Throughout	IN	O
the	DT	O
production	NN	O
,	,	O
the	DT	O
pH	NN	O
is	VBZ	O
adjusted	VBN	O
as	IN	O
necessary	JJ	O
to	TO	O
keep	VB	O
it	PRP	O
at	IN	O
around	IN	O
7.2	CD	O
.	.	O
After	IN	O
10	CD	O
days	NNS	O
,	,	O
or	CC	O
until	IN	O
the	DT	O
viability	NN	O
dropped	VBD	O
below	IN	O
70	CD	O
%	NN	O
,	,	O
the	DT	O
cell	NN	O
culture	NN	O
is	VBZ	O
harvested	VBN	O
by	IN	O
centrifugation	NN	O
and	CC	O
filtering	VBG	O
through	IN	O
a	DT	O
0.22	CD	O
μm	NN	O
filter	NN	O
.	.	O
The	DT	O
filtrate	NN	O
was	VBD	O
either	RB	O
stored	VBN	O
at	IN	O
4°	CD	O
C.	NNP	O
or	CC	O
immediately	RB	O
loaded	VBN	O
onto	IN	O
columns	NN	O
for	IN	O
purification	NN	O
.	.	O
For	IN	O
the	DT	O
poly-His	JJ	O
tagged	JJ	O
constructs	NNS	O
,	,	O
the	DT	O
proteins	NNS	O
are	VBP	O
purified	VBN	O
using	VBG	O
a	DT	O
Ni-NTA	JJ	O
column	NN	O
(	(	O
Qiagen	NNP	O
)	)	O
.	.	O
Before	IN	O
purification	NN	O
,	,	O
imidazole	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
the	DT	O
conditioned	VBN	O
media	NNS	O
to	TO	O
a	DT	O
concentration	NN	O
of	IN	O
5	CD	O
mM	NN	O
.	.	O
The	DT	O
conditioned	JJ	O
media	NNS	O
is	VBZ	O
pumped	VBN	O
onto	IN	O
a	DT	O
6	CD	O
ml	NN	O
Ni-NTA	NNP	O
column	NN	O
equilibrated	VBD	O
in	IN	O
20	CD	O
mM	NN	O
Hepes	NNP	O
,	,	O
pH	NN	O
7.4	CD	O
,	,	O
buffer	VBP	O
containing	VBG	O
0.3	CD	O
M	NNP	O
NaCl	NNP	O
and	CC	O
5	CD	O
mM	JJ	O
imidazole	NN	O
at	IN	O
a	DT	O
flow	JJ	O
rate	NN	O
of	IN	O
4-5	JJ	O
ml/min	NN	O
.	.	O
at	IN	O
4°	CD	O
C.	NNP	O
After	IN	O
loading	VBG	O
,	,	O
the	DT	O
column	NN	O
is	VBZ	O
washed	VBN	O
with	IN	O
additional	JJ	O
equilibration	NN	O
buffer	NN	O
and	CC	O
the	DT	O
protein	NN	O
eluted	VBD	O
with	IN	O
equilibration	NN	O
buffer	NN	O
containing	VBG	O
0.25	CD	O
M	NNP	O
imidazole	NN	O
.	.	O
The	DT	O
highly	RB	O
purified	JJ	O
protein	NN	O
is	VBZ	O
subsequently	RB	O
desalted	VBN	O
into	IN	O
a	DT	O
storage	NN	O
buffer	NN	O
containing	VBG	O
10	CD	O
mM	JJ	O
Hepes	NNP	O
,	,	O
0.14	CD	O
M	NNP	O
NaCl	NNP	O
and	CC	O
4	CD	O
%	NN	O
mannitol	NN	O
,	,	O
pH	NN	O
6.8	CD	O
,	,	O
with	IN	O
a	DT	O
25	CD	O
ml	NN	O
G25	NNP	O
Superfine	NNP	O
(	(	O
Pharmacia	NNP	O
)	)	O
column	NN	O
and	CC	O
stored	VBN	O
at	IN	O
−80°	NNP	O
C.	NNP	O
Immunoadhesin	NNP	O
(	(	O
Fc-containing	NNP	O
)	)	O
constructs	NNS	O
are	VBP	O
purified	VBN	O
from	IN	O
the	DT	O
conditioned	JJ	O
media	NNS	O
as	IN	O
follows	VBZ	O
.	.	O
The	DT	O
conditioned	JJ	O
medium	NN	O
is	VBZ	O
pumped	VBN	O
onto	IN	O
a	DT	O
5	CD	O
ml	NN	O
Protein	NNP	O
A	NNP	O
column	NN	O
(	(	O
Pharmacia	NNP	O
)	)	O
which	WDT	O
had	VBD	O
been	VBN	O
equilibrated	VBN	O
in	IN	O
20	CD	O
mM	NNS	O
Na	NNP	O
phosphate	NN	O
buffer	NN	O
,	,	O
pH	JJ	O
6.8	CD	O
.	.	O
After	IN	O
loading	VBG	O
,	,	O
the	DT	O
column	NN	O
is	VBZ	O
washed	VBN	O
extensively	RB	O
with	IN	O
equilibration	NN	O
buffer	NN	O
before	IN	O
elution	NN	O
with	IN	O
100	CD	O
mM	NNS	O
citric	JJ	O
acid	NN	O
,	,	O
pH	JJ	O
3.5	CD	O
.	.	O
The	DT	O
eluted	JJ	O
protein	NN	O
is	VBZ	O
immediately	RB	O
neutralized	VBN	O
by	IN	O
collecting	VBG	O
1	CD	O
ml	JJ	O
fractions	NNS	O
into	IN	O
tubes	NNS	O
containing	VBG	O
275	CD	O
μL	NN	O
of	IN	O
1	CD	O
M	NNP	O
Tris	NNP	O
buffer	NN	O
,	,	O
pH	JJ	O
9	CD	O
.	.	O
The	DT	O
highly	RB	O
purified	JJ	O
protein	NN	O
is	VBZ	O
subsequently	RB	O
desalted	VBN	O
into	IN	O
storage	NN	O
buffer	NN	O
as	IN	O
described	VBN	O
above	IN	O
for	IN	O
the	DT	O
poly-His	JJ	O
tagged	JJ	O
proteins	NNS	O
.	.	O
The	DT	O
homogeneity	NN	O
is	VBZ	O
assessed	VBN	O
by	IN	O
SDS	NNP	O
polyacrylamide	NN	O
gels	NNS	O
and	CC	O
by	IN	O
N-terminal	NNP	O
amino	NN	O
acid	NN	O
sequencing	NN	O
by	IN	O
Edman	NNP	O
degradation	NN	O
.	.	O
Example	RB	O
17	CD	O
Expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
in	IN	O
Yeast	NNP	O
The	DT	O
following	JJ	O
method	NN	O
describes	NNS	O
recombinant	JJ	O
expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
in	IN	O
yeast	NN	O
.	.	O
First	RB	O
,	,	O
yeast	PRP	O
expression	NN	O
vectors	NNS	O
are	VBP	O
constructed	VBN	O
for	IN	O
intracellular	JJ	O
production	NN	O
or	CC	O
secretion	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
from	IN	O
the	DT	O
ADH2/GAPDH	NNP	O
promoter	NN	O
.	.	O
DNA	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
and	CC	O
the	DT	O
promoter	NN	O
is	VBZ	O
inserted	VBN	O
into	IN	O
suitable	JJ	O
restriction	NN	O
enzyme	NN	O
sites	NNS	O
in	IN	O
the	DT	O
selected	VBN	O
plasmid	NN	O
to	TO	O
direct	VB	O
intracellular	JJ	O
expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
.	.	O
For	IN	O
secretion	NN	O
,	,	O
DNA	NNP	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
be	VB	O
cloned	VBN	O
into	IN	O
the	DT	O
selected	VBN	O
plasmid	NN	O
,	,	O
together	RB	O
with	IN	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
ADH2/GAPDH	NNP	O
promoter	NN	O
,	,	O
a	DT	O
native	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
signal	JJ	O
peptide	NN	O
or	CC	O
other	JJ	O
mammalian	JJ	O
signal	NN	O
peptide	NN	O
,	,	O
or	CC	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
yeast	JJ	O
alpha-factor	NN	O
or	CC	O
invertase	VB	O
secretory	JJ	O
signal/leader	NN	O
sequence	NN	O
,	,	O
and	CC	O
linker	NN	O
sequences	NNS	O
(	(	O
if	IN	O
needed	VBN	O
)	)	O
for	IN	O
expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
.	.	O
Yeast	NNP	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
yeast	NN	O
strain	NN	O
AB110	NNP	O
,	,	O
can	MD	O
then	RB	O
be	VB	O
transformed	VBN	O
with	IN	O
the	DT	O
expression	NN	O
plasmids	NNS	O
described	VBN	O
above	IN	O
and	CC	O
cultured	VBD	O
in	IN	O
selected	VBN	O
fermentation	NN	O
media	NNS	O
.	.	O
The	DT	O
transformed	VBN	O
yeast	NN	O
supernatants	NNS	O
can	MD	O
be	VB	O
analyzed	VBN	O
by	IN	O
precipitation	NN	O
with	IN	O
10	CD	O
%	NN	O
trichloroacetic	JJ	O
acid	NN	O
and	CC	O
separation	NN	O
by	IN	O
SDS-PAGE	NNP	O
,	,	O
followed	VBN	O
by	IN	O
staining	VBG	O
of	IN	O
the	DT	O
gels	NNS	O
with	IN	O
Coomassie	NNP	O
Blue	NNP	O
stain	NN	O
.	.	O
Recombinant	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
subsequently	RB	O
be	VB	O
isolated	VBN	O
and	CC	O
purified	VBN	O
by	IN	O
removing	VBG	O
the	DT	O
yeast	NN	O
cells	NNS	O
from	IN	O
the	DT	O
fermentation	NN	O
medium	NN	O
by	IN	O
centrifugation	NN	O
and	CC	O
then	RB	O
concentrating	VBG	O
the	DT	O
medium	NN	O
using	VBG	O
selected	VBN	O
cartridge	NN	O
filters	NNS	O
.	.	O
The	DT	O
concentrate	NN	O
containing	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
may	MD	O
further	RB	O
be	VB	O
purified	VBN	O
using	VBG	O
selected	VBN	O
column	NN	O
chromatography	NN	O
resins	NNS	O
.	.	O
Example	RB	O
18	CD	O
Expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
in	IN	O
Baculovirus-Infected	NNP	O
Insect	NNP	O
Cells	NNP	O
The	DT	O
following	JJ	O
method	NN	O
describes	NNS	O
recombinant	JJ	O
expression	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
in	IN	O
Baculovirus-infected	NNP	O
insect	NN	O
cells	NNS	O
.	.	O
The	DT	O
sequence	NN	O
coding	VBG	O
for	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
is	VBZ	O
fused	VBN	O
upstream	NN	O
of	IN	O
an	DT	O
epitope	NN	O
tag	NN	O
contained	VBD	O
within	IN	O
a	DT	O
baculovirus	JJ	O
expression	NN	O
vector	NN	O
.	.	O
Such	JJ	O
epitope	NN	O
tags	NNS	O
include	VBP	O
poly-his	JJ	O
tags	NNS	O
and	CC	O
immunoglobulin	NN	O
tags	NNS	O
(	(	O
like	IN	O
Fc	NNP	O
regions	NNS	O
of	IN	O
IgG	NNP	O
)	)	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
plasmids	NNS	O
may	MD	O
be	VB	O
employed	VBN	O
,	,	O
including	VBG	O
plasmids	NNS	O
derived	VBN	O
from	IN	O
commercially	RB	O
available	JJ	O
plasmids	NNS	O
such	JJ	O
as	IN	O
pVL1393	NN	O
(	(	O
Novagen	NNP	O
)	)	O
.	.	O
Briefly	NNP	O
,	,	O
the	DT	O
sequence	NN	O
encoding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
or	CC	O
the	DT	O
desired	JJ	O
portion	NN	O
of	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
such	JJ	O
as	IN	O
the	DT	O
sequence	NN	O
encoding	VBG	O
the	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
transmembrane	NN	O
protein	NN	O
or	CC	O
the	DT	O
sequence	NN	O
encoding	VBG	O
the	DT	O
mature	NN	O
protein	NN	O
if	IN	O
the	DT	O
protein	NN	O
is	VBZ	O
extracellular	JJ	O
is	VBZ	O
amplified	VBN	O
by	IN	O
PCR	NNP	O
with	IN	O
primers	NNS	O
complementary	VBP	O
to	TO	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
regions	NNS	O
.	.	O
The	DT	O
5′	CD	O
primer	NN	O
may	MD	O
incorporate	VB	O
flanking	NN	O
(	(	O
selected	VBN	O
)	)	O
restriction	NN	O
enzyme	NN	O
sites	NNS	O
.	.	O
The	DT	O
product	NN	O
is	VBZ	O
then	RB	O
digested	VBN	O
with	IN	O
those	DT	O
selected	VBN	O
restriction	NN	O
enzymes	NNS	O
and	CC	O
subcloned	VBD	O
into	IN	O
the	DT	O
expression	NN	O
vector	NN	O
.	.	O
Recombinant	JJ	O
baculovirus	NN	O
is	VBZ	O
generated	VBN	O
by	IN	O
co-transfecting	VBG	O
the	DT	O
above	NN	O
plasmid	NN	O
and	CC	O
BaculoGold™	NNP	O
virus	NN	O
DNA	NNP	O
(	(	O
Pharmingen	NNP	O
)	)	O
into	IN	O
Spodoptera	NNP	O
frugiperda	NN	O
(	(	O
“	JJ	O
Sf9	NNP	O
”	NNP	O
)	)	O
cells	NNS	O
(	(	O
ATCC	NNP	O
CRL	NNP	O
1711	CD	O
)	)	O
using	VBG	O
lipofectin	NN	O
(	(	O
commercially	RB	O
available	JJ	O
from	IN	O
GIBCO-BRL	NNP	O
)	)	O
.	.	O
After	IN	O
4-5	JJ	O
days	NNS	O
of	IN	O
incubation	NN	O
at	IN	O
28°	CD	O
C.	NNP	O
,	,	O
the	DT	O
released	VBN	O
viruses	NNS	O
are	VBP	O
harvested	VBN	O
and	CC	O
used	VBN	O
for	IN	O
further	JJ	O
amplifications	NNS	O
.	.	O
Viral	JJ	O
infection	NN	O
and	CC	O
protein	NN	O
expression	NN	O
are	VBP	O
performed	VBN	O
as	IN	O
described	VBN	O
by	IN	O
O'Reilley	NNP	B
et	FW	I
al.	NN	I
,	,	I
Baculovirus	NNP	I
expression	NN	I
vectors	NNS	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
,	,	I
Oxford	NNP	I
:	:	I
Oxford	NNP	I
University	NNP	I
Press	NNP	I
(	(	I
1994	CD	I
)	)	I
.	.	O
Expressed	VBN	O
poly-his	JJ	O
tagged	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
then	RB	O
be	VB	O
purified	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
Ni2+-chelate	NNP	O
affinity	NN	O
chromatography	NN	O
as	IN	O
follows	VBZ	O
.	.	O
Extracts	NNS	O
are	VBP	O
prepared	VBN	O
from	IN	O
recombinant	JJ	O
virus-infected	JJ	O
Sf9	NNP	O
cells	NNS	O
as	IN	O
described	VBN	O
by	IN	O
Rupert	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
362:175-179	NNP	I
(	(	I
1993	CD	I
)	)	I
.	.	O
Briefly	NNP	O
,	,	O
Sf9	NNP	O
cells	NNS	O
are	VBP	O
washed	VBN	O
,	,	O
resuspended	VBN	O
in	IN	O
sonication	NN	O
buffer	NN	O
(	(	O
25	CD	O
mL	NN	O
Hepes	NNP	O
,	,	O
pH	VBZ	O
7.9	CD	O
;	:	O
12.5	CD	O
mM	NN	O
MgCl2	NNP	O
;	:	O
0.1	CD	O
mM	NN	O
EDTA	NNP	O
;	:	O
10	CD	O
%	NN	O
glycerol	NN	O
;	:	O
0.1	CD	O
%	NN	O
NP-40	NNP	O
;	:	O
0.4	CD	O
M	NNP	O
KCl	NNP	O
)	)	O
,	,	O
and	CC	O
sonicated	VBD	O
twice	RB	O
for	IN	O
20	CD	O
seconds	NNS	O
on	IN	O
ice	NN	O
.	.	O
The	DT	O
sonicates	NNS	O
are	VBP	O
cleared	VBN	O
by	IN	O
centrifugation	NN	O
,	,	O
and	CC	O
the	DT	O
supernatant	NN	O
is	VBZ	O
diluted	VBN	O
50-fold	JJ	O
in	IN	O
loading	VBG	O
buffer	NN	O
(	(	O
50	CD	O
mM	NN	O
phosphate	NN	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
10	CD	O
%	NN	O
glycerol	NN	O
,	,	O
pH	RB	O
7.8	CD	O
)	)	O
and	CC	O
filtered	VBN	O
through	IN	O
a	DT	O
0.45	CD	O
μm	NN	O
filter	NN	O
.	.	O
A	DT	O
Ni2+-NTA	JJ	O
agarose	JJ	O
column	NN	O
(	(	O
commercially	RB	O
available	JJ	O
from	IN	O
Qiagen	NNP	O
)	)	O
is	VBZ	O
prepared	JJ	O
with	IN	O
a	DT	O
bed	NN	O
volume	NN	O
of	IN	O
5	CD	O
mL	NNS	O
,	,	O
washed	VBD	O
with	IN	O
25	CD	O
mL	NNS	O
of	IN	O
water	NN	O
and	CC	O
equilibrated	VBN	O
with	IN	O
25	CD	O
mL	NNS	O
of	IN	O
loading	VBG	O
buffer	NN	O
.	.	O
The	DT	O
filtered	VBN	O
cell	NN	O
extract	NN	O
is	VBZ	O
loaded	VBN	O
onto	IN	O
the	DT	O
column	NN	O
at	IN	O
0.5	CD	O
mL	NNS	O
per	IN	O
minute	NN	O
.	.	O
The	DT	O
column	NN	O
is	VBZ	O
washed	VBN	O
to	TO	O
baseline	VB	O
A280	NNP	O
with	IN	O
loading	VBG	O
buffer	NN	O
,	,	O
at	IN	O
which	WDT	O
point	NN	O
fraction	NN	O
collection	NN	O
is	VBZ	O
started	VBN	O
.	.	O
Next	RB	O
,	,	O
the	DT	O
column	NN	O
is	VBZ	O
washed	VBN	O
with	IN	O
a	DT	O
secondary	JJ	O
wash	NN	O
buffer	NN	O
(	(	O
50	CD	O
mM	NN	O
phosphate	NN	O
;	:	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
10	CD	O
%	NN	O
glycerol	NN	O
,	,	O
pH	RB	O
6.0	CD	O
)	)	O
,	,	O
which	WDT	O
elutes	VBZ	O
nonspecifically	RB	O
bound	VBN	O
protein	NN	O
.	.	O
After	IN	O
reaching	VBG	O
A280	NNP	O
baseline	NN	O
again	RB	O
,	,	O
the	DT	O
column	NN	O
is	VBZ	O
developed	VBN	O
with	IN	O
a	DT	O
0	CD	O
to	TO	O
500	CD	O
mM	NNS	O
Imidazole	NNP	O
gradient	NN	O
in	IN	O
the	DT	O
secondary	JJ	O
wash	NN	O
buffer	NN	O
.	.	O
One	CD	O
mL	NN	O
fractions	NNS	O
are	VBP	O
collected	VBN	O
and	CC	O
analyzed	VBN	O
by	IN	O
SDS-PAGE	NNP	O
and	CC	O
silver	VB	O
staining	NN	O
or	CC	O
Western	JJ	O
blot	NN	O
with	IN	O
Ni2+-NTA-conjugated	NNP	O
to	TO	O
alkaline	VB	O
phosphatase	NN	O
(	(	O
Qiagen	NNP	O
)	)	O
.	.	O
Fractions	NNS	O
containing	VBG	O
the	DT	O
eluted	JJ	O
His10-tagged	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
are	VBP	O
pooled	VBN	O
and	CC	O
dialyzed	VBN	O
against	IN	O
loading	VBG	O
buffer	NN	O
.	.	O
Alternatively	RB	O
,	,	O
purification	NN	O
of	IN	O
the	DT	O
IgG	NNP	O
tagged	VBD	O
(	(	O
or	CC	O
Fc	NNP	O
tagged	VBD	O
)	)	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
can	MD	O
be	VB	O
performed	VBN	O
using	VBG	O
known	VBN	O
chromatography	NN	O
techniques	NNS	O
,	,	O
including	VBG	O
for	IN	O
instance	NN	O
,	,	O
Protein	NNP	O
A	NNP	O
or	CC	O
protein	NN	O
G	NNP	O
column	NN	O
chromatography	NN	O
.	.	O
Example	RB	O
19	CD	O
Preparation	NN	O
of	IN	O
Antibodies	NNS	O
that	WDT	O
Bind	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
This	DT	O
example	NN	O
illustrates	VBZ	O
preparation	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
which	WDT	O
can	MD	O
specifically	RB	O
bind	VB	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
.	.	O
Techniques	NNS	O
for	IN	O
producing	VBG	O
the	DT	O
monoclonal	JJ	O
antibodies	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
are	VBP	O
described	VBN	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
in	IN	O
Goding	NNP	O
,	,	O
supra	NN	O
.	.	O
Immunogens	NNS	O
that	WDT	O
may	MD	O
be	VB	O
employed	VBN	O
include	VBP	O
purified	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
,	,	O
fusion	NN	O
proteins	NNS	O
containing	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
,	,	O
and	CC	O
cells	NNS	O
expressing	VBG	O
recombinant	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
on	IN	O
the	DT	O
cell	NN	O
surface	NN	O
.	.	O
Selection	NN	O
of	IN	O
the	DT	O
immunogen	NN	O
can	MD	O
be	VB	O
made	VBN	O
by	IN	O
the	DT	O
skilled	JJ	O
artisan	NN	O
without	IN	O
undue	JJ	O
experimentation	NN	O
.	.	O
Mice	NNP	O
,	,	O
such	JJ	O
as	IN	O
Balb/c	NNP	O
,	,	O
are	VBP	O
immunized	VBN	O
with	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
immunogen	NN	O
emulsified	VBD	O
in	IN	O
complete	JJ	O
Freund	NNP	O
's	POS	O
adjuvant	NN	O
and	CC	O
injected	VBD	O
subcutaneously	RB	O
or	CC	O
intraperitoneally	RB	O
in	IN	O
an	DT	O
amount	NN	O
from	IN	O
1-100	JJ	O
micrograms	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
immunogen	NN	O
is	VBZ	O
emulsified	VBN	O
in	IN	O
MPL-TDM	NNP	O
adjuvant	NN	O
(	(	O
Ribi	NNP	B
Immunochemical	NNP	I
Research	NNP	I
,	,	I
Hamilton	NNP	I
,	,	I
Mont	NNP	I
.	.	I
)	)	O
and	CC	O
injected	VBN	O
into	IN	O
the	DT	O
animal	NN	O
's	POS	O
hind	JJ	O
foot	NN	O
pads	NNS	O
.	.	O
The	DT	O
immunized	JJ	O
mice	NN	O
are	VBP	O
then	RB	O
boosted	VBD	O
10	CD	O
to	TO	O
12	CD	O
days	NNS	O
later	RB	O
with	IN	O
additional	JJ	O
immunogen	NN	O
emulsified	VBN	O
in	IN	O
the	DT	O
selected	VBN	O
adjuvant	NN	O
.	.	O
Thereafter	RB	O
,	,	O
for	IN	O
several	JJ	O
weeks	NNS	O
,	,	O
the	DT	O
mice	NN	O
may	MD	O
also	RB	O
be	VB	O
boosted	VBN	O
with	IN	O
additional	JJ	O
immunization	NN	O
injections	NNS	O
.	.	O
Serum	NNP	O
samples	NNS	O
may	MD	O
be	VB	O
periodically	RB	O
obtained	VBN	O
from	IN	O
the	DT	O
mice	NN	O
by	IN	O
retro-orbital	JJ	O
bleeding	NN	O
for	IN	O
testing	VBG	O
in	IN	O
ELISA	NNP	O
assays	NNS	O
to	TO	O
detect	VB	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibodies	NNS	O
.	.	O
After	IN	O
a	DT	O
suitable	JJ	O
antibody	NN	O
titer	NN	O
has	VBZ	O
been	VBN	O
detected	VBN	O
,	,	O
the	DT	O
animals	NNS	O
“	VBP	O
positive	JJ	O
”	NN	O
for	IN	O
antibodies	NNS	O
can	MD	O
be	VB	O
injected	VBN	O
with	IN	O
a	DT	O
final	JJ	O
intravenous	JJ	O
injection	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
.	.	O
Three	CD	O
to	TO	O
four	CD	O
days	NNS	O
later	RB	O
,	,	O
the	DT	O
mice	NN	O
are	VBP	O
sacrificed	VBN	O
and	CC	O
the	DT	O
spleen	JJ	O
cells	NNS	O
are	VBP	O
harvested	VBN	O
.	.	O
The	DT	O
spleen	JJ	O
cells	NNS	O
are	VBP	O
then	RB	O
fused	VBN	O
(	(	O
using	VBG	O
35	CD	O
%	NN	O
polyethylene	NN	O
glycol	NN	O
)	)	O
to	TO	O
a	DT	O
selected	VBN	O
murine	NN	O
myeloma	NN	O
cell	NN	O
line	NN	O
such	JJ	O
as	IN	O
P3X63AgU.1	NNP	O
,	,	O
available	JJ	O
from	IN	O
ATCC	NNP	O
,	,	O
No	NNP	O
.	.	O
CRL	NN	O
1597	CD	O
.	.	O
The	DT	O
fusions	NNS	O
generate	VBP	O
hybridoma	NN	O
cells	NNS	O
which	WDT	O
can	MD	O
then	RB	O
be	VB	O
plated	VBN	O
in	IN	O
96	CD	O
well	RB	O
tissue	JJ	O
culture	NN	O
plates	VBZ	O
containing	VBG	O
HAT	NNP	O
(	(	O
hypoxanthine	NN	O
,	,	O
aminopterin	NN	O
,	,	O
and	CC	O
thymidine	NN	O
)	)	O
medium	NN	O
to	TO	O
inhibit	VB	O
proliferation	NN	O
of	IN	O
non-fused	JJ	O
cells	NNS	O
,	,	O
myeloma	NN	O
hybrids	NNS	O
,	,	O
and	CC	O
spleen	JJ	O
cell	NN	O
hybrids	NNS	O
.	.	O
The	DT	O
hybridoma	NN	O
cells	NNS	O
will	MD	O
be	VB	O
screened	VBN	O
in	IN	O
an	DT	O
ELISA	NNP	O
for	IN	O
reactivity	NN	O
against	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
.	.	O
Determination	NN	O
of	IN	O
“	NNP	O
positive	JJ	O
”	NNP	O
hybridoma	NN	O
cells	NNS	O
secreting	VBG	O
the	DT	O
desired	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
against	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
is	VBZ	O
within	IN	O
the	DT	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
positive	JJ	O
hybridoma	NN	O
cells	NNS	O
can	MD	O
be	VB	O
injected	VBN	O
intraperitoneally	RB	O
into	IN	O
syngeneic	JJ	O
Balb/c	NNP	O
mice	NN	O
to	TO	O
produce	VB	O
ascites	NNS	O
containing	VBG	O
the	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
hybridoma	NN	O
cells	NNS	O
can	MD	O
be	VB	O
grown	VBN	O
in	IN	O
tissue	NN	O
culture	NN	O
flasks	NNS	O
or	CC	O
roller	NN	O
bottles	NNS	O
.	.	O
Purification	NN	O
of	IN	O
the	DT	O
monoclonal	JJ	O
antibodies	NNS	O
produced	VBN	O
in	IN	O
the	DT	O
ascites	NNS	O
can	MD	O
be	VB	O
accomplished	VBN	O
using	VBG	O
ammonium	NN	O
sulfate	NN	O
precipitation	NN	O
,	,	O
followed	VBN	O
by	IN	O
gel	JJ	O
exclusion	NN	O
chromatography	NN	O
.	.	O
Alternatively	RB	O
,	,	O
affinity	NN	O
chromatography	NN	O
based	VBN	O
upon	IN	O
binding	NN	O
of	IN	O
antibody	NN	O
to	TO	O
protein	VB	O
A	DT	O
or	CC	O
protein	JJ	O
G	NNP	O
can	MD	O
be	VB	O
employed	VBN	O
.	.	O
Example	RB	O
20	CD	O
Purification	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
PRO10096	NNP	O
PRO21384	NNP	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
Polypeptides	NNP	O
Using	NNP	O
Specific	NNP	O
Antibodies	NNP	O
Native	NNP	O
or	CC	O
recombinant	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
may	MD	O
be	VB	O
purified	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
standard	JJ	O
techniques	NNS	O
in	IN	O
the	DT	O
art	NN	O
of	IN	O
protein	NN	O
purification	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
pro-PRO227	JJ	O
,	,	O
pro-PRO233	JJ	O
,	,	O
pro-PRO238	JJ	O
,	,	O
pro-PRO1328	JJ	O
,	,	O
pro-PRO4342	JJ	O
,	,	O
pro-PRO7423	JJ	O
;	:	O
pro-PRO10096	JJ	O
;	:	O
pro-PRO21384	JJ	O
;	:	O
pro-PRO353	JJ	O
or	CC	O
pro-PRO1885	JJ	O
polypeptide	NN	O
,	,	O
mature	NN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
or	CC	O
pre-PRO227	JJ	O
,	,	O
pre-PRO233	JJ	O
,	,	O
pre-PRO238	JJ	O
,	,	O
pre-PRO1328	JJ	O
,	,	O
pre-PRO4342	JJ	O
,	,	O
pre-PRO7423	JJ	O
;	:	O
pre-PRO10096	JJ	O
;	:	O
pre-PRO21384	JJ	O
;	:	O
pre-PRO353	JJ	O
or	CC	O
pre-PRO1885	JJ	O
polypeptide	NN	O
is	VBZ	O
purified	VBN	O
by	IN	O
immunoaffinity	NN	O
chromatography	NN	O
using	VBG	O
antibodies	NNS	O
specific	JJ	O
for	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
of	IN	O
interest	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
an	DT	O
immunoaffinity	NN	O
column	NN	O
is	VBZ	O
constructed	VBN	O
by	IN	O
covalently	RB	O
coupling	VBG	O
the	DT	O
anti-PRO227	JJ	O
,	,	O
anti-PRO233	JJ	O
,	,	O
anti-PRO238	JJ	O
,	,	O
anti-PRO1328	JJ	O
,	,	O
anti-PRO4342	JJ	O
,	,	O
anti-PRO7423	JJ	O
,	,	O
anti-PRO10096	JJ	O
,	,	O
anti-PRO21384	JJ	O
,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
polypeptide	NN	O
antibody	NN	O
to	TO	O
an	DT	O
activated	JJ	O
chromatographic	JJ	O
resin	NN	O
.	.	O
Polyclonal	JJ	O
immunoglobulins	NNS	O
are	VBP	O
prepared	VBN	O
from	IN	O
immune	JJ	O
sera	NN	O
either	CC	O
by	IN	O
precipitation	NN	O
with	IN	O
ammonium	NN	O
sulfate	NN	O
or	CC	O
by	IN	O
purification	NN	O
on	IN	O
immobilized	JJ	O
Protein	NNP	O
A	NNP	O
(	(	O
Pharmacia	NNP	O
LKB	NNP	O
Biotechnology	NNP	O
,	,	O
Piscataway	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
.	.	O
Likewise	RB	O
,	,	O
monoclonal	JJ	O
antibodies	NNS	O
are	VBP	O
prepared	VBN	O
from	IN	O
mouse	NN	O
ascites	NNS	O
fluid	VBN	O
by	IN	O
ammonium	NN	O
sulfate	NN	O
precipitation	NN	O
or	CC	O
chromatography	NN	O
on	IN	O
immobilized	JJ	O
Protein	NNP	O
A	NNP	O
.	.	O
Partially	RB	O
purified	VBN	O
immunoglobulin	NN	O
is	VBZ	O
covalently	RB	O
attached	VBN	O
to	TO	O
a	DT	O
chromatographic	JJ	O
resin	NN	O
such	JJ	O
as	IN	O
CnBr-activated	JJ	O
SEPHAROSE™	NNP	O
(	(	O
Pharmacia	NNP	O
LKB	NNP	O
Biotechnology	NNP	O
)	)	O
.	.	O
The	DT	O
antibody	NN	O
is	VBZ	O
coupled	VBN	O
to	TO	O
the	DT	O
resin	NN	O
,	,	O
the	DT	O
resin	NN	O
is	VBZ	O
blocked	VBN	O
,	,	O
and	CC	O
the	DT	O
derivative	JJ	O
resin	NN	O
is	VBZ	O
washed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O
Such	JJ	O
an	DT	O
immunoaffinity	NN	O
column	NN	O
is	VBZ	O
utilized	VBN	O
in	IN	O
the	DT	O
purification	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
by	IN	O
preparing	VBG	O
a	DT	O
fraction	NN	O
from	IN	O
cells	NNS	O
containing	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
in	IN	O
a	DT	O
soluble	JJ	O
form	NN	O
.	.	O
This	DT	O
preparation	NN	O
is	VBZ	O
derived	VBN	O
by	IN	O
solubilization	NN	O
of	IN	O
the	DT	O
whole	JJ	O
cell	NN	O
or	CC	O
of	IN	O
a	DT	O
subcellular	JJ	O
fraction	NN	O
obtained	VBN	O
via	IN	O
differential	JJ	O
centrifugation	NN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
detergent	NN	O
or	CC	O
by	IN	O
other	JJ	O
methods	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Alternatively	RB	O
,	,	O
soluble	JJ	O
polypeptide	NN	O
containing	VBG	O
a	DT	O
signal	JJ	O
sequence	NN	O
may	MD	O
be	VB	O
secreted	VBN	O
in	IN	O
useful	JJ	O
quantity	NN	O
into	IN	O
the	DT	O
medium	NN	O
in	IN	O
which	WDT	O
the	DT	O
cells	NNS	O
are	VBP	O
grown	VBN	O
.	.	O
A	DT	O
soluble	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-containing	JJ	O
preparation	NN	O
is	VBZ	O
passed	VBN	O
over	IN	O
the	DT	O
immunoaffinity	NN	O
column	NN	O
,	,	O
and	CC	O
the	DT	O
column	NN	O
is	VBZ	O
washed	VBN	O
under	IN	O
conditions	NNS	O
that	WDT	O
allow	VBP	O
the	DT	O
preferential	JJ	O
absorbance	NN	O
of	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
(	(	O
e.g.	UH	O
,	,	O
high	JJ	O
ionic	JJ	O
strength	NN	O
buffers	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
detergent	NN	O
)	)	O
.	.	O
Then	RB	O
,	,	O
the	DT	O
column	NN	O
is	VBZ	O
eluted	VBN	O
under	IN	O
conditions	NNS	O
that	WDT	O
disrupt	VBP	O
antibody/PRO227	NNS	O
,	,	O
antibody/PRO233	NN	O
,	,	O
antibody/PRO238	NN	O
,	,	O
antibody/PRO1328	NN	O
,	,	O
antibody/PRO4342	NN	O
,	,	O
antibody/PRO7423	NN	O
;	:	O
antibody/PRO10096	CC	O
;	:	O
antibody/PRO21384	NN	O
;	:	O
antibody/PRO353	CC	O
or	CC	O
antibody/PRO1885	JJ	O
polypeptide	NN	O
binding	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
low	JJ	O
pH	NN	O
buffer	NN	O
such	JJ	O
as	IN	O
approximately	RB	O
pH	JJ	O
2-3	JJ	O
,	,	O
or	CC	O
a	DT	O
high	JJ	O
concentration	NN	O
of	IN	O
a	DT	O
chaotrope	NN	O
such	JJ	O
as	IN	O
urea	JJ	O
or	CC	O
thiocyanate	JJ	O
ion	NN	O
)	)	O
,	,	O
and	CC	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
collected	VBN	O
.	.	O
Example	JJ	O
21	CD	O
Drug	NNP	O
Screening	NNP	O
This	DT	O
invention	NN	O
is	VBZ	O
particularly	RB	O
useful	JJ	O
for	IN	O
screening	VBG	O
compounds	NNS	O
by	IN	O
using	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
or	CC	O
binding	VBG	O
fragment	JJ	O
thereof	NN	O
in	IN	O
any	DT	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
drug	NN	O
screening	VBG	O
techniques	NNS	O
.	.	O
The	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
fragment	JJ	O
employed	VBN	O
in	IN	O
such	JJ	O
a	DT	O
test	NN	O
may	MD	O
either	RB	O
be	VB	O
free	JJ	O
in	IN	O
solution	NN	O
,	,	O
affixed	VBN	O
to	TO	O
a	DT	O
solid	JJ	O
support	NN	O
,	,	O
borne	NN	O
on	IN	O
a	DT	O
cell	NN	O
surface	NN	O
,	,	O
or	CC	O
located	VBN	O
intracellularly	RB	O
.	.	O
One	CD	O
method	NN	O
of	IN	O
drug	NN	O
screening	VBG	O
utilizes	JJ	O
eukaryotic	JJ	O
or	CC	O
prokaryotic	JJ	O
host	NN	O
cells	NNS	O
which	WDT	O
are	VBP	O
stably	RB	O
transformed	VBN	O
with	IN	O
recombinant	JJ	O
nucleic	JJ	O
acids	NNS	O
expressing	VBG	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
fragment	NN	O
.	.	O
Drugs	NNS	O
are	VBP	O
screened	VBN	O
against	IN	O
such	JJ	O
transformed	JJ	O
cells	NNS	O
in	IN	O
competitive	JJ	O
binding	NN	O
assays	NNS	O
.	.	O
Such	JJ	O
cells	NNS	O
,	,	O
either	RB	O
in	IN	O
viable	JJ	O
or	CC	O
fixed	JJ	O
form	NN	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
standard	JJ	O
binding	NN	O
assays	NNS	O
.	.	O
One	CD	O
may	MD	O
measure	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
formation	NN	O
of	IN	O
complexes	NNS	O
between	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
or	CC	O
a	DT	O
fragment	NN	O
and	CC	O
the	DT	O
agent	NN	O
being	VBG	O
tested	VBN	O
.	.	O
Alternatively	RB	O
,	,	O
one	CD	O
can	MD	O
examine	VB	O
the	DT	O
diminution	NN	O
in	IN	O
complex	JJ	O
formation	NN	O
between	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
and	CC	O
its	PRP$	O
target	NN	O
cell	NN	O
or	CC	O
target	NN	O
receptors	NNS	O
caused	VBN	O
by	IN	O
the	DT	O
agent	NN	O
being	VBG	O
tested	VBN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
screening	VBG	O
for	IN	O
drugs	NNS	O
or	CC	O
any	DT	O
other	JJ	O
agents	NNS	O
which	WDT	O
can	MD	O
affect	VB	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-associated	JJ	O
disease	NN	O
or	CC	O
disorder	NN	O
.	.	O
These	DT	O
methods	NNS	O
comprise	VBP	O
contacting	VBG	O
such	PDT	O
an	DT	O
agent	NN	O
with	IN	O
an	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
fragment	NN	O
thereof	NN	O
and	CC	O
assaying	NN	O
(	(	O
I	PRP	O
)	)	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
complex	NN	O
between	IN	O
the	DT	O
agent	NN	O
and	CC	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
fragment	NN	O
,	,	O
or	CC	O
(	(	O
ii	NN	O
)	)	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
complex	NN	O
between	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
fragment	NN	O
and	CC	O
the	DT	O
cell	NN	O
,	,	O
by	IN	O
methods	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
In	IN	O
such	JJ	O
competitive	JJ	O
binding	NN	O
assays	NNS	O
,	,	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
fragment	NN	O
is	VBZ	O
typically	RB	O
labeled	VBN	O
.	.	O
After	IN	O
suitable	JJ	O
incubation	NN	O
,	,	O
free	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
fragment	NN	O
is	VBZ	O
separated	VBN	O
from	IN	O
that	DT	O
present	JJ	O
in	IN	O
bound	NN	O
form	NN	O
,	,	O
and	CC	O
the	DT	O
amount	NN	O
of	IN	O
free	JJ	O
or	CC	O
uncomplexed	JJ	O
label	NN	O
is	VBZ	O
a	DT	O
measure	NN	O
of	IN	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
particular	JJ	O
agent	NN	O
to	TO	O
bind	VB	O
to	TO	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
or	CC	O
to	TO	O
interfere	VB	O
with	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide/cell	VBP	O
complex	JJ	O
.	.	O
Another	DT	O
technique	NN	O
for	IN	O
drug	NN	O
screening	VBG	O
provides	VBZ	O
high	JJ	O
throughput	NN	O
screening	VBG	O
for	IN	O
compounds	NNS	O
having	VBG	O
suitable	JJ	O
binding	VBG	O
affinity	NN	O
to	TO	O
a	DT	O
polypeptide	NN	O
and	CC	O
is	VBZ	O
described	VBN	O
in	IN	O
detail	NN	O
in	IN	O
WO	NNP	O
84/03564	CD	O
,	,	O
published	VBN	O
on	IN	O
Sep.	NNP	O
13	CD	O
,	,	O
1984	CD	O
.	.	O
Briefly	NNP	O
stated	VBD	O
,	,	O
large	JJ	O
numbers	NNS	O
of	IN	O
different	JJ	O
small	JJ	O
peptide	NN	O
test	NN	O
compounds	NNS	O
are	VBP	O
synthesized	VBN	O
on	IN	O
a	DT	O
solid	JJ	O
substrate	NN	O
,	,	O
such	JJ	O
as	IN	O
plastic	NN	O
pins	NNS	O
or	CC	O
some	DT	O
other	JJ	O
surface	NN	O
.	.	O
As	IN	O
applied	VBN	O
to	TO	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
,	,	O
the	DT	O
peptide	JJ	O
test	NN	O
compounds	NNS	O
are	VBP	O
reacted	VBN	O
with	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
washed	VBD	O
.	.	O
Bound	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
detected	VBN	O
by	IN	O
methods	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Purified	NNP	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
can	MD	O
also	RB	O
be	VB	O
coated	VBN	O
directly	RB	O
onto	IN	O
plates	NNS	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
aforementioned	JJ	O
drug	NN	O
screening	VBG	O
techniques	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
non-neutralizing	JJ	O
antibodies	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
capture	VB	O
the	DT	O
peptide	NN	O
and	CC	O
immobilize	VB	O
it	PRP	O
on	IN	O
the	DT	O
solid	JJ	O
support	NN	O
.	.	O
This	DT	O
invention	NN	O
also	RB	O
contemplates	VBZ	O
the	DT	O
use	NN	O
of	IN	O
competitive	JJ	O
drug	NN	O
screening	VBG	O
assays	NNS	O
in	IN	O
which	WDT	O
neutralizing	VBG	O
antibodies	NNS	O
capable	JJ	O
of	IN	O
binding	VBG	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
specifically	RB	O
compete	JJ	O
with	IN	O
a	DT	O
test	NN	O
compound	NN	O
for	IN	O
binding	VBG	O
to	TO	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
fragments	NNS	O
thereof	NN	O
.	.	O
In	IN	O
this	DT	O
manner	NN	O
,	,	O
the	DT	O
antibodies	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
detect	VB	O
the	DT	O
presence	NN	O
of	IN	O
any	DT	O
peptide	NN	O
which	WDT	O
shares	NNS	O
one	CD	O
or	CC	O
more	JJR	O
antigenic	JJ	O
determinants	NNS	O
with	IN	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
.	.	O
Example	JJ	O
22	CD	O
Rational	JJ	O
Drug	NNP	O
Design	NNP	O
The	DT	O
goal	NN	O
of	IN	O
rational	JJ	O
drug	NN	O
design	NN	O
is	VBZ	O
to	TO	O
produce	VB	O
structural	JJ	O
analogs	NNS	O
of	IN	O
biologically	RB	O
active	JJ	O
polypeptide	NN	O
of	IN	O
interest	NN	O
(	(	O
i.e.	FW	O
,	,	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
)	)	O
or	CC	O
of	IN	O
small	JJ	O
molecules	NNS	O
with	IN	O
which	WDT	O
they	PRP	O
interact	VBP	O
,	,	O
e.g.	FW	O
,	,	O
agonists	NNS	O
,	,	O
antagonists	NNS	O
,	,	O
or	CC	O
inhibitors	NNS	O
.	.	O
Any	DT	O
of	IN	O
these	DT	O
examples	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
fashion	NN	O
drugs	NNS	O
which	WDT	O
are	VBP	O
more	RBR	O
active	JJ	O
or	CC	O
stable	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
which	WDT	O
enhance	NN	O
or	CC	O
interfere	VB	O
with	IN	O
the	DT	O
function	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
in	IN	O
vivo	NN	O
(	(	O
c.f.	NN	O
,	,	O
Hodgson	NNP	B
,	,	I
Bio/Technology	NNP	I
,	,	I
9	CD	I
:	:	I
19-21	JJ	I
(	(	I
1991	CD	I
)	)	I
)	)	O
.	.	O
In	IN	O
one	CD	O
approach	NN	O
,	,	O
the	DT	O
three-dimensional	JJ	O
structure	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
,	,	O
or	CC	O
of	IN	O
a	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-inhibitor	NN	O
complex	NN	O
,	,	O
is	VBZ	O
determined	VBN	O
by	IN	O
x-ray	JJ	O
crystallography	NN	O
,	,	O
by	IN	O
computer	NN	O
modeling	NN	O
or	CC	O
,	,	O
most	JJS	O
typically	RB	O
,	,	O
by	IN	O
a	DT	O
combination	NN	O
of	IN	O
the	DT	O
two	CD	O
approaches	NNS	O
.	.	O
Both	DT	O
the	DT	O
shape	NN	O
and	CC	O
charges	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
must	MD	O
be	VB	O
ascertained	VBN	O
to	TO	O
elucidate	VB	O
the	DT	O
structure	NN	O
and	CC	O
to	TO	O
determine	VB	O
active	JJ	O
site	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
molecule	NN	O
.	.	O
Less	RBR	O
often	RB	O
,	,	O
useful	JJ	O
information	NN	O
regarding	VBG	O
the	DT	O
structure	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
gained	VBN	O
by	IN	O
modeling	VBG	O
based	VBN	O
on	IN	O
the	DT	O
structure	NN	O
of	IN	O
homologous	JJ	O
proteins	NNS	O
.	.	O
In	IN	O
both	DT	O
cases	NNS	O
,	,	O
relevant	JJ	O
structural	JJ	O
information	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
design	VB	O
analogous	JJ	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-like	JJ	O
molecules	NNS	O
or	CC	O
to	TO	O
identify	VB	O
efficient	JJ	O
inhibitors	NNS	O
.	.	O
Useful	JJ	O
examples	NNS	O
of	IN	O
rational	JJ	O
drug	NN	O
design	NN	O
may	MD	O
include	VB	O
molecules	NNS	O
which	WDT	O
have	VBP	O
improved	VBN	O
activity	NN	O
or	CC	O
stability	NN	O
as	IN	O
shown	VBN	O
by	IN	O
Braxton	NNP	B
and	CC	I
Wells	NNP	I
,	,	I
Biochemistry	NNP	I
,	,	I
31:7796-7801	NNP	I
(	(	I
1992	CD	I
)	)	I
or	CC	O
which	WDT	O
act	NN	O
as	IN	O
inhibitors	NNS	O
,	,	O
agonists	NNS	O
,	,	O
or	CC	O
antagonists	NNS	O
of	IN	O
native	JJ	O
peptides	NNS	O
as	IN	O
shown	VBN	O
by	IN	O
Athauda	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
113:742-746	CD	I
(	(	I
1993	CD	I
)	)	I
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
possible	JJ	O
to	TO	O
isolate	VB	O
a	DT	O
target-specific	JJ	O
antibody	NN	O
,	,	O
selected	VBN	O
by	IN	O
functional	JJ	O
assay	NN	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
and	CC	O
then	RB	O
to	TO	O
solve	VB	O
its	PRP$	O
crystal	JJ	O
structure	NN	O
.	.	O
This	DT	O
approach	NN	O
,	,	O
in	IN	O
principle	NN	O
,	,	O
yields	VBZ	O
a	DT	O
pharmacore	NN	O
upon	IN	O
which	WDT	O
subsequent	JJ	O
drug	NN	O
design	NN	O
can	MD	O
be	VB	O
based	VBN	O
.	.	O
It	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
bypass	VB	O
protein	NN	O
crystallography	NN	O
altogether	RB	O
by	IN	O
generating	VBG	O
anti-idiotypic	JJ	O
antibodies	NNS	O
(	(	O
anti-ids	NNS	O
)	)	O
to	TO	O
a	DT	O
functional	JJ	O
,	,	O
pharmacologically	RB	O
active	JJ	O
antibody	NN	O
.	.	O
As	IN	O
a	DT	O
mirror	NN	O
image	NN	O
of	IN	O
a	DT	O
mirror	NN	O
image	NN	O
,	,	O
the	DT	O
binding	VBG	O
site	NN	O
of	IN	O
the	DT	O
anti-ids	NNS	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
be	VB	O
an	DT	O
analog	NN	O
of	IN	O
the	DT	O
original	JJ	O
receptor	NN	O
.	.	O
The	DT	O
anti-id	NN	O
could	MD	O
then	RB	O
be	VB	O
used	VBN	O
to	TO	O
identify	VB	O
and	CC	O
isolate	VB	O
peptides	NNS	O
from	IN	O
banks	NNS	O
of	IN	O
chemically	RB	O
or	CC	O
biologically	RB	O
produced	VBN	O
peptides	NNS	O
.	.	O
The	DT	O
isolated	JJ	O
peptides	NNS	O
would	MD	O
then	RB	O
act	VB	O
as	IN	O
the	DT	O
pharmacore	NN	O
.	.	O
By	IN	O
virtue	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
sufficient	JJ	O
amounts	NNS	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
be	VB	O
made	VBN	O
available	JJ	O
to	TO	O
perform	VB	O
such	JJ	O
analytical	JJ	O
studies	NNS	O
as	IN	O
X-ray	JJ	O
crystallography	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
knowledge	NN	O
of	IN	O
the	DT	O
PRO227	NNP	O
,	,	O
PRO233	NNP	O
,	,	O
PRO238	NNP	O
,	,	O
PRO1328	NNP	O
,	,	O
PRO4342	NNP	O
,	,	O
PRO7423	NNP	O
,	,	O
PRO10096	NNP	O
,	,	O
PRO21384	NNP	O
,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
amino	NN	O
acid	NN	O
sequence	NN	O
provided	VBD	O
herein	NN	O
will	MD	O
provide	VB	O
guidance	NN	O
to	TO	O
those	DT	O
employing	VBG	O
computer	NN	O
modeling	VBG	O
techniques	NNS	O
in	IN	O
place	NN	O
of	IN	O
or	CC	O
in	IN	O
addition	NN	O
to	TO	O
x-ray	JJ	O
crystallography	NN	O
.	.	O
Claims	NNS	O
(	(	O
3	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
5	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
1	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=41609740	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
2	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
1	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
1	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
1	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
3	CD	O
)	)	O
Citations	NNPS	O
(	(	O
15	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
15	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
50	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
1	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Effective	JJ	O
date	NN	O
:	:	O
20160724	CD	O
